Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)

ABSTRACT

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.

SEQUENCE LISTING

The sequence listing submitted via EFS, in compliance with 37 CFR §1.52(e)(5), is incorporated herein by reference. The sequence listingtext file submitted via EFS contains the File “SequenceListingSIRONC2”,created on Jul. 25, 2011 which is 2,173,912 bytes in size.

BACKGROUND OF THE INVENTION

Beta catenin (also known as cadherin-associated protein and β-catenin),is a member of the catenin family of cytosolic proteins. β-catenin isencoded by the CTNNB1 gene.

β-catenin is a pivotal player in the Wnt/Wg signaling pathway, mediatorsof several developmental processes. In the absence of Wnt, glycogensynthase kinase 3 (GSK-3β), a serine/threonine protein kinaseconstitutively phosphorylates the 3-catenin protein. When Wnt is presentand binds to any of the family members of the frizzled receptors (Fz),an intracellular signaling protein known as dishevelled (Dsh) isrecruited to the membrane and phosphorylated. GSK-3β is inhibited by theactivation of Dsh. As a result, β-catenin levels increase in the cytosoland are translocated into the nucleus to perform a variety of functions.β-catenin acts together with the transcription factors TCF and LEF toactivate specific target genes involved in different processes.

β-catenin undergoes phosphorylation upon growth factor stimulationresulting in reduced cell adhesion, thereby functioning as a componentof adherin junctions which are multiprotein complexes that mediate celladhesion, cell-cell communication and cytoskeletal anchoring. (Willettet 1998, Curr. Opin, Genet, Dev. 8:95-102).

Thompson et al. suggest that β-catenin plays an important role invarious aspects of liver biology including liver development (bothembryonic and postnatal), liver regeneration following partialhepatectomy, hepatocyte growth factor (HGF)-induced hepatomegaly, liverzonation, and pathogenesis of liver cancer. (Thompson M D., 2007,Hepatology May; 45(5):1298-305).

Wang et al, (2008) have shown that β-catenin can function as anoncogene. (Wang et al., 2008, Cancer Epidemiol. Biomarkers Prev. 17(8):2101-8). In patients with basal cell carcinoma an increased level inβ-catenin is present and leads to the increase in proliferation ofrelated tumors. Mutations in the β-catenin gene area cause of colorectalcancer (CRC), pilomatrixoma (PTR), medulloblastoma (MDB),hepatoblastoma, and ovarian cancer.

The role of β-catenin in the development of colorectal cancer has beenshown to be regulated by the expression product of the APC (adenomatouspolyposis of the colon) gene, a tumor suppressor. (Korinek et al.,Science, 1997, 275:1784-1787; Morin et al., Science, 1997,275:1787-1790). The APC protein normally binds β-catenin in conjunctionwith TCF/LEF forming a transcription factor complex. Morin el al. (Morinet al., Science, 1997, 275:1787-1790) report that APC proteindown-regulates the transcriptional activation mediated by β-catenin andTcf-4 in colon cancer. Their results indicate that the regulation ofβ-catenin is critical to APC's tumor suppressive effect and that thisregulation can be circumvented by mutations in either APC or β-catenin.

Mutations in the β-catenin gene are either truncations that lead todeletion of part of the N-terminus of β-catenin, or point mutations thataffect the serine and threonine residues that are targeted by GSK3α/β orCKIα, These mutant β-catenin proteins are refractory to phosphorylationand thus escape proteasomal degradations. Consequently, β-cateninaccumulates within affected cells. Stabilized and nuclear-localizedβ-catenin is a hallmark of nearly all cases of colon cancer. (Clevers,H., 2006, Cell 127:469-480). Morin et al. demonstrated that mutations ofβ-catenin that altered phosphorylation sites rendered the cellsinsensitive to APC-mediated down-regulation of β-catenin and that thisdisrupted mechanism was critical to colorectal tumorigenesis. (Morin etal., 1997, Science 275:1787-1790).

Other studies also report on the detection of mutations in β-catenin invarious cancer cell lines (see e.g., Chan et al., 1999, Nature Genet.21:410-413: Blaker et al., 1999, Genes Chromosomes Cancer 25:399-402;Sagae et al., 1999, Jpn. J. Cancer Res. 90:510-515; Wang et al., 2008,Cancer Epidemiol Biomarkers Prev. 17(8):2101-8). Additionally,abnormally high amounts of β-catenin have also been found in melanomacell lines (see e.g, Ruhinfeld et al., 1997, Science, 275:1790-1792).

Likewise other cancers, such as hepatocellular carcinoma (HCC), havealso been associated with the Wnt/beta-catenin pathway, HCC is a complexand heterogeneous disease accounting for more than 660,000 new cases peryear worldwide. Multiple reports have shown that Wnt signalingcomponents are activated in human HCC patients. Ativated Wnt signalingand nuclear beta-catenin correlate with recurrence of disease and poorprognosis (Takigawa et al. 2008, Curr Drug Targets November;901):1013-24). Elevated nuclear beta-catenin staining has beendocumented in 17-66% of HCC patients (Zulehner et al. 2010, Am J Pathol.January; 176(1):472-81; Yu et al, 2009, Hepatol. May; 50(5):948-57).Merck's internal dataset on 300 HCC patient tumors generated incollaboration with the Hong Kong University indicates Writ signalingcomponents are activated in 50% of HCC patients. External data haveshown activating beta-catenin mutations in 13-40% of HCC patients, whileinactivating Axin 1 or 2 mutations were present in 10% of HCC patients(Lee et al. 2006, Frontiers in Bioscience May 1:11:1901-1915).

Preclinical studies provide evidence that activation of theWnt/beta-catenin pathway is important in the generation and maintenanceof HCC. Liver-targeted disruption of APC in mice activates beta-cateninsignaling and leads to the formation of HCC (Colnot et al. 2004, Proc.Natl Acad Sci USA. December 7; 101(49):17216-21). Althoughoverexpression of a beta-catenin mutant lacking the GSK-3betaphosphorylation sites alone is not sufficient for hepatocarcinogenesis(Harada et al, 2002, Cancer Res. April 1; 62(7):1971-7), overexpressionof tumorigenic mutant beta-catenin has been shown to make micesusceptible to HCC induced by DEN (diethylnitrosamine), a knowncarcinogen (Nejak-Bowen et al. 2010, Hepatology 2010 May; 51(5):1603-13.Interestingly, 95% of HCC tumors initiated by overexpression of thehuman Met receptor in mice (Tre-Met transgenic mouse model) harborbeta-catenin activating mutations (Tward et al. 2007, Proc Natl Acad SciUSA. September 11; 104(37); 14771-6). This finding reflects the humandisease and suggests that the Wnt pathway cooperates with Met signalingduring hepatocarcinogenesis. High rates of beta-catenin activatingmutations are also found in other transgenic mouse models for HCC (16%beta-catenin mutations in FGF19, 55% in c-Myc and 41% in H-Rastransgenic mice) (Nicholes et al, 2002, Am J Pathol. June;160(6):2295-307 de la. Coste et al 1998, Proc Natl Acad Sci USA. July21; 95(15):8847-51).

Preclinical studies have also shown that beta-catenin is a valid targetfor HCC. Beta-catenin siRNAs inhibit proliferation and viability ofhuman HCC cell lines (Zeng et al. 2007). Similarly, treatment of humanHCC cell lines with an anti-Wnt-1 antibody or TCF4/beta-cateninantagonists induce apoptosis, reduction of c-Myc, cyclin D1 and survivinexpression as well as suppress tumor growth in vivo (Wei et al. 2009,Mol Cancer September 24; 8:76; Wei el al. 2010, Int J Cancer. May 15;126(10):2426-36.2010).

Hepatocellular carcinoma (HCC) is a common and aggressive cancer forwhich effective therapies are lacking. The Wnt/beta-catenin pathway isactivated in a high proportion of HCC cases (˜50%), frequently owing tomutations in beta-catenin (i.e. CTNNB1) or in the beta-catenindestruction complex (e.g. Axin1). Moreover, the Writ pathway as a targethas proven to be challenging and is currently undruggable by smallmolecule inhibitors, making beta-catenin an attractive target for anRNAi-based therapeutic approach (Llovet et al. 2008, Hepatology October:48: 1312-1327).

Alteration of gene expression, specifically CTNNB1 gene expression,through RNA interference (hereinafter “RNAi”) is one approach formeeting this need. RNAi is induced by short single-stranded RNA(“ssRNA”) or double-stranded RNA (“dsRNA”) molecules. The short dsRNAmolecules, called “short interfering nucleic acids (“siNA”)” or “shortinterfering RNA” or “siRNA” or “RNAi inhibitors” silence the expressionof messenger RNAs (“mRNAs”) that share sequence homology to the siNA.This can occur via cleavage of the mRNA mediated by an endonucleasecomplex containing a siNA, commonly referred to as an RNA-inducedsilencing complex (RISC). Cleavage of the target RNA typically takesplace in the middle of the region complementary to the guide sequence ofthe siNA duplex (Elbashir et al., 2001, Genes Dev., 15:188). Inaddition, RNA interference can also involve small RNA (e.g., micro-RNAor miRNA) mediated gene silencing, presumably through cellularmechanisms that either inhibit translation or that regulate chromatinstructure and thereby prevent transcription of target gene sequences(see for example Allshire, 2002, Science, 297:1818-1819; Volpe et al.,2002, Science, 297:1833-1837: Jenuwein, 2002, Science, 297:2215-2218:and Hall et al., 2002, Science, 297:2232-2237). Despite significantadvances in the field of RNAi, there remains a need for agents that caninhibit CTNNB1 gene expression and that can treat disease associatedwith CTNNB1 expression such as cancer.

SUMMARY OF THE INVENTION

The invention provides a solution to the problem of treating diseasesthat respond to the modulation of the CTNNB1 gene expression using novelshort interfering nucleic acid (siNA) molecules to modulate CTNNB1expression.

The present invention provides compounds, compositions, and methodsuseful for modulating the expression of CTNNB1 genes, specifically thoseCTNNB1 genes associated with cancer and for treating such conditions byRNA interference (RNAi) using small nucleic acid molecules.

In particular, the instant invention features small nucleic acidmolecules, i.e., short interfering nucleic acid (siNA) moleculesincluding, but not limited to, short interfering RNA (siRNA),double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA(shRNA) and circular RNA molecules and methods used to modulate theexpression of CTNNB1 genes and/or other genes involved in pathways ofCTNNB1 gene expression and/or activity.

In one aspect, the invention provides double-stranded short interferingnucleic acid (siNA) molecules that inhibit the expression of a CTNNB1gene in a cell or mammal, wherein the double-stranded siNAs comprise asense and an antisense stand. The antisense strand comprises a sequencethat is complementary to at least a part of an RNA associated with theexpression of the CTNNB1 gene. The sense strand comprises a sequencethat is complementary to the antisense strand. In various embodiments,at least one strand comprises at least a 15 nucleotide sequence selectedfrom the group of sequences consisting of SEQ ID NOS:1-6374. In certainembodiments, the antisense strand comprises at least 15, 16, 17, 18, or19 nucleotides having sequence complementarity to a target sequence setforth in Table 1a. In other and/or in the same embodiments, theantisense strand comprises at least a 15, 16, 17, 18, or 19 nucleotidesequence of one of the antisense sequences set forth in Table 1b. Insome embodiments, the sense strand comprises at least a 15, 16, 17, 18,or 19 nucleotide sequence of a sense strand sequence as set forth inTable 1b.

In certain embodiments of this aspect of the invention, double-strandedshort interfering nucleic acid (siNA) molecules are provided wherein theantisense stand comprises a modified sequence as set forth in Table 1cthat has sequence complementarity to a target sequence of the invention.In some embodiments, the sense strand also comprises a modified sequenceas set for in Table 1c.

In certain embodiments, the present invention provides a double-strandedshort interfering nucleic acid (siNA) molecule that modulates theexpression of CTNNB1, wherein the siNA comprises a sense strand and anantisense strand; each strand is independently 15 to 30 nucleotides inlength; and the antisense strand comprises at least 15, 16, 17, 18, or19 nucleotides having sequence complementary to any of:

(SEQ ID NO: 5) 5′-CUGUUGGAUUGAUUCGAAA-3′; (SEQ ID NO: 194)5′-ACGACUAGUUCAGUUGCUU-3′; (SEQ ID NO: 196) 5′-GGAUGAUCCUAGCUAUCGU-3′;or (SEQ ID NO: 151) 5′-CCAGGAUGAUCCUAGCUAU-3′.

In some embodiments of the invention, the antisense strand of a siNAmolecule comprises at least a 15, 16, 17, 18, or 19 nucleotide sequenceof

(SEQ ID NO: 4918) 5′-UUUCGAAUCAAUCCAACAG-3′; (SEQ ID NO: 5107)5′-AAGCAACUGAACUAGUCGU-3′; (SEQ ID NO: 5109) 5′-ACGAUAGCUAGGAUCAUCC-3′;or (SEQ ID NO: 5064) 5′-AUAGCUAGGAUCAUCCUGG-3′;

In some embodiments, the sense strand of a siNA molecule of theinvention comprises at least a 15, 16, 17, 18, or 19 nucleotide sequenceof:

(SEQ ID NO: 5) 5′-CUGUUGGAUUGAUUCGAAA-3′; (SEQ ID NO: 194)5′-ACGACUAGUUCAGUUGCUU-3′; (SEQ ID NO: 196) 5′-GGAUGAUCCUAGCUAUCGU-3′;or (SEQ ID NO: 151) 5′-CCAGGAUGAUCCUAGCUAU-3′.

In some embodiments, a siNA molecule of the invention comprises any of:

(SEQ ID NO: 5) 5′-CUGUUGGAUUGAUUCGAAA-3′ and (SEQ ID NO: 4918)5′-UUUCGAAUCAAUCCAACAG-3′; or (SEQ ID NO: 194) 5′-ACGACUAGUUCAGUUGCUU-3′and (SEQ ID NO: 5107) 5′-AAGCAACUGAACUAGUCGU-3′; or (SEQ ID NO: 196)5′-GGAUGAUCCUAGCUAUCGU-3′ and (SEQ ID NO: 5109)5′-ACGAUAGCUAGGAUCAUCC-3′; or (SEQ ID NO: 151) 5′-CCAGGAUGAUCCUAGCUAU-3′and (SEQ ID NO: 5064) 5′-AUAGCUAGGAUCAUCCUGG-3′.

In some embodiments, a siNA molecule of the invention comprises SEQ IDNOS: 6372 and 6374.

In some embodiments, a siNA molecule of the invention comprises SEQ IDNOS: 6370 and 6369.

In some embodiments, a siNA molecule of the invention comprises SEQ IDNOS: 2021 and 2068.

In some embodiments, a siNA molecule of the invention comprises SEQ IDNOS: 6372 and 6373.

In some embodiments, a siNA molecule of the invention comprises SEQ IDNOS: 2147 and 6368

In some embodiments, the invention features a composition comprising:

-   -   (a) a double-stranded short interfering nucleic acid (siNA) of        the invention;    -   (b) a cationic lipid compound having any of compound numbers        1-46 or any combination thereof:    -   (c) cholesterol:    -   (d) DSPC; and    -   (e) PEG-DMG.

In some embodiments, the invention features a composition comprising:

(a) a double-stranded short interfering nucleic acid (siNA) of theinvention;

(b) (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,1b-dien-1-amine;

(c) cholesterol;

(d) DSPC; and

(e) PEG-DMG.

In some embodiments, the invention features a composition comprising:

-   -   (a) a double-stranded short interfering, nucleic acid (siNA)        having SEQ ID NOS: 6372 and 6374;    -   (b) (13 Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine;    -   (c) cholesterol;    -   (d) DSPC; and    -   (e) PEG-DMG.

In some embodiments, she invention features a composition comprising:

-   -   (a) a double-stranded short interfering nucleic acid (siNA)        having SEQ ID NOS: 6370 and 6369;    -   (b) (13Z,6Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine;    -   (c) cholesterol;    -   (d) DSPC; and    -   (e) PEG-DMG.

In some embodiments, the invention features a composition comprising:

-   -   (a) a double-stranded short interfering nucleic acid (siNA)        having SEQ ID NOS: 2021 and 2068;    -   (b) (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine;    -   (c) cholesterol;    -   (d) DSPC; and    -   (e) PEG-DMG.

In some embodiments, the invention features a composition comprising:

-   -   (a) a double-stranded short interfering nucleic acid (siNA)        having SEQ ID NOS: 6372 and 6373;    -   (b) (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine;    -   (c) cholesterol;    -   (d) DSPC; and    -   (e) PEG-DIM.

In some embodiments, the invention features a composition comprising:

-   -   (a) a double-stranded short interfering nucleic acid (siNA)        having SEQ ID NOS: 2147 and 6368;    -   (b) (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine;    -   (c) cholesterol;    -   (d) DSPC; and    -   (e) PEG-DMG.

In some embodiments, a composition of the invention comprises anyCationic Lipid having any of compound numbers 1-46 in the followingmolar ratios:

Cationic Lipid/Cholesterol/PEG-DMG 56.6/38/5.4;

Cationic Lipid/Cholesterol/PEG-DMG 60/38/2;

Cationic Lipid/Cholesterol/PEG-DMG 67.3/29/3.7;

Cationic Lipid/Cholesterol/PEG-DMG 49.3/47/3.7;

Cationic Lipid/Cholesterol/PEG-DMG 50.3/44.3/5.4;

Cationic Lipid/Cholesterol/PEG-C-DMA/DSPC 40/48/2/10;

Cationic Lipid/Cholesterol/PEG-DMG/DSPC 40/48/2/10; and

Cationic Lipid/Cholesterol/PEG-DMG/DSPC 58/30/2/10.

In some embodiments, a composition of the invention comprises(13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, cholesterol,DSPC, and PEG-DMG, having a molar ratio of 50:30:10:2 respectively.

In some embodiments, a composition of the invention further comprises acryo-protectant. In some embodiments, the cryoprotectant is Sucrose,Trehalose, Raffinose, Stachyose, Verbascose, Mannitol, Glucose, Lactose,Maltose, Maltotriose-heptose, Dextran, hydroxyethyl Starch, Insulin,Sorbitol, Glycerol, Arginine, Histidine, Lysine, Praline,Dimethylsulfoxide or any combination thereof. In some embodiments, thecryoprotectant is Sucrose. In some embodiments, the cryoprotectant isTrehalose. In some embodiments, the cryoprotectant is a combination ofSucrose and Trehalose.

In some embodiments of the invention, all of the nucleotides of siNAs ofthe invention are unmodified. In other embodiments, one or more (e.g.,1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 26, 27, 28, 29, or 30) of the nucleotide positionsindependently in either one or both strands of an siNA molecule aremodified. Modifications include nucleic acid sugar modifications, basemodifications, backbone (internucleotide linkage) modifications,non-nucleotide modifications, and/or any combination thereof. In certaininstances, purine and pyrimidine nucleotides are differentiallymodified. For example, purine and pyrimidine nucleotides can bedifferentially modified at the 2′-sugar position (i.e., at least onepurine has a different modification from at least one pyrimidine in thesame or different strand at the 2′-sugar position). In certain instancesthe purines are unmodified in one or both strands, while the pyrimidinesin one or both strands are modified. In certain other instances, thepyrimidines are unmodified in one or both strands, while the purines inone or both strands are modified. In some instances, at least onemodified nucleotide is a 2′-deoxy-2′-fluoro nucleotide, a 2′-deoxynucleotide, or a 2′-O-alkyl nucleotide. In some instances, at least 5 ormore of the pyrimidine nucleotides in one or both stands are either all2′-deoxy-2′-fluoro or all 2′-O-methyl pyrimidine nucleotides. In someinstances, at least 5 or more of the purine nucleotides in one or bothstands are either all 2′-deoxy-2′-fluoro or all 2′-O-methyl purinenucleotides. In certain instances, wherein the siNA molecules compriseone or more modifications as described herein, the nucleotides atpositions 1, 2, and 3 at the 5′ end of the guide (antisense) strand areunmodified.

In certain embodiments, the siNA molecules of the invention have 3′overhangs of one, two, three, or tour nucleotide(s) on one or bath ofthe strands. In other embodiments, the siNA molecules lack overhangs(i.e., have blunt ends). Preferably, the siNA molecule has 3′ overhangsof two nucleotides on both the sense and antisense strands. Theoverhangs can be modified or unmodified. Examples of modifiednucleotides in the overhangs include, but are not limited to, 2′-O-alkylnucleotides, 2′-deoxy-2′-fluoro nucleotides, locked nucleic acid (LNA)nucleotides, or 2′-deoxy nucleotides. The overhang nucleotides in theantisense strand can comprise nucleotides that are complementary tonucleotides in the CTNNB1 target sequence. Likewise, the overhangs inthe sense stand can comprise nucleotides that are in the CTNNB1 targetsequence. In certain instances, the siNA molecules of the invention havetwo 3′ overhang nucleotides on the antisense stand that are 2′-O-alkyl(e.g., 2′-O-methyl) nucleotides and two 3′ overhang nucleotides on thesense stand that are 2′-deoxy nucleotides. In other instances, the siNAmolecules of the invention have two 3′ overhang nucleotides that are2′-O-alkyl 2′-O-methyl) nucleotides on both the antisense stand and onthe sense stand. In certain embodiments, the 2′-O-alkyl nucleotides are2′-O-methyl uridine nucleotides. In certain instances, the overhangsalso comprise one or more phosphorothioate linkages between nucleotidesof the overhang.

In some embodiments, the siNA molecules of the invention have caps (alsoreferred to herein as “terminal caps.” The cap can be present at the5′-terminus (5′-cap) or at the 3′-terminus (3′-cap) or can be present onboth termini, such as at the 5′ and 3′ termini of the sense strand ofthe siNA.

In some embodiments, the siNA molecules of the invention arephosphorylated at the 5′ end of the antisense strand. The phosphategroup can be a phosphate, a diphosphate or a triphosphate.

The siNA molecules of the invention when double stranded can besymmetric or asymmetric. Each strand of these double stranded siNAsindependently can range in nucleotide length between 3 and 30nucleotides. Generally, each strand of the siNA molecules of theinvention is about 15 to 30 (i.e., about 19, 20, 21, 22, 23 or 24)nucleotides in length.

The siNA molecules of the invention, which are double stranded or have aduplex structure, independently comprise about 3 to about 30 (e.g.,about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) base pairs. Generally, theduplex structure of siNAs of the invention is between 15 and 30, moregenerally between 18 and 25, yet more generally between 19 and 24, andmost generally between 19 and 21 base pairs in length.

In certain embodiments, double-stranded short interfering nucleic acid(siNA) molecules are provided, wherein the molecule has a sense strandand an antisense strand and comprises formula (A):

-   -   wherein, the upper strand is the sense strand and the lower        strand is the antisense strand of the double-stranded nucleic        acid molecule; wherein the antisense strand comprises at least a        15, 16, 17, 18, or 19 nucleotide sequence of SEQ ID NO: 4918,        SEQ ID NO: 5107, SEQ ID NO: 5109, or SEQ ID NO: 5064, and the        sense strand comprises a sequence having complementarity to the        antisense strand;    -   each N is independently a nucleotide which is unmodified or        chemically modified or a non-nucleotide;    -   each B is a terminal cap that is present or absent;    -   (N) represents overhanging nucleotides, each of which is        independently unmodified or chemically modified;    -   [N] represents nucleotides that are ribonucleotides;    -   X1 and X2 are independently integers from 0 to 4;    -   X3 is an integer from 15 to 30;    -   X4 is an integer from 9 to 30; and    -   X5 is an integer from 0 to 6, provided that the sum of X4 and X5        is 15-30.

In one embodiment, the invention features a double-stranded shortinterfering nucleic acid (siNA) of formula (A); wherein

-   -   (a) one or more pyrimidine nucleotides in N_(X4) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl        nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any        combination thereof,    -   (b) one or more purine nucleotides in N_(X4) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl        nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any        combination thereof;    -   (c) one or more pyrimidine nucleotides in N_(X3) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl        nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any        combination thereof; and    -   (d) one or more purine nucleotides in N_(X3) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl        nucleotides, 2′-deoxy nucleotides, ribonucleotides,

The present invention further provides compositions comprising thedouble-stranded nucleic acid molecules described herein with optionallya pharmaceutically acceptable carrier or diluent.

The administration of the composition can be carried out by knownmethods, wherein the nucleic acid is introduced into a desired targetcell in vitro or in vivo.

Commonly used techniques for introduction of the nucleic acid moleculesof the invention into cells, tissues, and organisms include the use ofvarious carrier systems, reagents and vectors. Non-limiting examples ofsuch carrier systems suitable for use in the present invention includeconjugates, nucleic-acid-lipid particles, lipid nanoparticles (LNP),liposomes, lipoplexes, micelles, virosomes, virus like particles (VLP),nucleic acid complexes, and mixtures thereof.

The compositions of the invention can be in the form of an aerosol,dispersion, solution (e.g., an injectable solution), a cream, ointment,tablet, powder, suspension or the like. These compositions may beadministered in any suitable way, e.g. orally, sublingually, buccally,parenterally, nasally, or topically. In some embodiments, thecompositions are aerosolized and delivered via inhalation.

The molecules and compositions of the present invention have utilityover a broad range of therapeutic applications. Accordingly anotheraspect of this invention relates to the use of the compounds andcompositions of the invention in treating a subject. The invention thusprovides a method for treating a subject, such as a human, sufferingfrom a condition which is mediated by the action, or by the loss ofaction, of CTNNB1, wherein the method comprises administering to thesubject an effective amount of a double-stranded short interferingnucleic acid (siNA) molecule of the invention. In certain embodiments,the condition is cancer.

These and other aspects of the invention will be apparent upon referenceto the following detailed description and attached figures. Moreover, itis contemplated that any method or composition described herein can beimplemented with respect to any other method or composition describedherein and that different embodiments may be combined.

Additionally, patents, patent applications, and other documents arecited throughout the specification to describe and more specifically setforth various aspects of this invention. Each of these references citedherein is hereby incorporated by reference in its entirety, includingthe drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a non-limiting proposed mechanistic representation oftarget RNA degradation involved in RNAi, Double-stranded RNA (dsRNA),which is generated by RNA-dependent. RNA polymerase (RdRP) from foreignsingle-stranded RNA, for example transposon, or other exogenous RNA,activates the DICER enzyme that in turn generates siNA duplexes.Alternately, synthetic or expressed siNA can be introduced directly intoa cell by appropriate means. An active siNA complex forms thatrecognizes a target RNA, resulting in degradation of the target RNA bythe RISC endonuclease complex or in the synthesis of additional RNA byRNA-dependent RNA polymerase (RdRP), which can activate DICER and resultin additional siNA molecules, thereby amplifying the RNAi response,

FIG. 2 shows non-limiting examples of chemically modified siNAconstructs of the present invention using a generalized structure of arepresentative siNA duplex. The specific modifications shown in thefigure can be utilized alone or in combination with other modificationsof the figure, in addition to other modifications and features describedherein with reference to any siNA molecule of the invention. In thefigure, N stands for any nucleotide or optionally a non-nucleotide asdescribed here. The upper strand, having B—N_(X3)—(N)_(X2)—B-3′ is thesense (or passenger) strand of the siNA, whereas the lower strand,having B(N)_(X1)—N_(X4)—[N]_(X5)-5′ is the antisense (or guide) strandof the siNA. Nucleotides (or optional non-nucleotides) of internalportions of the sense strand are designated N_(X3) and nucleotides (oroptional non-nucleotides) of internal portions of the antisense strandare designated N_(X4). Nucleotides (or optional non-nucleotides) of theinternal portions are generally base paired between the two strands, butcan optionally lack base pairing (e.g. have mismatches or gaps) in someembodiments. Nucleotides (or optional non-nucleotides) of overhangregions are designated by parenthesis (N). Nucleotides of the5′-terminal portion of the antisense strand are designated [N]. Terminalcaps are optionally present at the 5′ and/or 3′ end of the sense strandand further optionally present at the 3′-end of the antisense strand.Generally, each strand can independently range from about 15 to about 30nucleotides in length, but can vary depending on the presence of anyoverhang nucleotides. In certain embodiments, X1 and X2 areindependently integers front 0 to 4; X3 is an integer from 15 to 30; X4is an integer from 9 to 30; X5 is an integer from 0 to 6, provided thatthe sum of X4 and X5 is 15-30. Various modifications are shown for thenucleotides of the sense and antisense strands of the siNA constructs.The (N) overhang nucleotide positions can be chemically modified asdescribed herein (e.g., 2′-O-methyl, 2′-deoxy-2′-fluoro, 2′-deoxy, UNA,universal bases etc.) and can be either derived from a correspondingtarget nucleic acid sequence or not. The constructs shown in the figurecan also comprise phosphorothioate linkages as described herein. Forexample, phosphorothioate linkages can exist between any N, (N), and/or[N] positions. Such phosphorothioate incorporation can be utilizedbetween purine “R” and pyrimidine “Y” positions, or for stabilization ofpyrimidine linkages in general. Furthermore, although not depicted onthe Figure, the constructs shown in the figure can optionally include aribonucleotide at the 9^(th) position from the 5′-end of the sensestrand or the 11^(th) position based on the 5′-end of the guide strandby counting 11 nucleotide positions in from the 5′-terminus of the guidestrand. Similarly, the antisense strand can include a ribonucleotide atthe 14^(th) position from the 5′-end, or alternately can be selected ordesigned so that a 2′-O-alkyl nucleotide (e.g., a 2′-O-methyl purine) isnot present at this position. Furthermore, although not shown in theFigure, the 5′-terminal position of the antisense strand can comprise aterminal phosphate group as described herein. The antisense strandgenerally comprises sequence complementary to any target nucleic acidsequence of the invention, such as those set forth in Table 1a herein.

FIG. 3 shows non-limiting examples of certain combinations ofmodifications applied to the representative siNA, duplex described inFIG. 2 . The table shown below the representative structure providesspecific combinations of (N)_(X1), (N)_(X2), N_(X3), N_(X4), and/or[N]_(X5) nucleotide (and optional non-nucleotide) positions. Forexample, combinations of 5 or more (e.g., 5, 6, 7, 8, 9, or 10 or more)N_(X3) and 5 or more (e.g., 5, 6, 7, 8, 9, or 10 or more) N_(X4)pyrimidine “Y” and purine “R” nucleotides are specified, each of whichcan independently have specific (N)_(X1), and/or (N)_(X2), substitutionsas shown in the figure, in addition to optional phosphorothioatesubstitutions. The 5′-terminal antisense strand [N] nucleotides aregenerally ribonucleotides, but can also be modified or unmodifieddepending on if they are purine “R” or pyrimidine “Y” nucleotides

FIG. 4A-C shows non-limiting examples of different siNA constructs ofthe invention. The criteria of the representative structures shown inFIGS. 2 and 3 can be applied to any of the structures shown in FIG.4A-C.

The examples shown in FIG. 4A (constructs 1, 2, and 3) have 19representative base pairs; however, different embodiments of theinvention include any number of base pairs described herein. Bracketedregions represent nucleotide overhangs, for example, comprising about 1,2, 3, or 4 nucleotides in length, preferably about 2 nucleotides.Constructs 1 and 2 can be used independently for RNAi activity.Construct 2 can comprise a polynucleotide or non-nucleotide linker,which can optionally be designed as a biodegradable linker. In oneembodiment, the loop structure shown in construct 2 can comprise abiodegradable linker that results in the formation of construct 1 invivo and/or in vitro. In another example, construct 3 can be used togenerate construct 2 under the same principle wherein a linker is usedto generate the active siNA construct 2 in vivo and/or in vitro, whichcan optionally utilize another biodegradable linker to generate theactive siNA construct 1 in vivo and/or in vitro. As such, the stabilityand/or activity of the siNA constructs can be modulated based on thedesign of the siNA construct for use in vivo or in vitro and/or invitro.

The examples shown in FIG. 4B represent different variations ofdouble-stranded nucleic acid molecule of the invention, such asmicroRNA, that can include overhangs, bulges, loops, and stem-loopsresulting from partial complementarity. Such motifs having bulges,loops, and stem-loops are generally characteristics of miRNA. Thebulges, loops, and stem-loops can result from any degree of partialcomplementarily, such as mismatches or bulges of about 1, 2, 3, 4, 5, 6,7, 8, 9, 10 or more nucleotides in one or both strands of thedouble-stranded nucleic acid molecule of the invention.

The example shown in FIG. 4C represents a model double-stranded nucleicacid molecule of the invention comprising a 19 base pair duplex of two21 nucleotide sequences having dinucleotide 3′-overhangs. The top strand(1) represents the sense strand (passenger strand), the middle strand(2) represents the antisense (guide strand), and the lower strand (3)represents a target polynucleotide sequence. The dinucleotide overhangs(NN) can comprise a sequence derived from the target polynucleotide. Forexample, the 3′-(NN) sequence in the guide strand can be complementaryto the 5′-[NN] sequence of the target polynucleotide. In addition, the5′-(NN) sequence of the passenger strand can comprise the same sequenceas the 5′-[NN] sequence of the target polynucleotide sequence. In otherembodiments, the overhangs (NN) are not derived from the targetpolynucleotide sequence, for example where the 3′-(NN) sequence in theguide strand are not complementary to the 5′-[NN] sequence of the targetpolynucleotide and the 5′-(NN) sequence of the passenger strand cancomprise different sequence from the 5′-[NN] sequence of the targetpolynucleotide sequence. In additional embodiments, any (NN) nucleotidesare chemically modified, e.g., as 2′-O-methyl, 2′-deoxy-2′-fluoro,and/or other modifications herein. Furthermore, the passenger strand cancomprise a ribonucleotide position N of the passenger strand. For therepresentative 19 base pair 21 mer duplex shown, position N can be 9nucleotides in from the 3′ end of the passenger strand. However, induplexes of differing length, the position. N is determined based on the5′-end of the guide strand by counting 11 nucleotide positions in fromthe 5′-terminus of the guide strand and picking the corresponding basepaired nucleotide in the passenger strand. Cleavage by Agog takes placebetween positions 10 and 11 as indicated by the arrow. In additionalembodiments, there are two ribonucleotides, NN, at positions 10 and 11based on the 5′-end of the guide strand by counting 10 and 11 nucleotidepositions in from the 5′-terminus of the guide strand and picking thecorresponding base paired nucleotides in the passenger strand.

FIG. 5 shows non-limiting examples of different stabilizationchemistries (1-10) that can be used, for example, to stabilize the 5′and/or 3′-ends of siNA sequences of the invention, including (1)[3-3′]-inverted deoxyribose, (2) deoxyribonucleotide; (3)[5′-3′]-3′-deoxyribonucleotide; (4) [5′-3]-ribonucleotide; (5)[5′-3′]-3′-O-methyl ribonucleotide; (6) 3′-glyceryl; (7)[3′-5′]-3′-deoxyribonucleotide; (8) [3′-3′]-deoxyribonucleotide; (9)[5′-2′]-deoxyribonucleotide; and (10) [5′-3′]-dideoxyribonucleotide(when X═O). In addition to modified and unmodified backbone chemistriesindicated in the figure, these chemistries can be combined withdifferent sugar and base nucleotide modifications as described herein.

FIG. 6 shows a non-limiting example of a strategy used to identifychemically modified siNA constructs of the invention that are nucleaseresistant while preserving the ability to mediate RNAi activity.Chemical modifications are introduced into the siNA construct based oneducated design parameters (e.g. introducing 2′-modifications, basemodifications; backbone modifications, terminal cap modifications etc).The modified construct is tested in an appropriate system (e.g., humanserum for nuclease resistance, shown, or an animal model for PK/deliveryparameters). In parallel, the siNA construct is tested for RNAiactivity, for example in a cell culture system such as a luciferasereporter assay and/or against endogenous mRNA). Lead siNA constructs arethen identified which possess a particular characteristic whilemaintaining RNAi activity, and can be further modified and assayed onceagain. This same approach can be used to identify siNA-conjugatemolecules with improved pharmacokinetic profiles, delivery, and RNAiactivity.

FIG. 7 shows non-limiting examples of phosphotylated siNA molecules ofthe invention, including linear and duplex constructs and asymmetricderivatives thereof.

FIG. 8 shows non-limiting examples of chemically modified terminalphosphate groups of the invention.

FIG. 9 shows a non-limiting example of a cholesterol linkedphosphoramidite that can be used to synthesize cholesterol conjugatedsiNA molecules of the invention. An example is shown with thecholesterol moiety linked to the 5′-end of the sense strand of an siNAmolecule.

FIG. 10 depicts an embodiment of 5′ and 3′ inverted abasic cap linked toa nucleic acid strand.

DETAILED DESCRIPTION OF THE INVENTION A. Terms and Definitions

The following terminology and definitions apply as used in the presentapplication.

The term “abasic” as used herein refers to its meaning as is generallyaccepted in the art. The term generally refers to sugar moieties lackinga nucleobase or having a hydrogen atom (H) or other non-nucleobasechemical groups in place of a nucleobase at the position of the sugarmoiety, see for example Adamic et al., U.S. Pat. No. 5,998,203. In oneembodiment, an abasic moiety of the invention is a ribose, deoxyribose,or dideoxyribose sugar.

The term “acyclic nucleotide” as used herein refers to its meaning as isgenerally accepted in the art. The term generally refers to anynucleotide having an acyclic ribose sugar, for example where any of theribose carbon/carbon or carbon/oxygen bonds are independently or incombination absent from the nucleotide.

The term “alkyl” as used herein refers to its meaning as is generallyaccepted in the art. The term generally refers to a saturated orunsaturated hydrocarbons, including straight-chain, branched-chain,alkenyl, alkynyl groups and cyclic groups, but excludes aromatic groups.Notwithstanding the foregoing, alkyl also refers to non-aromaticheterocyclic: groups. Preferably, the alkyl group has 1 to 12 carbons.More preferably, it is a lower alkyl of from 1 to 7 carbons, morepreferably 1 to 4 carbons. The alkyl group can be substituted orunsubstituted. When substituted, the substituted group(s) is preferably,hydroxyl, halogen, cyano C1-C4 alkoxy, ═O, ═S, —NO₂, SH, NH₂, or NR₁R₂,where R₁ and R₂ independently are H or C1-C4 alkyl.

The phrase “agents that interfere with cell cycle checkpoints” refers tocompounds that inhibit protein kinases that transduce cell cyclecheckpoint signals, thereby sensitizing the cancer cell to DNA damagingagents.

The phrase “agents that interfere with receptor tyrosine kinases (RTKs)”refers to compounds that inhibit RTKs and therefore inhibit mechanismsinvolved in oncogenesis and tumor progression.

The phrase “androgen receptor modulators” refers to compounds thatinterfere or inhibit the binding of androgens to the receptor,regardless of mechanism.

The phrase “angiogenesis inhibitors” refers to compounds that inhibitthe formation of new blood vessels, regardless of mechanism.

The term “aryl” as used herein refers to its meaning as is generallyaccepted in the art. The term generally refers to an aromatic group thathas at least one ring having a conjugated pi electron system andincludes carbocyclic aryl, heterocyclic aryl and biaryl groups, all ofwhich can be optionally substituted. The preferred substituent(s) ofaryl groups are halogen, trihalomethyl, hydroxyl, SH, OH, cyano, C1-C4alkoxy, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, NH₂, and NR₁, R₂groups, where R₁ and R₂ independently are H or C1-C4

The term “alkylaryl” as used herein refers to its meaning as isgenerally accepted in the art. The term generally refers to an alkylgroup (as described above) covalently joined to an aryl group (asdescribed above). Carbocyclic aryl groups are groups wherein the ringatoms on the aromatic ring are all carbon atoms. The carbon atoms areoptionally substituted. Heterocyclic aryl groups are groups having from1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainderof the ring atoms are carbon atoms. Suitable heteroatoms include oxygen,sulfur, and nitrogen, and examples of heterocyclic aryl groups havingsuch heteroatoms include furanyl, thienyl, pyridyl, pyrrolyl, N-loweralkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, alloptionally substituted. Preferably, the alkyl group is a C1-C4 alkylgroup.

The term “amide” as used herein refers to its meaning as is generallyaccepted in the art. The term generally refers to an —C(O)—NH—R, where Ris either alkyl, aryl, alkylaryl or hydrogen.

The phrase “antisense region” as used herein refers to its meaning as isgenerally accepted in the art. With reference to exemplary nucleic acidmolecules of the invention, the term refers to a nucleotide sequence ofan siNA molecule having complementarity to a target nucleic acidsequence. In addition, the antisense region of an siNA molecule canoptionally comprise a nucleic acid sequence having complementarily to asense region of the siNA molecule. In one embodiment, the antisenseregion of the siNA molecule is referred to as the antisense strand orguide strand.

The phrase “asymmetric hairpin” refers to a linear siNA moleculecomprising an antisense region, a loop portion that can comprisenucleotides or non-nucleotides, and a sense region that comprises fewernucleotides than the antisense region to the extent that the senseregion has enough complementary nucleotides to base pair with theantisense region and form a duplex with loop. For example, an asymmetrichairpin siNA molecule or the invention can comprise an antisense regionhaving length sufficient to mediate RNAi in a cell or in vitro system(e.g. about 15 to about 30, or about 15, 16, 17, 18, 19, 20, 21, 22, 23,24, 25, 26, 27, 28, 29, or 30 nucleotides) and a loop region comprisingabout 4 to about 12 (e.g., about 4, 5, 6, 7, 8, 9, 10, 11, or 12)nucleotides, and a sense region having about 3 to about 25 (e.g., about3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, or 25) nucleotides that are complementary to the antisenseregion. The asymmetric hairpin siNA molecule can also comprise a5′-terminal phosphate group that can be chemically modified. The loopportion of the asymmetric hairpin siNA molecule can comprisenucleotides, non-nucleotides, linker molecules, or conjugate moleculesas described herein.

The term “biodegradable” as used herein refers to its meaning as isgenerally accepted in the art. The term generally refers to degradationin a biological system, for example, enzymatic degradation or chemicaldegradation.

The term “biodegradable linker” as used herein refers to its meaning asis generally accepted in the art. With reference to exemplary nucleicacid molecules of the invention, the term refers to a linker moleculethat is designed to connect one molecule to another molecule, and whichis susceptible to degradation in a biological system. The linker can bea nucleic acid or non-nucleic acid based linker. For example, abiodegradable linker can be used to attach a ligand or biologicallyactive molecule to an siNA molecule of the invention. Alternately,biodegradable linker can be used to connect the sense and antisensestrands of an siNA molecule of the invention. The biodegradable linkeris designed such that its stability can be modulated for a particularpurpose, such as delivery to a particular tissue or cell type. Thestability of a nucleic acid-based biodegradable linker molecule can bemodulated by using various chemistries, for example combinations ofribonucleotides, deoxyribonucleotides, and chemically modifiednucleotides, such as 2′-O-methyl, 2′-fluoro, 2′-amino, 2′-O-amino,T-C-allyl, 2′-O-allyl, and other 2′-modified or base modifiednucleotides. The biodegradable nucleic acid linker molecule can be adirtier, trimer, tetramer or longer nucleic acid molecule, for example,an oligonucleotide of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, or 20 nucleotides in length, or can comprise asingle nucleotide with a phosphorus-based linkage, for example, aphosphoramidate or phosphodiester linkage. The biodegradable nucleicacid linker molecule can also comprise nucleic acid backbone, nucleicacid sugar, or nucleic acid base modifications.

The phrase “biologically active molecule” as used herein refers to itsmeaning as is generally accepted in the art. With reference to exemplarynucleic acid molecules of the invention, the term refers to compounds ormolecules that are capable of eliciting or modifying a biologicalresponse in a system and/or are capable of modulating thepharmacokinetics and/or pharmacodynamics of other biologically activemolecules. Examples of biologically active molecules, include siNAmolecules alone or in combination with other molecules including, butnot limited to therapeutically active molecules such as antibodies,cholesterol, hormones, antivirals, peptides, proteins,chemotherapeutics, small molecules, vitamins, co-factors, nucleosides,nucleotides, oligonucleotides, enzymatic nucleic acids, antisensenucleic acids, triplex forming oligonucleotides, polyamines, polyamides,polyethylene glycol, other polyethers, 2-5A chimeras, siNA, dsRNA,allozymes, aptamers, decoys and analogs thereof.

The phrase “biological system” as used herein refers to its meaning asis generally accepted in the art. The term generally refers to material,in a purified or unpurified form, from biological sources including, butnot limited to, human or animal, wherein the system comprises thecomponents required for RNAi activity. Thus, the phrase includes, forexample, a cell, tissue, subject, or organism, or extract thereof. Theterm also includes reconstituted material from a biological source.

The phrase “blunt end” as used herein refers to its meaning as isgenerally accepted in the art. With reference to exemplary nucleic acidmolecules of the invention, the term refers to termini of adouble-stranded siNA molecule having no overhanging nucleotides. Forexample, the two strands of a double-stranded siNA molecule having bluntends align with each other with matched base-pairs without overhangingnucleotides at the termini. A siNA duplex molecule of the invention cancomprise blunt ends at one or both termini of the duplex, such astermini located at the 5′-end of the antisense strand, the 5′-end of thesense strand, or both termini of the duplex.

The term “cap” also referred to herein as “terminal cap,” as used hereinrefers to its meaning as is generally accepted in the art. Withreference to exemplary nucleic acid molecules of the invention, the termrefers to a moiety, which can be a chemically modified nucleotide ornon-nucleotide that can be incorporated at one or more termini of one ormore nucleic acid molecules of the invention. These terminalmodifications protect the nucleic acid molecule from exonucleasedegradation, and can help in delivery and/or localization within a cell.The cap can be present at the 5′-terminus (5′-cap) or at the 3′-terminal(3′-cap) or can be present on both termini of any nucleic acid moleculeof the invention. A cap can be present at the 5′-end, 3-end and/or 5′and 3′-ends of the sense strand of a nucleic acid molecule of theinvention. Additionally, a cap can optionally be present at the 3′-endof the antisense strand of a nucleic acid molecule of the invention. Innon-limiting examples, the 5′-cap includes, but is not limited to, LNA;glyceryl; inverted deoxy abasic residue (moiety); 4°,5′-methylenenucleotide; 1-(beta-D-erythrofuranosyl) nucleotide, 4′-thio nucleotide;carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides;alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage;threo-pentofuranosyl nucleotide; acyclic 3′,4′-seco nucleotide; acyclic3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide;3′-3′-inverted nucleotide moiety; 3′-3′-inverted abasic moiety;3′-2′-inverted nucleotide moiety; 3′-2′-inverted abasic moiety;1,4-butanediol phosphate; 3′-phosphoramidate; hexylphosphate; aminohexylphosphate; 3′-phosphate; 3′-phosphorothioate; phosphorodithioate; orbridging or non-bridging methylphosphonate moiety. Non-limiting examplesof the 3′-cap include, but are not limited to, LNA; glyceryl; inverteddeoxy abasic residue (moiety); 4′, 5′-methylene nucleotide;1-(beta-D-erythrofuranosyl) nucleotide; 4′-thio nucleotide; carbocyclicnucleotide; 5′-amino-alkyl phosphate; 1,3-diamino-2-propyl phosphate;3-aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aminododecylphosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide;nucleotide; alpha-nucleotide; modified base nucleotide;phosphorodithioate; threo-pentofuranosyl nucleotide; acyclic 3′,4′-seconucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentylnucleotide, 5′-5′-inverted nucleotide moiety; 5′-5′-inverted abasicmoiety; 5′-phosphoramidate; 5′-phosphorothioate; 1,4-butanediolphosphate; 5′-amino; bridging and/or non-bridging 5′-phosphoramidate;phosphorothioate and/or phosphorodithioate; bridging or non bridgingmethylphosphonate; and 5′-mercapto moieties (for more details seeBeaucage and Iyer, 1993, Tetrahedron 49, 1925; incorporated by referenceherein). FIG. 5 shows some non-limiting examples of various caps.

The term “cell” as used herein refers to its meaning as is generallyaccepted in the art. With reference to exemplary nucleic acid moleculesof the invention, the term is used in its usual biological sense, anddoes not refer to an entire multicellular organism, e.g., specificallydoes not refer to a human being. The cell can be present in an organism,e.g., birds, plants and mammals, such as humans, cows, sheep, apes,monkeys, swine, dogs, and cats. The cell can be prokaryotic (e.g.,bacterial cell) or eukaryotic (e.g., mammalian or plant cell). The cellcan be of somatic or germ line origin, totipotent or pluripotent,dividing or non-dividing. The cell can also be derived from or cancomprise a gamete or embryo, a stem cell, or a fully differentiatedcell.

The phrase “chemical modification” as used herein refers to its meaningas is generally accepted in the art. With reference to exemplary nucleicacid molecules of the invention, the term refers to any modification ofthe chemical structure of the nucleotides that differs from nucleotidesof native siRNA or RNA in general. The term “chemical modification”encompasses the addition, substitution, or modification of native siRNAor RNA at the sugar, base, or internucleotide Linkage, as describedherein or as is otherwise known in the art. In certain embodiments, theterm “chemical modification” can refer to certain forms of RNA that arenaturally occurring in certain biological systems, for example2′-O-methyl modifications or inosine modifications.

The term “CTNNB1” refers to catering (cadherin-associated protein), beta1 which is gene that encodes CTNNB1 proteins, CTNNB1 peptides, CTNNB1polypeptides, CTNNB1 regulatory polynucleotides CTNNB1 miRNAs andsiNAs), mutant CTNNB1 genes, and splice variants of a CTNNB1 genes, aswell as other genes involved in CTNNB1 pathways of gene expressionand/or activity. Thus, each of the embodiments described herein withreference to the term “CTNNB1” are applicable to all of the protein,peptide, polypeptide, and/or polynucleotide molecules covered by theterm “CTNNB1”, as that term is defined herein. Comprehensively, suchgene targets are also referred to herein generally as “target” sequences(including the target sequences listed in Table 1a).

The term “complementarity” or “complementary” as used herein refers toits meaning as is generally accepted in the art. With reference toexemplary nucleic acid molecules of the invention, the terms generallyrefer to the formation or existence of hydrogen bond(s) between onenucleic acid sequence and another nucleic acid sequence by eithertraditional Watson-Crick or other non-traditional types of bonding asdescribed herein. In reference to the nucleic molecules of the presentinvention, the binding free energy for a nucleic acid molecule with itscomplementary sequence is sufficient to allow the relevant function ofthe nucleic acid to proceed, e.g., RNAi activity. Determination ofbinding free energies for nucleic acid molecules is well known in theart (see, e.g., Turner et al., 1987, CSII Symb. Quant. Biol. LII pp.123-133; Frier et al., 1986, Proc. Nat. Acad. Sci. USA 83:9373-9377;Turner et al., 1987, J. Am. Chem. Soc. 109:3783-3785). Perfectcomplementary means that all the contiguous residues of a nucleic acidsequence will hydrogen bond with the same number of contiguous residuesin a second nucleic acid sequence. Partial complementarity can includevarious mismatches or non-based paired nucleotides (e.g., 1, 2, 3, 4, 5,6, 7, 8, 9, 10 or more mismatches, non-nucleotide linkers, or non-basedpaired nucleotides) within the nucleic acid molecule, which can resultin bulges, loops, or overhangs that result between the sense strand orsense region and the antisense strand or antisense region of the nucleicacid molecule or between the antisense strand or antisense region of thenucleic acid molecule and a corresponding target nucleic acid molecule.Such partial complementarity can be represented by a % complementaritythat is determined by the number of non-base paired nucleotides, i.e.,about 50%, 60%, 70%, 80%, 90% etc, depending on the total number ofnucleotides involved. Such partial complementarity is permitted to theextent that the nucleic acid molecule (e.g., siNA) maintains itsfunction, for example the ability to mediate sequence specific RNAi.

The terms “composition” or “formulation” as used herein refer to theirgenerally accepted meaning in the art. These terms generally refer to acomposition or formulation, such as in a pharmaceutically acceptablecarrier or diluent, in a form suitable for administration, e.g.,systemic or local administration, into a cell or subject, including, forexample, a human. Suitable forms, in part, depend upon the use or theroute of entry, for example oral, transdermal, inhalation, or byinjection. Such forms should not prevent the composition or formulationfrom reaching a target cell (i.e., a cell to which the negativelycharged nucleic acid is desirable for delivery). For example,compositions injected into the blood stream should be soluble. Otherfactors are known in the art, and include considerations such astoxicity and forms that prevent the composition or formulation fromexerting its effect. As used herein, pharmaceutical formulations includeformulations for human and veterinary use. Non-limiting examples ofagents suitable for formulation with the nucleic acid molecules of theinstant invention include: Lipid Nanoparticles (see for example Sempleet al., 2010, Nat Biotechnol., February; 28(2):172-6); P-glycoproteininhibitors (such as Pluronic P85); biodegradable polymers, such as poly(DL-lactide-coglycolide) microspheres for sustained release delivery(Einerich, D F et al, 1999, Cell Transplant, 8, 47-58); and loadednanoparticles, such as those made of polybutylcyanoacrylate. Othernon-limiting examples of delivery strategies for the nucleic acidmolecules of the instant invention include material described in Boadoet al., 1998, J. Pharm. Sci., 87, 1308-1315; Tyler et al., 1999, FEBSLett., 421, 280-284; Pardridge et al., 1995, PNAS USA., 92, 5592-5596;Boado, 1995, Adv. Drug Delivery Rev., 15, 73-107; Aldrian-Herrada etal., 1998, Nucleic Acids Res., 26, 4910-4916; and Tyler et al., 1999,PNAS USA., 96, 7053-7058. A “pharmaceutically acceptable composition” or“pharmaceutically acceptable formulation” can refer to a composition orformulation that allows fir the effective distribution of the nucleicacid molecules of the instant invention to the physical location mostsuitable for their desired activity.

The phrase “cytotoxic/cytostatic agents” refer to compounds that causecell death or inhibit cell proliferation primarily by interferingdirectly with the cell's functioning or inhibit or interfere with cellmytosis, including alkylating agents, tumor necrosis factors,intercalators, hypoxia activatable compounds, microtubule inhibitors;microtubule-stabilizing agents, inhibitors of mitotic kinesins,inhibitors of histone deacetylase, inhibitors of kinases involved inmitotic progression, antimetabolites; biological response modifiers;hormonal/anti-hormonal therapeutic agents, hematopoetic growth factors,monoclonal antibody targeted therapeutic agents, topoisomeraseinhibitors, proteasome inhibitors and ubiquitin ligase inhibitors.

The phrase “estrogen receptor modulators” refers to compounds thatinterfere with or inhibit the binding of estrogen to the receptor,regardless of mechanism.

The term “gene” or “target gene” as used herein refers to their meaningas is generally accepted in the art. The terms generally refer a nucleicacid (e.g., DNA or RNA) sequence that comprises partial length or entirelength coding sequences necessary for the production of a polypeptide.The target gene can also include the UTR or non-coding region of thenucleic acid sequence. A gene or target gene can also encode afunctional RNA (fRNA) or non-coding RNA (ncRNA), such as small temporalRNA (stRNA), micro RNA (miRNA), small nuclear RNA (snRNA), shortinterfering RNA (siRNA), small nucleolar RNA (snRNA), ribosomal RNA(rRNA), transfer RNA (tRNA) and precursor RNAs thereof. Such non-codingRNAs can serve as target nucleic acid molecules fir siNA mediated RNAinterference in modulating the activity of fRNA or ncRNA involved infunctional or regulatory cellular processes. Aberrant fRNA or ncRNAactivity leading to disease can therefore be modulated by siNA moleculesof the invention. siNA molecules targeting fRNA and ncRNA can also beused to manipulate or alter the genotype or phenotype of a subject,organism or cell, by intervening in cellular processes such as geneticimprinting, transcription, translation, or nucleic acid processing(e.g., transamination, methylation etc.). The target gene can be a genederived from a cell, an endogenous gene, a transgene, or exogenous genessuch as genes of a pathogen, for example a virus, which is present inthe cell after infection thereof. The cell containing the target genecan be derived from or contained in any organism, for example a plant,animal, protozoan, virus, bacterium, or fungus. Non-limiting examples ofplants include monocots, divots, or gymnosperms. Non-limiting examplesof animals include vertebrates or invertebrates. Non-limiting examplesof fungi include molds or yeasts. For a review, see for example Snyderand Gerstein, 2003, Science, 300, 258-260.

The phrase “HMG-CoA reductase inhibitors” refers to inhibitors of3-hydroxy-3-methylglutaryl-CoA reductase. The term HMG-CoA reductaseinhibitor as used herein includes all pharmaceutically acceptablelactone and open-acid forms (i.e., where the lactone ring is opened toform the free acid) as well as salt and ester forms of compounds thathave HMG-CoA reductase inhibitory activity, and therefore the use ofsuch salts, esters, open-acid and lactone forms is included within thescope of this invention.

The phrase “homologous sequence” as used herein refers to its meaning asis generally accepted in the art. The term generally refers a nucleotidesequence that is shared by one or more polynucleotide sequences, such asgenes, gene transcripts and/or non-coding polynucleotides. For example,a homologous sequence can be a nucleotide sequence that is shared by twoor more genes encoding related but different proteins, such as differentmembers of a gene family, different protein epitopes, different proteinisoforms or completely divergent genes. A homologous sequence can be anucleotide sequence that is shared by two or more non-codingpolynucleotides, such as noncoding DNA or RNA, regulatory sequences,introns, and sites of transcriptional control or regulation. Homologoussequences can also include sequence regions shared by more than onepolynucleotide sequence. Homology does not need to be perfect identity(100%), as partially homologous sequences are also contemplated by andwithin the scope of the instant invention (e.g., at least 95%, 94%, 93%,92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80% etc.).Percent homology is the number of matching nucleotides between twosequences divided by the total length being compared, multiplied by 100.

The phrase “improved RNAi activity” refers to an increase in RNAiactivity measured in vitro and/or in vivo, where the RNAi activity is areflection of both the ability of the siNA to mediate RNAi and thestability of the siNAs of the invention. In this invention, the productof these activities can be increased in vitro and/or in vivo compared toan all RNA siNA or an siNA containing a plurality of ribonucleotides. Insome cases, the activity or stability of the siNA molecule can bedecreased (i.e., less than ten-fold), but the overall activity of thesiNA molecule is enhanced in vitro and/or in vivo.

The terms “inhibit,” “down-regulate,” or “reduce” as used herein refersto its meaning as is generally accepted in the art. With reference toexemplary nucleic acid molecules of the invention, he term generallyrefers the reduction in the expression of the gene, or level of RNAmolecules or equivalent RNA molecules encoding one or more proteins orprotein subunits, or activity of one or more proteins or proteinsubunits, below that observed in the absence of the nucleic acidmolecules (e.g., siNA) of the invention. Down-regulation can also beassociated with post-transcriptional silencing, such as, RNAi mediatedcleavage or by alteration in DNA methylation patterns or DNA chromatinstructure. Inhibition, down-regulation or reduction with an siNAmolecule can be in reference to an inactive molecule, an attenuatedmolecule, an siNA molecule with a scrambled sequence, or an siNAmolecule with mismatches or alternatively, it cart be in reference tothe system in the absence of the nucleic acid.

The phrase “inhibitors of cell proliferation and survival signalingpathway” refers to pharmaceutical agents that inhibit cell surfacereceptors and signal transduction cascades downstream of those surfacereceptors.

The term “integrin blockers” refers to compounds which selectivelyantagonize, inhibit or counteract binding of a physiological ligand tothe α_(ω)β₃ integrin, to compounds which selectively antagonize, inhibitor counteract binding of a physiological ligand to the α_(ω)β₅ integrin,to compounds which antagonize, inhibit or counteract binding of aphysiological ligand to both the α_(ω)β₃ integrin and the α_(ω)β₅integrin, and to compounds which antagonize, inhibit or counteract theactivity of the particular integrin(s) expressed on capillaryendothelial cells. The term also refers to antagonists of the α_(ω)β₆α_(ω)β₈ α₁β₁ α₂β₁ α₅β₁ α₆β₁ and α₆β₄ integrins. The term also refers toantagonists of any combination of α_(ω)β₃, α_(ω)β₅, α_(ω)β₆ α_(ω)β₈ α₁β₁α₂β₁ α₅β₁ α₆β₁ and α₆β₄ integrins.

The terms “intermittent” or “intermittently” as used herein refers toits meaning as is generally accepted in the art. The term generallyrefers to periodic stopping and starting at either regular or irregularintervals.

The terms “internucleoside linkage” or “internucleoside linker” or“internucleotide linkage” or “internucleotide linker” are used hereininterchangeably and refer to any linker or linkage between twonucleoside units, as is known in the art, including, for example, butnot limitation, phosphate, analogs of phosphate, phosphonate, guanidium,hydroxylamine, hydroxylhydrazinyl, amide, carbamate, alkyl, andsubstituted alkyl linkages. The internucleoside linkages constitute thebackbone of a nucleic acid molecule.

The terms “mammalian” or “mammal” as used herein refers to its meaningas is generally accepted in the art. The term generally refers to anywarm blooded vertebrate species, such as a human, mouse, rat, dog, cat,hamster, guinea pig, rabbit, livestock, and the like.

The phrase “metered dose inhaler” or MDI refers to a unit comprising acan, a secured cap covering the can and a formulation metering valvesituated in the cap, MDI systems includes a suitable channeling device.Suitable channeling devices comprise for example, a valve actuator and acylindrical or cone-like passage through which medicament can bedelivered from the filled canister via the metering valve to the nose ormouth of a patient such as a mouthpiece actuator.

The term “microRNA” or “miRNA” as used herein refers to its meaning asis generally accepted in the art. The term generally refers a smalldouble-stranded RNA that regulates the expression of target messengerRNAs either by mRNA cleavage, translational repression/inhibition orheterochromatic silencing (see for example Ambros, 2004, Nature, 431,350-355; Bartel, 2004, Cell, 116, 281-297; Cullen, 2004, VirusResearch., 102, 3-9; He et al., 2004, Nat. Rev. Genet., 5, 522-531; Wingat al., 2004, Gene, 342, 25-28; and Sethupathy et al., 2006, RNA,12:192-197).

The term “modulate” as used herein refers to its meaning as is generallyaccepted in the art. With reference to exemplary nucleic acid moleculesof the invention, the term refers to when the expression of a gene, orlevel of one or more RNA molecules (coding or non-coding), or activityof one or more RNA molecules or proteins or protein subunits, isup-regulated or down-regulated, such that expression, level, or activityis greater than or less than that observed in the absence of themolecule that effects modulation. For example, the term “modulate” insome embodiments can refer to inhibition and in other embodiments canrefer to potentiation or up-regulation, e.g., of gene expression.

The phrase “modified nucleotide” as used herein refers to its meaning asis generally accepted in the art. The term generally refers anucleotide, which contains a modification in the chemical structure ofthe base, sugar and/or phosphate of the unmodified (or natural)nucleotide as is generally known in the art. Non-limiting examples ofmodified nucleotides are described herein and in U.S. application Ser.No. 12/064,014.

The phrase “NSAIDs that are selective COX-2 inhibitors” for purposesherein, refers to NSAIDs, which possess a specificity for inhibitingCOX-2 over COX-1 of at least 100 fold as measured by the ratio of IC₅₀for COX-2 over IC₅₀ for COX-1 evaluated by cell or microsomal assays.

The phrase “non-base paired” refers to nucleotides that are not basepaired between the sense strand or sense region and the antisense strandor antisense region of an double-stranded siNA molecule; and can includefor example, but not limitation, mismatches, overhangs, single strandedloops, etc.

The term “non-nucleotide” refers to any group or compound which can beincorporated into a nucleic acid chain in the place of one or morenucleotide units, such as for example hut not limitation abasic moietiesor alkyl chains. The group or compound is “abasic” in that it does notcontain a commonly recognized nucleotide base, such as adenosine,guanine, cytosine, uracil or thymine and therefore lacks a nucleobase atthe 1′-position.

The term “nucleotide” is used as is generally recognized in the art.Nucleotides generally comprise a nucleobase, a sugar, and aninternucleoside linkage, e.g., a phosphate. The base can be a naturalbases (standard), modified bases, or a base analog, as are well known inthe art. Such bases are generally located at the 1′ position of anucleotide sugar moiety. Additionally, the nucleotides can be unmodifiedor modified at the sugar, internucleoside linkage, and/or base moiety,(also referred to interchangeably as nucleotide analogs, modifiednucleotides, non-natural nucleotides, non-standard nucleotides andothers; see, for example, U.S. application Ser. No. 12/064,014.

The term “overhang” as used herein refers to its meaning as is generallyaccepted in the art. With reference to exemplary double stranded nucleicacid molecules, the term generally refers to the terminal portion of anucleotide sequence that is not base paired between the two strands of adouble-stranded nucleic acid molecule (see for example, FIG. 4 ).Overhangs, when present, are typically at the 3′-end of one or bothstrands in a siNA duplex.

The term “parenteral” as used herein refers to its meaning as isgenerally accepted in the art. The term generally refers methods ortechniques of administering a molecule, drug, agent, or compound in amanner other than through the digestive tract, and includesepicutaneous, subcutaneous, intravascular (e.g., intravenous),intramuscular, or intrathecal injection or infusion techniques and thelike.

The phrase “pathway target” refers to any target involved in pathways ofgene expression or activity. For example, any given target can haverelated pathway targets that can include upstream, downstream, ormodifier genes in a biologic pathway. These pathway target genes canprovide additive or synergistic effects in the treatment of diseases,conditions, and traits herein.

The term “phosphorothioate” refers to an internucleotide phosphatelinkage comprising one or more sulfur atoms in place of an oxygen atom.Hence, the term phosphorothioate refers to both phosphorothioate andphosphorodithioate internucleotide linkages.

“Prenyl-protein transferase inhibitor” refers to a compound thatinhibits any one or any combination of the prenyl-protein transferaseenzymes, including farnesyl-protein transferase (FPTase),geranylgeranyl-protein transferase type I (GGPTase-I), andgeranylgeranyl-protein transferase type-II (GGPTase-II, also called RabGGPTase).

The phrase “retinoid receptor modulators” refers to compounds thatinterfere or inhibit the binding of retinoids to the receptor,regardless of mechanism.

The term “ribonucleotide” as used herein refers to its meaning as isgenerally accepted in the art. The term generally refers to a nucleotidewith a hydroxyl group at the 2′ position of a β-D-ribofuranose moiety.

The term “RNA” as used herein refers to its generally accepted meaningin the art. Generally, the term RNA refers to a molecule comprising atleast one ribofuranoside moiety. The term can include double-strandedRNA, single-stranded RNA, isolated RNA such as partially purified RNA,essentially pure RNA, synthetic RNA, recombinantly produced RNA, as wellas altered RNA that differs from naturally occurring RNA by theaddition, deletion, substitution and/or alteration of one or morenucleotides. Such alterations can include addition of non-nucleotidematerial, such as to the end(s) of the siNA or internally, for exampleat one or more nucleotides of the RNA. Nucleotides in the RNA moleculesof the instant invention can also comprise non-standard nucleotides,such as non-naturally occurring nucleotides or chemically synthesizednucleotides or deoxynucleotides. These altered RNAs can be referred toas analogs or analogs of naturally-occurring RNA.

The phrase “RNA interference” or term “RNAi.” refer to the biologicalprocess of inhibiting or down regulating gene expression in a cell, asis generally known in the art, and which is mediated by shortinterfering nucleic acid molecules, see for example Zamore and Haley,2005, Science, 309, 1519-1524; Vaughn and Martienssen, 2005, Science,309, 1525-1526; Zamore et al., 2000, Cell, 101, 25-33; Bass, 2001,Nature, 411, 428-429; Elbashir et al., 2001, Nature, 411, 191-498; andKreutzer et al., international PCT Publication No. WO 00/14895;Zernieka-Goetz et al., International PCT Publication No. WO 01/36646;Fire, International PCT Publication No. WO 99/32619; Plaetinck et al.,International PCT Publication No. WO 00/01846; Mello and Fire,International PCT Publication No. WO 01/29058; Deschamps-Depaillette,International PCT Publication No. WO 99/07409; and Li et internationalPCT Publication No. WO 00/44914; Allshire, 2002. Science, 297,1818-1819; Volpe et al., 2002, Science, 297, 1833-1837; Jenuwein, 2002,Science, 297, 2215-2218; and Hall et al., 2002, Science, 297, 2232-2237;Hutvagner and Zamore, 2002. Science, 297, 2056-60; McManus et al., 2002,RNA, 8, 842-850; Reinhart et al., 2002, Gene & Lev., 16, 1616-1626; andReinhart & Bartel, 2002, Science, 297, 1831). Additionally, the termRNAi is meant to be equivalent to other terms used to describe sequencespecific RNA interference, such as post transcriptional gene silencing,translational inhibition, transcriptional inhibition, or epigenetics.For example, siNA molecules of the invention can be used toepigenetically silence genes at either the post-transcriptional level orthe pre-transcriptional level. In a non-limiting example, epigeneticmodulation of gene expression by siNA molecules of the invention canresult from siNA mediated modification of chromatin structure ormethylation patterns to alter gene expression (see, for example, Verdelet al., 2004, Science, 303, 672-676; Pal-Bhadra et al., 2004, Science,303, 669-672; Alishire, 2002, Science, 297, 1818-1819; Volpe et al.,2002, Science, 297, 1833-1837; Jenuwein, 2002, Science, 297, 2215-2218;and Hall et al., 2002, Science, 297, 2232-2237). In another non-limitingexample, modulation of gene expression by siNA molecules of theinvention can result from siNA mediated cleavage of RNA (either codingor non-coding RNA) via RISC, or via translational inhibition, as isknown in the art or modulation can result from transcriptionalinhibition (see for example Janowski et al., 2005, Nature ChemicalBiology, 1, 216-222).

The phrase “RNAi inhibitor” refers to any molecule that can downregulate, reduce or inhibit RNA interference function or activity in acell or organism. An RNAi inhibitor can down regulate, reduce orinhibit. RNAi (e.g., RNAi mediated cleavage of a target polynucleotide,translational inhibition, or transcriptional silencing) by interactionwith or interfering with the function of any component of the RNAipathway, including protein components such as RISC, or nucleic acidcomponents such as miRNAs or siRNAs. A RNAi inhibitor can be an siNAmolecule, an antisense molecule, an aptamer, or a small molecule thatinteracts with or interferes with the function of RISC, a miRNA, or ansiRNA or any other component of the RNAi pathway in a cell or organism.By inhibiting RNAi (e.g., RNAi mediated cleavage of a targetpolynucleotide, translational inhibition, or transcriptional silencing),a RNAi inhibitor of the invention can be used to modulate (e.g.,up-regulate or down regulate) the expression of a target gene.

The phrase “sense region” as used herein refers to its meaning as isgenerally accepted in the art. With reference to exemplary nucleic acidmolecules of the invention, the term refers to a nucleotide sequence ofan siNA molecule having complementarity to an antisense region of thesiNA molecule. In addition, the sense region of an siNA molecule cancomprise a nucleic acid sequence having homology or sequence identitywith a target nucleic acid sequence. In one embodiment, the sense regionof the siNA molecule is also referred to as the sense strand orpassenger strand.

The phrases “short interfering nucleic acid”, “siNA”, “short interferingRNA”, “siRNA”, “short interfering nucleic acid molecule”, “shortinterfering oligonucleotide molecule”, or “chemically modified shortinterfering nucleic acid molecule” refer to any nucleic acid moleculecapable of inhibiting or down regulating gene expression or viralreplication by mediating RNA interference (“RNAi”) or gene silencing ina sequence-specific manner. These terms can refer to both individualnucleic acid molecules, a plurality of such nucleic acid molecules, orpools of such nucleic acid molecules. The siNA can be a double-strandednucleic acid molecule comprising self-complementary sense and antisensestrands, wherein the antisense strand comprises a nucleotide sequencethat is complementary to a nucleotide sequence in a target nucleic acidmolecule or a portion thereof and the sense strand comprises anucleotide sequence corresponding to the target nucleic acid sequence ora portion thereof. The siNA can be a polynucleotide with a duplex,asymmetric duplex, hairpin or asymmetric hairpin secondary structure,having self-complementary sense and antisense regions, wherein theantisense region comprises a nucleotide sequence that is complementaryto a nucleotide sequence in a separate target nucleic acid molecule or aportion thereof and the sense region comprises a nucleotide sequencecorresponding to the target nucleic acid sequence or a portion thereof.The siNA can be a circular single-stranded polynucleotide having two ormore loop structures and a stem comprising self-complementary sense andantisense regions, wherein the antisense region comprises nucleotidesequence that is complementary to a nucleotide sequence in a targetnucleic acid molecule or a portion thereof and the sense regioncomprises a nucleotide sequence corresponding to the target nucleic acidsequence or a portion thereof, and wherein the circular polynucleotidecan be processed either in vivo or in vitro to generate an active siNAmolecule capable of mediating RNAi. The siNA can also comprise asingle-stranded polynucleotide having a nucleotide sequencecomplementary to nucleotide sequence in a target nucleic acid moleculeor a portion thereof (for example, where such siNA molecule does notrequire the presence within the siNA molecule of a nucleotide sequencecorresponding to the target nucleic acid sequence or a portion thereof),wherein the single-stranded polynucleotide can further comprise aterminal phosphate group, such as a 5′-phosphate (see for example,Martinez et al., 2002, Cell 110, 563-574 and Schwarz et al., 2002,Molecular Cell, 10, 537-568), or 5′,3′-diphosphate.

The term “subject” as used herein refers to its meaning as is generallyaccepted in the art. The term generally refers an organism to which thenucleic acid molecules of the invention can be administered. A subjectcan be a mammal or mammalian cells, including a human or human cells.The term also refers to an organism, which is a donor or recipient ofexplanted cells or the cells themselves.

The phrase “systemic administration” as used herein refers to itsmeaning as is generally accepted in the art. The term generally refersin vivo systemic absorption or accumulation of drugs in the blood streamfollowed by distribution throughout the entire body.

The term “target” as it refers to CTNNB1 refers to any CTNNB1 targetprotein, peptide, or polypeptide, such as encoded by Genbank AccessionNos. shown in Table 5. The term also refers to nucleic acid sequences ortarget polynucleotide sequence encoding any target protein, peptide, orpolypeptide, such as proteins, peptides, or polypeptides encodedby-sequences having Genbank Accession Nos, shown in Table 5. The targetof interest can include target polynucleotide sequences, such as targetDNA or target RNA. The term “target” is also meant to include othersequences, such as differing isoforms, mutant target genes, splicevariants of target polynucleotides, target polymorphisms, and non-coding(e.g., ncRNA, miRNA, stRNA, sRNA) or other regulatory polynucleotidesequences as described herein.

The phrase “target site” as used herein refers to its meaning as isgenerally accepted in the art. The term generally refers to a sequencewithin a target nucleic acid molecule, (e.g., RNA) that is “targeted”,e.g., for cleavage mediated by an siNA construct, which containssequences within its antisense region that are complementary to thetarget sequence.

The phrase “therapeutically effective amount” as used herein refers toits meaning as is generally accepted in the art. The term generallyrefers to the amount of the compound or composition that will elicit thebiological or medical response of a cell, tissue, system, animal orhuman that is be sought by the researcher, veterinarian, medical doctoror other clinician. For example, if a given clinical treatment isconsidered effective when there is at least a 25% reduction in ameasurable parameter associated with a disease or disorder, atherapeutically effective amount of a drug for the treatment of thatdisease or disorder is that amount necessary to effect at least a 25%reduction in that parameter.

The phrase “universal base” as used herein refers to its meaning as isgenerally accepted in the art. The term universal base generally refersto nucleotide base analogs that form base pairs with each of the naturalDNA/RNA bases with little or no discrimination between them.Non-limiting examples of universal bases include C-phenyl, C-naphthyland other aromatic derivatives, inosine, azole carboxamides, andnitroazole derivatives such as 3-nitropyrrole, 4-nitroindole,5-nitroindole, and 6-nitroindole as known in the art (see for example,Loakes, 2001, Nucleic Acids Research, 29, 2437-2447).

The term “up-regulate” as used herein refers to its meaning as isgenerally accepted in the art. With reference to exemplary nucleic acidmolecules of the invention, the term refers to an increase in theexpression of a gene, or level of RNA molecules or equivalent RNAmolecules encoding one or more proteins or protein subunits, or activityof one or more RNAs, proteins or protein subunits, above that observedin the absence of the nucleic acid molecules (e.g., siNA) of theinvention. In certain instances, up-regulation or promotion of geneexpression with an siNA molecule is above that level observed in thepresence of an inactive or attenuated molecule. In other instances,up-regulation or promotion of gene expression with siNA molecules isabove that level observed in the presence of, for example, an siNAmolecule with scrambled sequence or with mismatches. In still otherinstances, up-regulation or promotion of gene expression with a nucleicacid molecule of the instant invention is greater in the presence of thenucleic acid molecule than in its absence. In some instances,up-regulation or promotion of gene expression is associated withinhibition of RNA mediated gene silencing, such as RNAi mediatedcleavage or silencing of a coding or non-coding RNA target that downregulates, inhibits, or silences the expression of the gene of interestto be up-regulated. The down regulation of gene expression can, forexample, be induced by a coding RNA or its encoded protein, such asthrough negative feedback or antagonistic effects. The down regulationof gene expression can, for example, be induced by a non-coding RNAhaving regulatory control over a gene of interest, for example bysilencing expression of the gene via translational inhibition, chromatinstructure, methylation, RISC mediated RNA cleavage, or translationalinhibition. As such, inhibition or down regulation of targets that downregulate, suppress, or silence a gene of interest can be used toup-regulate expression of the gene of interest toward therapeutic use.

The term “vector” as used herein refers to its meaning as is generallyaccepted in the art. The term vector generally refers to any nucleicacid- and/or viral-based expression system or technique used to deliverone or more nucleic acid molecules.

B. siNA Molecules of the Invention

The present invention provides compositions and methods comprising siNAstargeted to CTNTNB1 that can be used to treat diseases, malignanciesand/or cancers associated with CTNNB1 expression. In particular aspectsand embodiments of the invention, the nucleic acid molecules of theinvention comprise at least a 15 nucleotide sequence of the sequencesshown in Table 1a and Table 1b. The siNAs can be provided in severalforms. For example, the siNA can be isolated as one or more siNAcompounds, or it may be in the form of a transcriptional cassette in aDNA plasmid. The siNA may also be chemically synthesized and can includemodifications as shown, for example, but not limitation, in Table 1c andTable 6. Thus, in various embodiments, at least one strand or region ofthe nucleic acids of the invention comprises at least a 15 nucleotidesequence selected from the group of sequences consisting of SEQ IDNOS:1-6374. The siNAs can be administered alone or co-administered withother siNA molecules or with conventional agents that treat a CTNNB1related disease or condition.

The siNA molecules of the invention can be used to mediate genesilencing, specifically CTNNB1, via interaction with RNA transcripts oralternately by interaction with particular gene sequences, wherein suchinteraction results in modulation of gene silencing either at thetranscriptional level or post-transcriptional level such as, forexample, but not limited to, RNAi or through cellular processes thatmodulate the chromatin structure or methylation patterns of the targetand prevent transcription of the target gene, with the nucleotidesequence of the target thereby mediating silencing. More specifically,the target is any of CTNNB1 RNA, DNA, or mRNA,

In one aspect, the invention provides short interfering nucleic acid(siNA) molecules for inhibiting the expression of the CTNNB1 gene in acell or mammal. The siNA can be single-stranded or double-stranded. Whendouble-stranded, the siNA comprising a sense and an antisense stand. Theantisense strand is complementary to at least a part of an mRNA formedin the expression of the CTNNB1 gene. The sense strand comprises aregion that is complementary to the antisense strand. In specificembodiments, the antisense strand comprises at least a 15 nucleotidesequence of an antisense sequence listed in Table 1b. Generally, thedouble-stranded siNA comprises at least a 15 nucleotide sequence of thesense strand in Table 1b and at least a 15 nucleotide sequence of theantisense strand in Table 1b. One or more of the nucleotides of thesiNAs of the invention are optionally modified. In further embodimentshaving modifications, some siNAs of the invention comprises at least onenucleotide sequence selected from the groups of sequences provide inTable 1c. In other embodiments, the siNA comprises at least twosequences selected from the group of sequences provided in Table 1c,wherein one of the at least two sequences is complementary to another ofthe at least two sequences and one of the at least two sequences iscomplementary to a sequence of a mRNA generated in the expression of theCTNNB1 gene. Examples of certain modified siNAs of the invention are inTable 1c.

The double stranded RNA molecules of the invention can comprise twodistinct and separate strands that can be symmetric or asymmetric andare complementary, i.e., two single-stranded RNA molecules, or cancomprise one single-stranded molecule in which two complementaryportions, e.g., a sense region and an antisense region, are base-paired,and are covalently linked by one or more single-stranded “hairpin” areas(i.e. loops) resulting in, for example, a single-stranded short-hairpinpolynucleotide or a circular single-stranded polynucleotide.

The linker can be polynucleotide linker or a non-nucleotide linker. Insome embodiments, the linker is a non-nucleotide linker, in someembodiments, a hairpin or circular siNA molecule of the inventioncontains one or more loop motifs, wherein at least one of the loopportions of the siNA molecule is biodegradable. For example, asingle-stranded hairpin siNA molecule of the invention is designed suchthat degradation of the loop portion of the siNA molecule in vivo cangenerate a double-stranded siNA molecule with 3′-terminal overhangs,such as 3′-terminal nucleotide overhangs comprising 1, 2, 3 or 4nucleotides. Or alternatively, a circular siNA molecule of the inventionis designed such that degradation of the loop portions of the siNAmolecule in vivo can generate a double-stranded siNA molecule with3′-terminal overhangs, such as 3′-terminal nucleotide overhangscomprising about 2 nucleotides.

In symmetric siNA molecules of the invention, each strand, the sense(passenger) strand and antisense (guide) strand, are independently about15 to about 30 (e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, or 30) nucleotides in length. Generally, each strand ofthe symmetric siNA molecules of the invention are about 19-24 (e.g.,about 19, 20, 21, 22, 23 or 24) nucleotides in length.

In asymmetric siNA molecules, the antisense region or strand of themolecule is about 15 to about 30 (e.g., about 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 27, 28, 29, or 30) nucleotides in length, whereinthe sense region is about 3 to about 25 (e.g., about 3, 4, 5, 6, 7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24, or 25)nucleotides in length. Generally, each strand of the asymmetric siNAmolecules of the invention is about 19-24 (e.g., about 19, 20, 21, 22,23 or 24) nucleotides in length.

In yet other embodiments, siNA molecules of the invention comprisesingle stranded hairpin siNA molecules, wherein the siNA molecules areabout 25 to about 70 (e.g., about 25, 26, 27, 28, 29, 30, 31, 32, 33,34, 35, 36, 40, 45, 50, 55, 60, 65, or 70) nucleotides in length.

In still other embodiments, siNA molecules of the invention comprisesingle-stranded circular siNA molecules, wherein the siNA molecules areabout 38 to about 70 (e.g., about 38, 40, 45, 50, 55, 60, 65, or 70)nucleotides in length.

In still other embodiments, siNA molecules of the invention comprisesingle-stranded non-circular siNA molecules, wherein the siNA moleculesare independently about 15 to about 30 (e.g., about 15, 16, 17, 18, 19,20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) nucleotides in length.

In various symmetric embodiments, the siNA duplexes of the inventionindependently comprise about 15 to about 30 (e.g., about 15, 16, 17, 18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) base pairs.Generally, the duplex structure of siNAs of the invention is between 15and 30, more generally between 18 and 25, yet more generally between 19and 24, and most generally between 19 and 21 base pairs in length.

In yet other embodiments, where the duplex siNA molecules of theinvention are asymmetric, the siNA molecules comprise about 3 to 25(e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, 20, 21, 22, 23, 24, or 25) base pairs. Generally, the duplexstructure of siNAs of the invention is between 15 and 25, more generallybetween 18 and 25, yet more generally between 19 and 24, and mostgenerally between 19 and 21 base pairs in length.

In still other embodiments, where the siNA molecules of the inventionare hairpin or circular structures, the siNA molecules comprise about 15to about 30 (e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,27, 28, 29, or 30) base pairs.

The sense strand and antisense strand, or the sense region and antisenseregion, of the siNA molecules of the invention can be complementary.Also, the antisense strand or antisense region can be complementary to anucleotide sequence or a portion thereof of the CTNNB1 target RNA. Thesense strand or sense region of the siNA can comprise a nucleotidesequence of a CTNNB1 gene or a portion thereof. In certain embodiments,the sense region or sense strand of an siNA molecule of the invention iscomplementary to that portion of the antisense region or antisensestrand of the siNA molecule that is complementary to a CTNNB1 targetpolynucleotide sequence, such as for example, but not limited to, thosesequences represented by GENBANK Accession Nos. shown in Table 5.

In some embodiments, siNA molecules of the invention have perfectcomplementarity between the sense strand or sense region and theantisense strand or antisense region of the siNA molecule. In other orthe same embodiments, the antisense strand of the siNA molecules of theinvention are perfectly complementary to a corresponding target nucleicacid molecule.

In yet other embodiments, siNA molecules of the invention have partialcomplementarity (i.e., less than 100% complementarity) between the sensestrand or sense region and the antisense strand or antisense region ofthe siNA molecule or between the antisense strand or antisense region ofthe siNA molecule and a corresponding target nucleic acid molecule.Thus, in some embodiments, the double-stranded nucleic acid molecules ofthe invention, have between about 15 to about 30 (e.g., about 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) nucleotidesin one strand that are complementary to the nucleotides of the otherstrand. In other embodiments, the molecules have between about 15 toabout 30 (e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,27, 28, 29, or 30) nucleotides in the sense region that arecomplementary to the nucleotides of the antisense region of thedouble-stranded nucleic acid molecule. In certain embodiments, thedouble-stranded nucleic acid molecules of the invention have betweenabout 15 to about 30 (e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23,24, 25, 26, 27, 28, 29, or 30) nucleotides in the antisense strand thatare complementary to a nucleotide sequence of its corresponding targetnucleic acid molecule.

In other embodiments, the siNA molecule can contain one or morenucleotide deletions, substitutions, mismatches and/or additions;provided, however, that the siNA molecule maintains its activity, forexample, to mediate RNAi. In a non-limiting example, the deletion,substitution, mismatch and/or addition can result in a loop or bulge, oralternately a wobble or other alternative (non Watson-Crick) base pair.Thus, in some embodiments, for example, the double-stranded nucleic acidmolecules of the invention, have 1 or more (e.g., 1, 2, 3, 4, 5, or 6)nucleotides, in one strand or region that are mismatches ornon-base-paired with the other strand or region. In other embodiments,the double-stranded nucleic acid molecules of the invention, have 1 ormore (e.g., 1, 2, 3, 4, 5, or 6) nucleotides in each strand or regionthat are mismatches or non-base-paired with the other strand or region.In a preferred embodiment, the siNA of the invention contains no morethan 3 mismatches. If the antisense strand of the siNA containsmismatches to a target sequence, it is preferable that the area ofmismatch not be located in the center of the region of complementarity.

In other embodiments, the siNA molecule can contain one or morenucleotide deletions, substitutions, mismatches and/or additions to asequence in Table 1b provided, however, that the siNA molecule maintainsits activity, for example, to mediate RNAi. In a non-limiting example,the deletion, substitution, mismatch and/or addition can result in aloop or bulge, or alternately a wobble or other alternative (nonWatson-Crick) base pair.

The invention also comprises double-stranded nucleic acid (siNA)molecules as otherwise described hereinabove in which the first strandand second strand are complementary to each other and wherein at leastone strand is hybridisable to the polynucleotide sequence of a sequencein Table 1b under conditions of high stringency, and wherein any of thenucleotides is unmodified or chemically modified.

Hybridization techniques are well known to the skilled artisan (see forinstance, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2ndEd., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.(1989)). Preferred stringent hybridization conditions include overnightincubation at 42° C. in a solution comprising: 50% formamide, 5×SSC (150mM NaCl, 1.5 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6),5×Denhardt's solution, 10% dextran sulfate, and 20 microgram/mldenatured, sheared salmon sperm DNA; followed by washing the filters in0.1×SSC at about 65° C.

In one specific embodiment, the first strand has about 15, 16, 17, 18,19, 20 or 21 nucleotides that are complementary to the nucleotides ofthe other strand and at least one strand is hybridisable to apolynucleotide sequence in Table 1b. In a more preferred embodiment, thefirst strand has about 15, 16, 17, 18, 19, 20 or 21 nucleotides that arecomplementary to the nucleotides of the other strand and at least onestrand is hybridisable to SEQ ID NO: 1, SEQ NO: 1049, SEQ ID NO: 43, SEQID NO: 1091, SEQ ID NO: 51, SEQ ID NO: 1099, SEQ ID NO: 53, or SEQ IDNO:1101; under conditions of high stringency, and wherein any of thenucleotides is unmodified or chemically modified.

In certain embodiments, the siNA molecules of the invention compriseoverhangs of about 1 to about 4 (e.g., about 1, 2, 3 or 4) nucleotides.The nucleotides in the overhangs can be the same or differentnucleotides. In some embodiments, the overhangs occur at the 3′-end atone or both strands of the double-stranded nucleic acid molecule. Forexample, a double-stranded nucleic acid molecule of the invention cancomprise a nucleotide or non-nucleotide overhang at the 3′-end of theantisense strand/region, the 3′-end of the sense strand/region, or boththe antisense strand/region and the sense strand/region of thedouble-stranded nucleic acid molecule.

In some embodiments, the nucleotides comprising the overhang portion ofan siNA molecule of the invention comprise sequences based on the CTNNB1target polynucleotide sequence in which nucleotides comprising theoverhang portion of the antisense strand/region of an siNA molecule ofthe invention can be complementary to nucleotides in the CTNNB1 targetpolynucleotide sequence and/or nucleotides comprising the overhangportion of the sense strand/region of an siNA molecule of the inventioncan comprise the nucleotides in the CTNNB1 target polynucleotidesequence. Thus, in some embodiments, the overhang comprises a twonucleotide overhang that is complementary to a portion of the CTNNB1target polynucleotide sequence. In other embodiments, however, theoverhang comprises a two nucleotide overhang that is not complementaryto a portion of the CTNNB1 target polynucleotide sequence. In certainembodiments, the overhang comprises a overhang that is not complementaryto a portion of the CTNNB1 target polynucleotide sequence. In otherembodiments, the overhang comprises a UU overhang at the 3′ end of theantisense strand and a TT overhang at the 3′ end of the sense strand. Inother embodiments, the overhang comprises nucleotides as described inthe examples, Tables, and Figures herein.

In any of the embodiments of the siNA molecules described herein having3′-terminal nucleotide overhangs, the overhangs are optionallychemically modified at one or more nucleic acid sugar, base, or backbonepositions. Representative, but not limiting examples of modifiednucleotides in the overhang portion of a double-stranded nucleic acid(siNA) molecule of the invention include: 2′-O-alkyl (e.g.,2′-O-methyl), 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-deoxy-2′-fluoroarabino(FANA), 4′-thio, 2′-O-trifluoromethyl, 2′-O-ethyl-trifluoromethoxy,2′4)-difluoromethoxy-ethoxy, universal base, acyclic, or 5-C-methylnucleotides. In more preferred embodiments, the overhang nucleotides areeach independently, a 2′-O-alkyl nucleotide, a 2′-O-methyl nucleotide, a2′-dexoy-2-fluoro nucleotide, or a 2′-deoxy ribonucleotide. In someinstances the overhang nucleotides are linked by a one or morephosphorothioate linkages.

In yet other embodiments, siNA molecules of the invention compriseduplex nucleic acid molecules with blunt ends (i.e., without nucleotideoverhangs), where both ends are blunt, or alternatively, where one ofthe ends is blunt. In some embodiments, the siNA molecules of theinvention can comprises one blunt end, for example wherein the 5′-end ofthe antisense strand and the 3′-end of the sense strand do not have anyoverhanging nucleotides. In another example, the siNA molecule comprisesone blunt end, for example wherein the 3′-end of the antisense strandand the 5′-end of the sense strand do not have any overhangingnucleotides. In other embodiments, siNA molecules of the inventioncomprise two blunt ends, for example wherein the 3′-end of the antisensestrand and the 5′-end of the sense strand as well as the 5′-end of theantisense strand and 3′-end of the sense strand do not have anyoverhanging nucleotides.

In any of the embodiments or aspects of the siNA molecules of theinvention, the sense strand and/or the antisense strand can further havea cap, such as described herein or as known in the art, at the 3′-end,the 5′-end, or both of the 3′ and 5′-ends of the sense strand and/orantisense strand. Or as in the case of a hairpin siNA molecule, the capcan be at either one or both of the terminal nucleotides of thepolynucleotide. In some embodiments, the cap is at one of both of theends of the sense strand of a double-stranded siNA molecule. In otherembodiments, the cap is at the 3′-end of antisense (guide) strand. Inpreferred embodiments, the caps are at the 3′-end of the sense strandand the 5′-end of the sense strand.

Representative, but non-limiting examples of such terminal caps includean inverted abasic nucleotide, an inverted deoxy abasic nucleotide, aninverted nucleotide moiety, a group shown in FIG. 5 , a glycerylmodification, an alkyl or cycloalkyl group, a heterocycle, or any othercap as is generally known in the art.

Any of the embodiments of the siNA molecules of the invention can have a5′ phosphate termini. In some embodiments, the siNA molecules lackterminal phosphates.

Any siNA molecule or construct of the invention can comprise one or morechemical modifications. Modifications can be used to improve in vitro orin vivo characteristics such as stability, activity, toxicity, immuneresponse (e.g., prevent stimulation of an interferon response, aninflammatory or pro-inflammatory cytokine response, or a Toll-likeReceptor (TlF) response), and/or bioavailability.

Applicants describe herein chemically modified siNA molecules withimproved RNAi activity and/or stability compared to correspondingunmodified siNA molecules. Various chemically modified siNA motifsdisclosed herein provide the capacity to maintain RNAi activity that issubstantially similar to unmodified or minimally modified active siRNA(see for example Elbashir et al., 2001, EMBO J., 20:6877-6888) while atthe same time providing nuclease resistance and pharmacokineticproperties suitable for use in therapeutic applications.

In various embodiments, the siNA molecules of the invention comprisemodifications wherein any (e.g., one or more or all) nucleotides presentin the sense and/or antisense strand are modified nucleotides (e.g.,wherein one nucleotide is modified, some nucleotides (i.e., plurality ormore than one) are modified, or all nucleotides are modifiednucleotides. In some embodiments, the siNA molecules of the inventionare partially modified (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47,48, 49, 50, 55, or 59 nucleotides are modified) with chemicalmodifications. In some embodiments, an siNA molecule of the inventioncomprises at least about 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30,32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60nucleotides that are modified nucleotides. In other embodiments, thesiNA molecules of the invention are completely modified (e.g., 100%modified) with chemical modifications, i.e., the siNA molecule does notcontain any, ribonucleotides. In some or embodiments, one or more of thenucleotides in the sense strand of the siNA molecules of the inventionare modified. In the same or other embodiments, one or more of thenucleotides in the antisense strand of the siNA molecules of theinvention are modified.

The chemical modification within a single siNA molecule can be the sameor different. In some embodiments, at least one strand has at least onechemical modification. In other embodiments, each strand has at leastone chemical modifications, which can be the same or different, such as,sugar, base, or backbone (i.e., internucleotide linkage) modifications.In other embodiments, siNA molecules of the invention contain at least2, 3, 4, 5, or more different chemical modifications.

Non-limiting examples of chemical modifications that are suitable foruse in the present invention, are disclosed in U.S. patent applicationSer. Nos. 10/444,853; 10/981,966; 12/064,014 and in references citedtherein and include sugar, base, and phosphate, non-nucleotidemodifications, and/or any combination thereof.

In certain specific embodiments of the invention, at least one modifiednucleotide is a 2′-deoxy-2-fluoro nucleotide, a 2′-deoxy nucleotide, a2′-O-alkyl (e.g., 2′-O-methyl) nucleotide, or a locked nucleic acid(LNA) nucleotide as is generally recognized in the art.

In yet other embodiment of the invention, at least one nucleotide has aribo-like, Northern or A form helix configuration (see e.g., Saenger,Principles of Nucleic Acid Structure, Springer-Verlag ed., 1984).Non-limiting examples of nucleotides having a Northern configurationinclude locked nucleic acid (LNA) nucleotides (e.g., 2′-O,4′-C-methylene-(D-ribofuranosyl) nucleotides); 2′-methoxyethoxy (MOE)nucleotides; 2′-methyl-thio-ethyl nucleotides, 2′-deoxy-2′-fluoronucleotides; 2′-deoxy-2′-chloro nucleotides; 2′-azido nucleotides;2′-O-trifluoromethyl nucleotides; 2′-O-ethyl-trifluoromethoxynucleotides; 2′4)-difluoromethoxy-ethoxy nucleotides; 4′-thionucleotides and 2′-O-methyl nucleotides.

In various embodiments, a majority (e.g., greater than 50%) of thepyrimidine nucleotides present in the double-stranded siNA moleculecomprises a sugar modification. In some of the same and/or otherembodiments, a majority (e.g., greater than 50%) of the purinenucleotides present in the double-stranded siNA molecule comprises asugar modification.

In some embodiments, the pyrimidine nucleotides in the antisense strandare 2′-O-methyl or 2′-deoxy-2′-fluoro pyrimidine nucleotides and thepurine nucleotides present in the antisense strand are 2′-O-methylnucleotides or 2′-deoxy nucleotides. In other embodiments, thepyrimidine nucleotides in the sense strand are 2′-deoxy-2′-fluoropyrimidine nucleotides and the purine nucleotides present in the sensestrand are 2′-O-methyl or 2′-deoxy purine nucleotides.

In certain embodiments of the invention, all the pyrimidine nucleotidesin the complementary region on the sense strand are 2′-deoxy-2′-fluoropyrimidine nucleotides. In certain embodiments, all of the pyrimidinenucleotides in the complementary region of the antisense strand are2′-deoxy-2′-fluoro pyrimidine nucleotides. In certain embodiments, allthe purine nucleotides in the complementary region on the sense strandare 2′-deoxy purine nucleotides. In certain embodiments, all of thepurines in the complementary region on the antisense strand are2′-O-methyl purine nucleotides, in certain embodiments, all of thepyrimidine nucleotides in the complementary regions on the sense strandare 2′-deoxy-2′-fluoro pyrimidine nucleotides; all of the pyrimidinenucleotides in the complementary region of the antisense strand are2′-deoxy-2′-fluoro pyrimidine nucleotides; all the purine nucleotides inthe complementary region on the sense strand are 2′-deoxy purinenucleotides and all of the purines in the complementary region on theantisense strand are 2′-O-methyl purine nucleotides.

In some embodiments, at least 5 or more of the pyrimidine nucleotides inone or both stands are 2′-deoxy-2′-fluoro pyrimidine nucleotides, insome embodiments, at least 5 or more of the pyrimidine nucleotides inone or both stands are 2′-O-methyl pyrimidine nucleotides. In someembodiments, at least 5 or more of the purine nucleotides in one or bothstands are 2′-deoxy-2′-fluoro purine nucleotides In some embodiments, atleast 5 or more of the purine nucleotides in one or both stands are2′-O-methyl purine nucleotides.

In certain embodiments, the purines and pyrimidines are differentiallymodified at the 2′-sugar position (i.e., at least one purine has adifferent modification from at least one pyrimidine in the same ordifferent strand at the 2′-sugar position). For example, in someinstances, at least 5 or more of the pyrimidine nucleotides in one orboth stands are 2′-deoxy-2′-fluoro pyrimidine nucleotides and at least 5or more purine nucleotides in one or both strands are 2′-O-methyl purinenucleotides. In other instances at least 5 or more of the pyrimidinenucleotides in one or both stands are 2′-O-methyl pyrimidine nucleotidesand at least 5 or more purine nucleotides in one or both strands are2′-deoxy-2′-fluoro purine nucleotides.

Further non-limiting examples of sense and antisense strands of suchsiNA molecules having various modifications and modifications patternsare shown in FIGS. 2 and 3 .

Any of the above described modifications, or combinations thereof,including those in the references cited, can be applied to any of thesiNA molecules of the invention.

The modified siNA molecules of the invention can comprise modificationsat various locations within the siNA molecule. In some embodiments, thedouble-stranded siNA molecule of the invention comprises modifiednucleotides at internal base paired positions within the siNA duplex. Inother embodiments, a double-stranded siNA molecule of the inventioncomprises modified nucleotides at non-base paired or overhang regions ofthe siNA molecule. In yet other embodiments, a double-stranded siNAmolecule of the invention comprises modified nucleotides at terminalpositions of the siNA molecule. For example, such terminal regionsinclude the 3′-position and/or 5′-position of the sense and/or antisensestrand or region of the siNA molecule. Additionally, any of the modifiedsiNA molecules of the invention can have a modification in one or botholigonucleotide strands of the siNA duplex, for example in the sensestrand, the antisense strand, or both strands. Moreover, with regard tochemical modifications of the siNA molecules of the invention, eachstrand of the double-stranded siNA molecules of the invention can haveone or more chemical modifications, such that each strand comprises adifferent pattern of chemical modifications.

In certain embodiments each strand of a double-stranded siNA molecule ofthe invention comprises a different pattern of chemical modifications,such as any Stab modification chemistries described herein (see Table 9)or any combination thereof, i.e., different combinations of definedStabilization chemistry (Stab) sense and antisense strands. Further,non-limiting examples of modification schemes that could give rise todifferent patterns of modifications are shown in Table 9. Thestabilization chemistries referred to in Table 9 as Stab, cart becombined in any combination of sense/antisense chemistries, such as Slab7/8, Stab 7/11, Stab 8/8, Stab 18/8, Stab 18/11, Stab 12/13, Stab 7/13,Stab 18/13, Stab 7/19, Stab 8/19, Stab 18/19, Stab 7/20, Stab 8/20, Stab18/20, Stab 7/32, Stab 8/32, or Stab 18/32 or any other combination ofStabilization chemistries.

In any of the siNAs of the invention, one or more (for example 1, 2, 3,4 or 5) nucleotides at the 5′-end of the guide strand or guide region(also known as antisense strand or antisense region) of the siNAmolecule are ribonucleotides.

In certain embodiment, the present invention provides a double-strandedshort interfering nucleic acid (siNA) molecule that modulates theexpression of CTNNB1, wherein the siNA comprises a sense strand and anantisense strand; each strand is independently 15 to 30 nucleotides inlength; and the antisense strand comprises at least 15, 16, 17, 18, or19 nucleotides having sequence complementary to any of:

(SEQ ID NO: 5) 5′-CUGUUGGAUUGAUUCGAAA-3′; (SEQ ID NO: 194)5′-ACGACUAGUUCAGUUGCUU-3′; (SEQ ID NO: 196) 5′-GGAUGAUCCUAGCUAUCGU-3′;or (SEQ ID NO: 151) 5′-CCAGGAUGAUCCUAGCUAU-3′.

In some embodiments, the antisense strand of a siNA molecule of theinvention comprises at least a 15, 16, 17, 18, or 19 nucleotide sequenceof:

(SEQ ID NO: 4918) 5′-UUUCGAAUCAAUCCAACAG-3′; (SEQ ID NO: 5107)5′-AAGCAACUGAACUAGUCGU-3′; (SEQ ID NO: 5109) 5′-ACGAUAGCUAGGAUCAUCC-3′;or (SEQ ID NO: 5064) 5′-AUAGCUAGGAUCAUCCUGG-3′;

In some embodiments, the sense strand of a siNA molecule of theinvention comprises at least a 15, 16, 17, 18, or 19 nucleotide sequenceof:

(SEQ ID NO: 5) 5′-CUGUUGGAUUGAUUCGAAA-3′; (SEQ ID NO: 194)5′-ACGACUAGUUCAGUUGCUU-3′; (SEQ ID NO: 196) 5′-GGAUGAUCCUAGCUAUCGU-3′;or (SEQ ID NO: 151) 5′-CCAGGAUGAUCCUAGCUAU-3′.

In some embodiments, a siNA molecule of the invention comprises any of:

(SEQ ID NO: 5) 5′-CUGUUGGAUUGAUUCGAAA-3′ and (SEQ ID NO: 4918)5′-UUUCGAAUCAAUCCAACAG-3′; or (SEQ ID NO: 194) 5′-ACGACUAGUUCAGUUGCUU-3′and (SEQ ID NO: 5107) 5′-AAGCAACUGAACUAGUCGU-3′; or (SEQ ID NO: 196)5′-GGAUGAUCCUAGCUAUCGU-3′ and (SEQ ID NO: 5109)5′-ACGAUAGCUAGGAUCAUCC-3′; or (SEQ ID NO: 151) 5′-CCAGGAUGAUCCUAGCUAU-3′and (SEQ ID NO: 5064) 5′-AUAGCUAGGAUCAUCCUGG-3′.

Any of the above described modifications, or combinations thereof,including those in the references cited, can be applied to any of theseembodiments.

In certain embodiments, the nucleotides of the at least a 15, 16, 17,18, or 19 nucleotide sequence of SEQ ID NO: 5, SEQ ID NO: 4918, SEQ IDNO: 194, SEQ ID NO: 5107, SEQ ID NO: 196, SEQ ID NO: 5109, SEQ ID NO:151, or SEQ ID NO: 5064 form a contiguous stretch of nucleotides.

In some embodiments, the siNA molecule can contain one or morenucleotide deletions, substitutions, mismatches and/or additions to theat least 15, 16, 17, 18, or 19 nucleotide sequence of SEQ ID NO: 5, SEQID NO: 4918, SEQ ID NO: 194, SEQ ID NO: 5107, SEQ ID NO: 196, SEQ ID NO:5109, SEQ ID NO: 151, SEQ ID NO: 5064; provided, however, that the siNAmolecule maintains its activity, for example, to mediate RNAi. In anon-limiting example, the deletion, substitution, mismatch and/oraddition can result in a loop or bulge, or alternately a wobble or otheralternative (non Watson-Crick) base pair.

In certain embodiments of the invention, double-stranded siNA moleculesare provided, wherein the molecule has a sense strand and an antisensestrand and comprises the following formula (A):

-   -   wherein, the upper strand is the sense strand and the lower        strand is the antisense strand of the double-stranded nucleic        acid molecule; wherein the antisense strand comprises at least a        15, 16, 17, 18, or 19 nucleotide sequence of SEQ ID NO: 4918,        SEQ ID NO: 5107, SEQ ID NO: 5109, or SEQ ID NO: 5064, and the        sense strand comprises a sequence having complementarity to the        antisense strand;    -   each N is independently a nucleotide which is unmodified or        chemically modified or a non-nucleotide:    -   each B is a terminal cap that is present or absent;    -   (N) represents overhanging nucleotides, each of which is        independently unmodified or chemically modified;    -   [N] represents nucleotides that are ribonucleotides;    -   X1 and X2 are independently integers from 0 to 4;    -   X3 is an integer from 15 to 30:    -   X4 is an integer from 9 to 30; and    -   X5 is an integer from 0 to 6, provided that the sum of X4 and X5        is 15-30.

In certain embodiments, the nucleotides of the at least a 15, 16, 17,18, or 19 nucleotide sequence of SEQ ID NO: 4918, SEQ ID NO: 5107, SEQNO: 5109, or SEQ NO: 5064 form a contiguous stretch of nucleotides.

In some embodiments, the siNA molecule of formula A can contain one ormore nucleotide deletions, substitutions, mismatches and/or additions tothe at least 15, 16, 17, 18, or 19 nucleotide sequence of SEQ ID NO:4918, SEQ ID NO: 5107, SEQ ID NO: 5109, or SEQ ID NO: 5064; provided,however, that the siNA molecule maintains its activity, for example, tomediate RNAi. In a non-limiting example, the deletion, substitution,mismatch and/or addition can result in a loop or bulge, or alternately awobble or other alternative (non Watson-Crick) base pair.

In one embodiment, the invention features a double-stranded shortinterfering nucleic acid (siNA) of formula (A); wherein

-   -   (a) one or more pyrimidine nucleotides in N_(X4) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl        nucleotides, T-deoxy nucleotides, ribonucleotides, or any        combination thereof;    -   (b) one or more purine nucleotides in N_(X4) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2″-O-alkyl        nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any        combination thereof;    -   (c) one or more pyrimidine nucleotides in N_(X3) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl        nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any        combination thereof; and    -   (d) one or more purine nucleotides in N_(X3) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl        nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any        combination thereof.

In certain embodiments, the invention features a double-stranded shortinterfering nucleic acid (siNA) molecule of formula (A); wherein

-   -   (a) 1, 2, 3, 4, 5 or more pyrimidine nucleotides in N_(X4)        positions are 2′-deoxy-2′-fluoro nucleotides;    -   (b) 1, 2, 3, 4, 5 or more purine nucleotides in N_(X4) positions        are 2′-O-alkyl nucleotides;    -   (c) 1, 2, 3, 4, 5 or more pyrimidine nucleotides in N_(X3)        positions are 2′-deoxy-2′-fluoro nucleotides; and    -   (d) 1, 2, 3, 4, 5 or more purine nucleotides in N_(X3) positions        are 2′-deoxy nucleotides.

In certain embodiments, the invention Features a double-stranded shortinterfering nucleic acid (siNA) molecule of formula (A); wherein

-   -   (a) 1, 2, 3, 4, 5 or more pyrimidine nucleotides in N_(X4)        positions are 2′-O-alkyl nucleotides;    -   (b) 1, 2, 3, 4, 5 or more purine nucleotides in N_(X4) positions        are ribonucleotides;    -   (c) 1, 2, 3, 4, 5 or more pyrimidine nucleotides in N_(X3)        positions are 2′-O-alkyl nucleotides; and    -   (d) 1, 2, 3.4, 5 or more purine nucleotides in N_(X3) positions        are ribonucleotides.

In certain embodiments, the invention features a double-stranded shortinterfering nucleic acid (siNA) molecule of formula (A); wherein

-   -   (a) 1, 2, 3, 4, 5 or more pyrimidine nucleotides in N_(X4)        positions are 2′-deoxy-2′-fluoro nucleotides;    -   (b) 1, 2, 3, 4, 5 or more purine nucleotides in N_(X4) positions        are 2′-O-alkyl nucleotides;    -   (c) 1, 2, 3, 4, 5 or more pyrimidine nucleotides in N_(X3)        positions are 2′-O-alkyl nucleotides; and    -   (d) 1, 2, 3, 4, 5 or more purine nucleotides in N_(X3) positions        are 2′-deoxy-2′-fluoro nucleotides.

In certain embodiments, the invention features a double-stranded shortinterfering nucleic acid (siNA) molecule of formula (A) furthercomprising one or more phosphorothioate internucleotide linkages.

In some embodiments, siNA molecules having formula A comprise a terminalphosphate group at the 5′-end of the antisense strand or antisenseregion of the nucleic acid molecule.

In various embodiments, siNA molecules having formula A comprise X5=0,1, 2, or 3; each X1 and X2=1 or 2; X3=18, 19, 20, 21, 22, or 23, andX4=17, 18, 19, 20, 21, 22, or 23.

In certain embodiments, siNA molecules having formula. A comprise X5=3.In other embodiments siNA molecules having formula A comprise X5=0.

In certain embodiments, siNA molecules having formula A comprise X1=2and X2=2.

In various embodiments, siNA molecules having formula A comprise X5=0,X1=2, and X2=2. In other embodiments, siNA molecules having formula Acomprise X5=3, X1=2, and X2=2.

In one specific embodiment, an siNA molecule having formula A comprisesX5=3; each X1 and X2=2; X3=19, and X4=16.

In another specific embodiment, an siNA molecule having formula Acomprises X5=0; each X1 and X2=2; X3=19, and X4=19.

In certain embodiments, siNA molecules having formula A comprise caps Bat the 3′ and 5′ ends of the sense strand or sense region.

In certain embodiments, siNA molecules having formula A comprise caps(B) at the 3′-end of the antisense strand or antisense region.

In various embodiments, siNA molecules having formula A comprise caps(B) at the 3′ and 5′ ends of the sense strand or sense region and caps(B) at the 3′-end of the antisense strand or antisense region.

In yet other embodiments, siNA molecules having formula A comprise caps(B) only, at the 5′-end of the sense (upper) strand of thedouble-stranded nucleic acid molecule.

In some embodiments, siNA molecules having formula A further compriseone or more phosphorothioate internucleotide linkages between thenucleotides. In certain embodiments, siNA molecules having formula Acomprise one or more phosphorothioate internucleotide linkages betweenthe first terminal (N) and the adjacent nucleotide on the 3′ end of thesense strand, antisense strand, or both sense strand and antisensestrands of the nucleic acid molecule. For example, a double-strandednucleic acid molecule can comprise X1 and/or X2=2 having overhangingnucleotide positions with a phosphorothioate internucleotide linkage,(NsN) where “s” indicates phosphorothioate.

In some embodiments, one or more of the nucleotides of siNA moleculeshaving formula A have a universal base.

In certain embodiments, siNA molecules having formula A have at position14 from the 5′-end of the antisense strand a ribonucleotide when thenucleotide at that position 14 is a purine. In other embodiments, siNAmolecules having formula A have at position 14 from the 5′-end of theantisense strand a ribonucleotide, a 2′-deoxy-2′-fluoro nucleotide or a2′-O-methyl nucleotide when the nucleotide at that position 14 is apyrimidine nucleotide.

In some embodiments, siNA molecules having formula. A comprises (N)nucleotides in the antisense strand (lower strand) that arecomplementary to nucleotides in a CTNNB1 target polynucleotide sequence,which also has complementarity to the N and [N] nucleotides of theantisense (lower) strand.

In certain embodiments, one or more siNA molecules of the invention aremodified according to modification criteria as shown and described inU.S. Ser. No. 61/408,428 and U.S. Ser. No. 61/408,303, both of which areincorporated by reference herein.

Any of the above described modifications, or combinations thereof,discussed above as applicable to siNAs of the invention, including thosein the references cited, can be applied to any of the embodiments tosiNA molecules of the present invention.

C. Generation/Synthesis of siNA Molecules

The siNAs of the invention can be obtained using a number of techniquesknown to those of skill in the art. For example the siNA can bechemically synthesized or may be encoded by plasmid (e.g., transcribedas sequences that automatically fold into duplexes with hairpin loops).siNA can also be generated by cleavage of longer dsRNA dsRNA greaterthan about 25 nucleotides in length) by the E. coli RNase II or Dicer.These enzymes process the dsRNA into biologically active siNA (see,e.g., Yang et al., PNAS USA 99:9942-9947 (2002); Calegari et al. PNASUSA 99:14236 (2002) Byron el al. Ambion Tech Notes; 10 (11:4-6 (2009);Kawaski et al., Nucleic Acids Res., 31:981-987 (2003), Knight and Bass,Science, 293:2269-2271 (2001) and Roberston et al., J. Biol. Chem243:82(1969),

1. Chemical Synthesis

Preferably, siNA of the invention are chemically synthesized.Oligonucleotides (e.g., certain modified oligonucleotides or portions ofoligonucleotides lacking ribonucleotides) are synthesized usingprotocols known in the art, for example as described in Caruthers etal., 1992, Methods in Enzymology 211, 3-19, Thompson et al.,International PCT Publication No. WO 99/54459, Wincott et al., 1995,Nucleic Acids Res. 23, 2677-2684, Wincott et al., 1997, Methods Mol.Bio., 74, 59, Brennan et al., 1998, Biotechnol Bioeng., 61, 33-45, andBrennan, U.S. Pat. No. 6,001,311. The synthesis of oligonucleotidesintakes use of common nucleic acid protecting and coupling groups, suchas dimethoxytrityl at the 5′-end, and phosphoramidites at the 3′-end.

siNA molecules without modifications are synthesized using procedures asdescribed in Usinan et al., 1987J. Am. Chem. Soc., 109, 7845; Scaringeet al., 1990, Nucleic Acids Res., 18, 5433. These syntheses makes use ofcommon nucleic acid protecting and coupling groups, such asdimethoxytrityl at the 5′-end, and phosphoramidites at the 3′-end thatcan be used for certain siNA molecules of the invention.

In certain embodiments, the siNA molecules of the invention aresynthesized, deprotected, and analyzed according to methods described inU.S. Pat. Nos. 6,995,259, 6,686,463, 6,673,918, 6,649,751, 6,989,442,and U.S. patent application Ser. No. 10/190,359.

In a non-limiting synthesis example, small scale syntheses are conductedon a 394 Applied Biosystems, Inc. synthesizer using a 0.2 μmol scaleprotocol with a 2.5 min coupling step for 2′-O-methylated nucleotidesand a 45 second coupling step for 2′-deoxy nucleotides or2′-deoxy-2′-fluoro nucleotides. Table 10 outlines the amounts and thecontact times of the reagents used in the synthesis cycle.

Alternatively, the siNA molecules of the present invention can besynthesized separately and joined together post-synthetically, forexample, by ligation (Moore et al., 1992, Science 256, 9923; Draper etal., International PCT Publication No. WO 93/23569; Shaharova et al.,1991, Nucleic Acids Research 19, 4247; Bellon et al., 1997, Nucleosides& Nucleotides, 16, 951; Belton et al., 1997, Bioconjugate Chem. 8, 204),or by hybridization following synthesis and/or deprotection.

Various siNA molecules of the invention can also be synthesized usingthe teachings of Scaringe et al., U.S. Pat. Nos. 5,889,136; 6,008,400;and 6,111,086.

2. Vector Expression

Alternatively, siNA molecules of the invention that interact with anddown-regulate gene encoding target CTNNB1 molecules can be expressed anddelivered from transcription units (see for example Couture et al.,1996, TIG., 12, 510) inserted into DNA or RNA vectors. The recombinantvectors can be DNA plasmids or viral vectors. siNA expressing viralvectors can be constructed based on, but not limited to,adeno-associated virus, retrovirus, adenovirus, or alphavirus.

In some embodiments, pol III based constructs are used to expressnucleic acid molecules of the invention. Transcription of the siNAmolecule sequences can be driven from a promoter for eukaryotic RNApolymerase I (pol I), RNA polymerase II (pot II), or RNA polymerase III(pol III). (see for example, Thompson, U.S. Pat. Nos. 5,902,880 and6,146,886). (See also, Izant and Weintraub, 1985, Science, 229, 345;McGarr: and Lindquist, 1986, Proc. Natl. Acad. Sci., USA 83, 399;Scanlon et 1991, Proc, Natl. Acad. Sci. USA, 88, 10591-5; Kashani-Sabetet al. 1992, Antisense Res. Dev., 2, 3-15; Dropulic ci al., 1992, J.Virol., 66, 1432-41; Weerasinghe et al., 1991, J. Virol., 65, 5531-4;Qjwang et at, 1992, Proc. Natl. Acad. Sci. USA, 89, 10802-6; Chen etal., 1992, Nucleic Acids Res., 20, 4581-9; Sarver et at, 1990 Science,247, 1222-1225; Thompson et at, 1995, Nucleic Acids, Res., 23, 2259;Good et al., 1997, Gene Therapy, 4, 45. Transcripts from pol II or polIII promoters are expressed at high levels in all cells; the levels of agiven pol II promoter in a given cell type depends on the nature of thegene regulatory sequences (enhancers, silencers, etc.) present nearby.Prokaryotic RNA polymerase promoters are also used, providing that theprokaryotic RNA polymerase enzyme is expressed in the appropriate cells(Elroy-Stein and Moss, 1990, Proc. Natl, Acad. Sci. USA, 87, 6743-7;Ciao and Huang 1993, Nucleic Acids Res., 21, 2867-72; Lieber et al.1993, Methods Enzymol., 217, 47-66; Zhou et al., 1990, Mol. Cell. Biol.,10, 4529-37). Several investigators have demonstrated that nucleic acidmolecules expressed from such promoters can function in mammalian cells(e.g. Kashani-Sabet et at, 1992, Antisense Res. Dev., 2, 3-15; Ojwang etal., 1992, Proc. Natl. Acad. Sci. USA, 89, 10802-6; Chen et al., 1992,Nucleic Acids Res., 20, 4581-9; Yu et at, 1993, Proc. Natl. Acad. Sci.U.S.A, 90, 6340-4; L'Huilher et al., 1992, EMBO J., 11, 4411-8;Lisziewiez et al., 1993, Proc. Natl. Acad. Sci. U.S.A, 90, 8000-4;Thompson et al., 1995, Nucleic Acids Res., 23, 2259; Sullenger & Cech,1993, Science, 262, 1566). More specifically, transcription units suchas the ones derived from genes encoding U6 small nuclear (snRNA),transfer RNA (tRNA) and adenovirus VA RNA are useful in generating highconcentrations of desired RNA molecules such as siNA in cells (Thompsonet at, supra; Couture and Stinchcomb, 1996, supra; Noonberg et at, 1994,Nucleic Acid Res., 22, 2830; Noonberg et al., U.S. Pat. No. 5,624,803;Good et at, 1997, Gene Ther., 4, 45; Beigelman et at, International PCTPublication No. WO 96/18736. The above siNA transcription units can beincorporated into a variety of vectors for introduction into mammaliancells, including but not restricted to, plasmid DNA vectors, viral DNAvectors (such as adenovirus or adeno-associated virus vectors), or viralRNA vectors (such as retroviral or alphavirus vectors) (for a review seeCouture and Stinchcomb, 1996, supra).

Vectors used to express the siNA molecules of the invention can encodeone or both strands of an siNA duplex, or a single self-complementarystrand that self hybridizes into an siNA duplex. The nucleic acidsequences encoding the siNA molecules of the instant invention can beoperably linked in a manner that allows expression of the siNA molecule(see for example Paul et al., 2002, Nature Biotechnology, 19, 505;Miyagishi and Taira, 2002, Nature Biotechnology, 19, 497; Lee et al.,2002, Nature Biotechnology, 19, 500; and Novina et al., 2002, NatureMedicine, advance online publication doi:10.1038/nm725).

D. Carrier/Delivery Systems

The siNA molecules of the invention are added directly, or can becomplexed with cationic lipids, packaged within liposomes, or as arecombinant plasmid or viral vectors which express the siNA molecules,or otherwise delivered to target cells or tissues. Methods for thedelivery of nucleic acid molecules are described in Akhtar et al., 1992,Trends Cell Bio., 2, 139; Delivery Strategies for AntisenseOligonucleotide Therapeutics, ed. Akhtar, 1995, Maurer et al., 1999,Mol. Membr. Biol., 16, 129-140; Holland and Huang, 1999, Handb. Exp.Pharmacol., 137, 165-192; and Lee et al., 2000, ACS Symp. Ser., 752,184-192. Beigelman et al., U.S. Pat. No. 6,395,713 and Sullivan et al.,PCT WO 94/02595 further describe the general methods for delivery ofnucleic acid molecules. These protocols can be utilized for the deliveryof virtually any nucleic acid molecule. Nucleic acid molecules can beadministered to cells by a variety of methods known to those of skill inthe art, including, but not restricted to, encapsulation in liposomes,by iontophoresis, or by incorporation into other vehicles, such asbiodegradable polymers, hydrogels, cyclodextrins (see for example,Gonzalez et al., 1999, Bioconjugate Chem., 10, 1068-1074; Wang et al.,International PCT Publication Nos. WO 03/47518 and WO 03/46185),poly(lactic-co-glycolic)acid (PLGA) and PLCA microspheres (see forexample U.S. Pat. No. 6,447,796 and US Patent Application PublicationNo. US 2002130430), biodegradable nanocapsules, and bioadhesivemicrospheres, or by proteinaceous vectors (O'Hare and Normand,International PCT Publication No. WO 00/53722).

In one aspect, the present invention provides carrier systems containingthe siNA molecules described herein. In some embodiments, the carriersystem is a lipid-based carrier system, cationic lipid, or liposomenucleic acid complexes, a liposome, a micelle, a virosome, a lipidnanoparticle or a mixture thereof. In other embodiments, the carriersystem is a polymer-based carrier system such as a cationicpolymer-nucleic acid complex. In additional embodiments, the carriersystem is a cyclodextrin-based carrier system such as a cyclodextrinpolymer-nucleic acid complex. In further embodiments, the carrier systemis a protein-based carrier system such as a cationic peptide-nucleicacid complex. Preferably, the carrier system is a lipid nanoparticle(“LNP”) formulation.

In certain embodiments, the siNA molecules of the invention areformulated with a lipid nanoparticle composition such as is described inU.S. patent application Ser. Nos. 11/353,630, 11/586,102, 61/189,295,61/204,878, 61/235,476, 61/249,807, 61/298,022, 61/351,373, 61/347,640,61/345,754, 61/322,054, 12/640,342, and 12/617,079, and PCT ApplicationsNos. PCT/US10/020013 and PCT/US09/053336. In certain preferredembodiments, the siNA molecules of the invention are formulated with alipid nanoparticle composition comprising a cationiclipid/Cholesterol/PEG-C-DMA/DSPC in a 40/48/2/10 ratio or a cationiclipid/Cholesterol/PEG-DMG/DSPC in a 40/48/2/10 ratio. In more certainembodiments, the cationic lipid is DLinDMA (see Table 12), the PEG isPEG-DMG, and the N/P ratio of the formulation is 2.8. In more preferredembodiments, the cationic lipid is DLinDMA (see Tables 11 & 12).

In various embodiments, lipid nanoparticle formulations described inTable 11 are applied to any siNA molecule or combination of siNAmolecules herein. In some embodiments, the invention features acomposition comprising an siNA molecule of the invention formulated asany of formulation LNP-051; LNP-053; LNP-054; LNP-069; LNP-073; LNP-077;LNP-080; LNP-082; LNP-083; LNP-060; LIMP-061; LNP-086; LNP-097; LNP-098;LNP-099; LNP-100; LNP-101; LNP-102; LNP-103; or LNP-104 (see Table 11).

In certain other embodiments, the invention features a compositioncomprising an siNA molecule of the invention formulated with any of thecationic lipid formulations described in U.S. Patent Application Nos.61/189,295, 61/204,878, 61/235,476, 61/249,807, and 61/298,022.

In other embodiments, the invention features conjugates and/or complexesof siNA molecules of the invention. Such conjugates and/or complexes canbe used to facilitate delivery siNA molecules into a biological system,such as a cell. The conjugates and complexes provided by the instantinvention can impart therapeutic activity by transferring therapeuticcompounds across cellular membranes, altering the pharmacokinetics,and/or modulating the localization of nucleic acid molecules of theinvention. Non-limiting, examples of such conjugates are described inU.S. Publication Nos. US2008/0152661 A1 and US 2004/0162260 A1 (e.g.,CDM-LBA, CDM-Pip-LBA, CDM-PEG, CDM-NAG, etc) and U.S. patent applicationSer. Nos. 10/427,160 10/201,394, 61/322,422, and 61/315,223; and U.S.Pat. Nos. 6,528,631; 6,335,434; 6,235,886; 6,153,737; 5,214,136; and5,138,045.

In various embodiments, polyethylene glycol (PEG) can be covalentlyattached to siNA compounds of the present invention. The attached PEGcan be any molecular weight, preferably from about 100 to about 50,000daltons (Da).

In yet other embodiments, the invention features compositions orformulations comprising surface-modified liposomes containing poly(ethylene glycol) lipids (PEG-modified, or long-circulating liposomes orstealth liposomes) and siNA molecules of the invention, such as isdisclosed in for example, International PCT Publication No, WO 96/10391;Anson at al., International PCT Publication No, WO 96/10390; Holland etal., International PCT Publication No. WO 96/10392.

In some embodiments, the siNA molecules of the invention can also beformulated or complexed with polyethyleneimine and derivatives thereof,such as polyethyleneimine-polyethyleneglycol-N-acetylgalactosamine(PEI-PEG-GAL) or polyethyleneimine-polyethyleneglycol-tri-N-acetylgalactosamine (PEI-PEG-triGAL) derivatives. In one embodiment, thenucleic acid molecules of the invention are formulated as described inU.S. Patent Application Publication No. 20030077829.

In other embodiments, siNA molecules of the invention are complexed withmembrane disruptive agents such as those described in U.S. PatentApplication Publication No. 20010007666. In still other embodiments, themembrane disruptive agent or agents and the siNA molecule are alsocomplexed with a cationic lipid or helper lipid molecule, such as thoselipids described in U.S. Pat. No. 6,235,310.

In certain embodiments, siNA, molecules of the invention are complexedwith delivery systems as described in U.S. Patent ApplicationPublication Nos. 2003077829; 20050287551; 20050164220; 20050191627;20050118594; 20050153919; 20050085486; and 20030158133; andInternational PCT Publication Nos. WO 00/03683 and WO 02/087541.

In some embodiments, a liposomal formulation of the invention comprisesan siNA molecule of the invention (e.g., siNA) formulated or complexedwith compounds and compositions described in U.S. Pat. Nos. 6,858,224;6,534,484; 6,287,591; 6,835,395; 6,586,410; 6,858,225; 6,815,432;6,586,001; 6,120,798; 6,977,223; 6,998,115; 5,981,501; 5,976,567;5,705,385; and U.S. Patent Application Publication Nos. 2006/0019912;2006/0019258; 2006/0008909; 2005/0255151; 2005/0079212; 2005/0008689;2003/0077829, 2005/0064595, 2005/0175682, 2005/0118253; 2004/0071654;2005/0244504; 2005/0265961 and 2003/0077829.

Alternatively, recombinant plasmids and viral vectors, as discussedabove, which express siNAs of the invention can be used to deliver themolecules of the invention. Delivery of siNA molecule expressing vectorscan be systemic, such as by intravenous or intra-muscularadministration, by administration to target cells ex-planted from asubject followed by, reintroduction into the subject, or by any othermeans that would allow for introduction into the desired target cell(for a review see Couture el al., 1996, TIG., 12, 510). Such recombinantplasmids can also be administered directly or in conjunction with asuitable delivery reagents, including, for example, the Mirus TransitLT1 lipophilic reagent; lipofectin; lipofectamine; cellfectin;polycations polylysine) or liposomes lipid-based carrier system,cationic lipid, or liposome nucleic acid complexes, a micelle, avirosome, a lipid nanoparticle.

E. Kits

The present invention also provides nucleic acids in kit form. The kitmay comprise a container. The kit typically contains a nucleic acid ofthe invention with instructions for its administration. In certaininstances, the nucleic acids may have a targeting moiety attached.Methods of attaching targeting moieties (e.g. antibodies, proteins) areknown to those of skill in the art. In certain instances, the nucleicacids are chemically modified. In other embodiments, the kit containsmore than one siNA molecule of the invention. The kits may comprise ansiNA molecule of the invention with a pharmaceutically acceptablecarrier or diluent. The kits may further comprise excipients.

F. Therapeutic Uses/Pharmaceutical Compositions

The present body of knowledge in CTNNB1 research indicates the need formethods to assay CTNNB1 activity and for compounds that can regulateCTNNB1 expression for research, diagnostic, and therapeutic use. Asdescribed infra, the nucleic acid molecules of the present invention canbe used in assays to diagnose disease state related of CTNNB1 levels. Inaddition, the nucleic acid molecules and pharmaceutical compositions canbe used to treat disease states related to CTNNB1 RNA levels.

1. Disease States Associated with CTNNB1

Particular disease states that can be associated with CTNNB1 expressionmodulation include various cancers including solid tumors. Non-limitingexamples of such cancers include: bilary tract cancer, bladder cancer,transitional cell carcinoma, urothelial carcinoma, osteosarcoma, braincancer, gliomas, astrocytomas, breast carcinoma, metaplastic carcinoma,cervical cancer, cervical squamous cell carcinoma, rectal cancer,colorectal carcinoma, colon cancer, hereditary nonpolyposis colorectalcancer, colorectal adenocarcinomas, gastrointestinal stromal tumors(GISTs), endometrial carcinoma, endometrial stromal sarcomas, esophagealcancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma,ocular melanoma, uveal melanoma, gallbladder carcinomas, gallbladderadenocarcinoma, renal cell carcinoma, clear cell renal cell carcinoma,transitional cell carcinoma, urothelial carcinomas, Wilms tumor,leukemia, acute lymocylic leukemia (ALL), acute myeloid leukemia (AML),chronic lymphocytic (CLL), chronic myeloid (CML), chronic myelomonocytic(CMML), liver cancer, liver carcinoma, hepatoma, hepatocellularcarcinoma, cholangiocarcinoma, hepatoblastoma, Lung cancer, non-smallcell lung cancer (NSCLC), mesothelioma, B-cell lymphomas, non-Hodgkinlymphoma, diffuse large B-cell lymphoma, Mantle cell lymphoma, T-elllymphomas, non-Hodgkin lymphoma, precursor T-lymphoblasticlymphoma/leukemia, peripheral T-cell lymphomas, multiple myeloma,nasopharyngeal carcinoma (NPC), neuroblastoma, oropharyngeal cancer,oral cavity squamous cell carcinomas, osteosarcoma, ovarian carcinoma,pancreatic cancer, pancreatic ductal adenocarcinoma, pseudopapillaryneoplasms, acinar cell carcinomas, Prostate cancer, prostateadenocarcinoma, skin cancer, melanoma, malignant melanoma, cutaneousmelanoma, small intestine carcinomas, stomach cancer, gastric carcinoma,gastrointestinal stromal tumor (GIST), uterine cancer, and uterinesarcoma.

It is understood that the siNA molecules of the invention can degradethe target CTNNB1 mRNA (and thus inhibit the diseases stated above).Inhibition of a disease can be evaluated by directly measuring theprogress of the disease in a subject. It can also be inferred throughobserving a change or reversal in a condition associated with thedisease. Additionally, the siNA molecules of the invention can be usedas a prophylaxis. Thus, the use ref the nucleic acid molecules andpharmaceutical compositions of the invention can be used to ameliorate,treat, prevent, and/or cure these diseases and others associated withregulation of CTNNB1 gene expression.

2. Pharmaceutical Compositions

The siNA molecules of the instant invention provide useful reagents andmethods for a variety of therapeutic, prophylactic, cosmetic,veterinary, diagnostic, target validation, genomic discovery, geneticengineering, and pharmacogenomic applications.

a. Formulations

Thus, the present invention, in one aspect, also provides forpharmaceutical compositions of the siNA molecules described, i.e.,compositions in a pharmaceutically acceptable carrier or diluent. Thesepharmaceutical compositions include salts, esters, or salts of suchesters, of the above compounds, e.g., acid addition salts, for example,salts of hydrochloric, hydrobromic, hydroiodic, acetic acid, and benzenesulfonic acid. Other salts include for example, sodium, potassium,manganese, ammonium, and calcium salts. These formulations orcompositions can comprise a pharmaceutically acceptable carrier ordiluent as is generally known in the art.

In one embodiment, the invention features a pharmaceutical compositioncomprising an siNA molecule comprising at least a 15 nucleotide sequenceof SEQ ID NO: 5. In another embodiment, the invention features apharmaceutical composition comprising an siNA molecule comprising atleast a 15 nucleotide sequence of SEQ ID NO: 4918. In yet anotherembodiment, the invention features a pharmaceutical compositioncomprising an siNA molecule comprising at least a 15 nucleotide sequenceof SEQ ID NO: 194. In still another embodiment, the invention features apharmaceutical composition comprising an siNA molecule comprising atleast a 15 nucleotide sequence of SEQ ID NO: 5107. In anotherembodiment, the invention features a pharmaceutical compositioncomprising an siNA molecule comprising at least a 15 nucleotide sequenceof SEQ ID NO: 196. In another embodiment, the invention features apharmaceutical composition comprising an siNA molecule comprising atleast a 15 nucleotide sequence of SEQ ID NO: 5109. In anotherembodiment, the invention features a pharmaceutical compositioncomprising an siNA molecule comprising at least a 15 nucleotide sequenceof SEQ ID NO: 151. In yet another embodiment, the invention features apharmaceutical composition comprising an siNA molecule comprising atleast a 15 nucleotide sequence of SEQ ID NO: 5064. In still anotherembodiment, the invention features a pharmaceutical compositioncomprising an siNA molecule comprising formula (A).

The siNA molecules of the invention are preferably formulated aspharmaceutical compositions prior to administering to a subject,according to techniques known in the art. Pharmaceutical compositions ofthe present invention are characterized as being at least sterile andpyrogen-free. Methods for preparing pharmaceutical compositions of theinvention are within the skill in the art for example as described inRemington's Pharmaceutical Science, 17^(th) ed., Mack PublishingCompany, Easton, Pa. (1985).

In some embodiments, pharmaceutical compositions of the invention (e.g.siNA and/or LNP formulations thereof) further comprise conventionalpharmaceutical excipients and/or additives. Suitable pharmaceuticalexcipients include preservatives, flavoring agents, stabilizers,antioxidants, osmolality adjusting agents, buffers, and pH adjustingagents. Suitable additives include physiologically biocompatible buffers(e.g., trimethylamine hydrochloride), addition of chelants (such as, forexample, DTPA or DTPA-bisamide) or calcium chelate complexes (as forexample calcium DTPA, CaNaDTPA-bisamide), or, optionally, additions ofcalcium or sodium salts (for example, calcium chloride, calciumascorbate, calcium gluconate or calcium lactate). In addition,antioxidants and suspending agents can be used.

Non-limiting examples of various types of formulations for localadministration include ointments, lotions, creams, gels, foams,preparations for delivery by transdermal patches, powders, sprays,aerosols, capsules or cartridges for use in an inhaler or insufflator ordrops (for example eye or nose drops), solutions/suspensions fornebulization, suppositories, pessaries, retention enemas and chewable orsuckable tablets or pellets (for example for the treatment of aphthousulcers) or liposome or microencapsulation preparations.

Ointments, creams and gels, can, for example, can be formulated with anaqueous or oily base with the addition of suitable thickening and/orgelling agent and/or solvents. Non limiting examples of such bases canthus, for example, include water and/or an oil such as liquid paraffinor a vegetable oil such as arachis oil or castor oil, or a solvent suchas polyethylene glycol. Various thickening agents and gelling agents canbe used depending on the nature of the base. Non-limiting examples ofsuch agents include soft paraffin, aluminum stearate, cetostearylalcohol, polyethylene glycols, woolfat, beeswax, carboxypolymethyleneand cellulose derivatives, and/or glyceryl monostearate and/or non-ionicemulsifying agents.

In one embodiment lotions can be formulated with an aqueous or oily baseand will in general also contain one or more emulsifying agents,stabilizing agents, dispersing agents, suspending agents or thickeningagents.

In one embodiment powders for external application can be formed withthe aid of any suitable powder base, for example, talc, lactose orstarch. Drops can be formulated with an aqueous or non-aqueous base alsocomprising one or more dispersing agents, solubilizing agents,suspending agents or preservatives.

Compositions intended for oral use can be prepared according to anymethod known to the art for the manufacture of pharmaceuticalcompositions and such compositions can contain one or more suchsweetening agents, flavoring agents, coloring agents or preservativeagents in order to provide pharmaceutically elegant and palatablepreparations. Tablets contain the active ingredient in admixture withnontoxic pharmaceutically acceptable excipients that are suitable forthe manufacture of tablets. These excipients can be, for example, inertdiluents; such as calcium carbonate, sodium carbonate, lactose, calciumphosphate or sodium phosphate; granulating and disintegrating agents,for example, corn starch, or alginic acid; binding agents, for examplestarch, gelatin or acacia; and lubricating agents, for example magnesiumstearate, stearic acid or talc. The tablets can be uncoated or they canbe coated by known techniques. In some cases such coatings can beprepared by known techniques to delay disintegration and absorption inthe gastrointestinal tract and thereby provide a sustained action over alonger period. For example, a time delay material such as glycerylmonosterate or glyceryl distearate can be employed.

Formulations for oral use can also be presented as hard gelatin capsuleswherein the active ingredient is mixed with an inert solid diluent, forexample, calcium carbonate, calcium phosphate or kaolin, or as softgelatin capsules wherein the active ingredient is mixed with water or anoil medium, for example peanut oil, liquid paraffin or olive oil.

Aqueous suspensions contain the active materials in a mixture withexcipients suitable for the manufacture of aqueous suspensions. Suchexcipients are suspending agents, for example sodiumcarboxymethylcellulose, methylcellulose, hydropropyl-methylcellulose,sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia;dispersing or wetting agents can be a naturally-occurring phosphatide,for example, lecithin, or condensation products of an alkylene oxidewith fatty acids, for example polyoxyethylene stearate; or condensationproducts of ethylene oxide with long chain aliphatic alcohols, forexample heptadecaethyleneoxycetanol, or condensation products ofethylene oxide with partial esters derived from fatty acids and ahexitol such as polyoxyethylene sorbitol monooleate, or condensationproducts of ethylene oxide with partial esters derived from fatty acidsand hexitol anhydrides, for example polyethylene sorbitan monooleate.The aqueous suspensions can also contain one or more preservatives, forexample ethyl, or n-propyl p-hydroxybenzoate, one or more coloringagents, one or more flavoring agents, and one or more sweetening agents,such as sucrose or saccharin.

Oily suspensions can be formulated by suspending the active ingredientsin a vegetable oil, for example arachis oil, olive oil, sesame oil orcoconut oil, or in a mineral oil such as liquid paraffin. The oilysuspensions can contain a thickening agent, for example beeswax, hardparaffin or cetyl alcohol. Sweetening agents and flavoring agents can beadded to provide palatable oral preparations. These compositions can bepreserved by the addition of an anti-oxidant such as ascorbic acid

Pharmaceutical compositions of the invention can also be in the form ofoil-in-water emulsions. The oily phase can be a vegetable oil or amineral oil or mixtures of these. Suitable emulsifying agents can benaturally-occurring gums, for example gum acacia or gum tragacanth,naturally-occurring phosphatides, for example soy bean, lecithin, andesters or partial esters derived from fatty acids and hexitol,anhydrides, for example sorbitan monooleate, and condensation productsof the said partial esters with ethylene oxide, for examplepolyoxyethylene sorbitan monooleate. The emulsions can also containsweetening and flavoring agents.

Syrups and elixirs can be formulated with sweetening agents, for exampleglycerol, propylene glycol, sorbitol, glucose or sucrose. Suchformulations can also contain a demulcent, a preservative and flavoringand coloring agents. The pharmaceutical compositions can be in the formof a sterile injectable aqueous or oleaginous suspension. Thissuspension can be formulated according to the known art using thosesuitable dispersing or wetting agents and suspending agents that havebeen mentioned above. The sterile injectable preparation can also be asterile injectable solution or suspension in a non-toxic parentallyacceptable diluent or solvent, for example as a solution in1,3-butanediol. Among the acceptable vehicles and solvents that can beemployed are water, Ringer's solution and isotonic sodium chloridesolution. In addition, sterile, fixed oils are conventionally employedas a solvent or suspending medium. For this purpose, any bland fixed oilcan be employed including synthetic mono-or diglycerides. In addition,fatty acids such as oleic acid find use in the preparation ofinjectables.

The nucleic acid molecules of the invention can also be administered inthe form of suppositories, e.g., for rectal administration of the drug.These compositions can be prepared by mixing the drug with a suitablenon-irritating excipient that is solid at ordinary temperatures butliquid at the rectal temperature and will therefore melt in the rectumto release the drug. Such materials include cocoa butter andpolyethylene glycols.

Nucleic acid molecules of the invention can be administered parenterallyin a sterile medium. The drug, depending on the vehicle andconcentration used, can either be suspended or dissolved in the vehicle.Advantageously, adjuvants such as local anesthetics, preservatives andbuffering agents can be dissolved in the vehicle.

In other embodiments, the siNA and LNP compositions and formulationsprovided herein for use in pulmonary delivery further comprise one ormore surfactants. Suitable surfactants or surfactant components forenhancing the uptake of the compositions of the invention includesynthetic and natural as well as full and truncated forms of surfactantprotein A, surfactant protein B, surfactant protein C, surfactantprotein D and surfactant Protein E, di-saturated phosphatidylcholine(other than dipalmitoyl), dipalmitoylphosphatidylcholine,phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol,phosphatidylethanolamine, phosphatidylserine; phosphatidic acid,ubiquinones, lysophosphatidylethanolamine, lysophosphatidylcholine,palmitoyl-lysophosphatidylcholine, dehydroepiandrosterone, dolichols,sulfatidic acid, glycerol-3-phosphate, dihydroxyacetone phosphate,glycerol, glycero-3-phosphocholine, dihydroxyacetone, palmitate,cytidine diphosphate (CDP) diacylglycerol, CDP choline, choline, cholinephosphate; as well as natural and artificial lamellar bodies which arethe natural carrier vehicles for the components of surfactant, omega-3kitty acids, polyenic acid, polyenoic acid, lecithin, palmitinic acid,non-ionic block copolymers of ethylene or propylene oxides,polyoxypropylene, monomeric and polymeric, polyoxyethylene, monomericand polymeric, poly (vinyl amine) with dextran and/or alkanoyl sidechains, Brij 35, Triton X-100 and synthetic surfactants ALEC, Exosurf,Survan and Atovaquone, among others. These surfactants can be usedeither as single or part of a multiple component surfactant in aformulation, or as covalently bound additions to the 5′ and/or 3′ endsof the nucleic acid component of a pharmaceutical composition herein.

b. Combinations

The siNAs and pharmaceutical formulations according to the invention canbe administered to a subject alone or used in combination with orinclude one or more other therapeutic agents, for example, anticanceragents. Thus, combinations of the presently disclosed compounds withother anti-cancer or chemotherapeutic agents are within the scope of theinvention. Examples of such agents can be found in Cancer Principles andPractice of Oncology by V. T. Devita and S. Hellman (editors), 6^(th)edition (Feb. 15, 2001), Lippincott Williams & Wilkins Publishers. Aperson of ordinary skill in the art would be able to discern whichcombinations of agents would be useful based on the particularcharacteristics of the drugs and the cancer involved. Such anti-canceragents include, but are not limited to, the following: estrogen receptormodulators, androgen receptor modulators, retinoid receptor modulators,cytotoxic/cytostatic agents, antiproliferative agents, prenyl-proteintransferase inhibitors, HMG-CoA reductase inhibitors and otherangiogenesis inhibitors, inhibitors of cell proliferation and survivalsignaling, apoptosis inducing agents and agents that interfere with cellcycle checkpoints. The siNAs of the invention are also useful incombination with any therapeutic agent used in the treatment of HCC, forexample, but not limitation sorafenib. The instant compounds areparticularly useful when co-administered with radiation therapy.

In a further embodiment, therefore, the invention provides a combinationcomprising an siNA molecule of the invention, such as for example, butnot limitation, an siNA molecule comprising at least a 15 nucleotidesequence of SEQ ID NO: 5, SEQ ID NO: 4918, SEQ ID NO: 194, SEQ ID NO:5107, SEQ ID NO: 196, SEQ ID NO: 5109, SEQ ID NO: 151, or SEQ ID NO:5064; or formula (A) or a pharmaceutically acceptable salt, solvate, orphysiologically functional derivative thereof together with one or moreanti-cancer or chemotherapeutic agents.

In certain embodiments, the instant siNA molecules of the invention areuseful in combination with known anti-cancer agents including thefollowing: estrogen receptor modulators, androgen receptor modulators,retinoid receptor modulators, cytotoxic agents, antiproliferativeagents, prenyl-protein transferase inhibitors, HMG-CoA reductaseinhibitors, HIV protease inhibitors, reverse transcriptase inhibitors,and other angiogenesis inhibitors.

Examples of estrogen receptor modulators that can be used in combinationwith the compounds of the invention include, but are not limited to,tamoxifen, raloxifene, idoxifene, LY353381, LY117081, toremifene,fulvestrant,4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl-2,2-dimethylpropanoate,4,4′-dihydroxybenzophenone-2,4-dinitrophenyl-hydrazone, and SH646.

Examples of androgen receptor modulators that can be used in combinationwith the compounds of the invention include, hut are not limited to,finasteride and other 5α-reductase inhibitors, nilutamide, flutamide,bicalutamide, liarozole, and abiraterone acetate.

Examples of such retinoid receptor modulators that can be used incombination with the compounds of the invention include, but are notlimited to, bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoicacid, α-difluoromethylornithine, ILX23-7553, trans-N-(4′-hydroxyphenyl)retinamide, and N-4-carboxyphenyl retinamide.

Examples of cytotoxic agents that can be used in combination with thecompounds of the invention include, but are not limited to, sertenef,cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine,prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin,oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfantosilate, trofosfamide, nimustine, dibrospidium chloride, pumitepa,lobaplatin, satraplatin, profiromycin, cisplatin, irofulven,dexifosfamide, cis-aminediehloro(2-methyl-pyridine)platinum,benzylguanine, glufosfamide, GPX100, (trans, trans,trans)-bis-mu-(hexane-1,6-diamine)-mu-[diamine-platinum(II)]bis[diamine(chloro)platinum(II)]tetrachloride, diarizidinylspermine, arsenic trioxide,1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, zorubicin,idarubicin, daunorubicin, bisantrene, mitoxantrone, pirarubicin,pinafide, valrubicin, amrubicin, antineoplaston,3-deamino-3′-morpholino-13-deoxo-10-hydroxycarminomycin, annamycin,galarubicin, elinafide, MEN10755, and4-demethoxy-3-deamino-3-aziridinyl-4-methylsulphortyl-daunorubicin (seeWO 00/50032).

An example of a hypoxia activatable compound that can be used incombination with the compounds of the invention is tirapazamine.

Examples of proteasome inhibitors that can be used in combination withthe compounds of the invention include, but are not limited to,lactacystin and bortezomib.

Examples of microtubule inhibitors/microtubule-stabilising agents thatcan be used in combination with the compounds of the invention include,but are not limited to, paclitaxel, vindesine sulfate,3′,4′-didehydro-4′-deoxy-8′-norvincaleukoblastine, docetaxol, rhizoxin,dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881,BMS184476, vinflunine, cryptophycin,2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl) benzene sulfonamide,anhydrovinblastine,N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-prolyl-L-proline-t-butylamide,TDX258, the epothilones (see for example U.S. Pat. Nos. 6,284,781 and6,288,237) and BMS188797.

Some examples of topoisomerase inhibitors that can be used incombination with the compounds of the invention include, but are notlimited to, are topotecan, hycaptatmine, irinotecan, rubitecan,6-ethoxypropionyl-3′,4′-O-exo-benzylidene-chartreusin,9-methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kl]acridine-2-(6H)propanamine,1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3′,4′:b,7]-indolizino[1,2b]quinoline-10,13(9H,15H)dione,lurtotecan, 7-[2-(N-isopropylamino)ethyl]-(20S)camptothecin, BNP1350,BNPI1100, BN80915, BN80942, etoposide phosphate, teniposide, sobuzoxane,2′-dimethylamino-2′-deoxy-etoposide, GL331,N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide,asulacrine, (5a, 5aB,8aa,9b)-9-[2-[N-[2-(dimethylamino)ethyl]-N-methylamino]ethyl]-5-[4-hydro0xy-3,5-dimethoxyphenyl]-5,5a,6,8,8a,9-hexohydrofuro(3′,4′,6,7)naplitho(2,3-d)-1,3-dioxol-6-one,2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]-phenanthridinium,6,9-bis[(2-aminoethyl)amino]benzo[g]isoguinoline-5,10-dione,5-(3-aminopropylamino)-7,10-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrazolo[4,5,1-de]acridin-6-one,N-[1-[2(diethylamino)ethylaminol]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide,N-(2-(dimethylamino)ethyl)acridine-4-carboxamide,6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one, and dimesna.

Examples of inhibitors of mitotic kinesins, and in particular the humanmitotic kinesin KSP, that can be used in combination with the compoundsof the invention include, but are not limited to, inhibitors describedin PCT Publications WO 01/30768, WO 01/98278, WO 03/050,064, WO03/050,122, WO 03019,527, WO 03/049,679, WO 03/049,678, WO04/039774,WO03/079973, WO03/099211, WO03/105855, WO03/106417, 5004/037171,WO04/058148, WO04/058700, WO04/126699, WO05/018638, WO05/019206,WO05/019205, WO05/018547, 4005/017190, US2005/0176776. In an embodimentinhibitors of mitotic kinesins include, but are not limited toinhibitors of KSP, inhibitors of MKIP1, inhibitors of CENP-E, inhibitorsof MCAK, inhibitors of Kif14, inhibitors of Mphosph1 and inhibitors ofRabb-KIFL.

Examples of “histone deacetylase inhibitors” that can be used incombination with the compounds of the invention include, but are notlimited to, TSA, oxamflatin, PXD101, MG98, valproic acid and scriptaid.Further reference to other histone deacetylase inhibitors may be found mthe following manuscript; Miller, T. A. et al. J. Med. Chem.216(24):5097-5116 (2003).

Inhibitors of kinases involved in mitotic progression that can be usedin combination with the compounds of the invention include, but are notlimited to, inhibitors of aurora kinase, inhibitors of Polo-like kinases(PLK) (in particular inhibitors of PLK-1), inhibitors of bub-1 andinhibitors of bub-R1.

Antiproliferative agents that can be used in combination with thecompounds of the invention include, but are not limited to, antisenseRNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231,and INX3001, and antimetabolites such as enocitabine, carmofur, tegafur,pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine,galocitabine, cytarabine ocfosfate, fosteabine sodium hydrate,raltitrexed, paltitrexid, emitefur, tiazofurin, decitabine, nolatrexed,pemetrexed, nelzarabine, 2′-deoxy-2′-methylidenecytidine,2′-fluoromethylene-2′-deoxycytidine,N-[5-(2,3-dihydro-benzofuryl)sulfonyl]-N′-(3,4-dichlorophenyl)urea,N6-[4-deoxy-4-[N2-[2(E),4E)-tetradecadienoyl]glycylamino]-L-glycero-B-L-manno-heptopyranosyl]adenine,aplidine, ecteinascidin, troxacitabine,4-[2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimdino[5,4-b][1,4]thiazin-6-yl-(S)-ethyl]-2,5-thienoyl-L-glutamicacid, aminopterin, 5-flurouracil, alanosine,11-acetyl-8-(carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,11-diazatetracyclo(7.4.1.0.0)-tetradeca-2,4,6-trien-9-ylacetic acid ester, swaiusonine, lometrexol, dexrazoxane, methioninase,2′-cyatio-2′-deoxy-N4-palmitoyl-1-B-D-arabino furanosyl cytosine and3-aminopyridine-2-carboxaldehyde thiosemicarbazone.

Examples of monoclonal antibody targeted therapeutic agents that can beused in combination with the compounds of the invention include thosetherapeutic agents which have cytotoxic agents or radioisotopes attachedto a cancer cell specific or target cell specific monoclonal antibody,such as, for example, Bexxar.

Examples of HMG-CoA reductase inhibitors that may be used that can beused in combination with the compounds of the invention include, but arenot limited to, lovastatin (MEVACOR®; see U.S. Pat. Nos. 4,231,938,4,294,926 and 4,319,039), simvastatin (ZOCOR®; see U.S. Pat. Nos.4,444,784, 4,820,850 and 4,916,239), pravastatin (PRAVACHOL®; see U.S.Pat. Nos. 4,346,227, 4,537,859, 4,410,629, 5,030,447 and 5,180,589),fluvastatin (LESCOL®; see U.S. Pat. Nos. 5,354,772, 4,911,165,4,929,437, 5,189,164, 5,118,853, 5,290,946 and 5,356,896) andatorvastatin (LIPITOR®; see U.S. Pat. Nos. 5,273,995, 4,681,893,5,489,691 and 5,342,952). The structural formulas of these andadditional HMG-CoA reductase inhibitors that may be used in the instantmethods are described at page 87 of M. Yalpani, “Cholesterol Lowering,Drugs”, Chemistry & Industry, pp. 85-89 (5 Feb. 1996) and U.S. Pat. Nos.4,782,084 and 4,885,314.

Examples of prenyl-protein transferase inhibitors that can be used incombination with the compounds of the invention include, but are notlimited to, can be found in the following publications and patents: WO96/30343, WO 97/18813, WO 97/21701, WO 97/23478, WO 97/38665, WO98/28980, WO 98/29119, WO 95/32987, U.S. Pat. Nos. 5,420,245, 5,523,430,5,532,359, 5,510,510, 5,589,485, 5,602,098, European Patent Publ. 0 618221, European Patent 0 675 112, European Patent Publ. 0 604 181,European Patent Publ. 0 696 593, WO 94/19357, WO 95/08542, WO 95/11917,WO 95/12612, WO 95/12572, WO 95/10514, U.S. Pat. No. 5,661,152, WO95/10515, WO 95/10516, WO 95/24612, WO 95/3.4535, WO 95/25086, WO96/05529, WO 96/06138, WO 96/06193, WO 96/16443, WO 96/21701, WO96/21456, WO 96/22278, WO 96/24611, WO 96/24612, WO 96/05168, WO96/05169, WO 96/00736, U.S. Pat. No. 5,571,792, WO 96/17861, WO96/33159, WO 96/34850, WO 96/34851, WO 96/30017, WO 96/30018, WO96/30362, WO 96/30363, WO 96/31111, WO 96/31477, WO 96/31478, WO96/31501, WO 97/00252, WO 97/03047, WO 97/03050, WO 97/04785, WO97/02920, WO 97/17070, WO 97/23478, WO 97/26246, WO 97/30053, WO97/44350, WO 98/02436, and U.S. Pat. No. 5,532,359. For an example ofthe role of a prenyl-protein transferase inhibitor on angiogenesis seeEuropean J. of Cancer, Vol. 35, No. 9, pp. 1394-1401 (1999).

Examples of angiogenesis inhibitors that can be used in combination withthe compounds of the invention include, but are not limited to, tyrosinekinase inhibitors, such as inhibitors of the tyrosine kinase receptorsFlt-1 (VEGFR1) and Flk-1/KDR (VEGFR2), inhibitors of epidermal-derived,fibroblast-derived, or platelet derived growth factors, MMP (matrixmetalloprotease) inhibitors, integrin blockers, interferon-α,interleukin-12, pentosan polysulfate, cyclooxygenase inhibitors,including nonsteroidal anti-inflammatories (NSAIDs) like aspirin andibuprofen as well as selective cyclooxy-genase-2 inhibitors likecelecoxib and rofecoxib (PNAS, Vol, 89, p, 7384 (1992); JNCI, Vol, 69,p. 475 (1982); Arch. Opthalmol., Vol. 108, p. 573 (1990); Anat. Rec.,Vol. 238, p. 68 (1994); FEBS Letters, Vol. 372, p. 83 (1995), Clin.Orthop. Vol. 313, p. 76 (1995); J. Mol. Endocrinol., Vol. 16, p. 107(1996); Jpn. J. Pharmacol., Vol. 75, p. 105 (1997); Cancer Res., Vol.57, p. 1625 (1997); Cell, Vol. 93, p, 705 (1998); Intl. J. Mol. Med.,Vol. 2, p. 715 (1998); J. Biol. Chem., Vol. 274, p. 9116 (1999)),steroidal anti-inflammatories (such as corticosteroids,mineralocorticoids, dexamethasone, prednisone, prednisolone, methylpred,betamethasone), carboxyamidotriazole, combretastatin A-4, squalamine,6-O-chloroacetyl-carbonyl)-fumagillol, thalidomide, angiostatin,troponin-1, angiotensin II antagonists (see Fernandez et al., J. Lab.Clin. Med. 105:141-145 (1985)), and antibodies to VEGF (see, NatureBiotechnology, Vol. 17, pp. 963-968 (October 1999); Kim et al., Nature,362, 841-844 (1993); WO 00/44777; and WO 00/61186).

Other therapeutic agents that modulate or inhibit angiogenesis may alsobe used in combination with the compounds of the instant invention andinclude agents that modulate or inhibit the coagulation and fibrinolysissystems (see review in Clin. Chem. La. Med. 38:679-692 (2000)). Examplesof such agents that modulate or inhibit the coagulation and fibrinolysispathways that can be used in combination with the compounds of theinvention include, but are not limited to, heparin (see Thromb. Haemost.80:10-23 (1998)), low molecular weight heparins and carboxypeptidase Uinhibitors (also known as inhibitors of active thrombin activatablefibrinolysis inhibitor [TAFIa]) (see Thrombosis Res, 101:329-354(2001)). TAFIa inhibitors have been described in PCT Publication WO03/013,526 and U.S. Ser. No. 60/349,925 (filed Jan. 18, 2002).

Agents that interfere with cell cycle checkpoints that can be used incombination with the compounds of the invention include, but are notlimited to, inhibitors of ATR, ATM, the Chk1 and Chk2 kinases and cdkand cdc kinase inhibitors and are specifically exemplified by7-hydroxystaurosporin, flavopiridol, CYC202 (Cyclacel) and BMS-387032.

Agents that interfere with receptor tyrosine kinases (RTKs) that can beused in combination with the compounds of the invention include, but arenot limited to, inhibitors of c-Kit, Eph, PDGF, Flt3 and CTNNB1. Furtheragents include inhibitors of RTKs as described by Bunco-Jensen andHunter, Nature, 41.1:355-365, 2001.

Inhibitors of cell proliferation and survival signaling pathway that canbe used in combination with the compounds of the invention include, butare not limited to, inhibitors of EGER (for example gefitinib anderlotinib), inhibitors of ERB-2 (for example trastuzumab), inhibitors ofIGFR, inhibitors of cytokine receptors, inhibitors of CTNNB1, inhibitorsof PI3K (for example LY294002), serine/threonine kinases (including butnot limited to inhibitors of Akt such as described in WO 02/083064, WO02/083139, WO 02/083140, US 2004-0116432, WO 02/083138, US 2004-0102360,WO 03/086404, WO 03/086279, WO 03/086394, WO 03/084473, WO 03/086403, WO2004/041162, WO 2004/096131, WO 2004/096129, WO 2004/096135, WO2004/096130, WO 2005/100356, WO 2005/100344), inhibitors of Raf kinase(for example BAY-43-9006), inhibitors of MEK (for example CI-1040 andPD-098059) and inhibitors of mTOR (for example Wyeth CCI-779). Suchagents include small molecule inhibitor compounds and antibodyantagonists.

Apoptosis inducing agents that can be used in combination with thecompounds of the invention include, but are not limited to, activatorsof TNF receptor family members (including the TRAIL receptors).

NSAIDs that are selective COX-2 inhibitors that can be used incombination with the compounds of the invention include, but are notlimited to, those NSAIDs disclosed in U.S. Pat. Nos. 5,474,995,5,861,419, 6,001,843, 6,020,343, 5,409,944, 5,436,265, 5,536,752,5,550,142, 5,604,260, 5,698,584, 5,710,140, WO 94/15932, U.S. Pat. Nos.5,344,991, 5,134,142, 5,380,738, 5,393,790, 5,466,823, 5,633,272, and5,932,598, all of which are hereby incorporated by reference.

Inhibitors of COX-2 that are particularly useful in combination with thecompounds of the invention include:3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; and5-chloro-3-(4-methylsulfonyl)-phenyl-2-(2-methyl-5-pyridinyl)pyridine;or a pharmaceutically acceptable salt thereof.

Compounds that have been described as specific inhibitors of COX-2 andare therefore useful in the present invention include, but are notlimited to: parecoxib, CELEBREX® and BEXTRA® or a pharmaceuticallyacceptable salt thereof.

Angiogenesis inhibitors that can be used in combination with thecompounds of the invention include, but are not limited to, endostatin,ukrain, ranpirnase, IM862,5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2,5]oct-6-yl(chloroacetyl)carbamate,acetyldinanaline,5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)-phenyl]methyl]-1H-1,2,3-triazole-4-carboxamide,CM101, squalamine, combretastatin, RPI4610, NX31838, sulfatedmannopentaose phosphate,7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolocarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino]-bis-(1,3-naphthalenedisulfonate), and 3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone(SU5416).

Tyrosine kinase inhibitors that can be used in combination with thecompounds of the invention include, but are not limited to,N-(trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide,3-[(2,4-dimethylpyrrol-5-yl)methylidenyl)indolin-2-one,17-(allylamino)-17-demethoxygeldanamycin,4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxyl]quinazoline,N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine,BIBX1382,2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-hydroxy-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one,SH268, genistein, imatirtib (ST1571), CEP2563,4-(3-chlorophenylamino)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidinemethanesulfonate, 4-(3-bromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline,4-(4′-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, SU6668, ST1571A,N-4-chlorophenyl-4-(4-pyridylmethyl)-1-phthalazinamine, and EMD 121974.

Combinations with compounds other than anti-cancer compounds are alsoencompassed in the instant compositions and methods. For example,combinations of the instantly claimed compounds with PPAR-γ (i.e.,PPAR-gamma) agonists and PPAR-δ (i.e., PPAR-delta) agonists are usefulin the treatment of certain malignancies. PPAR-γ and PPAR-δ are thenuclear peroxisome proliferator-activated receptors γ and δ. Theexpression of PPAR-γ on endothelial cells and its involvement inangiogenesis has been reported in the literature (see J. Cardiovasc,Pharmacol, 31:909-913 (1993); J. Biol. Chem. 274:9116-9121 (1999):Invest. Ophthalmol Vis. Sci. 41:2309-2317 (2000)). More recently, PPAR-γagonists have been shown to inhibit the angiogenic response to VEGE invitro; both troglitazone and rosiglitazone maleate inhibit thedevelopment of retinal neovascularization in mice. (Arch. Ophthalmol.119:709-717 (2001)). Examples of PPAR-γ agonists and PPAR-γ/α agoniststhat can be used in combination with the compounds of the inventioninclude, but are not limited to, thiazolidinediones (such as DRF2725,CS-011, troglitazone, rosiglitazone, and pioglitazone), fenofibrate,gemfibrozil, clofibrate, GW2570, SB219994, AR-H039242, HT-501, MCC-555,GW2331, (GW409544, NN2344, KRP297, NP0110, DRF4158, NN622, GI262570,PNU182716, DRF552926,2-[(5,7-dipropyl-3-trifluoromethyl-1,2-benzisoxazol-6-yl)oxy]-2-methylpropionicacid (disclosed in U.S. Ser. No. 09/782,856), and2(R)-7-(3-(2-chloro-4-(4-fluorophenoxy)phenoxy)propoxy)-2-ethylchromone-2-carboxylic acid (disclosed in U.S.Ser. No. 60/235,708 and 60/244,697).

Another embodiment of the instant invention is the use of the presentlydisclosed compounds in combination with gene therapy for the treatmentof cancer. For an overview of genetic strategies to treating cancer seeHall et al. (Am J Hum Genet 61:785-789 (1997)) and Kufe et al. (CancerMedicine, 5th Ed, pp 876-889, BC Decker, Hamilton, 2000). Gene therapycan be used to deliver any tumor suppressing gene. Examples of suchgenes include, but are not limited to, p53, which can be delivered viarecombinant virus-mediated gene transfer (see U.S. Pat. No. 6,069,134,for example), a uPA/uPAR antagonist (“Adenovirus-Mediated Delivery of auPA/uPAR Antagonist Suppresses Angiogenesis-Dependent Tumor Growth andDissemination in Mice,” Gene Therapy, August 5(8):1105-13 (1998)), andinterferon gamma (J Immunol 164:217-222 (2000)).

The compounds of the instant invention may also be administered incombination with an inhibitor of inherent multidrug resistance (MDR), inparticular MDR associated with high levels of expression of transporterproteins. Such MDR inhibitors include inhibitors of p-glycoprotein(P-gp), such as LY335979, XR9576, OC144-093, R101922, VX853 and PSC833(vaispodar).

A compound of the present invention may be employed in conjunction withanti-emetic agents to treat nausea or emesis, including acute, delayed,late-phase, and anticipatory emesis, which may result from the use of acompound of the present invention, alone or with radiation therapy. Forthe prevention or treatment of emesis, a compound of the presentinvention may be used in conjunction with other anti-emetic agents,especially neurokinin-1 receptor antagonists, 5H T3 receptorantagonists, such as ondansetron, granisetron, tropisetron, andzatisetron, GABAB receptor agonists, such as baclofen, a corticosteroidsuch as Decadron (dexamethasone), Kenalog, Aristocort, Nasalide,Preferid, Benecorten or others such as disclosed in U.S. Pat. Nos.2,789,118, 2,990,401, 3,048,581, 3,126,375, 3,929,768, 3,996,359,3,928,326 and 3,749,712, an antidopaminergic, such as the phenothiazines(for example prochlorperazine, fluphenazine, thioridazine andmesoridazine), metoclopramide or dronabinol. In an embodiment, ananti-emesis agent selected from a neurokinin-1 receptor antagonist, a5HT3 receptor antagonist and a corticosteroid is administered as anadjuvant for the treatment or prevention of emesis that may result uponadministration of the instant compounds.

Neurokinin-1 receptor antagonists of use in conjunction with thecompounds of the present invention are fully described, for example, inU.S. Pat. Nos. 5,162,339, 5,232,929, 5,242,930, 5,373,003, 5,387,595,5,459,270, 5,494,926, 5,496,833, 5,637,699, 5,719,147; European PatentPublication Nos. EP 0 360 390, 0 394 989, 0 428 434, 0 429 366, 0 430771, 0 436 334, 0 443 132, 0 482 539, 0 498 069, 0 499 313, 0 512 901, 0512 902, 0 514 273, 0 514 274, 0 514 275, 0 514 276, 0 515 681, 0 517589, 0 520 555, 0 522 808, 0 528 495, 0 532 456, 0 533 280, 0 536 817, 0545 478, 0 558 156, 0 577 394, 0 585 913, 0 590 152, 0 599 538, 0 610793, 0 634 402, 0 686 629, 0 693 489, 0 694 535, 0 699 655, 0 699 674, 0707 006, 0 708 101, 0 709 375, 0 709 376, 0 714 891, 0 723 959, 0 733632 and 0 776 893; PCT International Patent Publication Nos. WO90/05525, 90/05729, 91/09844, 91/18899, 92/01688, 92/06079, 92/12151,92/15585, 92/17449, 92/20661, 92/20676, 92/21677, 92/22569, 93/00330,93/00331, 93/01159, 93/01165, 93/01169, 93/01170, 93/06099, 93/09116,93/10073, 93/14084, 93/14113, 93/18023, 93/19064, 93/21155, 93/21181,93/23380, 93/24465, 94/00440, 94/01402, 94/02461, 94/02595, 94/03429,94/03445, 94/04494, 94/04496, 94/05625, 94/07843, 94/08997, 94/10165,94/10167, 94/10168, 94/10170, 94/11368, 94/13639, 94/13663, 94/14767,94/15903, 94/19320, 94/19323, 94/20500, 94/26735, 94/26740, 94/29309,95/02595, 95/04040, 95/04042, 95/06645, 95/07886, 95/07908, 95/08549,95/11880, 95/14017, 95/15311, 95/16679, 95/17382, 95/18124, 95/18129,95/19344, 95/20575, 95/21819, 95/22525, 95/23798, 95/26338, 95/28418,95/30674, 95/30687, 95/33744, 96/05181, 96/05193, 96/05203, 96/06094,96/07649, 96/10562, 96/16939, 96/18643, 96/20197, 96/21661, 96/29304,96/29317, 96/29326, 96/29328, 96/31214, 96/32385, 96/37489, 97/01553,97/01554, 97/03066, 9708144, 97/14671, 97/17362, 97/18206, 97/19084,97/19942 and 97/21702; and in British Patent Publication Nos. 2 266 529,2 268 931, 2 269 170, 2 269 590, 2 271 774, 2 292 144, 2 293 168, 2 293169, and 2 302 689. The preparation of such compounds is fully describedin the aforementioned patents and publications, which are incorporatedherein by reference.

In an embodiment, the neurokinin-1 receptor antagonist for use inconjunction with the compounds of the present invention is selectedfrom:2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine,or a pharmaceutically acceptable salt thereof, which is described inU.S. Pat. No. 5,719,147.

A compound of the instant invention may also be useful for treating orpreventing cancer, including bone cancer, in combination withbisphosphonates (understood to include bisphosphonates, diphosphonates,bisphosphonic acids and diphosphonic acids). Examples of bisphosphonatesinclude but are not limited to: etidronate (Didronel), pamidronate(Aredia), alendronate (Fosamax), risedronate (Actonel), zoledronate(Zometa), ihandronate (Boniva), incadronate or cimadronate clodronate,EB-1053, minodronate, neridronate, piridronate and tiludronate includingany and all pharmaceutically acceptable salts, derivatives, hydrates andmixtures thereof.

A compound of the instant invention may also be administered with anagent useful in the treatment of anemia. Such an anemia treatment agentis, for example, a continuous eyttropolesis receptor activator (such asepoetin alfa).

A compound of the instant invention may also be administered with anagent useful in the treatment of neutropenia. Such a neutropeniatreatment agent is, for example, a hematopoletic growth factor whichregulates the production and function of neutrophils such as a humangranulocyte colony stimulating factor, (G-CSF). Examples of a G-CSFinclude filgrastim and PEG-filgrastim.

A compound of the instant invention may also be administered with animmunologic-enhancing drug, such as levamisole, isoprinosine andZadaxin.

A compound of the instant invention may also be useful for treating orpreventing breast cancer in combination with aromatase inhibitors.Examples of aromatase inhibitors include but are not limited to:anastrozole, letrozole and exemestane.

A compound of the instant invention may also be useful for treating orpreventing cancer in combination with other siNA therapeutics.

The compounds of the instant invention may also be administered incombination with γ-secretase inhibitors and/or inhibitors of NOTCHsignaling. Such inhibitors include compounds described in WO 01/90084,WO 02/30912, WO 01/70677, WO 03/013506, WO 02/36555, WO 03/093252, WO03/093264, WO 03/093251, WO 03/093253, WO 2004/039800, WO 2004/039370,WO 2005/030731, WO 2005/014553, U.S. Ser. No. 10/957,251, WO2004/089911, WO 02/081435, WO 02/081433, WO 03/018543, WO 2004/031137,WO 2004/031139, WO 2004/031138, WO 2004/101538, WO 2004/101539 and WO02/47671 (including LY-450139).

A compound of the instant invention may also be useful for treating orpreventing cancer in combination with PARP inhibitors.

A compound of the instant invention may also be useful for treatingcancer in combination with the following therapeutic agents: abarelix(Plenaxis Depot®); aldesleukin (Prokine®); Aldesleukin (Proleukin®);Alemtuzumahh (Carripath®); alitretinoin (Panretin®); allopurinol(Zyloprin®); altretamine (Hexalen®); amifostine (Ethyol®); anastrozole(Arimidex®); arsenic trioxide (Trisenox®); asparaginase (Elspar®);azacitidine. (Vidaza®); bendamustine hydrochloride (Treanda®);bevacuzimab (Avastir®); bexaroiene capsules (Targretin®), bexarotene gel(Targretin®); bleomycin (Blenoxane®); bortezotnib (Velcade®); brefeldinbusulfan intravenous (Busulfex®); busulfan oral (Myleran®); calusterone(Methosarb®); capecitabine (Xeloda®); carboplatin (Paraplatin®);carmustine (BCNU®, BiCNU®); carmustine (Gliadel®); carmustine withPolifeprosan 20 Implant (Gliadel Wafer®), celecoxib (Celebrex®);cetuximab (Erbitux®); chlorambucil (Leukeran®); cisplatin (Platinol®);ciadribine (Leustatin®, 2-CdA®); clofarahine (Clolar®); cyclophosphamide(Cytoxan®, Neosar®); cyclophosphamide (Cytoxan Injection®);cyclophosphamide (Cytoxan Tablet®) cytarabine (Cytosar-Uφ); cytarabineliposomal (DepoCyt®); dacarbazine (MIC-Dome®); dactinomycin, actinomycinD (Cosmegen®); dalteparin sodium injection (Fragmin®); Darhepoetin alfa(Aranesp®); dasatinib (Sprycel®); daunorubicin liposomal (DanuoXome®);daunorubicin, daunomycin (Daunorubicin®); daunorubicin, daunomycin(Cerubidine®); degarelix (Firmagon®); Denileukin diftitox (Ontak®);dexrazoxane (Zinecard®); dexrazoxane hydrochloride (Totec®); didemnin B;17-DMAG; docetaxel (Taxotere®); doxorubicin (Adriamycin PFS®);doxorubicin (Adriamycin®, Rubex®); doxorubicin (Adriamycin PFSInjection®); doxorubicin liposomal (Doxil®); dromostanolone propionate(Dromostanolone®); droniostanolone propionate (Masterorte Injection®);eculizumab injection (Soliris®); B Solution (Elliott's B Solution®);eltrombopag (Promacta®); epirubicin (Ellence®); Epoetin alfa (Epogen®);erlotinib (Tarceva®); estramustine (Emcyt®); ethinyl estradiol;etoposide phosphate (Etopophos®); etoposide, VP-16 (Vepesid®);everolimus tablets (Afinitor®); exemestane (Aromasin®); ferurnoxytol(Feraherne Injection®); Filgrastim (Neupogen®); floxuridine(intraarterial) (FLTDR®); fludarabine (Fludara®); fluorouracil, 5-FU(Adrucil®); fulvestrant (Faslodex®); gefitinib (Iressa®); geldariamyein;gemcitabine (Gemzar®); gemtuzumab ozogamicin (Mylotarg®); goserelinacetate (Zoladex Implant®); goserelin acetate (Zoladex®); histrelinacetate (Histrelin Implant®); hydroxyurea (Hydrea®); IbritumomabTiuxetan (Zevalin®); idarubicin (Idamycin®); ifosfatnide (IFEX®);iniatinib mesylate (Gleevec®); interferon alfa 2a (Roferon A®);Interferon alfa-2b (Intron A®); iobengmane I 123 injection (AdreView®);irinotecan (Camptosar®); ixabepilone (Ixempra®); lapatinib tablets(Tykerh®); lenalidomide (Revlimid®); letrozole (Femara®); leucovorin(Wellcovorin®, Leucovorin®); Leuprolide Acetate (Eligard®); levamisole(Ergamisol®); lomustine, CCNU (CeeBU®); meclorethamine, nitrogen mustard(Mustargen®); megestrol acetate (Megace®); melphalan, PAM (Alkeran®);mercaptopurine, 6-MP (Purinethol®); mesna (Mesnex®); mesna (MesnexTabs®); methotrexate (Methotrexate®); methoxsalen (Uvadex®);8-methoxypsoralen, mitomycin C (Mutarnycin®); mitotane (Lysodren®);mitoxantrone (Novantrone®); mitramycin; nandrolone phenpropionate(Durabolin-50®); nelarabine (Arration®); nilotinih (Tasigna®);Nofetumomab (Verluma®); ofatumumab (Arzerra®); Oprelvekin (Neumega®);oxaliplatin (Eloxatin®); paclitaxel (Paxene®); paclitaxel (Taxol®);paclitaxel protein-bound particles (Abraxane®); palifermin(Kepivarice®); pamidronate (Aredia®); panitumumab (Vectibix®); pazoparibtablets (Votrientim®); pegademase (Adagen (Pegademase Bovine)®);pegaspargase (Oncaspar®); Pegfilgrastirn (Neulasta®); pemetrexeddisodium (Alitntan; pentostatin (Nipent®); pipobroman (Vereyte®);plerixafor (Mozobiln; plicamyein, mithramycin (Mithracin®); porfimersodium (Photofring); pralatrexate injection (Folotyn®); procarbazine(Matulane®); quinacrine (Atabrine®); rapamycin; Rasburicase (Elitek®);raloxifene hydrochloride (Evista®); Rituximab (Rituxart®); romidepsin(Istodax®); romiplostim (Nplate®); sargramostim (Leukine®); Sargramostim(Prokine®); sorafenib (Nexavar®); streptozocin (Zanosar®); sunning)maleate (Sutent®); talc (Scierosol®); tamoxifen (Nolvadex®);temozolomide (Temodar®); temsirolimus (Torisel®); teniposide, VM-26(Vumon®); testolactone (Teslac®); thioguanine, 6-TG (Thioguanine®);thiopurire; thiotepa (Thioplex®); topotecan (Hycamtin®); toremifene(Fareston®); Tositumomab (Bexxar®); Tositurnomab/I-131 tositumomab(Bexxar®); trans-retinoic acid; Trastuzumab (Herceptin®); tretinoin,ATRA (Vesanoid®); triethylenemelamine; Uracil Mustard (Uracil MustardCapsules®); vatrubicin (Valstar®); vinblastine (Velban®); vincristine(Oncovin®); vinorelbine (Navelbine®); vorinostat (Zolinza®); wortmannin;and zoledronate (Zometa®).

The invention also provides a combination comprising an siNA molecule ofthe invention comprising at least a 15 nucleotide sequence of SEQ ID NO:5, SEQ ID NO: 4918, SEQ ID NO: 194, SEQ ID NO: 5107, SEQ ID NO: 196, SEQID NO: 5109, SEQ ID NO: 151, or SEQ ID NO: 5064; or formula (A) and/or apharmaceutically acceptable salt, solvate or physiologically functionalderivative thereof together with another CTNNB1 inhibitor.

The combinations referred to above can conveniently be presented for usein the form of a pharmaceutical formulation and thus pharmaceuticalcompositions comprising a combination as defined above together with apharmaceutically acceptable diluent or carrier represent a furtheraspect of the invention.

The individual compounds of such combinations can be administered eithersequentially or simultaneously in separate or combined pharmaceuticalformulations. In one embodiment, the individual compounds will beadministered simultaneously in a combined pharmaceutical formulation.

Thus, the described molecules could be used in combination with one ormore known compounds, treatments, or procedures to prevent or treatdiseases, disorders, conditions, and traits described herein in asubject or organism as are known in the art, such as other CTNNB1inhibitors.

3. Therapeutic Applications

The present body of knowledge in CTNNB1 research indicates the need formethods that can regulate CTNNB1 expression for therapeutic use.

Thus, one aspect of the invention comprises a method of treating asubject including, but not limited to, a human suffering from acondition which is mediated by the action, or by loss of action, ofCTNNB1 gene expression, which method comprises administering to saidsubject an effective amount of a double-stranded siNA molecule of theinvention. In one embodiment of this aspect, the siNA moleculescomprises at least a 15 nucleotide sequence of SEQ ID NO: 5, SEQ ID NO:4918, SEQ ID NO: 194, SEQ ID NO: 5107, SEQ ID NO: 196, SEQ ID NO: 5109,SEQ ID NO: 151, or SEQ ID NO: 5064; or formula (A). In anotherembodiment of this aspect, the condition is or is caused by cancer.Thus, in certain embodiments the molecules and compositions of theinstant invention are useful in a method for treating cancer. Cancerstreatable according to this aspect of the invention include bilary tractcancer, bladder cancer, transitional cell carcinoma, urothelialcarcinoma, osteosarcoma, brain cancer, gliomas, astrocytomas, breastcarcinoma, metaplastic carcinoma, cervical cancer, cervical squamouscell carcinoma, rectal cancer, colorectal carcinoma, colon cancer,hereditary nonpolyposis colorectal cancer, colorectal adenocarcinomas,gastrointestinal stromal tumors (GISTs), endotnetrial carcinoma,endometrial stromal sarcomas, esophageal cancer, esophageal squamouscell carcinoma, esophageal adenocarcinoma, ocular melanoma, uvealmelanoma, gallbladder carcinomas, gallbladder adenocarcinoma, renal cellcarcinoma, clear cell renal cell carcinoma, transitional cell carcinoma,urothehal carcinomas, wilms tumor, leukemia, acute lymocytic leukemia(ALL), acute myeloid leukemia (AML), chronic lymphocytic (CLL), chronicmyeloid (CML), chronic myelomonocytic (CMML), liver cancer, livercarcinoma, hepatoma, hepatocellular carcinoma, cholangiocarcinoma,hepatoblastoma, lung cancer, non-small cell lung cancer (NSCLC),mesothelioma, B-cell lymphomas, non-Hodgkin lymphoma, diffuse largeB-cell lymphoma, Mantle cell lymphoma, T-cell lymphomas, non-Hodgkinlymphoma, precursor T-lymphoblastic lymphoma/leukemia, peripheral I-celllymphomas, multiple myeloma, nasopharyngeal carcinoma (NPC),neuroblastoma, oropharyngeal cancer, oral cavity squamous cellcarcinomas, osteosarcoma, ovarian carcinoma, pancreatic cancer,pancreatic ductal adenocarcinoma, pseudopapillary neoplasms, acinar cellcarcinomas, prostate cancer, prostate adenocarcinoma, skin cancer,melanoma, malignant melanoma, cutaneous melanoma, small intestinecarcinomas, stomach cancer, gastric carcinoma, gastrointestinal stromaltumor (GIST), uterine cancer, uterine sarcoma

In one embodiment, the siNA molecules of the instant invention areuseful in a method for treating or preventing cancer selected from:brain cancer, breast carcinoma, cervical cancer, colorectal carcinoma,renal cell carcinoma, leukemia, hepatocellular carcinoma, lung cancer,B-cell lymphomas, multiple myeloma, ovarian carcinoma, pancreaticcancer, prostate cancer, melanoma, and gastric carcinoma. In certainembodiments, the compounds of the instant invention are useful fortreating breast carcinoma, colorectal carcinoma, hepatocellularcarcinoma, lung cancer; and prostate cancer. In a particular embodiment,the compounds of the instant invention are useful for treatinghepatocellular carcinoma.

In another embodiment, the siNA molecules of the instant invention areuseful in a method for the prevention or modulation of the metastases ofcancer cells and cancer. In particular, the siNA molecules of theinstant invention are useful in a method to prevent or modulate themetastases of brain cancer, breast carcinoma, cervical cancer,colorectal carcinoma, renal cell carcinoma, leukemia, hepatocellularcarcinoma, lung cancer, B-cell lymphomas, multiple myeloma, ovariancarcinoma, pancreatic cancer, prostate cancer, melanoma, and gastriccarcinoma.

In certain embodiments, the administration of the siNA molecule is vialocal administration or systemic administration. In other embodiments,the invention features contacting the subject or organism with an siNAmolecule of the invention via local administration to relevant tissuesor cells, such as lung cells and tissues, such as via pulmonarydelivery. In yet other embodiments, the invention features contactingthe subject or organism with an siNA molecule of the invention viasystemic administration (such as via intravenous or subcutaneousadministration of siNA) to relevant tissues or cells, such as canceroustissues or cells in a subject or organism.

siNA molecules of the invention are also used as reagents in ex vivoapplications. For example, siNA reagents are introduced into tissue orcells that are transplanted into a subject for therapeutic effect. Thecells and/or tissue can be derived from an organism or subject thatlater receives the explant, or can be derived from another organism orsubject prior to transplantation. The siNA molecules can be used tomodulate the expression of one or more genes in the cells or tissue,such that the cells or tissue obtain a desired phenotype or are able toperform a function when transplanted in vivo. In one embodiment, certainCTNNB1 target cells from a patient are extracted. These extracted cellsare contacted with CTNNB1 siNAs targeting a specific nucleotide sequencewithin the cells under conditions suitable for uptake of the siNAs bythese cells (e.g., using delivery reagents such as cationic lipids,liposomes and the like or using techniques such as electroporation tofacilitate the delivery of siNAs into cells). The cells are thenreintroduced back into the same patient or other patients.

For therapeutic applications, a pharmaceutically effective dose of thesiNA molecules or pharmaceutical compositions of the invention isadministered to the subject. A pharmaceutically effective dose is thatdose required to prevent, inhibit the occurrence, or treat (alleviate asymptom to some extent, preferably all of the symptoms) a disease state.One skilled in the art can readily determine a therapeutically effectivedose of the siNA of the invention to be administered to a given subject,by taking into account factors, such as the size and weight of thesubject, the extent of the disease progression or penetration, the age,health, and sex of the subject, the route of administration, and whetherthe administration is regional or systemic. Generally, an amount between0.1 μg/kg and 100 mg/kg body weight/day of active ingredients isadministered dependent upon potency of the negatively charged polymer.Optimal dosing schedules can be calculated from measurements of drugaccumulation in the body of the patient. The siNA molecules of theinvention can be administered in a single dose or in multiple doses.

siNA molecules of the instant invention can be administered oncemonthly, once weekly, once daily (QD), or divided into multiple monthly,weekly, or daily doses, such as, for example, but not limitation, twicedaily (BID), three times daily (TID), once every two weeks. Persons ofordinary skill in the art can easily estimate repetition rates fordosing based on measured residence times and concentrations of the drugin bodily fluids or tissues.

In addition, the administration can be continuous, i.e., every day, orintermittently. For example, intermittent administration of a compoundof the instant invention may be administration one to six days per weekor it may mean administration in cycles (e.g. daily administration fortwo to eight consecutive weeks, then a rest period with noadministration for up to one week) or it may mean administration onalternate days.

G. Administration

Compositions or formulations can be administered in a variety of sways.Non-limiting examples of administration methods of the invention includeoral, buccal, sublingual, parenteral (i.e., intraarticularly,intravenously, intraperitoneally, subcutaneously, or intramuscularly),local rectal administration or other local administration. In oneembodiment, the composition of the invention can be administered byinsufflation and inhalation. Administration can be accomplished viasingle or divided doses. In some embodiments, the pharmaceuticalcompositions are administered intravenously or intraperitoneally by abolus injection (see, e.g., U.S. Pat. No. 5,286,634). Lipid nucleic acidparticles can be administered by direct injection at the site of diseaseor by injection at a site distal from the site of disease (see, e.g.,Culver, HUMAN GENE THERAPY, MaryAnn Liebert, Inc., Publishers, New York.pp. 70-71 (1994)). In one embodiment, the siNA molecules of theinvention and formulations or compositions thereof are administered to acell, subject, or organism as is described herein and as is generallyknown in the art.

1. in Vivo Administration

In any of the methods of treatment of the invention, the siNA can beadministered to the subject systemically as described herein orotherwise known in the art, either alone as a monotherapy or incombination with additional therapies described herein or as are knownin the art. Systemic administration can include, for example, pulmonary(inhalation, nebulization etc.) intravenous, subcutaneous,intramuscular, catheterization, nasopharangeal, transdermal, ororal/gastrointestinal administration as is generally known in the art.

In any of the methods of treatment or prevention of the invention, thesiNA can be administered to the subject locally or to local tissues asdescribed herein or otherwise known in the art, either alone as amonotherapy or in combination with additional therapies as are known inthe art. Local administration can include, for example, inhalation,nebulization, catheterization, implantation, direct injection,dermal/transdermal application, patches, stenting, ear/eye drops, orportal vein administration to relevant tissues, or any other localadministration technique, method or procedure, as is generally known inthe art.

In one embodiment, the siNA molecules of the invention and formulationsor compositions thereof are administered to the liver as is generallyknown in the art (see for example Wen et al., 2004, World JGastroenterol., 10, 244-9; Murao et al., 2002, Pharm Res., 19, 1808-14;Liu et al., 2003, gene Ther., 10, 180-7; Hong et al., 2003, J PharmPharmacol., 54, 51-8; Herrmann et al., 2004, Arch Virol., 149, 1611-7;and Matsuno et al., 2003, gene Ther, 10, 1559-66).

In one embodiment, the invention features the use of methods to deliverthe siNA molecules of the instant invention to hematopoietic cells,including monocytes and lymphocytes. These methods are described indetail by Hartmann et al., 1998, J. Phamacol. Exp. Ther., 285(2),920-928; Kronenwett et al., 1998, Blood, 91(3), 852-862; Rion andPhillips, 1997, Biochim. Biophys. Acta., 1329(2), 345-356; Ma and Wei,1996, Leuk. Res., 20(11/12), 925-930; and Bongartz et al., 1994, NucleicAcids Research, 22(22), 4681-8.

In one embodiment, the siNA molecules of the invention and formulationsor compositions thereof are administered directly or topically (e.g.,locally) to the dermis or follicles as is generally known in the art(see for example Brand, 2001, Curr. Opin. Mol. Ther., 3, 244-8; Regnieret al., 1998, J. Drug Target, 5, 275-89; Kanikkannan, 2002, BioDrugs,16, 339-47; Wraight et al., 2001, Pharmacol. Ther., 90, 89-104; andPreat and Dujardin, 2001, STP PharmaSciences, 11, 57-68). In oneembodiment, the siNA molecules of the invention and formulations orcompositions thereof are administered directly or topically using ahydroalcoholic gel formulation comprising an alcohol (e.g., ethanol orisopropanol), water, and optionally including additional agents suchisopropyl myristate and carbomer 980. In other embodiments, the siNA areformulated to be administered topically to the nasal cavity. Topicalpreparations can be administered by one or more applications per day tothe affected area; over skin areas occlusive dressings canadvantageously be used. Continuous or prolonged delivery can be achievedby an adhesive reservoir system.

In one embodiment, an siNA molecule of the invention is administerediontophoretically, for example to a particular organ or compartment(e.g., the eye, back of the eye, heart, liver, kidney, bladder,prostate, tumor, CNS etc.). Non-limiting examples of iontophoreticdelivery are described in, for example, WO 03/043689 and WO 03/030989,which are incorporated by reference in their entireties herein.

In one embodiment, the siNA molecules of the invention and formulationsor compositions thereof are administered to the lung as is describedherein and as is generally known in the art. In another embodiment, thesiNA molecules of the invention and formulations or compositions thereofare administered to lung tissues and cells as is described in U.S.Patent Publication Nos, 2006/0062758; 2006/0011289; and 2004/0077540.

2. Aerosols and Delivery Devices

a. Aerosol Formulations

The compositions of the present invention, either alone or incombination with other suitable components, can be made into aerosolformulations (i.e., they can be “nebulized”) to be administered viainhalation (e.g., intranasally or intratracheally) (see, Brigham et al,Am. J. Sci., 298:278 (1989)). Aerosol formulations can be placed intopressurized acceptable propellants, such as dichlorodifluoromethane,propane, nitrogen, and the like.

In one embodiment, the siNA molecules of the invention and formulationsthereof are administered via pulmonary delivery, such as by inhalationof an aerosol or spray dried formulation administered by an inhalationdevice or nebulizer, providing rapid local uptake of the nucleic acidmolecules into relevant pulmonary tissues. Solid particulatecompositions containing respirable dry particles of micronized nucleicacid compositions can be prepared by grinding dried or lyophilizednucleic acid compositions, and then passing the micronized compositionthrough, for example, a 400 mesh screen to break up or separate outlarge agglomerates. A solid particulate composition comprising the siNAcompositions of the invention cart optionally contain a dispersant whichserves to facilitate the formation of an aerosol as well as othertherapeutic compounds. A suitable dispersant is lactose, which can beblended with the nucleic acid compound in any suitable ratio, such as a1 to 1 ratio by weight.

Spray compositions comprising siNA molecules or compositions of theinvention can, for example, be formulated as aqueous solutions orsuspensions or as aerosols delivered from pressurized packs, such as ametered dose inhaler, with the use of a suitable liquefied propellant.In one embodiment, aerosol compositions of the invention suitable forinhalation can be either a suspension or a solution and generallycontain an siNA molecule comprising at least a 15 nucleotide sequence ofSEQ ID NO: 5, SEQ ID NO: 4918, SEQ ID NO: 194, SEQ ID NO: 5107, SEQ IDNO: 196, SEQ ID NO: 5109, SEQ ID NO: 151, or SEQ ID NO: 5064; or formula(A), and a suitable propellant such as a fluorocarbon orhydrogen-containing chlorofluorocarbon or mixtures thereof, particularlyhydrofluoroalkanes, especially 1,1,1,2-tetrafluoroethane,1,1,1,2,3,3,3-heptafluoro-n-propane or a mixture thereof. The aerosolcomposition can optionally contain additional formulation excipientswell known in the art such as surfactants. Non-limiting examples includeoleic acid, lecithin or an oligolactic acid or derivative such as thosedescribed in WO94/21229 and WO98/34596 and co-solvents for exampleethanol. In one embodiment a pharmaceutical aerosol formulation of theinvention comprising a compound of the invention and a fluorocarbon orhydrogen-containing chlorofluorocarbon or mixtures thereof aspropellant, optionally in combination with a surfactant and/or aco-solvent.

The aerosol formulations of the invention can be buffered by theaddition of suitable buffering agents.

Aerosol formulations can include optional additives includingpreservatives if the formulation is not prepared sterile. Non-limitingexamples include, methyl hydroxybenzoate, anti-oxidants, flavorings,volatile oils, buffering agents and emulsifiers and other formulationsurfactants. In one embodiment, fluorocarbon or perfluorocarbon carriersare used to reduce degradation and provide safer biocompatiblenon-liquid particulate suspension compositions of the invention siNAand/or LNP formulations thereof). In another embodiment, a devicecomprising a nebulizer delivers a composition of the invention (e.g.,siNA and/or LNP formulations thereof) comprising fluorochemicals thatare bacteriostatic thereby decreasing the potential for microbial growthin compatible devices.

Capsules and cartridges comprising the composition of the invention foruse in an inhaler or insufflator, of for example gelatine, can beformulated containing a powder mix for inhalation of a compound of theinvention and a suitable powder base such as lactose or starch. In oneembodiment, each capsule or cartridge contains an siNA moleculecomprising at least a 15 nucleotide sequence of SEQ ID NO: 5, SEQ ID NO:4918, SEQ ID NO: 194, SEQ ID NO: 5107, SEQ ID NO: 196, SEQ ID NO: 5109,SEQ ID NO: 151, or SEQ ID NO: 5064; or formula (A), and one or moreexcipients. In another embodiment, the compound of the invention can bepresented without excipients such as lactose

The aerosol compositions of the present invention can be administeredinto the respiratory system as a formulation including particles ofrespirable size, particles of a size sufficiently small to pass throughthe nose, mouth and larynx upon inhalation and through the bronchi andalveoli of the lungs. In general, respirable particles range from about0.5 to 10 microns in size. In one embodiment, the particulate range canbe from 1 to 5 microns. In another embodiment, the particulate range canbe from 2 to 3 microns. Particles of non-respirable size which areincluded in the aerosol tend to deposit in the throat and be swallowed,and the quantity of non-respirable particles in the aerosol is thusminimized. For nasal administration, a particle size in the range of10-500 um is preferred to ensure retention in the nasal cavity.

In some embodiments, an siNA composition of the invention isadministered topically to the nose for example, for the treatment ofrhinitis via pressurized aerosol formulations, aqueous formulationsadministered to the nose by pressurized pump or by nebulization.Suitable formulations contain water as the diluent or carrier for thispurpose. In certain embodiments, the aqueous formulations foradministration of the composition of the invention to the lung or nosecan be provided with conventional excipients such as buffering agents,tonicity modifying agents and the like.

b. Devices

The siNA molecules of the invention can be formulated and delivered asparticles and/or aerosols as discussed above and dispensed from variousaerosolization devices known by, those of skill in the art.

Aerosols of liquid or non-liquid particles comprising an siNA moleculeor formulation of the invention can be produced by any suitable means,such as with a device comprising a nebulizer (see for example U.S. Pat.No. 4,501,729) such as ultrasonic or air jet nebulizers.

Solid particle aerosols comprising an siNA molecule or formulation ofthe invention and surfactant can be produced with any solid particulateaerosol generator. One type of solid particle aerosol generator usedwith the siNA molecules of the invention is an insufflator. A secondtype of illustrative aerosol generator comprises a metered dose inhaler(“MDI”). MDIs containing siNA molecules or formulations taught hereincan be prepared by methods of the art (for example, see Byron, above andWO96/32099).

The siNA molecules can also be formulated as a fluid formulation fordelivery from a fluid dispenser, such as those described and illustratedin WO05/044354.

In certain embodiments of the invention, nebulizer devices are used inapplications for conscious, spontaneously breathing subjects, and forcontrolled ventilated subjects of all ages. The nebulizer devices can beused for targeted topical and systemic drug delivery to the lung. In oneembodiment, a device comprising a nebulizer is used to deliver an siNAmolecule or formulation of the invention locally to lung or pulmonarytissues. In another embodiment, a device comprising a nebulizer is usedto deliver a an siNA molecule or formulation of the inventionsystemically.

H. Other Applications/Uses of siNA Molecules of the Invention

The siNA molecules of the invention can also be used for diagnosticapplications, research applications, and/or manufacture of medicants.

In one aspect, the invention features a method for diagnosing a disease,trait, or condition in a subject comprising administering to the subjecta composition of the invention under conditions suitable for thediagnosis of the disease, trait, or condition in the subject.

In one embodiment, siNA molecules of the invention are used to downregulate or inhibit the expression of CTNNB1 proteins arising fromhaplotype polymorphisms that are associated with a trait, disease orcondition in a subject or organism. Analysis of CTNNB1 genes, or CTNNB1protein or RNA levels can be used to identify subjects with suchpolymorphisms or those subjects who are at risk of developing traits,conditions, or diseases described herein. These subjects are amenable totreatment, for example, treatment with siNA molecules of the inventionand any other composition useful in treating diseases related to targetgene expression. As such, analysis of CTNNB1 protein or RNA levels canbe used to determine treatment type and the course of therapy intreating a subject. Monitoring of CTNNB1 protein or RNA levels can beused to predict treatment outcome and to determine the efficacy ofcompounds and compositions that modulate the level and/or activity ofcertain CTNNB1 proteins associated with a trait, disorder, condition, ordisease.

In another embodiment, the invention comprises use of a double-strandednucleic acid according to the invention for use in the manufacture of amedicament. In an embodiment, the medicament is for use in treating acondition that is mediated by the action, or by loss of action, ofCTNNB1. In one embodiment, the medicament is for use for the treatmentof cancer. In an embodiment, the medicament is for use for the treatmentof brain cancer, breast carcinoma, cervical cancer, colorectalcarcinoma, renal cell carcinoma, leukemia, hepatocellular carcinoma,lung cancer, B-cell lymphomas, multiple myeloma, ovarian carcinoma,pancreatic cancer, prostate cancer, melanoma, and gastric carcinoma. Ina particular embodiment, the compounds of the instant invention areuseful for treating hepatocellular carcinoma.

In certain embodiments, siNAs wherein at least one strand comprises atleast a 15 nucleotide sequence of SEQ ID NO: 5, SEQ ID NO: 4918, SEQ IDNO: 194, SEQ ID NO: 5107, SEQ ID NO: 196, SEQ ID NO: 5109, SEQ ID NO:151, or SEQ ID NO: 5064; or formula (A),are for use in a method fortreating a cancer, such as, for example but not limitation, braincancer, breast carcinoma, cervical cancer, colorectal carcinoma, renalcell carcinoma, leukemia, hepatocellular carcinoma, lung cancer, B-celllymphomas, multiple myeloma, ovarian carcinoma, pancreatic cancer,prostate cancer, melanoma, and gastric carcinoma.

I. Examples

The invention will now be illustrated with the following non-limitingexamples. Those of skill in the art will readily recognize a variety ofnon-critical parameters which can be changed or modified to yieldessentially the same results.

Example 1: Design, Synthesis, and Identification of siNAs Active AgainstCTNNB1

CTNNB1 siNA Synthesis

A series of siNA molecules were designed, synthesized and evaluated forefficacy against CTNNB1 gene expression. Certain CTNNB1 sequences weredesigned and selected by methods set forth in U.S. Application No.60/182,604. Other sequences were designed and selected using aproprietary algorithm. The primary criteria for design of certain of theCTNNB1 sequences for human siNAs were (i) homology between two species(human and rhesus monkey) and (ii) high efficacy scores as determined bya proprietary algorithm. The effects of the siNAs on CTNNB1 RNA levels.The target sequences of the siNAs that were selected are set forth inTable 1a (target sequences). The sense and antisense strands of thesiNA, sequences corresponding to the target sequences in Table 1a areset forth in Table 1b. Various chemically modified siNAs that weresynthesized are set forth in Table 1c.

TABLE 1a CTNNB1 Target Sequences, noting human target sites. Target SiteSEQ ID Target Sequence (human) NO: 1 UCGAGCUCAGAGGGUACGA  535    1GAGGCUCUUGUGCGUACUG 1601    2 GCCCAGAAUGCAGUUCGCC 1709    3CGAGCUCAGAGGGUACGAG  536    4 CUGUUGGAUUGAUUCGAAA 1797    5GUCUGCUAUUGUACGUACC  853    6 AAUUCUUGGCUAUUACGAC 1143    7GGAUGUUCACAACCGAAUU 2014    8 ACAGUAUGCAAUGACUCGA  520    9AGCUUCCAGACACGCUAUC  814   10 UGUCUGCUAUUGUACGUAC  852   11ACUGUUGGAUUGAUUCGAA 1796   12 CAGGAUACCCAGCGCCGUA 1901   13GACACGCUAUCAUGCGUUC  822   14 UACUGUUGGAUUGAUUCGA 1795   15UUCUUGGCUAUUACGACAG 1145   16 ACACGCUAUCAUGCGUUCU  823   17CAGACACGCUAUCAUGCGU  820   18 UGUUGGAUUGAUUCGAAAU 1798   19CAGAUCCAAGUCAACGUCU 1380   20 AGGCUCUUGUGCGUACUGU 1602   21GCGUACUGUCCUUCGGGCU 1612   22 ACUAAUGUCCAGCGUUUGG  626   23CACAUCCUAGCUCGGGAUG 2000   24 GUUGCUGAGAGGGCUCGAG 2665   25CAUCUGACCAGCCGACACC 1676   26 UGCGUACUGUCCUUCGGGC 1611   27ACAAGAUUACAAGAAACGG 2269   28 GUUGUAAACUUGAUUAACU  674   29UAAACUUGAUUAACUAUCA  678   30 AUAUAAUGAGGACCUAUAC 1245   31AAACUUGAUUAACUAUCAA  679   32 GAAAUAGUUGAAGGUUGUA 1970   33AUAAUGAGGACCUAUACUU 1247   34 UUAAAUUCUUGGCUAUUAC 1140   35UGUAAACUUGAUUAACUAU  676   36 GUAAACUUGAUUAACUAUC  677   37UUGUAAACUUGAUUAACUA  675   38 GCUUUAGUAAAUAUAAUGA 1235   39UGGCCACCACCCUGGUGCU 2488   40 CUUUAGUAAAUAUAAUGAG 1236   41UUUAGUAAAUAUAAUGAGG 1237   42 GUAAAUCGUCCUUUAGGUA 2555   43ACCUCACUUGCAAUAAUUA 1545   44 UACCAUUCCAUUGUUUGUG 2050   45UCCAAAGAGUAGCUGCAGG 2097   46 UAUCCAGUUGAUGGGCUGC 2510   47CAUGCAGAAUACAAAUGAU  871   48 CCAAAGAGUAGCUGCAGGG 2098   49CACCAUCCCACUGGCCUCU 1767   50 ACCAUGCAGAAUACAAAUG  869   51AAGACAUCACUGAGCCUGC 1641   52 AAUCAGCUGGCCUGGUUUG 2582   53AACCUCACUUGCAAUAAUU 1544   54 ACCUCAUGGAUGGGCUGCC 2550   55ACCAUUCCAUUGUUUGUGC 2051   56 CCAUGCAGAAUACAAAUGA  870   57CUUCGUCAUCUGACCAGCC 1670   58 CUGUGAACUUGCUCAGGAC 2122   59AGACAUCACUGAGCCUGCC 1642   60 GAGCCAAUGGCUUGGAAUG 2324   61ACUGAGCCUGCCAUCUGUG 1649   62 AUUGAAGCUGAGGGAGCCA 2159   63GUUAUGGUCCAUCAGCUUU  785   64 AAUGUGGUCACCUGUGCAG 1511   65AGCUGGCCUGGUUUGAUAC 2586   66 UGGCUGAACCAUCACAGAU  642   67CACCCACCAUCCCACUGGC 1763   68 CAAUGGCUUGGAAUGAGAC 2328   69UGGACCACAAGCAGAGUGC 1280   70 CCAUUCCAUUGUUUGUGCA 2052   71CAGGACCUCAUGGAUGGGC 2546   72 GUGAACUUGCUCAGGACAA 2124   73CCAGGACCUCAUGGAUGGG 2545   74 GGCUGAACCAUCACAGAUG  643   75GGUGCUGACUAUCCAGUUG 2501   76 AUGGCUUGGAAUGAGACUG 2330   77GGGAAGACAUCACUGAGCC 1638   78 UGGUGACAGGGAAGACAUC 1630   79UGCUCAUCCCACUAAUGUC  616   80 CUAUCCAGUUGAUGGGCUG 2509   81GGACCUCAUGGAUGGGCUG 2548   82 CCCACUGGCCUCUGAUAAA 1773   83UCCGAAUGUCUGAGGACAA 2247   84 UGGCUUGGAAUGAGACUGC 2331   85UUCAGAUGAUAUAAAUGUG 1498   86 CCACAAGAUUACAAGAAAC 2267   87CUCACUUGCAAUAAUUAUA 1547   88 CACUUGCAAUAAUUAUAAG 1549   89GUACCAUGCAGAAUACAAA  867   90 UCAACGUCUUGUUCAGAAC 1390   91AUCCCAUCUACACAGUUUG  593   92 UACUCAAGCUGAUUUGAUG  274   93ACCAGGUGGUGGUUAAUAA  759   94 GCUGCAACUAAACAGGAAG 1439   95UGGAUUGAUUCGAAAUCUU 1801   96 CAGAUGAUAUAAAUGUGGU 1500   97AUGGUGUCUGCUAUUGUAC  848   98 CACAAGAUUACAAGAAACG 2268   99CAAAUGAUGUAGAAACAGC  882  100 GCCACAAGAUUACAAGAAA 2266  101UACAAAUGAUGUAGAAACA  880  102 UCGAAAUCUUGCCCUUUGU 1810  103GAUUAACUAUCAAGAUGAU  685  104 CCAGUGGAUUCUGUGUUGU 1007  105AAAGGCUACUGUUGGAUUG 1789  106 ACAAGUAGCUGAUAUUGAU  499  107GAUGGAACAUGAGAUGGGU 2470  108 UCAAGAUGAUGCAGAACUU  674  109CAAGCUGAUUUGAUGGAGU  278  110 UGGACUCUCAGGAAUCUUU 1415  111UAAAUACCAUUCCAUUGUU 2046  112 AUUACAUCAAGAAGGAGCU 1057  113UCAGGAAUCUUUCAGAUGC 1422  114 UGAUUAACUAUCAAGAUGA  684  115ACUUCACUCUAGGAAUGAA 2197  116 AACAUGCAGUUGUAAACUU  666  117AAGCUGAUUUGAUGGAGUU  279  118 UCUGGGUUCAGAUGAUAUA 1492  119UUACUUCACUCUAGGAAUG 2195  120 AGGAAUCUUUCAGAUGCUG 1424  121GCUGAAACAUGCAGUUGUA  661  122 GUUGCUUGUUCGUGCACAU 1882  123GGAAGAAAUAGUUGAAGGU 1966  124 AGGACAAGCCACAAGAUUA 2259  125CAUGCGUUCUCCUCAGAUG  832  126 GAUGAUCCCAGCUACCGUU 2346  127AGCCUGCCAUCUGUGCUCU 1653  128 UGGAUAUCGCCAGGAUGAU 2389  129UCUUCGUCAUCUGACCAGC 1669  130 UGUGAACUUGCUCAGGACA 2123  131CCUGUGCAGCUGGAAUUCU 1521  132 UGAACUUGCUCAGGACAAG 2125  133UGCUGACUAUCCAGUUGAU 2503  134 GAUGAUAUAAAUGUGGUCA 1502  135GUGCUGACUAUCCAGUUGA 2502  136 UGACUAUCCAGUUGAUGGG 2506  137AACUUGCUCAGGACAAGGA 2127  138 CUGACUAUCCAGUUGAUGG 2505  139GCUCAUCCCACUAAUGUCC  617  140 GCUGACUAUCCAGUUGAUG 2504  141AUGAUAUAAAUGUGGUCAC 1503  142 CUCAUCCCACUAAUGUCCA  618  143GCUUUAUUCUCCCAUUGAA 2074  144 CUGGUGCUGACUAUCCAGU 2499  145AACUGUCUUUGGACUCUCA 1406  146 AGGGCAUGCAGAUCCCAUC  582  147GAUAUAAAUGUGGUCACCU 1505  148 UUCAGAUGCUGCAACUAAA 1432  149AAGAAAUAGUUGAAGGUUG 1968  150 CCAGGAUGAUCCUAGCUAU 2398  151UGGCCAUCUUUAAGUCUGG  954  152 AGCUGAUAUUGAUGGACAG  505  153UCGGGAUGUUCACAACCGA 2011  154 UGUAGAAGCUGGUGGAAUG 1339  155UAAAUAUAAUGAGGACCUA 1242  156 CUGAGACAUUAGAUGAGGG  567  157AGUAAAUAUAAUGAGGACC 1240  158 UGGAUACCUCCCAAGUCCU  438  159AGGAUGCCUUGGGUAUGGA 2445  160 AUUGUACGUACCAUGCAGA  860  161UUUGGACUCUCAGGAAUCU 1413  162 UUGGAUUGAUUCGAAAUCU 1800  163UCAGAGGACUAAAUACCAU 2037  164 CCAGGAUGCCUUGGGUAUG 2443  165AUGGAACAUGAGAUGGGUG 2471  166 GGCUACUGUUGGAUUGAUU 1792  167AGGACCUCAUGGAUGGGCU 2547  168 UCUGUGCUCUUCGUCAUCU 1662  169UGAUGGAGUUGGACAUGGC  288  170 AUGAGGGCAUGCAGAUCCC  579  171ACUAUCCAGUUGAUGGGCU 2508  172 UGAGGGCAUGCAGAUCCCA  580  173UUGGAUAUCGCCAGGAUGA 2388  174 GCCCAGGACCUCAUGGAUG 2543  175AACUUGCCACACGUGCAAU  708  176 CCCAAGUCCUGUAUGAGUG  447  177CACAGAUGCUGAAACAUGC  654  178 CUGGGACCUUGCAUAACCU  912  179AGUGGAUUCUGUGUUGUUU 1009  180 AAUGCAAGCUUUAGGACUU 1354  181AGAAAUAGUUGAAGGUUGU 1969  182 UCCGCAUGGAAGAAAUAGU 1959  183GCUAUGUUCCCUGAGACAU  557  184 UCUGAGUGGUAAAGGCAAU  403  185UGCAAGCUUUAGGACUUCA 1356  186 UGGACAGUAUGCAAUGACU  517  187UUAGUAAAUAUAAUGAGGA 1238  188 CUCAGAUGGUGUCUGCUAU  843  189AGAACAAGUAGCUGAUAUU  496  190 CUUGGAUAUCGCCAGGAUG 2387  191CAUCUGUGCUCUUCGUCAU 1660  192 CCCUGGUGCUGACUAUCCA 2497  193ACGACUAGUUCAGUUGCUU 1870  194 UCUUGGACUUGAUAUUGGU 2353  195GGAUGAUCCUAGCUAUCGU 2401  196 AAUACAAAUGAUGUAGAAA  878  197GAACCAUCACAGAUGCUGA  647  198 UUCACAUCCUAGCUCGGGA 1998  199UGCAGAUCCCAUCUACACA  588  200 GGACUAAAUACCAUUCCAU 2042  201CUGCUAUUGUACGUACCAU  855  202 CAGAGGACUAAAUACCAUU 2038  203GAUAAAGGCUACUGUUGGA 1786  204 AGAUGAUAUAAAUGUGGUC 1501  205AAAUCAUGCACCUUUGCGU 1834  206 ACGACAGACUGCCUUCAAA 1157  207UAGUAAAUAUAAUGAGGAC 1239  208 UAAUGAGGACCUAUACUUA 1248  209UGCUGAAACAUGCAGUUGU  660  210 AUUUGAUGGAGUUGGACAU  285  211CUGCCAAGUGGGUGGUAUA 1582  212 UGGACUACCAGUUGUGGUU 1735  213UUAAUAAGGCUGCAGUUAU  771  214 ACAUCAAGAAGGAGCUAAA 1060  215GGAUAUCGCCAGGAUGAUC 2390  216 CUGACAGAGUUACUUCACU 2186  217GUGACAGGGAAGACAUCAC 1632  218 UCAUCCCACUAAUGUCCAG  619  219CUGCCAUCUGUGCUCUUCG 1656  220 AUAUAAAUGUGGUCACCUG 1506  221CCACCCUGGUGCUGACUAU 2494  222 UGCUCUUCGUCAUCUGACC 1666  223ACAGGGAAGACAUCACUGA 1635  224 AGUUGGACAUGGCCAUGGA  294  225UUGGCUGAACCAUCACAGA  641  226 UAGAUGAGGGCAUGCAGAU  576  227AGAUGAGGGCAUGCAGAUC  577  228 AUCUGUGCUCUUCGUCAUC 1661  229GAACUUGCCACACGUGCAA  707  230 CCAUCUGUGCUCUUCGUCA 1659  231AUGGCAACCAAGAAAGCAA 1185  232 GAAACAUGCAGUUGUAAAC  664  233UGGUUAAGCUCUUACACCC 1749  234 AGCUUUAGUAAAUAUAAUG 1234  235CUAUCAAGAUGAUGCAGAA  691  236 AAGUCAACGUCUUGUUCAG 1387  237GAUCCAAGUCAACGUCUUG 1382  238 CUAUCAUGCGUUCUCCUCA  828  239AAUAUAAUGAGGACCUAUA 1244  240 GUGCUAUCUGUCUGCUCUA 1304  241UAAUUAUAAGAACAAGAUG  812  242 AUACAAAUGAUGUAGAAAC 1558  243AUACAAAUGAUGUAGAAAC  879  244 CUGUCUGCUCUAGUAAUAA 1311  245UGCUAUUGUACGUACCAUG  856  246 UGCUGAAGGUGCUAUCUGU 1296  247UCUUUAAGUCUGGAGGCAU  960  248 AUACCAUUCCAUUGUUUGU 2049  249AGGCUACUGUUGGAUUGAU 1791  250 CAGUUAUGGUCCAUCAGCU  783  251ACAAGAUGAUGGUCUGCCA 1569  252 GACAUAUGCAGCUGCUGUU 2224  253CCAUCAUCGUGAGGGCUUA  934  254 GACAGAUCCAAGUCAACGU 1378  255GAGACAUUAGAUGAGGGCA  569  256 UUCGCCUUCACUAUGGACU 1722  257UGUUCAGCUUCUGGGUUCA 1473  258 AUCUUGGACUUGAUAUUGG 2352  259CGUGCAAUCCCUGAACUGA  719  260 AGGUGGUGGUUAAUAAGGC  762  261UCUACACAGUUUGAUGCUG  599  262 AGAUGGCCCAGAAUGCAGU 1704  263CAAGAUUACAAGAAACGGC 2270  264 CUGAAACAUGCAGUUGUAA  662  265CUCCUUCUCUGAGUGGUAA  396  266 AGCAAGCUCAUCAUACUGG 1199  267AUUAUAAGAACAAGAUGAU 1560  268 UCUGUCUGCUCUAGUAAUA 1310  269AAGCUUUAGUAAAUAUAAU 1233  270 GCCGGCUAUUGUAGAAGCU 1330  271UGUCUGCUCUAGUAAUAAG 1312  272 AAUAAUUAUAAGAACAAGA 1556  273UAUGGCCAGGAUGCCUUGG 2438  274 UGUCCCGCAAAUCAUGCAC 1829  275CUUGUUCAGAACUGUCUUU 1397  276 GCUGUGAUACGAUGCUUCA 3181  277GCGCCGUACGUCCAUGGGU 1912  278 AGAUGGUGUCUGCUAUUGU  846  279AGAACUGUCUUUGGACUCU 1404  280 CAUGCAGAUCCCAUCUACA  586  281CUCCUUGGGACUCUUGUUC 1469  282 GGUGCCACUACCACAGCUC  380  283AGCUGGUGGAAUGCAAGCU 1345  284 CCAUUCCACGACUAGUUCA 1863  285CAGCGUUUGGCUGAACCAU  635  286 AUCUUUAAGUCUGGAGGCA  959  287UGGCCAGGAUGCCUUGGGU 2440  288 GAAUACAAAUGAUGUAGAA  877  289UGGAUGGGCUGCCUCCAGG 2556  290 CGUACGUCCAUGGGUGGGA 1916  291GGUGUCUGCUAUUGUACGU  850  292 GGUGCUAUCUGUCUGCUCU 1303  293CCUUCACUAUGGACUACCA 1726  294 GACUCUUGUUCAGCUUCUG 1477  295AUCUACACAGUUUGAUGCU  598  296 GUUUGUGCAGCUGCUUUAU 2062  297CAAGAAACGGCUUUCAGUU 2278  298 GUUCAGUUGCUUGUUCGUG 1877  299UCAGAUGAUAUAAAUGUGG 1499  300 AAUGUUAAAUUCUUGGCUA 1136  301UGGGUUCAGAUGAUAUAAA 1494  302 AAUAGUUGAAGGUUGUACC 1972  303CAUGCAGUUGUAAACUUGA  668  304 AAUCUGAAUAAAGUGUAAC 2945  305CACCACCCUGGUGCUGACU 2492  306 GAGUUGGACAUGGCCAUGG  293  307AUACCCAGCGCCGUACGUC 1905  308 GAGGGCUUACUGGCCAUCU  944  309GAGGGCAUGCAGAUCCCAU  581  310 GAAGGGAUGGAAGGUCUCC 1454  311GUCUGAGGACAAGCCACAA 2254  312 UCAUGCACCUUUGCGUGAG 1837  313GGAAUCUUUCAGAUGCUGC 1425  314 UCACCUGACAGAUCCAAGU 1372  315CUGAAGGUGCUAUCUGUCU 1298  316 GUCAUCUGACCAGCCGACA 1674  317CAUUCCACGACUAGUUCAG 1864  318 UGAUCCUAGCUAUCGUUCU 2404  319GAGCCCUUCACAUCCUAGC 1992  320 GAUGAGGGCAUGCAGAUCC  578  321AUGGGUAGGGUAAAUCAGU 3081  322 GUGCAAUCCCUGAACUGAC  720  323AUUCCAUUGUUUGUGCAGC 2054  324 CAUUCUGGUGCCACUACCA  374  325UACCAUGCAGAAUACAAAU  868  326 AUGCAGUUCGCCUUCACUA 1716  327UUACUGGCCAUCUUUAAGU  950  328 GCUUCUGGGUUCAGAUGAU 1489  329CAGGAAGGGAUGGAAGGUC 1451  330 GCUUAUGGCAACCAAGAAA 1181  331UGACAGGGAAGACAUCACU 1633  332 AUCGCCAGGAUGAUCCUAG 2395  333AGUAAUAAGCCGGCUAUUG 1322  334 AAUGAUGUAGAAACAGCUC  884  335UCUGAGGACAAGCCACAAG 2255  336 GGUCUCCUUGGGACUCUUG 1466  337UGUUCAGAACUGUCUUUGG 1399  338 CUGGUGCCACUACCACAGC  378  339GUCCAUGGGUGGGACACAG 1921  340 GUGCGUUUAGCUGGUGGGC 1085  341ACGUACCAUGCAGAAUACA  865  342 GAUGUUCACAACCGAAUUG 2015  343AGAAAGCAAGCUCAUCAUA 1195  344 GUUCAGCUUCUGGGUUCAG 1484  345GCAGGGUGCCAUUCCACGA 1855  346 UAGAAGCUGGUGGAAUGCA 1341  347CAUGGAAGAAAUAGUUGAA 1963  348 UGAUAUUGGUGCCCAGGGA 2362  349GGCAUGCAGAUCCCAUCUA  584  350 CGUACUGUCCUUCGGGCUG 1613  351UUACGACAGACUGCCUUCA 1155  352 UAGUCACUGGCAGCAACAG  334  353GCCAUUACAACUCUCCACA 1031  354 GCCUUCACUAUGGACUACC 1725  355GUUCACAACCGAAUUGUUA 2018  356 GGGACCUUGCAUAACCUUU  915  357AAGCCACAAGAUUACAAGA 2264  358 GCAGCAACAGUCUUACCUG  343  359UAUUACAUCAAGAAGGAGC 1056  360 UAAUAAGGCUGCAGUUAUG  772  361GGUGGUGGUUAAUAAGGCU  763  362 UAAUGUCCAGCGUUUGGCU  628  363CUUCUCUGAGUGGUAAAGG  399  364 ACCAGCCGACACCAAGAAG 1682  365AUACCUCCCAAGUCCUGUA  441  366 UCACUAUGGACUACCAGUU 1729  367AGGAUACCCAGCGCCGUAC 1902  368 AGGGAAGACAUCACUGAGC 1637  369GAUAUCGCCAGGAUGAUCC 2391  370 AAGUAGCUGAUAUUGAUGG  501  371CAAGCUUUAGGACUUCACC 1358  372 CCCUUUGUCCCGCAAAUCA 1821  373UUAGAUGAGGGCAUGCAGA  575  374 CAAUGACUCGAGCUCAGAG  528  375GUGGAUAUGGCCAGGAUGC 2433  376 GUUCAGAUGAUAUAAAUGU 1497  377UCAGGACAAGGAAGCUGCA 2134  378 UUGAAGCUGAGGGAGCCAC 2160  379UGGAGUUGGACAUGGCCAU  291  380 AGAUGCUGAAACAUGCAGU  657  381UGAUGGUCUGCCAAGUGGG 1575  382 ACAUGCAGUUGUAAACUUG  667  383CAGAGUUACUUCACUCUAG 2190  384 GACUCGAGCUCAGAGGGUA  532  385CUGGCCAUCUUUAAGUCUG  953  386 UACGAUGCUUCAAGAGAAA 3188  387UGACCAGCUCUCUCUUCAG 2301  388 CUCUCUUCAGAACAGAGCC 2310  389GCUUUCAGUUGAGCUGACC 2287  390 GGGUGGGACACAGCAGCAA 1927  391UGCCACACGUGCAAUCCCU  712  392 UCUGUGAACUUGCUCAGGA 2121  393UGAGUAAUGGUGUAGAACA 2898  394 GUUGGAUUGAUUCGAAAUC 1799  395UACAACUCUCCACAACCUU 1036  396 CAAGUCCUGUAUGAGUGGG  449  397AGGAAGGGAUGGAAGGUCU 1452  398 AGCUCAUCAUACUGGCUAG 1203  399GCAAGCUUUAGGACUUCAC 1357  400 AUGUGGUCACCUGUGCAGC 1512  401ACUCAAGCUGAUUUGAUGG  275  402 GACAUGGCCAUGGAACCAG  299  403GUAAAUAUAAUGAGGACCU 1241  404 CGCAUGGAAGAAAUAGUUG 1961  405GAUGCUGCAACUAAACAGG 1436  406 UGAUGGAACAUGAGAUGGG 2469  407CCAGGUGGUGGUUAAUAAG  760  408 UGAGGACAAGCCACAAGAU 2257  409ACUGGCCAUCUUUAAGUCU  952  410 AACGGCUUUCAGUUGAGCU 2283  411CUACUGUUGGAUUGAUUCG 1794  412 GUUGUGGUUAAGCUCUUAC 1745  413AUACUGGCUAGUGGUGGAC 1211  414 GACCUCAUGGAUGGGCUGC 2549  415UAGCUCGGGAUGUUCACAA 2007  416 GAACAUGAGAUGGGUGGCC 2474  417CAGAAUGCAGUUCGCCUUC 1712  418 ACGUCCAUGGGUGGGACAC 1919  419UGGUUCACCAGUGGAUUCU 1000  420 AUAUCGCCAGGAUGAUCCU 2392  421AACAGGAAGGGAUGGAAGG 1449  422 GUUGAGCUGACCAGCUCUC 2294  423AAAUGUUAAAUUCUUGGCU 1135  424 GGCUAUUGUAGAAGCUGGU 1333  425CAGUUGUGGUUAAGCUCUU 1743  426 CUACACAGUUUGAUGCUGC  600  427UGGAGGCAUUCCUGCCCUG  970  428 GGACAGUUUACCAGUUGCC 3137  429UCCAUUCUGGUGCCACUAC  372  430 UACACCCACCAUCCCACUG 1761  431CUGAGCCUGCCAUCUGUGC 1650  432 GAGGCAUUCCUGCCCUGGU  972  433CUUGGCUAUUACGACAGAC 1147  434 CCCUGAGACAUUAGAUGAG  565  435AUGCAAUGACUCGAGCUCA  525  436 UAGAGGCUCUUGUGCGUAC 1599  437UUCACUCUAGGAAUGAAGG 2199  438 GACAAGCCACAAGAUUACA 2261  439CAGAACUUGCCACACGUGC  705  440 GACCUUGCAUAACCUUUCC  916  441CACUACCACAGCUCCUUCU  385  442 CUAUUUGGGAUAUGUAUGG 3076  443UCUUGUUCAGAACUGUCUU 1396  444 GAUGCCUUGGGUAUGGACC 2447  445UUGUAGAAGCUGGUGGAAU 1338  446 AGGUGUGGCGACAUAUGCA 2215  447GCAAUCCCUGAACUGACAA  722  448 UGCUCUAGUAAUAAGCCGG 1316  449CCGACACCAAGAAGCAGAG 1687  450 AGAUGAUGCAGAACUUGCC  697  451UUGAUGGGCUGCCAGAUCU 2517  452 AGCCGACACCAAGAAGCAG 1685  453UAUGGGUAGGGUAAAUCAG 3090  454 CUCAUCAUACUGGCUAGUG 1205  455UAUUACGACAGACUGCCUU 1153  456 CAAUCCCUGAACUGACAAA  723  457UCUCCUUGGGACUCUUGUU 1468  458 GAGAUGGGUGGCCACCACC 2480  459CAGGGUGCCAUUCCACGAC 1856  460 AGUUACUUCACUCUAGGAA 2193  461UUGGACUUGAUAUUGGUGC 2355  462 CCCUUCACAUCCUAGCUCG 1995  463AGACACGCUAUCAUGCGUU  821  464 AAUGCAGUUCGCCUUCACU 1715  465CUUAUGGCAACCAAGAAAG 1182  466 CUCCCAAGUCCUGUAUGAG  445  467CUUACACCCACCAUCCCAC 1759  468 UGGAAGGUCUCCUUGGGAC 1461  469AGCCCUUCACAUCCUAGCU 1993  470 GAUGGGCUGCCUCCAGGUG 2558  471AGCUUCUGGGUUCAGAUGA 1488  472 GAGCCUGCCAUCUGUGCUC 1652  473UUAAGUCUGGAGGCAUUCC  963  474 ACCUGUGCAGCUGGAAUUC 1520  475UCCCGCAAAUCAUGCACCU 1828  476 AAGGUGUGGCGACAUAUGC 2214  477AGCUAUUGAAGCUGAGGGA 2155  478 GUUAGUCACUGGCAGCAAC  332  479UUCAGUUGCUUGUUCGUGC 1878  480 GAUGAUGGUCUGCCAAGUG 1573  481CUAAACAGGAAGGGAUGGA 1446  482 CCACGACUAGUUCAGUUGC 1868  483ACUAGUUCAGUUGCUUGUU 1873  484 GUUCACCAGUGGAUUCUGU 1002  485GUGGUAAAGGCAAUCCUGA  408  486 UUGAUGGAGUUGGACAUGG  287  487ACUUGCUCAGGACAAGGAA 2128  488 CCAGUUGAUGGGCUGCCAG 2513  489GAAAGCAAGCUCAUCAUAC 1196  490 ACAUUAGAUGAGGGCAUGC  572  491UCCCACUAAUGUCCAGCGU  622  492 GGCAACCAAGAAAGCAAGC 1187  493AAAUAGUUGAAGGUUGUAC 1971  494 GGAUAUGUAUGGGUAGGGU 3083  495UAAUCUGAAUAAAGUGUAA 2944  496 UGCACAUCAGGAUACCCAG 1894  497GUAAUAAGCCGGCUAUUGU 1323  498 AAGCUCAUCAUACUGGCUA 1202  499ACGUGCAAUCCCUGAACUG  718  500 AGUUGUGGUUAAGCUCUUA 1744  501AGGACCAGGUGGUGGUUAA  756  502 GCUCUAGUAAUAAGCCGGC 1317  503GAUUUGAUGGAGUUGGACA  284  504 UGAUGUAGAAACAGCUCGU  886  505CUGGUGGAUAUGGCCAGGA 2430  506 CAUCAUACUGGCUAGUGGU 1207  507GAUCCCAUCUACACAGUUU  592  508 CACGCUAUCAUGCGUUCUC  824  509GACAGUAUGCAAUGACUCG  519  510 AAGUUGUUGUAACCUGCUG 3166  511GCUAUUACGACAGACUGCC 1151  512 GCCUCCAGGUGACAGCAAU 2566  513UCCUGUAUGAGUGGGAACA  453  514 AUGCAGAUCCCAUCUACAC  587  515UUUCCCAUCAUCGUGAGGG  930  516 CCAAGUGGGUGGUAUAGAG 1585  517GGACCUUGCAUAACCUUUC  915  518 UCCCAAGUCCUGUAUGAGU  446  519CACGACUAGUUCAGUUGCU 1869  520 CCGCAUGGAAGAAAUAGUU 1960  521GGCCCAGAAUGCAGUUCGC 1708  522 CCAUGGAACCAGACAGAAA  303  523GAAACGGCUUUCAGUUGAG 2281  524 GGGAUAUGUAUGGGUAGGG 3082  525UUGGGACUCUUGUUCAGCU 1473  526 UAUGUUCCCUGAGACAUUA  559  527GGACUCUCAGGAAUCUUUC 1416  528 AAGCUGCAGAAGCUAUUGA 2145  529GCCCUUCACAUCCUAGCUC 1994  530 AGAGAUGGCCCAGAAUGCA 1702  531GCAAUCCUGAGGAAGAGGA  417  532 CAGGAUGCCUUGGGUAUGG 2444  533CUGCUAUGUUCCCUGAGAC  555  534 UUCACAACCGAAUUGUUAU 2019  535AAAGCAAGCUCAUCAUACU 1197  536 AGGCAAUCCUGAGGAAGAG  415  537UGUUUGUGCAGCUGCUUUA 2061  538 GGAAUGCAAGCUUUAGGAC 1352  539CCGGCUAUUGUAGAAGCUG 1331  540 AAUAAGCCGGCUAUUGUAG 1325  541UCAGCUUCUGGGUUCAGAU 1486  542 CCUGUAUGAGUGGGAACAG  454  543CACUCAAGAACAAGUAGCU  490  544 CCUUCACAUCCUAGCUCGG 1996  545AUGCACCUUUGCGUGAGCA 1839  546 UGUUCGUGCACAUCAGGAU 1888  547UCAGUUGCUUGUUCGUGCA 1879  548 CCCGCAAAUCAUGCACCUU 1829  549GCUGAUUUGAUGGAGUUGG  281  550 AUAGAGGCUCUUGUGCGUA 1598  551CAGGACAAGGAAGCUGCAG 2135  552 AGCUCUUACACCCACCAUC 1755  553CAUCACAGAUGCUGAAACA  651  554 CUAUUGUAGAAGCUGGUGG 1335  555AUGCCCAGGACCUCAUGGA 2541  556 UGACUCGAGCUCAGAGGGU  531  557AGUUUGAUGCUGCUCAUCC  606  558 UCCUUCGGGCUGGUGACAG 1620  559AUGAAGGUGUGGCGACAUA 2211  560 AGUUGAGCUGACCAGCUCU 2293  561CUGUAUGAGUGGGAACAGG  455  562 CUCAGAGGGUACGAGCUGC  540  563GGCAAUCCUGAGGAAGAGG  416  564 CAUACUGGCUAGUGGUGGA 1210  565ACAAGCCACAAGAUUACAA 2262  566 GCUCUUGUGCGUACUGUCC 1604  567AUGUGGAUACCUCCCAAGU  435  568 UUGUUUGUGCAGCUGCUUU 2060  569ACAUAUGCAGCUGCUGUUU 2225  570 UCAGUCCUUCACUCAAGAA  481  571ACCUUGCAUAACCUUUCCC  917  572 GGCGACAUAUGCAGCUGCU 2221  573UGGUGUCUGCUAUUGUACG  849  574 GUUCCCUGAGACAUUAGAU  562  575AUAAAGGCUACUGUUGGAU 1787  576 GUGCCAUUCCACGACUAGU 1860  577UGGGUGGUAUAGAGGCUCU 1590  578 GGCCAUCUUUAAGUCUGGA  955  579UAUUGGUGCCCAGGGAGAA 2365  580 CUCGAGCUCAGAGGGUACG  534  581AGAACUUGCCACACGUGCA  706  582 UACCAGUUGUGGUUAAGCU 1740  583CGUUUGGCUGAACCAUCAC  638  584 GCUAUUGUAGAAGCUGGUG 1334  585GGAGGCAUUCCUGCCCUGG  971  586 ACCACCCUGGUGCUGACUA 2493  587AAUCUUGCCCUUUGUCCCG 1814  588 CGUUUAGCUGGUGGGCUGC 1088  589CAGUUGAGCUGACCAGCUC 2292  590 UGAUAUAAAUGUGGUCACC 1504  591CUGAGUGGUAAAGGCAAUC  404  592 AAGGUGCUAUCUGUCUGCU 1301  593UCCUAGCUCGGGAUGUUCA 2004  594 UCAAGCUGAUUUGAUGGAG  277  595CCAGCUCUCUCUUCAGAAC 2304  596 ACAUGGCCAUGGAACCAGA  300  597UACCCAGCGCCGUACGUCC 1906  598 AUAGUUGAAGGUUGUACCG 1973  599AGCUUUAGGACUUCACCUG 1360  600 ACAUCCAAAGAGUAGCUGC 2094  601UUGCAUAACCUUUCCCAUC  920  602 UGGCCCAGAAUGCAGUUCG 1707  603AUUCGAAAUCUUGCCCUUU 1808  604 AUAAGCCGGCUAUUGUAGA 1324  605CGACAGACUGCCUUCAAAU 1158  606 UGCAGUUAUGGUCCAUCAG  781  607GUUUGAUGCUGCUCAUCCC  607  608 CUAAUGUCCAGCGUUUGGC  627  609CAAGUAGCUGAUAUUGAUG  500  610 UCUGACAGAGUUACUUCAC 2185  611GGUGGUAUAGAGGCUCUUG 1592  612 GACCAGGUGGUGGUUAAUA  758  613CCUCAUGGAUGGGCUGCCU 2551  614 UGUCUUUGGACUCUCAGGA 1409  615GAACAAGUAGCUGAUAUUG  497  616 GUGCCACUACCACAGCUCC  381  617GCACCUUUGCGUGAGCAGG 1841  618 GACUUCACCUGACAGAUCC 1368  619AAAUACCAUUCCAUUGUUU 2047  620 CUCAAGAACAAGUAGCUGA  492  621UCCUCUGUGAACUUGCUCA 2118  622 UCUGGAGGCAUUCCUGCCC  968  623AAGUCUGGAGGCAUUCCUG  965  624 UUGAAGGUUGUACCGGAGC 1977  625ACAUCCUAGCUCGGGAUGU 2001  626 ACCAAGAAAGCAAGCUCAU 1191  627UUUGGCUGAACCAUCACAG  640  628 CACACGUGCAAUCCCUGAA  715  629GCUCAUCAUACUGGCUAGU 1204  630 GGGUAGGGUAAAUCAGUAA 3093  631UUCACCUGACAGAUCCAAG 1371  632 UGGUAAAGGCAAUCCUGAG  409  633GAUCCUAGCUAUCGUUCUU 2405  634 UUCGUCAUCUGACCAGCCG 1671  635AAUCUUUCAGAUGCUGCAA 1427  636 UGCAGUUCGCCUUCACUAU 1717  637AGGAUGAUCCUAGCUAUCG 2400  638 CAGCUCUCUCUUCAGAACA 2305  639GGUGGGACACAGCAGCAAU 1928  640 CAGGAUGAUCCUAGCUAUC 2399  641AGGAAGAGGAUGUGGAUAC  426  642 AUCUGUCUGCUCUAGUAAU 1309  643UAACCUUUCCCAUCAUCGU  925  644 CUGCUUUAUUCUCCCAUUG 2072  645AAUUGUAAUCUGAAUAAAG 2939  646 UCUUGUUCAGCUUCUGGGU 1480  647GUUCGUGCACAUCAGGAUA 1889  648 AUGAUGCAGAACUUGCCAC  699  649GCUGAUAUUGAUGGACAGU  506  650 GGUUAAGCUCUUACACCCA 1750  651GCCCUUUGUCCCGCAAAUC 1820  652 UCAGAGGGUACGAGCUGCU  541  653AAACAUGCAGUUGUAAACU  665  654 CUUGCCCUUUGUCCCGCAA 1817  655UUACAAGAAACGGCUUUCA 2275  656 CACUCUGGUGGAUAUGGCC 2426  657CAUCUUUAAGUCUGGAGGC  958  658 UGCCAUCUGUGCUCUUCGU 1657  659UCUUGGCUAUUACGACAGA 1146  660 AUUUGGGAUAUGUAUGGGU 3078  661CAGUGGAUUCUGUGUUGUU 1008  662 CCUUCGGGCUGGUGACAGG 1621  663GGACACAGCAGCAAUUUGU 1932  664 CCAGCGCCGUACGUCCAUG 1909  665AAGAAACGGCUUUCAGUUG 2279  666 AUUAGAUGAGGGCAUGCAG  574  667ACCAGCUCUCUCUUCAGAA 2303  668 AGUUAUGGUCCAUCAGCUU  784  669GACUAUCCAGUUGAUGGGC 2507  670 AUGCUUGGUUCACCAGUGG  995  671CUAGCUCGGGAUGUUCACA 2006  672 CUCUUACACCCACCAUCCC 1757  673CUUGCUCAGGACAAGGAAG 2129  674 AGAUUACAAGAAACGGCUU 2272  675ACCACAGCUCCUUCUCUGA  389  676 AGAUGCUGCAACUAAACAG 1435  677UUAAGCUCUUACACCCACC 1752  678 AAUAAGGCUGCAGUUAUGG  773  679UUGGGAUAUGUAUGGGUAG 3080  680 GUAACCUGCUGUGAUACGA 3174  681UGGUCUGCCAAGUGGGUGG 1578  682 CCUUCUCUGAGUGGUAAAG  398  683GAAGCUAUUGAAGCUGAGG 2153  684 AUGCAGAACUUGCCACACG  702  685GUAGCUGAUAUUGAUGGAC  503  686 CUCAAGCUGAUUUGAUGGA  278  687GCAUGGAAGAAAUAGUUGA 1962  688 CUGGUGGAAUGCAAGCUUU 1347  689CCCAGGACCUCAUGGAUGG 2544  690 UUUGGGAUAUGUAUGGGUA 3079  691CAAAGUUGUUGUAACCUGC 3164  692 CCGAAUUGUUAUCAGAGGA 2026  693UAAUUGUAAUCUGAAUAAA 2938  694 AUUGUAAUCUGAAUAAAGU 2940  695CGAAUUGUUAUCAGAGGAC 2027  696 CCAAGUCCUGUAUGAGUGG  448  697AAGCCGGCUAUUGUAGAAG 1328  698 AUCCUAGCUAUCGUUCUUU 2406  699AUAACCUUUCCCAUCAUCG  924  700 GCCAAGUGGGUGGUAUAGA 1584  701CGACUAGUUCAGUUGCUUG 1871  702 UUGGUUCACCAGUGGAUUC  999  703GUUCAGAACUGUCUUUGGA 1400  704 UGCUGUGAUACGAUGCUUC 3180  705UCCAGGUGACAGCAAUCAG 2569  706 UAUGGUCCAUCAGCUUUCU  787  707UGCCAUUCCACGACUAGUU 1861  708 AACCAAGAAAGCAAGCUCA 1190  709AUAAUUAUAAGAACAAGAU 1557  710 GUUAAGCUCUUACACCCAC 1751  711UUGAGUAAUGGUGUAGAAC 2897  712 GUGUGGCGACAUAUGCAGC 2217  713GACCAGCUCUCUCUUCAGA 2302  714 UUGUACCGGAGCCCUUCAC 1984  715AUGGCCAUGGAACCAGACA  302  716 UGGUGGAUAUGGCCAGGAU 2431  717CCUCUGACAGAGUUACUUC 2183  718 AUGAUCCUAGCUAUCGUUC 2403  719AUGGUCCAUCAGCUUUCUA 788  720 GGACUCUUGUUCAGCUUCU 1476  721GCUAUCAUGCGUUCUCCUC  827  722 GCUGACCAGCUCUCUCUUC 2299  723UCGUGCACAUCAGGAUACC 1891  724 UACUUCACUCUAGGAAUGA 2196  725UGAAACAUGCAGUUGUAAA  663  726 UAUGCCAUUACAACUCUCC 1028  727UGUUAUCAGAGGACUAAAU 2032  728 GAUGGAAGGUCUCCUUGGG 1459  729CAUCCAAAGAGUAGCUGCA 2095  730 GCCGACACCAAGAAGCAGA 1686  731CUUUGGACUCUCAGGAAUC 1412  732 GGAACAUGAGAUGGGUGGC 2473  733UGGCAGUGCGUUUAGCUGG 1080  734 GGAAGCUGCAGAAGCUAUU 2143  735CUCUAGGAAUGAAGGUGUG 2203  736 GUACGAGCUGCUAUGUUCC 548  737UCCACGACUAGUUCAGUUG 1867  738 CCUCAGAUGGUGUCUGCUA  842  739CUCUGUGAACUUGCUCAGG 2120  740 GCAGUUAUGGUCCAUCAGC  782  741UCUUACACCCACCAUCCCA 1758  742 CGCCAGGAUGAUCCUAGCU 2396  743CACCUGACAGAUCCAAGUC 1373  744 UCACCUGUGCAGCUGGAAU 1518  745GGAUGGGCUGCCUCCAGGU 2557  746 UACCGGAGCCCUUCACAUC 1987  747UGAGACAUUAGAUGAGGGC  568  748 CACUCUAGGAAUGAAGGUG 2201  749UUGAUGCUGCUCAUCCCAC  609  750 UUCUCUGAGUGGUAAAGGC  400  751UGUUAGUCACUGGCAGCAA  331  752 GAAGAAAUAGUUGAAGGUU 1967  753CUUCACUCUAGGAAUGAAG 2198  754 CUGGGUUCAGAUGAUAUAA 1493  755GGACAAGCCACAAGAUUAC 2260  756 ACCCUGGUGCUGACUAUCC 2496  757UUGAUAUUGGUGCCCAGGG 2361  758 ACCUCCCAAGUCCUGUAUG  443  759GUAUGCAAUGACUCGAGCU  523  760 CCAGUUGUGGUUAAGCUCU 1742  761AUGACUCGAGCUCAGAGGG  530  762 UUGUUGUAACCUGCUGUGA 3168  763CCAAGUCAACGUCUUGUUC 1385  764 AUCAGAGGACUAAAUACCA 2036  765UGUAUGGGUAGGGUAAAUC 3088  766 CGUGAGCAGGGUGCCAUUC 1850  767UGAUGGGCUGCCAGAUCUG 2518  768 CUUGUUCGUGCACAUCAGG 1886  769CCAUCACAGAUGCUGAAAC  650  770 ACAGUUUACCAGUUGCCUU 3139  771ACCGAAUUGUUAUCAGAGG 2025  772 GCAGUGCGUUUAGCUGGUG 1082  773AACAUGAGAUGGGUGGCCA 2475  774 CCUGACAGAUCCAAGUCAA 1375  775GGGAUGUUCACAACCGAAU 2013  776 GGAUUGAUUCGAAAUCUUG 1802  777GAAGCUGCAGAAGCUAUUG 2144  778 AAUGACUCGAGCUCAGAGG  529  779UUGUUCAGCUUCUGGGUUC 1482  780 CCUCACUUGCAAUAAUUAU 1546  781CAGAUGGUGUCUGCUAUUG  845  782 CUUCACUCAAGAACAAGUA  487  783AUCACAGAUGCUGAAACAU  652  784 AGUUCGCCUUCACUAUGGA 1720  785UACUGGCCAUCUUUAAGUC  951  786 CAAGCUUUAGUAAAUAUAA 1232  787AGCCACAAGAUUACAAGAA 2265  788 AAGCAGAGAUGGCCCAGAA 1698  789GAUGCAGAACUUGCCACAC  701  790 AUCUUUCAGAUGCUGCAAC 1428  791UGGGACACAGCAGCAAUUU 1930  792 ACAGAUCCAAGUCAACGUC 1379  793ACAGCAGCAAUUUGUGGAG 1936  794 UGCAACUAAACAGGAAGGG 1441  795GCUCAGGACAAGGAAGCUG 2132  796 GACUAAAUACCAUUCCAUU 2043  797UUUGAUGCUGCUCAUCCCA  608  798 UGGCAGCAACAGUCUUACC  341  799AAGAAAGCAAGCUCAUCAU 1194  800 UGAUCUUGGACUUGAUAUU 2350  801CUGAAUAAAGUGUAACAAU 2948  802 ACUAAAUACCAUUCCAUUG 2044  803AUCCCACUAAUGUCCAGCG  621  804 CCACUACCACAGCUCCUUC  384  805CAUCAGGAUACCCAGCGCC 1898  806 UCACAGAUGCUGAAACAUG  653  807UUUGCGUGAGCAGGGUGCC 1846  808 GCUGAUCUUGGACUUGAUA 2348  809GGCUAUUACGACAGACUGC 1150  810 GGACAUGGCCAUGGAACCA  298  811AACAAGAUGAUGGUCUGCC 1568  812 UUACAUCAAGAAGGAGCUA 1058  813AAUCAUGCACCUUUGCGUG 1835  814 GCAAAUCAUGCACCUUUGC 1832  815GAGUGGUAAAGGCAAUCCU  406  816 UCGCCUUCACUAUGGACUA 1723  817AUCCAUUCUGGUGCCACUA  371  818 AUCAGGAUACCCAGCGCCG 1899  819AGUAUGCAAUGACUCGAGC  522  820 CGGCUUUCAGUUGAGCUGA 2285  821GCUGCAGUUAUGGUCCAUC  779  822 AUUGAGUAAUGGUGUAGAA 2896  823GUAAUCUGAAUAAAGUGUA 2943  824 UUGAUGGACAGUAUGCAAU  513  825GAUAUGUAUGGGUAGGGUA 3084  826 GAACAAGAUGAUGGUCUGC 1567  827UUAUCAGAGGACUAAAUAC 2034  828 UUCACCAGUGGAUUCUGUG 1003  829AAGGUUGUACCGGAGCCCU 1980  830 GUAGAAGCUGGUGGAAUGC 1340  831AUGCUGCAACUAAACAGGA 1437  832 UCACUCUGGUGGAUAUGGC 2425  833CUGAUUUGAUGGAGUUGGA  282  834 UCAUCAUACUGGCUAGUGG 1206  835GCUUGUUCGUGCACAUCAG 1885  836 UCUGCUCUAGUAAUAAGCC 1314  837UAUCUGUCUGCUCUAGUAA 1308  838 GCAAGCUCAUCAUACUGGC 1200  839AGAGGGUACGAGCUGCUAU  543  840 UGUGCGUACUGUCCUUCGG 1609  841GGAAGGGAUGGAAGGUCUC 1453  842 AUGCGUUCUCCUCAGAUGG  833  843GACAGAGUUACUUCACUCU 2188  844 UUGGCUAUUACGACAGACU 1148  845GGACUACCAGUUGUGGUUA 1736  846 UUCAGAACUGUCUUUGGAC 1401  847AUCUGACCAGCCGACACCA 1677  848 ACACAGCAGCAAUUUGUGG 1934  849UACCACAGCUCCUUCUCUG  388  850 CGUCCAUGGGUGGGACACA 1920  851UGUGGUUAAGCUCUUACAC 1747  852 UUGUACGUACCAUGCAGAA  861  853GAUACCCAGCGCCGUACGU 1904  854 UCAUGCGUUCUCCUCAGAU  831  855GCACAUCAGGAUACCCAGC 1895  856 GAUUACAAGAAACGGCUUU 2273  857ACUACCAGUUGUGGUUAAG 1738  858 GUCUUGUUCAGAACUGUCU 1395  859UCAUCUGACCAGCCGACAC 1675  860 CUUUGCGUGAGCAGGGUGC 1845  861CUGUCUUUGGACUCUCAGG 1408  862 UACAUCAAGAAGGAGCUAA 1059  863AGAUCCAAGUCAACGUCUU 1381  864 CAAGUCAACGUCUUGUUCA 1386  865UCCUUGGGACUCUUGUUCA 1470  866 GGUGGAAUGCAAGCUUUAG 1349  867CUGCAACUAAACAGGAAGG 1440  868 UUAGGACUUCACCUGACAG 1364  869AGUAGCUGAUAUUGAUGGA  502  870 UAUAAUGAGGACCUAUACU 1246  871CCUGCUGUGAUACGAUGCU 3178  872 AUGGGUGGCCACCACCCUG 2483  873GACUCUCAGGAAUCUUUCA 1417  874 GUGCACAUCAGGAUACCCA 1893  875UUCCAGACACGCUAUCAUG  817  876 UUGCCACACGUGCAAUCCC  711  877UCAGAUGCUGCAACUAAAC 1433  878 CUUUAGGACUUCACCUGAC 1362  879CAUGCACCUUUGCGUGAGC 1838  880 ACAACUCUCCACAACCUUU 1037  881UGGGACUCUUGUUCAGCUU 1474  882 GCUUGGUUCACCAGUGGAU  997  883UUCCCAUCAUCGUGAGGGC  931  884 GUCUGCUCUAGUAAUAAGC 1313  885CAGCUUCUGGGUUCAGAUG 1487  886 CGUCAUCUGACCAGCCGAC 1673  887UGUUCCCUGAGACAUUAGA  561  888 GCAACCAAGAAAGCAAGCU 1188  889GGAGUUGGACAUGGCCAUG  292  890 GUCCGCAUGGAAGAAAUAG 1958  891CUGAUCUUGGACUUGAUAU 2349  892 AUGGAAGGUCUCCUUGGGA 1460  893GAUGGUCUGCCAAGUGGGU 1576  894 ACUAUCAAGAUGAUGCAGA  690  895ACAGAUGCUGAAACAUGCA  655  896 UUCAGUUGAGCUGACCAGC 2290  897AGAGGCUCUUGUGCGUACU 1600  898 GGUGGAUAUGGCCAGGAUG 2432  899CUUGCCACACGUGCAAUCC  710  900 GAAUGCAGUUCGCCUUCAC 1714  901CCUAGCUCGGGAUGUUCAC 2005  902 UUCACUAUGGACUACCAGU 1728  903GAUGGGUGGCCACCACCCU 2482  904 UGGUUAAUAAGGCUGCAGU  768  905AUCAAGAUGAUGCAGAACU  693  906 CUGCUGUGAUACGAUGCUU 3179  907AUGCCUUGGGUAUGGACCC 2448  908 UGUGAUACGAUGCUUCAAG 3183  909GAGUGCUGAAGGUGCUAUC 1293  910 GAGGGUACGAGCUGCUAUG  544  911UUAAUUGUAAUCUGAAUAA 2937  912 CACCAAGAAGCAGAGAUGG 1691  913GAAUGCAAGCUUUAGGACU 1353  914 ACCUUUGCGUGAGCAGGGU 1843  915AGGUGCUAUCUGUCUGCUC 1302  916 UUGCUCAGGACAAGGAAGC 2130  917GCUGAGGGAGCCACAGCUC 2165  918 CUACCACAGCUCCUUCUCU  387  919UGGAACAUGAGAUGGGUGG 2472  920 GCUAUUGUACGUACCAUGC  857  921UCUUGCCCUUUGUCCCGCA 1816  922 UUAUAAGAACAAGAUGAUG 1561  923GGAAGCUUCCAGACACGCU  811  924 UAAGCCGGCUAUUGUAGAA 1327  925GGACCAGGUGGUGGUUAAU  757  926 CUGAUAUUGAUGGACAGUA  507  927UGGGUAGGGUAAAUCAGUA 3092  928 ACUUGAUAUUGGUGCCCAG 2359  929UAAGCUCUUACACCCACCA 1753  930 CUACUCAAGCUGAUUUGAU  273  931GGUGCCAUUCCACGACUAG 1859  932 UUGGACAUGGCCAUGGAAC  296  933CUGCUCAUCCCACUAAUGU  615  934 CAUGGCCAUGGAACCAGAC  301  935UAUGGCAACCAAGAAAGCA 1184  936 ACCAGUGGAUUCUGUGUUG 1006  937ACAGAGUUACUUCACUCUA 2189  938 UAGGACUUCACCUGACAGA 1365  939GCCAGGAUGCCUUGGGUAU 2442  940 AAUGAGGACCUAUACUUAC 1249  941AUUCUUGGCUAUUACGACA 1144  942 CUUUAUUCUCCCAUUGAAA 2075  943UAGCUGAUAUUGAUGGACA  504  944 GAACUGUCUUUGGACUCUC 1405  945UUAGUCACUGGCAGCAACA  333  946 CCAUUACAACUCUCCACAA 1032  947GUGGUUAAGCUCUUACACC 1748  948 UGAUUUGAUGGAGUUGGAC  283  949GCAGAGAUGGCCCAGAAUG 1700  950 ACUAAACAGGAAGGGAUGG 1445  951ACAAAUGUUAAAUUCUUGG 1133  952 GCAAUGACUCGAGCUCAGA  527  953CUCGGGAUGUUCACAACCG 2010  954 GUGUCUGCUAUUGUACGUA  851  955UGUGGAUACCUCCCAAGUC  436  956 GGAUGCCUUGGGUAUGGAC 2446  957AAAUUCUUGGCUAUUACGA 1142  958 UACGAGCUGCUAUGUUCCC  549  959CAGUGCGUUUAGCUGGUGG 1083  960 CAAGAUGAUGCAGAACUUG  695  961AUGAUGUAGAAACAGCUCG  885  962 UGCAGCUGCUUUAUUCUCC 2067  963CCACAGCUCCUUCUCUGAG  390  964 CAGUUCGCCUUCACUAUGG 1719  965AAGCUUCCAGACACGCUAU  813  966 UUUCAGUUGAGCUGACCAG 2289  967UCUGGUGCCACUACCACAG  377  968 CGCUAUCAUGCGUUCUCCU  826  969GACAGGGAAGACAUCACUG 1634  970 AUCAUACUGGCUAGUGGUG 1208  971GCUGGUGACAGGGAAGACA 1628  972 AUCCUAGCUCGGGAUGUUC 2003  973GUCCUGUAUGAGUGGGAAC  452  974 UGGGAUAUGUAUGGGUAGG 3081  975CUUGGACUUGAUAUUGGUG 2354  976 CCUUUGUCCCGCAAAUCAU 1822  977UGAAGGUGCUAUCUGUCUG 1299  978 CCUUCACUCAAGAACAAGU  486  979GAAGGUCUCCUUGGGACUC 1463  980 AGAAACGGCUUUCAGUUGA 2280  981ACCCAGCGCCGUACGUCCA 1907  982 CAUAACCUUUCCCAUCAUC  823  983GAAGGUUGUACCGGAGCCC 1979  984 GUCCCGCAAAUCAUGCACC 1827  985CAAGCUCAUCAUACUGGCU 1201  986 CGCCGUACGUCCAUGGGUG 1913  987AGAGUUACUUCACUCUAGG 2191  988 GUUGGACAUGGCCAUGGAA  295  989UGGCUAUUACGACAGACUG 1149  990 ACUCGAGCUCAGAGGGUAC  533  991ACAGUUUGAUGCUGCUCAU  604  992 GGUGGUUAAUAAGGCUGCA  766  993CUUUGUCCCGCAAAUCAUG 1823  994 AAUACCAUUCCAUUGUUUG 2045  995CCACACGUGCAAUCCCUGA  714  996 AUGGCCAGGAUGCCUUGGG 2439  997GGAUACCCAGCGCCGUACG 1903  998 UCGCCAGGAUGAUCCUAGC 2395  999UGGUCCAUCAGCUUUCUAA  789 1000 AUAUGUAUGGGUAGGGUAA 3085 1001CCCAGAAUGCAGUUCGCCU 1710 1002 UAUUGUAGAAGCUGGUGGA 1336 1003GUAUGGGUAGGGUAAAUCA 3089 1004 GAUCUUGGACUUGAUAUUG 2351 1005ACACGUGCAAUCCCUGAAC  716 1006 AGCGCCGUACGUCCAUGGG 1911 1007UGUACCGGAGCCCUUCACA 1985 1008 GUUGAUGGGCUGCCAGAUC 2516 1009ACACCCACCAUCCCACUGG 1762 1010 UACGACAGACUGCCUUCAA 1156 1011UUGUUCGUGCACAUCAGGA 1887 1012 CAAAUCAUGCACCUUUGCG 1833 1013GUCUGGAGGCAUUCCUGCC  967 1014 CACUAUGGACUACCAGUUG 1730 1015UAUCAUGCGUUCUCCUCAG  829 1016 GUAGAAACAGCUCGUUGUA  890 1017CUCCUCUGACAGAGUUACU 2181 1018 UGCUCAGGACAAGGAAGCU 2131 1019CAAGUGGGUGGUAUAGAGG 1586 1020 UGGUGGUUAAUAAGGCUGC  765 1021ACUUCACCUGACAGAUCCA 1369 1022 CGCCUUCACUAUGGACUAC 1724 1023UGCGUUCUCCUCAGAUGGU  834 1024 GUUGUACCGGAGCCCUUCA 1983 1025CGACACCAAGAAGCAGAGA 1688 1026 UCACCAGUGGAUUCUGUGU 1004 1027GGUGACAGGGAAGACAUCA 1631 1028 UCUAGUAAUAAGCCGGCUA 1319 1029GUGGUUAAUAAGGCUGCAG  767 1030 UCCUCAGAUGGUGUCUGCU  841 1031AUGGACAGUAUGCAAUGAC  516 1032 UGCGUGAGCAGGGUGCCAU 1848 1033ACUCUAGGAAUGAAGGUGU 2202 1034 GACAUUAGAUGAGGGCAUG  571 1035CUGGUGACAGGGAAGACAU 1629 1036 UGAUUCGAAAUCUUGCCCU 1806 1037GCUCUUACACCCACCAUCC 1756 1038 GUCCUUCGGGCUGGUGACA 1619 1039GUGCGUACUGUCCUUCGGG 1610 1040 UGGUGCUGACUAUCCAGUU 2500 1041GCUAUUGAAGCUGAGGGAG 2156 1042 CAACCAAGAAAGCAAGCUC 1189 1043GUGCAGCUGCUUUAUUCUC 2066 1044 CUAUCUGUCUGCUCUAGUA 1307 1045AAACAGGAAGGGAUGGAAG 1448 1046 ACUGGCUAGUGGUGGACCC 1213 1047CCUCUGUGAACUUGCUCAG 2119 1048 UGUAGAAACAGCUCGUUGU  889 1049CUGACAGAUCCAAGUCAAC 1376 1050 GGAAGAGGAUGAGGAUACC  427 1051ACCAUCACAGAUGCUGAAA  649 1052 CCGUACGUCCAUGGGUGGG 1915 1053CAUUCCAUUGUUUGUGCAG 2053 1054 CUCCAGGUGACAGCAAUCA 2568 1055CUACCAGUUGUGGUUAAGC 1739 1056 UUGUGGUUAAGCUCUUACA 1746 1057UAGUAAUAAGCCGGCUAUU 1321 1058 CAGUCCUUCACUCAAGAAC  482 1059AGCUGAUUUGAUGGAGUUG  280 1060 AGGUCUCCUUGGGACUCUU 1465 1061ACUAUGGACUACCAGUUGU 1731 1062 CAGCAGCAAUUUGUGGAGG 1937 1063CGUGCACAUCAGGAUACCC 1892 1064 CGUUCUCCUCAGAUGGUGU  836 1065CAGUAUGCAAUGACUCGAG  521 1066 GGUAUAGAGGCUCUUGUGC 1595 1067AUCCAGUUGAUGGGCUGCC 2511 1068 UGCCAAGUGGGUGGUAUAG 1583 1069ACAUCAGGAUACCCAGCGC 1897 1070 GCCAUCUUUAAGUCUGGAG  926 1071AACCUUUCCCAUCAUCGUG  926 1072 CUAGUUCAGUUGCUUGUUC 1874 1073UUCACUCAAGAACAAGUAG  488 1074 AAGAAGCAGAGAUGGCCCA 1695 1075UCCUCUGACAGAGUUACUU 2182 1076 AAUUGUUAUCAGAGGACUA 2029 1077UCUCAGUCCUUCACUCAAG  479 1078 UCCAGACACGCUAUCAUGC  818 1079CACUAAUGUCCAGCGUUUG  625 1080 UUGUAACCUGCUGUGAUAC 3172 1081CUUCUGGGUUCAGAUGAUA 1490 1082 GCCGUACGUCCAUGGGUGG 1914 1083UAGUUGAAGGUUGUACCGG 1974 1084 GAGGACAAGCCACAAGAUU 2258 1085GGGAGCCACAGCUCCUCUG 2170 1086 CUUCACCUGACAGAUCCAA 1370 1087UCUUUCAGAUGCUGCAACU 1429 1088 UGUAACCUGCUGUGAUACG 3173 1089CCUCCCAAGUCCUGUAUGA  444 1090 GGCAGUGCGUUUAGCUGGU 1081 1091CUCUAGUAAUAAGCCGGCU 1318 1092 GCUGUUAGUCACUGGCAGC  329 1093GUCAACGUCUUGUUCAGAA 1389 1094 GAAGAGGAUGUGGAUACCU  428 1095UAACCUGCUGUGAUACGAU 3175 1096 GUUAUUUGGAACCUUGUUU 3117 1097UCACAACCGAAUUGUUAUC 2020 1098 CGGGCUGGUGACAGGGAAG 1625 1099ACAACCGAAUUGUUAUCAG 2022 1100 CCACUAAUGUCCAGCGUUU  624 1101CACUGAGCCUGCCAUCUGU 1648 1102 GGUCCAUCAGCUUUCUAAA  790 1103AUCCCAAAGUUGUUGUAAC 3160 1104 UGAGGACCUAUACUUACGA 1251 1105UGUCUGAGGACAAGCCACA 2253 1106 AGUUGAUGGGCUGCCAGAU 2515 1107UGACCAGCCGACACCAAGA 1680 1108 AGGGAGCCACAGCUCCUCU 2169 1109AAAGUUGUUGUAACCUGCU 3165 1110 CUGCAGUUAUGGUCCAUCA  780 1111UGAAGGUUGUACCGGAGCC 1978 1112 UUCCCUGAGACAUUAGAUG  563 1113CUUCGGGCUGGUGACAGGG 1622 1114 UUGAGCUGACCAGCUCUCU 2295 1115GAACUUGCUCAGGACAAGG 2126 1116 CCAGCCGACACCAAGAAGC 1683 1117AGGGUGCCAUUCCACGACU 1857 1118 UUGUGCAGCUGCUUUAUUC 2064 1119UCACUCAAGAACAAGUAGC  489 1120 GCUGGUGGAAUGCAAGCUU 1346 1121GCAACUAAACAGGAAGGGA 1442 1122 AGGUUGUACCGGAGCCCUU 1981 1123AGGCUGCAGUUAUGGUCCA  777 1124 GCAGAUCCCAUCUACACAG  589 1125CUAGGAAUGAAGGUGUGGC 2205 1126 AGCUCCUUCUCUGAGUGGU  394 1127UUACAACUCUCCACAACCU 1035 1128 GGUAAAGGCAAUCCUGAGG  410 1129GUUCGCCUUCACUAUGGAC 1721 1230 CAAAUGUUAAAUUCUUGGC 1134 1231CUGUGAUACGAUGCUUCAA 3182 1232 ACAAAUGAUGUAGAAACAG  881 1133GGUACGAGCUGCUAUGUUC  547 1134 GAAUUGUUAUCAGAGGACU 2028 1135CAACCGAAUUGUUAUCAGA 2023 1136 GUGAUACGAUGCUUCAAGA 3184 1137AAAGGCAAUCCUGAGGAAG  413 1138 CAGCUCCUCUGACAGAGUU 2178 1139AUGGUCUGCCAAGUGGGUG 1577 1140 GCUACUGUUGGAUUGAUUC 1793 1141UGCAAUGACUCGAGCUCAG  526 1142 GACUUGAUAUUGGUGCCCA 2358 1143CAGAACUGUCUUUGGACUC 1403 1144 UAGUUCAGUUGCUUGUUCG 1875 1145ACAGACUGCCUUCAAAUUU 1160 1146 GGGUGGUAUAGAGGCUCUU 1591 1147AUGGACUACCAGUUGUGGU 1734 1148 AUUGUUAUCAGAGGACUAA 2030 1149UAAGGCUGCAGUUAUGGUC  775 1150 AAAUCUUGCCCUUUGUCCC 1813 1151AGCAGCAAUUUGUGGAGGG 1938 1152 AGAGGACUAAAUACCAUUC 2039 1153GCUGAAGGUGCUAUCUGUC 1297 1154 UGUAUGAGUGGGAACAGGG  456 1155CAGAUCCCAUCUACACAGU  590 1156 GACAGACAGCAAUUUGUG 1933 1157GGGCAUGCAGAUCCCAUCU  583 1158 CAUGCCCAGGACCUCAUGG 2540 1159GAAGCUGAGGGAGCCACAG 2162 1160 CUGUUAGUCACUGGCAGCA  330 1161CUUGUUCAGCUUCUGGGUU 1481 1162 AAGCUGGUGGAAUGCAAGC 1344 1163GAGGAUGUGGAUACCUCCC  431 1164 AUAAAUGUGGUCACCUGUG 1508 1165UACGUCCAUGGGUGGGACA 1918 1166 GAUGGAGUUGGACAUGGCC  289 1167UGUCCAGCGUUUGGCUGAA  631 1168 GAGCAGGGUGCCAUUCCAC 1853 1169AAAUAUAAUGAGGACCUAU 1243 1170 UACUGGCUAGUGGUGGACC 1212 1171UGCUUGGUUCACCAGUGGA  996 1172 CUGAGGACAAGCCACAAGA 2256 1173CUUGUGCGUACUGUCCUUC 1607 1174 UGUUAUUUGGAACCUUGUU 3116 1175UAGCUUAUGGCAACCAAGA 1179 1176 UGAUACGAUGCUUCAAGAG 3185 1177UGGUAUAGAGGCUCUUGGU 1594 1178 GAUGUAGAAACAGCUCGUU  887 1179CCUUUCCCAUCAUCGUGAG  928 1180 GCGUUCUCCUCAGAUGGUG  835 1181UCAGGAUACCCAGCGCCGU 1900 1182 ACGGCUUUCAGUUGAGCUG 2284 1183GUUGAAGGUUGUACCGGAG 1976 1184 UAUCGCCAGGAUGAUCCUA 2393 1185GUGCUGAAGGUGCUAUCUG 1295 1186 GUCUUUGGACUCUCAGGAA 1410 1187GGGAUGGAAGGUCUCCUUG 1457 1188 UGAGCUGACCAGCUCUCUC 2296 1189CUUUCCCAUCAUCGUGAGG  929 1190 AAGCUUUAGGACUUCACCU 1359 1191UGGAAUGCAAGCUUUAGGA 1351 1192 CUGGAGGCAUUCCUGCCCU  969 1193AGUUCAGUUGCUUGUUCGU 1876 1194 GAGCUGCUAUGUUCCCUGA  552 1195GGCCAGGAUGCCUUGGGUA 2441 1196 GAUGAUCCUAGCUAUCGUU 2402 1197GAUUGAUUCGAAAUCUUGC 1803 1198 CAGAGAUGGCCCAGAAUGC 1701 1199CAGCGCCGUACGUCCAUGG 1910 1200 AUGUAGAAACAGCUCGUUG  888 1201AGUGCUGAAGGUGCUAUCU 1294 1202 GACUACCAGUUGUGGUUAA 1737 1203ACAGGAAGGGAUGGAAGGU 1450 1204 CAGGUGGUGGUUAAUAAGG  761 1205AAGGCUGCAGUUAUGGUCC  776 1206 UAAAUGUGGUCACCUGUGC 1509 1207UAAAGGCUACUGUUGGAUU 1788 1208 GAUGGACAGUAUGCAAUGA  515 1209UUCUGGGUUCAGAUGAUAU 1491 1210 GUACUGUCCUUCGGGCUGG 1614 1211CUUGGUUCACCAGUGGAUU  998 1212 UAUUGAAGCUGAGGGAGCC 2158 1213GUUGUUGUAACCUGCUGUG 3168 1214 AGCAGGGUGCCAUUCCACG 1854 1215GUCCUCUGUGAACUUGCUC 2117 1216 UCUGACCAGCCGACACCAA 1678 1217GCCAUGGAACCAGACAGAA  305 1218 AAGCUAUUGAAGCUGAGGG 2154 1219GAUUCGAAAUCUUGCCCUU 1807 1220 AGUUGCUUGUUCGUGCACA 1881 1221AAGAACAAGAUGAUGGUCU 1565 1222 AGUGGUAAAGGCAAUCCUG  407 1223CAGAUGCUGCAACUAAACA 1434 1224 CCUGAGACAUUAGAUGAGG  566 1225UCCCAAAGUUGUUGUAACC 3161 1226 CUGACCAGCCGACACCAAG 1679 1227AUCCAAAGAGUAGCUGCAG 2096 1228 AUGUCCAGCGUUUGGCUGA  630 1229UCUUGUGCGUACUGUCCUU 1606 1230 AGGAUGUGGAUACCUCCCA  432 1231GGCUGCAGUUAUGGUCCAU  778 1232 UCACAUCCUAGCUCGGGAU 1999 1233ACCAAGAAGCAGAGAUGGC 1692 1234 GCCACCACCCUGGUGCUGA 2490 1235CCCACUAAUGUCCAGCGUU  623 1236 ACUGGCAGCAACAGUCUUA  339 1237AUCUGAAUAAAGUGUAACA 2946 1238 GCCUGCCAUCUGUGCUCUU 1654 1239CAUUACAACUCUCCACAAC 1033 1240 CUCCUCAGAUGGUGUCUGC  840 1241CAGUUGCUUGUUCGUGCAC 1880 1242 AUCCUGAGGAAGAGGAUGU  420 1243CACCAGUGGAUUCUGUGUU 1005 1244 CAAGAAAGCAAGCUCAUCA 1193 1245CUUGCAUAACCUUUCCCAU  919 1246 CUUCACUAUGGACUACCAG 1727 1247UUGCUUGUUCGUGCACAUC 1883 1248 UAUUGUACGUACCAUGCAG  859 1249GAAAUCUUGCCCUUUGUCC 1812 1250 CUCUUGUGCGUACUGUCCU 1605 1251CACAACCGAAUUGUUAUCA 2021 1252 GCUCCUCUGACAGAGUUAC 2180 1253AGCGUUUGGCUGAACCAUC  636 1254 AAACGGCUUUCAGUUGAGC 2282 1255UUUGUCCCGCAAAUCAUGC 1824 1256 UCUAGGAAUGAAGGUGUGG 2204 1257AAGUCCUGUAUGAGUGGGA  450 1258 GGUUCACCAGUGGAUUCUG 1001 1259GGUCUGCCAAGUGGGUGGU 1579 1260 AGCUCCUCUGACAGAGUUA 2179 1261UUCUGGUGCCACUACCACA  376 1262 UGCUAUGUUCCCUGAGACA  556 1263AUUGAUUCGAAAUCUUGCC 1804 1264 CUCAUGGAUGGGCUGCCUC 2552 1265GCUGCUUUAUUCUCCCAUU 2071 1266 AUCAUGCACCUUUGCGUGA 1836 1267GUCACUGGCAGCAACAGUC  336 1268 UGAGUGGGAACAGGGAUUU  460 1269AAUUAUAAGAACAAGAUGA 1559 1270 UGGACAGUUUACCAGUUGC 3136 1271AUGAGGACCUAUACUUACG 1250 1272 GGAAGGUCUCCUUGGGACU 1462 1273UGGAAGAAAUAGUUGAAGG 1954 1274 GGUGUUAUUUGGAACCUUG 3114 1275GUGCUCUUCGUCAUCUGAC 1665 1276 GGCCAUGGAACCAGACAGA  304 1277CGGCUGUUAGUCACUGGCA  327 1278 UUCCACGACUAGUUCAGUU 1866 1279AGCAGAGAUGGCCCAGAAU 1699 1280 GCCAGGAUGAUCCUAGCUA 2397 1281GCCAUCUGUGCUCUUCGUC 1658 1282 UAGAAACAGCUCGUUGUAC  891 1283AGAUGAUGGUCUGCCAAGU 1572 1284 ACCUUUCCCAUCAUCGUGA  927 1285AUGGAGUUGGACAUGGCCA  290 1286 CUGUGCUCUUCGUCAUCUG 1663 1287UAUAAGAACAAGAUGAUGG 1562 1288 UCUGAAUAAAGUGUAACAA 2947 1289CCAGAAUGCAGUUCGCCUU 1711 1290 AGAACAAGAUGAUGGUCUG 1566 1291AUCUUGCCCUUUGUCCCGC 1815 1292 GCGUUUAGCUGGUGGGCUG 1087 1293GGGUUCAGAUGAUAUAAAU 1495 1294 UUUAGGACUUCACCUGACA 1363 1295CACAGCUCCUUCUCUGAGU  391 1296 AACGUCUUGUUCAGAACUG 1392 1297CACAGCAGCAAUUUGUGGA 1935 1298 GACUAGUUCAGUUGCUUGU 1872 1299GACAGACUGCCUUCAAAUU 1159 1300 CUCUCUCUUCAGAACAGAG 2308 1301GUCCAGCGUUUGGCUGAAC  632 1302 UAAGAACAAGAUGAUGGUC 1564 1303UCCAAGUCAACGUCUUGUU 1384 1304 ACACCAAGAAGCAGAGAUG 1690 1305CUCAGGAAUCUUUCAGAUG 1421 1306 UAAAUUCUUGGCUAUUACG 1141 1307CUAUGGACUACCAGUUGUG 1732 1308 CCAGCGUUUGGCUGAACCA  634 1309UCCCAUCAUCGUGAGGGCU  932 1310 AGGACUUCACCUGACAGAU 1366 1311UUGUGCGUACUGUCCUUCG 1608 1312 CCAUGGGUGGGACACAGCA 1923 1313GGAUGGAAGGUCUCCUUGG 1458 1314 CCCAGCGCCGUACGUCCAU 1908 1315GCUCAGAGGGUACGAGCUG  539 1316 AUGUUCACAACCGAAUUGU 2016 1317UGCUUGUUCGUGCACAUCA 1884 1318 AUGUUCCCUGAGACAUUAG  560 1319GUAAAGGCAAUCCUGAGGA  411 1320 CACUGGCAGCAACAGUCUU  338 1321AUCAUGCGUUCUCCUCAGA  830 1322 UAUGUAUGGGUAGGGUAAA 3086 1323GUGUUAUUUGGAACCUUGU 3115 1324 ACAGCUCCUCUGACAGAGU 2177 1325UAUGGACUACCAGUUGUGG 1733 1326 AUUCUGGUGCCACUACCAC  375 1327UGCCUCCAGGUGACAGCAA 2565 1328 UACCUCCCAAGUCCUGUAU  442 1329CCAGACACGCUAUCAUGCG  819 1330 UGAUGCAGAACUUGCCACA  700 1331GUUUAGCUGGUGGGCUGCA 1089 1332 GUCUGCCAAGUGGGUGGUA 1580 1333GGUUGUACCGGAGCCCUUC 1982 1334 GUACCGGAGCCCUUCACAU 1986 1335CAAUCCUGAGGAAGAGGAU  418 1336 GCUAUCUGUCUGCUCUAGU 1306 1337UGACAGAUCCAAGUCAACG 1377 1338 CAUGAUGGAACAUGAGAUG 2467 1339UUGGACUCUCAGGAAUCUU 1414 1340 CUCUUCGUCAUCUGACCAG 1668 1341UUGCCCUUUGUCCCGCAAA 1818 1342 GAAGCAGAGAUGGCCCAGA 1697 1343CCUUGCAUAACCUUUCCCA  918 1344 CAGUUUGAUGCUGCUCAUC  605 1345ACCUGACAGAUCCAAGUCA 1374 1346 CUUUCAGAUGCUGCAACUA 1430 1347GAUACGAUGCUUCAAGAGA 3186 1348 AUGCAAGCUUUAGGACUUC 1355 1349GGAUGUGGAUACCUCCCAA  433 1350 AGAAUGCAGUUCGCCUUCA 1713 1351CGAAAUCUUGCCCUUUGUC 1811 1352 ACUCAAGAACAAGUAGCUG  491 1353GAAUGAAGGUGUGGCGACA 2209 1354 UGCACCUUUGCGUGAGCAG 1840 1355ACGAGCUGCUAUGUUCCCU  550 1356 AAGAGGAUGUGGAUACCUC  429 1357GAUAUGGCCAGGAUGCCUU 2436 1358 UAUAGAGGCUCUUGUGCGU 1597 1359GGUUCAGAUGAUAUAAAUG 1496 1360 AGGGAUGGAAGGUCUCCUU 1456 1361UAUCCCAAAGUUGUUGUAA 3159 1362 UCUCUCUUCAGAACAGAGC 2309 1363CUGACCAGCUCUCUCUUCA 2300 1364 ACCUGCUGUGAUACGAUGC 3177 1365AUGGCAGUGCGUUUAGCUG 1079 1366 AUCCAAGUCAACGUCUUGU 1383 1367GCUGCCUCCAGGUGACAGC 2563 1368 AGUGCGUUUAGCUGGUGGG 1084 1369AGCCGGCUAUUGUAGAAGC 1329 1370 CAUUAGAUGAGGGCAUGCA  573 1371GAAGGUGUGGCGACAUAUG 2213 1372 AAGUGGGUGGUAUAGAGGC 1587 1373CUGAGGGAGCCACAGCUCC 2166 1374 GCGUUUGGCUGAACCAUCA  637 1375UCCUUCUCUGAGUGGUAAA  397 1376 GCAGUUCGCCUUCACUAUG 1718 1377GGACUUGAUAUUGGUGCCC 2357 1378 GUUUGGCUGAACCAUCACA  639 1379GCAUGCAGAUCCCAUCUAC  585 1380 GAUGGGCUGCCAGAUCUGG 2519 1381GGACUUCACCUGACAGAUC 1367 1382 CAACGUCUUGUUCAGAACU 1391 1383GAUAUUGAUGGACAGUAUG  509 1384 UGGCCAUGGAACCAGACAG  303 1385CAAGAACAAGUAGCUGAUA  494 1386 GGCUGUUAGUCACUGGCAG  328 1387CAUUGUUUGUGCAGCUGCU 2058 1388 UAAACAGGAAGGGAUGGAA 1447 1389AUAAGAACAAGAUGAUGGU 1563 1390 GUGGAAUGCAAGCUUUAGG 1350 1391GGAAUGAAGGUGUGGCGAC 2208 1392 GACACCAAGAAGCAGAGAU 1689 1393ACUGUCUUUGGACUCUCAG 1407 1394 GGACAAGGAAGCUGCAGAA 2137 1395UCUGCUAUUGUACGUACCA  854 1396 AGCUGCUUUAUUCUCCCAU 2070 1397AGGGUACGAGCUGCUAUGU  545 1398 GAAGACAUCACUGAGCCUG 1640 1399CGGGAUGUUCACAACCGAA 2012 1400 CAGCCGACACCAAGAAGCA 1684 1401UGUUCACAACCGAAUUGUU 2017 1402 GCUCUCUCUUCAGAACAGA 2307 1403UCAGAUGGUGUCUGCUAUU  844 1404 UGAGUGGUAAAGGCAAUCC  405 1405UGGUGCCACUACCACAGCU  379 1406 UUGUCCCGCAAAUCAUGCA 1825 1407CACCCUGGUGCUGACUAUC 2495 1408 AAUGUCCAGCGUUUGGCUG  629 1409GGGCUGCCUCCAGGUGACA 2561 1410 GAGUUACUUCACUCUAGGA 2192 1411UUCGAAAUCUUGCCCUUUG 1809 1412 GUAUAGAGGCUCUUGUGCG 1596 1413AGCUGACCAGCUCUCUCUU 2298 1414 CUAUUGUACGUACCAUGCA  858 1415UAUGCAAUGACUCGAGCUC  524 1416 UGCCCAGGACCUCAUGGAU 2542 1417AACAAGUAGCUGAUAUUGA  597 1418 AAGGCAAUCCUGAGGAAGA  414 1419CAAGAUGAUGGUCUGCCAA 1570 1420 UGCCAUUACAACUCUCCAC 1030 1421AUGUAUGGGUAGGGUAAAU 3087 1422 UGUGCUCUUCGUCAUCUGA 1664 1423AAGGCUACUGUUGGAUUGA 1790 1424 UACUGUCCUUCGGGCUGGU 1615 1425AUAAGGCUGCAGUUAUGGU  774 1426 UCGUCAUCUGACCAGCCGA 1672 1427GUUGUAACCUGCUGUGAUA 3171 1428 AAGAUUACAAGAAACGGCU 2271 1429UUAUGGCAACCAAGAAAGC 1183 1430 UCCAGUUGAUGGGCUGCCA 2512 1431GGGACACAGCAGCAAUUUG 1931 1432 AUGAUGGAACAUGAGAUGG 2468 1433UAUUUGGGAUAUGUAUGGG 3077 1434 CAGCUGCUUUAUUCUCCCA 2069 1435GCUACUCAAGCUGAUUUGA  272 1436 UCCCUGAGACAUUAGAUGA  564 1437GUGGAUACCUCCCAAGUCC  437 1438 UAGGAAUGAAGGUGUGGCG 2206 1439UGACAGAGUUACUUCACUC 2187 1440 AGCGGCUGUUAGUCACUGG  325 1441AUGGUUCAGAAUUAAACUU 3222 1442 AACCGAAUUGUUAUCAGAG 2024 1443GGGUGCCAUUCCACGACUA 1858 1444 AUGAUGGUCUGCCAAGUGG 1574 1445CACAUCAGGAUACCCAGCG 1896 1446 AGGAAUGAAGGUGUGGCGA 2207 1447GAAGGUGCUAUCUGUCUGC 1300 1448 CCAAGAAAGCAAGCUCAUC 1192 1449CGAGCUGCUAUGUUCCCUG  551 1450 CCUGGUGCUGACUAUCCAG 2498 1451UGCUAUCUGUCUGCUCUAG 1305 1452 AUUGUAGAAGCUGGUGGAA 1337 1453

TABLE 1b Various c-CTNNB1 siNA sense and antisene sequencescorresponding to the identified target sequences in Table 1a.Target Site (human) SEQ ID NO: Sense Sequence Antisense SequenceSEQ ID NO:  535    1 UCGAGCUCAGAGGGUACGA UCGUACCCUCUGAGCUCGA 4914 1601   2 GAGGCUCUUGUGCGUACUG CAGUACGCACAAGAGCCUC 4915 1709    3GCCCAGAAUGCAGUUCGCC GGCGAACUGCAUUCUGGGC 4916  536    4CGAGCUCAGAGGGUACGAG CUCGUACCCUCUGAGCUCG 4917 1797    5CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAG 4918  853    6GUCUGCUAUUGUACGUACC GGUACGUACAAUAGCAGAC 4919 1143    7AAUUCUUGGCUAUUACGAC GUCGUAAUAGCCAAGAAUU 4920 2014    8GGAUGUUCACAACCGAAUU AAUUCGGUUGUGAACAUCC 4921  520    9ACAGUAUGCAAUGACUCGA UCGAGUCAUUGCAUACUGU 4922  815   10AGCUUCCAGACACGCUAUC GAUAGCGUGUCUGGAAGCU 4923  852   11UGUCUGCUAUUGUACGUAC GUACGUACAAUAGCAGACA 4924 1796   12ACUGUUGGAUUGAUUCGAA UUCGAAUCAAUCCAACAGU 4925 1901   13CAGGAUACCCAGCGCCGUA UACGGCGCUGGGUAUCCUG 4926  822   14GACACGCUAUCAUGCGUUC GAACGCAUGAUAGCGUGUC 4927 1795   15UACUGUUGGAUUGAUUCGA UCGAAUCAAUCCAACAGUA 4928 1145   16UUCUUGGCUAUUACGACAG CUGUCGUAAUAGCCAAGAA 4929  823   17ACACGCUAUCAUGCGUUCU AGAACGCAUGAUAGCGUGU 4930  820   18CAGACACGCUAUCAUGCGU ACGCAUGAUAGCGUGUCUG 4931 1798   19UGUUGGAUUGAUUCGAAAU AUUUCGAAUCAAUCCAACA 4932 1380   20CAGAUCCAAGUCAACGUCU AGACGUUGACUUGGAUCUG 4933 1602   21AGGCUCUUGUGCGUACUGU ACAGUACGCACAAGAGCCU 4934 1612   22GCGUACUGUCCUUCGGGCU AGCCCGAAGGACAGUACGC 4935  626   23ACUAAUGUCCAGCGUUUGG CCAAACGCUGGACAUUAGU 4936 2000   24CACAUCCUAGCUCGGGAUG CAUCCCGAGCUAGGAUGUG 4937 2665   25GUUGCUGAGAGGGCUCGAG CUCGAGCCCUCUCAGCAAC 4938 1676   26CAUCUGACCAGCCGACACC GGUGUCGGCUGGUCAGAUG 4939 1611   27UGCGUACUGUCCUUCGGGC GCCCGAAGGACAGUACGCA 4940 2269   28ACAAGAUUACAAGAAACGG CCGUUUCUUGUAAUCUUGU 4941  674   29GUUGUAAACUUGAUUAACU AGUUAAUCAAGUUUACAAC 4942  678   30UAAACUUGAUUAACUAUCA UGAUAGUUAAUCAAGUUUA 4943 1245   31AUAUAAUGAGGACCUAUAC GUAUAGGUCCUCAUUAUAU 4944  679   32AAACUUGAUUAACUAUCAA UUGAUAGUUAAUCAAGUUU 4945 1970   33GAAAUAGUUGAAGGUUGUA UACAACCUUCAACUAUUUC 4946 1247   34AUAAUGAGGACCUAUACUU AAGUAUAGGUCCUCAUUAU 4947 1140   35UUAAAUUCUUGGCUAUUAC GUAAUAGCCAAGAAUUUAA 4948  676   36UGUAAACUUGAUUAACUAU AUAGUUAAUCAAGUUUACA 4949  677   37GUAAACUUGAUUAACUAUC GAUAGUUAAUCAAGUUUAC 4950  675   38UUGUAAACUUGAUUAACUA UAGUUAAUCAAGUUUACAA 4951 1235   39GCUUUAGUAAAUAUAAUGA UCAUUAUAUUUACUAAAGC 4952 2488   40UGGCCACCACCCUGGUGCU AGCACCAGGGUGGUGGCCA 4953 1236   41CUUUAGUAAAUAUAAUGAG CUCAUUAUAUUUACUAAAG 4954 1237   42UUUAGUAAAUAUAAUGAGG CCUCAUUAUAUUUACUAAA 4955 2555   43GUAAAUCGUCCUUUAGGUA UACCUAAAGGACGAUUUAC 4956 1545   44ACCUCACUUGCAAUAAUUA UAAUUAUUGCAAGUGAGGU 4957 2050   45UACCAUUCCAUUGUUUGUG CACAAACAAUGGAAUGGUA 4958 2097   46UCCAAAGAGUAGCUGCAGG CCUGCAGCUACUCUUUGGA 4959 2510   47UAUCCAGUUGAUGGGCUGC GCAGCCCAUCAACUGGAUA 4960  871   48CAUGCAGAAUACAAAUGAU AUCAUUUGUAUUCUGCAUG 4961 2098   49CCAAAGAGUAGCUGCAGGG CCCUGCAGCUACUCUUUGG 4962 1767   50CACCAUCCCACUGGCCUCU AGAGGCCAGUGGGAUGGUG 4963  869   51ACCAUGCAGAAUACAAAUG CAUUUGUAUUCUGCAUGGU 4964 1641   52AAGACAUCACUGAGCCUGC GCAGGCUCAGUGAUGUCUU 4965 2582   53AAUCAGCUGGCCUGGUUUG CAAACCAGGCCAGCUGAUU 4966 1544   54AACCUCACUUGCAAUAAUU AAUUAUUGCAAGUGAGGUU 4967 2550   55ACCUCAUGGAUGGGCUGCC GGCAGCCCAUCCAUGAGGU 4968 2051   56ACCAUUCCAUUGUUUGUGC GCACAAACAAUGGAAUGGU 4969  870   57CCAUGCAGAAUACAAAUGA UCAUUUGUAUUCUGCAUGG 4970 1670   58CUUCGUCAUCUGACCAGCC GGCUGGUCAGAUGACGAAG 4971 2122   59CUGUGAACUUGCUCAGGAC GUCCUGAGCAAGUUCACAG 4972 1642   60AGACAUCACUGAGCCUGCC GGCAGGCUCAGUGAUGUCU 4973 2324   61GAGCCAAUGGCUUGGAAUG CAUUCCAAGCCAUUGGCUC 4974 1649   62ACUGAGCCUGCCAUCUGUG CACAGAUGGCAGGCUCAGU 4975 2159   63AUUGAAGCUGAGGGAGCCA UGGCUCCCUCAGCUUCAAU 4976  785   64GUUAUGGUCCAUCAGCUUU AAAGCUGAUGGACCAUAAC 4977 1511   65AAUGUGGUCACCUGUGCAG CUGCACAGGUGACCACAUU 4978 2586   66AGCUGGCCUGGUUUGAUAC GUAUCAAACCAGGCCAGCU 4979  642   67UGGCUGAACCAUCACAGAU AUCUGUGAUGGUUCAGCCA 4980 1763   68CACCCACCAUCCCACUGGC GCCAGUGGGAUGGUGGGUG 4981 2328   69CAAUGGCUUGGAAUGAGAC GUCUCAUUCCAAGCCAUUG 4982 1280   70UGGACCACAAGCAGAGUGC GCACUCUGCUUGUGGUCCA 4983 2052   71CCAUUCCAUUGUUUGUGCA UGCACAAACAAUGGAAUGG 4984 2546   72CAGGACCUCAUGGAUGGGC GCCCAUCCAUGAGGUCCUG 4985 2124   73GUGAACUUGCUCAGGACAA UUGUCCUGAGCAAGUUCAC 4986 2545   74CCAGGACCUCAUGGAUGGG CCCAUCCAUGAGGUCCUGG 4987  643   75GGCUGAACCAUCACAGAUG CAUCUGUGAUGGUUCAGCC 4988 2501   76GGUGCUGACUAUCCAGUUG CAACUGGAUAGUCAGCACC 4989 2330   77AUGGCUUGGAAUGAGACUG CAGUCUCAUUCCAAGCCAU 4990 1638   78GGGAAGACAUCACUGAGCC GGCUCAGUGAUGUCUUCCC 4991 1630   79UGGUGACAGGGAAGACAUC GAUGUCUUCCCUGUCACCA 4992  616   80UGCUCAUCCCACUAAUGUC GACAUUAGUGGGAUGAGCA 4993 2509   81CUAUCCAGUUGAUGGGCUG CAGCCCAUCAACUGGAUAG 4994 2548   82GGACCUCAUGGAUGGGCUG CAGCCCAUCCAUGAGGUCC 4995 1773   83CCCACUGGCCUCUGAUAAA UUUAUCAGAGGCCAGUGGG 4996 2247   84UCCGAAUGUCUGAGGACAA UUGUCCUCAGACAUUCGGA 4997 2331   85UGGCUUGGAAUGAGACUGC GCAGUCUCAUUCCAAGCCA 4998 1498   86UUCAGAUGAUAUAAAUGUG CACAUUUAUAUCAUCUGAA 4999 2267   87CCACAAGAUUACAAGAAAC GUUUCUUGUAAUCUUGUGG 5000 1547   88CUCACUUGCAAUAAUUAUA UAUUAAUUAUUGCAAGUGAG 5001 1549   89CACUUGCAAUAAUUAUAAG CUUAUAAUUAUUGCAAGUG 5002  867   90GUACCAUGCAGAAUACAAA UUUGUAUUCUGCAUGGUAC 5003 1390   91UCAACGUCUUGUUCAGAAC GUUCUGAACAAGACGUUGA 5004 593   92AUCCCAUCUACACAGUUUG CAAACUGUGUAGAUGGGAU 5005  274   93UACUCAAGCUGAUUUGAUG CAUCAAAUCAGCUUGAGUA 5006  759   94ACCAGGUGGUGGUUAAUAA UUAUUAACCACCACCUGGU 5007 1439   95GCUGCAACUAAACAGGAAG CUUCCUGUUUAGUUGCAGC 5008 1801   96UGGAUUGAUUCGAAAUCUU AAGAUUUCGAAUCAAUCCA 5009 1500   97CAGAUGAUAUAAAUGUGGU ACCACAUUUAUAUCAUCUG 5010  848   98AUGGUGUCUGCUAUUGUAC GUACAAUAGCAGACACCAU 5011 2268   99CACAAGAUUACAAGAAACG CGUUUCUUGUAAUCUUGUG 5012  882  100CAAAUGAUGUAGAAACAGC GCUGUUUCUACAUCAUUUG 5013 2266  101GCCACAAGAUUACAAGAAA UUUCUUGUAAUCUUGUGGC 5014  880  102UACAAAUGAUGUAGAAACA UGUUUCUACAUCAUUUGUA 5015 1810  103UCGAAAUCUUGCCCUUUGU ACAAAGGGCAAGAUUUCGA 5016  685  104GAUUAACUAUCAAGAUGAU AUCAUCUUGAUAGUUAAUC 5017 1007  105CCAGUGGAUUCUGUGUUGU ACAACACAGAAUCCACUGG 5018 1789  106AAAGGCUACUGUUGGAUUG CAAUCCAACAGUAGCCUUU 5019  499  107ACAAGUAGCUGAUAUUGAU AUCAAUAUCAGCUACUUGU 5020 2470  108GAUGGAACAUGAGAUGGGU ACCCAUCUCAUGUUCCAUC 5021  694  109UCAAGAUGAUGCAGAACUU AAGUUCUGCAUCAUCUUGA 5022  278  110CAAGCUGAUUUGAUGGAGU ACUCCAUCAAAUCAGCUUG 5023 1415  111UGGACUCUCAGGAAUCUUU AAAGAUUCCUGAGAGUCCA 5024 2046  112UAAAUACCAUUCCAUUGUU AACAAUGGAAUGGUAUUUA 5025 1057  113AUUACAUCAAGAAGGAGCU AGCUCCUUCUUGAUGUAAU 5026 1422  114UCAGGAAUCUUUCAGAUGC GCAUCUGAAAGAUUCCUGA 5027  684  115UGAUUAACUAUCAAGAUGA UCAUCUUGAUAGUUAAUCA 5028 2197  116ACUUCACUCUAGGAAUGAA UUCAUUCCUAGAGUGAAGU 5029  666  117AACAUGCAGUUGUAAACUU AAGUUUACAACUGCAUGUU 5030  279  118AAGCUGAUUUGAUGGAGUU AACUCCAUCAAAUCAGCUU 5031 1492  119UCUGGGUUCAGAUGAUAUA UAUAUCAUCUGAACCCAGA 5032 2195  120UUACUUCACUCUAGGAAUG CAUUCCUAGAGUGAAGUAA 5033 1424  121AGGAAUCUUUCAGAUGCUG CAGCAUCUGAAAGAUUCCU 5034  661  122GCUGAAACAUGCAGUUGUA UACAACUGCAUGUUUCAGC 5035 1882  123GUUGCUUGUUCGUGCACAU AUGUGCACGAACAAGCAAC 5036 1966  124GGAAGAAAUAGUUGAAGGU ACCUUCAACUAUUUCUUCC 5037 2259  125AGGACAAGCCACAAGAUUA UAAUCUUGUGGCUUGUCCU 5038  832  126CAUGCGUUCUCCUCAGAUG CAUCUGAGGAGAACGCAUG 5039 2346  127GAUGAUCCCAGCUACCGUU AACGGUAGCUGGGAUCAUC 5040 1653  128AGCCUGCCAUCUGUGCUCU AGAGCACAGAUGGCAGGCU 5041 2389  129UGGAUAUCGCCAGGAUGAU AUCAUCCUGGCGAUAUCCA 5042 1669  130UCUUCGUCAUCUGACCAGC GCUGGUCAGAUGACGAAGA 5043 2123  131UGUGAACUUGCUCAGGACA UGUCCUGAGCAAGUUCACA 5044 1521  132CCUGUGCAGCUGGAAUUCU AGAAUUCCAGCUGCACAGG 5045 2125  133UGAACUUGCUCAGGACAAG CUUGUCCUGAGCAAGUUCA 5046 2503  134UGCUGACUAUCCAGUUGAU AUCAACUGGAUAGUCAGCA 5047 1502  135GAUGAUAUAAAUGUGGUCA UGACCACAUUUAUAUCAUC 5048 2502  136GUGCUGACUAUCCAGUUGA UCAACUGGAUAGUCAGCAC 5049 2506  137UGACUAUCCAGUUGAUGGG CCCAUCAACUGGAUAGUCA 5050 2127  138AACUUGCUCAGGACAAGGA UCCUUGUCCUGAGCAAGUU 5051 2505  139CUGACUAUCCAGUUGAUGG CCAUCAACUGGAUAGUCAG 5052  617  140GCUCAUCCCACUAAUGUCC GGACAUUAGUGGGAUGAGC 5053 2504  141GCUGACUAUCCAGUUGAUG CAUCAACUGGAUAGUCAGC 5054 1503  142AUGAUAUAAAUGUGGUCAC GUGACCACAUUUAUAUCAU 5055  618  143CUCAUCCCACUAAUGUCCA UGGACAUUAGUGGGAUGAG 5056 2074  144GCUUUAUUCUCCCAUUGAA UUCAAUGGGAGAAUAAAGC 5057 2499  145CUGGUGCUGACUAUCCAGU ACUGGAUAGUCAGCACCAG 5058 1406  146AACUGUCUUUGGACUCUCA UGAGAGUCCAAAGACAGUU 5059  582  147AGGGCAUGCAGAUCCCAUC GAUGGGAUCUGCAUGCCCU 5060 1505  148GAUAUAAAUGUGGUCACCU AGGUGACCACAUUUAUAUC 5061 1432  149UUCAGAUGCUGCAACUAAA UUUAGUUGCAGCAUCUGAA 5062 1968  150AAGAAAUAGUUGAAGGUUG CAACCUUCAACUAUUUCUU 5063 2398  151CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGG 5064  954  152UGGCCAUCUUUAAGUCUGG CCAGACUUAAAGAUGGCCA 5065 505 153 AGCUGAUAUUGAUGGACAGCUGUCCAUCAAUAUCAGCU 5066 2011 154 UCGGGAUGUUCACAACCGAUCGGUUGUGAACAUCCCGA 5067 1339 155 UGUAGAAGCUGGUGGAAUGCAUUCCACCAGCUUCUACA 5068 1242 156 UAAAUAUAAUGAGGACCUAUAGGUCCUCAUUAUAUUUA 5069 567 157 CUGAGACAUUAGAUGAGGG CCCUCAUCUAAUGUCUCAG5070 1240 158 AGUAAAUAUAAUGAGGACC GGUCCUCAUUAUAUUUACU 5071 438 159UGGAUACCUCCCAAGUCCU AGGACUUGGGAGGUAUCCA 5072 2445 160AGGAUGCCUUGGGUAUGGA UCCAUACCCAAGGCAUCCU 5073 860 161 AUUGUACGUACCAUGCAGAUCUGCAUGGUACGUACAAU 5074 1413 162 UUUGGACUCUCAGGAAUCUAGAUUCCUGAGAGUCCAAA 5075 1800 163 UUGGAUUGAUUCGAAAUCUAGAUUUCGAAUCAAUCCAA 5076 2037 164 UCAGAGGACUAAAUACCAUAUGGUAUUUAGUCCUCUGA 5077 2443 165 CCAGGAUGCCUUGGGUAUGCAUACCCAAGGCAUCCUGG 5078 2471 166 AUGGAACAUGAGAUGGGUGCACCCAUCUCAUGUUCCAU 5079 1792 167 GGCUACUGUUGGAUUGAUUAAUCAAUCCAACAGUAGCC 5080 2547 168 AGGACCUCAUGGAUGGGCUAGCCCAUCCAUGAGGUCCU 5081 1662 169 UCUGUGCUCUUCGUCAUCUAGAUGACGAAGAGCACAGA 5082 288 170 UGAUGGAGUUGGACAUGGC GCCAUGUCCAACUCCAUCA5083 579 171 AUGAGGGCAUGCAGAUCCC GGGAUCUGCAUGCCCUCAU 5084 2508 172ACUAUCCAGUUGAUGGGCU AGCCCAUCAACUGGAUAGU 5085 580 173 UGAGGGCAUGCAGAUCCCAUGGGAUCUGCAUGCCCUCA 5086 2388 174 UUGGAUAUCGCCAGGAUGAUCAUCCUGGCGAUAUCCAA 5087 2543 175 GCCCAGGACCUCAUGGAUGCAUCCAUGAGGUCCUGGGC 5088 708 176 AACUUGCCACACGUGCAAU AUUGCACGUGUGGCAAGUU5089 447 177 CCCAAGUCCUGUAUGAGUG CACUCAUACAGGACUUGGG 5090 654 178CACAGAUGCUGAAACAUGC GCAUGUUUCAGCAUCUGUG 5091 912 179 CUGGGACCUUGCAUAACCUAGGUUAUGCAAGGUCCCAG 5092 1009 180 AGUGGAUUCUGUGUUGUUUAAACAACACAGAAUCCACU 5093 1354 181 AAUGCAAGCUUUAGGACUUAAGUCCUAAAGCUUGCAUU 5094 1969 182 AGAAAUAGUUGAAGGUUGUACAACCUUCAACUAUUUCU 5095 1959 183 UCCGCAUGGAAGAAAUAGUACUAUUUCUUCCAUGCGGA 5096 557 184 GCUAUGUUCCCUGAGACAU AUGUCUCAGGGAACAUAGC5097 403 185 UCUGAGUGGUAAAGGCAAU AUUGCCUUUACCACUCAGA 5098 1356 186UGCAAGCUUUAGGACUUCA UGAAGUCCUAAAGCUUGCA 5099 517 187 UGGACAGUAUGCAAUGACUAGUCAUUGCAUACUGUCCA 5100 1238 188 UUAGUAAAUAUAAUGAGGAUCCUCAUUAUAUUUACUAA 5101 843 189 CUCAGAUGGUGUCUGCUAU AUAGCAGACACCAUCUGAG5102 496 190 AGAACAAGUAGCUGAUAUU AAUAUCAGCUACUUGUUCU 5103 2387 191CUUGGAUAUCGCCAGGAUG CAUCCUGGCGAUAUCCAAG 5104 1660 192CAUCUGUGCUCUUCGUCAU AUGACGAAGAGCACAGAUG 5105 2497 193CCCUGGUGCUGACUAUCCA UGGAUAGUCAGCACCAGGG 5106 1870 194ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGU 5107 2353 195UCUUGGACUUGAUAUUGGU ACCAAUAUCAAGUCCAAGA 5108 2401 196GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCC 5109 878 197 AAUACAAAUGAUGUAGAAAUUUCUACAUCAUUUGUAUU 5110 647 198 GAACCAUCACAGAUGCUGA UCAGCAUCUGUGAUGGUUC5111 1998 199 UUCACAUCCUAGCUCGGGA UCCCGAGCUAGGAUGUGAA 5112 588 200UGCAGAUCCCAUCUACACA UGUGUAGAUGGGAUCUGCA 5113 2042  201GGACUAAAUACCAUUCCAU AUGGAAUGGUAUUUAGUCC 5114  855  202CUGCUAUUGUACGUACCAU AUGGUACGUACAAUAGCAG 5115 2038  203CAGAGGACUAAAUACCAUU AAUGGUAUUUAGUCCUCUG 5116 1786  204GAUAAAGGCUACUGUUGGA UCCAACAGUAGCCUUUAUC 5117 1501  205AGAUGAUAUAAAUGUGGUC GACCACAUUUAUAUCAUCU 5118 1834  206AAAUCAUGCACCUUUGCGU ACGCAAAGGUGCAUGAUUU 5119 1157  207ACGACAGACUGCCUUCAAA UUUGAAGGCAGUCUGUCGU 5120 1239  208UAGUAAAUAUAAUGAGGAC GUCCUCAUUAUAUUUACUA 5121 1248  209UAAUGAGGACCUAUACUUA UAAGUAUAGGUCCUCAUUA 5122  660  210UGCUGAAACAUGCAGUUGU ACAACUGCAUGUUUCAGCA 5123  285  211AUUUGAUGGAGUUGGACAU AUGUCCAACUCCAUCAAAU 5124 1582  212CUGCCAAGUGGGUGGUAUA UAUACCACCCACUUGGCAG 5125 1735  213UGGACUACCAGUUGUGGUU AACCACAACUGGUAGUCCA 5126  771  214UUAAUAAGGCUGCAGUUAU AUAACUGCAGCCUUAUUAA 5127 1060  215ACAUCAAGAAGGAGCUAAA UUUAGCUCCUUCUUGAUGU 5128 2390  216GGAUAUCGCCAGGAUGAUC GAUCAUCCUGGCGAUAUCC 5129 2186  217CUGACAGAGUUACUUCACU AGUGAAGUAACUCUGUCAG 5130 1632  218GUGACAGGGAAGACAUCAC GUGAUGUCUUCCCUGUCAC 5131  619  219UCAUCCCACUAAUGUCCAG CUGGACAUUAGUGGGAUGA 5132 1656  220CUGCCAUCUGUGCUCUUCG CGAAGAGCACAGAUGGCAG 5133 1506  221AUAUAAAUGUGGUCACCUG CAGGUGACCACAUUUAUAU 5134 2494  222CCACCCUGGUGCUGACUAU AUAGUCAGCACCAGGGUGG 5135 1666  223UGCUCUUCGUCAUCUGACC GGUCAGAUGACGAAGAGCA 5136 1635  224ACAGGGAAGACAUCACUGA UCAGUGAUGUCUUCCCUGU 5137  294  225AGUUGGACAUGGCCAUGGA UCCAUGGCCAUGUCCAACU 5138  641  226UUGGCUGAACCAUCACAGA UCUGUGAUGGUUCAGCCAA 5139  576  227UAGAUGAGGGCAUGCAGAU AUCUGCAUGCCCUCAUCUA 5140  577  228AGAUGAGGGCAUGCAGAUC GAUCUGCAUGCCCUCAUCU 5141 1661  229AUCUGUGCUCUUCGUCAUC GAUGACGAAGAGCACAGAU 5142  707  230GAACUUGCCACACGUGCAA UUGCACGUGUGGCAAGUUC 5143 1657  231CCAUCUGUGCUCUUCGUCA UGACGAAGAGCACAGAUGG 5144 1185  232AUGGCAACCAAGAAAGCAA UUGCUUUCUUGGUUGCCAU 5145  664  233GAAACAUGCAGUUGUAAAC GUUUACAACUGCAUGUUUC 5146 1749  234UGGUUAAGCUCUUACACCC GGGUGUAAGAGCUUAACCA 5147 1234  235AGCUUUAGUAAAUAUAAUG CAUUAUAUUUACUAAAGCU 5148  691  236CUAUCAAGAUGAUGCAGAA UUCUGCAUCAUCUUGAUAG 5149 1387  237AAGUCAACGUCUUGUUCAG CUGAACAAGACGUUGACUU 5150 1382  238GAUCCAAGUCAACGUCUUG CAAGACGUUGACUUGGAUC 5151  828  239CUAUCAUGCGUUCUCCUCA UGAGGAGAACGCAUGAUAG 5152 1244  240AAUAUAAUGAGGACCUAUA UAUAGGUCCUCAUUAUAUU 5153 1304  241GUGCUAUCUGUCUGCUCUA UAGAGCAGACAGAUAGCAC 5154  812  242GAAGCUUCCAGACACGCUA UAGCGUGUCUGGAAGCUUC 5155 1558  243UAAUUAUAAGAACAAGAUG CAUCUUGUUCUUAUAAUUA 5156  879  244AUACAAAUGAUGUAGAAAC GUUUCUACAUCAUUUGUAU 5157 1311  245CUGUCUGCUCUAGUAAUAA UUAUUACUAGAGCAGACAG 5158  856  246UGCUAUUGUACGUACCAUG CAUGGUACGUACAAUAGCA 5159 1296  247UGCUGAAGGUGCUAUCUGU ACAGAUAGCACCUUCAGCA 5160  960  248UCUUUAAGUCUGGAGGCAU AUGCCUCCAGACUUAAAGA 5161 2049  249AUACCAUUCCAUUGUUUGU ACAAACAAUGGAAUGGUAU 5162 1791  250AGGCUACUGUUGGAUUGAU AUCAAUCCAACAGUAGCCU 5163  783  251CAGUUAUGGUCCAUCAGCU AGCUGAUGGACCAUAACUG 5164 1569  252ACAAGAUGAUGGUCUGCCA UGGCAGACCAUCAUCUUGU 5165 2224  253GACAUAUGCAGCUGCUGUU AACAGCAGCUGCAUAUGUC 5166  934  254CCAUCAUCGUGAGGGCUUA UAAGCCCUCACGAUGAUGG 5167 1378  255GACAGAUCCAAGUCAACGU ACGUUGACUUGGAUCUGUC 5168  569  256GAGACAUUAGAUGAGGGCA UGCCCUCAUCUAAUGUCUC 5169 1722  257UUCGCCUUCACUAUGGACU AGUCCAUAGUGAAGGCGAA 5170 1483  258UGUUCAGCUUCUGGGUUCA UGAACCCAGAAGCUGAACA 5171 2352  259AUCUUGGACUUGAUAUUGG CCAAUAUCAAGUCCAAGAU 5172  719  260CGUGCAAUCCCUGAACUGA UCAGUUCAGGGAUUGCACG 5173  762  261AGGUGGUGGUUAAUAAGGC GCCUUAUUAACCACCACCU 5174  599  262UCUACACAGUUUGAUGCUG CAGCAUCAAACUGUGUAGA 5175 1704  263AGAUGGCCCAGAAUGCAGU ACUGCAUUCUGGGCCAUCU 5176 2270  264CAAGAUUACAAGAAACGGC GCCGUUUCUUGUAAUCUUG 5177  662  265CUGAAACAUGCAGUUGUAA UUACAACUGCAUGUUUCAG 5178  396  266CUCCUUCUCUGAGUGGUAA UUACCACUCAGAGAAGGAG 5179 1199  267AGCAAGCUCAUCAUACUGG CCAGUAUGAUGAGCUUGCU 5180 1560  268AUUAUAAGAACAAGAUGAU AUCAUCUUGUUCUUAUAAU 5181 1310  269UCUGUCUGCUCUAGUAAUA UAUUACUAGAGCAGACAGA 5182 1233  270AAGCUUUAGUAAAUAUAAU AUUAUAUUUACUAAAGCUU 5183 1330  271GCCGGCUAUUGUAGAAGCU AGCUUCUACAAUAGCCGGC 5184 1312  272UGUCUGCUCUAGUAAUAAG CUUAUUACUAGAGCAGACA 5185 1556  273AAUAAUUAUAAGAACAAGA UCUUGUUCUUAUAAUUAUU 5186 2438  274UAUGGCCAGGAUGCCUUGG CCAAGGCAUCCUGGCCAUA 5187 1826  275UGUCCCGCAAAUCAUGCAC GUGCAUGAUUUGCGGGACA 5188 1397  276CUUGUUCAGAACUGUCUUU AAAGACAGUUCUGAACAAG 5189 3181  277GCUGUGAUACGAUGCUUCA UGAAGCAUCGUAUCACAGC 5190 1912  278GCGCCGUACGUCCAUGGGU ACCCAUGGACGUACGGCGC 5191  846  279AGAUGGUGUCUGCUAUUGU ACAAUAGCAGACACCAUCU 5192 1404  280AGAACUGUCUUUGGACUCU AGAGUCCAAAGACAGUUCU 5193  586  281CAUGCAGAUCCCAUCUACA UGUAGAUGGGAUCUGCAUG 5194 1469  282CUCCUUGGGACUCUUGUUC GAACAAGAGUCCCAAGGAG 5195  380  283GGUGCCACUACCACAGCUC GAGCUGUGGUAGUGGCACC 5196 1345  284AGCUGGUGGAAUGCAAGCU AGCUUGCAUUCCACCAGCU 5197 1863  285CCAUUCCACGACUAGUUCA UGAACUAGUCGUGGAAUGG 5198  635  286CAGCGUUUGGCUGAACCAU AUGGUUCAGCCAAACGCUG 5199  959  287AUCUUUAAGUCUGGAGGCA UGCCUCCAGACUUAAAGAU 5200 2440  288UGGCCAGGAUGCCUUGGGU ACCCAAGGCAUCCUGGCCA 5201  877  289GAAUACAAAUGAUGUAGAA UUCUACAUCAUUUGUAUUC 5202 2556  290UGGAUGGGCUGCCUCCAGG CCUGGAGGCAGCCCAUCCA 5203 1916  291CGUACGUCCAUGGGUGGGA UCCCACCCAUGGACGUACG 5204  850  292GGUGUCUGCUAUUGUACGU ACGUACAAUAGCAGACACC 5205 1303  293GGUGCUAUCUGUCUGCUCU AGAGCAGACAGAUAGCACC 5206 1726  294CCUUCACUAUGGACUACCA UGGUAGUCCAUAGUGAAGG 5207 1477  295GACUCUUGUUCAGCUUCUG CAGAAGCUGAACAAGAGUC 5208  598  296AUCUACACAGUUUGAUGCU AGCAUCAAACUGUGUAGAU 5209 2062  297GUUUGUGCAGCUGCUUUAU AUAAAGCAGCUGCACAAAC 5210 2278  298CAAGAAACGGCUUUCAGUU AACUGAAAGCCGUUUCUUG 5211 1877  299GUUCAGUUGCUUGUUCGUG CACGAACAAGCAACUGAAC 5212 1499  300UCAGAUGAUAUAAAUGUGG CCACAUUUAUAUCAUCUGA 5213 1136  301AAUGUUAAAUUCUUGGCUA UAGCCAAGAAUUUAACAUU 5214 1494  302UGGGUUCAGAUGAUAUAAA UUUAUAUCAUCUGAACCCA 5215 1972  303AAUAGUUGAAGGUUGUACC GGUACAACCUUCAACUAUU 5216  668  304CAUGCAGUUGUAAACUUGA UCAAGUUUACAACUGCAUG 5217 2945  305AAUCUGAAUAAAGUGUAAC GUUACACUUUAUUCAGAUU 5218 2492  306CACCACCCUGGUGCUGACU AGUCAGCACCAGGGUGGUG 5219  293  307GAGUUGGACAUGGCCAUGG CCAUGGCCAUGUCCAACUC 5220 1905  308AUACCCAGCGCCGUACGUC GACGUACGGCGCUGGGUAU 5221  944  309GAGGGCUUACUGGCCAUCU AGAUGGCCAGUAAGCCCUC 5222  581  310GAGGGCAUGCAGAUCCCAU AUGGGAUCUGCAUGCCCUC 5223 1454  311GAAGGGAUGGAAGGUCUCC GGAGACCUUCCAUCCCUUC 5224 2254  312GUCUGAGGACAAGCCACAA UUGUGGCUUGUCCUCAGAC 5225 1837  313UCAUGCACCUUUGCGUGAG CUCACGCAAAGGUGCAUGA 5226 1425  314GGAAUCUUUCAGAUGCUGC GCAGCAUCUGAAAGAUUCC 5227 1372  315UCACCUGACAGAUCCAAGU ACUUGGAUCUGUCAGGUGA 5228 1298  316CUGAAGGUGCUAUCUGUCU AGACAGAUAGCACCUUCAG 5229 1674  317GUCAUCUGACCAGCCGACA UGUCGGCUGGUCAGAUGAC 5230 1864  318CAUUCCACGACUAGUUCAG CUGAACUAGUCGUGGAAUG 5231 2404  319UGAUCCUAGCUAUCGUUCU AGAACGAUAGCUAGGAUCA 5232 1992  320GAGCCCUUCACAUCCUAGC GCUAGGAUGUGAAGGGCUC 5233  578  321GAUGAGGGCAUGCAGAUCC GGAUCUGCAUGCCCUCAUC 5234 3091  322AUGGGUAGGGUAAAUCAGU ACUGAUUUACCCUACCCAU 5235  720  323GUGCAAUCCCUGAACUGAC GUCAGUUCAGGGAUUGCAC 5236 2054  324AUUCCAUUGUUUGUGCAGC GCUGCACAAACAAUGGAAU 5237  374  325CAUUCUGGUGCCACUACCA UGGUAGUGGCACCAGAAUG 5238  686  326UACCAUGCAGAAUACAAAU AUUUGUAUUCUGCAUGGUA 5239 1716  327AUGCAGUUCGCCUUCACUA UAGUGAAGGCGAACUGCAU 5240  950  328UUACUGGCCAUCUUUAAGU ACUUAAAGAUGGCCAGUAA 5241 1489  329GCUUCUGGGUUCAGAUGAU AUCAUCUGAACCCAGAAGC 5242 1451  330CAGGAAGGGAUGGAAGGUC GACCUUCCAUCCCUUCCUG 5243 1181  331GCUUAUGGCAACCAAGAAA UUUCUUGGUUGCCAUAAGC 5244 1633  332UGACAGGGAAGACAUCACU AGUGAUGUCUUCCCUGUCA 5245 2394  333AUCGCCAGGAUGAUCCUAG CUAGGAUCAUCCUGGCGAU 5246 1322  334AGUAAUAAGCCGGCUAUUG CAAUAGCCGGCUUAUUACU 5247  884  335AAUGAUGUAGAAACAGCUC GAGCUGUUUCUACAUCAUU 5248 2255  336UCUGAGGACAAGCCACAAG CUUGUGGCUUGUCCUCAGA 5249 1466  337GGUCUCCUUGGGACUCUUG CAAGAGUCCCAAGGAGACC 5250 1399  338UGUUCAGAACUGUCUUUGG CCAAAGACAGUUCUGAACA 5251  378  339CUGGUGCCACUACCACAGC GCUGUGGUAGUGGCACCAG 5252 1920  340GUCCAUGGGUGGGACACAG CUGUGUCCCACCCAUGGAC 5253 1085  341GUGCGUUUAGCUGGUGGGC GCCCACCAGCUAAACGCAC 5254  865  342ACGUACCAUGCAGAAUACA UGUAUUCUGCAUGGUACGU 5255 2015  343GAUGUUCACAACCGAAUUG CAAUUCGGUUGUGAACAUC 5256 1195  344AGAAAGCAAGCUCAUCAUA UAUGAUGAGCUUGCUUUCU 5257 1484  345GUUCAGCUUCUGGGUUCAG CUGAACCCAGAAGCUGAAC 5258 1855  346GCAGGGUGCCAUUCCACGA UCGUGGAAUGGCACCCUGC 5259 1341  347UAGAAGCUGGUGGAAUGCA UGCAUUCCACCAGCUUCUA 5260 1963  348CAUGGAAGAAAUAGUUGAA UUCAACUAUUUCUUCCAUG 5261 2362  349UGAUAUUGGUGCCCAGGGA UCCCUGGGCACCAAUAUCA 5262  584  350GGCAUGCAGAUCCCAUCUA UAGAUGGGAUCUGCAUGCC 5263 1613  351CGUACUGUCCUUCGGGCUG CAGCCCGAAGGACAGUACG 5264 1155  352UUACGACAGACUGCCUUCA UGAAGGCAGUCUGUCGUAA 5265  334  353UAGUCACUGGCAGCAACAG CUGUUGCUGCCAGUGACUA 5266 1031  354GCCAUUACAACUCUCCACA UGUGGAGAGUUGUAAUGGC 5267 1725  355GCCUUCACUAUGGACUACC GGUAGUCCAUAGUGAAGGC 5268 2018  356GUUCACAACCGAAUUGUUA UAACAAUUCGGUUGUGAAC 5269  914  357GGGACCUUGCAUAACCUUU AAAGGUUAUGCAAGGUCCC 5270 2264  358AAGCCACAAGAUUACAAGA UCUUGUAAUCUUGUGGCUU 5271  343  359GCAGCAACAGUCUUACCUG CAGGUAAGACUGUUGCUGC 5272 1056  360UAUUACAUCAAGAAGGAGC GCUCCUUCUUGAUGUAAUA 5273  772  361UAAUAAGGCUGCAGUUAUG CAUAACUGCAGCCUUAUUA 5274  763  362GGUGGUGGUUAAUAAGGCU AGCCUUAUUAACCACCACC 5275  628  363UAAUGUCCAGCGUUUGGCU AGCCAAACGCUGGACAUUA 5276  399  364CUUCUCUGAGUGGUAAAGG CCUUUACCACUCAGAGAAG 5277 1682  365ACCAGCCGACACCAAGAAG CUUCUUGGUGUCGGCUGGU 5278  441  366AUACCUCCCAAGUCCUGUA UACAGGACUUGGGAGGUAU 5279 1729  367UCACUAUGGACUACCAGUU AACUGGUAGUCCAUAGUGA 5280 1902  368AGGAUACCCAGCGCCGUAC GUACGGCGCUGGGUAUCCU 5281 1637  369AGGGAAGACAUCACUGAGC GCUCAGUGAUGUCUUCCCU 5282 2391  370GAUAUCGCCAGGAUGAUCC GGAUCAUCCUGGCGAUAUC 5283  501  371AAGUAGCUGAUAUUGAUGG CCAUCAAUAUCAGCUACUU 5284 1358  372CAAGCUUUAGGACUUCACC GGUGAAGUCCUAAAGCUUG 5285 1821  373CCCUUUGUCCCGCAAAUCA UGAUUUGCGGGACAAAGGG 5286  575  374UUAGAUGAGGGCAUGCAGA UCUGCAUGCCCUCAUCUAA 5287  528  375CAAUGACUCGAGCUCAGAG CUCUGAGCUCGAGUCAUUG 5288 2433  376GUGGAUAUGGCCAGGAUGC GCAUCCUGGCCAUAUCCAC 5289 1497  377GUUCAGAUGAUAUAAAUGU ACAUUUAUAUCAUCUGAAC 5290 2134  378UCAGGACAAGGAAGCUGCA UGCAGCUUCCUUGUCCUGA 5291 2160  379UUGAAGCUGAGGGAGCCAC GUGGCUCCCUCAGCUUCAA 5292  291  380UGGAGUUGGACAUGGCCAU AUGGCCAUGUCCAACUCCA 5293  657  381AGAUGCUGAAACAUGCAGU ACUGCAUGUUUCAGCAUCU 5294 1575  382UGAUGGUCUGCCAAGUGGG CCCACUUGGCAGACCAUCA 5295  667  383ACAUGCAGUUGUAAACUUG CAAGUUUACAACUGCAUGU 5296 2190  384CAGAGUUACUUCACUCUAG CUAGAGUGAAGUAACUCUG 5297  532  385GACUCGAGCUCAGAGGGUA UACCCUCUGAGCUCGAGUC 5298  953  386CUGGCCAUCUUUAAGUCUG CAGACUUAAAGAUGGCCAG 5299 3188  387UACGAUGCUUCAAGAGAAA UUUCUCUUGAAGCAUCGUA 5300 2301  388UGACCAGCUCUCUCUUCAG CUGAAGAGAGAGCUGGUCA 5301 2310  389CUCUCUUCAGAACAGAGCC GGCUCUGUUCUGAAGAGAG 5302 2287  390GCUUUCAGUUGAGCUGACC GGUCAGCUCAACUGAAAGC 5303 1927  391GGGUGGGACACAGCAGCAA UUGCUGCUGUGUCCCACCC 5304  712  392UGCCACACGUGCAAUCCCU AGGGAUUGCACGUGUGGCA 5305 2121  393UCUGUGAACUUGCUCAGGA UCCUGAGCAAGUUCACAGA 5306 2898  394UGAGUAAUGGUGUAGAACA UGUUCUACACCAUUACUCA 5307 1799  395GUUGGAUUGAUUCGAAAUC GAUUUCGAAUCAAUCCAAC 5308 1036  396UACAACUCUCCACAACCUU AAGGUUGUGGAGAGUUGUA 5309  449  397CAAGUCCUGUAUGAGUGGG CCCACUCAUACAGGACUUG 5310 1452  398AGGAAGGGAUGGAAGGUCU AGACCUUCCAUCCCUUCCU 5311 1203  399AGCUCAUCAUACUGGCUAG CUAGCCAGUAUGAUGAGCU 5312 1357  400GCAAGCUUUAGGACUUCAC GUGAAGUCCUAAAGCUUGC 5313 1512  401AUGUGGUCACCUGUGCAGC GCUGCACAGGUGACCACAU 5314  275  402ACUCAAGCUGAUUUGAUGG CCAUCAAAUCAGCUUGAGU 5315  299  403GACAUGGCCAUGGAACCAG CUGGUUCCAUGGCCAUGUC 5316 1241  404GUAAAUAUAAUGAGGACCU AGGUCCUCAUUAUAUUUAC 5317 1961  405CGCAUGGAAGAAAUAGUUG CAACUAUUUCUUCCAUGCG 5318 1436  406GAUGCUGCAACUAAACAGG CCUGUUUAGUUGCAGCAUC 5319 2469  407UGAUGGAACAUGAGAUGGG CCCAUCUCAUGUUCCAUCA 5320  760  408CCAGGUGGUGGUUAAUAAG CUUAUUAACCACCACCUGG 5321 2257  409UGAGGACAAGCCACAAGAU AUCUUGUGGCUUGUCCUCA 5322  952  410ACUGGCCAUCUUUAAGUCU AGACUUAAAGAUGGCCAGU 5323 2283  411AACGGCUUUCAGUUGAGCU AGCUCAACUGAAAGCCGUU 5324 1794  412CUACUGUUGGAUUGAUUCG CGAAUCAAUCCAACAGUAG 5325 1745  413GUUGUGGUUAAGCUCUUAC GUAAGAGCUUAACCACAAC 5326 1211  414AUACUGGCUAGUGGUGGAC GUCCACCACUAGCCAGUAU 5327 2549  415GACCUCAUGGAUGGGCUGC GCAGCCCAUCCAUGAGGUC 5328 2007  416UAGCUCGGGAUGUUCACAA UUGUGAACAUCCCGAGCUA 5329 2474  417GAACAUGAGAUGGGUGGCC GGCCACCCAUCUCAUGUUC 5330 1712  418CAGAAUGCAGUUCGCCUUC GAAGGCGAACUGCAUUCUG 5331 1919  419ACGUCCAUGGGUGGGACAC GUGUCCCACCCAUGGACGU 5332 1000  420UGGUUCACCAGUGGAUUCU AGAAUCCACUGGUGAACCA 5333 2392  421AUAUCGCCAGGAUGAUCCU AGGAUCAUCCUGGCGAUAU 5334 1449  422AACAGGAAGGGAUGGAAGG CCUUCCAUCCCUUCCUGUU 5335 2294  423GUUGAGCUGACCAGCUCUC GAGAGCUGGUCAGCUCAAC 5336 1135  424AAAUGUUAAAUUCUUGGCU AGCCAAGAAUUUAACAUUU 5337 1333  425GGCUAUUGUAGAAGCUGGU ACCAGCUUCUACAAUAGCC 5338 1743  426CAGUUGUGGUUAAGCUCUU AAGAGCUUAACCACAACUG 5339  600  427CUACACAGUUUGAUGCUGC GCAGCAUCAAACUGUGUAG 5340  670  428UGGAGGCAUUCCUGCCCUG CAGGGCAGGAAUGCCUCCA 5341 3137  429GGACAGUUUACCAGUUGCC GGCAACUGGUAAACUGUCC 5342  372  430UCCAUUCUGGUGCCACUAC GUAGUGGCACCAGAAUGGA 5343 1761  431UACACCCACCAUCCCACUG CAGUGGGAUGGUGGGUGUA 5344 1650  432CUGAGCCUGCCAUCUGUGC GCACAGAUGGCAGGCUCAG 5345  972  433GAGGCAUUCCUGCCCUGGU ACCAGGGCAGGAAUGCCUC 5346 1147  434CUUGGCUAUUACGACAGAC GUCUGUCGUAAUAGCCAAG 5347  565  435CCCUGAGACAUUAGAUGAG CUCAUCUAAUGUCUCAGGG 5348  525  436AUGCAAUGACUCGAGCUCA UGAGCUCGAGUCAUUGCAU 5349 1599  437UAGAGGCUCUUGUGCGUAC GUACGCACAAGAGCCUCUA 5350 2199  438UUCACUCUAGGAAUGAAGG CCUUCAUUCCUAGAGUGAA 5351 2261  439GACAAGCCACAAGAUUACA UGUAAUCUUGUGGCUUGUC 5352  705  440CAGAACUUGCCACACGUGC GCACGUGUGGCAAGUUCUG 5353  916  441GACCUUGCAUAACCUUUCC GGAAAGGUUAUGCAAGGUC 5354  385  442CACUACCACAGCUCCUUCU AGAAGGAGCUGUGGUAGUG 5355 3076  443CUAUUUGGGAUAUGUAUGG CCAUACAUAUCCCAAAUAG 5356 1396  444UCUUGUUCAGAACUGUCUU AAGACAGUUCUGAACAAGA 5357 2447  445GAUGCCUUGGGUAUGGACC GGUCCAUACCCAAGGCAUC 5358 1338  446UUGUAGAAGCUGGUGGAAU AUUCCACCAGCUUCUACAA 5359 2215  447AGGUGUGGCGACAUAUGCA UGCAUAUGUCGCCACACCU 5360  722  448GCAAUCCCUGAAUCGACAA UUGUCAGUUCAGGGAUUGC 5361 1316  449UGCUCUAGUAAUAAGCCGG CCGGCUUAUUACUAGAGCA 5362 1687  450CCGACACCAAGAAGCAGAG CUCUGCUUCUUGGUGUCGG 5363  697  451AGAUGAUGCAGAACUUGCC GGCAAGUUCUGCAUCAUCU 5364 2517  452UUGAUGGGCUGCCAGAUCU AGAUCUGGCAGCCCAUCAA 5365 1685  453AGCCGACACCAAGAAGCAG CUGCUUCUUGGUGUCGGCU 5366 3090  454UAUGGGUAGGGUAAAUCAG CUGAUUUACCCUACCCAUA 5367 1205  455CUCAUCAUACUGGCUAGUG CACUAGCCAGUAUGAUGAG 5368 1153  456UAUUACGACAGACUGCCUU AAGGCAGUCUGUCGUAAUA 5369  723  457CAAUCCCUGAACUGACAAA UUUGUCAGUUCAGGGAUUG 5370 1468  458UCUCCUUGGGACUCUUGUU AACAAGAGUCCCAAGGAGA 5371 2480  459GAGAUGGGUGGCCACCACC GGUGGUGGCCACCCAUCUC 5372 1856  460CAGGGUGCCAUUCCACGAC GUCGUGGAAUGGCACCCUG 5373 2193  461AGUUACUUCACUCUAGGAA UUCCUAGAGUGAAGUAACU 5374 2355  462UUGGACUUGAUAUUGGUGC GCACCAAUAUCAAGUCCAA 5375 1995  463CCCUUCACAUCCUAGCUCG CGAGCUAGGAUGUGAAGGG 5376  821  464AGACACGCUAUCAUGCGUU AACGCAUGAUAGCGUGUCU 5377 1715  465AAUGCAGUUCGCCUUCACU AGUGAAGGCGAACUGCAUU 5378 1182  466CUUAUGGCAACCAAGAAAG CUUUCUUGGUUGCCAUAAG 5379  445  467CUCCCAAGUCCUGUAUGAG CUCAUACAGGACUUGGGAG 5380 1759  468CUUACACCCACCAUCCCAC GUGGGAUGGUGGGUGUAAG 5381 1461  469UGGAAGGUCUCCUUGGGAC GUCCCAAGGAGACCUUCCA 5382 1993  470AGCCCUUCACAUCCUAGCU AGCUAGGAUGUGAAGGGCU 5383 2558  471GAUGGGCUGCCUCCAGGUG CACCUGGAGGCAGCCCAUC 5384 1488  472AGCUUCUGGGUUCAGAUGA UCAUCUGAACCCAGAAGCU 5385 1652  473GAGCCUGCCAUCUGUGCUC GAGCACAGAUGGCAGGCUC 5386  963  474UUAAGUCUGGAGGCAUUCC GGAAUGCCUCCAGACUUAA 5387 1520  475ACCUGUGCAGCUGGAAUUC GAAUUCCAGCUGCACAGGU 5388 1828  476UCCCGCAAAUCAUGCACCU AGGUGCAUGAUUUGCGGGA 5389 2214  477AAGGUGUGGCGACAUAUGC GCAUAUGUCGCCACACCUU 5390 2155  478AGCUAUUGAAGCUGAGGGA UCCCUCAGCUUCAAUAGCU 5391  332  479GUUAGUCACUGGCAGCAAC GUUGCUGCCAGUGACUAAC 5392 1878  480UUCAGUUGCUUGUUCGUGC GCACGAACAAGCAACUGAA 5393 1573  481GAUGAUGGUCUGCCAAGUG CACUUGGCAGACCAUCAUC 5394 1446  482CUAAACAGGAAGGGAUGGA UCCAUCCCUUCCUGUUUAG 5395 1868  483CCACGACUAGUUCAGUUGC GCAACUGAACUAGUCGUGG 5396 1873  484ACUAGUUCAGUUGCUUGUU AACAAGCAACUGAACUAGU 5397 1002  485GUUCACCAGUGGAUUCUGU ACAGAAUCCACUGGUGAAC 5398  408  486GUGGUAAAGGCAAUCCUGA UCAGGAUUGCCUUUACCAC 5399  287  487UUGAUGGAGUUGGACAUGG CCAUGUCCAACUCCAUCAA 5400 2128  488ACUUGCUCAGGACAAGGAA UUCCUUGUCCUGAGCAAGU 5401 2513  489CCAGUUGAUGGGCUGCCAG CUGGCAGCCCAUCAACUGG 5402 1196  490GAAAGCAAGCUCAUCAUAC GUAUGAUGAGCUUGCUUUC 5403  572  491ACAUUAGAUGAGGGCAUGC GCAUGCCCUCAUCUAAUGU 5404  622  492UCCCACUAAUGUCCAGCGU ACGCUGGACAUUAGUGGGA 5405 1187  493GGCAACCAAGAAAGCAAGC GCUUGCUUUCUUGGUUGCC 5406 1971  494AAAUAGUUGAAGGUUGUAC GUACAACCUUCAACUAUUU 5407 3083  495GGAUAUGUAUGGGUAGGGU ACCCUACCCAUACAUAUCC 5408 2944  496UAAUCUGAAUAAAGUGUAA UUACACUUUAUUCAGAUUA 5409 1894  497UGCACAUCAGGAUACCCAG CUGGGUAUCCUGAUGUGCA 5410 1323  498GUAAUAAGCCGGCUAUUGU ACAAUAGCCGGCUUAUUAC 5411 1202  499AAGCUCAUCAUACUGGCUA UAGCCAGUAUGAUGAGCUU 5412  718  500ACGUGCAAUCCCUGAACUG CAGUUCAGGGAUUGCACGU 5413 1744  501AGUUGUGGUUAAGCUCUUA UAAGAGCUUAACCACAACU 5414  756  502AGGACCAGGUGGUGGUUAA UUAACCACCACCUGGUCCU 5415 1317  503GCUCUAGUAAUAAGCCGGC GCCGGCUUAUUACUAGAGC 5416  284  504GAUUUGAUGGAGUUGGACA UGUCCAACUCCAUCAAAUC 5417  886  505UGAUGUAGAAACAGCUCGU ACGAGCUGUUUCUACAUCA 5418 2430  506CUGGUGGAUAUGGCCAGGA UCCUGGCCAUAUCCACCAG 5419 1207  507CAUCAUACUGGCUAGUGGU ACCACUAGCCAGUAUGAUG 5420  592  508GAUCCCAUCUACACAGUUU AAACUGUGUAGAUGGGAUC 5421  824  509CACGCUAUCAUGCGUUCUC GAGAACGCAUGAUAGCGUG 5422  519  510GACAGUAUGCAAUGACUCG CGAGUCAUUGCAUACUGUC 5423 3166  511AAGUUGUUGUAACCUGCUG CAGCAGGUUACAACAACUU 5424 1151  512GCUAUUACGACAGACUGCC GGCAGUCUGUCGUAAUAGC 5425 2566  513GCCUCCAGGUGACAGCAAU AUUGCUGUCACCUGGAGGC 5426  453  514UCCUGUAUGAGUGGGAACA UGUUCCCACUCAUACAGGA 5427  587  515AUGCAGAUCCCAUCUACAC GUGUAGAUGGGAUCUGCAU 5428  630  516UUUCCCAUCAUCGUGAGGG CCCUCACGAUGAUGGGAAA 5429 1585  517CCAAGUGGGUGGUAUAGAG CUCUAUACCACCCACUUGG 5430  915  518GGACCUUGCAUAACCUUUC GAAAGGUUAUGCAAGGUCC 5431  446  519UCCCAAGUCCUGUAUGAGU ACUCAUACAGGACUUGGGA 5432 1869  520CACGACUAGUUCAGUUGCU AGCAACUGAACUAGUCGUG 5433 1960  521CCGCAUGGAAGAAAUAGUU AACUAUUUCUUCCAUGCGG 5434 1708  522GGCCCAGAAUGCAGUUCGC GCGAACUGCAUUCUGGGCC 5435  306  523CCAUGGAACCAGACAGAAA UUUCUGUCUGGUUCCAUGG 5436 2281  524GAAACGGCUUUCAGUUGAG CUCAACUGAAAGCCGUUUC 5437 3082  525GGGAUAUGUAUGGGUAGGG CCCUACCCAUACAUAUCCC 5438 1473  526UUGGGACUCUUGUUCAGCU AGCUGAACAAGAGUCCCAA 5439  559  527UAUGUUCCCUGAGACAUUA UAAUGUCUCAGGGAACAUA 5440 1416  528GGACUCUCAGGAAUCUUUC GAAAGAUUCCUGAGAGUCC 5441 2145  529AAGCUGCAGAAGCUAUUGA UCAAUAGCUUCUGCAGCUU 5442 1994  530GCCCUUCACAUCCUAGCUC GAGCUAGGAUGUGAAGGGC 5443 1702  531AGAGAUGGCCCAGAAUGCA UGCAUUCUGGGCCAUCUCU 5444  417  532GCAAUCCUGAGGAAGAGGA UCCUCUUCCUCAGGAUUGC 5445 2444  533CAGGAUGCCUUGGGUAUGG CCAUACCCAAGGCAUCCUG 5446  555  534CUGCUAUGUUCCCUGAGAC GUCUCAGGGAACAUAGCAG 5447 2019  535UUCACAACCGAAUUGUUAU AUAACAAUUCGGUUGUGAA 5448 1197  536AAAGCAAGCUCAUCAUACU AGUAUGAUGAGCUUGCUUU 5449  415  537AGGCAAUCCUGAGGAAGAG CUCUUCCUCAGGAUUGCCU 5450 2061  538UGUUUGUGCAGCUGCUUUA UAAAGCAGCUGCACAAACA 5451 1352  539GGAAUGCAAGCUUUAGGAC GUCCUAAAGCUUGCAUUCC 5452 1331  540CCGGCUAUUGUAGAAGCUG CAGCUUCUACAAUAGCCGG 5453 1325  541AAUAAGCCGGCUAUUGUAG CUACAAUAGCCGGCUUAUU 5454 1486  542UCAGCUUCUGGGUUCAGAU AUCUGAACCCAGAAGCUGA 5455  454  543CCUGUAUGAGUGGGAACAG CUGUUCCCACUCAUACAGG 5456  490  544CACUCAAGAACAAGUAGCU AGCUACUUGUUCUUGAGUG 5457 1996  545CCUUCACAUCCUAGCUCGG CCGAGCUAGGAUGUGAAGG 5458 1839  546AUGCACCUUUGCGUGAGCA UGCUCACGCAAAGGUGCAU 5459 1888  547UGUUCGUGCACAUCAGGAU AUCCUGAUGUGCACGAACA 5460 1879  548UCAGUUGCUUGUUCGUGCA UGCACGAACAAGCAACUGA 5461 1829  549CCCGCAAAUCAUGCACCUU AAGGUGCAUGAUUUGCGGG 5462  281  550GCUGAUUUGAUGGAGUUGG CCAACUCCAUCAAAUCAGC 5463 2598  551AUAGAGGCUCUUGUGCGUA UACGCACAAGAGCCUCUAU 5464 2135  552CAGGACAAGGAAGCUGCAG CUGCAGCUUCCUUGUCCUG 5465 1755  553AGCUCUUACACCCACCAUC GAUGGUGGGUGUAAGAGCU 5466  651  554CAUCACAGAUGCUGAAACA UGUUUCAGCAUCUGUGAUG 5467 1335  555CUAUUGUAGAAGCUGGUGG CCACCAGCUUCUACAAUAG 5468 2541  556AUGCCCAGGACCUCAUGGA UCCAUGAGGUCCUGGGCAU 5469  531  557UGACUCGAGCUCAGAGGGU ACCCUCUGAGCUCGAGUCA 5470  606  558AGUUUGAUGCUGCUCAUCC GGAUGAGCAGCAUCAAACU 5471 1620  559UCCUUCGGGCUGGUGACAG CUGUCACCAGCCCGAAGGA 5472 2211  560AUGAAGGUGUGGCGACAUA UAUGUCGCCACACCUUCAU 5473 2293  561AGUUGAGCUGACCAGCUCU AGAGCUGGUCAGCUCAACU 5474  455  562CUGUAUGAGUGGGAACAGG CCUGUUCCCACUCAUACAG 5475  540  563CUCAGAGGGUACGAGCUGC GCAGCUCGUACCCUCUGAG 5476  416  564GGCAAUCCUGAGGAAGAGG CCUCUUCCUCAGGAUUGCC 5477 1210  565CAUACUGGCUAGUGGUGGA UCCACCACUAGCCAGUAUG 5478 2262  566ACAAGCCACAAGAUUACAA UUGUAAUCUUGUGGCUUGU 5479 1604  567GCUCUUGUGCGUACUGUCC GGACAGUACGCACAAGAGC 5480  435  568AUGUGGAUACCUCCCAAGU ACUUGGGAGGUAUCCACAU 5481 2060  569UUGUUUGUGCAGCUGCUUU AAAGCAGCUGCACAAACAA 5482 2225  570ACAUAUGCAGCUGCUGUUU AAACAGCAGCUGCAUAUGU 5483  481  571UCAGUCCUUCACUCAAGAA UUCUUGAGUGAAGGACUGA 5484  917  572ACCUUGCAUAACCUUUCCC GGGAAAGGUUAUGCAAGGU 5485 2221  573GGCGACAUAUGCAGCUGCU AGCAGCUGCAUAUGUCGCC 5486  849  574UGGUGUCUGCUAUUGUACG CGUACAAUAGCAGACACCA 5487  562  575GUUCCCUGAGACAUUAGAU AUCUAAUGUCUCAGGGAAC 5488 1787  576AUAAAGGCUACUGUUGGAU AUCCAACAGUAGCCUUUAU 5489 1860  577GUGCCAUUCCACGACUAGU ACUAGUCGUGGAAUGGCAC 5490 1590  578UGGGUGGUAUAGAGGCUCU AGAGCCUCUAUACCACCCA 5491  955  579GGCCAUCUUUAAGUCUGGA UCCAGACUUAAAGAUGGCC 5492 2365  580UAUUGGUGCCCAGGGAGAA UUCUCCCUGGGCACCAAUA 5493  534  581CUCGAGCUCAGAGGGUACG CGUACCCUCUGAGCUCGAG 5494  706  582AGAACUUGCCACACGUGCA UGCACGUGUGGCAAGUUCU 5495 1740  583UACCAGUUGUGGUUAAGCU AGCUUAACCACAACUGGUA 5496  638  584CGUUUGGCUGAACCAUCAC GUGAUGGUUCAGCCAAACG 5497 1334  585GCUAUUGUAGAAGCUGGUG CACCAGCUUCUACAAUAGC 5498  971  586GGAGGCAUUCCUGCCCUGG CCAGGGCAGGAAUGCCUCC 5499 2493  587ACCACCCUGGUGCUGACUA UAGUCAGCACCAGGGUGGU 5500 1814  588AAUCUUGCCCUUUGUCCCG CGGGACAAAGGGCAAGAUU 5501 1088  589CGUUUAGCUGGUGGGCUGC GCAGCCCACCAGCUAAACG 5502 2292  590CAGUUGAGCUGACCAGCUC GAGCUGGUCAGCUCAACUG 5503 1504  591UGAUAUAAAUGUGGUCACC GGUGACCACAUUUAUAUCA 5504  404  592CUGAGUGGUAAAGGCAAUC GAUUGCCUUUACCACUCAG 5505 1301  593AAGGUGCUAUCUGUCUGCU AGCAGACAGAUAGCACCUU 5506 2004  594UCCUAGCUCGGGAUGUUCA UGAACAUCCCGAGCUAGGA 5507  277  595UCAAGCUGAUUUGAUGGAG CUCCAUCAAAUCAGCUUGA 5508 2304  596CCAGCUCUCUCUUCAGAAC GUUCUGAAGAGAGAGCUGG 5509  300  597ACAUGGCCAUGGAACCAGA UCUGGUUCCAUGGCCAUGU 5510 1906  598UACCCAGCGCCGUACGUCC GGACGUACGGCGCUGGGUA 5511 1973  599AUAGUUGAAGGUUGUACCG CGGUACAACCUUCAACUAU 5512 1360  600AGCUUUAGGACUUCACCUG CAGGUGAAGUCCUAAAGCU 5513 2094  601ACAUCCAAAGAGUAGCUGC GCAGCUACUCUUUGGAUGU 5514  920  602UUGCAUAACCUUUCCCAUC GAUGGGAAAGGUUAUGCAA 5515 1707  603UGGCCCAGAAUGCAGUUCG CGAACUGCAUUCUGGGCCA 5516 1808  604AUUCGAAAUCUUGCCCUUU AAAGGGCAAGAUUUCGAAU 5517 1326  605AUAAGCCGGCUAUUGUAGA UCUACAAUAGCCGGCUUAU 5518 1158  606CGACAGACUGCCUUCAAAU AUUUGAAGGCAGUCUGUCG 5519  781  607UGCAGUUAUGGUCCAUCAG CUGAUGGACCAUAACUGCA 5520  607  608GUUUGAUGCUGCUCAUCCC GGGAUGAGCAGCAUCAAAC 5521  627  609CUAAUGUCCAGCGUUUGGC GCCAAACGCUGGACAUUAG 5522  500  610CAAGUAGCUGAUAUUGAUG CAUCAAUAUCAGCUACUUG 5523 2185  611UCUGACAGAGUUACUUCAC GUGAAGUAACUCUGUCAGA 5524 1592  612GGUGGUAUAGAGGCUCUUG CAAGAGCCUCUAUACCACC 5525  758  613GACCAGGUGGUGGUUAAUA UAUUAACCACCACCUGGUC 5526 2551  614CCUCAUGGAUGGGCUGCCU AGGCAGCCCAUCCAUGAGG 5527 1409  615UGUCUUUGGACUCUCAGGA UCCUGAGAGUCCAAAGACA 5528  497  616GAACAAGUAGCUGAUAUUG CAAUAUCAGCUACUUGUUC 5529  381  617GUGCCACUACCACAGCUCC GGAGCUGUGGUAGUGGCAC 5530 1841  618GCACCUUUGCGUGAGCAGG CCUGCUCACGCAAAGGUGC 5531 1368  619GACUUCACCUGACAGAUCC GGAUCUGUCAGGUGAAGUC 5532 2047  620AAAUACCAUUCCAUUGUUU AAACAAUGGAAUGGUAUUU 5533  492  621CUCAAGAACAAGUAGCUGA UCAGCUACUUGUUCUUGAG 5534 2118  622UCCUCUGUGAACUUGCUCA UGAGCAAGUUCACAGAGGA 5535  968  623UCUGGAGGCAUUCCUGCCC GGGCAGGAAUGCCUCCAGA 5536  965  624AAGUCUGGAGGCAUUCCUG CAGGAAUGCCUCCAGACUU 5537 1977  625UUGAAGGUUGUACCGGAGC GCUCCGGUACAACCUUCAA 5538 2001  626ACAUCCUAGCUCGGGAUGU ACAUCCCGAGCUAGGAUGU 5539 1191  627ACCAAGAAAGCAAGCUCAU AUGAGCUUGCUUUCUUGGU 5540  640  628UUUGGCUGAACCAUCACAG CUGUGAUGGUUCAGCCAAA 5541  715  629CACACGUGCAAUCCCUGAA UUCAGGGAUUGCACGUGUG 5542 1204  630GCUCAUCAUACUGGCUAGU ACUAGCCAGUAUGAUGAGC 5543 3093  631GGGUAGGGUAAAUCAGUAA UUACUGAUUUACCCUACCC 5544 1371  632UUCACCUGACAGAUCCAAG CUUGGAUCUGUCAGGUGAA 5545  409  633UGGUAAAGGCAAUCCUGAG CUCAGGAUUGCCUUUACCA 5546 2405  634GAUCCUAGCUAUCGUUCUU AAGAACGAUAGCUAGGAUC 5547 1671  635UUCGUCAUCUGACCAGCCG CGGCUGGUCAGAUGACGAA 5548 1427  636AAUCUUUCAGAUGCUGCAA UUGCAGCAUCUGAAAGAUU 5549 1717  637UGCAGUUCGCCUUCACUAU AUAGUGAAGGCGAACUGCA 5550 2400  638AGGAUGAUCCUAGCUAUCG CGAUAGCUAGGAUCAUCCU 5551 2305  639CAGCUCUCUCUUCAGAACA UGUUCUGAAGAGAGAGCUG 5552 1928  640GGUGGGACACAGCAGCAAU AUUGCUGCUGUGUCCCACC 5553 2399  641CAGGAUGAUCCUAGCUAUC GAUAGCUAGGAUCAUCCUG 5554  426  642AGGAAGAGGAUGUGGAUAC GUAUCCACAUCCUCUUCCU 5555 1309  643AUCUGUCUGCUCUAGUAAU AUUACUAGAGCAGACAGAU 5556  925  644UAACCUUUCCCAUCAUCGU ACGAUGAUGGGAAAGGUUA 5557 2072  645CUGCUUUAUUCUCCCAUUG CAAUGGGAGAAUAAAGCAG 5558 2939  646AAUUGUAAUCUGAAUAAAG CUUUAUUCAGAUUACAAUU 5559 1480  647UCUUGUUCAGCUUCUGGGU ACCCAGAAGCUGAACAAGA 5560 1889  648GUUCGUGCACAUCAGGAUA UAUCCUGAUGUGCACGAAC 5561  699  649AUGAUGCAGAACUUGCCAC GUGGCAAGUUCUGCAUCAU 5562  506  650GCUGAUAUUGAUGGACAGU ACUGUCCAUCAAUAUCAGC 5563 1750  651GGUUAAGCUCUUACACCCA UGGGUGUAAGAGCUUAACC 5564 1820  652GCCCUUUGUCCCGCAAAUC GAUUUGCGGGACAAAGGGC 5565  541  653UCAGAGGGUACGAGCUGCU AGCAGCUCGUACCCUCUGA 5566  665  654AAACAUGCAGUUGUAAACU AGUUUACAACUGCAUGUUU 5567 1817  655CUUGCCCUUUGUCCCGCAA UUGCGGGACAAAGGGCAAG 5568 2275  656UUACAAGAAACGGCUUUCA UGAAAGCCGUUUCUUGUAA 5569 2426  657CACUCUGGUGGAUAUGGCC GGCCAUAUCCACCAGAGUG 5570  958  658CAUCUUUAAGUCUGGAGGC GCCUCCAGACUUAAAGAUG 5571 1657  659UGCCAUCUGUGCUCUUCGU ACGAAGAGCACAGAUGGCA 5572 1146  660UCUUGGCUAUUACGACAGA UCUGUCGUAAUAGCCAAGA 5573 3078  661AUUUGGGAUAUGUAUGGGU ACCCAUACAUAUCCCAAAU 5574 1008  662CAGUGGAUUCUGUGUUGUU AACAACACAGAAUCCACUG 5575 1621  663CCUUCGGGCUGGUGACAGG CCUGUCACCAGCCCGAAGG 5576 1932  664GGACACAGCAGCAAUUUGU ACAAAUUGCUGCUGUGUCC 5577 1909  665CCAGCGCCGUACGUCCAUG CAUGGACGUACGGCGCUGG 5578 2279  666AAGAAACGGCUUUCAGUUG CAACUGAAAGCCGUUUCUU 5579  574  667AUUAGAUGAGGGCAUGCAG CUGCAUGCCCUCAUCUAAU 5580 2303  668ACCAGCUCUCUCUUCAGAA UUCUGAAGAGAGAGCUGGU 5581  784  669AGUUAUGGUCCAUCAGCUU AAGCUGAUGGACCAUAACU 5582 2507  670GACUAUCCAGUUGAUGGGC GCCCAUCAACUGGAUAGUC 5583  995  671AUGCUUGGUUCACCAGUGG CCACUGGUGAACCAAGCAU 5584 2006  672CUAGCUCGGGAUGUUCACA UGUGAACAUCCCGAGCUAG 5585 1757  673CUCUUACACCCACCAUCCC GGGAUGGUGGGUGUAAGAG 5586 2129  674CUUGCUCAGGACAAGGAAG CUUCCUUGUCCUGAGCAAG 5587 2272  675AGAUUACAAGAAACGGCUU AAGCCGUUUCUUGUAAUCU 5588  389  676ACCACAGCUCCUUCUCUGA UCAGAGAAGGAGCUGUGGU 5589 1435  677AGAUGCUGCAACUAAACAG CUGUUUAGUUGCAGCAUCU 5590 1752  678UUAAGCUCUUACACCCACC GGUGGGUGUAAGAGCUUAA 5591  773  679AAUAAGGCUGCAGUUAUGG CCAUAACUGCAGCCUUAUU 5592 3080  680UUGGGAUAUGUAUGGGUAG CUACCCAUACAUAUCCCAA 5593 3174  681GUAACCUGCUGUGAUACGA UCGUAUCACAGCAGGUUAC 5594 1578  682UGGUCUGCCAAGUGGGUGG CCACCCACUUGGCAGACCA 5595  398  683CCUUCUCUGAGUGGUAAAG CUUUACCACUCAGAGAAGG 5596 2153  684GAAGCUAUUGAAGCUGAGG CCUCAGCUUCAAUAGCUUC 5597  702  685AUGCAGAACUUGCCACACG CGUGUGGCAAGUUCUGCAU 5598  503  686GUAGCUGAUAUUGAUGGAC GUCCAUCAAUAUCAGCUAC 5599  276  687CUCAAGCUGAUUUGAUGGA UCCAUCAAAUCAGCUUGAG 5600 1962  688GCAUGGAAGAAAUAGUUGA UCAACUAUUUCUUCCAUGC 5601 1347  689CUGGUGGAAUGCAAGCUUU AAAGCUUGCAUUCCACCAG 5602 2544  690CCCAGGACCUCAUGGAUGG CCAUCCAUGAGGUCCUGGG 5603 3079  691UUUGGGAUAUGUAUGGGUA UACCCAUACAUAUCCCAAA 5604 3164  692CAAAGUUGUUGUAACCUGC GCAGGUUACAACAACUUUG 5605 2026  693CCGAAUUGUUAUCAGAGGA UCCUCUGAUAACAAUUCGG 5606 2938  694UAAUUGUAAUCUGAAUAAA UUUAUUCAGAUUACAAUUA 5607 2940  695AUUGUAAUCUGAAUAAAGU ACUUUAUUCAGAUUACAAU 5608 2027  696CGAAUUGUUAUCAGAGGAC GUCCUCUGAUAACAAUUCG 5609  448  697CCAAGUCCUGUAUGAGUGG CCACUCAUACAGGACUUGG 5610 1328  698AAGCCGGCUAUUGUAGAAG CUUCUACAAUAGCCGGCUU 5611 2406  699AUCCUAGCUAUCGUUCUUU AAAGAACGAUAGCUAGGAU 5612  924  700AUAACCUUUCCCAUCAUCG CGAUGAUGGGAAAGGUUAU 5613 1584  701GCCAAGUGGGUGGUAUAGA UCUAUACCACCCACUUGGC 5614 1871  702CGACUAGUUCAGUUGCUUG CAAGCAACUGAACUAGUCG 5615  999  703UUGGUUCACCAGUGGAUUC GAAUCCACUGGUGAACCAA 5616 1400  704GUUCAGAACUGUCUUUGGA UCCAAAGACAGUUCUGAAC 5617 3180  705UGCUGUGAUACGAUGCUUC GAAGCAUCGUAUCACAGCA 5618 2569  706UCCAGGUGACAGCAAUCAG CUGAUUGCUGUCACCUGGA 5619  787  707UAUGGUCCAUCAGCUUUCU AGAAAGCUGAUGGACCAUA 5620 1861  708UGCCAUUCCACGACUAGUU AACUAGUCGUGGAAUGGCA 5621 1190  709AACCAAGAAAGCAAGCUCA UGAGCUUGCUUUCUUGGUU 5622 1557  710AUAAUUAUAAGAACAAGAU AUCUUGUUCUUAUAAUUAU 5623 1751  711GUUAAGCUCUUACACCCAC GUGGGUGUAAGAGCUUAAC 5624 2897  712UUGAGUAAUGGUGUAGAAC GUUCUACACCAUUACUCAA 5625 2217  713GUGUGGCGACAUAUGCAGC GCUGCAUAUGUCGCCACAC 5626 2302  714GACCAGCUCUCUCUUCAGA UCUGAAGAGAGAGCUGGUC 5627 1984  715UUGUACCGGAGCCCUUCAC GUGAAGGGCUCCGGUACAA 5628  302  716AUGGCCAUGGAACCAGACA UGUCUGGUUCCAUGGCCAU 5629 2431  717UGGUGGAUAUGGCCAGGAU AUCCUGGCCAUAUCCACCA 5630 2183  718CCUCUGACAGAGUUACUUC GAAGUAACUCUGUCAGAGG 5631 2404  719AUGAUCCUAGCUAUCGUUC GAACGAUAGCUAGGAUCAU 5632  788  720AUGGUCCAUCAGCUUUCUA UAGAAAGCUGAUGGACCAU 5633 1476  721GGACUCUUGUUCAGCUUCU AGAAGCUGAACAAGAGUCC 5634  827  722GCUAUCAUGCGUUCUCCUC GAGGAGAACGCAUGAUAGC 5635 2299  723GCUGACCAGCUCUCUCUUC GAAGAGAGAGCUGGUCAGC 5636 1891  724UCGUGCACAUCAGGAUACC GGUAUCCUGAUGUGCACGA 5637 2196  725UACUUCACUCUAGGAAUGA UCAUUCCUAGAGUGAAGUA 5638  663  726UGAAACAUGCAGUUGUAAA UUUACAACUGCAUGUUUCA 5639 1028  727UAUGCCAUUACAACUCUCC GGAGAGUUGUAAUGGCAUA 5640 2032  728UGUUAUCAGAGGACUAAAU AUUUAGUCCUCUGAUAACA 5641 1459  729GAUGGAAGGUCUCCUUGGG CCCAAGGAGACCUUCCAUC 5642 2095  730CAUCCAAAGAGUAGCUGCA UGCAGCUACUCUUUGGAUG 5643 1686  731GCCGACACCAAGAAGCAGA UCUGCUUCUUGGUGUCGGC 5644 1412  732CUUUGGACUCUCAGGAAUC GAUUCCUGAGAGUCCAAAG 5645 2473  733GGAACAUGAGAUGGGUGGC GCCACCCAUCUCAUGUUCC 5646 1080  734UGGCAGUGCGUUUAGCUGG CCAGCUAAACGCACUGCCA 5647 2143  735GGAAGCUGCAGAAGCUAUU AAUAGCUUCUGCAGCUUCC 5648 2203  736CUCUAGGAAUGAAGGUGUG CACACCUUCAUUCCUAGAG 5649  548  737GUACGAGCUGCUAUGUUCC GGAACAUAGCAGCUCGUAC 5650 1867  738UCCACGACUAGUUCAGUUG CAACUGAACUAGUCGUGGA 5651  843  739CCUCAGAUGGUGUCUGCUA UAGCAGACACCAUCUGAGG 5652 2120  740CUCUGUGAACUUGCUCAGG CCUGAGCAAGUUCACAGAG 5653  782  741GCAGUUAUGGUCCAUCAGC GCUGAUGGACCAUAACUGC 5654 1758  742UCUUACACCCACCAUCCCA UGGGAUGGUGGGUGUAAGA 5655 2396  743CGCCAGGAUGAUCCUAGCU AGCUAGGAUCAUCCUGGCG 5656 1373  744CACCUGACAGAUCCAAGUC GACUUGGAUCUGUCAGGUG 5657 1518  745UCACCUGUGCAGCUGGAAU AUUCCAGCUGCACAGGUGA 5658 2557  746GGAUGGGCUGCCUCCAGGU ACCUGGAGGCAGCCCAUCC 5659 1987  747UACCGGAGCCCUUCACAUC GAUGUGAAGGGCUCCGGUA 5660  568  748UGAGACAUUAGAUGAGGGC GCCCUCAUCUAAUGUCUCA 5661 2201  749CACUCUAGGAAUGAAGGUG CACCUUCAUUCCUAGAGUG 5662  609  750UUGAUGCUGCUCAUCCCAC GUGGGAUGAGCAGCAUCAA 5663  400  751UUCUCUGAGUGGUAAAGGC GCCUUUACCACUCAGAGAA 5664  331  752UGUUAGUCACUGGCAGCAA UUGCUGCCAGUGACUAACA 5665 1967  753GAAGAAAUAGUUGAAGGUU AACCUUCAACUAUUUCUUC 5666 2198  754CUUCACUCUAGGAAUGAAG CUUCAUUCCUAGAGUGAAG 5667 1493  755CUGGGUUCAGAUGAUAUAA UUAUAUCAUCUGAACCCAG 5668 2260  756GGACAAGCCACAAGAUUAC GUAAUCUUGUGGCUUGUCC 5669 2496  757ACCCUGGUGCUGACUAUCC GGAUAGUCAGCACCAGGGU 5670 2361  758UUGAUAUUGGUGCCCAGGG CCCUGGGCACCAAUAUCAA 5671  443  759ACCUCCCAAGUCCUGUAUG CAUACAGGACUUGGGAGGU 5672  523  760GUAUGCAAUGACUCGAGCU AGCUCGAGUCAUUGCAUAC 5673 1742  761CCAGUUGUGGUUAAGCUCU AGAGCUUAACCACAACUGG 5674  530  762AUGACUCGAGCUCAGAGGG CCCUCUGAGCUCGAGUCAU 5675 3169  763UUGUUGUAACCUGCUGUGA UCACAGCAGGUUACAACAA 5676 1385  764CCAAGUCAACGUCUUGUUC GAACAAGACGUUGACUUGG 5677 2036  765AUCAGAGGACUAAAUACCA UGGUAUUUAGUCCUCUGAU 5678 3088  766UGUAUGGGUAGGGUAAAUC GAUUUACCCUACCCAUACA 5679 1850  767CGUGAGCAGGGUGCCAUUC GAAUGGCACCCUGCUCACG 5680 2518  768UGAUGGGCUGCCAGAUCUG CAGAUCUGGCAGCCCAUCA 5681 1886  769CUUGUUCGUGCACAUCAGG CCUGAUGUGCACGAACAAG 5682  650  770CCAUCACAGAUGCUGAAAC GUUUCAGCAUCUGUGAUGG 5683 3139  771ACAGUUUACCAGUUGCCUU AAGGCAACUGGUAAACUGU 5684 2025  772ACCGAAUUGUUAUCAGAGG CCUCUGAUAACAAUUCGGU 5685 1082  773GCAGUGCGUUUAGCUGGUG CACCAGCUAAACGCACUGC 5686 2475  774AACAUGAGAUGGGUGGCCA UGGCCACCCAUCUCAUGUU 5687 1375  775CCUGACAGAUCCAAGUCAA UUGACUUGGAUCUGUCAGG 5688 2013  776GGGAUGUUCACAACCGAAU AUUCGGUUGUGAACAUCCC 5689 1802  777GGAUUGAUUCGAAAUCUUG CAAGAUUUCGAAUCAAUCC 5690 2144  778GAAGCUGCAGAAGCUAUUG CAAUAGCUUCUGCAGCUUC 5691  529  779AAUGACUCGAGCUCAGAGG CCUCUGAGCUCGAGUCAUU 5692 1482  780UUGUUCAGCUUCUGGGUUC GAACCCAGAAGCUGAACAA 5693 1546  781CCUCACUUGCAAUAAUUAU AUAAUUAUUGCAAGUGAGG 5694  845  782CAGAUGGUGUCUGCUAUUG CAAUAGCAGACACCAUCUG 5695  487  783CUUCACUCAAGAACAAGUA UACUUGUUCUUGAGUGAAG 5696  652  784AUCACAGAUGCUGAAACAU AUGUUUCAGCAUCUGUGAU 5697 1720  785AGUUCGCCUUCACUAUGGA UCCAUAGUGAAGGCGAACU 5698  951  786UACUGGCCAUCUUUAAGUC GACUUAAAGAUGGCCAGUA 5699 1232  787CAAGCUUUAGUAAAUAUAA UUAUAUUUACUAAAGCUUG 5700 2265  788AGCCACAAGAUUACAAGAA UUCUUGUAAUCUUGUGGCU 5701 1698  789AAGCAGAGAUGGCCCAGAA UUCUGGGCCAUCUCUGCUU 5702  701  790GAUGCAGAACUUGCCACAC GUGUGGCAAGUUCUGCAUC 5703 1428  791AUCUUUCAGAUGCUGCAAC GUUGCAGCAUCUGAAAGAU 5704 1930  792UGGGACACAGCAGCAAUUU AAAUUGCUGCUGUGUCCCA 5705 1379  793ACAGAUCCAAGUCAACGUC GACGUUGACUUGGAUCUGU 5706 1936  794ACAGCAGCAAUUUGUGGAG CUCCACAAAUUGCUGCUGU 5707 1441  795UGCAACUAAACAGGAAGGG CCCUUCCUGUUUAGUUGCA 5708 2132  796GCUCAGGACAAGGAAGCUG CAGCUUCCUUGUCCUGAGC 5709 2043  797GACUAAAUACCAUUCCAUU AAUGGAAUGGUAUUUAGUC 5710  608  798UUUGAUGCUGCUCAUCCCA UGGGAUGAGCAGCAUCAAA 5711  341  799UGGCAGCAACAGUCUUACC GGUAAGACUGUUGCUGCCA 5712 1194  800AAGAAAGCAAGCUCAUCAU AUGAUGAGCUUGCUUUCUU 5713 2350  801UGAUCUUGGACUUGAUAUU AAUAUCAAGUCCAAGAUCA 5714 2948  802CUGAAUAAAGUGUAACAAU AUUGUUACACUUUAUUCAG 5715 2044  803ACUAAAUACCAUUCCAUUG CAAUGGAAUGGUAUUUAGU 5716  621  804AUCCCACUAAUGUCCAGCG CGCUGGACAUUAGUGGGAU 5717  384  805CCACUACCACAGCUCCUUC GAAGGAGCUGUGGUAGUGG 5718 1898  806CAUCAGGAUACCCAGCGCC GGCGCUGGGUAUCCUGAUG 5719  653  807UCACAGAUGCUGAAACAUG CAUGUUUCAGCAUCUGUGA 5720 1846  808UUUGCGUGAGCAGGGUGCC GGCACCCUGCUCACGCAAA 5721 2348  809GCUGAUCUUGGACUUGAUA UAUCAAGUCCAAGAUCAGC 7522 1150  810GGCUAUUACGACAGACUGC GCAGUCUGUCGUAAUAGCC 5723  298  811GGACAUGGCCAUGGAACCA UGGUUCCAUGGCCAUGUCC 5724 1568  812AACAAGAUGAUGGUCUGCC GGCAGACCAUCAUCUUGUU 5725 1058  813UUACAUCAAGAAGGAGCUA UAGCUCCUUCUUGAUGUAA 5726 1835  814AAUCAUGCACCUUUGCGUG CACGCAAAGGUGCAUGAUU 5727 1832  815GCAAAUCAUGCACCUUUGC GCAAAGGUGCAUGAUUUGC 5728  406  816GAGUGGUAAAGGCAAUCCU AGGAUUGCCUUUACCACUC 5729 1723  817UCGCCUUCACUAUGGACUA UAGUCCAUAGUGAAGGCGA 5730  371  818AUCCAUUCUGGUGCCACUA UAGUGGCACCAGAAUGGAU 5731 1899  819AUCAGGAUACCCAGCGCCG CGGCGCUGGGUAUCCUGAU 5732  522  820AGUAUGCAAUGACUCGAGC GCUCGAGUCAUUGCAUACU 5733 2285  821CGGCUUUCAGUUGAGCUGA UCAGCUCAACUGAAAGCCG 5734  779  822GCUGCAGUUAUGGUCCAUC GAUGGACCAUAACUGCAGC 5735 2896  823AUUGAGUAAUGGUGUAGAA UUCUACACCAUUACUCAAU 5736 2943  824GUAAUCUGAAUAAAGUGUA UACACUUUAUUCAGAUUAC 5737  513  825UUGAUGGACAGUAUGCAAU AUUGCAUACUGUCCAUCAA 5738 3084  826GAUAUGUAUGGGUAGGGUA UACCCUACCCAUACAUAUC 5739 1567  827GAACAAGAUGAUGGUCUGC GCAGACCAUCAUCUUGUUC 5740 2034  828UUAUCAGAGGACUAAAUAC GUAUUUAGUCCUCUGAUAA 5741 1003  829UUCACCAGUGGAUUCUGUG CACAGAAUCCACUGGUGAA 5742 1980  830AAGGUUGUACCGGAGCCCU AGGGCUCCGGUACAACCUU 5743 1340  831GUAGAAGCUGGUGGAAUGC GCAUUCCACCAGCUUCUAC 5744 1437  832AUGCUGCAACUAAACAGGA UCCUGUUUAGUUGCAGCAU 5745 2425  833UCACUCUGGUGGAUAUGGC GCCAUAUCCACCAGAGUGA 5746  282  834CUGAUUUGAUGGAGUUGGA UCCAACUCCAUCAAAUCAG 5747 1206  835UCAUCAUACUGGCUAGUGG CCACUAGCCAGUAUGAUGA 5748 1885  836GCUUGUUCGUGCACAUCAG CUGAUGUGACGAACAAGC 5749 1314  837UCUGCUCUAGUAAUAAGGC GGCUUAUUACUAGAGCAGA 5750 1308  838UAUCUGUCUGCUCUAGUAA UUACUAGAGCAGACAGAUA 5751 1200  839GCAAGCUCAUCAUACUGGC GCCAGUAUGAUGAGCUUGC 5752  543  840AGAGGGUACGAGCUGCUAU AUAGCAGCUCGUACCCUCU 5753 1609  841UGUGCGUACUGUCCUUCGG CCGAAGGACAGUACGCACA 5754 1453  842GGAAGGGAUGGAAGGUCUC GAGACCUUCCAUCCCUUCC 5755  833  843AUGCGUUCUCCUCAGAUGG CCAUCUGAGGAGAACGCAU 5756 2188  844GACAGAGUUACUUCACUCU AGAGUGAAGUAACUCUGUC 5757 1148  845UUGGCUAUUACGACAGACU AGUCUGUCGUAAUAGCCAA 5758 1736  846GGACUACCAGUUGUGGUUA UAACCACAACUGGUAGUCC 5759 1401  847UUCAGAACUGUCUUUGGAC GUCCAAAGACAGUUCUGAA 5760 1677  848AUCUGACCAGCCGACACCA UGGUGUCGGCUGGUCAGAU 5761 1934  849ACACAGCAGCAAUUUGUGG CCACAAAUUGCUGCUGUGU 5762  388  850UACCACAGCUCCUUCUCUG CAGAGAAGGAGCUGUGGUA 5763 1920  851CUGCCAUGGGUGGGACACA UGUGUCCCACCCAUGGACG 5764 1747  852UGUGGUUAAGCUCUUACAC GUGUAAGAGCUUAACCACA 5765  861  853UUGUACGUACCAUGCAGAA UUCUGCAUGGUACGUACAA 5766 1904  854GAUACCCAGCGCCGUACGU ACGUACGGCGCUGGGUAUC 5767  831  855UCAUGCGUUCUCCUCAGAU AUCUGAGGAGAACGCAUGA 5768 1895  856GCACAUCAGGAUACCCAGC GCUGGGUAUCCUGAUGUGC 5769 2273  857GAUUACAAGAAACGGCUUU AAAGCCGUUUCUUGUAAUC 5770 1738  858ACUACCAGUUGUGGUUAAG CUUAACCACAACUGGUAGU 5771 1395  859GUCUUGUUCAGAACUGUCU AGACAGUUCUGAACAAGAC 5772 1675  860UCAUCUGACCAGCCGACAC GUGUCGGCUGGUCAGAUGA 5773 1845  861CUUUGCGUGAGCAGGGUGC GCACCCUGCUCACGCAAAG 5774 1408  862CUGUCUUUGGACUCUCAGG CCUGAGAGUCCAAAGACAG 5775 1059  863UACAUCAAGAAGGAGCUAA UUAGCUCCUUCUUGAUGUA 5776 1381  864AGAUCCAAGUCAACGUCUU AAGACGUUGACUUGGAUCU 5777 1386  865CAAGUCAACGUCUUGUUCA UGAACAAGACGUUGACUUG 5778 1470  866UCCUUGGGACUCUUGUUCA UGAACAAGAGUCCCAAGGA 5779 1349  867GGUGGAAUGCAAGCUUUAG CUAAAGCUUGCAUUCCACC 5780 1440  868CUGCAACUAAACAGGAAGG CCUUCCUGUUUAGUUGCAG 5781 1364  869UUAGGACUUCACCUGACAG CUGUCAGGUGAAGUCCUAA 5782  502  870AGUAGCUGAUAUUGAUGGA UCCAUCAAUAUCAGCUACU 5783 1246  871UAUAAUGAGGACCUAUACU AGUAUAGGUCCUCAUUAUA 5784 3178  872CCUGCUGUGAUACGAUGCU AGCAUCGUAUCACAGCAGG 5785 2483  873AUGGGUGGCCACCACCCUG CAGGGUGGUGGCCACCCAU 5786 1417  874GACUCUCAGGAAUCUUUCA UGAAAGAUUCCUGAGAGUC 5787 1893  875GUGCACAUCAGGAUACCCA UGGGUAUCCUGAUGUGCAC 5788  817  876UUCCAGACACGCUAUCAUG CAUGAUAGCGUGUCUGGAA 5789  711  877UUGCCACACGUGCAAUCCC GGGAUUGCACGUGUGGCAA 5790 1433  878UCAGAUGCUGCAACUAAAC GUUUAGUUGCAGCAUCUGA 5791 1362  879CUUUAGGACUUCACCUGAC GUCAGGUGAAGUCCUAAAG 5792 1838  880CAUGCACCUUUGCGUGAGC GCUCACGCAAAGGUGCAUG 5793 1037  881ACAACUCUCCACAACCUUU AAAGGUUGUGGAGAGUUGU 5794 1474  882UGGGACUCUUGUUCAGCUU AAGCUGAACAAGAGUCCCA 5795  997  883GCUUGGUUCACCAGUGGAU AUCCACUGGUGAACCAAGC 5796  931  884UUCCCAUCAUCGUGAGGGC GCCCUCACGAUGAUGGGAA 5797 1313  885GUCUGCUCUAGUAAUAAGC GCUUAUUACUAGAGCAGAC 5798 1487  886CAGCUUCUGGGUUCAGAUG CAUCUGAACCCAGAAGCUG 5799 1673  887CGUCAUCUGACCAGCCGAC GUCGGCUGGUCAGAUGACG 5800  561  888UGUUCCCUGAGACAUUAGA UCUAAUGUCUCAGGGAACA 5801 1188  889GCAACCAAGAAAGCAAGCU AGCUUGCUUUCUUGGUUGC 5802  292  890GGAGUUGGACAUGGCCAUG CAUGGCCAUGUCCAACUCC 5803 1958  891GUCCGCAUGGAAGAAAUAG CUAUUUCUUCCAUGCGGAC 5804 2349  892CUGAUCUUGGACUUGAUAU AUAUCAAGUCCAAGAUCAG 5805 1460  893AUGGAAGGUCUCCUUGGGA UCCCAAGGAGACCUUCCAU 5806 1576  894GAUGGUCUGCCAAGUGGGU ACCCACUUGGCAGACCAUC 5807  590  895ACUAUCAAGAUGAUGCAGA UCUGCAUCAUCUUGAUAGU 5808  655  896ACAGAUGCUGAAACAUGCA UGCAUGUUUCAGCAUCUGU 5809 2290  897UUCAGUUGAGCUGACCAGC GCUGGUCAGCUCAACUGAA 5810 1600  898AGAGGCUCUUGUGCGUACU AGUACGCACAAGAGCCUCU 5811 2432  899GGUGGAUAUGGCCAGGAUG CAUCCUGGCCAUAUCCACC 5812  710  900CUUGCCACACGUGCAAUCC GGAUUGCACGUGUGGCAAG 5813 1714  901GAAUGCAGUUCGCCUUCAC GUGAAGGCGAACUGCAUUC 5814 2005  902CCUAGCUCGGGAUGUUCAC GUGAACAUCCCGAGCUAGG 5815 1728  903UUCACUAUGGACUACCAGU ACUGGUAGUCCAUAGUGAA 5816 2482  904GAUGGGUGGCCACCACCCU AGGGUGGUGGCCACCCAUC 5817  768  905UGGUUAAUAAGGCUGCAGU ACUGCAGCCUUAUUAACCA 5818  693  906AUCAAGAUGAUGCAGAACU AGUUCUGCAUCAUCUUGAU 5819 3179  907CUGCUGUGAUACGAUGCUU AAGCAUCGUAUCACAGCAG 5820 2448  908AUGCCUUGGGUAUGGACCC GGGUCCAUACCCAAGGCAU 5821 3183  909UGUGAUACGAUGCUUCAAG CUUGAAGCAUCGUAUCACA 5822 1293  910GAGUGCUGAAGGUGCUAUC GAUAGCACCUUCAGCACUC 5823  544  911GAGGGUACGAGCUGCUAUG CAUAGCAGCUCGUACCCUC 5824 2937  912UUAAUUGUAAUCUGAAUAA UUAUUCAGAUUACAAUUAA 5825 1691  913CACCAAGAAGCAGAGAUGG CCAUCUCUGCUUCUUGGUG 5826 1353  914GAAUGCAAGCUUUAGGACU AGUCCUAAAGCUUGCAUUC 5827 1843  915ACCUUUGCGUGAGCAGGGU ACCCUGCUCACGCAAAGGU 5828 1302  916AGGUGCUAUCUGUCUGCUC GAGCAGACAGAUAGCACCU 5829 2130  917UUGCUCAGGACAAGGAAGC GCUUCCUUGUCCUGAGCAA 5830 2165  918GCUGAGGGAGCCACAGCUC GAGCUGUGGCUCCCUCAGC 5831  387  919CUACCACAGCUCCUUCUCU AGAGAAGGAGCUGUGGUAG 5832 2474  920UGGAACAUGAGAUGGGUGG CCACCCAUCUCAUGUUCCA 5833  857  921GCUAUUGUACGUACCAUGC GCAUGGUACGUACAAUAGC 5834 1816  922UCUUGCCCUUUGUCCCGCA UGCGGGACAAAGGGCAAGA 5835 1561  923UUAUAAGAACAAGAUGAUG CAUCAUCUUGUUCUUAUAA 5836  811  924GGAAGCUUCCAGACACGCU AGCGUGUCUGGAAGCUUCC 5837 1327  925UAAGCCGGCUAUUGUAGAA UUCUACAAUAGCCGGCUUA 5838  757  926GGACCAGGUGGUGGUUAAU AUUAACCACCACCUGGUCC 5839  507  927CUGAUAUUGAUGGACAGUA UACUGUCCAUCAAUAUCAG 5840 3092  928UGGGUAGGGUAAAUCAGUA UACUGAUUUACCCUACCCA 5841 2359  929ACUUGAUAUUGGUGCCCAG CUGGGCACCAAUAUCAAGU 5842 1753  930UAAGCUCUUACACCCACCA UGGUGGGUGUAAGAGCUUA 5843  273  931CUACUCAAGCUGAUUUGAU AUCAAAUCAGCUUGAGUAG 5844 1859  932GGUGCCAUUCCACGACUAG CUAGUCGUGGAAUGGCACC 5845  296  933UUGGACAUGGCCAUGGAAC GUUCCAUGGCCAUGUCCAA 5846  615  934CUGCUCAUCCCACUAAUGU ACAUUAGUGGGAUGAGCAG 5847  301  935CAUGGCCAUGGAACCAGAC GUCUGGUUCCAUGGCCAUG 5848 1184  936UAUGGCAACCAAGAAAGCA UGCUUUCUUGGUUGCCAUA 5849 1006  937ACCAGUGGAUUCUGUGUUG CAACACAGAAUCCACUGGU 5850 2189  938ACAGAGUUACUUCACUCUA UAGAGUGAAGUAACUCUGU 5851 1365  939UAGGACUUCACCUGACAGA UCUGUCAGGUGAAGUCCUA 5852 2442  940GCCAGGAUGCCUUGGGUAU AUACCCAAGGCAUCCUGGU 5853 1249  941AAUGAGGACCUAUACUUAC GUAAGUAUAGGUCCUCAUU 5854 1144  942AUUCUUGGCUAUUACGACA UGUCGUAAUAGCCAAGAAU 5855 2075  943CUUUAUUCUCCCAUUGAAA UUUCAAUGGGAGAAUAAAG 5856  504  944UAGCUGAUAUUGAUGGACA UGUCCAUCAAUAUCAGCUA 5857 1405  945GAACUGUCUUUGGACUCUC GAGAGUCCAAAGACAGUUC 5858  333  946UUAGUCACUGGCAGCAACA UGUUGCUGCCAGUGACUAA 5859 1032  947CCAUUACAACUCUCCACAA UUGUGGAGAGUUGUAAUGG 5860 1748  948GUGGUUAAGCUCUUACACC GGUGUAAGAGCUUAACCAC 5861  283  949UGAUUUGAUGGAGUUGGAC GUCCAACUCCAUCAAAUCA 5862 1700  950GCAGAGAUGGCCCAGAAUG CAUUCUGGGCCAUCUCUGC 5863 1445  951ACUAAACAGGAAGGGAUGG CCAUCCCUUCCUGUUUAGU 5864 1133  952ACAAAUGUUAAAUUCUUGG CCAAGAAUUUAACAUUUGU 5865  527  953GCAAUGACUCGAGCUCAGA UCUGAGCUCGAGUCAUUGC 5866 2010  954CUCGGGAUGUUCACAACCG CGGUUGUGAACAUCCCGAG 5867  851  955GUGUCUGCUAUUGUACGUA UACGUACAAUAGCAGACAC 5868  436  956UGUGGAUACCUCCCAAGUC GACUUGGGAGGUAUCCACA 5869 2446  957GGAUGCCUUGGGUAUGGAC GUCCAUACCCAAGGCAUCC 5870 1142  958AAAUUCUUGGCUAUUACGA UCGUAAUAGCCAAGAAUUU 5871  549  959UACGAGCUGCUAUGUUCCC GGGAACAUAGCAGCUCGUA 5872 1083  960CAGUGCGUUUAGCUGGUGG CCACCAGCUAAACGCACUG 5873  695  961CAAGAUGAUGCAGAACUUG CAAGUUCUGCAUCAUCUUG 5874  885  962AUGAUGUAGAAACAGCUCG CGAGCUGUUUCUACAUCAU 5875 2067  963UGCAGCUGCUUUAUUCUCC GGAGAAUAAAGCAGCUGCA 5876  390  964CCACAGCUCCUUCUCUGAG CUCAGAGAAGGAGCUGUGG 5877 1719  965CAGUUCGCCUUCACUAUGG CCAUAGUGAAGGCGAACUG 5878  813  966AAGCUUCCAGACACGCUAU AUAGCGUGUCUGGAAGCUU 5879 2289  967UUUCAGUUGAGCUGACCAG CUGGUCAGCUCAACUGAAA 5880  377  968UCUGGUGCCACUACCACAG CUGUGGUAGUGGCACCAGA 5881  826  969CGCUAUCAUGCGUUCUCCU AGGAGAACGCAUGAUAGCG 5882 1634  970GACAGGGAAGACAUCACUG CAGUGAUGUCUUCCCUGUC 5883 1208  971AUCAUACUGGCUAGUGGUG CACCACUAGCCAGUAUGAU 5884 1628  972GCUGGUGACAGGGAAGACA UGUCUUCCCUGUCACCAGC 5885 2003  973AUCCUAGCUCGGGAUGUUC GAACAUCCCGAGCUAGGAU 5886  452  974GUCCUGUAUGAGUGGGAAC GUUCCCACUCAUACAGGAC 5887 3081  975UGGGAUAUGUAUGGGUAGG CCUACCCAUACAUAUCCCA 5888 2354  976CUUGGACUUGAUAUUGGUG CACCAAUAUCAAGUCCAAG 5889 1822  977CCUUUGUCCCGCAAAUCAU AUGAUUUGCGGGACAAAGG 5890 1299  978UGAAGGUGCUAUCUGUCUG CAGACAGAUAGCACCUUCA 5891  486  979CCUUCACUCAAGAACAAGU ACUUGUUCUUGAGUGAAGG 5892 1463  980GAAGGUCUCCUUGGGACUC GAGUCCCAAGGAGACCUUC 5893 2280  981AGAAACGGCUUUCAGUUGA UCAACUGAAAGCCGUUUCU 5894 1907  982ACCCAGCGCCGUACGUCCA UGGACGUACGGCGCUGGGU 5895  923  983CAUAACCUUUCCCAUCAUC GAUGAUGGGAAAGGUUAUG 5896 1979  984GAAGGUUGUACCGGAGCCC GGGCUCCGGUACAACCUUC 5897 1827  985GUCCCGCAAAUCAUGCACC GGUGCAUGAUUUGCGGGAC 5898 1201  986CAAGCUCAUCAUACUGGCU AGCCAGUAUGAUGAGCUUG 5899 1913  987CGCCGUACGUCCAUGGGUG CACCCAIGGACGIACGGCG 5900 2191  988AGAGUUACUUCACUCUAGG CCUAGAGUGAAGUAACUCU 5901  295  989GUUGGACAUGGCCAUGGAA UUCCAUGGCCAUGUCCAAC 5902 1149  990UGGCUAUUACGACAGACUG CAGUCUGUCGUAAUAGCCA 5903  533  991ACUCGAGCUCAGAGGGUAC GUACCCUCUGAGCUCGAGU 5904  604  992ACAGUUUGAUGCUGCUCAU AUGAGCAGCAUCAAACUGU 5905  766  993GGUGGUUAAUAAGGCUGCA UGCAGCCUUAUUAACCACC 5906 1823  994CUUUGUCCCGCAAAUCAUG CAUGAUUUGCGGGACAAAG 5907 2048  995AAUACCAUUCCAUUGUUUG CAAACAAUGGAAUGGUAUU 5908  714  996CCACACGUGCAAUCCCUGA UCAGGGAUUGCACGUGUGG 5909 2439  997AUGGCCAGGAUGCCUUGGG CCCAAGGCAUCCUGGCCAU 5910 1903  998GGAUACCCAGCGCCGUACG CGUACGGCGCUGGGUAUCC 5911 2395  999UCGCCAGGAUGAUCCUAGC GCUAGGAUCAUCCUGGCGA 5912  789 1000UGGUCCAUCAGCUUUCUAA UUAGAAAGCUGAUGGACCA 5913 3085 1001AUAUGUAUGGGUAGGGUAA UUACCCUACCCAUACAUAU 5914 1710 1002CCCAGAAUGCAGUUCGCCU AGGCGAACUGCAUUCUGGG 5915 1336 1003UAUUGUAGAAGCUGGUGGA UCCACCAGCUUCUACAAUA 5916 3089 1004GUAUGGGUAGGGUAAAUCA UGAUUUACCCUACCCAUAC 5917 2351 1005GAUCUUGGACUUGAUAUUG CAAUAUCAAGUCCAAGAUC 5918  716 1006ACACGUGCAAUCCCUGAAC GUUCAGGGAUUGCACGUGU 5919 1911 1007AGCGCCGUACGUCCAUGGG CCCAUGGACGUACGGCGCU 5920 1985 1008UGUACCGGAGCCCUUCACA UGUGAAGGGCUCCGGUACA 5921 2516 1009GUUGAUGGGCUGCCAGAUC GAUCUGGCAGCCCAUCAAC 5922 1762 1010ACACCCACCAUCCCACUGG CCAGUGGGAUGGUGGGUGU 5923 1156 1011UACGACAGACUGCCUUCAA UUGAAGGCAGUCUGUCGUA 5924 1887 1012UUGUUCGUGCACAUCAGGA UCCUGAUGUGCACGAACAA 5925 1833 1013CAAAUCAUGCACCUUUGCG CGCAAAGGUGCAUGAUUUG 5926  967 1014GUCUGGAGGCAUUCCUGCC GGCAGGAAUGCCUCCAGAC 5927 1730 1015CACUAUGGACUACCAGUUG CAACUGGUAGUCCAUAGUG 5928  829 1016UAUCAUGCGUUCUCCUCAG CUGAGGAGAACGCAUGAUA 5929  890 1017GUAGAAACAGCUCUGGUGA UACAACGAGCUGUUUCUAC 5930 2181 1018CUCCUCUGACAGAGUUACU AGUAACUCUGUCAGAGGAG 5931 2131 1019UGCUCAGGACAAGGAAGCU AGCUUCCUUGUCCUGAGCA 5932 1586 1020CAAGUGGGUGGUAUAGAGG CCUCUAUACCACCCACUUG 5933  765 1021UGGUGGUUAAUAAGGCUGC GCAGCCUUAUUAACCACCA 5934 1369 1022ACUUCACCUGACAGAUCCA UGGAUCUGUCAGGUGAAGU 5935 1724 1023CGCCUUCACUAUGGACUAC GUAGUCCAUAGUGAAGGCG 5936  834 1024UGCGUUCUCCUCAGAUGGU ACCAUCUGAGGAGAACGCA 5937 1983 1025GUUGUACCGGAGCCCUUCA UGAAGGGCUCCGGUACAAC 5938 1688 1026CGACACCAAGAAGCAGAGA UCUCUGCUUCUUGGUGUCG 5939 1004 1027UCACCAGUGGAUUCUGUGU ACACAGAAUCCACUGGUGA 5940 1631 1028GGUGACAGGGAAGACAUCA UGAUGUCUUCCCUGUCACC 5941 1319 1029UCUAGUAAUAAGCCGGCUA UAGCCGGCUUAUUACUAGA 5942  767 1030GUGGUUAAUAAGGCUGCAG CUGCAGCCUUAUUAACCAC 5943  841 1031UCCUCAGAUGGUGUCUGCU AGCAGACACCAUCUGAGGA 5944  516 1032AUGGACAGUAUGCAAUGAC GUCAUUGCAUACUGUCCAU 5945 1848 1033UGCGUGAGCAGGGUGCCAU AUGGCACCCUGCUCACGCA 5946 2202 1034ACUCUAGGAAUGAAGGUGU ACACCUUCAUUCCUAGAGU 5947  571 1035GACAUUAGAUGAGGGCAUG CAUGCCCUCAUCUAAUGUC 5948 1629 1036CUGGUGACAGGGAAGACAU AUGUCUUCCCUGUCACCAG 5949 1806 1037UGAUUCGAAAUCUUGCCCU AGGGCAAGAUUUCGAAUCA 5950 1756 1038GCUCUUACACCCACCAUCC GGAUGGUGGGUGUAAGAGC 5951 1619 1039GUCCUUCGGGCUGGUGACA UGUCACCAGCCCGAAGGAC 5952 1610 1040GUGCGUACUGUCCUUCGGG CCCGAAGGACAGUACGCAC 5953 2500 1041UGGUGCUGACUAUCCAGUU AACUGGAUAGUCAGCACCA 5954 2156 1042GCUAUUGAAGCUGAGGGAG CUCCCUCAGCUUCAAUAGC 5955 1189 1043CAACCAAGAAAGCAAGCUC GAGCUUGCUUUCUUGGUUG 5956 2066 1044GUGCAGCUGCUUUAUUCUC GAGAAUAAAGCAGCUGCAC 5957 1307 1045CUAUCUGUCUGCUCUAGUA UACUAGAGCAGACAGAUAG 5958 1448 1046AAACAGGAAGGGAUGGAAG CUUCCAUCCCUUCCUGUUU 5959 1213 1047ACUGGCUAGUGGUGGACCC GGGUCCACCACUAGCCAGU 5960 2119 1048CCUCUGUGAACUUGCUCAG CUGAGCAAGUUCACAGAGG 5961  889 1049UGUAGAAACAGCUCGUUGU ACAACGAGCUGUUUCUACA 5962 1376 1050CUGACAGAUCCAAGUCAAC GUUGACUUGGAUCUGUCAG 5963  427 1051GGAAGAGGAUGUGGAUACC GGUAUCCACAUCCUCUUCC 5964  649 1052ACCAUCACAGAUGCUGAAA UUUCAGCAUCUGUGAUGGU 5965 1915 1053CCGUACGUCCAUGGGUGGG CCCACCCAUGGACGUACGG 5966 2053 1054CAUUCCAUUGUUUGUGCAG CUGCACAAACAAUGGAAUG 5967 2568 1055CUCCAGGUGACAGCAAUCA UGAUUGCUGUCACCUGGAG 5968 1739 1056CUACCAGUUGUGGUUAAGC GCUUAACCACAACUGGUAG 5969 1746 1057UUGUGGUUAAGCUCUUACA UGUAAGAGCUUAACCACAA 5970 1321 1058UAGUAAUAAGCCGGCUAUU AAUAGCCGGCUUAUUACUA 5971  482 1059CAGUCCUUCACUCAAGAAC GUUCUUGAGUGAAGGACUG 5972  280 1060AGCUGAUUUGAUGGAGUUG CAACUCCAUCAAAUCAGCU 5973 1465 1061AGGUCUCCUUGGGACUCUU AAGAGUCCCAAGGAGACCU 5974 1731 1062ACUAUGGACUACCAGUUGU ACAACUGGUAGUCCAUAGU 5975 1937 1063CAGCAGCAAUUUGUGGAGG CCUCCACAAAUUGCUGCUG 5976 1892 1064CGUGCACAUCAGGAUACCC GGGUAUCCUGAUGUGCACG 5977  836 1065CGUUCUCCUCAGAUGGUGU ACACCAUCUGAGGAGAACG 5978  521 1066CAGUAUGCAAUGACUCGAG CUCGAGUCAUUGCAUACUG 5979 1595 1067GGUAUAGAGGCUCUUGUGC GCACAAGAGCCUCUAUACC 5980 2511 1068AUCCAGUUGAUGGGCUGCC GGCAGCCCAUCAACUGGAU 5981 1583 1069UGCCAAGUGGGUGGUAUAG CUAUACCACCCACUUGGCA 5982 1897 1070ACAUCAGGAUACCCAGCGC GCGCUGGGUAUCCUGAUGU 5983  956 1071GCCAUCUUUAAGUCUGGAG CUCCAGACUUAAAGAUGGC 5984  923 1072AACCUUUCCCAUCAUCGUG CACGAUGAUGGGAAAGGUU 5985 1874 1073CUAGUUCAGUUGCUUGUUC GAACAAGCAACUGAACUAG 5986  488 1074UUCACUCAAGAACAAGUAG CUACUUGUUCUUGAGUGAA 5987 1695 1075AAGAAGCAGAGAUGGCCCA UGGGCCAUCUCUGCUUCUU 5988 2182 1076UCCUCUGACAGAGUUACUU AAGUAACUCUGUCAGAGGA 5989 2029 1077AAUUGUUAUCAGAGGACUA UAGUCCUCUGAUAACAAUU 5990  479 1078UCUCAGUCCUUCACUCAAG CUUGAGUGAAGGACUGAGA 5991  818 1079UCCAGACACGCUAUCAUGC GCAUGAUAGCGUGUCUGGA 5992  625 1080CACUAAUGUCCAGCGUUUG CAAACGCUGGACAUUAGUG 5993 3172 1081UUGUAACCUGCUGUGAUAC GUAUCACAGCAGGUUACAA 5994 1490 1082CUUCUGGGUUCAGAUGAUA UAUCAUCUGAACCCAGAAG 5995 1914 1083GCCGUACGUCCAUGGGUGG CCACCCAUGGACGUACGGC 5996  974 1084UAGUUGAAGGUUGUACCGG CCGGUACAACCUUCAACUA 5997 2258 1085GAGGACAAGCCACAAGAUU AAUCUUGUGGCUUGUCCUC 5998 2170 1086GGGAGCCACAGCUCCUCUG CAGAGGAGCUGUGGCUCCC 5999 1370 1087CUUCACCUGACAGAUCCAA UUGGAUCUGUCAGGUGAAG 6000 1429 1088UCUUUCAGAUGCUGCAACU AGUUGCAGCAUCUGAAAGA 6001 3173 1089UGUAACCUGCUGUGAUACG CGUAUCACAGCAGGUUACA 6002  444 1090CCUCCCAAGUCCUGUAUGA UCAUACAGGACUUGGGAGG 6003 1081 1091GGCAGUGCGUUUAGCUGGU ACCAGCUAAACGCACUGGC 6004 1318 1092CUCUAGUAAUAAGCCGGCU AGCCGGCUUAUUACUAGAG 6005  329 1093GCUGUUAGUCACUGGCAGC GCUGCCAGUGACUAACAGC 6006 1389 1094GUCAACGUCUUGUUCAGAA UUCUGAACAAGACGUUGAC 6007  428 1095GAAGAGGAUGUGGAUACCU AGGUAUCCACAUCCUCUUC 6008 3175 1096UAACCUGCUGUGAUACGAU AUCGUAUCACAGCAGGUUA 6009 3117 1097GUUAUUUGGAACCUUGUUU AAACAAGGUUCCAAAUAAC 6010 2020 1098UCACAACCGAAUUGUUAUC GAUAACAAUUCGGUUGUGA 6011 1625 1099CGGGCUGGUGACAGGGAAG CUUCCCUGUCACCAGCCCG 6012 2022 1100ACAACCGAAUUGUUAUCAG CUGAUAACAAUUCGGUUGU 6013  624 1101CCACUAAUGUCCAGCGUUU AAACGCUGGACAUUAGUGG 6014 1648 1102CACUGAGCCUGCCAUCUGU ACAGAUGGCAGGCUCAGUG 6015  790 1103GGUCCAUCAGCUUUCUAAA UUUAGAAAGCUGAUGGACC 6016 3160 1104AUCCCAAAGUUGUUGUAAC GUUACAACAACUUUGGGAU 6017 1251 1105UGAGGACCUAUACUUACGA UCGUAAGUAUAGGUCCUCA 6018 2253 1106UGUCUGAGGACAAGCCACA UGUGGCUUGUCCUCAGACA 6019 2515 1107AGUUGAUGGGCUGCCAGAU AUCUGGCAGCCCAUCAACU 6020 1680 1108UGACCAGCCGACACCAAGA UCUUGGUGUCGGCUGGUCA 6021 2169 1109AGGGAGCCACAGCUCCUCU AGAGGAGCUGUGGCUCCCU 6022 3165 1110AAAGUUGUUGUAACCUGCU AGCAGGUUACAACAACUUU 6023  780 1111CUGCAGUUAUGGUCCAUCA UGAUGGACCAUAACUGCAG 6024 1978 1112UGAAGGUUGUACCGGAGCC GGCUCCGGUACAACCUUCA 6025  563 1113UUCCCUGAGACAUUAGAUG CAUCUAAUGUCUCAGGGAA 6026 1622 1114CUUCGGGCUGGUGACAGGG CCCUGUCACCAGCCCGAAG 6027 2295 1115UUGAGCUGACCAGCUCUCU AGAGAGCUGGUCAGCUCAA 6028 2126 1116GAACUUGCUCAGGACAAGG CCUUGUCCUGAGCAAGUUC 6029 1683 1117CCAGCCGACACCAAGAAGC GCUUCUUGGUGUCGGCUGG 6030 1857 1118AGGGUGCCAUUCCACGACU AGUCGUGGAAUGGCACCCU 6031 2064 1119UUGUGCAGCUGCUUUAUUC GAAUAAAGCAGCUGCACAA 6032  489 1120UCACUCAAGAACAAGUAGC GCUACUUGUUCUUGAGUGA 6033 1346 1121GCUGGUGGAAUGCAAGCUU AAGCUUGCAUUCCACCAGC 6034 1442 1122GCAACUAAACAGGAAGGGA UCCCUUCCUGUUUAGUUGC 6035 1981 1123AGGUUGUACCGGAGCCCUU AAGGGCUCCGGUACAACCU 6036  777 1124AGGCUGCAGUUAUGGUCCA UGGACCAUAACUGCAGCCU 6037  589 1125GCAGAUCCCAUCUACACAG CUGUGUAGAUGGGAUCUGC 6038 2205 1126CUAGGAAUGAAGGUGUGGC GCCACACCUUCAUUCCUAG 6038  394 1127AGCUCCUUCUCUGAGUGGU ACCACUCAGAGAAGGAGCU 6040 1035 1128UUACAACUCUCCACAACCU AGGUUGUGGAGAGUUGUAA 6041  410 1129GGUAAAGGCAAUCCUGAGG CCUCAGGAUUGCCUUUACC 6042 1721 1130GUUCGCCUUCACUAUGGAC GUCCAUAGUGAAGGCGAAC 6043 1134 1131CAAAUGUUAAAUUCUUGGC GCCAAGAAUUUAACAUUUG 6044 3182 1132CUGUGAUACGAUGCUUCAA UUGAAGCAUCGUAUCACAG 6045  881 1133ACAAAUGAUGUAGAAACAG CUGUUUCUACAUCAUUUGU 6046  547 1134GGUACGAGCUGCUAUGUUC GAACAUAGCAGCUCGUACC 6047 2028 1135GAAUUGUUAUCAGAGGACU AGUCCUCUGAUAACAAUUC 6048 2023 1136CAACCGAAUUGUUAUCAGA UCUGAUAACAAUUCGGUUG 6049 3184 1137GUGAUACGAUGCUUCAAGA UCUUGAAGCAUCGUAUCAC 6050  413 1138AAAGGCAAUCCUGAGGAAG CUUCCUCAGGAUUGCCUUU 6051 2178 1139CAGCUCCUCUGACAGAGUU AACUCUGUCAGAGGAGCUG 6052 1577 1140AUGGUCUGCCAAGUGGGUG CACCCACUUGGCAGACCAU 6053 1793 1141GCUACUGUUGGAUUGAUUC GAAUCAAUCCAACAGUAGC 6054  526 1142UGCAAUGACUCGAGCUCAG CUGAGCUCGAGUCAUUGCA 6055 2358 1143GACUUGAUAUUGGUGCCCA UGGGCACCAAUAUCAAGUC 6056 1403 1144CAGAACUGUCUUUGGACUC GAGUCCAAAGACAGUUCUG 6057 1875 1145UAGUUCAGUUGCUUGUUCG CGAACAAGCAACUGAACUA 6058 1160 1146ACAGACUGCCUUCAAAUUU AAAUUUGAAGGCAGUCUGU 6059 1591 1147GGGUGGUAUAGAGGCUCUU AAGAGCCUCUAUACCACCC 6060 1734 1148AUGGACUACCAGUUGUGGU ACCACAACUGGUAGUCCAU 6061 2030 1149AUUGUUAUCAGAGGACUAA UUAGUCCUCUGAUAACAAU 6062  775 1150UAAGGCUGCAGUUAUGGUC GACCAUAACUGCAGCCUUA 6063 1813 1151AAAUCUUGCCCUUUGUCCC GGGACAAAGGGCAAGAUUU 6064 1938 1152AGCAGCAAUUUGUGGAGGG CCCUCCACAAAUUGCUGCU 6065 2039 1153AGAGGACUAAAUACCAUUC GAAUGGUAUUUAGUCCUCU 6066 1297 1154GCUGAAGGUGCUAUCUGUC GACAGAUAGCACCUUCAGC 6067  456 1155UGUAUGAGUGGGAACAGGG CCCUGUUCCCACUCAUACA 6068  590 1156CAGAUCCCAUCUACACAGU ACUGUGUAGAUGGGAUCUG 6069 1933 1157GACACAGCAGCAAUUUGUG CACAAAUUGCUGCUGUGUC 6070  583 1158GGGCAUGCAGAUCCCAUCU AGAUGGGAUCUGCAUGCCC 6071 2540 1159CAUGCCCAGGACCUCAUGG CCAUGAGGUCCUGGGCAUG 6072 2162 1160GAAGCUGAGGGAGCCACAG CUGUGGCUCCCUCAGCUUC 6073  330 1161CUGUUAGUCACUGGCAGCA UGCUGCCAGUGACUAACAG 6074 1481 1162CUUGUUCAGCUUCUGGGUU AACCCAGAAGCUGAACAAG 6075 1344 1163AAGCUGGUGGAAUGCAAGC GCUUGCAUUCCACCAGCUU 6076  431 1164GAGGAUGUGGAUACCUCCC GGGAGGUAUCCACAUCCUC 6077 1508 1165AUAAAUGUGGUCACCUGUG CACAGGUGACCACAUUUAU 6078 1918 1166UACGUCCAUGGGUGGGACA UGUCCCACCCAUGGACGUA 6079  289 1167GAUGGAGUUGGACAUGGCC GGCCAUGUCCAACUCCAUC 6080  631 1168UGUCCAGCGUUUGGCUGAA UUCAGCCAAACGCUGGACA 6081 1853 1169GAGCAGGGUGCCAUUCCAC GUGGAAUGGCACCCUGCUC 6082 1243 1170AAAUAUAAUGAGGACCUAU AUAGGUCCUCAUUAUAUUU 6083 1212 1171UACUGGCUAGUGGUGGACC GGUCCACCACUAGCCAGUA 6084  996 1172UGCUUGGUUCACCAGUGGA UCCACUGGUGAACCAAGCA 6085 2256 1173CUGAGGACAAGCCACAAGA UCUUGUGGCUUGUCCUCAG 6086 1607 1174CUUGUGCGUACUGUCCUUC GAAGGACAGUACGCACAAG 6087 3116 1175UGUUAUUUGGAACCUUGUU AACAAGGUUCCAAAUAACA 6088 1179 1176UAGCUUAUGGCAACCAAGA UCUUGGUUGCCAUAAGCUA 6089 3185 1177UGAUACGAUGCUUCAAGAG CUCUUGAAGCAUCGUAUCA 6090 1594 1178UGGUAUAGAGGCUCUUGUG CACAAGAGCCUCUAUACCA 6091  887 1179GAUGUAGAAACAGCUCGUU AACGAGCUGUUUCUACAUC 6092  928 1180CCUUUCCCAUCAUCGUGAG CUCACGAUGAUGGGAAAGG 6093  835 1181GCGUUCUCCUCAGAUGGUG CACCAUCUGAGGAGAACGC 6094 1900 1182UCAGGAUACCCAGCGCCGU ACGGCGCUGGGUAUCCUGA 6095 2284 1183ACGGCUUUCAGUUGAGCUG CAGCUCAACUGAAAGCCGU 6096 1976 1184GUUGAAGGUUGUACCGGAG CUCCGGUACAACCUUCAAC 6097 2393 1185UAUCGCCAGGAUGAUCCUA UAGGAUCAUCCUGGCGAUA 6098 1295 1186GUGCUGAAGGUGCUAUCUG CAGAUAGCACCUUCAGCAC 6099 1410 1187GUCUUUGGACUCUCAGGAA UUCCUGAGAGUCCAAAGAC 6100 1457 1188GGGAUGGAAGGUCUCCUUG CAAGGAGACCUUCCAUCCC 6101 2296 1189UGAGCUGACCAGCUCUCUC GAGAGAGCUGGUCAGCUCA 6102  929 1190CUUUCCCAUCAUCGUGAGG CCUCACGAUGAUGGGAAAG 6103 1359 1191AAGCUUUAGGACUUCACCU AGGUGAAGUCCUAAAGCUU 6104 1351 1192UGGAAUGCAAGCUUUAGGA UCCUAAAGCUUGCAUUCCA 6105  969 1193CUGGAGGCAUUCCUGCCCU AGGGCAGGAAUGCCUCCAG 6106 1876 1194AGUUCAGUUGCUUGUUCGU ACGAACAAGCAACUGAACU 6107  552 1195GAGCUGCUAUGUUCCCUGA UCAGGGAACAUAGCAGCUC 6108 2441 1196GGCCAGGAUGCCUUGGGUA UACCCAAGGCAUCCUGGCC 6109 2402 1197GAUGAUCCUAGCUAUCGUU AACGAUAGCUAGGAUCAUC 6110 1803 1198GAUUGAUUCGAAAUCUUGC GCAAGAUUUCGAAUCAAUC 6111 1701 1199CAGAGAUGGCCCAGAAUGC GCAUUCUGGGCCAUCUCUG 6112 1910 1200CAGCGCCGUACGUCCAUGG CCAUGGACGUACGGCGCUG 6113  888 1201AUGUAGAAACAGCUCGUUG CAACGAGCUGUUUCUACAU 6114 1294 1202AGUGCUGAAGGUGCUAUCU AGAUAGCACCUUCAGCACU 6115 1737 1203GACUACCAGUUGUGGUUAA UUAACCACAACUGGUAGUC 6116 1450 1204ACAGGAAGGGAUGGAAGGU ACCUUCCAUCCCUUCCUGU 6117  761 1205CAGGUGGUGGUUAAUAAGG CCUUAUUAACCACCACCUG 6118  776 1206AAGGCUGCAGUUAUGGUCC GGACCAUAACUGCAGCCUU 6119 1509 1207UAAAUGUGGUCACCUGUGC GCACAGGUGACCACAUUUA 6120 1788 1208UAAAGGCUACUGUUGGAUU AAUCCAACAGUAGCCUUUA 6121  515 1209GAUGGACAGUAUGCAAUGA UCAUUGCAUACUGUCCAUC 6122 1491 1210UUCUGGGUUCAGAUGAUAU AUAUCAUCUGAACCCAGAA 6123 1614 1211GUACUGUCCUUCGGGCUGG CCAGCCCGAAGGACAGUAC 6124  998 1212CUUGGUUCACCAGUGGAUU AAUCCACUGGUGAACCAAG 6125 2158 1213UAUUGAAGCUGAGGGAGCC GGCUCCCUCAGCUUCAAUA 6126 3168 1214GUUGUUGUAACCUGCUGUG CACAGCAGGUUACAACAAC 6127 1854 1215AGCAGGGUGCCAUUCCACG CGUGGAAUGGCACCCUGCU 6128 2117 1216GUCCUCUGUGAACUUGCUC GAGCAAGUUCACAGAGGAC 6129 1678 1217UCUGACCAGCCGACACCAA UUGGUGUCGGCUGGUCAGA 6130  305 1218GCCAUGGAACCAGACAGAA UUCUGUCUGGUUCCAUGGC 6131 2154 1219AAGCUAUUGAAGCUGAGGG CCCUCAGCUUCAAUAGCUU 6132 1807 1220GAUUCGAAAUCUUGCCCUU AAGGGCAAGAUUUCGAAUC 6133 1881 1221AGUUGCUUGUUCGUGCACA UGUGCACGAACAAGCAACU 6134 1565 1222AAGAACAAGAUGAUGGUCU AGACCAUCAUCUUGUUCUU 6135  407 1223AGUGGUAAAGGCAAUCCUG CAGGAUUGCCUUUACCACU 6136 1434 1224CAGAUGCUGCAACUAAACA UGUUUAGUUGCAGCAUCUG 6137  566 1225CCUGAGACAUUAGAUGAGG CCUCAUCUAAUGUCUCAGG 6138 3161 1226UCCCAAAGUUGUUGUAACC GGUUACAACAACUUUGGGA 6139 1678 1227CUGACCAGCCGACACCAAG CUUGGUGUCGGCUGGUCAG 6140 2096 1228AUCCAAAGAGUAGCUGCAG CUGCAGCUACUCUUUGGAU 6141  630 1229AUGUCCAGCGUUUGGCUGA UCAGCCAAACGCUGGACAU 6142 1606 1230UCUUGUGCGUACUGUCCUU AAGGACAGUACGCACAAGA 6143  432 1231AGGAUGUGGAUACCUCCCA UGGGAGGUAUCCACAUCCU 6144  778 1232GGCUGCAGUUAUGGUCCAU AUGGACCAUAACUGCAGCC 6145 1999 1233UCACAUCCUAGCUCGGGAU AUCCCGAGCUAGGAUGUGA 6146 1692 1234ACCAAGAAGCAGAGAUGGC GCCAUCUCUGCUUCUUGGU 6147 2490 1235GCCACCACCCUGGUGCUGA UCAGCACCAGGGUGGUGGC 6148  623 1236CCCACUAAUGUCCAGCGUU AACGCUGGACAUUAGUGGG 6149  339 1237ACUGGCAGCAACAGUCUUA UAAGACUGUUGCUGCCAGU 6150 2946 1238AUCUGAAUAAAGUGUAACA UGUUACACUUUAUUCAGAU 6151 1654 1239GCCUGCCAUCUGUGCUCUU AAGAGCACAGAUGGCAGGC 6152 1033 1240CAUUACAACUCUCCACAAC GUUGUGGAGAGUUGUAAUG 6153  840 1241CUCCUCAGAUGGUGUCUGC GCAGACACCAUCUGAGGAG 6154 1880 1242CAGUUGCUUGUUCGUGCAC GUGCACGAACAAGCAACUG 6155  420 1243AUCCUGAGGAAGAGGAUGU ACAUCCUCUUCCUCAGGAU 6156 1005 1244CACCAGUGGAUUCUGUGUU AACACAGAAUCCACUGGUG 6157 1193 1245CAAGAAAGCAAGCUCAUCA UGAUGAGCUUGCUUUCUUG 6158  919 1246CUUGCAUAACCUUUCCCAU AUGGGAAAGGUUAUGCAAG 6159 1727 1247CUUCACUAUGGACUACCAG CUGGUAGUCCAUAGUGAAG 6160 1883 1248UUGCUUGUUCGUGCACAUC GAUGUGCACGAACAAGCAA 6161  859 1249UAUUGUACGUACCAUGCAG CUGCAUGGUACGUACAAUA 6162 1812 1250GAAAUCUUGCCCUUUGUCC GGACAAAGGGCAAGAUUUC 6163 1605 1251CUCUUGUGCGUACUGUCCU AGGACAGUACGCACAAGAG 6164 2021 1252CACAACCGAAUUGUUAUCA UGAUAACAAUUCGGUUGUG 6165 2180 1253GCUCCUCUGACAGAGUUAC GUAACUCUGUCAGAGGAGC 6166  636 1254AGCGUUUGGCUGAACCAUC GAUGGUUCAGCCAAACGCU 6167 2282 1255AAACGGCUUUCAGUUGAGC GCUCAACUGAAAGCCGUUU 6168 1824 1256UUUGUCCCGCAAAUCAUGC GCAUGAUUUGCGGGACAAA 6169 2204 1257UCUAGGAAUGAAGGUGUGG CCACACCUUCAUUCCUAGA 6170  450 1258AAGUCCUGUAUGAGUGGGA UCCCACUCAUACAGGACUU 6171 1001 1259GGUUCACCAGUGGAUUCUG CAGAAUCCACUGGUGAACC 6172 1579 1260GGUCUGCCAAGUGGGUGGU ACCACCCACUUGGCAGACC 6173 2189 1261AGCUCCUCUGACAGAGUUA UAACUCUGUCAGAGGAGCU 6174  376 1262UUCUGGUGCCACUACCACA UGUGGUAGUGGCACCAGAA 6175  556 1263UGCUAUGUUCCCUGAGACA UGUCUCAGGGAACAUAGCA 6176 1804 1264AUUGAUUCGAAAUCUUGCC GGCAAGAUUUCGAAUCAAU 6177 2552 1265CUCAUGGAUGGGCUGCCUC GAGGCAGCCCAUCCAUGAG 6178 2071 1266GCUGCUUUAUUCUCCCAUU AAUGGGAGAAUAAAGCAGC 6179 1836 1267AUCAUGCACCUUUGCGUGA UCACGCAAAGGUGCAUGAU 6180  336 1268GUCACUGGCAGCAACAGUC GACUGUUGCUGCCAGUGAC 6181  460 1269UGAGUGGGAACAGGGAUUU AAAUCCCUGUUCCCACUCA 6182 1559 1270AAUUAUAAGAACAAGAUGA UCAUCUUGUUCUUAUAAUU 6183 3136 1271UGGACAGUUUACCAGUUGC GCAACUGGUAAACUGUCCA 6184 1250 1272AUGAGGACCUAUACUUACG CGUAAGUAUAGGUCCUCAU 6185 1462 1273GGAAGGUCUCCUUGGGACU AGUCCCAAGGAGACCUUCC 6186 1965 1274UGGAAGAAAUAGUUGAAGG CCUUCAACUAUUUCUUCCA 6187 3114 1275GGUGUUAUUUGGAACCUUG CAAGGUUCCAAAUAACACC 6188 1665 1276GUGCUCUUCGUCAUCUGAC GUCAGAUGACGAAGAGCAC 6189  307 1277GGCCAUGGAACCAGACAGA UCUGUCUGGUUCCAUGGCC 6190  327 1278CGGCUGUUAGUCACUGGCA UGCCAGUGACUAACAGCCG 6191 1866 1279UUCCACGACUAGUUCAGUU AACUGAACUAGUCGUGGAA 6192 1699 1280AGCAGAGAUGGCCCAGAAU AUUCUGGGCCAUCUCUGCU 6193 2397 1281GCCAGGAUGAUCCUAGCUA UAGCUAGGAUCAUCCUGGC 6194 1658 1282GCCAUCUGUGCUCUUCGUC GACGAAGAGCACAGAUGGC 6195  891 1283UAGAAACAGCUCGUUGUAC GUACAACGAGCUGUUUCUA 6196 1572 1284AGAUGAUGGUCUGCCAAGU ACUUGGCAGACCAUCAUCU 6197  927 1285ACCUUUCCCAUCAUCGUGA UCACGAUGAUGGGAAAGGU 6198  290 1286AUGGAGUUGGACAUGGCCA UGGCCAUGUCCAACUCCAU 6199 1663 1287CUGUGCUCUUCGUCAUCUG CAGAUGACGAAGAGCACAG 6200 1562 1288UAUAAGAACAAGAUGAUGG CCAUCAUCUUGUUCUUAUA 6201 2947 1289UCUGAAUAAAGUGUAACAA UUGUUACACUUUAUUCAGA 6202 1711 1290CCAGAAUGCAGUUCGCCUU AAGGCGAACUGCAUUCUGG 6203 1566 1291AGAACAAGAUGAUGGUCUG CAGACCAUCAUCUUGUUCU 6204 1815 1292AUCUUGCCCUUUGUCCCGC GCGGGACAAAGGGCAAGAU 6205 1087 1293GCGUUUAGCUGGUGGGCUG CAGCCCACCAGCUAAACGC 6206 1495 1294GGGUUCAGAUGAUAUAAAU AUUUAUAUCAUCUGAACCC 6207 1363 1295UUUAGGACUUCACCUGACA UGUCAGGUGAAGUCCUAAA 6208  391 1296CACAGCUCCUUCUCUGAGU ACUCAGAGAAGGAGCUGUG 6209 1392 1297AACGUCUUGUUCAGAACUG CAGIICIGAACAAGACGUU 6210 1935 1298CACAGCAGCAAUUUGUGGA UCCACAAAUUGCUGCUGUG 6211 1872 1299GACUAGUUCAGUUGCUUGU ACAAGCAACUGAACUAGUC 6212 1159 1300GACAGACUGCCUUCAAAUU AAUUUGAAGGCAGUCUGUC 6213 2308 1301CUCUCUCUUCAGAACAGAG CUCUGUUCUGAAGAGAGAG 6214  632 1302GUCCAGCGUUUGGCUGAAC GUUCAGCCAAACGCUGGAC 6215 1564 1303UAAGAACAAGAUGAUGGUC GACCAUCAUCUUGUUCUUA 6216 1384 1304UCCAAGUCAACGUCUUGUU AACAAGACGUUGACUUGGA 6217 1690 1305ACACCAAGAAGCAGAGAUG CAUCUCUGCUUCUUGGUGU 6218 1421 1306CUCAGGAAUCUUUCAGAUG CAUCUGAAAGAUUCCUGAG 6219 1141 1307UAAAUUCUUGGCUAUUACG CGUAAUAGCCAAGAAUUUA 6220 1732 1308CUAUGGACUACCAGUUGUG CACAACUGGUAGUCCAUAG 6221  634 1309CCAGCGUUUGGCUGAACCA UGGUUCAGCCAAACGCUGG 6222  932 1310UCCCAUCAUCGUGAGGGCU AGCCCUCACGAUGAUGGGA 6223 1366 1311AGGACUUCACCUGACAGAU AUCUGUCAGGUGAAGUCCU 6224 1608 1312UUGUGCGUACUGUCCUUCG CGAAGGACAGUACGCACAA 6225 1923 1313CCAUGGGUGGGACACAGCA UGCUGUGUCCCACCCAUGG 6226 1458 1314GGAUGGAAGGUCUCCUUGG CCAAGGAGACCUUCCAUCC 6227 1908 1315CCCAGCGCCGUACGUCCAU AUGGACGUACGGCGCUGGG 6228  539 1316GCUCAGAGGGUACGAGCUG CAGCUCGUACCCUCUGAGC 6229 2016 1317AUGUUCACAACCGAAUUGU ACAAUUCGGUUGUGAACAU 6230 1884 1318UGCUUGUUCGUGCACAUCA UGAUGUGCACGAACAAGCA 6231  560 1319AUGUUCCCUGAGACAUUAG CUAAUGUCUCAGGGAACAU 6232  411 1320GUAAAGGCAAUCCUGAGGA UCCUCAGGAUUGCCUUUAC 6233  338 1321CACUGGCAGCAACAGUCUU AAGACUGUUGCUGCCAGUG 6234  830 1322AUCAUGCGUUCUCCUCAGA UCUGAGGAGAACGCAUGAU 6235 3086 1323UAUGUAUGGGUAGGGUAAA UUUACCCUACCCAUACAUA 6236 3115 1324GUGUUAUUUGGAACCUUGU ACAAGGUUCCAAAUAACAC 6237 2177 1325ACAGCUCCUCUGACAGAGU ACUCUGUCAGAGGAGCUGU 6238 1733 1326UAUGGACUACCAGUUGUGG CCACAACUGGUAGUCCAUA 6239  375 1327AUUCUGGUGCCACUACCAC GUGGUAGUGGCACCAGAAU 6240 2565 1328UGCCUCCAGGUGACAGCAA UUGCUGUCACCUGGAGGCA 6241 442 1329UACCUCCCAAGUCCUGUAU AUACAGGACUUGGGAGGUA 6242  819 1330CCAGACACGCUAUCAUGCG CGCAUGAUAGCGUGUCUGG 6243  700 1331UGAUGCAGAACUUGCCACA UGUGGCAAGUUCUGCAUCA 6244 1089 1332GUUUAGCUGGUGGGCUGCA UGCAGCCCACCAGCUAAAC 6245 1580 1333GUCUGCCAAGUGGGUGGUA UACCACCCACUUGGCAGAC 6246 1982 1334GGUUGUACCGGAGCCCUUC GAAGGGCUCCGGUACAACC 6247 1986 1335GUACCGGAGCCCUUCACAU AUGUGAAGGGCUCCGGUAC 6248  418 1336CAAUCCUGAGGAAGAGGAU AUCCUCUUCCUCAGGAUUG 6249 1306 1337GCUAUCUGUCUGCUCUAGU ACUAGAGCAGACAGAUAGC 6250 1377 1338UGACAGAUCCAAGUCAACG CGUUGACUUGGAUCUGUCA 6251 2467 1339CAUGAUGGAACAUGAGAUG CAUCUCAUGUUCCAUCAUG 6252 1414 1340UUGGACUCUCAGGAAUCUU AAGAUUCCUGAGAGUCCAA 6253 1668 1341CUCUUCGUCAUCUGACCAG CUGGUCAGAUGACGAAGAG 6254 1818 1342UUGCCCUUUGUCCCGCAAA UUUGCGGGACAAAGGGCAA 6255 1697 1343GAAGCAGAGAUGGCCCAGA UCUGGGCCAUCUCUGCUUC 6256  918 1344CCUUGCAUAACCUUUCCCA UGGGAAAGGUUAUGCAAGG 6257  605 1345CAGUUUGAUGCUGCUCAUC GAUGAGCAGCAUCAAACUG 6258 1374 1346ACCUGACAGAUCCAAGUCA UGACUUGGAUCUGUCAGGU 6259 1430 1347CUUUCAGAUGCUGCAACUA UAGUUGCAGCAUCUGAAAG 6260 3186 1348GAUACGAUGCUUCAAGAGA UCUCUUGAAGCAUCGUAUC 6261 1355 1349AUGCAAGCUUUAGGACUUC GAAGUCCUAAAGCUUGCAU 6262  433 1350GGAUGUGGAUACCUCCCAA UUGGGAGGUAUCCACAUCC 6263 1713 1351AGAAUGCAGUUCGCCUUCA UGAAGGCGAACUGCAUUCU 6264 1811 1352CGAAAUCUUGCCCUUUGUC GACAAAGGGCAAGAUUUCG 6265  491 1353ACUCAAGAACAAGUAGCUG CAGCUACUUGUUCUUGAGU 6266 2209 1354GAAUGAAGGUGUGGCGACA UGUCGCCACACCUUCAUUC 6267 1840 1355UGCACCUUUGCGUGAGCAG CUGCUCACGCAAAGGUGCA 6268  550 1356ACGAGCUGCUAUGUUCCCU AGGGAACAUAGCAGCUCGU 6269  429 1357AAGAGGAUGUGGAUACCUC GAGGUAUCCACAUCCUCUU 6270 2436 1358GAUAUGGCCAGGAUGCCUU AAGGCAUCCUGGCCAUAUC 6271 1597 1359UAUAGAGGCUCUUGUGCGU ACGCACAAGAGCCUCUAUA 6272 1496 1360GGUUCAGAUGAUAUAAAUG CAUUUAUAUCAUCUGAACC 6273 1456 1361AGGGAUGGAAGGUCUCCUU AAGGAGACCUUCCAUCCCU 6274 3159 1362UAUCCCAAAGUUGUUGUAA UUACAACAACUUUGGGAUA 6275 2309 1363UCUCUCUUCAGAACAGAGC GCUCUGUUCUGAAGAGAGA 6276 2300 1364CUGACCAGCUCUCUCUUCA UGAAGAGAGAGCUGGUCAG 6277 3177 1365ACCUGCUGUGAUACGAUGC GCAUCGUAUCACAGCAGGU 6278 1079 1366AUGGCAGUGCGUUUAGCUG CAGCUAAACGCACUGCCAU 6279 1383 1367AUCCAAGUCAACGUCUUGU ACAAGACGUUGACUUGGAU 6280 2563 1368GCUGCCUCCAGGUGACAGC GCUGUCACCUGGAGGCAGC 6281 1084 1369AGUGCGUUUAGCUGGUGGG CCCACCAGCUAAACGCACU 6282 1329 1370AGCCGGCUAUUGUAGAAGC GCUUCUACAAUAGCCGGCU 6283  573 1371CAUUAGAUGAGGGCAUGCA UGCAUGCCCUCAUCUAAUG 6284 2213 1372GAAGGUGUGGCGACAUAUG CAUAUGUCGCCACACCUUC 6285 1587 1373AAGUGGGUGGUAUAGAGGC GCCUCUAUACCACCCACUU 6286 2166 1374CUGAGGGAGCCACAGCUCC GGAGCUGUGGCUCCCUCAG 2687  637 1375GCGUUUGGCUGAACCAUCA UGAUGGUUCAGCCAAACGC 6288  397 1376UCCUUCUCUGAGUGGUAAA UUUACCACUCAGAGAAGGA 6289 1718 1377GCAGUUCGCCUUCACUAUG CAUAGUGAAGGCGAACUGC 6290 2357 1378GGACUUGAUAUUGGUGCCC GGGCACCAAUAUCAAGUCC 6291  639 1379GUUUGGCUGAACCAUCACA UGUGAUGGUUCAGCCAAAC 6292  585 1380GCAUGCAGAUCCCAUCUAC GUAGAUGGGAUCUGCAUGC 6293 2519 1381GAUGGGCUGCCAGAUCUGG CCAGAUCUGGCAGCCCAUC 6294 1367 1382GGACUUCACCUGACAGAUC GAUCUGUCAGGUGAAGUCC 6295 1391 1383CAACGUCUUGUUCAGAACU AGUUCUGAACAAGACGUUG 6296  509 1384GAUAUUGAUGGACAGUAUG CAUACUGUCCAUCAAUAUC 6297  303 1385UGGCCAUGGAACCAGACAG CUGUCUGGUUCCAUGGCCA 6298  494 1386CAAGAACAAGUAGCUGAUA UAUCAGCUACUUGUUCUUG 6299  328 1387GGCUGUUAGUCACUGGCAG CUGCCAGUGACUAACAGCC 6300 2058 1388CAUUGUUUGUGCAGCUGCU AGCAGCUGCACAAACAAUG 6301 1447 1389UAAACAGGAAGGGAUGGAA UUCCAUCCCUUCCUGUUUA 6302 1563 1390AUAAGAACAAGAUGAUGGU ACCAUCAUCUUGUUCUUAU 6303 1350 1391GUGGAAUGCAAGCUUUAGG CCUAAAGCUUGCAUUCCAC 6304 2208 1392GGAAUGAAGGUGUGGCGAC GUCGCCACACCUUCAUUCC 6305 1689 1393GACACCAAGAAGCAGAGAU AUCUCUGCUUCUUGGUGUC 6306 1407 1394ACUGUCUUUGGACUCUCAG CUGAGAGUCCAAAGACAGU 6307 2137 1395GGACAAGGAAGCUGCAGAA UUCUGCAGCUUCCUUGUCC 6308  854 1396UCUGCUAUUGUACGUACCA UGGUACGUACAAUAGCAGA 6309 2070 1397AGCUGCUUUAUUCUCCCAU AUGGGAGAAUAAAGCAGCU 6310  545 1398AGGGUACGAGCUGCUAUGU ACAUAGCAGCUCGUACCCU 6311 1640 1399GAAGACAUCACUGAGCCUG CAGGCUCAGUGAUGUCUUC 6312 2012 1400CGGGAUGUUCACAACCGAA UUCGGUUGUGAACAUCCCG 6313 1684 1401CAGCCGACACCAAGAAGCA UGCUUCUUGGUGUCGGCUG 6314 2017 1402UGUUCACAACCGAAUUGUU AACAAUUCGGUUGUGAACA 6315 2307 1403GCUCUCUCUUCAGAACAGA UCUGUUCUGAAGAGAGAGC 6316  844 1404UCAGAUGGUGUCUGCUAUU AAUAGCAGACACCAUCUGA 6317  405 1405UGAGUGGUAAAGGCAAUCC GGAUUGCCUUUACCACUCA 6318  379 1406UGGUGCCACUACCACAGCU AGCUGUGGUAGUGGCACCA 6319 1825 1407UUGCUUUGCAAAUCAUGCA UGCAUGAUUUGCGGGACAA 6320 2495 1408CACCCUGGUGCUGACUAUC GAUAGUCAGCACCAGGGUG 6321  629 1409AAUGUCCAGCGUUUGGCUG CAGCCAAACGCUGGACAUU 6322 2561 1410GGGCUGCCUCCAGGUGACA UGUCACCUGGAGGCAGCCC 6323 2192 1411GAGUUACUUCACUCUAGGA UCCUAGAGUGAAGUAACUC 6324 1809 1412UUCGAAAUCUUGCCCUUUG CAAAGGGCAAGAUUUCGAA 6325 1596 1413GUAUAGAGGCUCUUGUGCG CGCACAAGAGCCUCUAUAC 6326 2298 1414AGCUGACCAGCUCUCUCUU AAGAGAGAGCUGGUCAGCU 6327  858 1415CUAUUGUACGUACCAUGCA UGCAUGGUACGUACAAUAG 6328  524 1416UAUGCAAUGACUCGAGCUC GAGCUCGAGUCAUUGCAUA 6329 2542 1417UGCCCAGGACCUCAUGGAU AUCCAUGAGGUCCUGGGCA 6330 7498 1418AACAAGUAGCUGAUAUUGA UCAAUAUCAGCUACUUGUU 6331  414 1419AAGGCAAUCCUGAGGAAGA UCUUCCUCAGGAUUGCCUU 6332 1570 1420CAAGAUGAUGGUCUGCCAA UUGGCAGACCAUCAUCUUG 6333 1030 1421UGCCAUUACAACUCUCCAC GUGGAGAGUUGUAAUGGCA 6334 3087 1422AUGUAUGGGUAGGGUAAAU AUUUACCCUACCCAUACAU 6335 1664 1423UGUGCUCUUCGUCAUCUGA UCAGAUGACGAAGAGCACA 6336 1790 1424AAGGCUACUGUUGGAUUGA UCAAUCCAACAGUAGCCUU 6337 1615 1425UACUGUCCUUCGGGCUGGU ACCAGCCCGAAGGACAGUA 6338  774 1426AUAAGGCUGCAGUUAUGGU ACCAUAACUGCAGCCUUAU 6339 1672 1427UCGUCAUCUGACCAGCCGA UCGGCUGGUCAGAUGACGA 6340 3171 1428GUUGUAACCUGCUGUGAUA UAUCACAGCAGGUUACAAC 6341 2271 1429AAGAUUACAAGAAACGGCU AGCCGUUUCUUGUAAUCUU 6342 1183 1430UUAUGGCAACCAAGAAAGC GCUUUCUUGGUUGCCAUAA 6343 2512 1431UCCAGUUGAUGGGCUGCCA UGGCAGCCCAUCAACUGGA 6344 1931 1432GGGACACAGCAGCAAUUUG CAAAUUGCUGCUGUGUCCC 6345 2468 1433AUGAUGGAACAUGAGAUGG CCAUCUCAUGUUCCAUCAU 6346 3077 1434UAUUUGGGAUAUGUAUGGG CCCAUACAUAUCCCAAAUA 6347 2069 1435CAGCUGCUUUAUUCUCCCA UGGGAGAAUAAAGCAGCUG 6348 272 1436GCUACUCAAGCUGAUUUGA UCAAAUCAGCUUGAGUAGC 6349  564 1437UCCCUGAGACAUUAGAUGA UCAUCUAAUGUCUCAGGGA 6350  437 1438GUGGAUACCUCCCAAGUCC GGACUUGGGAGGUAUCCAC 6351 2206 1439UAGGAAUGAAGGUGUGGCG CGCCACACCUUCAUUCCUA 6352 2197 1440UGACAGAGUUACUUCACUC GAGUGAAGUAACUCUGUCA 6353  325 1441AGCGGCUGUUAGUCACUGG CCAGUGACUAACAGCCGCU 6354 3222 1442AUGGUUCAGAAUUAAACUU AAGUUUAAUUCUGAACCAU 6355 2024 1443AACCGAAUUGUUAUCAGAG CUCUGAUAACAAUUCGGUU 6356 1858 1444GGGUGCCAUUCCACGACUA UAGUCGUGGAAUGGCACCC 6357 1574 1445AUGAUGGUCUGCCAAGUGG CCACUUGGCAGACCAUCAU 6358 1896 1446CACAUCAGGAUACCCAGCG CGCUGGGUAUCCUGAUGUG 6359 2207 1447AGGAAUGAAGGUGUGGCGA UCGCCACACCUUCAUUCCU 6360 1300 1448GAAGGUGCUAUCUGUCUGC UCGCCACACCUUCAUUCCU 6361 1192 1449CCAAGAAAGCAAGCUCAUC GAUGAGCUUGCUUUCUUGG 6362  551 1450CGAGCUGCUAUGUUCCCUG CAGGGAACAUAGCAGCUCG 6363 2498 1451CCUGGUGCUGACUAUCCAG CUGGAUAGUCAGCACCAGG 6364 1305 1452UGCUAUCUGUCUGCUCUAG CUAGAGCAGACAGAUAGCA 6365 1337 1453AUUGUAGAAGCUGGUGGAA UUCCACCAGCUUCUACAAU 6366

For each oligonucleotide of a target sequence, the two individual,complementary strands of the siNA were synthesized separately usingsolid phase synthesis, then purified separately by reversed phase solidphase extraction (SPE). The complementary strands were annealed to formthe double strand (duplex) and delivered in the desired concentrationand buffer of choice.

Briefly, the single strand oligonucleotides were synthesized usingphosphoramidite chemistry on an automated solid-phase synthesizer, usingprocedures as are generally known in the art (see for example U.S.application Ser. No. 12/064,014). A synthesis column was packed withsolid support derivatized with the first nucleoside residue (natural orchemically modified). Synthesis was initiated by detritylation of theacid labile 5′-O-dimethoxytrityl group to release the 5′-hydroxyl. Asuitably protected phosphoramidite and a suitable activator inacetonitrile were delivered simultaneously to the synthesis columnresulting in coupling of the amidite to the 5′-hydroxyl. The column wasthen washed with a solvent, such as acetonitrile. An oxidizing solution,such as an iodine solution was pumped through the column to oxidize thephosphite triester linkage P(III) to its phosphotriester P(V) analog.Unreacted 5′-hydroxyl groups were capped using reagents such as aceticanhydride in the presence of 2,6-lutidine and N-methylimidazole. Theelongation cycle was resumed with the detritylation step for the nextphosphoramidite incorporation. This process was repeated until thedesired sequence was synthesized. The synthesis concluded with the final5′-terminus protecting group (trityl or 5′-O-dimethoxytrityl).

Upon completion of the synthesis, the solid-support and associatedoligonucleotide were dried under argon pressure or vacuum. Aqueous basewas added and the mixture was heated to effect cleavage of the succinyllinkage, removal of the cyanoethyl phosphate protecting group, anddeprotection of the exocyclic amine protection.

The following process was performed on single strands that do notcontain ribonucleotides. After treating the solid support with theaqueous base, the mixture was filtered to separate the solid supportfrom the deprotected crude synthesis material. The solid support wasthen rinsed with water, which is combined with the filtrate. Theresultant basic solution allows for retention of the5′-O-dimethoxytrityl group to remain on the 5′ terminal position(trityl-on).

For single strands that contain ribonucleotides, the following processwas performed. After treating the solid support with the aqueous base,the mixture was filtered to separate the solid support from thedeprotected crude synthesis material. The solid support was then rinsedwith dimethylsulfoxide (DMSO), which was combined with the filtrate.Fluoride reagent, such as triethylamine trihydrofluoride, was added tothe mixture, and the solution was heated. The reaction was quenched withsuitable buffer to provide a solution of crude single strand with the5′-O-dimethoxytrityl group on the final 5′ terminal position.

The trityl-on solution of each crude single strand was purified usingchromatographic purification, such as SPE RPC purification. Thehydrophobic nature of the trityl group permits stronger retention of thedesired full-length oligo than the non-tritylated truncated failuresequences. The failure sequences were selectively washed from the resinwith a suitable solvent, such as low percent acetonitrile. Retainedoligonucleotides were then detritylated on-column with trifluoroaceticacid to remove the acid-labile trityl group. Residual acid was washedfrom the column, a salt exchange was performed, and a final desalting ofthe material commenced. The full-length oligo was recovered in apurified form with an aqueous-organic solvent. The final product wasthen analyzed for purity (HPLC), identity (Maldi-TOF MS), and yield (UVA₂₆₀). The oligos were dried via lyophilization or vacuum condensation.

Annealing: Based on the analysis of the product, the dried oligos weredissolved in appropriate buffers followed by mixing equal molar amounts(calculated using the theoretical extinction coefficient) of the senseand antisense oligonucleotide strands. The solution was then analyzedfor purity of duplex by chromatographic methods and desired finalconcentration. If the analysis indicated an excess of either strand,then the additional non-excess strand was titrated until duplexing wascomplete. When analysis indicated that the target product purity hasbeen achieved the material was delivered and ready for use.

Below is a table showing various modified siNAs synthesized using thisprotocol or that can be synthesized using this protocol or using methodsknown in the art.

TABLE 1cCTNNB1 siNA Strands Synthesized (Antisense sequences are readily identified as being complementary to the target sequence shown). Tar- get SEQ SEQSite ID ID (hu- NO: NO: R Number man) 1 Target SequenceModified Sequence 2 R-008247452-000C  535    1 UCGAGCUCAGAGGGUACGAB ucGAGcucAGAGGGuAcGATT B 1454 R-008247452-000C  535    1UCGAGCUCAGAGGGUACGA UCGuAcccucuGAGcucGAUU 1455 R-008247449-000W 1601   2 GAGGCUCUUGUGCGUACUG B GAGGcucuuGuGcGuAcuGTT B 1456 R-008247449-000W1601    2 GAGGCUCUUGUGCGUACUG CAGuAcGcAcAAGAGccucUU 1457R-008247575-000Y 1709    3 GCCCAGAAUGCAGUUCGCC B GcccAGAAuGcAGuucGccTT B1458 R-008247575-000Y 1709       3 GCCCAGAAUGCAGUUCGCCGGCGAAcuGcAuucuGGGcUU 1459 R-008247572-000X  536    4CGAGCUCAGAGGGUACGAG B cGAGcucAGAGGGuAcGAGTT B 1460 R-008247572-000X  536   4 CGAGCUCAGAGGGUACGAG CUCGuAcccucuGAGcucGUU 1461 R-008247569-000R1797    5 CUGUUGGAUUGAUUCGAAA UUUcGAAucAAuccAAcAGUU 1463R-008247569-000R 1797    5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAATT B1462 R-008247446-000V  853    6 GUCUGCUAUUGUACGUACCB GucuGcuAuuGuAcGuAccTT B 1464 R-008247446-000V  853    6GUCUGCUAUUGUACGUACC GGUAcGuAcAAuAGcAGAcUU 1465 R-008247566-000P 1143   7 AAUUCUUGGCUAUUACGAC GUCGuAAuAGccAAGAAuuUU 1467 R-008247566-000P1143    7 AAUUCUUGGCUAUUACGAC B AAuucuuGGccAuuAcGAcTT B 1466R-008247563-000N 2014    8 GGAUGUUCACAACCGAAUU B GGAuGuucAcAAccGAAuuTT B1468 R-008247563-000N 2014    8 GGAUGUUCACAACCGAAUUAAUucGGuuGuGAAcAuccUU 1469 R-008247560-000M  520    9ACAGUAUGCAAUGACUCGA B AcAGuAuGcAAuGAcucGATT B 1470 R-008247560-000M  520   9 ACAGUAUGCAAUGACUCGA UCGAGucAuuGcAuAcuGuUU 1471 R-008247443-000U 814   10 AGCUUCCAGACACGCUAUC B AGcuuccAGAcAcGcuAucTT B 1472R-008247443-000U  814   10 AGCUUCCAGACACGCUAUC GAUAGcGuGucuGGAAGcuUU1473 R-008247440-000T  852   11 UGUCUGCUAUUGUACGUACGUAcGuAcAAuAGcAGAcAUU 1475 R-008247440-000T  852   11UGUCUGCUAUUGUACGUAC B uGucuGcuAuuGuAcGuAcTT B 1474 R-008247557-000F 1796  12 ACUGUUGGAUUGAUUCGAA UUCGAAucAAuccAAcAGuUU 1477 R-008247557-000F1796   12 ACUGUUGGAUUGAUUCGAA B AcuGuuGGAuuGAuucGAATT B 1476R-008247437-000L 1901   13 CAGGAUACCCAGCGCCGUA UACGGcGcuGGGuAuccuGUU1479 R-008247437-000L 1901   13 CAGGAUACCCAGCGCCGUAB cAGGAuAcccAGcGccGuATT B 1478 R-008247554-000E  822   14GACACGCUAUCAUGCGUUC B GAcAcGcuAucAuGcGuucTT B 1480 R-008247554-000E  822  14 GACACGCUAUCAUGCGUUC GAAcGcAuGAuAGcGuGucUU 1481 R-008247551-000D1795   15 UACUGUUGGAUUGAUUCGA UCGAAucAAuccAAcAGuAUU 1483R-008247551-000D 1795   15 UACUGUUGGAUUGAUUCGA B uAcuGuuGGAuuGAuucGATT B1482 R-008247548-000X 1145   16 UUCUUGGCUAUUACGACAGB uucuuGGcuAuuAcGAcAGTT B 1484 R-008247548-000X 1145   16UUCUUGGCUAUUACGACAG CUGucGuAAuAGccAAGAAUU 1485 R-008247545-000W  823  17 ACACGCUAUCAUGCGUUCU B AcAcGcuAucAuGcGuucuTT B 1486 R-008247545-000W 823   17 ACACGCUAUCAUGCGUUCU AGAAcGcAuGAuAGcGuGuUU 1487R-008247434-000K  820   18 CAGACACGCUAUCAUGCGU B cAGAcAcGcuAucAuGcGuTT B1488 R-008247434-000K  820   18 CAGACACGCUAUCAUGCGUACGcAuGAuAGcGuGucuGUU 1489 R-008247431-000J 1798   19UGUUGGAUUGAUUCGAAAU B uGuuGGAuuGAuucGAAAuTT B 1490 R-008247431-000J 1798  19 UGUUGGAUUGAUUCGAAAU AUUucGAAucAAuccAAcAUU 1491 R-008247428-000C1380   20 CAGAUCCAAGUCAACGUCU B cAGAuccAAGucAAcGucuTT B 1492R-008247428-000C 1380   20 CAGAUCCAAGUCAACGUCU AGAcGuuGAcuuGGAucuGUU1493 R-008247542-000V 1602   21 AGGCUCUUGUGCGUACUGUB AGGcucuuGuGcGuAcuGuTT B 1494 R-008247542-000V 1602   21AGGCUCUUGUGCGUACUGU ACAGuAcGcAcAAGAGccuUU 1495 R-008247539-000N 1612  22 GCGUACUGUCCUUCGGGCU B GcGuAcuGuccuucGGGcuTT B 1496 R-008247539-000N1612   22 GCGUACUGUCCUUCGGGCU AGCccGAAGGAcAGuAcGcUU 1497R-008247425-000B  626   23 ACUAAUGUCCAGCGUUUGG B AcuAAuGuccAGcGuuuGGTT B1498 R-008247425-000B  626   23 ACUAAUGUCCAGCGUUUGGCCAAAcGcuGGAcAuuAGuUU 1499 R-008247536-000M 2000   24CACAUCCUAGCUCGGGAUG B cAcAuccuAGcucGGGAuGTT B 1500 R-008247536-000M 2000  24 CACAUCCUAGCUCGGGAUG CAUcccGAGcuAGGAuGuGUU 1501 R-008247422-000A2665   25 GUUGCUGAGAGGGCUCGAG B GuuGcuGAGAGGGcucGAGTT B 1502R-008247422-000A 2665   25 GUUGCUGAGAGGGCUCGAG CUCGAGcccucucAGcAAcUU1503 R-008247533-000L 1676   26 CAUCUGACCAGCCGACACCGGUGucGGcuGGucAGAuGUU 1505 R-008247533-000L 1676   26CAUCUGACCAGCCGACACC B cAucuGAccAGccGAcAccTT B 1504 R-008247530-000K 1611  27 UGCGUACUGUCCUUCGGGC B uGcGuAcuGuccuucGGGcTT B 1506 R-008247530-000K1611   27 UGCGUACUGUCCUUCGGGC GCCcGAAGGAcAGuAcGcAUU 1507R-008247419-000U 2269   28 ACAAGAUUACAAGAAACGG B AcAAGAuuAcAAGAAAcGGTT B1508 R-008247419-000U 2269   28 ACAAGAUUACAAGAAACGGCCGuuucuuGuAAucuuGuUU 1509 R-008247527-000D  674   29GUUGUAAACUUGAUUAACU B GuuGuAAAcuuGAuuAAcuTT B 1510 R-008247527-000D  674  29 GUUGUAAACUUGAUUAACU AGUuAAucAAGuuuAcAAcUU 1511 R-008247602-000K 678   30 UAAACUUGAUUAACUAUCA B uAAAcuuGAuuAAcuAucATT B 1512R-008247602-000K  678   30 UAAACUUGAUUAACUAUCA UGAuAGuuAAucAAGuuuAUU1513 R-008247599-000T 1245   31 AUAUAAUGAGGACCUAUACB AuAuAAuGAGGAccuAuAcTT B 1514 R-008247599-000T 1245   31AUAUAAUGAGGACCUAUAC GUAuAGGuccucAuuAuAuUU 1515 R-008247596-000S  679  32 AAACUUGAUUAACUAUCAA B AAAcuuGAuuAAcuAucAATT B 1516 R-008247596-000S 679   32 AAACUUGAUUAACUAUCAA UUGAuAGuuAAucAAGuuuUU 1517R-008247593-000R 1970   33 GAAAUAGUUGAAGGUUGUA B GAAAuAGuuGAAGGuuGuATT B1518 R-008247593-000R 1970   33 GAAAUAGUUGAAGGUUGUAUACAAccuucAAcuAuuucUU 1519 R-008247590-000P 1247   34AUAAUGAGGACCUAUACUU AAGuAuAGGuccucAuuAuUU 1521 R-008247590-000P 1247  34 AUAAUGAGGACCUAUACUU B AuAAuGAGGAccuAuAcuuTT B 1520 R-008247464-000M1140   35 UUAAAUUCUUGGCUAUUAC B uuAAAuucuuGGcuAuuAcTT B 1522R-008247464-000M 1140   35 UUAAAUUCUUGGCUAUUAC GUAAuAGccAAGAAuuuAAUU1523 R-008247587-000H  676   36 UGUAAACUGGAUUAACUAUB uGuAAAcuuGAuuAAcuAuTT B 1524 R-008247587-000H  676   36UGUAAACUGGAUUAACUAU AUAGuuAAucAAGuuuAcAUU 1525 R-008247461-000L  677  37 GUAAACUUGAUUAACUAUC GAUAGuuAAucAAGuuuAcUU 1527 R-008247461-000L 677   37 GUAAACUUGAUUAACUAUC B GuAAAcuuGAuuAAcuAucTT B 1526R-008247458-000E  675   38 UUGUAAACUUGAUUAACUA B uuGuAAAcuuGAuuAAcuATT B1528 R-008247458-000E  675   38 UUGUAAACUUGAUUAACUAUAGuuAAucAAGuuuAcAAUU 1529 R-008247584-000G 1235   39GCUUUAGUAAAUAUAAUGA B GcuuuAGuAAAuAuAAuGATT B 1530 R-008247584-000G 1235  39 GCUUUAGUAAAUAUAAUGA UCAuuAuAuuuAcuAAAGcUU 1531 R-008247581-000F2488   40 UGGCCACCACCCUGGUGCU B uGGccAccAcccuGGuGcuTT B 1532R-008247581-000F 2488   40 UGGCCACCACCCUGGUGCU AGCAccAGGGuGGuGGccAUU1533 R-008247578-000Z 1236   41 CUUUAGUAAAUAUAAUGAGB cuuuAGuAAAuAuAAuGAGTT B 1534 R-008247578-000Z 1236   41CUUUAGUAAAUAUAAUGAG CUCAuuAuAuuuAcuAAAGUU 1535 R-008247455-000D 1237  42 UUUAGUAAAUAUAAUGAGG CCUcAuuAuAuuuAcuAAAUU 1537 R-008247455-000D1237   42 UUUAGUAAAUAUAAUGAGG B uuuAGuAAAuAuAAuGAGGTT B 1536R-008042883-001A 2555   43 GUAAAUCGUCCUUUAGGUA B GuAAAucGuccuuuAGGuATT B1538 R-008042883-001A 2555   43 GUAAAUCGUCCUUUAGGUAUACcuAAAGGAcGAuuuAcUU 1539 R-008308583-000P 1545   44ACCUCACUUGCAAUAAUUA B AccucAcuuGcAAuAAuuATT B 1540 R-008308583-000P 1545  44 ACCUCACUUGCAAUAAUUA UAAuuAuuGcAAGuGAGGuUU 1541 R-008308520-000J2050   45 UACCAUUCCAUUGUUUGUG B uAccAuuccAuuGuuuGuGTT B 1542R-008308520-000J 2050   45 UACCAUUCCAUUGUUUGUG CACAAAcAAuGGAAuGGuAUU1543 R-008308622-000L 2097   46 UCCAAAGAGUAGCUGCAGGCCUGcAGcuAcucuuuGGAUU 1545 R-008308622-000L 2097   46UCCAAAGAGUAGCUGCAGG B uccAAAGAGuAGcuGcAGGTT B 1544 R-008308652-000N 2510  47 UAUCCAGUUGAUGGGCUGC B uAuccAGuuGAuGGGcuGcTT B 1546 R-008308652-000N2510   47 UAUCCAGUUGAUGGGCUGC GCAGcccAucAAcuGGAuAUU 1547R-008308718-000F  871   48 CAUGCAGAAUACAAAUGAU AUCAuuuGuAuucuGcAuGUU1549 R-008308718-000F  871   48 CAUGCAGAAUACAAAUGAUB cAuGcAGAAuAcAAAuGAuTT B 1548 R-008308694-000A 2098   49CCAAAGAGUAGCUGCAGGG CCCuGcAGcuAcucuuuGGUU 1551 R-008308694-000A 2098  49 CCAAAGAGUAGCUGCAGGG B ccAAAGAGuAGcuGcAGGGTT B 1550 R-008308517-000C1767   50 CACCAUCCCACUGGCCUCU B cAccAucccAcuGGccucuTT B 1552R-008308517-000C 1767   50 CACCAUCCCACUGGCCUCU AGAGGccAGuGGGAuGGuGUU1553 R-008308619-000E  869   51 ACCAUGCAGAAUACAAAUGB AccAuGcAGAAuAcAAAuGTT B 1554 R-008308619-000E  869   51ACCAUGCAGAAUACAAAUG CAUuuGuAuucuGcAuGGuUU 1555 R-008308514-000B 1641  52 AAGACAUCACUGAGCCUGC B AAGAcAucAcuGAGccuGcTT B 1556 R-008308514-000B1641   52 AAGACAUCACUGAGCCUGC GCAGGcucAGuGAuGucuuUU 1557R-008308616-000D 2582   53 AAUCAGCUGGCCUGGUUUG B AAucAGcuGGccuGGuuuGTT B1558 R-008308616-000D 2582   53 AAUCAGCUGGCCUGGUUUGCAAAccAGGccAGcuGAuuUU 1559 R-008308580-000N 1544   54AACCUCACUUGCAAUAAUU AAUuAuuGcAAGuGAGGuu 1561 R-008308580-000N 1544   54AACCUCACUUGCAAUAAUU B AAccucAcuuGcAAuAAuuTT B 1560 R-008308736-000Y 2550  55 ACCUCAUGGAUGGGCUGCC B AccucAuGGAuGGGcuGccTT B 1562 R-008308736-000Y2550   55 ACCUCAUGGAUGGGCUGCC GGCAGcccAuccAuGAGGuUU 1563R-008308613-000C 2051   56 ACCAUUCCAUUGUUUGUGC GCAcAAAcAAuGGAAuGGuUU1565 R-008308613-000C 2051   56 ACCAUUCCAUUGUUUGUGCB AccAuuccAuuGuuuGuGcTT B 1564 R-008308577-000G  870   57CCAUGCAGAAUACAAAUGA UCAuuuGuAuucuGcAuGGUU 1567 R-008308577-000G  870  57 CCAUGCAGAAUACAAAUGA B ccAuGcAGAAuAcAAAuGATT B 1566 R-008308691-000Z1670   58 CUUCGUCAUCUGACCAGCC B cuucGucAucuGAccAGccTT B 1568R-008308691-000Z 1670   58 CUUCGUCAUCUGACCAGCC GGCuGGucAGAuGAcGAAGUU1569 R-008308649-000G 2122   59 CUGUGAACUUGCUCAGGACB cuGuGAAcuuGcucAGGAcTT B 1570 R-008308649-000G 2122   59CUGUGAACUUGCUCAGGAC GUCcuGAGcAAGuucAcAGUU 1571 R-008308553-000M 1642  60 AGACAUCACUGAGCCUGCC B AGAcAucAcuGAGccuGccTT B 1572 R-008308553-000M1642   60 AGACAUCACUGAGCCUGCC GGCAGGcucAGuGAuGucuUU 1573R-008308574-000F 2324   61 GAGCCAAUGGCUUGGAAUG B GAGccAAuGGcuuGGAAuGTT B1574 R-008308574-000F 2324   61 GAGCCAAUGGCUUGGAAUGCAUuccAAGccAuuGGcucUU 1575 R-008308688-000T 1649   62ACUGAGCCUGCCAUCUGUG B AcuGAGccuGccAucuGuGTT B 1576 R-008308688-000T 1649  62 ACUGAGCCUGCCAUCUGUG CACAGAuGGcAGGcucAGuUU 1577 R-008308550-000L2159   63 AUUGAAGCUGAGGGAGCCA B AuuGAAGcuGAGGGAGccATT B 1578R-008308550-000L 2159   63 AUUGAAGCUGAGGGAGCCA UGGcucccucAGcuucAAuUU1579 R-008308511-000A  785   64 GUUAUGGUCCAUCAGCUUUB GuuAuGGuccAucAGcuuuTT B 1580 R-008308511-000A  785   64GUUAUGGUCCAUCAGCUUU AAAGcuGAuGGAccAuAAcUU 1581 R-008308685-000S 1511  65 AAUGUGGUCACCUGUGCAG B AAuGuGGucAccuGuGcAGTT B 1582 R-008308685-000S1511   65 AAUGUGGUCACCUGUGCAG CUGcAcAGGuGAccAcAuuUU 1583R-008308610-000B 2586   66 AGCUGGCCUGGUUUGAUAC B AGcuGGccuGGuuuGAuAcTT B1584 R-008308610-000B 2586   66 AGCUGGCCUGGUUUGAUACGUAucAAAccAGGccAGcuUU 1585 R-008308571-000E  642   67UGGCUGAACCAUCACAGAU B uGGcuGAAccAucAcAGAuTT B 1586 R-008308571-000E  642  67 UGGCUGAACCAUCACAGAU AUCuGuGAuGGuucAGccAUU 1587 R-008308715-000E1763   68 CACCCACCAUCCCACUGGC B cAcccAccAucccAcuGGcTT B 1588R-008308715-000E 1763   68 CACCCACCAUCCCACUGGC GCCAGuGGGAuGGuGGGuGUU1589 R-008308682-000R 2328   69 CAAUGGCUUGGAAUGAGACGUCucAuuccAAGccAuuGUU 1591 R-008308682-000R 2328   69CAAUGGCUUGGAAUGAGAC B cAAuGGcuuGGAAuGAGAcTT B 1590 R-008308646-000F 1280  70 UGGACCACAAGCAGAGUGC GCAcucuGcuuGuGGuccAUU 1593 R-008308646-000F1280   70 UGGACCACAAGCAGAGUGC B uGGAccAcAAGcAGAGuGcTT B 1592R-008308508-000U 2052   71 CCAUUCCAUUGUUUGUGCA B ccAuuccAuuGuuuGuGcATT B1594 R-008308508-000U 2052   71 CCAUUCCAUUGUUUGUGCAUGCAcAAAcAAuGGAAuGGUU 1595 R-008308547-000E 2546   72CAGGACCUCAUGGAUGGGC GCCcAuccAuGAGGuccuGUU 1597 R-008308547-000E 2546  72 CAGGACCUCAUGGAUGGGC B cAGGAccucAuGGAuGGGcTT B 1596 R-008308505-000T2124   73 GUGAACUUGCUCAGGACAA UUGuccuGAGcAAGuucAcUU 1599R-008308505-000T 2124   73 GUGAACUUGCUCAGGACAA B GuGAAcuuGcucAGGAcAATT B1598 R-008308733-000X 2545   74 CCAGGACCUCAUGGAUGGGCCCAuccAuGAGGuccuGGUU 1601 R-008308733-000X 2545   74CCAGGACCUCAUGGAUGGG B ccAGGAccucAuGGAuGGGTT B 1600 R-008308544-000D  643  75 GGCUGAACCAUCACAGAUG B GGcuGAAccAucAcAGAuGTT B 1602 R-008308544-000D 643   75 GGCUGAACCAUCACAGAUG CAUcuGuGAuGGuucAGccUU 1603R-008308643-000E 2501   76 GGUGCUGACUAUCCAGUUG B GGuGcuGAcuAuccAGuuGTT B1604 R-008308643-000E 2501   76 GGUGCUGACUAUCCAGUUGCAAcuGGAuAGucAGcAccUU 1605 R-008308712-000D 2330   77AUGGCUUGGAAUGAGACUG B AuGGcuuGGAAuGAGAcuGTT B 1606 R-008308712-000D 2330  77 AUGGCUUGGAAUGAGACUG CAGucucAuuccAAGccAuUU 1607 R-008308568-000Y1638   78 GGGAAGACAUCACUGAGCC GGCucAGuGAuGucuucccUU 1609R-008308568-000Y 1638   78 GGGAAGACAUCACUGAGCC B GGGAAGAcAucAcuGAGccTT B1608 R-008308640-000D 1630   79 IGGUGACAGGGAAGACAUCB uGGuGAcAGGGAAGAcAucTT B 1610 R-008308640-000D 1630   79UGGUGACAGGGAAGACAUC GAUGucuucccuGucAccAUU 1611 R-008308541-000C  616  80 UGCUCAUCCCACUAAUGUC GACAuuAGuGGGAuGAGcAUU 1613 R-008308541-000C 616   80 UGCUCAUCCCACUAAUGUC B uGcucAucccAcuAAuGucTT B 1612R-008308679-000J 2509   81 CUAUCCAGUUGAUGGGCUG B cuAuccAGuuGAuGGGcuGTT B1614 R-008308679-000J 2509   81 CUAUCCAGUUGAUGGGCUGCAGcccAucAAcuGGAuAGUU 1615 R-008308565-000X 2548   82GGACCUCAUGGAUGGGCUG B GGAccucAuGGAuGGGcuGTT B 1616 R-008308565-000X 2548  82 GGACCUCAUGGAUGGGCUG CAGcccAuccAuGAGGuccUU 1617 R-008308538-000W1773   83 CCCACUGGCCUCUGAUAAA UUUAucAGAGGccAGuGGGUU 1619R-008308538-000W 1773   83 CCCACUGGCCUCUGAUAAA B cccAcuGGccucuGAuAAATT B1618 R-008308535-000V 2247   84 UCCGAAUGUCUGAGGACAAUUGuccucAGAcAuucGGAUU 1621 R-008308535-000V 2247   84UCCGAAUGUCUGAGGACAA B uccGAAuGucuGAGGAcAATT B 1620 R-008308637-000X 2331  85 UGGCUUGGAAUGAGACUGC B uGGcuuGGAAuGAGAcuGcTT B 1622 R-008308637-000X2331   85 UGGCUUGGAAUGAGACUGC GCAGucucAuuccAAGccAUU 1623R-008309111-000F 1498   86 UUCAGAUGAUAUAAAUGUG CACAuuuAuAucAucuGAAUU1625 R-008309111-000F 1498   86 UUCAGAUGAUAUAAAUGUGB uucAGAuGAuAuAAAuGuGTT B 1624 R-008309108-000Z 2267   87CCACAAGAUUACAAGAAAC B ccAcAAGAuuAcAAGAAAcTT B 1626 R-008309108-000Z 2267  87 CCACAAGAUUACAAGAAAC GUUucuuGuAAucuuGuGGUU 1627 R-008308994-000E1547   88 CUCACUUGCAAUAAUUAUA UAUAAuuAuuGcAAGuGAGUU 1629R-008308994-000E 1547   88 CUCACUUGCAAUAAUUAUA B cucAcuuGcAAuAAuuAuATT B1628 R-008309075-000K 1549   89 CACUUGCAAUAAUUAUAAGCUUAuAAuuAuuGcAAGuGUU 1631 R-008309075-000K 1549   89CACUUGCAAUAAUUAUAAG B cAcuuGcAAuAAuuAuAAGTT B 1630 R-008309045-000H  867  90 GUACCAUGCAGAAUACAAA UUUGuAuucuGcAuGGuAcUU 1633 R-008309045-000H 867   90 GUACCAUGCAGAAUACAAA B GuAccAuGcAGAAuAcAAATT B 1632R-008309072-000J 1390   91 UCAACGUCUUGUUCAGAAC B ucAAcGucuuGuucAGAAcTT B1634 R-008309072-000J 1390   91 UCAACGUCUUGUUCAGAACGUUcuGAAcAAGAcGuuGAUU 1635 R-008309027-000R  593   92AUCCCAUCUACACAGUUUG CAAAcuGuGuAGAuGGGAuUU 1637 R-008309027-000R  593  92 AUCCCAUCUACACAGUUUG B AucccAucuAcAcAGuuuGTT B 1636 R-008309009-000Y 274   93 UACUCAAGCUGAUUUGAUG CAUcAAAucAGcuuGAGuAUU 1639R-008309009-000Y  274   93 UACUCAAGCUGAUUUGAUG B uAcucAAGcuGAuuuGAuGTT B1638 R-008309024-000P  759   94 ACCAGGUGGUGGUUAAUAAB AccAGGuGGuGGuuAAuAATT B 1640 R-008309024-000P  759   94ACCAGGUGGUGGUUAAUAA UUAuuAAccAccAccuGGuUU 1641 R-008309093-000C 1439  95 GCUGCAACUAAACAGGAAG B GcuGcAAcuAAAcAGGAAGTT B 1642 R-008309093-000C1439   95 GCUGCAACUAAACAGGAAG CUUccuGuuuAGuuGcAGcUU 1643R-008309069-000C 1801   96 UGGAUUGAUUCGAAAUCUU B uGGAuuGAuucGAAAucuuTT B1644 R-008309069-000C 1801   96 UGGAUUGAUUCGAAAUCUUAAGAuuucGAAucAAuccAUU 1645 R-008309021-000N 1500   97CAGAUGAUAUAAAUGUGGU B cAGAuGAuAuAAAuGuGGuTT B 1646 R-008309021-000N 1500  97 CAGAUGAUAUAAAUGUGGU ACCAcAuuuAuAucAucuGUU 1647 R-008309066-000B 848   98 AUGGUGUCUGCUAUUGUAC B AuGGuGucuGcuAuuGuAcTT B 1648R-008309066-000B  848   98 AUGGUGUCUGCUAUUGUAC GUAcAAuAGcAGAcAccAuUU1649 R-008309105-000Y 2268   99 CACAAGAUUACAAGAAACGCGUuucuuGuAAucuuGuGUU 1651 R-008309105-000Y 2268   99CACAAGAUUACAAGAAACG B cAcAAGAuuAcAAGAAAcGTT B 1650 R-008309042-000G  882 100 CAAAUGAUGUAGAAACAGC GCUGuuucuAcAucAuuuGUU 1653 R-008309042-000G 882  100 CAAAUGAUGUAGAAACAGC B cAAAuGAuGuAGAAAcAGcTT B 1652R-008309063-000A 2266  101 GCCACAAGAUUACAAGAAA UUUcuuGuAAucuuGuGGcUU1655 R-008309063-000A 2266  101 GCCACAAGAUUACAAGAAAB GccAcAAGAuuAcAAGAAATT B 1654 R-008309018-000G  880  102UACAAAUGAUGUAGAAACA B uAcAAAuGAuGuAGAAAcATT B 1656 R-008309018-000G  880 102 UACAAAUGAUGUAGANACA UGUuucuAcAucAuuuGuAUU 1657 R-008309039-000A1810  103 UCGAAAUCUUGCCCUUUGU ACAAAGGGcAAGAuuucGAUU 1659R-008309039-000A 1810  103 UCGAAAUCUUGCCCUUUGU B ucGAAAucuuGcccuuuGuTT B1658 R-008309015-000F  685  104 GAUUAACUAUCAAGAUGAUB GAuuAAcuAucAAGAuGAuTT B 1660 R-008309015-000F  685  104GAUUAACUAUCAAGAUGAU AUCAucuuGAuAGuuAAucUU 1661 R-008309060-000Z 1007 105 CCAGUGGAUUCUGUGUUGU ACAAcAcAGAAuccAcuGGUU 1663 R-008309060-000Z1007  105 CCAGUGGAUUCUGUGUUGU B ccAGuGGAuucuGuGuuGuTT B 1662R-008309057-000T 1789  106 AAAGGCUACUGUUGGAUUG B AAAGGcuAcuGuuGGAuuGTT B1664 R-008309057-000T 1789  106 AAAGGCUACUGUUGGAUUGCAAuccAAcAGuAGccuuuUU 1665 R-008309054-000S  499  107ACAAGUAGCUGAUAUUGAU AUCAAuAucAGcuAcuuGuUU 1667 R-008309054-000S  499 107 ACAAGUAGCUGAUAUUGAU B AcAAGuAGcuGAuAuuGAuTT B 1666 R-008309090-000B2470  108 GAUGGAACAUGAGAUGGGU B GAuGGAAcAuGAGAuGGGuTT B 1668R-008309090-000B 2470  108 GAUGGAACAUGAGAUGGGU ACCcAucucAuGuuccAucUU1669 R-008309051-000R  694  109 UCAAGAUGAUGCAGAACUUB ucAAGAuGAuGcAGAAcuuTT B 1670 R-008309051-000R  694  109UCAAGAUGAUGCAGAACUU AAGuucuGcAucAucuuGAUU 1671 R-008309036-000Z  278 110 CAAGCUGAUUUGAUGGAGU ACUccAucAAAucAGcuuGUU 1673 R-008309036-000Z 278  110 CAAGCUGAUUUGAUGGAGU B cAAGcuGAuuuGAuGGAGuTT B 1672R-008309102-000X 1415  111 UGGACUCUCAGGAAUCUUU B uGGAcucucAGGAAucuuuTT B1674 R-008309102-000X 1415  111 UGGACUCUCAGGAAUCUUUAAAGAuuccuGAGAGuccAUU 1675 R-008308991-000D 2046  112UAAAUACCAUUCCAUUGUU AACAAuGGAAuGGuAuuuAUU 1677 R-008308991-000D 2046 112 UAAAUACCAUUCCAUUGUU B uAAAuAccAuuccAuuGuuTT B 1676 R-008309006-000X1057  113 AUUACAUCAAGAAGGAGCU AGCuccuucuuGAuGuAAuUU 1679R-008309006-000X 1057  113 AUUACAUCAAGAAGGAGCU B AuuAcAucAAGAAGGAGcuTT B1678 R-008309087-000V 1422  114 UCAGGAAUCUUUCAGAUGCB ucAGGAAucuuucAGAuGcTT B 1680 R-008309087-000V 1422  114UCAGGAAUCUUUCAGAUGC GCAucuGAAAGAuuccuGAUU 1681 R-008309084-000U  684 115 UGAUUAACUAUCAAGAUGA UCAucuuGAuAGuuAAucAUU 1683 R-008309084-000U 684  115 UGAUUAACUAUCAAGAUGA B uGAuuAAcuAucAAGAuGATT B 1682R-008309099-000E 2197  116 ACUUCACUCUAGGAAUGAA B AcuucAcucuAGGAAuGAATT B1684 R-008309099-000E 2197  116 ACUUCACUCUAGGAAUGAAUUCAuuccuAGAGuGAAGuUU 1685 R-008309003-000W  666  117AACAUGCAGUUGUAAACUU B AAcAuGcAGuuGuAAAcuuTT B 1686 R-008309003-000W  666 117 AACAUGCAGUUGUAAACUU AAGuuuAcAAcuGcAuGuuUU 1687 R-008309012-000E 279  118 AAGCUGAUUUGAUGGAGUU AACuccAucAAAucAGcuuUU 1689R-008309012-000E  279  118 AAGCUGAUUUGAUGGAGUU B AAGcuGAuuuGAuGGAGuuTT B1688 R-008309033-000Y 1492  119 UCUGGGUUCAGAUGAUAUAB ucuGGGuucAGAuGAuAuATT B 1690 R-008309033-000Y 1492  119UCUGGGUUCAGAUGAUAUA UAUAucAucuGAAcccAGAUU 1691 R-008309081-000T 2195 120 UUACUUCACUCUAGGAAUG CAUuccuAGAGuGAAGuAAUU 1693 R-008309081-000T2195  120 UUACUUCACUCUAGGAAUG B uuAcuucAcucuAGGAAuGTT B 1692R-008309048-000J 1424  121 AGGAAUCUUUCAGAUGCUG B AGGAAucuuucAGAuGcuGTT B1694 R-008309048-000J 1424  121 AGGAAUCUUUCAGAUGCUGCAGcAucuGAAAGAuuccuUU 1695 R-008309000-000V  661  122GCUGAAACAUGCAGUUGUA UACAAcuGcAuGuuucAGcUU 1697 R-008309000-000V  661 122 GCUGAAACAUGCAGUUGUA B GcuGAAAcAuGcAGuuGuATT B 1696 R-008309078-000L1882  123 GUUGCUUGUUCGUGCACAU B GuuGcuuGuucGuGcAcAuTT B 1698R-008309078-000L 1882  123 GUUGCUUGUUCGUGCACAU AUGuGcAcGAAcAAGcAAcUU1699 R-008309096-000D 1966  124 GGAAGAAAUAGUUGAAGGUB GGAAGAAAuAGuuGAAGGuTT B 1700 R-008309096-000D 1966  124GGAAGAAAUAGUUGAAGGU ACCuucAAcuAuuucuuccUU 1701 R-008308997-000F 2259 125 AGGACAAGCCACAAGAUUA B AGGAcAAGccAcAAGAuuATT B 1702 R-008308997-000F2259  125 AGGACAAGCCACAAGAUUA UAAucuuGuGGcuuGuccuUU 1703R-008309030-000X  832  126 CAUGCGUUCUCCUCAGAUG B cAuGcGuucuccucAGAuGTT B1704 R-008309030-000X  832  126 CAUGCGUUCUCCUCAGAUGCAUcuGAGGAGAAcGcAuGUU 1705 R-008042849-001H 2346  127GAUGAUCCCAGCUACCGUU AACGGuAGcuGGGAucAucUU 1707 R-008042849-001H 2346 127 GAUGAUCCCAGCUACCGUU B GAuGAucccAGcuAccGuuTT B 1706 R-008308601-000T1653  128 AGCCUGCCAUCUGDGCUCU B AGccuGccAucuGuGcucuTT B 1708R-008308601-000T 1653  128 AGCCUGCCAUCUGDGCUCU AGAGcAcAGAuGGcAGGcuUU1709 R-008308562-000W 2389  129 UGGAUAUCGCCAGGAUGAUB uGGAuAucGccAGGAuGAuTT B 1710 R-008308562-000W 2389  129UGGAUAUCGCCAGGAUGAU AUCAuccuGGcGAuAuccAUU 1711 R-008308709-000X 1669 130 UCUUCGUCAUCUGACCAGC B ucuucGucAucuGAccAGcTT B 1712 R-008308709-000X1669  130 UCUUCGUCAUCUGACCAGC GCUGGucAGAuGAcGAAGAUU 1713R-008308634-000W 2123  131 UGUGAACUUGCUCAGGACA B uGuGAAcuuGcucAGGAcATT B1714 R-008308634-000W 2123  131 UGUGAACUUGCUCAGGACAUGUccuGAGcAAGuucAcAUU 1715 R-008308667-000Z 1521  132CCUGUGCAGCUGGAAUUCU B ccuGuGcAGcuGGAAuucuTT B 1716 R-008308667-000Z 1521 132 CCUGUGCAGCUGGAAUUCU AGAAuuccAGcuGcAcAGGUU 1717 R-008308706-000W2125  133 UGAACUUGCUCAGGACAAG CUUGuccuGAGcAAGuucAUU 1719R-008308706-000W 2125  133 UGAACUUGCUCAGGACAAG B uGAAcuuGcucAGGAcAAGTT B1718 R-008308724-000N 2503  134 UGCUGACUAUCCAGUUGAUB uGcuGAcuAuccAGuuGAuTT B 1720 R-008308724-000N 2503  134UGCUGACUAUCCAGUUGAU AUCAAcuGGAuAGucAGcAUU 1721 R-008308703-000V 1502 135 GAUGAUAUAAAUGUGGUCA UGAccAcAuuuAuAucAucUU 1723 R-008308703-000V1502  135 GAUGAUAUAAAUGUGGUCA B GAuGAuAuAAAuGuGGucATT B 1722R-008308496-000Y 2502  136 GUGCUGACUAUCCAGUUGA UCAAcuGGAuAGucAGcAcUU1725 R-008308496-000Y 2502  136 GAUGAUAUAAAUGUGGUCAB GuGcuGAcuAuccAGuuGATT B 1724 R-008308625-000M 2506  137UGACUAUCCAGUUGAUGGG CCCAucAAcuGGAuAGucAUU 1727 R-008308625-000M 2506 137 UGACUAUCCAGUUGAUGGG B uGAcuAuccAGuuGAuGGGTT B 1726 R-008308589-000S2127  138 AACUUGCUCAGGACAAGGA B AAcuuGcucAGGAcAAGGATT B 1728R-008308589-000S 2127  138 AACUUGCUCAGGACAAGGA UCCuuGuccuGAGcAAGuuUU1729 R-008308586-000R 2505  139 CUGACUAUCCAGUUGAUGGB cuGAcuAuccAGuuGAuGGTT B 1730 R-008308586-000R 2505  139CUGACUAUCCAGUUGAUGG CCAucAAcuGGAuAGucAGUU 1731 R-008308493-000X  617 140 GCUCAUCCCACUAAUGUCC B GcucAucccAcuAAuGuccTT B 1732 R-008308493-000X 617  140 CCUCAUCCCACUAAUGUCC GGAcAuuAGuGGGAuGAGcUU 1733R-008308697-000B 2504  141 GCUGACUAUCCAGUUGAUG B GcuGAcuAuccAGuuGAuGTT B1734 R-008308697-000B 2504  141 GCUGACUAUCCAGUUGAUGCAUcAAcuGGAuAGucAGcUU 1735 R-008308661-000X 1503  142AUGAUAUAAAUGUGGUCAC GUGAccAcAuuuAuAucAuUU 1737 R-008308661-000X 1503 142 AUGAUAUAAAUGUGGUCAC B AuGAuAuAAAuGuGGucAcTT B 1736 R-008308526-000L 618  143 CUCAUCCCACUAAUGUCCA UGGAcAuuAGuGGGAuGAGUU 1739R-008308526-000L  618  143 CUCAUCCCACUAAUGUCCA B cucAucccAcuAAuGuccATT B1738 R-008308556-000N 2074  144 GCUUUAUUCUCCCAUUGAAB GcuuuAuucucccAuuGAATT B 1740 R-008308556-000N 2074  144GCUUUAUUCUCCCAUUGAA UUCAAuGGGAGAAuAAAGcUU 1741 R-008308523-000K 2499 145 CUGGUGCUGACUAUCCAGU B cuGGuGcuGAcuAuccAGuTT B 1742 R-008308523-000K2499  145 CUGGUGCUGACUAUCCAGU ACUGGAuAGucAGcAccAGUU 1743R-008362860-000A 1406  146 AACUGUCUUUGGACUCUCA B AAcuGucuuuGGAcucucATT B1744 R-008362860-000A 1406  146 AACUGUCUUUGGACUCUCAUGAGAGuccAAAGAcAGuuUU 1745 R-008362809-000Z  582  147AGGGCAUGCAGAUCCCAUC GAUGGGAucuGcAuGcccuUU 1747 R-008362809-000Z  582 147 AGGGCAUGCAGAUCCCAUC B AGGGcAuGcAGAucccAucTT B 1746 R-008362908-000A1505  148 GAUAUAAAUGUGGUCACCU B GAuAuAAAuGuGGucAccuTT B 1748R-008362908-000A 1505  148 GAUAUAAAUGUGGUCACCU AGGuGAccAcAuuuAuAucUU1749 R-008362713-000E 1432  449 UUCAGAUGCUGCAACUAAAUUUAGuuGcAGcAucuGAAUU 1751 R-008362713-000E 1432  149UUCAGAUGCUGCAACUAAA B uucAGAuGcuGcAAcuAAATT B 1750 R-008363073-000K 1968 150 AAGAAAUAGUUGAAGGUUG B AAGAAAuAGuuGAAGGuuGTT B 1752 R-008363073-000K1968  150 AAGAAAUAGUUGAAGGUUG CAAccuucAAcuAuuucuuUU 1753R-008362947-000L 2398  151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuTT B1754 R-008362947-000L 2398  151 CCAGGAUGAUCCUAGCUAUAUAGcuAGGAucAuccuGGUU 1755 R-008363070-000J  954  152UGGCCAUCUUUAAGUCUUG CCAGAcuuAAAGAuGGccAUU 1757 R-008363070-000J  954 152 UGGCCAUCUUUAAGUCUGG B uGGccAucuuuAAGucuGGTT B 1756 R-008362857-000U 505  153 AGCUGAUAUUGAUGGACAG B AGcuGAuAuuGAuGGAcAGTT B 1758R-008362857-000U  505  153 AGCUGAUAUUGAUGGACAG CUGuccAucAAuAucAGcuUU1759 R-008363067-000C 2011  154 UCGGGAUGUUCACAACCGAB ucGGGAuGuucAcAAccGATT B 1760 R-008363067-000C 2011  154UCGGGAUGUUCACAACCGA UCGGuuGuGAAcAucccGAUU 1761 R-008362944-000K 1339 155 UGUAGAAGCUGGUGGAAUG B uGuAGAAGcuGGuGGAAuGTT B 1762 R-008362944-000K1339  155 UGUAGAAGCUGGUGGAAUG CAUuccAccAGcuucuAcAUU 1763R-008362761-000Z 1242  156 UAAAUAUAAUGAGGACCUA B uAAAuAuAAuGAGGAccuATT B1764 R-008362761-000Z 1242  156 UAAAUAUAAUGAGGACCUAUAGGuccucAuuAuAuuuAUU 1765 R-008362758-000T  567  157CUGAGACAUUAGAUGAGGG B cuGAGAcAuuAGAuGAGGGTT B 1766 R-008362758-000T  567 157 CUGAGACAUUAGAUGAGGG CCCucAucuAAuGucucAGUU 1767 R-008363007-000Y1240  158 AGUAAAUAUAAUGAGGACC B AGuAAAuAuAAuGAGGAccTT B 1768R-008363007-000Y 1240  158 AGUAAAUAUAAUGAGGACC GGUccucAuuAuAuuuAcuUU1769 R-008362854-000T  438  159 UGGAUACCUCCCAAGUCCUB uGGAuAccucccAAGuccuTT B 1770 R-008362854-000T  438  159UGGAUACCUCCCAAGUCCU AGGAcuuGGGAGGuAuccAUU 1771 R-008362755-000S 2445 160 AGGAUGCCUUGGGUAUGGA UCCAuAcccAAGGcAuccuUU 1773 R-008362755-000S2445  160 AGGAUGCCUUGGGUAUGGA B AGGAuGccuuGGGuAuGGATT B 1772R-008363064-000B  860  161 AUUGUACGUACCAUGCAGA B AuuGuAcGuAccAuGcAGATT B1774 R-008363064-000B  860  161 AUUGUACGUACCAUGGAGAUCUGcAuGGuAcGuAcAAuUU 1775 R-008362752-000R 1413  162UUUGGACUCUCAGGAAUCU B uuuGGAcucucAGGAAucuTT B 1776 R-008362752-000R 1413 162 UUUGGACUCUCAGGAAUCU AGAuuccuGAGAGuccAAAUU 1777 R-008363061-000A1800  163 UUGGAUUGAUUCGAAAUCU AGAuuucGAAucAAuccAAUU 1779R-008363061-000A 1800  163 UUGGAUUGAUUCGAAAUCU B uuGGAuuGAuucGAAAucuTT B1778 R-008363004-000X 2037  164 UCAGAGGACUNAAUACCAUAUGGuAuuuAGuccucuGAUU 1781 R-008363004-000X 2037  164UCAGAGGACUAAAUACCAU B ucAGAGGAcuAAAuAccAuTT B 1780 R-008362851-000S 2443 165 CCAGGAUGCCUUGGGUAUG B ccAGGAuGccuuGGGuAuGTT B 1782 R-008362851-000S2443  165 CCAGGAUGCCUUGGGUAUG CAUAcccAAGGcAuccuGGUU 1783R-008363001-000W 2471  166 AUGGAACAUGAGAUGGGUG B AuGGAAcAuGAGAuGGGuGTT B1784 R-008363001-000W 2471  166 AUGGAACAUGAGAUGGGUGCACccAucucAuGuuccAuUU 1785 R-008362905-000Z 1792  167GGCUACUGUUGGAUUGAUU B GGcuAcuGuuGGAuuGAuuTT B 1786 R-008362905-000Z 1792 167 GGCUACUGUUGGAUUGAUU AAUcAAuccAAcAGuAGccUU 1787 R-008362902-000Y2547  168 AGGACCUCAUGGAUGGGCU B AGGAccucAuGGAuGGGcuTT B 1788R-008362902-000Y 2547  168 AGGACCUCAUGGAUGGGCU AGCccAuccAuGAGGuccuUU1789 R-008362998-000G 1662  169 UCUGUGCUCUUCGUCAUCUAGAuGAcGAAGAGcAcAGAUU 1791 R-008362998-000G 1662  169UCUGUGCUCUUCGUCAUCU B ucuGuGcucuucGucAucuTT B 1790 R-008362848-000K  288 170 UGAUGGAGUUGGACAUGGC GCCAuGuccAAcuccAucAUU 1793 R-008362848-000K 288  170 UGAUGGAGUUGGACAUGGC B uGAuGGAGuuGGAcAuGGcTT B 1792R-008362710-000D  579  171 AUGAGGGCAUGCAGAUCCC GGGAucuGcAuGcccucAuUU1795 R-008362710-000D  579  171 AUGAGGGCAUGCAGAUCCCB AuGAGGGcAuGcAGAucccTT B 1794 R-008362707-000X 2508  172ACUAUCCAGUUGAUGGGCU AGCccAucAAcuGGAuAGuUU 1797 R-008362707-000X 2508 172 ACUAUCCAGUUGAUGGGCU B AcuauccAGuuGAuGGGcuTT B 1796 R-008362806-000Y 580  173 UGAGGGCAUGCAGAUCCCA B uGAGGGcAuGcAGAucccATT B 1798R-008362806-000Y  580  173 UGAGGGCAUGGAGAUCCCA UGGGAucuGcAuGcccucAUU1799 R-008362803-000X 2388  174 UUGGAUAUCGCCAGGAUGAB uuGGAuAucGccAGGAuGATT B 1800 R-008362803-000X 2388  174UUGGAUAUCGCCAGGAUGA UCAuccuGGcGAuAuccAAUU 1801 R-008362899-000F 2543 175 GCCCAGGACCUCAUGGAUG B GcccAGGAccucAuGGAuGTT B 1802 R-008362899-000F2543  175 GCCCAGGACCUCAUGGAUG CAUccAuGAGGuccuGGGcUU 1803R-008362749-000J  708  176 AACUUGCCACACGUGCAAU B AAcuuGccAcAcGuGcAAuTT B1804 R-008362749-000J  708  176 AACUUGCCACACGUGCAAUAUUGcAcGuGuGGcAAGuuUU 1805 R-008362845-000J  447  177CCCAAGUCCUGUAUGAGUG B cccAAGuccuGuAuGAGuGTT B 1806 R-008362845-000J  447 177 CCCAAGUCCUGUAUGAGUG CACucAuAcAGGAcuuGGGUU 1807 R-008362842-000H 654  178 CACAGAUGCUGAAACAUGC GCAuGuuucAGcAucuGuGUU 1809R-008362842-000H  654  178 CACAGAUGCUGAAACAUGC B cAcAGAuGcuGAAAcAuGcTT B1808 R-008362896-000E  912  179 CUGGGACCUUGCAUAACCUB cuGGGAccuuGcAuAAccuTT B 1810 R-008362896-000E  912  179CUGGGACCUUGCAUAACCU AGGuuAuGcAAGGucccAGUU 1811 R-008363058-000U 1009 180 AGUGGAUUCUGUGUUGUUU AAAcAAcAcAGAAuccAcuUU 1813 R-008363058-000U1009  180 AGUGGAUUCUGUGUUGUUU B AGuGGAuucuGuGuuGuuuTT B 1812R-008362941-000J 1354  181 AAUGCAAGCUUUAGGACUU B AAuGcAAGcuuuAGGAcuuTT B1814 R-008362941-000J 1354  181 AAUGCAAGCUUUAGGACUUAAGuccuAAAGcuuGcAuuUU 1815 R-008362839-000B 1969  182AGAAAUAGUUGAAGGUUGU B AGAAAuAGuuGAAGGuuGuTT B 1816 R-008362839-000B 1969 182 AGAAAUAGUUGAAGGUUGU ACAAccuucAAcuAuuucuUU 1817 R-008363055-000T1959  183 UCCGCAUGGAAGAAAUAGU ACUAuuucuuccAuGcGGAUU 1819R-008363055-000T 1959  183 UCCGCAUGGAAGAAAUAGU B uccGcAuGGAAGAAAuAGuTT B1818 R-008362836-000A  557  184 GCUAUGUUCCCUGAGACAUB GcuAuGuucccuGAGAcAuTT B 1820 R-008362836-000A  557  184GCUAUGUUCCCUGAGACAU AUGucucAGGGAAcAuAGcUU 1821 R-008363052-000S  403 185 UCUGAGUGGUAAAGGCAAU AUUGccuuuAccAcucAGAUU 1823 R-008363052-000S 403  185 UCUGAGUGGUAAAGGCAAU B ucuGAGuGGuAAAGGcAAuTT B 1822R-008363049-000K 1356  186 UGCAAGCUUUAGGACUUCA B uGcAAGcuuuAGGAcuucATT B1824 R-008363049-000K 1356  186 UGCAAGCUUUAGGACUUCAUGAAGuccuAAAGcuuGcAUU 1825 R-008362893-000D  517  187UGGACAGUAUGCAAUGACU B uGGAcAGuAuGcAAuGAcuTT B 1826 R-008362893-000D  517 187 UGGACAGUAUGCAAUGACU AGUcAuuGcAuAcuGuccAUU 1827 R-008362890-000C1238  188 UUAGUAAAUAUAAUGAGGA UCCucAuuAuAuuuAcuAAUU 1829R-008362890-000C 1238  188 UUAGUAAAUAUAAUGAGGA B uuAGuAAAuAuAAuGAGGATT B1828 R-008362995-000F  843  189 CUCAGAUGGUGUCUGCUAUB cucAGAuGGuGucuGcuAuTT B 1830 R-008362995-000F  843  189CUCAGAUGGUGUCUGCUAU AUAGcAGAcAccAucuGAGUU 1831 R-008362992-000E  496 190 AGAACAAGUAGCUGAUAUU B AGAAcAAGuAGcuGAuAuuTT B 1832 R-008362992-000E 496  190 AGAACAAGUAGCUGAUAUU AAUAucAGcuAcuuGuucuUU 1833R-008363046-000J 2387  191 CUUGGAUAUCGCCAGGAUG B cuuGGAuAucGccAGGAuGTT B1834 R-008363046-000J 2387  191 CUUGGAUAUCGCCAGGAUGCAUccuGGcGAuAuccAAGUU 1835 R-008362704-000W 1660  192CAUCUGUGCUCUUCGUCAU AUGAcGAAGAGcAcAGAuGUU 1837 R-008362704-000W 1660 192 CAUCUGUGCUCUUCGUCAU B cAucuGuGcucuucGucAuTT B 1836 R-008362938-000C2497  193 CCCUGGUGCUGACUAUCCA B cccuGGuGcuGAcuAuccATT B 1838R-008362938-000C 2497  193 CCCUGGUGCUGACUAUCCA UGGAuAGucAGcAccAGGGUU1839 R-008363043-000H 1870  194 ACGACUAGUUCAGUUGCUUB AcGAcuAGuucAGuuGcuuTT B 1840 R-008363043-000H 1870  194ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUU 1841 R-008362746-000H 2353 195 UCUUGGACUUGAUAUUGGU B ucuuGGAcuuGAuAuuGGuTT B 1842 R-008362746-000H2353  195 UCUUGGACUUGAUAUUGGU ACCAAuAucAAGuccAAGAUU 1843R-008362743-000G 2401  196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuTT B1844 R-008362743-000G 2401  196 GGAUGAUCCUAGCUAUCGUACGAuAGcuAGGAucAuccUU 1845 R-008362887-000W 1238  188UUAGUAAAUAUAAUGAGGA B UUAGUAAAUAUAAUGAGGATT B 1846 R-008362887-000W 1238 188 UUAGUAAAUAUAAUGAGGA UCCUCAUUAUAUUUACUAAUU 1847 R-008363040-000G2125  133 UGAACUUGCUCAGGACAAG B UGAACUUGCUCAGGACAAGTT B 1848R-008363040-000G 2125  133 UGAACUUGCUCAGGACAAG CUUGUCCUGAGCAAGUUCAUU1849 R-008362935-000B  843  189 CUCAGAUGGUGUCUGCUAUAUAGCAGACACCAUCUGAGUU 1851 R-008362935-000B  843  189CUCAGAUGGUGUCUGCUAU B CUCAGAUGGUGUCUGCUAUTT B 1850 R-008362740-000F  496 190 AGAACAAGUAGCUGAUAUU AAUAUCAGCUACUUGUUCUUU 1853 R-008362740-000F 496  190 AGAACAAGUAGCUGAUAUU B AGAACAAGUAGCUGAUAUUTT B 1852R-008362884-000V 2074  144 GCUUUAUUCUCCCAUUGAA UUCAAUGGGAGAAUAAAGCUU1855 R-008362884-000V 2074  144 GCUUUAUUCUCCCAUUGAAB GCUUUAUUCUCCCAUUGAATT B 1854 R-008362701-000V 2503  134UGCUGACUAUCCAGUUGAU B UGCUGACUAUCCAGUUGAUTT B 1856 R-008362701-000V 2503 134 UGCUGACUAUCCAGUUGAU AUCAACUGGAUAGUCAGCAUU 1857 R-008362698-000C2387  191 CUUGGAUAUCGCCAGGAUG B CUUGGAUAUCGCCAGGAUGTT B 1858R-008362698-000C 2387  191 CUUGGAUAUCGCCAGGAUG CAUCCUGGCGAUAUCCAAGUU1859 R-008362800-000W 1660  192 CAUCUGUGCUCUUCGUCAUAUGACGAAGAGCACAGAUGUU 1861 R-008362800-000W 1660  192CAUCUGUGCUCUUCGUCAU B CAuCUGUGCUCUUCGUCAUTT B 1860 R-008362737-000Z 2497 193 CCCUGGUGCUGACUAUCCA B CCCUGGUGCUGACUAUCCATT B 1862 R-008362737-000Z2497  193 CCCUGGUGCUGACUAUCCA UGGAUAGUCAGCACCAGGGUU 1853R-008363037-000A 1503  142 AUGAUAUAAAUGUGGUCAC B AUGAUAUAAAUGUGGUCACTT B1864 R-008363037-000A 1503  142 AUGAUAUAAAUGUGGUCACGUGACCACAUUUAUAUCAUUU 1855 R-008362734-000Y 2506  137UGACUAUCCAGUUGAUGGG CCCAUCAACUGGAUAGUCAUU 1867 R-008362734-000Y 2506 137 UGACUAUCCAGUUGAUGGG B UGACUAUCCAGUUGAUGGGTT B 1866 R-008362797-000D2052   71 CCAUUCCAUUGUUUGUGCA UGCACAAACAAUGGAAUGGUU 1869R-008362797-000D 2052   71 CCAUUCCAUUGUUUGUGCA B CCAUUCCAUUGUUUGUGCATT B1868 R-008362731-000X 2389  129 UGGAUAUCGCCAGGAUGAUB UGGAUAUCGCCAGGAUGAUTT B 1870 R-008362731-000X 2389  129UGGAUAUCGCCAGGAUGAU AUCAUCCUGGCGAUAUCCAUU 1871 R-008362794-000C 1406 146 AACUGUCUUUGGACUCUCA B AACUGUCUUUGGACUCUCATT B 1872 R-008362794-000C1406  146 AACUGUCUUUGGACUCUCA UGAGAGUCCAAAGACAGUUUU 1873R-008362833-000Z 1796   12 ACUGUUGGAUUGAUUCGAA B ACUGUUGGAUUGAUUCGAATT B1874 R-008362833-000Z 1796   12 ACUGUUGGAUUGAUUCGAAUUCGAAUCAAUCCAACAGUUU 1875 R-008362989-000Y 2505  139CUGACUAUCCAGUUGAUGG B CUGAGUAUCCAGUUGAUGGTT B 1876 R-008362989-000Y 2505 139 CUGACUAUCCAGUUGAUGG CCAUCAACUGGAUAGUCAGUU 1877 R-008362791-000B1797    5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAATT B 1878R-008362791-000B 1797    5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUU1879 R-008362881-000U  643   75 GGCUGAACCAUCACAGAUGB GGCUGAACCAUCACAGAUGTT B 1880 R-008362881-000U  643   75GGCUGAACCAUCACAGAUG CAUCUGUGAUGGUUGAGCCUU 1881 R-008363034-000Z  582 147 AGGGCAUGCAGAUCCCAUC GAUGGGAUCUGCAUGCCCUUU 1883 R-008363034-000Z 582  147 AGGGCAUGCAGAUCCCAUC B AGGGCAUGCAGAUCCCAUCTT B 1882R-008362830-000Y 2502  136 GUGCUGACUAUCCAGUUGA B GUGCUGACUAUCCAGUUGATT B1884 R-008362830-000Y 2502  136 GUGCUGACUAUCCAGUUGAUCAACUGGAUAGUCAGCACUU 1885 R-008362827-000S 1505  148GAUAUAAAUGUGGUCACCU AGGUGACCACAUUUAUAUCUU 1887 R-008362827-000S 1505 148 GAUAUAAAUGUGGUCACCU B GAUAUAAAUGUGGUCACCUTT B 1886 R-008362728-000R1432  149 UUCAGAUGCUGCAACUAAA B UUCAGAUGCUGCAACUAAATT B 1888R-008362728-000R 1432  149 UUCAGAUGCUGCAACUAAA UUUAGUUGCAGCAUCUGAAUU1889 R-008362986-000X 1968  150 AAGAAAUAGUUGAAGGUUGCAACCUUCAACUAUUUCUUUU 1891 R-008362986-000X 1968  150AAGAAAUAGUUGAAGGUUG B AAGAAAUAGUUGAAGGUUGTT B 1890 R-008362878-000M  694 109 UCAAGAUGAUGCAGAACUU B UCAAGAUGAUGCAGAACUUTT B 1892 R-008362878-000M 694  109 UCAAGAUGAUGCAGAACUU AAGUUCUGGAUCAUCUUGAUU 1893R-008362824-000R 2398  151 CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUU1895 R-008362824-000R 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUGAUCCUAGCUAUTT B 1894 R-008362932-000A 2259  125AGGACAAGCCACAAGAUUA UAAUCUUGUGGCUUGUCCUUU 1897 R-008362932-000A 2259 125 AGGACAAGCCACAAGAUUA B AGGACAAGCCACAAGAUUATT B 1896 R-008362788-000V 954  152 UGGCCAUCUUUAAGUCUGG B UGGCCAUCUUUAAGUCUGGTT B 1898R-008362788-000V  954  152 UGGCCAUCUUUAAGUCUGG CCAGACUUAAAGAUGGCCAUU1899 R-008362983-000W 2197  116 ACUUCACUCUAGGAAUGAAB ACUUCACUCUAGGAAUGAATT B 1900 R-008362983-000W 2197  116ACUUCACUCUAGGAAUGAA UUCAUUCCUAGAGUGAAGUUU 1901 R-008362929-000U  505 153 AGCUGAUAUUGAUGGACAG B AGCUGAUAUUGAUGGACAGTT B 1902 R-008362929-000U 505  153 AGCUGAUAUUGAUGGACAG CUGUCCAUCAAUAUCAGCUUU 1903R-008362926-000T 2011  154 UCGGGAUGUUCACAACCGA B UCGGGAUGUUCACAACCGATT B1904 R-008362926-000T 2011  154 UCGGGAUGUUCACAACCGAUCGGUUGUGAACAUCCCGAUU 1905 R-008362923-000S 1339  155UGUAGAAGCUGGUGGAAUG B UGUAGAAGCUGGUGGAAUGTT B 1906 R-008362923-000S 1339 155 UGUAGAAGCUGGUGGAAUG CAUUCCACCAGCUUCUACAUU 1907 R-008362695-000B1242  156 UAAAUAUAAUGAGGACCUA B UAAAUAUAAUGAGGACCUATT B 1908R-008362695-000B 1242  156 UAAAUAUAAUGAGGACCUA UAGGUCCUCALUAUAUUUAUU1909 R-008362692-000A  499  107 ACAAGUAGCUGAUAUUGAUB ACAAGUAGCUGAUAUUGAUTT B 1910 R-008362692-000A  499  107ACAAGUAGCUGAUAUUGAU AUCAAUAUCAGCUACUUGUUU 1911 R-008362689-000U 1870 194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUU 1913 R-008362689-000U1870  194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUTT B 1912R-008362785-000U 2353  195 UCUUGGACUUGAUAUUGGU B UCUUGGACUUGAUAUUGGUTT B1914 R-008362785-000U 2353  195 UCUUGGACUUGAUAUUGGUACCAAUAUCAAGUCCAAGAUU 1915 R-008363031-000Y 2401  196GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUU 1917 R-008363031-000Y 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUTT B 1916 R-008362920-000R 878  197 AAUACAAAUGAUGUAGAAA UUUCUACAUCAUUUGUAUUUU 1919R-008362920-000R  878  197 AAUACAAAUGAUGUAGAAA B AAUACAAAUGAUGUAGAAATT B1918 R-008362917-000J 2046  112 UAAAUACCAUUCCAUUGUUAACAAUGGAAUGGUAUUUAUU 1921 R-008362917-000J 2046  112UAAAUACCAUUCCAUUGUU B UAAAUACCAUUCCAUUGUUTT B 1920 R-008362980-000V  647 198 GAACCAUCACAGAUGCUGA UCAGCAUCUGUGAUGGUUCUU 1923 R-008362980-000V 647  198 GAACCAUCACAGAUGCUGA B GAACCAUCACAGAUGCUGATT B 1922R-008362725-000P 1998  199 UUCACAUCCUAGCUCGGGA B UUCACAUCCUAGCUCGGGATT B1924 R-008362725-000P 1998  199 UUCACAUCCUAGCUCGGGAUCCCGAGCUAGGAUGUGAAUU 1925 R-008363028-000S  588  200UGCAGAUCCCAUCUACACA UGUGUAGAUGGGAUCUGCAUU 1927 R-008363028-000S  588 200 UGCAGAUCCCAUCUACACA B UGCAGAUCCCAUCUACACATT B 1926 R-008362782-000T2042  201 GGACUAAAUACCAUUCCAU AUGGAAUGGUAUUUAGUCCUU 1929R-008362782-000T 2042  201 GGACUAAAUACCAUUCCAU B GGACUAAAUACCAUUCCAUTT B1928 R-008362977-000N  855  202 CUGCUAUUGUACGUACCAUB CUGCUAUUGUACGUACCAUTT B 1930 R-008362977-000N  855  202CUGCUAUUGUACGUACCAU AUGGUACGUACAAUAGCAGUU 1931 R-008362686-000T 2038 203 CAGAGGACUAAAUACCAUU AAUGGUAUUUAGUCCUCUGUU 1933 R-008362686-000T2038  203 CAGAGGACUAAAUACCAUU B CAGAGGACUAAAUACCAUUTT B 1932R-008362875-000L 1786  204 GAUAAAGGCUACUGUUGGA UCCAACAGUAGCCUUUAUCUU1935 R-008362875-000L 1786  204 GAUAAAGGCUACUGUUGGAB GAUAAAGGCUACUGUUGGATT B 1934 R-008363025-000R 1501  205AGAUGAUAUAAAUGUGGUC B AGAUGAUAUAAAUGUGGUCTT B 1936 R-008363025-000R 1501 205 AGAUGAUAUAAAUGUGGUC GACCACAUUUAUAUCAUCUUU 1937 R-008362914-000H1834  206 AAAUCAUGCACCUUUGCGU ACGCAAAGGUGCAUGAUUUUU 1939R-008362914-000H 1834  206 AAAUCAUGCACCUUUGCGU B AAAUCAUGCACCUUUGCGUTT B1938 R-008362872-000K 1157  207 ACGACAGACUGCCUUCAAAB ACGACAGAGUGCCUUCAAATT B 1940 R-008362872-000K 1157  207ACGACAGACUGCCUUCAAA UUUGAAGGCAGUCUGUCGUUU 1941 R-008362974-000M 1239 208 UAGUAAAUAUAAUGAGGAC B UAGUAAAUAUAAUGAGGACTT B 1942 R-008362974-000M1239  208 UAGUAAAUAUANUGAGGAC GUCCUCAUUAUAUUUACUAUU 1943R-008362821-000P 1248  209 UAAUGAGGACCUAUACUUA B UAAUGAGGACCUAUACUUATT B1944 R-008362821-000P 1248  209 UAAUGAGGACCUAUACUUAUAAGUAUAGGUCCUCAUUAUU 1945 R-008362683-000S  660  210UGCUGAAACAUGCAGUUGU B UGCUGAAACAUGCAGUUGUTT B 1946 R-008362683-000S  660 210 UGCUGAAACAUGCAGUUGU ACAACUGCAUGUUUCAGCAUU 1947 R-008363022-000P 285  211 AUUUGAUGGAGUUGGACAU B AUUUGAUGGAGUUGGACAUTT B 1948R-008363022-000P  285  211 AUUUGAUGGAGUUGGACAU AUGUCCAACUCCAUCAAAUUU1949 R-008362779-000L 1582  212 CUGCCAAGUGGGUGGUAUAB CUGCCAAGUGGGUGGUAUATT B 1950 R-008362779-000L 1582  212CUGCCAAGUGGGUGGUAUA UAUACCACCCACUUGGCAGUU 1951 R-008363019-000H 1735 213 UGGACUACCAGUUGUGGUU AACCACAACUGGUAGUCCAUU 1953 R-008363019-000H1735  213 UGGACUACCAGUUGUGGUU B UGGACUACCAGUUGUGGUUTT B 1952R-008362776-000K  771  214 UUAAUAAGGCUGCAGUUAU AUAACUGCAGCCUUAUUAAUU1955 R-008362776-000K  771  214 UUAAUAAGGCUGCAGUUAUB UUAAUAAGGCUGCAGUUAUTT B 1954 R-008363016-000G 1060  215ACAUCAAGAAGGAGCUAAA B ACAUCAAGAAGGAGCUAAATT B 1956 R-008363016-000G 1060 215 ACAUCAAGAAGGAGCUAAA UUUAGCUCCUUCUUGAUGUUU 1957 R-008362773-000J2390  216 GGAUAUCGCCAGGAUGAUC GAUCAUCCUGGCGAUAUCCUU 1959R-008362773-000J 2390  216 GGAUAUCGCCAGGAUGAUC B GGAUAUCGCCAGGAUGAUCTT B1958 R-008362971-000L 2509   81 CUAUCCAGUUGAUGGGCUGCAGCCCAUCAACUGGAUAGUU 1961 R-008362971-000L 2509   81CUAUCCAGUUGAUGGGCUG B CUAUCCAGUUGAUGGGCUGTT B 1960 R-008362722-000N 2186 217 CUGACAGAGUUACUUCACU B CUGACAGAGUUACUUCACUTT B 1961 R-008362722-000N2186  217 CUGACAGAGUUACUUCACU AGUGAAGUAACUCUGUCAGUU 1963R-008363013-000F 1632  218 GUGACAGGGAAGACAUCAC B GUGACAGGGAAGACAUCACTT B1964 R-008363013-000F 1632  218 GUGACAGGGAAGACAUCACGUGAUGUCUUCCCUGUCACUU 1965 R-008362818-000H  619  219UCAUCCCACUAAUGUCCAG CUGGACAUUAGUGGGAUGAUU 1967 R-008362818-000H  619 219 UCAUCCCACUAAUGUCCAG B UCAUCCCACUAAUGUCCAGTT B 1966 R-008362968-000E1656  220 CUGCCAUCUGUGCUCUUCG B CUGCCAUCUGUGCUCUUCGTT B 1968R-008362968-000E 1656  220 CUGCCAUCUGUGCUCUUCG CGAAGAGCACAGAUGGCAGUU1969 R-008362815-000G 1506  221 AUAUAAAUGUGGUCACCUGB AUAUAAAUGUGGUCACCUGTT B 1970 R-008362815-000G 1506  221AUAUAAAUGUGGUCACCUG CAGGUGACCACAUUUAUAUUU 1971 R-008362869-000D 2501  76 GGUGCUGACUAUCCAGUUG B GGUGCUGACUAUCCAGUUGTT B 1972 R-008362869-000D2501   76 GGUGCUGACUAUCCAGUUG CAACUGGAUAGUCAGCACCUU 1973R-008362719-000G 2494  222 CCACCCUGGUGCUGACUAU AUAGUCAGCACCAGGGUGGUU1975 R-008362719-000G 2494  222 CCACCCUGGUGCUGACUAUB CCACCCUGGUGCUGACUAUTT B 1974 R-008362770-000H 1666  223UGCUCUUCGUCAUCUGACC GGUCAGAUGACGAAGAGCAUU 1977 R-008362770-000H 1666 223 UGCUCUTCGUCAUCUGACC B UGCUCUUCGUCAUCUGACCTT B 1976 R-008362680-000R1635  224 ACAGGGAAGACAUCACUGA B ACAGGGAAGACAUCACUGATT B 1978R-008362680-000R 1635  224 ACAGGGAAGACAUCACUGA UCAGUGAUGUCUUCCCUGUUU1979 R-008362866-000C  294  225 AGUUGGACAUGGCCAUGGAUCCAUGGCCAUGUCCAACUUU 1981 R-008362866-000C  294  225AGUUGGACAUGGCCAUGGA B AGUUGGACAUGGCCAUGGATT B 1980 R-008362863-000B  641 226 UUGGCUGAACCAUCACAGA B UUGGCUGAACCAUCACAGATT B 1982 R-008362863-000B 641  226 UUGGCUGAACCAUCACAGA UCUGUGAUGGUUCAGCCAAUU 1983R-008362965-000D  576  227 UAGAUGAGGGCAUGCAGAU AUCUGCAUGCCCUCAUGUAUU1985 R-008362965-000D  576  227 UAGAUGAGGGCAUGCAGAUB UAGAUGAGGGCALGCAGAUTT B 1984 R-008362911-000G  577  228AGAUGAGGGCAUGCAGAUC B AGAUGAGGGCAUGCAGAUCTT B 1986 R-008362911-000G  577 228 AGAUGAGGGCAUGCAGAUC GAUCUGCAUGCCCUCAUCUUU 1987 R-008362767-000B1661  229 AUCUGUGCUCUUCGUCAUC GAUGACGAAGAGCACAGAUUU 1989R-008362767-000B 1661  229 AUCUGUGCUCUUCGUCAUC B AUCUGUGCUCUUCGUCAUCTT B1988 R-008362962-000C  707  230 GAACUUGCCACACGUGCAAB GAACUUGCCACACGUGCAATT B 1990 R-008362962-000C  707  230GAACUUGCCACACGUGCAA UUGCACGUGUGGCAAGUUCUU 1991 R-008362677-000J 1659 231 CCAUCuGUGCUCUUCGUCA B CCAUCUGUGCUCUUCGUCATT B 1992 R-008362677-000J1659  231 CCAUCUGUGCUCUUCGUCA UGACGAAGAGCACAGAUGGUU 1993R-008362674-000H 1547   88 CUCACUUGCAAUANUUAUA UAUAAUUAUUGCAAGUGAGUU1995 R-008362674-000H 1547   88 CUCACUUGCAAUANUUAUAB CUCACUUGCAAUAAUUAUATT B 1994 R-008362959-000W  867   90GUACCAUGCAGAAUACAAA UUUGUAUUCUGCAUGGUACUU 1997 R-008362959-000W  867  90 GUACCAUGCAGAAUACAAA B GUACCAUGCAGAAUACAAATT B 1996 R-008362956-000V1185  232 AUGGCAACCAAGAAAGCAA UUGCUUUCUUGGUUGCCAUUU 1999R-008362956-000V 1185  232 AUGGCAACCAAGAAAGCAA B AUGGCAACCAAGAAAGCAATT B1998 R-008362764-000A  664  233 GAAACAUGCAGUUGUAAACGUUUACAACUGCAUGUUUCUU 2001 R-008362764-000A  664  233GAAACAUGCAGUUGUAAAC B GAAACAUGCAGUUGUAAACTT B 2000 R-008362716-000F  820  18 CAGACACGCUAUCAUGCGU B CAGACACGCUAUCAUGCGUTT B 2002 R-008362716-000F 820   18 CAGACACGCUAUCAUGCGU ACGCAUGAUAGCGUGUCUCUU 2003R-008362812-000F 2266  101 GCCACAAGAUUACAAGAAA UUUCUUGUAAUCUUGUGGCUU2005 R-008362812-000F 2266  101 GCCACAAGAUUACAAGAAAB GCCACAAGAUUACAAGAAATT B 2004 R-008362671-000G 1749  234UGGUUAAGCUCUUACACCC GGGUGUAAGAGUTUAACCAUU 2007 R-008362671-000G 1749 234 UGGUUAAGCUCUUACACCC B UGGUUAAGCUCUUACACCCTT B 2006 R-008362953-000U1234  235 AGCUUUAGUAAAUAUAAUG B AGCUUUAGUAAAUAUAAUGTT B 2008R-008362953-000U 1234  235 AGCUUUAGUAAAUAUAAUG CAUUAUAUUUACUAAAGCUUU2009 R-008362950-000T  691  236 CUAUCAAGAUGAUGCAGAAB CUAUCAAGAUGAUGCAGAATT B 2010 R-008362950-000T  691  236CUAUCAAGAUGAUGCAGAA UUCUGCAUCAUCUUGAUAGUU 2011 R-008363010-000E 1387 237 AAGUCAACGUCUUGUUCAG B AAGUCAACGUCUUGUUCAGTT B 2012 R-008363010-000E1387  237 AAGUCAACGUCUUGUUCAG CUGAACAAGACGUUGACUUUU 2013R-008381224-000R 1797    5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU2015 R-008381224-000R 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUGGAUUGAUUCGAAAUsU B 2014 R-008381214-000X 1797    5CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B 2017 R-008381211-000X1797    5 CUGUUGGAUUGAUUCGAAA uuucGAAucAAuccAAcAGUsU 2016R-008381038-000Y 1797    5 CUGUUGGAUUGAUUCGAAA UUUcGAAucAAuccAAcAGUsU2019 R-008381038-000Y 1797    5 CUGUUGGAUUGAUUCGAAAB cuGuuGGAuuGAuucGAAA UsU B 2018 R-008381052-000F 1797    5CUGUUGGAUUGAUUCGAAA uuucGAAucAAuccAAcAGUsU 2016 R-008381052-000F 1797   5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2020R-008381158-000T 1797    5 CUGUUGGAUUGAUUCGAAA uuucGAAucAAuccAAcAGUsU2016 R-008381158-000T 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUGGAUUGAUUCGAAAUsU B 2021 R-008381341-000J 1797    5CUGUUGGAUUGAUUCGAAA uuucGAAucAAuccAAcAGUsU 2016 R-008381341-000J 1797   5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B 2022R-008381109-000P 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUGGAUUGAUUCGAAAUsU B 2020 R-008381109-000P 1797    5CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU 2023 R-008380818-000X 1797   5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2021R-008380818-000X 1797    5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU2023 R-008381199-000W 1797    5 CUGUUGGAUUGAUUCGAAAUUUCgaaUCaaUCCaaCagUsU 2023 R-008381199-000W 1797    5CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B 2022 R-008381296-000E1797    5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2024R-008381296-000E 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUGGAUUGAUUCGAAAUsU B 2020 R-008381042-000N 1797    5CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2024 R-008381042-000N 1797   5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2021R-008380923-000F 1797    5 CUGUUGGAUUGAUUCGAAAB cuGuuGGAuuGAuucGAAAUsU B 2022 R-008380923-000F 1797    5CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2024 R-008381104-000W 1797   5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2025 R-008381104-000W1797    5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2020R-008381098-000C 1797    5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU2025 R-008381098-000C 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUGGAUUGAUUCGAAAUsU B 2021 R-008380916-000P 1797    5CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B 2022 R-008380916-000P1797    5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2025R-008380906-000X 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUGGAUUGAUUCGAAAUsU B 2020 R-008380906-000X 1797    5CUGUUGGAUUGAUUCGAAA UUUcGAAucAAuccAAcAGUsU 2019 R-008381291-000L 1797   5 CUGUUGGAUUGAUUCGAAA UUUcGAAucAAuccAAcAGUsU 2019 R-008381291-000L1797    5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2021R-008381334-000T 1797    5 CUGUUGGAUUGAUUCGAAA UUUcGAAucAAuccAAcAGUsU2019 R-008381334-000T 1797    5 CUGUUGGAUUGAUUCGAAAB cuGuuGGAuuGAuucGAAAUsU B 2022 R-008381330-000H 1797    5CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2020 R-008381330-000H1797    5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU 2026R-008381036-000F 1797    5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU2026 R-008381036-000F 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUGGAUUGAUUCGAAAUsU B 2021 R-008381287-000W 1797    5CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B 2022 R-008381287-000W1797    5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU 2026R-008381027-000X 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUGAUCCUAGCUAUUsU B 2027 R-008381027-000X 2398  151CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2028 R-008380896-000U 2398 151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B 2029R-008380896-000U 2398  151 CCAGGAUGAUCCUAGCUAU AuAGcuAGGAucAuccuGGUsU2030 R-008381153-000Z 2398  151 CCAGGAUGAUCCUAGCUAUAUAGcuAGGAucAuccuGGUsU 2032 R-008381153-000Z 2398  151CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcAAuUsU B 2031 R-008381323-000S2398  151 CCAGGAUGAUCCUAGCUAU AuAGcuAGGAucAuccuGGUsU 2030R-008381323-000S 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUGAUCCUAGCUAUUsU B 2033 R-008381315-000S 2398  151CCAGGAUGAUCCUAGCUAU AuAGcuAGGAucAuccuGGUsU 2030 R-008381315-000S 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2034R-008380888-000U 2398  151 CCAGGAUGAUCCUAGCUAU AuAGcuAGGAucAuccuGGUsU2030 R-008380888-000U 2398  151 CCAGGAUGAUCCUAGCUAUB ccAGGAuGAuccuAGcuAuUsU B 2035 R-008381013-000V 2398  151CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2033 R-008381013-000V2398  151 CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU 2036R-008381007-000M 2398  151 CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU2036 R-008381007-000M 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUGAUCCUAGCUAUUsU B 2034 R-008380995-000V 2398  151CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B 2035 R-008380995-000V2398  151 CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU 2036R-008380878-000B 2398  151 CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU2037 R-008380878-000B 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUGAUCCUAGCUAUUsU B 2033 R-008381143-000G 2398  151CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2037 R-008381143-000G 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2034R-008381282-000C 2398  151 CCAGGAUGAUCCUAGCUAUB ccAGGAuGAuccuAGcuAuUsU B 2035 R-008381282-000C 2398  151CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2037 R-008380985-000C 2398 151 CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2038 R-008380985-000C2398  151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2033R-008381278-000M 2398  151 CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU2038 R-008381278-000M 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUGAUCCUAGCUAUUsU B 2034 R-008381139-000S 2398  151CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2038 R-008381139-000S 2398 151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B 2035R-008380871-000R 2398  151 CCAGGAUGAUCCUAGCUAU AUAGcuAGGAucAuccuGGUsU2032 R-008380871-000R 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUGAUCCUAGCUAUUsU B 2033 R-008381272-000K 2398  151CCAGGAUGAUCCUAGCUAU AUAGcuAGGAucAuccuGGUsU 2032 R-008381272-000K 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2034R-008381268-000V 2398  151 CCAGGAUGAUCCUAGCUAU AUAGcuAGGAucAuccuGGUsU2032 R-008381268-000V 2398  151 CCAGGAUGAUCCUAGCUAUB ccAGGAuGAuccuAGcuAuUsU B 2035 R-008381133-000P 2398  151CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU 2039 R-008381133-000P 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2033R-008381261-000J 2398  151 CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU2039 R-008381261-000J 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUGAUCCUAGCUAUUsU B 2034 R-008381091-000S 2398  151CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B 2035 R-008381091-000S2398  151 CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU 2039R-008380861-000Y 1870  194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU2041 R-008380861-000Y 1870  194 ACGACUAGUUCAGUUGCUUB ACGACUAGUUCAGUUGCUUUsU B 2040 R-008380853-000Y 1870  194ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2043 R-008380853-000Y 1870 194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B 2042R-008380811-000L 1870  194 ACGACUAGUUCAGUUGCUUB AcGAcuAGuucAGuuGcuuUsU B 2044 R-008380811-000L 1870  194ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2045 R-008380974-000B 1870 194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2043 R-008380974-000B1870  194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2046R-008380966-000B 1870  194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU2043 R-008380966-000B 1870  194 ACGACUAGUUCAGUUGCUUB ACGACUAGUUCAGUUGCUUUsU B 2047 R-008381310-000Y 1870  194ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2043 R-008381310-000Y 1870 194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B 2048R-008381194-000C 1870  194 ACGACUAGUUCAGUUGCUUB ACGACUAGUUCAGUUGCUUUsU B 2046 R-008381194-000C 1870  194ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU 2049 R-008380833-000N 1870 194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2047R-008380833-000N 1870  194 ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU2049 R-008381115-000X 1870  194 ACGACUAGUUCAGUUGCUUAAGCaaCUgaaCUagUCgUUsU 2049 R-008381115-000X 1870  194ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B 2048 R-008381242-000H1870  194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU 2050R-008381242-000H 1870  194 ACGACUAGUUCAGUCGCUUB ACGACUAGUUCAGUUGCUUUsU B 2046 R-008381235-000S 1870  194ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2047 R-008381235-000S1870  194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU 2050R-008381231-000G 1870  194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU2050 R-008381231-000G 1870  194 ACGACUAGUUCAGUUGCUUB AcGAcuAGuucAGuuGcuuUsU B 2048 R-008381304-000R 1870  194ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU 2051 R-008381304-000R 1870 194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2046R-008380828-000P 1870  194 ACGACUAGUUCAGUUGCUUB ACGACUAGUUCAGUUGCUUUsU B 2047 R-008380828-000P 1870  194ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU 2051 R-008380926-000G 1870 194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU 2051 R-008380926-000G1870  194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B 2048R-008381350-000T 1870  194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU2045 R-008381350-000T 1870  194 ACGACUAGUUCAGUUGCUUB ACGACUAGUUCAGUUGCUUUsU B 2046 R-008381162-000H 1870  194ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2047 R-008381162-000H1870  194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2045R-008380823-000W 1870  194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU2045 R-008380823-000W 1870  194 ACGACUAGUUCAGUUGCUUB AcGAcuAGuucAGuuGcuuUsU B 2048 R-008381068-000A 1870  194ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU 2052 R-008381068-000A 1870 194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2046R-008381190-000T 1870  194 ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU2052 R-008381190-000T 1870  194 ACGACUAGUUCAGUUGCUUB ACGACUAGUUCAGUUGCUUUsU B 2047 R-008380959-000K 1870  194ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU 2052 R-008380959-000K 1870 194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B 2048R-008381084-000A 2401  196 GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU2054 R-008381084-000A 2401  196 GGAUGAUCCLAGCUAUCGUB GGAUGAUCCUAGCUAUCGUUsU B 2053 R-008380848-000Z 2401  196GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2055 R-008380848-000Z2401  196 GGAUGAUCCUAGCUAUCGU AcGAuAGcuAGGAucAuccUsU 2056R-008380807-000W 2401  196 GGAUGAUCCUAGCUAUCGUB GGAuGAuccuAGcuAucGuUsU B 2057 R-008380807-000W 2401  196GGAUGAUCCUAGCUAUCGU ACGAuAGcuAGGAucAuccUsU 2058 R-008380843-000F 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2059R-008380843-000F 2401  196 GGAUGAUCCUAGCUAUCGU AcGAuAGcuAGGAucAuccUsU2056 R-008381185-000U 2401  196 GGAUGAUCCUAGCUAUCCUB GGAUGAUCCUAGCUAUCGUUsU B 2060 R-008381185-000U 2401  196GGAUGAUCCUAGCUAUCGU AcGAuAGcuAGGAucAuccUsU 2056 R-008380951-000R 2401 196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061R-008380951-000R 2401  196 GGAUGAUCCUAGCUAUCGU AcGAuAGcuAGGAucAuccUsU2056 R-008380804-000V 2401  196 GGAUGAUCCUAGCUAUCCUB GGAUGAUCCUAGCUAUCGUUsU B 2059 R-008380804-000V 2401  196GGAUGAUCCUAGCUAUCGU ACGaUagCUaggaUCaUCCUsU 2062 R-008381179-000L 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2060R-008381179-000L 2401  196 GGAUGAUCCUAGCUAUCGU ACGaUagCUaggaUCaUCCUsU2062 R-008381127-000G 2401  196 GGAUGAUCCUAGCUAUCGUACGaUagCUaggaUCaUCCUsU 2062 R-008381127-000G 2401  196GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061 R-008380945-000H2401  196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2059R-008380945-000H 2401  196 GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU2063 R-008381071-000G 2401  196 GGAUGAUCCUAGCUAUCGUB GGAUGAUCCUAGCUAUCGUUsU B 2060 R-008381071-000G 2401  196GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU 2063 R-008381173-000J 2401 196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061R-008381173-000J 2401  196 GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU2063 R-008381122-000N 2401  196 GGAUGAUCCUAGCUAUCGUB GGAUGAUCCUAGCUAUCGUUsU B 2059 R-008381122-000N 2401  196GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU 2064 R-008380801-000U 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2060R-008380801-000U 2401  196 GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU2064 R-008380839-000R 2401  196 GGAUGAUCCUAGCUAUCGUB GGAuGAuccuAGcuAucGuUsU B 2061 R-008380839-000R 2401  196GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU 2064 R-008380835-000F 2401 196 GGAUGAUCCUAGCUAUCGU ACGAuAGcuAGGAucAuccUsU 2058 R-008380835-000F2401  196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2059R-008381258-000C 2401  196 GGAUGAUCCUGGCUAUCGU ACGAuAGcuAGGAucAuccUsU2058 R-008381258-000C 2401  196 GGAUGAUCCUAGCUAUCGUB GGAUGAUCCUAGCUAUCGUUsU B 2060 R-008381169-000U 2401  196GGAUGAUCCUAGCUAUCGU ACGAuAGcuAGGAucAuccUsU 2058 R-008381169-000U 2401 196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061R-008380937-000H 2401  196 GGAUGAUCCUAGCUAUCGUB GGAUGAUCCUAGCUAUCGUUsU B 2059 R-008380937-000H 2401  196GGAUGAUCCUAGCUAUCGU ACGaUagCUaggaUCaUCCUsU 2065 R-008381251-000S 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2060R-008381251-000S 2401  196 GGAUGAUCCUAGCUAUCGU ACGaUagCUaggaUCaUCCUsU2065 R-008380933-000Y 2401  196 GGAUGAUCCUAGCUAUCGUB GGAuGAuccuAGcuAucGuUsU B 2061 R-008380933-000Y 2401  196GGAUGAUCCUAGCUAUCGU ACGaUagCUaggaUCaUCCUsU 2065 R-008381748-000J 1797   5 CUGUUGGAUUGAUUCGAAA B CUgUu G GAUU GAUUCGaAAUsU B 2066R-008381748-000J 1797    5 CUGUUGGAUUGAUUCGAAA UUUCGaAUCAauccaACAGUsU2067 R-008381708-000P 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUuGGaUUGaUUCGAAaUsU B 2069 R-008381708-000P 1797    5CUGUUGGAUUGAUUCGAAA uuucGAauCaAUCcAaCaGUsU 2068 R-008381704-000E 1797   5 CUGUUGGAUUGAUUCGAAA uUUcgAaUCaAuCCAACAGUsU 2070 R-008381704-000E1797    5 CUGUUGGAUUGAUUCGAAA B CUGUuGgaUUG AUuCGaA A UsU B 2071R-008381746-000S 1797    5 CUGUUGGAUUGAUUCGAAA UUUCGaaUCAAUCcAacaGUsU2073 R-008381746-000S 1797    5 CUGUUGGAUUGAUUCGAAA B C UgUUGgaUUGaUUCgAA A UsU B 2072 R-008381728-000Z 1797    5 CUGUUGGAUUGAUUCGAAA B CUgU UGGA UUG AUuCgA AAUsU B 2074 R-008381728-000Z 1797    5 CUGUUGGAUUGAUUCGAAAUUucGaAUCAAUCcAAcagUsU 2075 R-008381686-000B 1797    5CUGUUGGAUUGAUUCGAAA uuUCGAAUcaaUCCAAcAgUsU 2076 R-008381686-000B 1797   5 CUGUUGGAUUGAUUCGAAA B CuG U UGgaUUgAuUCG AaaUsU B 2077R-008381726-000G 1797    5 CUGUUGGAUUGAUUCGAAA uuUcGAAUCaaUcCAACaGUsU2078 R-008381726-000G 1797    5 CUGUUGGAUUGAUUCGAAA B C UgUUgGaUU G AUUCGaaA UsU B 2079 R-008381629-000Y 1797    5 CUGUUGGAUUGAUUCGAAAUUucGAAuCaaUCCAacAGUsU 2081 R-008381629-000Y 1797    5CUGUUGGAUUGAUUCGAAA B CUGUUGG AU U GaUU C GAaAUsU B 2080R-008381724-000P 1797    5 CUGUUGGAUUGAUUCGAAA B CUgU U GgAUugAUUCgAAaUsU B 2083 R-008381724-000P 1797    5 CUGUUGGAUUGAUUCGAAAuuuCgaAUCAAUCcAACagUsU 2082 R-008381670-000G 1797    5CUGUUGGAUUGAUUCGAAA B CugUUGGA UUGaUUcgaaaUsU B 2084 R-008381670-000G1797    5 CUGUUGGAUUGAUUCGAAA UuuCgAAUCAAUCcaACAGUsU 2085R-008381666-000S 1797    5 CUGUUGGAUUGAUUCGAAA UuuCGaauCAaUccaACAGUsU2087 R-008381666-000S 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUgGaUugAUuCGaAAUsU B 2086 R-008381722-000X 1797    5CUGUUGGAUUGAUUCGAAA B CUG U UgGAU UG A UUCgA A AUsU B 2088R-008381722-000X 1797    5 CUGUUGGAUUGAUUCGAAA UUUCgAauCAAUCcAAcagUsU2089 R-008381700-000V 1797    5 CUGUUGGAUUGAUUCGAAAuUuCGAAUCAaUCcaaCAGUsU 2090 R-008381700-000V 1797    5CUGUUGGAUUGAUUCGAAA B CUgU UggAUUgaUUCGaAA UsU B 2091 R-008381650-000X1797    5 CUGUUGGAUUGAUUCGAAA UuUCGAAUcaauCCaACaGUsU 2093R-008381650-000X 1797    5 CUGUUGGAUUGAUUCGAAA B CU GUUG GaUUGaU UCgAAAUsU B 2092 R-008381647-000R 1797    5 CUGUUGGAUUGAUUCGAAA B CUGU UGGaUUgaU UCgAaaUsU B 2094 R-008381647-000R 1797    5 CUGUUGGAUUGAUUCGAAAUUUCgAAuCAauCcaaCAgUsU 2095 R-008381624-000E 1797    5CUGUUGGAUUGAUUCGAAA UUUcGaAUCAauCCAaCAGUsU 2097 R-008381624-000E 1797   5 CUGUUGGAUUGAUUCGAAA B CuGuUgGAUUgaU UCGAaAUsU B 2096R-008381682-000S 1797    5 CUGUUGGAUUGAUUCGAAA B CUGUUGgAUUGAUUCGaaaUsU B 2098 R-008381682-000S 1797    5 CUGUUGGAUUGAUUCGAAAUUUcgaAUcAAUcCAACagUsU 2099 R-008381622-000M 1797    5CUGUUGGAUUGAUUCGAAA UUUcGAaUcaAUCcaACAgUsU 2101 R-008381622-000M 1797   5 CUGUUGGAUUGAUUCGAAA B CUgUUggaUUgaUUCgaaaUsU B 2100R-008381680-000Z 2398  151 CCAGGAUGAUCCUAGCUAU AuaGCUAggAUCAuCCuGGUsU2103 R-008381680-000Z 2398  151 CCAGGAUGAUCCUAGCUAU B C C A GGAUgaUcCUaGCUAU UsU B 2102 R-008381606-000M 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGgaU GaUCCU AgCUA UUsU B 2104 R-008381606-000M 2398  151CCAGGAUGAUCCUAGCUAU AUAgcuaGgaUCAuCcUGgUsU 2105 R-008381714-000X 2398 151 CCAGGAUGAUCCUAGCUAU aUagCUAGGaUCauccUGgUsU 2106 R-008381714-000X2398  151 CCAGGAUGAUCCUAGCUAU B CCagG AUgAU CC UAGCUaUUsU B 2107R-008381642-000X 2398  151 CCAGGAUGAUCCUAGCUAU B CCAG GAUG AU CCUA G CUaUUsU B 2109 R-008381692-000X 2398  151 CCAGGAUGAUCCUAGCUAUaUagCuagGAUCAucCugGUsU 2108 R-008381662-000G 2398  151CCAGGAUGAUCCUAGCUAU AUAGcUAgGAuCauCCUggUsU 2111 R-008381662-000G 2398 151 CCAGGAUGAUCCUAGCUAU B cC AGgAUGaUCCUagCUA UUsU B 2110R-008381618-000X 2398  151 CCAGGAUGAUCCUAGCUAU auAgCUaGGAuCauCCUGGUsU2112 R-008381618-000X 2398  151 CCAGGAUGAUCCUAGCUAU B CCA GGAUGAUC C U AGCU AUUsU B 2113 R-008381698-000L 2398  151 CCAGGAUGAUCCUAGCUAUaUaGCuaggAUcaUcCUGGUsU 2114 R-008381698-000L 2398  151CCAGGAUGAUCCUAGCUAU B CCAGG A UGAUC C UagC UaUUsU B 2115R-008381742-000G 2398  151 CCAGGAUGAUCCUAGCUAU B CCAgGAUgaU C CUaGCU A UUsU B 2117 R-008381742-000G 2398  151 CCAGGAUGAUCCUAGCUAUaUagCUAggAuCAuCCuGgUsU 2116 R-008381738-000S 2398  151CCAGGAUGAUCCUAGCUAU B CCaggaUgaUCCUagCUaU UsU B 2118 R-008381738-000S2398  151 CCAGGAUGAUCCUAGCUAU AUAGCUaGGAUcauCCUgGUsU 2119R-008381660-000P 2398  151 CCAGGAUGAUCCUAGCUAU B C C AgGAUG AU CCUAGcUAUUsU B 2121 R-008381660-000P 2398  151 CCAGGAUGAUCCUAGCUAUaUagcUAGGAUcaUCCugGUsU 2120 R-008381696-000U 2398  151CCAGGAUGAUCCUAGCUAU B CCaGGaUG A U CCUA G C U AU UsU B 2123R-008381696-000U 2398  151 CCAGGAUGAUCCUAGCUAU auAGcUaggauCAUCCuGGUsU2122 R-008381636-000P 2398  151 CCAGGAUGAUCCUAGCUAUAUAGCUAGgaUCauCcuGGUsU 2125 R-008381636-000P 2398  151CCAGGAUGAUCCUAGCUAU B CC AGGaUGaUC CuAgCUA UUsU B 2124 R-008381634-000X2398  151 CCAGGAUGAUCCUAGGUAU AUaGCUagGAucAuCCUgGUsU 2127R-008381634-000X 2398  151 CCAGGAUGAUCCUAGCUAU B cCAGGaU G AuCCU aGCUaUUsU B 2126 R-008381632-000E 2398  151 CCAGGAUGAUCCUAGCUAUB CCaGgAUgAuCCU AGcU AUUsU B 2129 R-008381632-000E 2398  151CCAGGAUGAUCCUAGCUAU aUAGCuAGGAUCAUCcUggUsU 2128 R-008381736-000Z 2398 151 CCAGGAUGAUCCUAGCUAU AUaGCuAGGaUcAUcCUggUsU 2131 R-008381736-000Z2398  151 CCAGGAUGAUCCUAGCUAU B CcaggAugaUC CU AG CUaU UsU B 2130R-008381600-000K 2398  151 CCAGGAUGAUCCUAGCUAU aUaGcUaggAUCAucCUGGUsU2132 R-008381600-000K 2398  151 CCAGGAUGAUCCUAGCUAU B CCAgGaU GAUcCUaGCUA U UsU B 2133 R-008381732-000P 2398  151 CCAGGAUGAUCCUAGCUAUaUagCuAGGaUCAuCcUgGUsU 2134 R-008381732-000P 2398  151CCAGGAUGAUCCUAGCUAU B CCAggaUGAUC C UAgCU AuUsU B 2135 R-008381656-000Z2398  151 CCAGGAUGAUCCUAGCUAU B C CAGgAUgAU CCUAGcuaUUsU B 2136R-008381656-000Z 2398  151 CCAGGAUGAUCCUAGCUAU AuagCUAgGauCAUcCUGGUsU2137 R-008381750-000G 1870  194 ACGACUAGUUCAGUUGCUUaagCAaCUGaAcuAGUCgUUsU 2138 R-008381750-000G 1870  194ACGACUAGUUCAGUUGCUU B ACgACuAgUUcAGU U GCUU UsU B 2139 R-008381690-000S1870  194 ACGACUAGUUCAGUUGCUU aAGcAACUgAaCUaGUCguUsU 2140R-008381690-000S 1870  194 ACGACUAGUUCAGUUGCUU B aC GACUAGuUCAgUugcUUUsU B 2141 R-008381616-000E 1870  194ACGACUAGUUCAGUUGCUU AAGcaACuGaaCUaGuCGUUsU 2143 R-008381616-000E 1870 194 ACGACUAGUUCAGUUGCUU B aCGACUagUU CaGUUgCUU UsU B 2142R-008381688-000U 1870  194 ACGACUAGUUCAGUUGCUU aAgCaAcUGAACUAgUcGUUsU2144 R-008381688-000U 1870  194 ACGACUAGUUCAGUUGCUU B aCgaCuAGUuCAgUUgcUUUsU B 2145 R-008381614-000M 1870  194 ACGACUAGUUCAGUUGCUU B aCgaCUAguUCAGUUGCU U UsU B 2147 R-008381614-000M 1870  194ACGACUAGUUCAGUUGCUU aaGCAAcUgAaCuagUcGUUsU 2146 R-008381706-000X 1870 194 ACGACUAGUUCAGUUGCUU B ACGaCUA GUU CAGUU GCuU U sU B 2148R-008381706-000X 1870  194 ACGACUAGUUCAGUUGCUU AAgCAAcUGaACUaGUcgUUsU2149 R-008381672-000Z 1870  194 ACGACUAGUUCAGUUGCUUAAgCAacugAAcUagUCGUUsU 2151 R-008381672-000Z 1870  194ACGACUAGUUCAGUUGCUU B ACgAC UAGUUCaGU UGcU UUsU B 2150 R-008381730-000X1870  194 ACGACUAGUUCAGUUGCUU AagcAaCUgaaCUAGucgUUsU 2153R-008381730-000X 1870  194 ACGACUAGUUCAGUUGCUU B acG A CUagUUCagUuGCuUUsU B 2152 R-008381612-000V 1870  194 ACGACUAGUUCAGUUGCUU B aCGAcU A GUUCA GUUgCUUUsU B 2154 R-008381612-000V 1870  194 ACGACUAGUUCAGUUGCUUAaGCaAcUGAacUaGUcGUUsU 2155 R-008381702-000M 1870  194ACGACUAGUUCAGUUGCUU AAgcaaCUGAACuaGUCGUUsU 2157 R-008381702-000M 1870 194 ACGACUAGUUCAGUUGCUU B AC GA C UaGUUCaGUUgCUU UsU B 2156R-008381744-000Z 1870  194 ACGACUAGUUCAGUUGCUU B A CGaCUaGU U CA G U UGcUU UsU B 2158 R-008381744-000Z 1870  194 ACGACUAGUUCAGUUGCUUAaGCAACUgaACUAGuCGUUsU 2159 R-008381610-000C 1870  194ACGACUAGUUCAGUUGCUU aAgCAACUGAacUaGuCgUUsU 2160 R-008381610-000C 1870 194 ACGACUAGUUCAGUUGCUU B ACgACU AgUUCAgUUgCUUUsU B 2161R-008381608-000E 1870  194 ACGACUAGUUCAGUUGCUUB ACGaCUaGuUCagUUGCUUUsU B 2162 R-008381608-000E 1870  194ACGACUAGUUCAGUUGCUU AAgCAACUGaACUaGUCguUsU 2163 R-008381654-000G 1870 194 ACGACUAGUUCAGUUGCUU aAgCAaCuGaAcuaGUCgUUsU 2164 R-008381654-000G1870  194 ACGACUAGUUCAGUUGCUU B A C GaCUaG UUCaguUgCUuUsU B 2165R-008381668-000J 1870  194 ACGACUAGUUCAGUUGCUU B A CGAC U AG UUCAGUU GCUU UsU B 2167 R-008381668-000J 1870  194 ACGACUAGUUCAGUUGCUUaAgCAACugAACuaguCgUUsU 2166 R-008381627-000F 1870  194ACGACUAGUUCAGUUGCUU B aCgaCUAG UUCaGUUG C UUUsU B 2169 R-008381627-000F1870  194 ACGACUAGUUCAGUUGCUU aAGCAacUgaACUaGUcGUUsU 2168R-008381719-000R 1870  194 ACGACUAGUUCAGUUGCUU B ACgAcU AgUuC AgUUGCUUUsU B 2170 R-008381719-000R 1870  194 ACGACUAGUUCAGUUGCUUAAGCAAcUGAaCUaGUCGuUsU 2171 R-008381717-000Y 1870  194ACGACUAGUUCAGUUGCUU B aCgaCUagUUCagUUgCUU UsU B 2173 R-008381717-000Y1870  194 ACGACUAGUUCAGUUGCUU aaGCAACuGaACuagUcGuUsU 2172R-008381652-000P 2401  196 GGAUGAUCCUAGCUAUCGU ACgaUAGcuAGgauCAUCcUsU2175 R-008381652-000P 2401  196 GGAUGAUCCUAGCUAUCGUB gGaugaUcCUaGCuAUCgU UsU B 2174 R-008381684-000J 2401  196GGAUGAUCCUAGCUAUCGU B GgAUGaUCCuagcUAUCgUUsU B 2177 R-008381684-000J2401  196 GGAUGAUCCUAGCUAUCGU aCgAUagcuaGGAUcAUCCUsU 2176R-008381664-000Z 2401  196 GGAUGAUCCUAGCUAUCGU B gGA UgAUC CU A GCuaUCGUUsU B 2179 R-008381664-000Z 2401  196 GGAUGAUCCUAGCUAUCGUaCGauAGCuAgGaUcauCCUsU 2178 R-008381645-000Y 2401  196GGAUGAUCCUAGCUAUCGU acgAUAGCUaGgAUCAuCCUsU 2180 R-008381645-000Y 2401 196 GGAUGAUCCUAGCUAUCGU B gG A U GAUCCUAgC UauCGUUsU B 2181R-008381678-000B 2401  196 GGAUGAUCCUAGCUAUCGU ACgaUAgCUaGGAuCAUCcUsU2183 R-008381678-000B 2401  196 GGAUGAUCCUAGCUAUCGUB ggaUgaUCCUagCUaUCgU UsU B 2182 R-008381620-000V 2401  196GGAUGAUCCUAGCUAUCGU aCgauAgCUAggAucaUcCUsU 2184 R-008381620-000V 2401 196 GGAUGAUCCUAGCUAUCGU B G GaUGAUCCUAG CUaU CgU UsU B 2185R-008381712-000E 2401  196 GGAUGAUCCUAGCUAUCGU aCGAuaGCuAGGAuCaUCCUsU2186 R-008381712-000E 2401  196 GGAUGAUCCUAGCUAUCGU B GGaU G A U C CUaGCUAUCgUUsU B 2187 R-008381710-000M 2401  196 GGAUGAUCCUAGCUAUCGUB gGaUgAU CC UaGCUAUCG UUsU B 2188 R-008381710-000M 2401  196GGAUGAUCCUAGCUAUCGU ACGAuAgcUaGGAUCauCCUsU 2189 R-008381676-000J 2401 196 GGAUGAUCCUAGCUAUCGU aCGAuaGCUAGgAUCaUccUsU 2190 R-008381676-000J2401  196 GGAUGAUCCUAGCUAUCGU B GgAUGauC CUAGCUAU CguUsU B 2191R-008381604-000V 2401  196 GGAUGAUCCUAGCUAUCGUB GgaUgAUCcUagCUaUCGuUsU B 2192 R-008381604-000V 2401  196GGAUGAUCCUAGCUAUCGU ACGAuAgCUagGAuCAUCcUsU 2193 R-008381640-000E 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGaU C CUaGCUaUcgU UsU B 2194R-008381640-000E 2401  196 GGAUGAUCCUAGCUAUCGU AcGAUAGCUAGgaucaUCCUsU2195 R-008381740-000P 2401  196 GGAUGAUCCUAGCUAUCGUacgAuaGCUagGauCAUcCUsU 2196 R-008381740-000P 2401  196GGAUGAUCCUAGCUAUCGU B GgAUGA UCCUagCU A UC G U UsU B 2197R-008381674-000S 2401  196 GGAUGAUCCUAGCUAUCGU B G GAUG AuC CUaG CUAU CGU UsU B 2199 R-008381674-000S 2401  196 GGAUGAUCCUAGCUAUCGUaCgAUagcUAGGAuCAuCCUsU 2198 R-008381694-000B 2401  196GGAUGAUCCUAGCUAUCGU B GgaU GaUCCUAgCUAUCGUUsU B 2201 R-008381694-000B2401  196 GGAUGAUCCUAGCUAUCGU aCGAUaGCuAGGauCauCCUsU 2200R-008381638-000G 2401  196 GGAUGAUCCUAGCUAUCGU B G GA UgA UCC U AgcUAUCgUUsU B 2203 R-008381638-000G 2401  196 GGAUGAUCCUAGCUAUCGUaCGaUagcUAgGAUcAuCcUsU 2202 R-008381602-000C 2401  196GGAUGAUCCUAGCUAUCGU B GGaugaU CCuAG CuA UCGU UsU B 2204 R-008381602-000C2401  196 GGAUGAUCCUAGCUAUCGU AcGAUaGCUaGGauCAUccUsU 2205R-008381692-000J 2401  196 GGAUGAUCCUAGCUAUCGU AcgaUagCUAGGAUcAuCcUsU2207 R-008381692-000J 2401  196 GGAUGAUCCUAGCUAUCGUB GGAUGAUCCUagCUAuCGU UsU B 2206 R-008381658-000S 2401  196GGAUGAUCCUAGCUAUCGU B gGAUgaUCCUAGCUaU C GU UsU B 2208 R-008381658-000S2401  196 GGAUGAUCCUAGCUAUCGU ACGaUAGcuaggAuCAUcCUsU 2209R-008381178-000C 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUGGAUUGAUUCGAAAUsU B 2020 R-008381178-000C 1797    5CUGUUGGAUUGAUUCGAAA UUUCGaAUCAauccaACAGUsU 2067 R-008380929-000H 1797   5 CUGUUGGAUUGAUUCGAAA uuucGAauCaAUCcAaCaGUsU 2068 R-008380929-000H1797       5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2021R-008381019-000X 1797    5 CUGUUGGAUUGAUUCGAAA uUUcgAaUCaAuCCAACAGUsU2070 R-008381019-000X 1797    5 CUGUUGGAUUGAUUCGAAAB cuGuuGGAuuGAuucGAAAUsU B 2022 R-008381256-000K 1797    5CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2020 R-008381256-000K1797    5 CUGUUGGAUUGAUUCGAAA UUUCGaaUCAAUCcAacaGUsU 2073R-008381552-000E 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUGGAUUGAUUCGAAAUsU B 2021 R-008381552-000E 1797    5CUGUUGGAUUGAUUCGAAA UUucGaAUCAAUCcAAcagUsU 2075 R-008381002-000U 1797   5 CUGUUGGAUUGAUUCGAAA uuUCGAAUcaaUCCAAcAgUsU 2076 R-008381002-000U1797    5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B 2022R-008381394-000X 1797    5 CUGUUGGAUUGAUUCGAAA uuUcGAAUCaaUcCAACaGUsU2078 R-008381394-000X 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUGGAUUGAUUCGAAAUsU B 2020 R-008381383-000W 1797    5CUGUUGGAUUGAUUCGAAA UUucGAAuCaaUCCAacAGUsU 2081 R-008381383-000W 1797   5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2021R-008381093-000J 1797    5 CUGUUGGAUUGAUUCGAAAB cuGuuGGAuuGAuucGAAAUsU B 2022 R-008381093-000J 1797    5CUGUUGGAUUGAUUCGAAA uuuCgaAUCAAUCcAACagUsU 2082 R-008381375-000W 1797   5 CUGUUGGAUUGAUUCGAAA UuuCgAAUCAAUCcaACAGUsU 2085 R-008381375-000W1797    5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2020R-008381543-000W 1797    5 CUGUUGGAUUGAUUCGAAA UuuCGaauCAaUccaACAGUsU2087 R-008381543-000W 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUGGAUUGAUUCGAAAUsU B 2021 R-008381535-000W 1797    5CUGUUGGAUUGAUUCGAAA UUUCgAauCAAUCcAAcagUsU 2089 R-008381535-000W 1797   5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B 2022R-008381528-000E 1797    5 CUGUUGGAUUGAUUCGAAA uUuCGAAUCAaUCcaaCAGUsU2090 R-008381528-000E 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUGGAUUGAUUCGAAAUsU B 2020 R-008381365-000D 1797    5CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2021 R-008381365-000D1797    5 CUGUUGGAUUGAUUCGAAA UuUCGAAUcaauCCaACaGUsU 2093R-008381520-000K 1797    5 CUGUUGGAUUGAUUCGAAA UUUCgAAuCAauCcaaCAgUsU2095 R-008381520-000K 1797    5 CUGUUGGAUUGAUUCGAAAB cuGuuGGAuuGAuucGAAAUsU B 2022 R-008380915-000F 1797    5CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2020 R-008380915-000F1797    5 CUGUUGGAUUGAUUCGAAA UUUcGaAUCAauCCAaCAGUsU 2097R-008381359-000W 1797    5 CUGUUGGAUUGAUUCGAAA UUUcgaAUcAAUcCAACagUsU2099 R-008381359-000W 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUGGAUUGAUUCGAAAUsU B 2021 R-008381249-000U 1797    5CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B 2022 R-008381249-000U1797    5 CUGUUGGAUUGAUUCGAAA UUUcGAaUcaAUCcaACAgUsU 2101R-008381082-000H 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUGAUCCUAGCUAUUsU B 2033 R-008381082-000H 2398  151CCAGGAUGAUCCUAGCUAU AuaGCUAggAUCAuCCuGGUsU 2103 R-008381240-000R 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2034R-008381290-000R 2398  151 CCAGGAUGAUCCUAGCUAU AUAgcuaGgaUCAuCcUGgUsU2105 R-008380907-000F 2398  151 CCAGGAUGAUCCUAGCUAUB ccAGGAuGAuccuAGcuAuUsU B 2035 R-008380907-000F 2398  151CCAGGAUGAUCCUAGCUAU aUagCUAGGaUCauccUGgUsU 2106 R-008381164-000A 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2033R-008381164-000A 2398  151 CCAGGAUGAUCCUAUCUAU aUagCuagGAUCAucCugGUsU2108 R-008381072-000R 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUGAUCCUAGCUAUUsU B 2034 R-008381072-000R 2398  151CCAGGAUGAUCCUAGCUAU AUAGcUAgGAuCauCCUggUsU 2111 R-008381450-000C 2398 151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B 2035R-008381450-000C 2398  151 CCAGGAUGAUCCUAUCUAU auAgCUaGGAuCauCCUGGUsU2112 R-008381059-000S 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUGAUCCUAGCUAUUsU B 2033 R-008381059-000S 2398  151CCAGGAUGAUCCUAGCUAU aUaGCuaggAUcaUcCUGGUsU 2114 R-008381154-000H 2398 151 CCAGGAUGAUCCUAGCUAU aUagCUAggAuCAuCCuGgUsU 2116 R-008381154-000H2398  151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2034R-008389143-000L 2398  151 CCAGGAUGAUCCUAGCUAU AUAGCUaGGAUcauCCUgGUsU2119 R-008381493-000L 2398  151 CCAGGAUGAUCCUAGCUAUB ccAGGAuGAuccuAGcuAuUsU B 2035 R-008381049-000Z 2398  151CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2033 R-008381099-000Z2398  151 CCAGGAUGAUCCUAGCUAU aUagcUAGGAUcaUCCugGUsU 2120R-008381292-000V 2398  151 CCAGGAUGAUCCUAGCUAU auAGcUaggauCAUCCuGGUsU2122 R-008381292-000V 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUGAUCCUAGCUAUUsU B 2034 R-008381010-000U 2398  151CCAGGAUGAUCCUAGCUAU AUAGCUAGgaUCauCcuGGUsU 2125 R-008381010-000U 2398 151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B 2035R-008381284-000V 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUGAUCCUAGCUAUUsU B 2033 R-008381284-000V 2398  151CCAGGAUGAUCCUAGCUAU AUaGCUagGAucAuCCUgGUsU 2127 R-008381917-000U 2398 151 CCAGGAUGAUCCUAGCUAU aUAGCuAGGAUCAUCcUggUsU 2128 R-008381417-000U2398  151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2034R-008381265-000U 2398  151 CCAGGAUGAUCCUAGCUAU AUaGCuAGGaUcAUcCUggUsU2131 R-008381265-000U 2398  151 CCAGGAUGAUCCUAGCUAUB ccAGGAuGAuccuAGcuAuUsU B 2035 R-008381464-000E 2398  151CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2033 R-008381464-000E2398  151 CCAGGAUGAUCCUAGCUAU aUaGcUaggAUCAucCUGGUsU 2132R-008381170-000H 2398  151 CCAGGAUGAUCCUAGCUAU aUagCuAGGaUCAuCcUgGUsU2134 R-008381170-000H 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUGAUCCUAGCUAUUsU B 2034 R-008381408-000K 2398  151CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B 2035 R-008381408-000K2398  151 CCAGGAUGAUCCUAGCUAU AuagCUAgGauCAUcCUGGUsU 2137R-008381110-000D 1870  194 ACGACUAGUUCAGUUGCUU aagCAaCUGaAcuAGUCgUUsU2138 R-008381110-000D 1870  194 ACGACUAGUUCAGUUGCUUB ACGACUAGUUCAGUUGCUUUsU B 2046 R-008381558-000G 1870  194ACGACUAGUUCAGUUGCUU aAGcAACUgAaCUaGUCguUsU 2140 R-008381558-000G 1870 194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2047R-008381456-000E 1870  194 ACGACUAGUUCAGUUGCUU AAGcaACuGaaCUaGuCGUUsU2143 R-008381456-000E 1870  194 ACGACUAGUUCAGUUGCUUB AcGAcuAGuucAGuuGcuuUsU B 2048 R-008381401-000Z 1870  194ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2046 R-008381401-000Z1870  194 ACGACUAGUUCAGUUGCUU aAgCaAcUGAACUAgUcGUUsU 2144R-008380922-000X 1870  194 ACGACUAGUUCAGUUGCUU aaGCAAcUgAaCuagUcGUUsU2146 R-008380922-000X 1870  194 ACGACUAGUUCAGUUGCUUB ACGACUAGUUCAGUUGCUUUsU B 2047 R-008381101-000V 1870  194ACGACUAGUUCAGUUGCUU AAgCAAcUGaACUaGUcgUUsU 2149 R-008381101-000V 1870 194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B 2048R-008381556-000P 1870  194 ACGACUAGUUCAGUUGCUU AAgCAacugAAcUagUCGUUsU2151 R-008381556-000P 1870  194 ACGACUAGUUCAGUUGCUUB ACGACUAGUUCAGUUGCUUUsU B 2046 R-008381426-000C 1870  194ACGACUAGUUCAGUUGCUU AagcAaCUgaaCUAGucgUUsU 2153 R-008381126-000C 1870 194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2047R-008380979-000V 1870  194 ACGACUAGUUCAGUUGCUU AaGCaAcUGAacUaGUcGUUsU2155 R-008380979-000V 1870  194 ACGACUAGUUCAGUUGCUUB AcGAcuAGuucAGuuGcuuUsU B 2048 R-008380882-000S 1870  194ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2046 R-008380882-000S1870  194 ACGACUAGUUCAGUUGCUU AAgcaaCUGAACuaGUCGCUsU 2157R-008381204-000F 1870  194 ACGACUAGUUCAGUUGCUU AaGCAACUgaACUAGuCGUUsU2159 R-008381204-000F 1870  194 ACGACUAGUUCAGUUGCUUB ACGACUAGUUCAGUUGCUUUsU B 2047 R-008381471-000W 1870  194ACGACUAGUUCAGUUGCUU aAgCAACUGAacUaGuCgUUsU 2160 R-008381471-000W 1870 194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B 2048R-008381197-000D 1870  194 ACGACUAGUUCAGUUGCUUB ACGACUAGUUCAGUUGCUUUsU B 2046 R-008381197-000D 1870  194ACGACUAGUUCAGUUGCUU AAgCAACUGaACUaGUCguUsU 2163 R-008380970-000S 1870 194 ACGACUAGUUCAGUUGCUU aAgCAaCuGaAcuaGUCgUUsU 2164 R-008380970-000S1870  194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2047R-008381511-000B 1870  194 ACGACUAGUUCAGUUGCUU aAgCAACugAACuaguCgUUsU2166 R-008381511-000B 1870  194 ACGACUAGUUCAGUUGCUUB AcGAcuAGuucAGuuGcuuUsU B 2048 R-008380992-000U 1870  194ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2046 R-008380992-000U1870  194 ACGACUAGUUCAGUUGCUU aAGCAacUgaACUaGUcGUUsU 2168R-008381233-000Z 1870  194 ACGACUAGUUCAGUUGCUU AAGCAAcUGAaCUaGUCGuUsU2171 R-008381233-000Z 1870  194 ACGACUAGUUCAGUUGCUUB ACGACUAGUUCAGUUGCUUUsU B 2047 R-008381352-000K 1870  194ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B 2048 R-008381352-000K1870  194 ACGACUAGUUCAGUUGCUU aaGCAACuGaACUagUcGuUsU 2172R-008380987-000V 2401  196 GGAUGAUCCUAGCUAUCGU ACgaUAGcuAGgauCAUICUsU2175 R-008380987-000V 2401  196 GGAUGAUCCUAGCUAUCGUB GGAUGAUCCUAGCUAUCGUUsU B 2059 R-008381345-000U 2401  196GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2060 R-008381345-004U2401  196 GGAUGAUCCUAGCUAUCGU aCgAUagcuaGGAUcAUCCUsU 2176R-008381146-000H 2401  196 GGAUGAUCCUAGCUAUCGU aCGauAGCuAgGaUcauCCUsU2178 R-008381146-000H 2401  196 GGAUGAUCCUAGCUAUCGUB GGAuGAuccuAGcuAucGuUsU B 2061 R-008381503-000B 2401  196GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2059 R-008381503-000B2401  196 GGAUGAUCCUAGCUAUCGU acgAUAGCUaGgAUCAuCCUsU 2180R-008381137-000Z 2401  196 GGAUGAUCCUAGCUAUCGUB GGAUGAUCCUAGCUAUCGUUsU B 2060 R-008381137-000Z 2401  196GGAUGAUCCUAGCUAUCGU ACgaUAgCUaGGAuCAUCcUsU 2183 R-008381337-000U 2401 196 GGAUGAUCCUAGCUAUCGU aCgauAgCUAggAucaUcCUsU 2184 R-008381337-000U2401  196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061R-008380900-000V 2401  196 GGAUGAUCCUAGCUAUCGUB GGAUGAUCCUAGCUAUCGUUsU B 2059 R-008380900-000V 2401  196GGAUGAUCCUAGCUAUCGU aCGAuaGCuAGGAuCaUCCUsU 2186 R-008381328-000K 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2060R-008381328-000K 2401  196 GGAUGAUCCUAGCUAUCGU ACGAuAgcUaGGAUCauCCUsU2189 R-008381222-000Y 2401  196 GGAUGAUCCUAGCUAUCGUB GGAuGAuccuAGcuAucGuUsU B 2061 R-008381222-000Y 2401  196GGAUGAUCCUAGCUAUCGU aCGAuaGCUAGgAUCaUccUsU 2190 R-008381494-000G 2401 196 GGAUGAUCCUAGCUAUCGU ACGAuAgCUagGAuCAUCcUsU 2193 R-008381494-000G2401  196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2059R-008381212-000F 2401  196 GGAUGAUCCUAGCUAUCGUB GGAUGAUCCUAGCUAUCGUUsU B 2060 R-008381212-000F 2401  196GGAUGAUCCUAGCUAUCGU AcGAUAGCUAGgaucaUCCUsU 2195 R-008381434-000C 2401 196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061R-008381434-000C 2401  196 GGAUGAUCCUAGCUAUCGU acgAuaGCUagGauCAUcCUsU2196 R-008380895-000K 2401  196 GGAUGAUCCUAGCUAUCGUB GGAUGAUCCUAGCUAUCGUUsU B 2059 R-008380895-000K 2401  196GGAUGAUCCUAGCUAUCGU aCgAUagcUAGGAuCAuCCUsU 2198 R-008381488-000Z 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2060R-008381488-000Z 2101  196 GGAUGAUCCUAGCUAUCGU aCGAUaGCuAGGauCauCCUsU2200 R-008381126-000Y 2401  196 GGAUGAUCCUAGCUAUCGUaCGaUagcUAgGAUcAuCcUsU 2202 R-008381126-000Y 2401  196GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061 R-008381479-000R2401  196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2059R-008381479-000R 2401  196 GGAUGAUCCUAGCUAUCGU AcGAUaGCUaGGauCAUccUsU2205 R-008381319-000B 2401  196 GGAUGAUCCUAGCUAUCGUAcgaUagCUAGGAUcAucCUsU 2207 R-008381319-000B 2401  196GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2060 R-008380889-000C2401  196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061R-008380889-000C 2401  196 GGAUGAUCCUAGCUAUCGU ACGaUAGcuaggAuCAUcCUsU2209 R-008381831-000R 1797    5 CUGUUGGAUUGAUUCGAAAB CUgUuGGAUUGAUUCGaAAUsU B 2066 R-008381831-000R 1797    5CUGUUGGAUUGAUUCGAAA uuucGAAucAAuccAAcAGUsU 2016 R-008381842-000S 1797   5 CUGUUGGAUUGAUUCGAAA B CUGUuGGaUUGaUUCGAAaUsU B 2069R-008381842-000S 1797    5 CUGUUGGAUUGAUUCGAAA uuucGAAucAAuccAAcAGUsU2016 R-008381850-000S 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUuGgaUUGAUuCGaAAUsU B 2071 R-008381850-000S 1797    5CUGUUGGAUUGAUUCGAAA uuucGAAucAAuccAAcAGUsU 2016 R-008381815-000R 1797   5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaauCCaaCagUsU 2023 R-008381815-000R1797    5 CUGUUGGAUUGAUUCGAAA B CUgUUGgaUUGaUUCgAAAUsU B 2072R-008381783-000K 1797    5 CUGUUGGAUUGAUUCGAAAB CUgUUGGAUUGAUuCgAAAUsU B 2074 R-008381783-000K 1797    5CUGUUGGAUUGAUUCGAAA UUUCgaaUCaauCCaaCagUsU 2023 R-008381799-000E 1797   5 CUGUUGGAUUGAUUCGAAA B CuGUUGgaUUgAuUCGAaaUsU B 2077R-008381799-000E 1797    5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaauCCaaCagUsU2023 R-008381814-000G 1797    5 CUGUUGGAUUGAUUCGAAAB CUgUUgGaUUGAUUCGaaAUsU B 2079 R-008381814-000G 1797    5CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2024 R-008381780-000J 1797   5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2024 R-008381780-000J1797    5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGaUUCGAaAUsU B 2080R-008381841-000H 1797    5 CUGUUGGAUUGAUUCGAAAB CUgUUGgAUugAUUCgAAaUsU B 2083 R-008381841-000H 1797    5CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2024 R-008381791-000K 1797   5 CUGUUGGAUUGAUUCGAAA B CugUUGGAUUGaUUcgaaaUsU B 2084R-008381791-000K 1797    5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU2025 R-008381839-000K 1797    5 CUGUUGGAUUGAUUCGAAAUUUCGAAUCAAUCCAACAGUsU 2025 R-008381839-000K 1797    5CUGUUGGAUUGAUUCGAAA B CUGUUgGaUugAUuCGaAAUsU B 2086 R-008381796-000D1797    5 CUGUUGGAUUGAUUCGAAA B CUGUUgGAUUGAUUCgAAAUsU B 2088R-008381796-000D 1797    5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU2025 R-008381838-000B 1797    5 CUGUUGGAUUGAUUCGAAAUUUcGAAucAAuccAAcAGUsU 2019 R-008381838-000B 1797    5CUGUUGGAUUGAUUCGAAA B CUgUUggAUUgaUUCGaAAUsU B 2091 R-008381790-000B1797    5 CUGUUGGAUUGAUUCGAAA B CUGUUGGaUUGaUUCgAAAUsU B 2092R-008381790-000B 1797    5 CUGUUGGAUUGAUUCGAAA UUUcGAAucAAuccAAcAGUsU2019 R-008381825-000H 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUGGaUUgaUUCgAaaUsU B 2094 R-008381825-000H 1797    5CUGUUGGAUUGAUUCGAAA UUUcGAAucAAuccAAcAGUsU 2019 R-008381789-000M 1797   5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU 2026 R-008381789-000M1797    5 CUGUUGGAUUGAUUCGAAA B CuGuUgGAUUgaUUCGAaAUsU B 2096R-008381805-000Y 1797    5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU2026 R-008381805-000Y 1797    5 CUGUUGGAUUGAUUCGAAAB CUGUUGgAUUGAUUCGaaaUsU B 2098 R-008381788-000D 1797    5CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU 2026 R-008381788-000D 1797   5 CUGUUGGAUUGAUUCGAAA B CUgUUggaUUgaUUCgaaaUsU B 2100R-008381847-000K 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUgaUcCUaGCUAUUsU B 2102 R-008381847-000K 2398  151CCAGGAUGAUCCUAGCUAU AuAGcuAGGAucAuccuGGUsU 2030 R-008381837-000T 2398 151 CCAGGAUGAUCCUAGCUAU AuAGcuAGGAucAuccuGGUsU 2030 R-008381837-000T2398  151 CCAGGAUGAUCCUAGCUAU B CCSGgaUGaUCCUAgCUAUUsU B 2104R-008381824-000Z 2398  151 CCAGGAUGAUCCUAGCUAUB CCagGAUgAUCCUAGCUaUUsU B 2107 R-008381824-000Z 2398  151CCAGGAUGAUCCUAGCUAU AuAGcuAGGAucAuccuGGUsU 2030 R-008381810-000X 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUaUUsU B 2109R-008381810-000X 2398  151 CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU2036 R-008381802-000X 2398  151 CCAGGAUGAUCCUAGCUAUB cCAGgAUGaUCCUagCUAUUsU B 2110 R-008381802-000X 2398  151CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU 2036 R-008381820-000P 2398 151 CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU 2036 R-008381820-000P2398  151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2113R-008381819-000A 2398  151 CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU2037 R-008381819-000A 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGGAUGAUCCUagCUaUUsU B 2115 R-008381787-000V 2398  151CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2037 R-008381787-000V 2398 151 CCAGGAUGAUCCUAGGUAU B CCAgGAUgaUCCUaGCUAUUsU B 2117R-008381835-000A 2398  151 CCAGGAUGAUCCUAGCUAUB CCaggaUgaUCCUagCUaUUsU B 2118 R-008381835-000A 2398  151CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2037 R-008381844-000J 2398 151 CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2038 R-008381844-000J2398  151 CCAGGAUGAUCCUAGCUAU B CCAgGAUGAUCCUAGcUAUUsU B 2121R-008381853-000T 2398  151 CCAGGAUGAUCCUAGCUAUB CCaGGaUGAUCCUAGCUAUUsU B 2123 R-008381853-000T 2398  151CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2038 R-008381833-000H 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGaUGaUCCuAgCUAUUsU B 2124R-008381833-000H 2398  151 CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU2038 R-008381817-000H 2398  151 CCAGGAUGAUCCUAGCUAUAUAucuAGGAucAuccuGGUsU 2032 R-008381817-000H 2398  151CCAGGAUGAUCCUAGCUAU B cCAGGaUGAuCCUaGCUaUUsU B 2126 R-008381786-000L2398  151 CCAGGAUGAUCCUAGCUAU AUAGcuAGGAucAuccuGGUsU 2032R-008381786-000L 2398  151 CCAGGAUGAUCCUAGCUAUB CCaGgAUgAuCCUAGcUAUUsU B 2129 R-008381851-000A 2398  151CCAGGAUGAUCCUAGCUAU AUAGcuAGGAucAuccuGGUsU 2032 R-008381851-000A 2398 151 CCAGGAUGAUCCUAGCUAU B CcaggAugaUCCUAGCUaUUsU B 2130R-008381809-000H 2398  151 CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU2039 R-008381809-000H 2398  151 CCAGGAUGAUCCUAGCUAUB CCAgGaUGAUcCUaGCUAUUsU B 2133 R-008381808-000Z 2398  151CCAGGAUGAUCCUAGCUAU B CCAggaUGAUCCUAgCUAuUsU B 2135 R-008381808-000Z2398  151 CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU 2039R-008381784-000U 2398  151 CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU2039 R-008381784-000U 2398  151 CCAGGAUGAUCCUAGCUAUB CCAGgAUgAUCCUAGcuaUUsU B 2136 R-008381793-000C 1870  194ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2043 R-008381793-000C 1870 194 ACGACUAGUUCAGUUGCUU B ACgACuAgUUcAGUUGCUUUsU B 2139R-008381807-000R 1870  194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU2043 R-008381807-000R 1870  194 ACGACUAGUUCAGUUGCUUB aCGACUAGuUCAgUugcUUUsU B 2141 R-008381816-000Z 1870  194ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2043 R-008381816-000Z 1870 194 ACGACUAGUUCAGUUGCUU B aCGACUagUUCaGUUgCUUUsU B 2142R-008381830-000G 1870  194 ACGACUAGUUCAGUUGCUU AAGCaaCugaaCUagUCgUUsU2049 R-008381830-000G 1870  194 ACGACUAGUUCAGUUGCUUB aCgaCuAGUuCAgUUgcUUUsU B 2145 R-008381782-000B 1870  194ACGACUAGUUCAGUUGCUU B aCgaCUAguUCAGUUGCUUUsU B 2147 R-008381782-000B1870  194 ACGACUAGUUCAGUUGCUU AAGCaaCugaaCUagUCgUUsU 2049R-008381849-000C 1870  194 ACGACUAGUUCAGUUGCUUB ACGaCUAGUUCAGUUGCuUUsU B 2148 R-008381849-000C 1870  194ACGACUAGUUCAGUUGCUU AAGCaaCugaaCUagUCgUUsU 2049 R-008381781-000T 1870 194 ACGACUAGUUCAGUUGCUU B ACgACUAGUUCaGUUGcUUUsU B 2150R-008381781-000T 1870  194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU2050 R-008381829-000T 1870  194 ACGACUAGUUCAGUUGCUUB acGACUagUUCagUuGCuUUsU B 2152 R-008381829-000T 1870  194ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU 2050 R-008381792-000U 1870 194 ACGACUAGUUCAGUUGCUU B aCGScUAGUUCAGUUgCUUUsU B 2154R-008381792-000U 1870  194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU2050 R-008381798-000W 1870  194 ACGACUAGUUCAGUUGCUUAAGCAACUGAACUAGUCGUUsU 2051 R-008381798-000W 1870  194ACGACUAGUUCAGUUGCUU B ACGACUaGUUCaGUUgCUUUsU B 2156 R-008381828-000J1870  194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU 2051R-008381828-000J 1870  194 ACGACUAGUUCAGUUGCUUB ACGaCUaGUUCAGUUGcUUUsU B 2158 R-008381840-000Z 1870  194ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU 2051 R-008381840-000Z 1870 194 ACGACUAGUUCAGUUGCUU B ACgACUAgUUCAgUUgCUUUsU B 2161R-008381797-000M 1870  194 ACGACUAGUUCAGUUGCUUB ACGaCUaGuUCagUUGCUUUsU B 2162 R-008381797-000M 1870  194ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2045 R-008381813-000Y 1870 194 ACGACUAGUUCAGUUGCUU B ACGaCUaGUUCaguUgCUuUsU B 2165R-008381813-000Y 1870  194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU2045 R-008381827-000A 1870  194 ACGACUAGUUCAGUUGCUUB ACGACUAGUUCAGUUGCUUUsU B 2167 R-008381827-000A 1870  194ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2045 R-008381812-000P 1870 194 ACGACUAGUUCAGUUGCUU B aCgaCUAGUUCaGUUGCUUUsU B 2169R-008381812-000P 1870  194 ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU2052 R-008381848-000U 1870  194 ACGACUAGUUCAGUUGCUUB ACgAcUAgUuCAgUUGGUUUsU B 2170 R-008381848-000U 1870  194ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU 2052 R-008381779-000V 1870 194 ACGACUAGUUCAGUUGCUU B aCgaCUagUUCagUUgCUUUsU B 2173R-008381779-000V 1870  194 ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU2052 R-008381846-000B 2401  196 GGAUGAUCCUAGCUAUCGUAcGAuAGcuAGGAucAuccUsU 2056 R-008381846-000B 2401  196GGAUGAUCCUAGCUAUCGU B gGaugaUcCUaGCuAUCgUUsU B 2174 R-008381811-000F2401  196 GGAUGAUCCUAGCUAUCGU B GgAUGaUCCuagcUAUCgUUsU B 2177R-008381811-000F 2401  196 GGAUGAUCCUAGCUAUCGU AcGAuAGcuAGGAucAuccUsU2056 R-008381845-000T 2401  196 GGAUGAUCCUAGCUAUCGUB gGAUgAUCCUAGCuaUCGUUsU B 2179 R-008381845-000T 2401  196GGAUGAUCCUAGCUAUCGU AcGAuAGcuAGGAucAuccUsU 2056 R-008381795-000V 2401 196 GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU 2062 R-008381795-000V2401  196 GGAUGAUCCUAGCUAUCGU B gGAUGAUCCUAgCUauCGUUsU B 2181R-008381823-000R 2401  196 GGAUGAUCCUAGCUAUCGU ACGaUagCUaggaUCaUCCUsU2062 R-008381823-000R 2401  196 GGAUGAUCCUAGCUAUCGUB ggaUgaUCCUagCUaUCgUUsU B 2182 R-008381803-000F 2401  196GGAUGAUCCUAGCUAUCGU ACGaUagCUaggaUCaUCCUsU 2062 R-008381803-000F 2401 196 GGAUGAUCCUAGCUAUCGU B GGaUGAUCCUAGCUaUCgUUsU B 2185R-008381822-000G 2401  196 GGAUGAUCCUAGCUAUCGUB GGaUGAUCCUaGCUAUCgUUsU B 2187 R-008381822-000G 2401  196GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU 2063 R-008381836-000J 2401 196 GGAUGAUCCUAGCUAUCUU B gGaUgAUCCUaGCUAUCGUUsU B 2188R-008381836-000J 2401  196 GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU2063 R-008381854-000B 2401  196 GGAUGAUCCUAGCUAUCGUB GgAUGauCCUAGCUAUCguUsU B 2191 R-008381854-000B 2401  196GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU 2063 R-008381801-000N 2401 196 GGAUGAUCCUAGCUAUCUU B GgaUgAUCcUagCUaUCGuUsU B 2192R-008381801-000N 2401  196 GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU2064 R-008381800-000E 2401  196 GGAUGAUCCUAGCUAUCGUB GGAUGaUCCUsGCUaUchUsU B 2194 R-008381800-000E 2401  196GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU 2064 R-008381834-000S 2401 196 GGAUGAUCCUAGCUAUCGU B GgSUGSUCCUagCUAUCGUUsU B 2197R-008381834-000S 2401  196 GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU2064 R-008381852-000J 2401  196 GGAUGAUCCUAGCUAUCGUACGAuAGcuAGGAucAuccUsU 2058 R-008381852-000J 2401  196GGAUGAUCCUAGCUAUCGU B GGAUGAuCCUaGCUAUCGUUsU B 2199 R-008381843-000A2401  196 GGAUGAUCCUAGCUAUCGU ACGAuAGcuAGGAucAuccUsU 2058R-008381843-000A 2401  196 GGAUGAUCCUAGCUAUCGUB GgaUGaUCCUAgCUAUCGUUsU B 2201 R-008381832-000Z 2401  196GGAUGAUCCUAGCUAUCGU ACGAuAGcuAGGAucAuccUsU 2058 R-008381832-000Z 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUgAUCCUAgcUAUCgUUsU B 2203R-008381818-000S 2401  196 GGAUGAUCCUAGCUAUCGUB GGaUgaUCCuAGCuAUCGUUsU B 2204 R-008381818-000S 2401  196GGAUGAUCCUAGCUAUCGU A CGaUagCUaggaUCaUCCUsU 2065 R-008381785-000C 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUagCUAuCGUUsU B 2206R-008381785-000C 2401  196 GGAUGAUCCUAGCUAUCGU A CGaUagCUaggaUCaUCCUsU2065 R-008381794-000L 2401  196 GGAUGAUCCUAGCUAUCGUA CGaUagCUaggaUCaUCCUsU 2065 R-008381794-000L 2401  196GGAUGAUCCUAGCUAUCGU B gGAUgaUCCUAGCUaUCGUUsU B 2208 R-008395187-000D1797    5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAATT B 2210R-008395187-000D 1797    5 CUGUUGGAUUGAUUCGAAA UUUcGAAucAAuccAAcAGUU1463 R-008395214-000T 1797    5 CUGUUGGAUUGAUUCGAAAB cuGuuGGAuuGAuucGAAATT B 2210 R-008395244-000T 1797    5CUGUUGGAUUGAUUCGAAA IUUcGAAucAAuccAAcAGUU 2211 R-008395198-000E 1797   5 CUGUUGGAUUGAUUCGAAA UIUcGAAucAAuccAAcAGUU 2212 R-008395198-000E1797    5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAATT B 2210R-008395222-000R 1797    5 CUGUUGGAUUGAUUCGAAA UUIcGAAucAAuccAAcAGUU2213 R-008395222-000R 1797    5 CUOUUGGAUUGAUUCGAAAB cuGuuGGAuuGAuucGAAATT B 2210 R-008395155-000J 1797    5CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAATT B 2210 R-008395155-000J 1797   5 CUGUUGGAUUGAUUCGAAA UUUIGAAucAAuccAAcAGUU 2214 R-008395242-000A1797    5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAATT B 2210R-008395242-000A 1797    5 CUGUUGGAUUGAUUCGAAA UUUcIAAucAAuccAAcAGUU2215 R-008395267-000D 1797    5 CUGUUGGAUUGAUUCGAAAB cuGuuGGAuuGAuucGAAATT B 2210 R-008395267-000D 1797    5CUGUUGGAUUGAUUCGAAA UUUcGIAucAAuccAAcAGUU 2216 R-008395153-000S 1797   5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAATT B 2210 R-008395153-000S1797    5 CUGUUGGAUUGAUUCGAAA UUUcGAUucAAuccAAcAGUU 2217R-008395286-000E 1797    5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAATT B2210 R-008395286-000E 1797    5 CUGUUGGAUUGAUUCGAAAUUUcGAAIcAAuccAAcAGUU 2218 R-008395196-000M 1870  194ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B 2219 R-008395196-000M 1870 194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUU 1841 R-008395168-000C1870  194 ACGACUAGUUCAGUUGCUU IAGcAAcuGAAcuAGucGuUU 2220R-008395168-000C 1870  194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B2219 R-008395265-000L 1870  194 ACGACUAGUUCAGUUGCUUAIGcAAcuGAAcuAGucGuUU 2221 R-008395265-000L 1870  194ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B 2219 R-008395150-000R 1870 194 ACGACUAGUUCAGUUGCUU AAIcAAcuGAAcuAGucGuUU 2222 R-008395150-000R1870  194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B 2219R-008395263-000U 1870  194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B2219 R-008395263-000U 1870  194 ACGACUAGUUCAGUUGCUUAAGIAAcuGAAcuAGucGuUU 2223 R-008395172-000T 1870  194ACGACUAGUUCAGUUGCUU AAGcIAcuGAAcuAGucGuUU 2224 R-008395172-000T 1870 194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B 2219 R-008395170-000A1870  194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B 2219R-008395170-000A 1870  194 ACGACUAGUUCAGUUGCUU AAGcAIcuGAAcuAGucGuUU2225 R-008395226-000A 1870  194 ACGACUAGUUCAGUUGCUUB AcGAcuAGuucAGuuGcuuTT B 2219 R-008395226-000A 1870  194ACGACUAGUUCAGUUGCUU AAGcAAIuGAAcuAGucGuUU 2226 R-008395207-000Z 1870 194 ACGACUAGUUCAGUUGCUU AAGcAAcIGAAcuAGucGuUU 2227 R-008395207-000Z1870  194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B 2219R-008395205-000G 2398  151 CCAGGAUGAUCCUAGCUAU AUAGcuAGGAucAuccuGGUU1755 R-008395205-000G 2398  151 CCAGGAUGAUCCUAGCUAUB ccAGGAuGAuccuAGcuAuTT B 2228 R-008395250-000A 2398  151CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuTT B 2228 R-008395250-000A 2398 151 CCAGGAUGAUCCUAGCUAU IUAGcuAGGAucAuccuGGUU 2229 R-008395248-000C2398  151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuTT B 2228R-008395248-000C 2398  151 CCAGGAUGAUCCUAGCUAU AIAGcuAGGAucAuccuGGUU2230 R-008395275-000D 2398  151 CCAGGAUGAUCCUAGCUAUAUIGcuAGGAucAuccuGGUU 2231 R-008395275-000D 2398  151CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuTT B 2228 R-008395163-000J 2398 151 CCAGGAUGAUCCUAGCUAU AUAIcuAGGAucAuccuGGUU 2232 R-008395163-000J2398  151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuTT B 2228R-008395224-000H 2398  151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuTT B2228 R-008395224-000H 2398  151 CCAGGAUGAUCCUAGCUAUAUAGIuAGGAucAuccuGGUU 2233 R-008395161-000S 2398  151CCAGGAUGAUCCUAGCUAU AUAGcIAGGAucAuccuGGUU 2234 R-008395161-000S 2398 151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuTT B 2228 R-008395290-000V2398  151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuTT B 2228R-008395290-000V 2398  151 CCAGGAUGAUCCUAGCUAU AUAGcuIGGAucAuccuGGUU2235 R-008395273-000L 2398  151 CCAGGAUGAUCCUAGCUAUB ccAGGAuGAuccuAGcuAuTT B 2228 R-008395273-000L 2398  151CCAGGAUGAUCCUAGCUAU AUAGcuAIGAucAuccuGGUU 2236 R-008395188-000M 2401 196 GGAUGAUCCUAGCUAUCGU ACGAuAGcuAGGAucAuccUU 1845 R-008395188-000M2401  196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuTT B 2237R-008395204-000Y 2401  196 GGAUGAUCCUAGCUAUCGU ICGAuAGcuAGGAucAuccUU2238 R-008395204-000Y 2401  196 GGAUGAUCCUAGCUAUCGUB GGAuGAuccuAGcuAucGuTT B 2237 R-008395202-000F 2401  196GGAUGAUCCUAGCUAUCGU AIGAuAGcuAGGAucAuccUU 2239 R-008395202-000F 2401 196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuTT B 2237 R-008395158-000K2401  196 GGAUGAUCCUAGCUAUCGU ACIAuAGcuAGGAucAuccUU 2240R-008395158-000K 2401  196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuTT B2237 R-008395296-000K 2401  196 GGAUGAUCCUAGCUAUCGUACGIuAGcuAGGAucAuccUU 2241 R-008395246-000K 2401  196GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuTT B 2237 R-008395271-000U 2401 196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuTT B 2237 R-008395271-000U2401  196 GGAUGAUCCUAGCUAUCGU ACGAIAGcuAGGAucAuccUU 2242R-008395200-000N 2401  196 GGAUGAUCCUAGCUAUCGU ACGAuIGcuAGGAucAuccUU2243 R-008395200-000N 2401  196 GGAUGAUCCUAGCUAUCGUB GGAuGAuccuAGcuAucGuTT B 2237 R-008395288-000X 2401  196GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuTT B 2237 R-008395288-000X 2401 196 GGAUGAUCCUAGCUAUCGU ACGAuAIcuAGGAucAuccUU 2244 R-008395269-000W2401  196 GGAUGAUCCUAGCUAUCGU ACGAuAGIuAGGAucAuccUU 2245R-008395269-000W 2401  196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuTT B2237 R-008397891-000B 1382  238 GAUCCAAGUCAACGUCUUGB GAUCCAAGUCAACGUCUUGTT B 2246 R-008397891-000B 1382  238GAUCCAAGUCAACGUCUUG CAAGACGUUGACUUGGAUCUU 2247 R-008397894-000C  828 239 CUAUCAUGCGUUCUCCUCA B CUAUCAUGCGUUCUCCUCATT B 2248 R-008397894-000C 828  239 CUAUCAUGCGUUCUCCUCA UGAGGAGAACGCAUGAUAGUU 2249R-008396925-000E 1244  240 AAUAUAAUGAGGACCUAUA B ASUAUSAUGAGGACCUAUATT B2250 R-008396925-000E 1244  240 AAUAUAAUGAGGACCUAUAUAUAGGUCCUCAUUAUAUUUU 2251 R-008395991-000K 1304  241GUGCUAUCUGUCUGCUCUA B GUGCUAUGUGUCUGCUCUATT B 2252 R-008395941-000K 1304 241 GUGCUAUCUGUCUGCUCUA UAGAGCAGACAGAUAGCACUU 2253 R-008395944-000L 812  242 GAAGCUUCCAGACACGCUA B GAAGCUUCCAGACACGCUATT B 2254R-008395944-000L  812  242 GAAGCUUCCAGACACGCUA UAGCGUGUCUGGAAGCUUCUU2255 R-008397498-000Y 1558  243 UAAUUAUAAGAACAAGAUGB UAAUUAUAAGAACAAGAUGTT B 2256 R-008397498-000Y 1558  243UAAUUAUAAGAACAAGAUG CAUCUUGUUCUUAUAAUUAUU 2257 R-008397501-000R  879 244 AUACAAAUGAUGUAGAAAC B AUACAAAUGAUGUAGAAACTT B 2258 R-008397501-000R 879  244 AUACAAAUGAUGUAGAAAC GUUUCUACAUCAUUUGUAUUU 2259R-008396451-000Y 1311  245 CUGUCUGCUCUAGUAAUAA UUAUUACUAGAGCAGACAGUU2261 R-008396451-000Y 1311  245 CUGUCUGCUCUAGUAAUAAB CUGUCUGCUCUAGUAAUAATT B 2260 R-008397504-000S  856  246UGCUAUUGUACGUACCAUG B UGCUAUUGUACGUACCAUGTT B 2262 R-008397504-000S  856 246 UGCUAUUGUACGUACCAUG CAUGGUACGUACAAUAGCAUU 2263 R-008396961-000P1296  247 UGCUGAAGGUGCUAUCUGU B UGCUGAAGGUGCUAUCUGUTT B 2264R-008396961-000P 1296  247 UGCUGAAGGUGCUAUCUGU ACAGAUAGCACCUUCAGCAUU2265 R-008396967-000S 1235   39 GCUUUAGUAAAUAUAAUGAB GCUUUAGUAAAUAUAAUGATT B 2266 R-008396967-000S 1235   39GCUUUAGUAAAUAUAAUGA UCAUUAUAUUUACUAAAGCUU 2267 R-008396463-000H  960 248 UCUUUAAGUCUGGAGGCAU AUGCCUCCAGACUUAAAGAUU 2269 R-008396463-000H 960  248 UCUUUAAGUCUGGAGGCAU B UCUUUAAGUCUGGAGGCAUTT B 2268R-008398998-000S 2099  249 AUACCAUUCCAUUGUUUGU B AUACCAUUCCAUUGUUUGUTT B2270 R-008398998-000S 2049  249 AUACCAUUCCAUUGUUUGUACAAACAAUGGAAUGGUAUUU 2271 R-008398515-000M 1791  250AGGCUACUGUUGGAUUGAU AUCAAUCCAACAGUAGCCUUU 2273 R-008398515-000M 1791 250 AGGCUACUGUUGGAUUGAU B AGGCUACUGUUGGAUUGAUTT B 2272 R-008395947-000M 783  251 CAGUUAUGGUCCAUCAGCU B CAGUUAUGGUCCAUCAGCUTT B 2274R-008395997-000M  783  251 CAGUUAUGGUCCAUCAGCU AGCUGAUGGACCAUAACUGUU2275 R-008396466-000J 1569  252 ACAAGAUGAUGGUCUGCCAB ACAAGAUGAUGGUCUGCCATT B 2276 R-008396466-000J 1569  252ACAAGAUGAUGGUCUGCCA UGGCAGACCAUCAUCUUGUUU 2277 R-008396970-000Y 2224 253 GACAUAUGCAGCUGCUGUU AACAGCAGCUGCAUAUGUCUU 2279 R-008396970-000Y2224  253 GACAUAUGCAGCUGCUGUU B GACAUAUGCAGGUGCUGUUTT B 2278R-008395989-000Z 1882  123 GUUGCUUGUUCGUGCACAU B GUUGCUUGUUCGUGCACAUTT B2280 R-008395989-000Z 1882  123 GUUGCUUGUUCGUGCACAUAUGUGCACGAACAAGCAACUU 2281 R-008398626-000Y  934  254CCAUCAUCGUGAGGGCUUA B CCAUCAUCGUGAGGGCUUATT B 2282 R-008398626-000Y  934 254 CCAUCAUCGUGAGGGCUUA UAAGCCCUCACGAUGAUGGUU 2283 R-008396121-000S1378  255 GACAGAUCCAAGUCAACGU B GACAGAUCCAAGUCAACGUTT B 2284R-008396121-000S 1378  255 GACAGAUCCAAGUCAACGU ACGUUGACUUGGAUCUGUCUU2285 R-008396001-000X  569  256 GAGACAUUAGAUGAGGGCAUGCCCUCAUCUAAUGUCUCUU 2287 R-008396001-000X  569  256GAGACAUUAGAUGAGGGCA B GAGACAUUAGAUGAGGGCATT B 2286 R-008396007-000Z 1722 257 UUCGCCUUCACUAUGGACU B UUCGCCUUCACUAUGGACUTT B 2288 R-008396007-000Z1722  257 UUCGCCUUCACUAUGGACU AGUCCAUAGUGAAGGCGAAUU 2289R-008396547-000T 1483  258 UGUUCAGCUUCUGGGUUCA B UGUUCAGCUUCUGGGUUCATT B2290 R-008396547-000T 1483  258 UGUUCAGCUUCUGGGUUCAUGAACCCAGAAGCUGAACAUU 2291 R-008399088-000F 2352  259AUCUUGGACUUGAUAUUGG CCAAUAUCAAGUCCAAGAUUU 2293 R-008399088-000F 2352 259 AUCUUGGACUUGAUAUUGG B AUCUUGGACUUGAUAUUGGTT B 2292 R-008398596-000K 719  260 CGUGCAAUCCCUGAACUGA B CGUGCAAUCCCUGAACUGATT B 2294R-008398596-000K  719  260 CGUGCAAUCCCUGAACUGA UCAGUUCAGGGAUUGCACGUU2295 R-008399094-000N  762  261 AGGUGGUGGUUAAUAAGGCB AGGUGGUGGUUAAUAAGGCTT B 2296 R-008399094-000N  762  261AGGUGGUGGUUAAUAAGGC GCCUUAUUAACCACCACCUUU 2297 R-008397585-000P  599 262 UCUACACAGUUUGAUGCUG B UCUACACAGUUUGAUGCUGTT B 2298 R-008397585-000P 599  262 UCUACACAGUUUGAUGCUG CAGCAUCAAACUGUGUAGAUU 2299R-008396073-000L 1704  263 AGAUGGCCCAGAAUGCAGU B AGAUGGCCCAGAAUGCAGUTT B2300 R-008396073-000L 1704  263 AGAUGGCCCAGAAUGCAGUACUGCAUUCUGGGCCAUCUUU 2301 R-008398599-000L 2270  264CAAGAUUACAAGAAACGGC GCCGUUUCUUGUAAUCUUGUU 2303 R-008398599-000L 2270 264 CAAGAUUACAAGAAACGGC B CAAGADUACAAGAAACGGCTT B 2302 R-008399532-000R1810  103 UCGAAAUCUUGCCCUUUGU ACAAAGGGCAAGAUUUCGAUU 2305R-008399532-000R 1810  103 UCGAAAUCUUGCCCUUUGU B UCGAAAUCUUGCCCUUUGUTT B2304 R-008398602-000D  662  265 CUGAAACAUGCAGUUGUAAB CUGAAACAUGCAGUUGUAATT B 2306 R-008398602-000D  662  265CUGAAACAUGCAGUUGUAA UUACAACUGCAUGUUUCAGUU 2307 R-008399106-000J  396 266 CUCCUUCUCUGAGUGGUAA UUACCACUCAGAGAAGGAGUU 2309 R-008399106-000J 396  266 CUCCUUCUCUGAGUGGUAA B CUCCUUCUCUGAGUGGUAATT B 2308R-008398053-000R 1199  267 AGCAAGCUCAUCAUACUGG CCAGUAUGAUGAGCUUGCUUU2311 R-008398053-000R 1199  267 AGCAAGCUCAUCAUACUGGB AGCAAGCUCAUCAUACUGGTT B 2310 R-008396583-000C 1560  268AUUAUAAGAACAAGAUGAU B AUUAUAAGAACAAGAUGAUTT B 2312 R-008396583-000C 1560 268 AUUAUAAGAACAAGAUGAU AUCAUCUUGUUCUUAUAAUUU 2313 R-008399028-000B 593   92 AUCCCAUCUACACAGUUUG CAAACUGUGUAGAUGGGAUUU 2315R-008399028-000B  593   92 AUCCCAUCUACACAGUUUG B AUCCCAUCUACACAGUUUGTT B2314 R-008398104-000X 1310  269 UCUGUCUGCUCUAGUAAUAB UCUGUCUGCUCUAGUAAUATT B 2316 R-008398104-000X 1310  269UCUGUCUGCUCUAGUAAUA UAUUACUAGAGCAGACAGAUU 2317 R-008398113-000F 1233 270 AAGCUUUAGUAAAUAUAAU B AAGCUUUAGUAAAUAUAAUTT B 2318 R-008398113-000F1233  270 AAGCUUUAGUAAAUAUAAU AUUAUAUUUACUAAAGCUUUU 2319R-008399622-000H 1330  271 GCCGGCUAUUGUAGAAGCU B GCCGGCUAUUGUAGAAGCUTT B2320 R-008399622-000H 1330  271 GCCGGCUAUUGUAGAAGCUAGCUUCUACAAUAGCCGGCUU 2321 R-008399151-000C 1312  272UGUCUGCUCUAGUAAUAAG B UGUCUGCUCUAGUAAUAAGTT B 2322 R-008399151-000C 1312 272 UGUCUGCUCUAGUAAUAAG CUUAUUACUAGAGCAGACAUU 2323 R-008396127-000U1556  273 AAUAAUUAUAAGAACAAGA UCUUGUUCUUAUAAUUAUUUU 2325R-008396127-000U 1556  273 AAUAAUUAUAAGAACAAGA B AAUAAUUAUAAGAACAAGATT B2324 R-008395707-000Y 2438  274 UAUGGCCAGGAUGCCUUGGB UAUGGCCAGGAUGCCUUGGTT B 2326 R-008395707-000Y 2438  274UAUGGCCAGGAUGCCUUGG CCAAGGCAUCCUGGCCAUAUU 2327 R-008395710-000E 1826 275 UGUCCCGCAAAUCAUGCAC GUGCAUGAUUUGCGGGACAUU 2329 R-008395710-000E1826  275 UGUCCCGCAAAUCAUGCAC B UGUCCCGCAAAUCAUGCACTT B 2328R-008395713-000F 1397  276 CUUGUUCAGAACUGUCUUU B CUUGUUCAGAACUGUCUUUTT B2330 R-008395713-000F 1397  276 CUUGUUCAGAACUGUCUUUAAAGACAGUUCUGAACAAGUU 2331 R-008395716-000G 3181  277GCUGUGAUACGAUGCUUCA UGAAGCAUCGUAUCACAGCUU 2333 R-008395716-000G 3181 277 GCUGUGAUACGAUGCUUCA B GCUGUGAUACGAUGCUUCATT B 2332 R-008395719-000H1912  278 GCGCCGUACGUCCAUGGGU B GCGCCGUACGUCCAUGGGUTT B 2334R-008395719-000H 1912  278 GCGCCGUACGUCCAUGGGU ACCCAUGGACGUACGGCGCUU2335 R-008395722-000P  846  279 AGAUGGUGUCUGCUAUUGUB AGAUGGUGUCUGCUAUUGUTT B 2336 R-008395722-000P  846  279AGAUGGUGUCUGCUAUUGU ACAAUAGCAGACACCAUCUUU 2337 R-008395725-000R 1404 280 AGAACUGUCUUUGGACUCU B AGAACUGUCUUUGGACUCUTT B 2338 R-008395725-000R1404  280 AGAACUGUCUUUGGACUCU AGAGUCCAAAGACAGUUCUUU 2339R-008395728-000S  586  281 CAUGCAGAUCCCAUCUACA UGUAGAUGGGAUCUGCAUGUU2341 R-008395728-000S  586  281 CAUGCAGAUCCCAUCUACAB CAUGCAGAUCCCAUCUACATT B 2340 R-008395731-000Y 1469  282CUCCUUGGGACUCUUGUUC GAACAAGAGUCCCAAGGAGUU 2343 R-008395731-000Y 1469 282 CUCCUUGGGACUCUUGUUC B CUCCUUGGGACUCUUGUUCTT B 2342 R-008395734-000Z 380  283 GGUGCCACUACCACAGCGC B GGUGCCACUACCACAGCUCTT B 2344R-008395734-000Z  380  283 GGUGCCACUACCACAGCGC GAGCUGUGGUAGUGGCACCUU2345 R-008395737-000A 1345  284 AGCUGGUGGAAUGCAAGCUB AGCUGGUGGAAUGCAAGCUTT B 2346 R-008395737-000A 1345  284AGCUGGUGGAAUGCAAGCU AGCUUGCAUUCCACCAGCUUU 2347 R-008395740-000G 1863 285 CCAUUCCACGAGUAGUUCA B CCAUUCCACGACUAGUUCATT B 2348 R-008395740-000G1863  285 CCAUUCCACGAGUAGUUCA UGAACUAGUCGUGGAAUGGUU 2349R-008395743-000H  635  286 CAGCGUUUGGCUGAACCAU AUGGUUCAGCCAAACGCUGUU2351 R-008395743-000H  635  286 CAGCGUUUGGCUGAACCAUB CAGCGUUUGGCUGAACCAUTT B 2350 R-008395746-000J  959  287AUCUGUAAGUCUGGAGGCA UGCCUCCAGACUUAAAGAUUU 2353 R-008395746-000J  959 287 AUGUUUAAGGCUGGAGGCA B AUCUUUAAGUCUGGAGGCATT B 2352 R-008395749-000K2440  288 UGGCCAGGAUGCCUUGGGU B UGGCCAGGAUGCCUUGGGUTT B 2354R-008395749-000K 2440  288 UGGCCAGGAUGCCUUGGGU ACCCAAGGCAUCCUGGCCAUU2355 R-008395752-000S  877  289 GAAUACAAAUGAUGUAGAAUUCUACAUCAUUUGUAUUCUU 2357 R-008395752-000S  877  289GAAUACAAAUGAUGUAGAA B GAAUACAAAUGAUGUAGAATT B 2356 R-008395755-000T 2556 290 UGGAUGGGCUGCCUCCAGG CCUGGAGGCAGCCCAUCCAUU 2359 R-008395755-000T2556  290 UGGAUGGGCUGCCUCCAGG B UGGAUGGGCUGCCUCCAGGTT B 2358R-008395758-000U 1916  291 CGUACGUCCAUGGGUGGGA B CGUACGUCCAUGGGUGGGATT B2360 R-008395758-000U 1916  291 CGUACGUCCAUGGGUGGGAUCCCACCCAUGGACGUACGUU 2361 R-008395761-000A  850  292GGUGUCUGCUAUUGUACGU B GGUGUCUGGUAUUGUACGUTT B 2362 R-008395761-000A  850 292 GGUGUCUGCUAUUGUACGU ACGUACAAUAGCAGACACCUU 2363 R-008395764-000B1303  293 GGUGCUAUCUGUCUGCUCU B GGUGCUAUCUGUCUGCUCUTT B 2364R-008395764-000B 1303  293 GGUGCUAUCUGUCUGCUCU AGAGCAGACAGAUAGCACCUU2365 R-008395767-000C 1726  294 CCUUCACUAUGGACUACCAUGGUAGUCCAUAGUGAAGGUU 2367 R-008395767-000C 1726  294CCUUCACUAUGGACUACCA B CCUUCACUAUGGACUACCATT B 2366 R-008395770-000J 1477 295 GACUCUUGUUCAGCUUCUG CAGAAGCUGAACAAGAGUCUU 2369 R-008395770-000J1477  295 GACUCUUGUUCAGCUUCUG B GACUCUUGUUCAGCUUCUGTT B 2368R-008395773-000K  598  296 AUCUACACAGUUUGAUGCU B AUCUACACAGUUUGAUGCUTT B2370 R-008395773-000K  598  296 AUCUACACAGUUUGAUGCUAGCAUCAAACUGUGUAGAUUU 2371 R-008395776-000L 2062  297GUUUGUGCAGCUGCUUUAU B GUUUGUGCAGGUGCUUUAUTT B 2372 R-008395776-000L 2062 297 GUUUGUGCAGCUGCUUUAU AUAAAGCAGCUGCACAAACUU 2373 R-008395779-000M2278  298 CAAGAAACGGCUUUCAGUU B CAAGAAACGGCUUUCAGUUTT B 2374R-008395779-000M 2278  298 CAAGAAACGGCUUUCAGUU AACUGAAAGCCGUUUCUUGUU2375 R-008395782-000U 1877  299 GUUCAGUUGCUUGUUCGUGCACGAACAAGCAACUGAACUU 2377 R-008395782-000U 1877  299GUUCAGUUGCUUGUUCGUG B GUUCAGUUGCUUGUUCGUGTT B 2376 R-008395785-000V 1499 300 UCAGAUGAUAUAAAUGUGG B UCAGAUGAUAUAAAUGUGGTT B 2378 R-008395785-000V1499  300 UCAGAUGAUAUAAAUGUGG CCACAUUUAUAUCAUCUGAUU 2379R-008395788-000W 1136  301 AAUGUUAAAUUCUUGGCUA B AAUGUUAAAUUCUUGGGUATT B2380 R-008395788-000W 1136  301 AAUGUUAAAUUCUUGGCUAUAGCCAAGAAUUUAACAUUUU 2381 R-008395791-000C 1494  302UGGGUUCAGAUGAUAUAAA UUUAUAUCAUCUGAACCCAUU 2383 R-008395791-000C 1494 302 UGGGUUCAGAUGAUAUAAA B UGGGIICAGAIGAIAIAAATT B 2382 R-008395794-000D1972  303 AAUAGUUGAAGGUUGUACC B AAUAGUUGAAGGUUGUACCTT B 2384R-008395794-000D 1972  303 AAUAGUUGAAGGUUGUACC GGUACAACCUUCAACUAUUUU2385 R-008395797-000E  668  304 CAUGCAGUUGUAAACUUGAUCAAGUUUACAACUGCAUGUU 2387 R-008395797-000E  668  304CAUGCAGUUGUAAACUUGA B CAUGCAGUUGUAAACUUGATT B 2386 R-008395800-000X 2945 305 AAUCUGAAUAAAGUGUAAC GUUACACUUUAUUCAGAUUUU 2389 R-008395800-000X2945  305 AAUCUGAAUAAAGUGUAAC B AAUCUGAAUAAAGUGUAACTT B 2388R-008395803-000Y 2492  306 CACCACCCUGGUGCUGACU B CACCACCCUGGUGCUGACUTT B2390 R-008395803-000Y 2492  306 CACCACCCUGGUGCUGACUAGUCAGCACCAGGGUGGUGUU 2391 R-008395806-000Z  293  307GAGUUGGACAUGGCCAUGG B GAGUUGGACAUGGCCAUGGTT B 2392 R-008395806-000Z  293 307 GAGUUGGACAUGGCCAUGG CCAUGGCCAUGUCCAACUCUU 2393 R-008395809-000A1905  308 AUACCCAGCGCCGUACGUC B AUACCCAGCGCCGUACGUCTT B 2394R-008395809-000A 1905  308 AUACCCAGCGCCGUACGUC GACGUACGGCGCUGGGUAUUU2395 R-008395812-000G  944  309 GAGGGCUUACUGGCCAUCUAGAUGGCCAGUAAGCCCUCUU 2397 R-008395812-000G  944  309GAGGGCUUACUGGCCAUCU B GAGGGCUUACUGGCCAUCUTT B 2396 R-008395815-000H  581 310 GAGGGCAUGCAGAUCCCAU B GAGGGCAUGCAGAUCCCAUTT B 2398 R-008395815-000H 581  310 GAGGGCAUGCAGAUCCCAU AUGGGAUCUGCAUGCCCUCUU 2399R-008395818-000J 1454  311 GAAGGGAUGGAAGGUCUCC B GAAGGGAUGGAAGGUCUCCTT B2400 R-008395818-000J 1454  311 GAAGGGAUGGAAGGUCUCCGGAGACCUUCCAUCCCUUCUU 2401 R-008395821-000R 2254  312GUCUGAGGACAAGCCACAA B GUCUGAGGACAAGCCACAATT B 2402 R-008395821-000R 2254 312 GUCUGAGGACAAGCCACAA UUGUGGCUUGUCCUCAGACUU 2403 R-008395824-000S1837  313 UCAUGCACCUUUGCGUGAG CUCACGCAAAGGUGCAUGAUU 2405R-008395824-000S 1837  313 UCAUGCACCUUUGCGUGAG B UCAUGCACCUUUGCGUGAGTT B2404 R-008395827-000T 1425  314 GGAAUCUUUCAGAUGCUGCB GGAAUCUUUCAGAUGCUGCTT B 2406 R-008395827-000T 1425  314GGAAUCUUUCAGAUGCUGC GCAGCAUCUGAAAGAUUCCUU 2407 R-008395830-000Z 1372 315 UCACCUGACAGAUCCAAGU ACUUGGAUCUGUCAGGUGAUU 2409 R-008395830-000Z1372  315 UCACCUGACAGAUCCAAGU B UCACCUGACAGAUCCAAGUTT B 2408R-008395833-000A 1298  316 CUGAAGGUGCUAUCUGUCU B CUGAAGGUGCUAUCUGUCUTT B2410 R-008395833-000A 1298  316 CUGAAGGUGCUAUCUGUCUAGACAGAUAGCACCUUCAGUU 2411 R-008395836-000B 1674  317GUCAUCUGACCAGCCGACA B GUCAUCUGACCAGCCGACATT B 2412 R-008395836-000C 1674 317 GUCAUCUGACCAGCCGACA UGUCGGCUGGUCAGAUGACUU 2413 R-008395839-000C1864  318 CAUUCCACGACUAGUUCAG CUGAACUAGUCGUGGAAUGUU 2415R-008395839-000C 1864  318 CAUUCCACGACUAGUUCAG B CAUUCCACGACUAGUUCAGTT B2414 R-008395842-000J 2404  319 UGAUCCUAGCUAUCGUUCUAGAACGAUAGCUAGGAUCAUU 2417 R-008395842-000J 2404  319UGAUCCUAGCUAUCGUUCU B UGAUCCUAGCUAUCGUUCUTT B 2416 R-008395845-000K 1992 320 GAGCCCUUCACAUCCUAGC GCUAGGAUGUGAAGGGCUCUU 2419 R-008395845-000K1992  320 GAGCCCUUCACAUCCUAGC B GAGCCCUUCACAUCCUAGCTT B 2418R-008395848-000L 2124   73 GUGAACUUGCUCAGGACAA UUGUCCUGAGCAAGUUCACUU2421 R-008395848-000L 2124   73 GUGAACUUGCUCAGGACAAB GUGAACUUGCUCAGGACAATT B 2420 R-008395851-000T  578  321GAUGAGGGCAUGCAGAUCC GGAUCUGCAUGCCCUCAUCUU 2423 R-008395851-000T  578 321 GAUGAGGGCAUGCAGAUCC B GAUGAGGGCAUGCAGAUCCTT B 2422 R-008395854-000U3091  322 AUGGGUAGGGUAAAUCAGU B AUGGGUAGGGUAAAUCAGUTT B 2424R-008395854-000U 3091  322 AUGGGUAGGGUAAAUCAGU ACUGAUUUACCCUACCCAUUU2425 R-008395857-000V  720  323 GUGCAAUCCCUGAACUGACB GUGCAAUCCCUGAACUGACTT B 2426 R-008395857-000V  720  323GUGCAAUCCCUGAACUGAC GUCAGUUCAGGGAUUGCACUU 2427 R-008395860-000B 2054 324 AUUCCAUUGUUUGUGCAGC B AUUCCAUUGUUUGUGCAGCTT B 2428 R-008395860-000B2054  324 AUUCCAUUGUUUGUGCAGC GCUGCACAAACAAUGGAAUUU 2429R-008395863-000C 1237   42 UUUAGUAAAUAUAAUGAGG CCUCAUUAUAUUUACUAAAUU2431 R-008395863-000C 1237   42 UUUAGUAAAUAUAAUGAGGB UUUAGUAAAUAUAAUGAGGTT B 2430 R-008395866-000D  374  325CAUUCUGGUGCCACUACCA UGGUAGUGGCACCAGAAUGUU 2433 R-008395866-000D  374 325 CAUUCUGGUGCCACUACCA B CAUUCUGGUGCCACUACCATT B 2432 R-008395869-000E 868  326 UACCAUGCAGAAUACAAAU AUUUGUAUUCUGCAUGGUAUU 2435R-008395869-000E  868  326 UACCAUGCAGAAUACAAAU B UACCAUGCAGAAUACAAAUTT B2434 R-008395872-000L  626   23 ACUAAUGUCCAGCGUUUGGCCAAACGCUGGACAUUAGUUU 2437 R-008395872-000L  626   23ACUAAUGUCCAGCGUUUGG B ACUAAUGUCCAGCGUUUGGTT B 2436 R-008395875-000M 1716 327 AUGCAGUUCGCCUUCACUA B AUGCAGUUCGCCUUCACUATT B 2438 R-008395875-000M1716  327 AUGCAGUUCGCCUUCACUA UAGUGAAGGCGAACUGCAUUU 2439R-008395878-000N  950  328 UUACUGGCCAUCUUUAAGU B UUACUGGCCAUCUUUAAGUTT B2440 R-008395878-000N  950  328 UUACUGGCCAUCUUUAAGUACUUAAAGAUGGCCAGUAAUU 2441 R-008395881-000V 1489  329GCUUCUGGGUUCAGAUGAU B GCUUCUGGGUUCAGAUGAUTT B 2442 R-008395881-000V 1489 329 GCUUCUGGGUUCAGAUGAU AUCAUCUGAACCCAGAAGCUU 2443 R-008395884-000W1451  330 CAGGAAGGGAUGGAAGGUC B CAGGAAGGGAUGGAAGGUCTT B 2444R-008395884-000W 1451  330 CAGGAAGGGAUGGAAGGUC GACCUUCCAUCCCUUCCUGUU2445 R-008395S87-000X  438  159 UGGAUACCUCCCAAGUCCUAGGACUUGGGAGGUAUCCAUU 2447 R-008395887-000X  438  159UGGAUACCUCCCAAGUCCU B UGGAUACCUCCCAAGUCCUTT B 2446 R-008395890-000D 1181 331 GCUUAUGGCAACCAAGAAA UUUCUUGGUUGCCAUAAGCUU 2449 R-008395890-000D1181  331 GCUUAUGGCAACCAAGAAA B GCUUAUGGCAACCAAGAAATT B 2448R-008395893-000E 1633  332 UGACAGGGAAGACAUCACU AGUGAUGUCUUCCCUGUCAUU2451 R-008395893-000E 1633  332 UGACAGGGAAGACAUCACUB UGACAGGGAAGACAUCACUTT B 2450 R-008395896-000F 2394  333AUCGCCAGGAUGAUCCUAG CUAGGAUCAUCCUGGCGAUUU 2453 R-008395896-000F 2394 333 AUCGCCAGGAUGAUCCUAG B AUCGCCAGGAUGAUCCUAGTT B 2452 R-008395899-000G1322  334 AGUAAUAAGCCGGCUAUUG B AGUAAUAAGCCGGGUAUUGTT B 2454R-008395899-000G 1322  334 AGUAAUAAGCCGGCUAUUG CAAUAGCCGGCUUAUUACUUU2455 R-008395902-000Z  884  335 AAUGAUGUAGAAACAGCUCGAGCUGUUUCUACAUCAUUUU 2457 R-008395902-000Z  884  335AAUGAUGUAGAAACAGCUC B AAUGAUGUAGAAACAGCUCTT B 2456 R-008395905-000A 2255 336 UCUGAGGACAAGCCACAAG B UCUGAGGACAAGCCACAAGTT B 2458 R-008395905-000A2255  336 UCUGAGGACAAGCCACAAG CUUGUGGCUUGUCCUCAGAUU 2459R-008395908-000B 1466  337 GGUCUCCUUGGGACUCUUG CAAGAGUCCCAAGGAGACCUU2461 R-008395908-000B 1466  337 GGUCUCCUUGGGACUCUUGB GGUCUCCUUGGGACUCUUGTT B 2460 R-008395911-000H 1399  338UGUUCAGAACUGUCUUUGG CCAAAGACAGUUJUGAACAUU 2463 R-008395911-000H 1399 338 UGUUCAGAACUGUCUUUGG B UGUUCAGAACUGUCUUUGGTT B 2462 R-008395914-000J 378  339 CUGGUGCCACUACCACAGC B CUGGUGCCACUACCACAGCTT B 2464R-008395914-000J  378  339 CUGGUGCCACUACCACAGC GCUGUGGUAGUGGCACCAGUU2465 R-008395917-000K 1921  340 GUCCAUGGGUGGGACACAGCUGUGUCCCACCCAUGGACUU 2467 R-008395917-000K 1921  340GUCCAUGGGUGGGACACAG B GUCCAUGGGUGGGACACAGTT B 2466 R-008395920-000S 1085 341 GUGCGUUUAGCUGGUGGGC B GUGCGUUUAGCUGGUGGGCTT B 2468 R-008395920-000S1085  341 GUGCGUUUAGCUGGUGGGC GCCCACCAGCUAAACGCACUU 2469R-008395923-000T  865  342 ACGUACCAUGCAGAAUACA B ACGUACCAUGCAGAAUACATT B2470 R-008395923-000T  865  342 ACGUACCAUGCAGAAUACAUGUAUUCUGCAUGGUACGUUU 2471 R-008395926-000U 2015  343GAUGUUCACAACCGAAUUG B GAUGUUCACAACCGAAUUGTT B 2472 R-008395926-000U 2015 343 GAUGUUCACAACCGAAUUG CAAUUCGGUUGUGAACAUCUU 2473 R-008395929-000V1195  344 AGAAAGCAAGCUCAUCAUA B AGAAAGCAAGCUCAUCAUATT B 2474R-008395929-000V 1195  344 AGAAAGCAAGCUCAUCAUA UAUGAUGAGCUUGCUUUCUUU2475 R-008395932-000B 1484  345 GUUCAGCUUCUGGGUUCAGCUGAACCCAGAAGCUGAACUU 2477 R-008395932-000B 1484  345GUUCAGCUUCUGGGUUCAG B GUUCAGCUUCUGGGUUCAGTT B 2476 R-008395935-000C 1855 346 GCAGGGUGCCAUUCCACGA B GCAGGGUGCCAUUCCACGATT B 2478 R-008395935-000C1855  346 GCAGGGUGCCAUUCCACGA UCGUGGAAUGGCACCCUGCUU 2479R-008395938-000D 1341  347 UAGAAGCUGGUGGAAUGCA B UAGAAGCUGGUGGAAUGCATT B2480 R-008395938-000D 1341  347 UAGAAGCUGGUGGAAUGCAUGCAUUCCACCAGCUUCUAUU 2481 R-008395950-000U 1963  348CAUGGAAGAAAUAGUUGAA UUCAACUAUUUCUUCCAUGUU 2483 R-008395950-000U 1963 348 CAUGGAAGAAAUAGUUGAA B CAUGGAAGAAAUAGUUGAATT B 2482 R-008395953-000V2362  349 UGAUAUUGGUGCCCAGGGA B UGAUAUUGGUGCCCAGGGATT B 2484R-008395953-000V 2362  349 UGAUAUUGGUGCCCAGGGA UCCCUGGGCACCAAUAUCAUU2485 R-008395956-000W  584  350 GGCAUGCAGAUCCCAUCUAB GGCAUGCAGAUCCCAUCUATT B 2486 R-008395956-000W  584  350GGCAUGCAGAUCCCAUCUA UAGAUGGGAUCUGCAUGCCUU 2487 R-008395959-000X 1613 351 CGUACUGUCCUUCGGGCUG B CGUACUGUCCUUCGGGCUGTT B 2488 R-008395959-000X1613  351 CGUACUGUCCUUCGGGCUG CAGCCCGAAGGACAGUACGUU 2489R-008395962-000D 1155  352 UUACGACAGACUGCCUUCA UGAAGGCAGUCUGUCGUAAUU2491 R-008395962-000D 1155  352 UUACGACAGACUGCCUUCAB UUACGACAGACUGCCUUCATT B 2490 R-008395965-000E  334  353UAGUCACUGGCAGCAACAG B UAGUCACUGGCAGCAACAGTT B 2492 R-008395965-000E  334 353 UAGUCACUGGCAGCAACAG CUGUUGCUGCCAGUGACUAUU 2493 R-008395968-000F1031  354 GCCAUUACAACUCUCCACA B GCCAUUACAACUCUCCACATT B 2494R-008395968-000F 1031  354 GCCAUUACAACUCUCCACA UGUGGAGAGUUGUAAUGGCUU2495 R-008395971-000M 1725  355 GCCUUCACUAUGGACUACCB GCCUUCACUAUGGACUACCTT B 2496 R-008395971-000M 1725  355GCCUUCACUAUGGACUACC GGUAGUCCAUAGUGAAGGCUU 2497 R-008395974-000N 2018 356 GUUCACAACCGAAUUGUUA B GUUCACAACCGAAUUGUUATT B 2498 R-008395974-000N2018  356 GUUCACAACCGAAUUGUUA UAACAAUUCGGUUGUGAACUU 2499R-008395977-000P  914  357 GGGACCUUGCAUAACCUUU AAAGGUUAUGCAAGGUCCCUU2501 R-008395977-000P  914  357 GGGACCUUGCAUAACCUUUB GGGACCUUGCAUAACCUUUTT B 2500 R-008395980-000W 2264  358AAGCCACAAGAUUACAAGA B AAGCCACAAGAUUACAAGATT B 2502 R-008395980-000W 2264 358 AAGCCACAAGAUUACAAGA UCUUGUAAUCUUGUGGCUUUU 2503 R-008395983-000X 343  359 GCAGCAACAGUCUUACCUG CAGGUAAGACUGUUGCUGCUU 2505R-008395983-000X  343  359 GCAGCAACAGUCUUACCUG B GCAGCAACAGUCUUACCUGTT B2504 R-008395986-000Y 1056  360 UAUUACAUCAAGAAGGAGCB UAUUACAUCAAGAAGGAGCTT B 2506 R-008395986-000Y 1056  360UAUUACAUCAAGAAGGAGC GCUCCUUCUUGAUGUAAUAUU 2507 R-008395992-000F  772 361 UAAUAAGGCUGCAGUUAUG B UAAUAAGGCUGCAGUUAUGTT B 2508 R-008395992-000F 772  361 UAAUAAGGCUGCAGUUAUG CAUAACUGCAGCCUUAUUAUU 2509R-008395995-000G 1390   91 UCAACGUCUUGUUCAGAAC GUUCUGAACAAGACGUUGAUU2511 R-008395995-000G 1390   91 UCAACGUCUUGUUCAGAACB UCAACGUCUUGUUCAGAACTT B 2510 R-008395998-000H 1959  183UCCGCAUGGAAGAAAUAGU ACUAUUUCUUCCAUGCGGAUU 2513 R-008395998-000H 1959 183 UCCGCAUGGAAGAAAUAGU B UCCGCAUGGAAGAAAUAGUTT B 2512 R-008396004-000Y 763  362 GGUGGUGGUUAAUAAGGCU B GGUGGUGGUUAAUAAGGCUTT B 2514R-008396004-000Y  763  362 GGUGGUGGUUAAUAAGGCU AGCCUUAUUAACCACCACCUU2515 R-008396010-000F  628  363 UAAUGUCCAGCGUUUGGCUB UAAUGUCCAGCGUUUGGCUTT B 2516 R-008396010-000F  628  363UAAUGUCCAGCGUUUGGCU AGCCAAACGCUGGACAUUAUU 2517 R-008396013-000G  399 364 CUUCUCUGAGUGGUAAAGG B CUUCUCUGAGUGGUAAAGGTT B 2518 R-008396013-000G 399  364 CUUCUCUGAGUGGUAAAGG CCUUUACCACUCAGAGAAGUU 2519R-008396016-000H 1682  365 ACCAGCCGACACCAAGAAG CUUCUUGGUGUCGGCUGGUUU2521 R-008396016-000H 1682  365 ACCAGCCGACACCAAGAAGB ACCAGCCGACACCAAGAAGTT B 2520 R-008396019-000J  441  366AUACCUCCCAAGUCCUGUA B AUACCUCCCAAGUCCUGUATT B 2522 R-008396019-000J  441 366 AUACCUCCCAAGUCCUGUA UACAGGACUUGGGAGGUAUUU 2523 R-008396022-000R1729  367 UCACUAUGGACUACCAGUU B UCACUAUGGACUACCAGUUTT B 2524R-008396022-000R 1729  367 UCACUAUGGACUACCAGUU AACUGGUAGUCCAUAGUGAUU2525 R-008396025-000S 1902  368 AGGAUACCCAGCGCCGUACGUACGGCGCUGGGUAUCCUUU 2527 R-008396025-000S 1902  368AGGAUACCCAGCGCCGUAC B AGGAUACCCAGCGCCGUACTT B 2526 R-008396028-000T 1637 369 AGGGAAGACAUCACUGAGC B AGGGAAGACAUCACUGAGCTT B 2528 R-008396028-000T1637  369 AGGGAAGACAUCACUGAGC GCUCAGUGAUGUCUUCCCUUU 2529R-008396031-000Z 2391  370 GAUAUCGCCAGGAUGAUCC B GAUAUCGCCAGGAUGAUCCTT B2530 R-008396031-000Z 2391  370 GAUAUCGCCAGGAUGAUCCGGAUCAUCCUGGCGAUAUCUU 2531 R-008396034-000A  501  371AAGUAGCUGAUAUUGAUGG B AAGUAGCUGAUAUUGAUGGTT B 2532 R-008396034-000A  501 371 AAGUAGCUGAUAUUGAUGG CCAUCAAUAUCAGCUACUUUU 2533 R-008396037-000B1358  372 CAAGCUUUAGGACUUCACC B CAAGCUUUAGGACUUCACCTT B 2534R-008396037-000B 1358  372 CAAGCUUUAGGACUUCACC GGUGAAGUCCUAAAGCUUGUU2535 R-008396040-000H 1821  373 CCCUUUGUCCCGCAAAUCAB CCCUUUGUCCCGCAAAUCATT B 2536 R-008396040-000H 1821  373CCCUUUGUCCCGCAAAUCA UGAUUUGCGGGACAAAGGGUU 2537 R-008396043-000J  575 374 UUAGAUGAGGGCAUGCAGA B UUAGAUGAGGGCAUGCAGATT B 2538 R-008396043-000J 575  374 UUAGAUGAGGGCAUGCAGA UCUGCAUGCCCUCAUCUAAUU 2539R-008396046-000K  528  375 CAAUGACUCGAGCUCAGAG B CAAUGACUCGAGCUCAGAGTT B2540 R-008396046-000K  528  375 CAAUGACUCGAGCUCAGAGCUCUGAGCUCGAGUCAUUGUU 2541 R-008396049-000L 2433  376GUGGAUAUGGCCAGGAUGC B GUGGAUAUGGCCAGGAUGCTT B 2542 R-008396049-000L 2433 376 GUGGAUAUGGCCAGGAUGC GCAUCCUGGCCAUAUCCACUU 2543 R-008396052-000T1497  377 GUUCAGAUGAUAUAAAUGU ACAUUUAUAUCAUCUGAACUU 2545R-008396052-000T 1497  377 GUUCAGAUGAUAUAAAUGU B GUUCAGAUGAUAUAAAUGUTT B2544 R-008396055-000U 2134  378 UCAGGACAAGGAAGCUGCAB UCAGGACAAGGAAGCUGCATT B 2546 R-008396055-000U 2134  378UCAGGACAAGGAAGCUGCA UGCAGCUUCCUUGUCCUGAUU 2547 R-008396058-000V 2160 379 UUGAAGCUGAGGGAGCCAC GUGGCUCCCUCAGCUUCAAUU 2549 R-008396058-000V2160  379 UUGAAGCUGAGGGAGCCAC B UUGAAGCUGAGGGAGCCACTT B 2548R-008396061-000B  291  380 UGGAGUUGGACAUGGCCAU A UGGCCAUGUCCAACUCAUU2551 R-008396061-000B  291  380 UGGAGUUGGACAUGGCCAUB UGGAGUUGGACAUGGCCAUTT B 2550 R-008396064-000C  657  381AGAUGCUGAAACAUGCAGU B AGAUGCUGAAACAUGCAGUTT B 2552 R-008396064-000C  657 381 AGAUGCUGAAACAUGCAGU ACUGCAUGUUUCAGCAUCUUU 2553 R-008396067-000D1575  382 UGAUGGUCUGCCAAGUGGG B UGAUGGUCUGCCAAGUGGGTT B 2554R-008396067-000D 1575  382 UGAUGGUCUGCCAAGUGGG CCCACUUGGCAGACCAUCAUU2555 R-008396070-000K  667  383 ACAUGCAGUUGUAAACUUGCAAGUUUACAACUGCAUGUUU 2557 R-008396070-000K  667  383ACAUGCAGIUGUAAACUUG B ACAUGCAGUUGUAAACUUGTT B 2556 R-008396076-000M 2190 384 CAGAGUUACUUCACUCUAG B CAGAGUUACUUCACUCUAGTT B 2558 R-008396076-000M2190  384 CAGAGUUACUUCACUCUAG CUAGAGUGAAGUAACUCUGUU 2559R-008396079-000N  532  385 GACUCGAGCUCAGAGGGUA UACCCUCUGAGCUCGAGUCUU2561 R-008396079-000N  532  385 GACUCGAGCUCAGAGGGUAB GACUCGAGCUCAGAGGGUATT B 2560 R-008396082-000V  953  386CUGGCCAUCUUUAAGUCUG CAGACUUAAAGAUGGCCAGUU 2563 R-008396082-000V  953 386 CUGGCCAUCUUUAAGUCUG B CUGGCCAUCUUUAAGUCUGTT B 2562 R-008396085-000W3188  387 UACGAUGCUUCAAGAGAAA UUUCUCUUGAAGCAUCGUAUU 2565R-008396085-000W 3188  387 UACGAUGCUUCAAGAGAAA B UACGAUGCUUCAAGAGAAATT B2564 R-008396088-000X 2301  388 UGACCAGCUCUCUCUUCAGB UGACCAGCUCUCUCUUCAGTT B 2566 R-008396088-000X 2301  388UGACCAGCUCUCUCUUCAG CUGAAGAGAGAGCUGGUCAUU 2567 R-008396091-000D 2310 389 CUCUCUUCAGAACAGAGCC B CUCUCUUCAGAACAGAGCCTT B 2568 R-008396091-000D2310  389 CUCUCUUCAGAACAGAGCC GGCUCUGUUCUGAAGAGAGUU 2569R-008396094-000E 2287  390 GCUUUCAGUUGAGCUGACC B GCUUUCAGUUGAGCUGACCTT B2570 R-008396094-000E 2287  390 GCUUUCAGUUGAGCUGACCGGUCAGCUCAACUGAAAGCUU 2571 R-008396097-000F 1927  391GGGUGGGACACAGCAGCAA UUGCUGCUGUGUCCCACCCUU 2573 R-008396097-000F 1927 391 GGGUGGGACACAGCAGCAA B GGGUGGGACACAGCAGCAATT B 2572 R-008396100-000Y 712  392 UGCCACACGUGCAAUCCCU AGGGAUUGCACGUGUGGCAUU 2575R-008396100-000Y  712  392 UGCCACACGUGCAAUCCCU B UGCCACACGUGCAAUCCCUTT B2574 R-008396103-000Z 2121  393 UCUGUGAACUUGCUCAGGAB UCUGUGAACUUGCUCAGGATT B 2576 R-008396103-000Z 2121  393UCUGUGAACUUGCUCAGGA UCCUGAGCAAGUUCACAGAUU 2577 R-008396106-000A 2898 394 UGAGUAAUGGUGUAGAACA B UGAGUAAUGGUGUAGAACATT B 2578 R-008396106-000A2898  394 UGAGUAAUGGUGUAGAACA UGUUCUACACCAUUACUCAUU 2579R-008396109-000B 1799  395 GUUGGAUUGAUUCGAAAUC B GUUGGAUUGAUUCGAAAUCTT B2580 R-008396109-000B 1799  395 GUUGGAUUGAUUCGAAAUCGAUUUCGAAUCAAUCCAACUU 2581 R-008396112-000H 1036  396UACAACUCUCCACAACCUU AAGGUUGUGGAGAGUUGUAUU 2583 R-008396112-000H 1036 396 UACAACUCUCCACAACCUU B UACAACUCUCCACAACCUUTT B 2582 R-008396115-000J 449  397 CAAGUCCUGUAUGAGUGGG CCCACUCAUACAGGACUUGUU 2585R-008396115-000J  499  397 CAAGUCCUGUAUGAGUGGG B CAAGUCCUGUAUGAGUGGGTT B2584 R-008396118-000K 1452  398 AGGAAGGGAUGGAAGGUCUB AGGAAGGGAUGGAAGGUCUTT B 2586 R-008396118-000K 1452  398AGGAAGGGAUGGAAGGUCU AGACCUUCCAUCCCUUCCUUU 2587 R-008396124-000T 1203 399 AGCUCAUCAUACUGGCUAG B AGCUCAUCAUACUGGCUAGTT B 2588 R-008396124-000T1203  399 AGCUCAUCAUACUGGCUAG CUAGCCAGUAUGAUGAGCUUU 2589R-008396130-000A 1357  400 GCAAGCUUUAGGACUUCAC GUGAAGUCCUAAAGCUUGCUU2591 R-008396130-000A 1357  400 GCAAGCUUUAGGACUUCACB GCAAGCUUUAGGAGUUCACTT B 2590 R-008396133-000B 1512  401AUGUGGUCACCUGUGCAGC GCUGCACAGGUGACCACAUUU 2593 R-008396133-000B 1512 401 AUGUGGUCACCUGUGCAGC B AUGUGGUCACCUGUGCAGCTT B 2592 R-008396136-000C 275  402 ACUCAAGCUGAUUUGAUGG B ACUCAAGCUGAUUUGAUGGTT B 2594R-008396136-000C  275  402 ACUCAAGCUGAUUUGAUGG CCAUCAAAUCAGCUUGAGUUU2595 R-008396139-000D  299  403 GACAUGGCCAUGGAACCAGCUGGUUCCAUGGCCAUGUCUU 2597 R-008396139-000D  299  403GACAUGGCCAUGGAACCAG B GACAUGGCCAUGGAACCAGTT B 2596 R-008396192-000K 1241 404 GUAAAUAUAAUGAGGACCU B GUAAAUAUAAUGAGGACCUTT B 2598 R-008396142-000K1241  404 GUAAAUAUAAUGAGGACCU AGGUCCUCAUUAUAUUUACUU 2599R-008396195-000L 1961  405 CGCAUGGAAGAAAUAGUUG CAACUAUUUCUUCCAUGCGUU2601 R-008396145-000L 1961  405 CGCAUGGAAGAAAUAGUUGB CGCAUGGAAGAAAUAGUUGTT B 2600 R-008396198-000M 1436  406GAUGGUGCAACUAAACAGG B GAUGCUGCAACUAAACAGGTT B 2602 R-008396148-000M 1436 406 GAUGGUGCAACUAAACAGG CCUGUUUAGUUGCAGCAUCUU 2603 R-008396151-000U2469  407 UGAUGGAACAUGAGAUGGG B UGAUGGAACAUGAGAUGGGTT B 2604R-008396151-000U 2469  407 UGAUGGAACAUGAGAUGGG CCCAUCUCAUGUUCCAUCAUU2605 R-008396154-000V  760  408 CCAGGUGGUGGUUAAUAAGB CCAGGUGGUGGUUAAUAAGTT B 2606 R-008396154-000V  760  408CCAGGUGGUGGUUAAUAAG CUUAUUAACCACCACCUGGUU 2607 R-008396157-000W 2504 141 GCUGACUAUCCAGUUGAUG CAUCAACUGGAUAGUCAGCUU 2609 R-008396157-000W2504  141 GCUGACUAUCCAGUUGAUG B GCUGACUAUCCAGUUGAUGTT B 2608R-008396160-000C 2257  409 UGAGGAGAAGCCACAAGAU AUCUUGUGGCUUGUCCUCAUU2611 R-008396160-000C 2257  409 UGAGGAGAAGCCACAAGAUB UGAGGACAAGCCACAAGAUTT B 2610 R-008396163-000D  952  410ACUGGCCAUCUUUAAGUCU AGACUUAAAGAUGGCCAGUUU 2613 R-008396163-000D  952 410 ACUGGCCAUCUUUAAGUCU B ACUGGCCAUCUUUAAGUCUTT B 2612 R-008396166-000E2283  411 AACGGCUUUCAGUUGAGCU B AACGGCUUUCAGUUGAGCUTT B 2614R-008396166-000E 2283  411 AACGGCUUUCAGUUGAGCU AGCUCAACUGAAAGCCGUUUU2615 R-008396169-000F 1649   62 ACUGAGCCUGCCAUCUGUGB ACUGAGCCUGCCAUCUGUGTT B 2616 R-008396169-000F 1649   62ACUGAGCCUGCCAUCUGUG CACAGAUGGCAGGCUCAGUUU 2617 R-008396172-000M 2014   8 GGAUGUUCACAACCGAAUU AAUUCGGUUGUGAACAUCCUU 2619 R-008396172-000M2014       8 GGAUGUUCACAACCGAAUU B GGAUGUUCACAACCGAAUUTT B 2618R-008396175-000N 1794  412 CUACUGUUGGAUUGAUUCG CGAAUCAAUCCAACAGUAGUU2621 R-008396175-000N 1794  412 CUACUGUUGGAUUGAUUCGB CUACUGUUGGAUUGAUUCGTT B 2620 R-008396178-000P 1745  413GUUGUGGUUAAGCUCUUAC B GUUGUGGUUAAGCUCUUACTT B 2622 R-008396178-000P 1745 413 GUUGUGGUUAAGCUCUUAC GUAAGAGCUUAACCACAACUU 2623 R-008396181-000W1211  414 AUACUGGCUAGUGGUGGAC GUCCACCACUAGCCAGUAUUU 2625R-008396181-000W 1211  414 AUACUGGCUAGUGGUGGAC B AUACUGGCUAGUGGUGGACTT B2624 R-008396184-000X 2549  415 GACCUCAUGGAUGGGCUGCB GACCUCAUGGAUGGGCUGGTT B 2626 R-008396184-000X 2549  415GACCUCAUGGAUGGGCUGC GCAGCCCAUCCAUGAGGUCUU 2627 R-008396187-000Y 2007 416 UAGCUCGGGAUGUUCACAA UUGUGAACAUCCCGAGCUAUU 2629 R-008396187-000Y2007  416 UAGCUCGGGAUGUUCACAA B UAGCUCGGGAUGUUCACAATT B 2628R-008396190-000E 2474  417 GAACAUGAGAUGGGUGGCC B GAACAUGAGAUGGGUGGCCTT B2630 R-008396190-000E 2474  417 GAACAUGAGAUGGGUGGCCGGCCACCCAUCUCAUGUUCUU 2631 R-008396193-000F 1712  418CAGAAUGCAGUUCGCCUUC GAAGGCGAACUGCAUUCUGUU 2633 R-008396193-000F 1712 418 CAGAAUGCAGUUCGCCUUC B CAGAAUGCAGUUCGCCUUCTT B 2632 R-008396196-000G1919  419 ACGUCCAUGGGUGGGACAC B ACGUCCAUGGGUGGGACACTT B 2634R-008396196-000G 1919  419 ACCUCCAUGGGUGGGACAC GUGUCCGACCCAUGGACGUUU2635 R-008396199-000H 1000  420 UGGUUCACCAGUGGAUUCUAGAAUCCACUGGUGAACCAUU 2637 R-008396199-000H 1000  420UGGUUCACCAGUGGAUUCU B UGGUUCACCAGUGGAUUCUTT B 2636 R-008396202-000A 2392 421 AUAUCGCCAGGAUGAUCCU AGGAUCAUCCUGGCGAUAUUU 2639 R-008396202-000A2392  421 AUAUCGCCAGGAUGAUCCU B AUAUGGCCAGGAUGAUCCUTT B 2638R-008396205-000B 1449  422 AACAGGAAGGGAUGGAAGG B AACAGGAAGGGAUGGAAGGTT B2640 R-008396205-000B 1449  422 AACAGGAAGGGAUGGAAGGCCUUCCAUCCCUUCCUGUUUU 2641 R-008396208-000C 2294  423GUUGAGCUGACCAGCUCUC GAGAGCUGGUCAGCUCAACUU 2643 R-008396208-000C 2294 423 GUUGAGCUGACCAGCUCUC B GUUGAGCUGACCAGCUCUCTT B 2642 R-008396211-000J1135  424 AAAUGUUAAAUUCUUGGCU B AAAUGUUAAAUUCUUGGCUTT B 2644R-008396211-000J 1135  424 AAAUGUUAAAUUCUUGGCU AGCCAAGAAUUUAACAUUUUU2645 R-008396214-000K  822   14 GACACGCUAUCAUGCGUUCB GACACGCUAUCAUGCGUUCTT B 2646 R-008396214-000K  822   14GACACGCUAUCAUGCGUUC GAACGCAUGAUAGCGUGUCUU 2647 R-008396217-000L 1333 425 GGCUAUUGUAGAAGCUGGU ACCAGCUUCUACAAUAGCCUU 2649 R-008396217-000L1333  425 GGCUAUUGUAGAAGCUGGU B GGCUAUUGUAGAAGCUGGUTT B 2648R-008396220-000T 1743  426 CAGUUGUGGUUAAGCUCUU AAGAGCUUAACCACAACUGUU2651 R-008396220-000T 1743  426 CAGUUGUGGUUAAGCUCUUB CAGUUGUGGUUAAGCUCUUTT B 2650 R-008396223-000U  600  427CUACACAGUUUGAUGCUGC GCAGCAUCAAACUGUGUAGUU 2653 R-008396223-000U  600 427 CUACACAGUUUGAUGCUGC B CUACACAGUUUGAUGCUGUTT B 2652 R-008396226-000V 970  428 UGGAGGCAUUCCUGCCCUG CAGGGGAGGAAUGCCUCCAUU 2655R-008396226-000V  970  428 UGGAGGCAUUCCUGCCCUG B UGGAGGCAUUCCUGCCCUGTT B2654 R-008396229-000W 3137  429 GGACAGUUUACCAGUUGCCB GGACAGUUUACCAGUUGCCTT B 2656 R-008396229-000W 3137  429GGACAGUUUACCAGUUGCC GGCAACUGGUAAACUGUCCUU 2657 R-008396232-000C  372 430 UCCAUUCUGGUGCCACUAC GUAGUGGCACCAGAAUGGAUU 2659 R-008396232-000C 372  430 UCCAUUCUGGUGCCACUAC B UCCAUUCUGGUGCCACUACTT B 2658R-008396235-000D 1761  431 UACACCCACCAUCCCACUG B UACACCCACCAUCCCACUGTT B2660 R-008396235-000D 1761  431 UACACCCACCAUCCCACUGCAGUGGGAUGGUGGGUGUAUU 2661 R-008396238-000E 1650  432CUGAGCCUGCCAUCUGUGC GCACAGAUGGCAGGCUCAGUU 2663 R-008396238-000E 1650 432 CUGAGCCUGCCAUCUGUGC B CUGAGCCUGCCAUCUGUGCTT B 2662 R-008396241-000L 972  433 GAGGCAUUCCUGCCGUGGU B GAGGCAUUCCUGCCCUGGUTT B 2664R-008396241-000L  972  433 GAGGCAUUCCUGCCCUGGU ACCAGGGCAGGAAUGCCUCUU2665 R-008396244-000M 1147  434 CUUGGCUAUUACGACAGACGUCUGUCGUAAUAGCCAAGUU 2667 R-008396244-000M 1147  434CUUGGCUAUUACGACAGAC B CUUGGCUAUUACGACAGACTT B 2666 R-008396297-000N  565 435 CCCUGAGACAUUAGAUGAG B CCCUGAGACAUUAGAUGAGTT B 2668 R-008396247-000N 565  435 CCCUGAGACAUUAGAUGAG CUCAUCUAAUGUCUCAGGGUU 2669R-008396250-000V  525  436 AUGCAAUGACUCGAGCUCA B AUGCAAUGACUCGAGCUCATT B2670 R-008396250-000V  525  436 AUGCAAUGACUCGAGCUCAUGAGCUCGAGUCAUUGCAUUU 2671 R-008396253-000W 1599  437UAGAGGCUCUUGUGCGUAC B UAGAGGCUCUUGUGCGUACTT B 2672 R-008396253-000W 1599 437 UAGAGGCUCUUGUGCGUAC GUACGCACAAGAGCCUCUAUU 2673 R-008396256-000X2199  438 UUCACUCUAGGAAUGAAGG B UUCACUCUAGGAAUGAAGGTT B 2674R-008396256-000X 2199  438 UUCACUCUAGGAAUGAAGG CCUUCAUUCCUAGAGUGAAUU2675 R-008396259-000Y 2261  439 GACAAGCCACAAGAUUACAB GACAAGCCACAAGAUUACATT B 2676 R-008396259-000Y 2261  439GACAAGCCACAAGAUUACA UGUAAUCUUGUGGCUUGUCUU 2677 R-008396262-000E  705 440 CAGAACUUGCCACACGUGC B CAGAACUUGCCACACGUGCTT B 2678 R-008396262-000E 705  440 CAGAACUUGCCACACGUGC GCACGUGUGGCAAGUUCUGUU 2679R-008396265-000F  916  441 GACCUUGCAUAACCUUUCC B GACCUUGCAUAACCUUUCCTT B2680 R-008396265-000F  916  441 GACCUUGCAUAACCUUUCCGGAAAGGUUAUGCAAGGUCUU 2681 R-008396268-000G  385  442CACUACCACAGCUCCUUCU AGAAGGAGCUGUGGUAGUGUU 2683 R-008396268-000G  385 442 CACUACCACAGCUCCUUCU B CACUACCACAGCUCCUUCUTT B 2682 R-008396271-000N3076  443 CUAUUUGGGAUAUGUAUGG B CUAUUUGGGAUAUGUAUGGTT B 2684R-008396271-000N 3076  443 CUAUUUGGGAUAUGUAUGG CCAUACAUAUCCCAAAUAGUU2685 R-008396274-000P 1396  444 UCUUGUUCAGAACUGUCUUB UCUUGUUCAGAACUGUCUUTT B 2686 R-008396274-000P 1396  444UCUUGUUCAGAACUGUCUU AAGACAGUUCUGAACAAGAUU 2687 R-008396277-000R 2447 445 GAUGCCUUGGGUAUGGACC GGUCCAUACCCAAGGCAUCUU 2689 R-008396277-000R2447  445 GAUGCCUUGGGUAUGGACC B GAUGCCUUGGGUAUGGACCTT B 2688R-008396280-000X 1338  446 UUGUAGAAGCUGGUGGAAU B UUGUAGAAGCUGGUGGAAUTT B2690 R-008396280-000X 1338  446 UUGUAGAAGCUGGUGGAAUAUUCCACCAGCUUCUACAAUU 2691 R-008396283-000Y 2215  447AGGUGUGGCGACAUAUGCA UGCAUAUGUCGCCACACCUUU 2693 R-008396283-000Y 2215 447 AGGUGUGGCGACAUAUGCA B AGGUGUGGCGACAUAUGCATT B 2692 R-008396286-000Z 722  448 GCAAUCCCUGAACUGACAA B GCAAUCCCUGAACUGACAATT B 2694R-008396286-000Z  722  448 GCAAUCCCUGAACUGACAA UUGUCAGUUCAGGGAUUGCUU2695 R-008396289-000A 1316  449 UGCUCUAGUAAUAAGCCGGCCGGCUUAUUACUAGAGCAUU 2697 R-008396289-000A 1316  449UGCUCUAGUAAUAAGCCGG B UGCUCUAGUAAUAAGCCGGTT B 2696 R-008396292-000G 1687 450 CCGACACCAAGAAGCAGAG B CCGACACCAAGAAGCAGAGTT B 2698 R-008396292-000G1687  450 CCGACACCAAGAAGCAGAG CUCUGCUUCUUGGUGUCGGUU 2699R-008396295-000H  697  451 AGAUGAUGCAGAACUUGCC B AGAUGAUGCAGAACUUGCCTT B2700 R-008396295-000H  697  451 AGAUGAUGCAGAACUUGCCGGCAAGUUCUGCAUCAUCUUU 2701 R-008396298-000J 2517  452UUGAUGGGCUGCCAGAUCU B UUGAUGGGCUGCCAGAUCUTT B 2702 R-008396298-000J 2517 452 UUGAUGGGCUGCCAGAUCU AGAUCUGGCAGCCCAUCAAUU 2703 R-008396301-000B1685  453 AGCCGACACCAAGAAGCAG B AGCCGACACCAAGAAGCAGTT B 2704R-008396301-000B 1685  453 AGCCGACACCAAGAAGCAG CUGCUUCUUGGUGUCGGCUUU2705 R-008396304-000C 3090  454 UAUGGGUAGGGUAAAUCAGCUGAUUUACCCUACCCAUAUU 2707 R-008396304-000C 3090  454UAUGGGUAGGGUAAAUCAG B UAUGGGUAGGGUAAAUCAGTT B 2706 R-008396307-000D 1205 455 CUCAUCAUACUGGCUAGUG B CUCAUCAUACUGGCUAGUGTT B 2708 R-008396307-000D1205  455 CUCAUCAUACUGGCUAGUG CACUAGCCAGUAUGAUGAGUU 2709R-008396310-000K 1153  456 UAUUACGACAGACUGCCUU B UAUUACGACAGACUGCCUUTT B2710 R-008396310-000K 1153  456 UAUUACGACAGACUGCCUUAAGGCAGUCUGUCGUAAUAUU 2711 R-008396313-000L  723  457CAAUCCCUGAACUGACAAA B CAAUCCCUGAACUGACAAATT B 2712 R-008396313-000L  723 457 CAAUCCCUGAACUGACAAA UUUGUCAGUUCAGGGAUUGUU 2713 R-008396316-000M1468  458 UCUCCUUGGGACUCUUGUU AACAAGAGUCCCAAGGAGAUU 2715R-008396316-000M 1468  458 UCUCCUUGGGACUCUUGUU B UCUCCUUGGGACUCUUGUUTT B2714 R-008396319-000N 2480  459 GAGAUGGGUGGCCACCACCB GAGAUGUGUGGCCACCACCTT B 2716 R-008396319-000N 2480  459GAGAUGGGUGGCCACCACC GGUGGUGGCCACCCAUCUCUU 2717 R-008396322-000V 1856 460 CAGGGUGCCAUUCCACGAC B CAGGGUGCCAUUCCACGACTT B 2718 R-008396322-000V1856  460 CAGGGUGCCAUUCCACGAC GUCGUGGAAUGGCACCCUGUU 2719R-008396325-000W 2193  461 AGUUACUUCACUCUAGGAA B AGUUACUUCACUCUAGGAATT B2720 R-008396325-000W 2193  461 AGUUACUUCACUCUAGGAAUUCCUAGAGUGAAGUAACUUU 2721 R-008396328-000X 2355  462UUGGACUUGAUAUUGGUGC B UUGGACUUGAUAUUGGUGCTT B 2722 R-008396328-000X 2355 462 UUGGACUUGAUAUUGGUGC GCACCAAUAUCAAGUCCAAUU 2723 R-008396331-000D1995  463 CCCUUCACAUCCUAGCUCG CGAGCUAGGAUGUGAAGGGUU 2725R-008396331-000D 1995  463 CCCUUCACAUCCUAGCUCG B CCCUUCACAUCCUAGCUCGTT B2724 R-008396334-000E  821  464 AGACACGCUAUCAUGCGUUB AGACACGCUAUCAUGCGUUTT B 2726 R-008396334-000E  821  464AGACACGCUAUCAUGCGUU AACGCAUGAUAGCGUGUCUUU 2727 R-008396337-000F 1715 465 AAUGCAGUUCGCCUUCACU B AAUGCAGUUCGCCUUCACUTT B 2728 R-008396337-000F1715  465 AAUGCAGUUCGCCUUCACU AGUGAAGGCGAACUGCAUUUU 2729R-008396390-000M 1182  466 CUUAUGUCAACCAAGAAAG CUUUCUUGGUUGCCAUAAGUU2731 R-008396340-000M 1182  466 CUUAUGUCAACCAAGAAAGB CUUAUGGCAACCAAGAAAGTT B 2730 R-008396343-000N  445  467CUCCCAAGUCCUGUAUGAG B CUCCCAAGUCCUGUAUGAGTT B 2732 R-008396343-000N  445 467 CUCCCAAGUCCUGUAUGAG CUCAUACAGGACUUGGGAGUU 2733 R-008396396-000P1759  468 CUUACACCCACCAUCCCAC GUGGGAUGGUGGGUGUAAGUU 2735R-008396346-000P 1759  468 CUUACACCCACCAUCCCAC B CUUACACCCACCAUCCCACTT B2734 R-008396349-000R 1461  469 UGGAAGGUCUCCUUGGGACB UGGAAGGUCUCCUUGGGACTT B 2736 R-008396349-000R 1461  469UGGAAGGUCUCCUUGGGAC GUCCCAAGGAGACCUUCCAUU 2737 R-008396352-000X 1993 470 AGCCCUUCACAUCCUAGCU AGCUAGGAUGUGAAGGGCUUU 2739 R-008396352-000X1993  470 AGCCCUUCACAUCCUAGCU B AGCCCUUCACAUCCUAGCUTT B 2738R-008396355-000Y 2558  471 GAUGGGCUGCCUCCAGGUG B GAUGGGCUGCCUCCAGGUGTT B2740 R-008396355-000Y 2558  471 GAUGGGCUGCCUCCAGGUGCACCUGGAGGCAGCCCAUCUU 2741 R-008396358-000Z 1488  472AGCUUCUGGGUUCAGAUGA B AGCUUCUGGGUUCAGAUGATT B 2742 R-008396358-000Z 1488 472 AGCUUCUGGGUUCAGAUGA UCAUCUGAACCCAGAAGCUUU 2743 R-008396361-000F1652  473 GAGCCUGCCAUCUGUGCUC B GAGCCUGCCAUCUGUGCUCTT B 2744R-008396361-000F 1652  473 GAGCCUGCCAUCUGUGCUC GAGCACAGAUGGCAGGCUCUU2745 R-008396364-000G  963  474 UUAAGUGUGGAGGCAUUCCB UUAAGUCUGGAGGCAUUCCTT B 2746 R-008396364-000G  963  474UUAAGUGUGGAGGCAUUCC GGAAUGCCUCCAGACUUAAUU 2747 R-008396367-000H 1520 475 ACCUGUGGAGCUGGAAUUC B ACCUGUGCAGCUGGAAUUCTT B 2748 R-008396367-000H1520  475 ACCUGUGGAGCUGGAAUUC GAAUUCCAGCUGCACAGGUUU 2749R-008396370-000P 1828  476 UCCCGCAAAUCAUGCACCU AGGUGCAUGAUUUGCGGGAUU2751 R-008396370-000P 1828  476 UCCCGCAAAUCAUGCACCUB UCCCGCAAAUCAUGCACCUTT B 2750 R-008396373-000R 2214  477AAGGUGUGGCGACAUAUGC B AAGGUGUGGCGACAUAUGCTT B 2752 R-008396373-000R 2214 477 AAGGUGUGGCGACAUAUGC GCAUAUGUCGCCACACCUUUU 2753 R-008396376-000S2155  478 AGCUAUUGAAGCUGAGGGA UCCCUCAGCUUCAAUAGCUUU 2755R-008396376-000S 2155  478 AGCUAUUGAAGCUGAGGGA B AGCUAUUGAAGCUGAGGGATT B2754 R-008396379-000T  332  479 GUUAGUCACUGGCAGCAACGUUGCUGCCAGUGACUAACUU 2757 R-008396379-000T  332  479GUUAGUCACUGGCAGGAAC B GUUAGUCACUGGCAGCAACTT B 2756 R-008396382-000Z 2545  74 CCAGGACCUCAUGGAUGGG CCCAUCCAUGAGGUCCUGGUU 2759 R-008396382-000Z2545   74 CCAGGACCUCAUGGAUGGG B CCAGGACCUCAUGGAUGGGTT B 2758R-008396385-000A 1878  480 UUCAGUUGCUUGUUCGUGC B UUCAGUUGCUUGUUCGUGCTT B2760 R-008396385-000A 1878  480 UUCAGUUGCUUGUUCGUGCGCACGAACAAGCAACUGAAUU 2761 R-008396388-000B 1789  106AAAGGCUACUGUUGGAUUG CAAUCCAACAGUAGCCUUUUU 2763 R-008396388-000B 1789 106 AAAGGCUACUGUUGGAUUG B AAAGGCUACUGUUGGAUUGTT B 2762 R-008396391-000H2597  168 AGGACCUCAUGGAUGGGCU B AGGACCUCAUGGAUGGGCUTT B 2764R-008396391-000H 2547  168 AGGACCUCAUGGAUGGGCU AGCCCAUCCAUGAGGUCCUUU2765 R-008396394-000J 1573  481 GAUGAUGGUCUUCCAAGUGB GAUGAUGGUCUGCCAAGUGTT B 2766 R-008396394-000J 1573  481GAUGAUGGUCUGCCAAGUG CACUUGGCAGACCAUCAUCUU 2767 R-008396397-000K 1446 482 CUAAACAGGAAGGGAUGGA B CUAAACAGGAAGGGAUGGATT B 2768 R-008396397-000K1446  482 CUAAACAGGAAGGGAUGGA UCCAUCCCUUCCUGUUUAGUU 2769R-008396400-000C 1868  483 CCACGACUAGUUCAGUUGC GCAACUGAACUAGUCGUGGUU2771 R-008396400-000C 1868  483 CCACGACUAGUUCAGUUGCB CCACGACUAGUUCAGUUGCTT B 2770 R-008396403-000D 1873  484ACUAGUUCAGUUGCUUGUU AACAAGCAACUGAACUAGUUU 2773 R-008396403-000D 1873 484 ACUAGUUCAGUUGCUUGUU B ACUAGUUCAGUUGCUUGUUTT B 2772 R-008396406-000E1002  485 GUUCACCAGUGGAUUCUGU B GUUCACCAGUGGAUUCUGUTT B 2774R-008396406-000E 1002  485 GUUCACCAGUGGAUUCUGU ACAGAAUCCACUGGUGAACUU2775 R-008396409-000F  408  486 GUGGUAAAGGCAAUCCUGAB GUGGUAAAGGCAAUCCUGATT B 2776 R-008396409-000F  408  486GUGGUAAAGGCAAUCCUGA UCAGGAUUGCCUUUACCACUU 2777 R-008396412-000M  287 487 UUGAUGGAGUUGGACAUGG CCAUGUCCAACUCCAUCAAUU 2779 R-008396412-000M 287  487 UUGAUGGAGUUGGACAUGG B UUGAUGGAGUUGGACAUGGTT B 2778R-008396115-000N 1492  119 UCUGGGUUCAGAUGAUAUA UAUAUCAUCUGAACCCAGAUU2781 R-008396415-000N 1492  119 UCUGGGUUCAGAUGAUAUAB UCUGGGUUCAGAUGAUAUATT B 2780 R-008396418-000P  517  187UGGACAGUAUGCAAUGACU B UGGACAGUAUGCAAUGACUTT B 2782 R-008396418-000P  517 187 UGGACAGUAUGCAAUGACU AGUCAUUGCAUACUGUCCAUU 2783 R-008396421-000W 447  177 CCCAAGUCCUGUAUGAGUG B CCCAAGUCCUGUAUGAGUGTT B 2784R-008396421-000W  447  177 CCCAAGUCCUGUAUGAGUG CACUCAUACAGGACUUGGGUU2785 R-008396424-000X 2128  488 ACUUGCUCAGGACAAGGAAUUCCUUGUCCUGAGCAAGUUU 2787 R-008396424-000X 2128  488ACUUGCUCAGGACAAGGAA B ACUUGCUCAGGACAAGGAATT B 2786 R-008396427-000Y 2513 489 CCAGUUGAUGGGCUGCCAG B CCAGUUGAUGGGCUGCCAGTT B 2788 R-008396427-000Y2513  489 CCAGUUGAUGGGCUGCCAG CUGGCAGCCCAUCAACUGGUU 2789R-008396430-000E 1196  490 GAAAGCAAGCUCAUCAUAC GUAUGAUGAGCUUGCUUUCUU2791 R-008396430-000E 1196  490 GAAAGCAAGCUCAUCAUACB GAAAGCAAGCUCAUCAUACTT B 2790 R-008396433-000F  572  491ACAUUAGAUGAGGGCAUGC B ACAUUAGAUGAGGGCAUGCTT B 2792 R-008396433-000F  572 491 ACAUUAGAUGAGGGCAUGC GCAUGCCCUCAUCUAAUGUUU 2793 R-008396436-000G 622  492 UCCCACUAAUGUCCAGCGU B UCCCACUAAUGUCCAGCGUTT B 2794R-008396436-000G  622  492 UCCCACUAAUGUCCAGCGU ACGCUGGACAUUAGUGGGAUU2795 R-008396439-000H 1187  493 GGCAACCAAGAAAGCAAGCGCUUGCUUUCUUGGUUGCCUU 2797 R-008396439-000H 1187  493GGCAACCAAGAAAGCAAGC B GGCAACCAAGAAAGCAAGCTT B 2796 R-008396442-000P 2098  49 CCAAAGAGUAGCUGCAGGG B CCAAAGAGUAGCUGCAGGGTT B 2798 R-008396442-000P2098   49 CCAAAGAGUAGCUGCAGGG CCCUGCAGCUACUCUUUGGUU 2799R-008396445-000R 1971  494 AAAUAGUUGAAGGUUGUAC B AAAUAGUUGAAGGUUGUACTT B2800 R-008396445-000R 1971  494 AAAUAGUUGAAGGUUGUACGUACAACCUUCAACUAUUUUU 2801 R-008396448-000S 3083  495GGAUAUGUAUGGGUAGGGU ACCCUACCCAUACAUAUCCUU 2803 R-008396448-000S 3083 495 GGAUAUGUAUGGGUAGGGU B GGAUAUGUAUGGGUAGGGUTT B 2802 R-008396454-000Z2944  496 UAAUCUGAAUAAAGUGUAA UUACACUUUAUUCAGAUUAUU 2805R-008396454-000Z 2944  496 UAAUCUGAAUAAAGUGUAA B UAAUCUGAAUAAAGUGUAATT B2804 R-008396457-000A 1894  497 UGCACAUCAGGAUACCCAGB UGCACAUCAGGAUACCCAGTT B 2806 R-008396457-000A 1894  497UGCACAUCAGGAUACCCAG CUGGGUAUCCUGAUGUGCAUU 2807 R-008396460-000G 1323 498 GUAAUAAGCCGGCUAUUGU B GUAAUAAGCCGGCUAUUGUTT B 2808 R-008396460-000G1323  498 GUAAUAAGCCGGCUAUUGU ACAAUAGCCGGCUUAUUACUU 2809R-008396469-000K 1202  499 AAGCUCAUCAUACUGGCUA B AAGCUCAUCAUACUGGCUATT B2810 R-008396469-000K 1202  499 AAGCUCAUCAUACUGGCUAUAGCCAGUAUGAUGAGCUUUU 2811 R-008396472-000S  718  500ACGUGCAAUCCCUGAACUG CAGUUCAGGGAUUGCACGUUU 2813 R-008396472-000S  718 500 ACGUGCAAUCCCUGAACUG B ACGUGCAAUCCCUGAACUGTT B 2812 R-008396475-000T2097   46 UCCAAAGAGUAGCUGGAGG CCUGCAGCUACUCUUUGGAUU 2815R-008396475-000T 2097   46 UCCAAAGAGUAGCUGCAGG B UCCAAAGAGUAGCUGCAGGTT B2814 R-008396478-000U 1744  501 AGUUGUGGUUAAGCUCUUAB AGUUGUGGUUAAGCUCUUATT B 2816 R-008396478-000U 1714  501AGUUGUGGUUAAGCUCUUA UAAGAGCUUAACCACAACUUU 2817 R-008396481-000A  756 502 AGGACCAGGUGGUGGUUAA UUAACCACCACCUGGUCCUUU 2819 R-008396481-000A 756  502 AGGACCAGGUGGUGGUUAA B AGGACCAGGUGGUGGUUAATT B 2818R-008396484-000B 1317  503 GCUCUAGUAAUAAGCCGGC GCCGGCUUAUUACUAGAGCUU2821 R-008396484-000B 1317  503 GCUCUAGUAAUAAGCCGGCB GCUCUAGUAAUAAGCCGGCTT B 2820 R-008396487-000C  284  504GAUUUGAUGGAGUUGGACA B GAUUUGAUGGAGUUGGACATT B 2822 R-008396487-000C  284 504 GAUUUGAUGGAGUUGGACA UGUCCAACUCCAUCAAAUCUU 2823 R-008396490-000J 886  505 UGAUGUAGAAACAGCUCGU B UGAUGUAGAAACAGCUCGUTT B 2824R-008396490-000J  886  505 UGAUGUAGAAACAGCUCGU ACGAGCUGUUUCUACAUCAUU2825 R-008396493-000K 2430  506 CUGGUGGAUAUGGCCAGGAB CUGGUGGAUAUGGCCAGGATT B 2826 R-008396493-000K 2430  506CUGGUGGAUAUGGCCAGGA UCCUGGCCAUAUCCACCAGUU 2827 R-008396496-000L 1207 507 CAUCAUACUGGCUAGUGGU B CAUCAUACUGGCUAGUGGUTT B 2828 R-008396496-000L1207  507 CAUCAUACUGGCUAGUGGU ACCACUAGCCAGUAUGAUGUU 2829R-008396499-000M  592  508 GAUCCCAUCUACACAGUUU AAACUGUGUAGAUGGGAUCUU2831 R-008396499-000M  592  508 GAUCCCAUCUACACAGUUUB GAUCCCAUCUACACAGUUUTT B 2830 R-008396502-000E  824  509CACGCUAUCAUGCGUUCUC GAGAACGCAUGAUAGCGUGUU 2833 R-008396502-000E  824 509 CACGCUAUCAUGCGUUCUC B CACGCUAUCAUGCGUUCUCTT B 2832 R-008396505-000F 519  510 GACAGUAUGCAAUGACUCG B GACAGUAUGCAAUGACUCGTT B 2834R-008396505-000F  519  510 GACAGUAUGCAAUGACUCG CGAGUCAUUGCAUACUGUCUU2835 R-008396508-000G 3166  511 AAGUUGUUGUAACCUGCUGCAGCAGGUUACAACAACUUUU 2837 R-008396508-000G 3166  511AAGUUGUUGUAACCUGCUG B AAGUUGUUGUAACCUGCUGTT B 2836 R-008396511-000N 1151 512 GCUAUUACGACAGACUGCC B GCUAUUACGACAGACUGCCTT B 2838 R-008396511-000N1151  512 GCUAUUACGACAGACUGCC GGCAGUCUGUCGUAAUAGCUU 2839R-008396514-000P 2566  513 GCCUCCAGGUGACAGCAAU B GCCUCCAGGUGACAGCAAUTT B2840 R-008396514-000P 2566  513 GCCUCCAGGUGACAGCAAUAUUGCUGUCACCUGGAGGCUU 2841 R-008396517-000R  453  514UCCUGUAUGAGUGGGAACA UGUUCCCACUCAUACAGGAUU 2843 R-008396517-000R  453 514 UCCUGUAUGAGUGGGAACA B UCCUGUAUGAGUGGGAACATT B 2842 R-008396520-000X 587  515 AUGCAGAUCCCAUCUACAC GUGUAGAUGGGAUCUGCAUUU 2845R-008396520-000X  587  515 AUGCAGAUCCCAUCUACAC B AUGCAGAUCCCAUCUACACTT B2844 R-008396523-000Y  930  516 UUUCCCAUCAUCGUGAGGGB UUUCCCAUCAUCGUGAGGGTT B 2846 R-008396523-000Y  930  516UUUCCCAUCAUCGUGAGGG CCCUCACGAUGAUGGGAAAUU 2847 R-008396526-000Z 1585 517 CCAAGUGGGUGGUAUAGAG B CCAAGUGGCUGGUAUAGAGTT B 2848 R-008396526-000Z1585  517 CCAAGUGGGUGGUAUAGAG CUCUAUACCACCCACUUGGUU 2849R-008396529-000A  915  518 GGACCUUGCAUAACCUUUC B GGACCUUGCAUAACCUUUCTT B2850 R-008396529-000A  915  518 GGACCUUGCAUAACCUUUCGAAAGGUUAUGCAAGGUCCUU 2851 R-008396532-000G  446  519UCCCAAGUCCUGUAUGAGU ACUCAUACAGGACUUGGGAUU 2853 R-008396532-000G  446 519 UCCCAAGUCCUGUAUGAGU B UCCCAAGUCCUGUAUGAGUTT B 2852 R-008396535-000H1869  520 CACGACUAGUUCAGUUGCU AGCAACUGAACUAGUCGUGUU 2855R-008396535-000H 1869  520 CACGACUAGUUCAGUUGCU B CACGACUAGUUCAGUUGCUTT B2854 R-008396538-000J 1960  521 CCGCAUGGAAGAAAUAGUUAACUAUUUCUUCCAUGCGGUU 2857 R-008396538-000J 1960  521CCGCAUGGAAGAAAUAGUU B CCGCAUGGAAGAAAUAGUUTT B 2856 R-008396541-000R 1708 522 GGCCCAGAAUGCAGUUCGC B GGCCCAGAAUGCAGUUCGCTT B 2858 R-008396541-000R1708  522 GGCCCAGAAUGCAGUUCGC GCGAACUGCAUUCUGGGCCUU 2859R-008396544-000S  306  523 CCAUGGAACCAGACAGAAA UUUCUGUCUGGUUCCAUGGUU2861 R-008396544-000S  306  523 CCAUGGAACCAGACAGAAAB CCAUGGAACCAGACAGAAATT B 2860 R-008396550-000Z 2281  524GAAACGGCUUUCAGUUGAG B GAAACGGCUUUCAGUUGAGTT B 2862 R-008396550-000Z 2281 524 GAAACGGCUUUCAGUUGAG CUCAACUGAAAGCCGUUUCUU 2863 R-008396553-000A3082  525 GGGAUAUGUAUGGGUAGGG B GGGAUAUGUAUGGGUAGGGTT B 2864R-008396553-000A 3082  525 GGGAUAUGUAUGGGUAGGG CCCUACCCAUACAUAUCCCUU2865 R-008396556-000B 1473  526 UUGGGACUCUUGUUCAGCUAGCUGAACAAGAGUCCCAAUU 2867 R-008396556-000B 1473  526UUGGGACUCUUGUUCAGCU B UUGGGACUCUUGUUCAGCUTT B 2866 R-008396559-000C  559 527 UAUGUUCCCUGAGACAUUA UAAUGUCUCAGGGAACAUAUU 2869 R-008396559-000C 559  527 UAUGUUCCCUGAGACAUUA B UAUGUUCCCUGAGACAUUATT B 2868R-008396562-000J 1416  528 GGACUCUCAGGAAUCUGUC B GGACUCUCAGGAAUCUUUCTT B2870 R-008396562-000J 1416  528 GGACUCUCAGGAAUCUGUCGAAAGAUUCCUGAGAGUCCUU 2871 R-008396565-000K 2145  529AAGCUGCAGAAGCUAUUGA B AAGCUGCAGAAGCUAUUGATT B 2872 R-008396565-000K 2145 529 AAGCUGCAGAAGCUAUUGA UCAAUAGCUUCUGCAGCUUUU 2873 R-008396568-000L1994  530 GCCCUUCACAUCCUAGCUC B GCCCUUCACAUCCUAGCUCTT B 2874R-008396568-000L 1994  530 GCCCUUCACAUCCUAGCUC GAGCUAGGAUGUGAAGGGCUU2875 R-008396571-000T 1611   27 UGCGUACUGUCCUUCGGGCB UGCGUACUGUCCUUCGGGCTT B 2876 R-008396571-000T 1611   27UGCGUACUGUCCUUCGGGC GCCCGAAGGACAGUACGCAUU 2877 R-008396574-000U 1702 531 AGAGAUGGCCCAGAAUGCA B AGAGAUGGCCCAGAAUGCATT B 2878 R-008396574-000U1702  531 AGAGAUGGCCCAGAAUGCA UGCAUUCUGGGCCAUCUCUUU 2879R-008396577-000V  417  532 GCAAUCCUGAGGAAGAGGA B GCAAUCCUGAGGAAGAGGATT B2880 R-008396577-000V  417  532 GCAAUCCUGAGGAAGAGGAUCCUCUUCCUCAGGAUUGCUU 2881 R-008396580-000B 2444  533CAGGAUGCCUUGGGUAUGG B CAGGAUGCCUUGGGUAUGGTT B 2882 R-008396580-000B 2444 533 CAGGAUGCCUUGGGUAUGG CCAUACCCAAGGCAUCCUGUU 2883 R-008396586-000D 555  534 CUGCUAUGUUCCCUGAGAC B CUGCUAUGUUCCCUGAGACTT B 2884R-008396586-000D  555  534 CUGCUAUGUUCCCUGAGAC GUCUCAGGGAACAUAGCAGUU2885 R-008396589-000E 2019  535 UUCACAACCGAAUUGUUAUB UUCAGAACCGAAUUGUUAUTT B 2886 R-008396589-000E 2019  535UUCACAACCGAAUUGUUAU AUAACAAUUCGGUUGUGAAUU 2887 R-008396592-000L 1197 536 AAAGCAAGCUCAUCAUACU B AAAGCAAGCUCAUCAUACUTT B 2888 R-008396592-000L1197  536 AAAGCAAGCUCAUCAUACU AGUAUGAUGAGCUUGCUUUUU 2889R-008396595-000M  415  537 AGGCAAUCCUGAGGAAGAG CUCUUCCUCAGGAUUGCCUUU2891 R-008396595-000M  415  537 AGGCAAUCCUGAGGAAGAGB AGGCAAUCCUGAGGAAGAGTT B 2890 R-008396598-000N 2061  538UGUUUGUGCAGCUGCUUUA B UGUUUGUGCAGCUGCUUUATT B 2892 R-008396598-000N 2061 538 UGUUUGUGCAGCUGCUUUA UAAAGCAGCUGCACAAACAUU 2893 R-008396601-000F1352  539 GGAAUGCAAGCUUUAGGAC B GGAAUGCAAGCUUUAGGACTT B 2894R-008396601-000F 1352  539 GGAAUGCAAGCUUUAGGAC GUCCUAAAGCUUGCAUUCCUU2895 R-008396604-000G 1502  135 GAUGAUAUAAAUGUGGUCAUGACCACAUUUAUAUCAUCUU 2897 R-008396604-000G 1502  135GAUGAUAUAAAUGUGGUCA B GAUGAUAUAAAUGUGGUCATT B 2896 R-008396607-000H 1331 540 CCGGCUAUUGUAGAAGCUG B CCGGCUAUUGUAGAAGCUGTT B 2898 R-008396607-000H1331  540 CCGGCUAUUGUAGAAGCUG CAGCUUCUACAAUAGCCGGUU 2899R-008396610-000P 1325  541 AAUAAGCCGGCUAUUGUAG B AAUAAGCCGGCUAUUGUAGTT B2900 R-008396610-0001 1325  541 AAUAAGCCGGCUAUUGUAGCUACAAUAGCCGGCUUAUUUU 2901 R-008396613-000R 1486  542UCAGCUUCUGGGUUCAGAU B UCAGCUUCUGGGUUCAGAUTT B 2902 R-008396613-000R 1486 542 UCAGCUUCUGGGUUCAGAU AUCUGAACCCAGAAGCUGAUU 2903 R-008396616-000S 454  543 CCUGUAUGAGUGGGAACAG B CCUGUAUGAGUGGGAACAGTT B 2904R-008396616-000S  454  543 CCUGUAUGAGUGGGAACAG CUGUUCCCACUCAUACAGGUU2905 R-008396619-000T  490  544 CACUCAAGAACAAGUAGCUB CACUCAAGAACAAGUAGCUTT B 2906 R-008396619-000T  490  544CACUCAAGAACAAGUAGCU AGCUACUUGUUCUUGAGUGUU 2907 R-008396622-000Z 1996 545 CCUUCACAUCCUAGCUCGG B CCUUCACAUCCUAGCUCGGTT B 2908 R-008396622-000Z1996  545 CCUUCACAUCCUAGCUCGG CCGAGCUAGGAUGUGAAGGUU 2909R-008396625-000A 1839  546 AUGCACCUUCGCGUGAGCA B AUGCACCUUUGCGUGAGCATT B2910 R-008396625-000A 1839  546 AUGCACCUUCGCGUGAGCAUGCUCACGCAAAGGUGCAUUU 2911 R-008396628-000B 1888  547UGUUCGUGCACAUCAGGAU AUCCUGAUGUGCACGAACAUU 2913 R-008396628-000B 1888 547 UGUUCGUGCACAUCAGGAU B UGUUCGUGCACAUCAGGAUTT B 2912 R-008396631-000H1879  548 UCAGUUGCUUGUUCGUGCA B UCAGUUGCUUGUUCGUGCATT B 2914R-008396631-000H 1879  548 UCAGUUGCUUGUUCGUGCA UGGACGAACAAGCAACUGAUU2915 R-008396634-000J 2508  172 ACUAUCCAGUUGAUGGGCUB ACUAUCCAGUUGAUGGGCUTT B 2916 R-008396634-000J 2508  172ACUAUCCAGUUGAUGGGCU AGCCCAUCAACUGGAUAGUUU 2917 R-008396637-000K 1829 549 CCCGCAAAUCAUGCACCUU AAGGUGCAUGAUUUGCGGGUU 2919 R-008396637-000K1829  549 CCCGCAAAUCAUGCACCUU B CCCGCAAAUCAUGCACCUUTT B 2918R-008396640-000S  281  550 GCUGAUUUGAUGGAGUUGG B GCUGAUUUGAUGGAGUUGGTT B2920 R-008396640-000S  281  550 GCUGAUUUGAUGGAGUUGGCCAACUCCAUCAAAUCAGCUU 2921 R-008396643-000T 1598  551AUAGAGGCUCUUGUGCGUA UACGCACAAGAGCCUCUAUUU 2923 R-008396643-000T 1598 551 AUAGAGGCUCUUGUGCGUA B AUAGAGGCUCUUGUGCGUATT B 2922 R-008396646-000U2135  552 CAGGACAAGGAAGCUGCAG B CAGGACAAGGAAGCUGCAGTT B 2924R-008396646-000U 2135  552 CAGGACAAGGAAGCUGCAG CUGCAGCUUCCUUGUCCUGUU2925 R-008396649-000V  642   67 UGGCUGAACCAUCACAGAUAUCUGUGAUGGUUCAGCCAUU 2927 R-008396649-000V  642   67UGGCUGAACCAUCACAGAU B UGGCUGAACCAUCACAGAUTT B 2926 R-008396652-000B 1755 553 AGCUCUUACACCCACCAUC B AGCUCUUACACCCACCAUCTT B 2928 R-008396652-000B1755  553 AGCUCUUACACCCACCAUC GAUGGUGGGUGUAAGAGCUUU 2929R-008396655-000C  651  554 CAUCACAGAUGCUGAAACA B CAUCACAGAUGCUGAAACATT B2930 R-008396655-000C  651  554 CAUCACAGAUGCUGAAACAUGUUUCAGCAUCUGUGAUGUU 2931 R-008396658-000D 1335  555CUAUUGUAGAAGCUGGUGG CCACCAGCUUCUACAAUAGUU 2933 R-008396658-000D 1335 555 CUAUUGUAGAAGCUGGUGG B CUAUUGUAGAAGCUGGUGGTT B 2932 R-008396661-000K2541  556 AUGCCCAGGACCUCAUGGA UCCAUGAGGUCCUGGGCAUUU 2935R-008396661-000K 2541  556 AUGCCCAGGACCUCAUGGA B AUGCCCAGGACCUCAUGGATT B2934 R-008396664-000L  531  557 UGACUCGAGCUCAGAGGGUB UGACUCGAGCUCAGAGGGUTT B 2936 R-008396664-000L  531  557UGACUCGAGCUCAGAGGGU ACCCUCUGAGCUCGAGUCAUU 2937 R-008396667-000M  606 558 AGUUUGAUGCUGCUCAUCC B AGUUUGAUGCUGCUCAUCCTT B 2938 R-008396667-000M 606  558 AGUUUGAUGCUGCUCAUCC GGAUGAGCAGCAUCAAACUUU 2939R-008396670-000U 1620  559 UCCUUCGGGCUGGUGACAG B UCCUUCGGGCUGGUGACAGTT B2940 R-008396670-000U 1620  559 UCCUUCGGGCUGGUGACAGCUGUCACCAGCCCGAAGGAUU 2941 R-008396673-000V 2211  560AUGAAGGUGUGGCGACAUA B AUGAAGGUGUGGCGACAUATT B 2942 R-008396673-000V 2211 560 AUGAAGGUGUGGCGACAUA UAUGUCGCCACACCUUCAUUU 2943 R-008396676-000W2293  561 AGUUGAGCUGACCAGCUCU B AGUUGAGCUGACCAGCUCUTT B 2944R-008396676-000W 2293  561 AGUUGAGCUGACCAGCUCU AGAGCUGGUCAGCUCAACUUU2945 R-008396679-000X 1511   65 AAUGUGGUCACCUGUGCAGB AAUGUGGUCACCUGUGCAGTT B 2946 R-008396679-000X 1511   65AAUGUGGUCACCUGUGCAG CUGCACAGGUGACCACAUUUU 2947 R-008396682-000D  455 562 CUGUAUGAGUGGGAACAGG B CUGUAUGAGUGGGAACAGGTT B 2948 R-008396682-000D 455  562 CUGUAUGAGUGGUAACAGG CCUGUUCCCACUCAUACAGUU 2949R-008396685-000E  540  563 CUCAGAGGGUACGAGCUGC B CUCAGAGGGUAGGAGCUGCTT B2950 R-008396685-000E  540  563 CUGAGAGGGUACGAGCUGCGCAGCUCGUACCCUCUGAGUU 2951 R-008396688-000F  416  564GGCAAUCCUGAGGAAGAGG CCUCUUCCUCAGGAUUGCCUU 2953 R-008396688-000F  416 564 GGCAAUCCUGAGGAAGAGG B GGCAAUCCUGAGGAAGAGGTT B 2952 R-008396691-000M1669  130 UCUUCGUCAUCUGACCAGC GCUGGUCAGAUGACGAAGAUU 2955R-008396691-000M 1669  130 UCUUCGUCAUCUGACCAGC B UCUUCGUCAUCUGACCAGCTT B2954 R-008396694-000N 1210  565 CAUACUGGCUAGUGGUGGAB CAUACUGGCUAGUGGUGGATT B 2956 R-008396694-000N 1210  565CAUACUGGCUAGUGGUGGA UCCACCACUAGCCAGUAUGUU 2957 R-008396697-000P 2262 566 ACAAGCCACAAGAUUACAA UUGUAAUCUUGUGGCUUGUUU 2959 R-008396697-000P2262  566 ACAAGCCACAAGAUUACAA B ACAAGCCACAAGAUUACAATT B 2958R-008396700-000G 1604  567 GCUCUUGUGCGUACUGUCC GGACAGUACGCACAAGAGCUU2961 R-008396700-000G 1604  567 GCUCUUGUGCGUACUGUCCB GCUCUUGUGCGUACUGUCCTT B 2960 R-008396703-000H  435  568AUGUGGAUACCUCCCAAGU B AUGUGGAUACCUCCCAAGUTT B 2962 R-008396703-000H  435 568 AUGUGGAUACCUCCCAAGU ACUUGGGAGGUAUCCACAUUU 2963 R-008396706-000J2060  569 UUGUUUGUGCAGCUGCUUU B UUGUUUGUGCAGCUGCUUUTT B 2964R-008396706-000J 2060  569 UUGUUUGUGCAGCUGCUUU AAAGCAGCUGCACAAACAAUU2965 R-008396709-000K 2225  570 ACAUAUGCAGCUGCUGUUUB ACAUAUGGAGCUGCUGUUUTT B 2966 R-008396709-000K 2225  570ACAUAUGCAGCUGCUGUUU AAACAGCAGCUGCAUAUGUUU 2967 R-008396712-000S 2510  47 UAUCCAGUUGAUGGGCUGC B UAUCCAGUUGAUGGGCUGCTT B 2968 R-008396712-000S2510   47 UAUCCAGUUGAUGGGCUGC GCAGCCCAUCAACUGGAUAUU 2969R-008396715-000T  481  571 UCAGUCCUUCACUCAAGAA UUCUUGAGUGAAGGACUGAUU2971 R-008396715-000T  481  571 UCAGUCCUUCACUCAAGAAB UCAGUCCUUCACUCAAGAATT B 2970 R-008396718-000U  917  572ACCUUGCAUAACCUUUCCC B ACCUUGCAUAACCUUUCCCTT B 2972 R-008396718-000U  917 572 ACCUUGCAUAACCUUUCCC GGGAAAGGUUAUGCAAGGUUU 2973 R-008396721-000A2221  573 GGCGACAUAUGCAGCUGCU B GGCGACAUAUGCAGCUGCUTT B 2974R-008396721-000A 2221  573 GGCGACAUAUGCAGCUGCU AGCAGCUGCAUAUGUCGCCUU2975 R-008396724-000B  849  574 UGGUGUCUGCUAUUGUACGCGUACAAUAGCAGACACCAUU 2977 R-008396724-000B  849  574UGGUGUCUGCUAUUGUACG B UGGUGUCUGCUAUUGUACGTT B 2976 R-008396727-000C  562 575 GUUCCCUGAGACAUUAGAU B GUUCCCUGAGACAUUAGAUTT B 2978 R-008396727-000C 562  575 GUUCCCUGAGACAUUAGAU AUCUAAUGUCUCAGGGAACUU 2979R-008396730-000J  617  140 GCUCAUCCCACUAAUGUCC GGACAUUAGUGGGAUGAGCUU2981 R-008396730-000J  617  140 GCUCAUCCCACUAAUGUCCB GCUCAUCCCACUAAUGUCCTT B 2980 R-008396733-000K 1787  576AUAAAGGCUACUGUUGGAU B AUAAAGGCUACUGUUGGAUTT B 2982 R-008396733-000K 1787 576 AUAAAGGCUACUGUUGGAU AUCCAACAGUAGCCUUUAUUU 2983 R-008396736-000L1860  577 GUGCCAUUCCACGACUAGU ACUAGUCGUGGAAUGGCACUU 2985R-008396736-000L 1860  577 GUGCCAUUCCACGACUAGU B GUGCCAUUCCACGACUAGUTT B2984 R-008396739-000M 1590  578 UGGGUGGUAUAGAGGCUCUB UGGGUGGUAUAGAGGCUCUTT B 2986 R-008396739-000M 1590  578UGGGUGGUAUAGAGGCUCU AGAGCCUCUAUACCACCCAUU 2987 R-008396742-000U  955 579 GGCCAUCUUUAAGUCUGGA UCCAGACUUAAAGAUGGCCUU 2989 R-008396742-000U 955  579 GGCCAUCUUUAAGUCUGGA B GGCCAUCUUUAAGUCUGGATT B 2988R-008396745-000V 2365  580 UAUUGGUGCCCAGGGAGAA B UAUUGGUGCCCAGGGAGAATT B2990 R-008396745-000V 2365  580 UAUUGGUGCCCAGGGAGAAUUCUCCCUGGGCACCAAUAUU 2991 R-008396748-000W  534  581CUCGAGCUCAGAGGGUACG B CUCGAGCUCAGAGGGUACGTT B 2992 R-008396748-000W  534 581 CUCGAGCUCAGAGGGUACG CGUACCCUCUGAGCUCGAGUU 2993 R-008396751-000C 706  582 AGAACUUGCCACACGUGCA UGCACGUGUGGCAAGUUCUUU 2995R-008396751-000C  706  582 AGAACUUGCCACACGUGCA B AGAACUUGCCACACGUGCATT B2994 R-008396754-000D 1740  583 UACCAGUUGUGGUUAAGCUB UACCAGUUGUGGUUAAGCUTT B 2996 R-008396754-000D 1740  583UACCAGUUGUGGUUAAGCU AGCUUAACCACAACUGGUAUU 2997 R-008396757-000E  638 584 CGUUUGGCUGAACCAUCAC B CGUUUGGCUGAACCAUCACTT B 2998 R-008396757-000E 638  584 CGUUUGGCUGAACCAUCAC GUGAUGGUUCAGCCAAACGUU 2999R-008396760-000L 1334  585 GCUAUUGUAGAAGCUGGUG CACCAGCUUCUACAAUAGCUU3001 R-008396760-000L 1334  585 GCUAUUGUAGAAGCUGGUGB GCUAUUGUAGAAGCUGGUGTT B 3000 R-008396763-000M  971  586GGAGGCAUUCCUGCCCUGG B GGAGGCAUUCCUGCCCUGGTT B 3002 R-008396763-000M  971 586 GGAGGCAUUCCUGCCCUGG CCAGGGCAGGAAUGCCUCCUU 3003 R-008396766-000N2493  587 ACCACCCUGGUGCUGACUA UAGUCAGCACCAGGGUGGUUU 3005R-008396766-000N 2493  587 ACCACCCUGGUGCUGACUA B ACCACCCUGGUGCUGACUATT B3004 R-008396769-000P 1814  588 AAUCUUGCCGUUUGUCCCGB AAUCUUGCCCUUUGUCCCGTT B 3006 R-008396769-000P 1814  588AAUCUUGCCCUUUGUCCCG CGGGACAAAGGGCAAGAUUUU 3007 R-008396772-000W 1088 589 CGUUUAGCUGGUGGGCUGC GCAGCCCACCAGCUAAACGUU 3009 R-008396772-000W1088  589 CGUUUAGCUGGUGGGCUGC B CGUUUAGCUGGUGGGCUGCTT B 3008R-008396775-000X 2292  590 CAGUUGAGCUGACCAGCUC GAGCUGGUCAGCUCAACUGUU3011 R-008396775-000X 2292  590 CAGUUGAGCUGACCAGCUCB CAGUUGAGCUGACCAGCUCTT B 3010 R-008396778-000Y 1504  591UGAUAUAAAUGUGGUCACC GGUGACCACAUUUAUAUCAUU 3013 R-008396778-000Y 1504 591 UGAUAUAAAUGUGGUCACC B UGAUAUAAAUGUGGUCACCTT B 3012 R-008396781-000E 404  592 CUGAGUGGUAAAGGCAAUC GAUUGCCUUUACCACUCAGUU 3015R-008396781-000E  404  592 CUGAGUGGUAAAGGCAAUC B CUGAGUGGUAAAGGCAAUCTT B3014 R-008396784-000F 1301  593 AAGGUGCUAUCUGUCUGCUAGCAGACAGAUAGCACCUUUU 3017 R-008396784-000F 1301  593AAGGUGCUAUCUGUCUGCU B AAGGUGCUAUCUGUCUGCUTT B 3016 R-008396787-000G 2004 594 UCCUAGCUCGGGAUGUUCA UGAACAUCCCGAGCUAGGAUU 3019 R-008396787-000G2004  594 UCCUAGCUCGGGAUGUUCA B UCCUAGCUCGGGAUGUUCATT B 3018R-008396790-000N  853    6 GUCUGCUAUUGUACGUACC GGUACGUACAAUAGCAGACUU3021 R-008396790-000N  853     6 GUCUGCUAUUGUACGUACCB GUCUOCUAUUGUACGUACCTT B 3020 R-008396793-000P  277  595UCAAGCUGAUUUGAUGGAG B UCAAGCUGAUUUGAUGGAGTT B 3022 R-008396793-000P  277 595 UCAAGCUGAUUUGAUGGAG CUCCAUCAAAUCAGCUUGAUU 3023 R-008396796-000R2304  596 CCAGCUCUCUCUUCAGAAC GUUCUGAAGAGAGAGCUGGUU 3025R-008396796-000R 2304  596 CCAGCUCUCUCUUCAGAAC B CCAGCUCUCUCUUCAGAACTT B3024 R-008396799-000S  300  597 ACAUGGCCAUGGAACCAGAB ACAUGGCCAUGGAACCAGATT B 3026 R-008396799-000S  300  597ACAUGGCCAUGGAACCAGA UCUGGUUCCAUGGCCAUGUUU 3027 R-008396802-000J 1906 598 UACCCAGCGCCGUACGUCC B UACCCAGCGCCGUACGUCCTT B 3028 R-008396802-000J1906  598 UACCCAGCGCCGUACGUCC GGACGUACGGCGCUGGGUAUU 3029R-008396805-000K 1973  599 AUAGUUGAAGGUUGUACCG CGGUACAACCUUCAACUAUUU3031 R-008396805-000K 1973  599 AUAGUUGAAGGUUGUACCGB AUAGUUGAAGGUUGUACCGTT B 3030 R-008396808-000L 1360  600AGCUUUAGGACUUCACCUG B AGCUUUAGGACUUCACCUGTT B 3032 R-008396808-000L 1360 600 AGCUUUAGGACUUCACCUG CAGGUGAAGUCCUAAAGCUUU 3033 R-008396811-000T2094  601 ACAUCCAAAGAGUAGCUGC GCAGCUACUCUUUGGAUGUUU 3035R-008396811-000T 2094  601 ACAUCCAAAGAGUAGCUGC B ACAUCCAAAGAGUAGCUGCTT B3034 R-008396814-000U  920  602 UUGGAUAACCUUUCCCAUCB UUGCAUAACCUUUCCCAUCTT B 3036 R-008396814-000U  920  602UUGCAUAACCUUUCCCAUC GAUGGGAAAGGUUAUGCAAUU 3037 R-008396817-000V 1707 603 UGGCCCAGAAUGCAGUUCG CGAACUGCAUUCUGGGCCAUU 3039 R-008396817-000V1707  603 UGGCCCAGAAUGCAGUUCG B UGGCCCAGAAUGCAGUUCGTT B 3038R-008396820-000B 1808  604 AUUCGAAAUCUUGCCCUUU B AUUCGAAAUCUUGCCCUUUTT B3040 R-008396820-000B 1808  604 AUUCGAAAUCUUGCCCUUUAAAGGGCAAGAUUUCGAAUUU 3041 R-008396823-000C 1326  605AUAAGCCGGCUAUUGUAGA UGUACAAUAGCCGOCUUAUUU 3043 R-008396823-000C 1326 605 AUAAGCCGGCUAUUGUAGA B AUAAGCCGGCUAUUGUAGATT B 3042 R-008396826-000D1158  606 CGACAGACUGCCUUCAAAU B CGACAGACUGCCUUCAAAUTT B 3044R-008396826-000D 1158  606 CGACAGACUGCCUUCAAAU AUUUGAAGGCAGUCUGUCGUU3045 R-008396829-000E  781  607 UGCAGUUAUGGUCCAUCAGB UGCAGUUAUGGUCCAUCAGTT B 3046 R-008396829-000E  781  607UGCAGUUAUGGUCCAUCAG CUGAUGGACCAUAACUGCAUU 3047 R-008396832-000L  607 608 GUUUGAUGCUGGUCAUCCC B GUUUGAUGCUGCUCAUCCCTT B 3048 R-008396832-000L 607  608 GUUUGAUGCUGCUCAUCCC GGGAUGAGCAGCAUCAAACUU 3049R-008396835-000M  627  609 CUAAUGUCCAGCGUUUGGC GCCAAACGCUGGACAUUAGUU3051 R-008396835-000M  627  609 CUAAUGUCCAGCGUUUGGCB CUAAUGUCCAGCGUUUGGCTT B 3050 R-008396838-000N  500  610CAAGUAGCUGAUAUUGAUG B CAAGUAGCUGAUAUUGAUGTT B 3052 R-008396838-000N  500 610 CAAGUAGCUGAUAUUGAUG CAUCAAUAUCAGCUACUUGUU 3053 R-008396841-000V2185  611 UCUGACAGAGUUACUUCAC B UCUGACAGAGUUACUUCACTT B 3054R-008396841-000V 2185  611 UCUGACAGAGUUACUUCAC GUGAAGUAACUCUGUCAGAUU3055 R-008396844-000W 1592  612 GGUGGUAUAGAGGCUCUUGB GGUGGUAUAGAGGCUCUUGTT B 3056 R-008396844-000W 1592  612GGUGGUAUAGAGGCUCUUG CAAGAGCCUGUAUACCACCUU 3057 R-008396847-000X  758 613 GACCAGGUGGUGGUUAAUA B GACCAGGUGGUGGUUAAUATT B 3058 R-008396847-000X 758  613 GACCAGGUGGUGGUUAAUA UAUUAACCACCACCUGGUCUU 3059R-008396850-000D 2551  614 CCUCAUGGAUGGCCUGCCU B CCUCAUGGAUGGGCUGCCUTT B3060 R-008396850-000D 2551  614 CCUCAUGGAUGGCCUGCCUAGGCAGCCCAUCCAUGAGGUU 3061 R-008396853-000E 1409  615UGUCUUUGGACUCUCAGUA B UGUCUUUGGACUCUCAGGATT B 3062 R-008396853-000E 1409 615 UGUCUUUGGACUCUCAGGA UCCUGAGAGUCCAAAGACAUU 3063 R-008396856-000F 497  616 GAACAAGUAGCUGAUAUUG B GAACAAGUAGCUGAUAUUGTT B 3064R-008396856-000F  497  616 GAACAAGUAGCUGAUAUUG CAAUAUCAGCUACUUGUUCUU3065 R-008396859-000G  381  617 GUGCCACUACCACAGCUCCB GUGCCACUACCACAGCUCCTT B 3066 R-008396859-000G  381  617GUGCCACUACCACAGCUCC GGAGCUGUGGUAGUGGCACUU 3067 R-008396862-000N 1841 618 GCACCUUUGCGUGAGCAGG CCUGCUCACGCAAAGGUGCUU 3069 R-008396862-000N1841  618 GCACCUUUGCGUGAGCAGG B GCACCUUUGCGUGAGCAGGTT B 3068R-008396865-000P 1368  619 GACUUCACCUGACAGAUCC B GACUUCACCUGACAGAUCCTT B3070 R-008396865-000P 1368  619 GACUUCACCUGACAGAUCCGGAUCUGUCAGGUGAAGUCUU 3071 R-008396868-000R 2047  620AAAUACCAUUCCAUUGUUU AAACAAUGGAAUGGUAUUUUU 3073 R-008396868-000R 2047 620 AAAUACCAUUCCAUUGUUU B AAAUACCAUUCCAUUGUUUTT B 3072 R-008396871-000X 492  621 CUCAAGAACAAGUAGCUGA B CUCAAGAACAAGUAGCUGATT B 3074R-008396871-000X  492  621 CUCAAGAACAAGUAGCUGA UCACCUACUUGUUCUUGAGUU3075 R-008396874-000Y  832  126 CAUGCGUUCUCCUCAGAUGB CAUGCGUUCUCCUCAGAUGTT B 3076 R-008396874-000Y  832  126CAUGCGUUCUCCUCAGAUG CAUCUGAGGAGAACGCAUGUU 3077 R-008396877-000Z 2118 622 UCCUCUGUGAACUUGCUCA B UCCUCUGUGAACUUGCUCATT B 3078 R-008396877-000Z2118  622 UCCUCUGUGAACUUGCUCA UGAGCAAGUUCACAGAGGAUU 3079R-008396880-000F  968  623 UCUGGAGGCAUUCCUGCCC GGGCAGGAAUGCCUCCAGAUU3081 R-008396880-000F  968  623 UCUGGAGGCAUUCCUGCCCB UCUGGAGGCAUUCCUGCCCTT B 3080 R-008396883-000G  965  624AAGUCUGGAGGCAUUCCUG CAGGAAUGCCUCCAGACUUUU 3083 R-008396883-000G  965 624 AAGUCUGGAGGCAUUCCUG B AAGUCUGGAGGCAUUCCUGTT B 3082 R-008396886-000H1977  625 UUGAAGGUUGUACCGGAGC GCUCCGGUACAACCUUCAAUU 3085R-008396886-000H 1977  625 UUGAAGGUUGUACCGGAGC B UUGAAGGUUGUACCGGAGCTT B3084 R-008396889-000J 2001  626 ACAUCCUAGCUCGGGAUGUB ACAUCCUAGCUCGGGAUGUTT B 3086 R-008396889-000J 2001  626ACAUCCUAGCUCGGGAUGU ACAUCCCGAGCUAGGAUGUUU 3087 R-008396892-000R 1191 627 ACCAAGAAAGCAAGCUCAU B ACCAAGAAAGCAAGCUCAUTT B 3088 R-008396892-000R1191  627 ACCAAGAAAGCAAGCUCAU AUGAGCUUGCUUUCUUGGUUU 3089R-008396895-000S  640  628 UUUGGCUGAACCAUCACAG B UUUGGCUGAACCAUCACAGTT B3090 R-008396895-000S  640  628 UUUGGCUGAACCAUCACAGCUGUGAUGGUUCAGCCAAAUU 3091 R-008396898-000T  715  629CACACGUGCAAUCCCUGAA B CACACGUGCAAUCCCUGAATT B 3092 R-008396898-000T  715 629 CACACGUGCAAUCCCUGAA UUCAGGGAUUGCACGUGUGUU 3093 R-008396901-000K1204  630 GCUCAUCAUACUGGCUAGU ACUAGCCAGUAUGAUGAGCUU 3095R-008396901-000K 1204  630 GCUCAUCAUACUGGCUAGU B GCUCAUCAUACUGGCUAGUTT B3094 R-008396904-000L 3093  631 GGGUAGGGUAAAUCAGUAAB GGGUAGGGUAAAUCAGUAATT B 3096 R-008396904-000L 3093  631GGGUAGGGUAAAUCAGUAA UUACUGAUUUACCCUACCCUU 3097 R-008396907-000M 1371 632 UUCACCUGACAGAUCCAAG CUUGGAUCUGUCAGGUGAAUU 3099 R-008396907-000M1371  632 UUCACCUGACAGAUCCAAG B UUCACCUGACAGAUCCAAGTT B 3098R-008396910-000U 1424  121 AGGAAUCUUUCAGAUGCUG B AGGAAUCUUUCAGAUGCUGTT B3100 R-008396910-000U 1424  121 AGGAAUCUUUCAGAUGCUGCAGCAUCUGAAAGAUUCCUUU 3101 R-008396913-000V  860  161AUUGUACGUACCAUGCAGA B AUUGUACGUACCAUGCAGATT B 3102 R-008396913-000V  860 161 AUUGUACGUACCAUGCAGA UCUGCAUGGUACGUACAAUUU 3103 R-008396916-000W 409  633 UGGUAAAGGCAAUCCUGAG B UGGUAAAGGCAAUCCUGAGTT B 3104R-008396916-000W  409  633 UGGUAAAGGCAAUCCUGAG CUCAGGAUUGCCUUUACCAUU3105 R-008396919-000X 1143    7 AAUUCUUGGCUAUUACGACGUCGUAAUAGCCAAGAAUUUU 3107 R-008396919-000X 1143    7AAUUCUUGGCUAUUACGAC B AAUUCUUGGCUAUUACGACTT B 3106 R-008396922-000D 2405 634 GAUCCUAGCUAUCGUUCUU B GAUCCUAGCUAUCGUUCUUTT B 3108 R-008396922-000D2405  634 GAUCCUAGCUAUCGUUCUU AAGAACGAUAGCUAGGAUCUU 3109R-008396928-000F 1671  635 UUCGUCAUCUGACCAGCCG CGGCUGGUCAGAUGACGAAUU3111 R-008396928-000F 1671  635 UUCGUCAUCUGACCAGCCGB UUCGUCAUCUGACCAGCCGTT B 3110 R-008396931-000M 1427  636AAUCUUUCAGAUGCUGCAA B AAUCUUUCAGAUGCUGCAATT B 3112 R-008396931-000M 1427 636 AAUCUUUCAGAUGCUGCAA UUGCAGCAUCUGAAAGAUUUU 3113 R-008396934-000N1717  637 UGCAGUUCGCCUUCACUAU AUAGUGAAGGCGAACUGCAUU 3115R-008396934-000N 1717  637 UGCAGUUCGCCUUCACUAU B UGCAGUUCGCCUUCACUAUTT B3114 R-008396937-000P 2400  638 AGGAUGAUCCUAGCUAUCGCGAUAGCUAGGAUCAUCCUUU 3117 R-008396937-000P 2400  638AGGAUGAUCCUAGCUAUCG B AGGAUGAUCCUAGCUAUCGTT B 3116 R-008396940-000W 2305 639 CAGCUCUCUCUUCAGAACA B CAGCUCUCUCUUCAGAACATT B 3118 R-008396940-000W2305  639 CAGCUCUCUCUUCAGAACA UGUUCUGAAGAGAGAGCUGUU 3119R-008396943-000X 1928  640 GGUGGGACACAGCAGCAAU B GGUGGGACACAGCAGCAAUTT B3120 R-008396943-000X 1928  640 GGUGGGACACAGCAGCAAUAUUGCUGCUGUGUCCCACCUU 3121 R-008396946-000Y 2399  641CAGGAUGAUCCUAGCUAUC B CAGGAUGAUCCUAGCUAUCTT B 3122 R-008396946-000Y 2399 641 CAGGAUGAUCCUAGCUAUC GAUAGCUAGGAUCAUCCUGUU 3123 R-008396949-000Z 426  642 AGGAAGAGGAUGUGGAUAC B AGGAAGAGGAUGUGGAUACTT B 3124R-008396949-000Z  426  642 AGGAAGAGGAUGUGGAUAC GUAUCCACAUCCUCUUCCUUU3125 R-008396952-000F 1309  643 AUCUGUCUGCUCUAGUAAUAUUACUAGAGCAGACAGAUUU 3127 R-008396952-000F 1309  643AUGUGUCUGGUCUAGUAAU B AUCUGUCUGCUCUAGUAAUTT B 3126 R-008396955-000G  925 644 UAACCUUUCCCAUCAUCGU B UAACCUUUCCCAUCAUCGUTT B 3128 R-008396955-000G 925  644 UAACCUUUCCCAUCAUCGU ACGAUGAUGGGAAAGGUUAUU 3129R-008396958-000H 2072  645 CUGCUUUAUUCUCCCAUUG CAAUGGGAGAAUAAAGCAGUU3131 R-008396958-000H 2072  645 CUGCUUUAUUCUCCCAUUGB CUGCUUUAUUCUCCCAUUGTT B 3130 R-008396964-000R 2939  646AAUUGUAAUCUGAAUAAAG B AAUUGUAAUCUGAAUAAAGTT B 3132 R-008396964-000R 2939 646 AAUUGUAAUCUGAAUAAAG CUUUAUUCAGAUUACAAUUUU 3133 R-008396973-000Z1480  647 UCUUGUUCAGCUUCUGGGU B UCUUGUUCAGCUUCUGGGUTT B 3134R-008396973-000Z 1480  647 UCUUGUUCAGCUUCUGGGU ACCCAGAAGCUGAACAAGAUU3135 R-008396976-000A 1889  648 GUUCGUGCACAUCAGGAUAB GUUCGUGCACAUCAGGAUATT B 3136 R-008396976-000A 1889  648GUUCGUGCACAUCAGGAUA UAUCCUGAUGUGCACGAACUU 3137 R-008396979-000B  699 649 AUGAUGCAGAACUUGCCAC B AUGAUGCAGAACUUGCCACTT B 3138 R-008396979-000B 699  649 AUGAUGCAGAACUUGCCAC GUGGCAAGUUCUGCAUCAUUU 3139R-008396982-000H  506  650 GCUGAUAUUGAUGGACAGU B GCUGAUAUUGAUGGACAGUTT B3140 R-008396982-000H  506  650 GCUGAUAUUGAUGGACAGUACUGUCCAUCAAUAUCAGCUU 3141 R-008396985-000J 1750  651GGUUAAGCUCUUACACCCA UGGGUGUAAGAGCUUAACCUU 3143 R-008396985-000J 1750 651 GGUUAAGCUCUUACACCCA B GGUUAAGCUCUUACACCCATT B 3142 R-008396988-000K1820  652 GCCCUUUGUCCCGCAAAUC B GCCCUUUGUCCCGCAAAUCTT B 3144R-008396988-000K 1820  652 GCCCUUUGUCCCGCAAAUC GAUUUGCGGGACAAAGGGCUU3145 R-008396991-000S  541  653 UCAGAGGGUACGAGCUGCUAGCAGCUCGUACCCUCUGAUU 3147 R-008396991-000S  541  653UCAGAGGGUACGAGCUGCU B UCAGAGGGUACGAGCUGCUTT B 3146 R-008396994-000T  880 102 UACAAAUGAUGUAGAAACA B UACAAAUGAUGUAGAAACATT B 3148 R-008396994-000T 880  102 UACAAAUGAUGUAGAAACA UGUUUCUACAUCAUUUGUAUU 3149R-008396997-000U  665  654 AAACAUGCAGUUGUAAACU B AAACAUGCAGUUGUAAACUTT B3150 R-008396997-000U  665  654 AAACAUGCAGUUGUAAACUAGUUUACAACUGCAUGUUUUU 3151 R-008397000-000H 1817  655CUUGCCCUUUGUCCCGCAA UUGCGGGACAAAGGGCAAGUU 3153 R-008397000-000H 1817 655 CUUGCCCUUUGUCCCGCAA B CUUGCCCUUUGUCCCGCAATT B 3152 R-008397003-000J2275  656 UUACAAGAAACGGCUUUCA UGAAAGCCGUUUCUUGUAAUU 3155R-008397003-000J 2275  656 UUACAAGAAACGGCUUUCA B UUACAAGAAACGGCUUUCATT B3154 R-008397006-000K 2426  657 CACUCUGGUGGAUAUGGCCGGCCAUAUCCACCAGAGUGUU 3157 R-008397006-000K 2426  657CACUCUGGUGGAUAUGGCC B CACUCUGGUGGAUAUGGCCTT B 3156 R-008397009-000L  958 658 CAUCUUUAAGUCUGGAGGC B CAUCUUUAAGUCUGGAGGCTT B 3158 R-008397009-000L 958  658 CAUCUUUAAGUCUGGAGGC GCCUCCAGACUUAAAGAUGUU 3159R-008397012-000T 1657  659 UGCCAUCUGUGCUCUUCGU B UGCCAUCUGUGCUCUUCGUTT B3160 R-008397012-000T 1657  659 UGCCAUCUGUGCUCUUCGUACGAAGAOCACAGAUGGCAUU 3161 R-008397015-000U 1146  660UCUUGGCUAUUACGACAGA UCUGUCGUAAUAGCCAAGAUU 3163 R-008397015-000U 1146 660 UCUUGGCUAUUACGACAGA B UCUUGGCUAUUACGACAGATT B 3162 R-008397018-000V3078  661 AUUUGGGAUAUGUAUGGGU B AUUUGGGAUAUGUAUGGGUTT B 3164R-008397018-000V 3078  661 AUUUGGGAUAUGUAUGGGU ACCCAUACAUAUCCCAAAUUU3165 R-008397021-000B 1008  662 CAGUGGAUUCUGUGUUGUUAACAACACAGAAUCCACUGUU 3167 R-008397021-000B 1008  662CAGUGGAUUCUGUGUUGUU B CAGUGUAUUCUGUGUUGUUTT B 3166 R-008397024-000C 1621 663 CCUUCGGGCUGGUGACAGG CCUGUCACCAGCCCGAAGGUU 3169 R-008397024-000C1611  663 CCUUCGGGCUGGUGACAGG B CCUUCGGGCUGGUGACAGGTT B 3168R-008397027-000D 1932  664 GGACACAGCAGCAAUUUGU B GGACACAGCAGCAAUUUGUTT B3170 R-008397027-000D 1932  664 GGACACAUCAGCAAUUUGUACAAAUUGCUGCUGUGUCCUU 3171 R-008397030-000K 1909  665CCAGCGCCGUACGUCCAUG CAUGGACGUACGGCGCUGGUU 3173 R-008397030-000K 1909 665 CCAGCGCCGUACGUCCAUG B CCAGCGCCGUACGUCCAUGTT B 3172 R-008397033-000L2279  666 AAGAAACGGCUUUCAGUUG CAACUGAAAGCCGUUUCUUUU 3175R-008397033-000L 2279  666 AAGAAACGGCUUUCAGUUG B AAGAAACGGCUUUCAGUUGTT B3174 R-008397036-000M  574  667 AUUAGAUGAGGGCAUGCAGB AUUAGAUGAGGGCAUGCAGTT B 3176 R-008397036-000M  574  667AUUAGAUGAGGGCAUGCAG CUGCAUGCCCUCAUCUAAUUU 3177 R-008397039-000N 2303 668 ACCAGCUCUCUCUUCAGAA UUCUGAAGAGAGAGCUGGUUU 3179 R-008397039-000N2303  668 ACCAGCUCUCUCUUCAGAA B ACCAGCUCUCUCUUCAGAATT B 3178R-008397042-000V  784  669 AGUUAUGGUCCAUCAGCUU B AGUUAUGGUCCAUCAGCUUTT B3180 R-008397042-000V  784  669 AGUUAUGGUCCAUCAGCUUAAGCUGAUGGACCAUAACUUU 3181 R-008397045-000W 2507  670GACUAUCCAGUUGAUGGGC GCCCAUCAACUGGAUAGUCUU 3183 R-008397045-000W 2507 670 GACUAUCCAGUUGAUGGGC B GACUAUCCAGUUGAUGGGCTT B 3182 R-008397048-000X 995  671 AUGCUUGGUUCACCAGUGG B AUGCUUGGUUCACCAGUGGTT B 3184R-008397048-000X  995  671 AUGCUUGGUUCACCAGUGG CCACUGGUGAACCAAGCAUUU3185 R-008397051-000D 2006  672 CUAGCUCGGGAUGUUCACAUGUGAACAUCCCGAGCUAGUU 3187 R-008397051-000D 2006  672CUAGCUCGGGAUGUUCACA B CUAGCUCGGGAUGUUCACATT B 3186 R-008397054-000E 1757 673 CUCUUACACCCACCAUCCC GGGAUGGUGGGUGUAAGAGUU 3189 R-008397054-000E1757  673 CUCUUACACCCACCAUCCC B CUCUUACACCCACCAUCCCTT B 3188R-008397057-000F 2129  674 CUUGCUCAGGACAAGGAAG B CUUGCUCAGGACAAGGAAGTT B3190 R-008397057-000F 2129  674 CUUGCUCAGGACAAGGAAGCUUCCUUGUCCUGAGCAAGUU 3191 R-008397060-000M 2272  675AGAUUACAAGAAACGGCUU B AGAUUACAAGAAACGGCUUTT B 3192 R-008397060-000M 2272 675 AGAUUACAAGAAACGGCUU AAGCCGUUUCUUGUAAUCUUU 3193 R-008397063-000N 389  676 ACCACAGCUCCUUCUCUGA B ACCACAGCUCCUUCUCUGATT B 3194R-008397063-000N  389  676 ACCACAGCUCCUUCUCUGA UCAGAGAAGGAGCUGUGGUUU3195 R-008397066-000P  708  176 AACUUGCCACACGUGCAAUB AACUUGCCACACGUGCAAUTT B 3196 R-008397066-000P  708  176AACUUGCCACACGUGCAAU AUUGCACGUGUGGCAAGUUUU 3197 R-008397069-000R 1435 677 AGAUGCUGCAACUAAACAG CUGUUUAGUUGCAGCAUCUUU 3199 R-008397069-000R1435  677 AGAUGCUGCAACUAAACAG B AGAUGCUGCAACUAAACAGTT B 3198R-008397072-000X 1247   34 AUAAUGAGGACCUAUACUU B AUAAUGAGGACCUAUACUUTT B3200 R-008397072-000X 1247   34 AUAAUGAGGACCUAUACUUAAGUAUAGGUCCUCAUUAUUU 3201 R-008397075-000Y 1752  678UUAAGCUCUUACACCCACC GGUGGGUGUAAGAGCUUAAUU 3203 R-008397075-000Y 1752 678 UUAAGCUCUUACACCCACC B UUAAGCUCUUACACCCACCTT B 3202 R-008397078-000Z 773  679 AAUAAGGCUGCAGUUAUGG CCAUAACUGCAGCCUUAUUUU 3205R-008397078-000Z  773  679 AAUAAGGCUGCAGUUAUGG B AAUAAGGCUGCAGUUAUGGTT B3204 R-008397081-000F 3080  680 UUGGGAUAUGUAUGGGUAGCUACCCAUACAUAUCCCAAUU 3207 R-008397081-000F 3080  680UUGGGAUAUGUAUGGGUAG B UUGGGAUAUGUAUGGGUAGTT B 3206 R-008397084-000G 3174 681 GUAACCUGCUGUGAUACGA B GUAACCUGCUGUGAUACGATT B 3208 R-008397084-000G3174  681 GUAACCUGCUGUGAUACGA UCGUAUCACAGCAGGUUACUU 3209R-008397087-000H 1578  682 UGGUCUGCCAAGUGGGUGG B UGGUCUGCCAAGUGGGUGGTT B3210 R-008397087-000H 1578  682 UGGUCUGCCAAGUGGGUGGCCACCCACUUGGCAGACCAUU 3211 R-008397090-000P  398  683CCUUCUCUGAGUGGUAAAG B CCUUCUCUGAGUGGUAAAGTT B 3212 R-008397090-000P  398 683 CCUUCUCUGAGUGGUAAAG CUUUACCACUCAGAGAAGGUU 3213 R-008397093-000R2153  684 GAAGCUAUUGAAGCUGAGG CCUCAGCUUCAAVAGCUUCUU 3215R-008397093-000R 2153  684 GAAGCUAUUGAAGCUGAGG B GAAGCUAUUGAAGCUGAGGTT B3214 R-008397096-000S  702  685 AUGGAGAACUUGCCACACGCGUGUGGCAAGUUCUGCAUUU 3217 R-008397096-000S  702  685AUGCAGAACUUGCCACACG B AUGCAGAACUUGCCACACGTT B 3216 R-008397099-000T  503 686 GUAGCUGAUAUUGAUGGAC B GUAGCUGAUAUUGAUGGACTT B 3218 R-008397099-000T 503  686 GUAGCUGAUAUUGAUGGAC GUCCAUCAAUAUCAGCUACUU 3219R-008397102-000K  276  687 CUCAAGCUGAUUUGAUGGA B CUCAAGCUGAUUUGAUGGATT B3220 R-008397102-000K  276  687 CUCAAGCUGAUUUGAUGGAUCCAUCAAAUCAGCUUGAGUU 3221 R-008397105-000L 1962  688GCAUGGAAGAAAUAGUUGA B GCAUGGAAGAAAUAGUUGATT B 3222 R-008397105-000L 1962 688 GCAUGGAAGAAAUAGUUGA UCAACUAUUUCUUCCAUGCUU 3223 R-008397108-000M1347  689 CUGGUGGAAUGCAAGCUUU B CUGGUGGAAUGCAAGCUUUTT B 3224R-008397108-000M 1347  689 CUGGUGGAAUGCAAGCUUU AAAGCUUGCAUUCCACCAGUU3225 R-008397111-000U 2544  690 CCCAGGACCUCAUGGAUGGCCAUCCAUGAGGUCCUGGGUU 3227 R-008397111-000U 2544  690CCCAGGACCUCAUGGAUGG B CCCAGGACCUCAUGGAUGGTT B 3226 R-008397114-000V 3079 691 UUUGGGAUAUGUAUGGGUA B UUUGGGAUAUGUAUGGGUATT B 3728 R-008397114-000V3079  691 UUUGGGAUAUGUAUGGGUA UACCCAUACAUAUCCCAAAUU 3229R-008397117-000W 3164  692 CAAAGUUGUUGUAACCUGC GCAGGUUACAACAACUUUGUU3231 R-008397117-000W 3164  692 CAAAGUUGUUGUAACCUGCB CAAAGUUGUUGUAACCUGCTT B 3230 R-008397120-000C 2026  693CCGAAUUGUUAUCAGAGGA B CCGAAUUGUUAUCAGAGGATT B 3232 R-008397120-000C 2026 693 CCGAAUUGUUAUCAGAGGA UCCUCUGAUAACAAUUCGGUU 3233 R-008397123-000D2938  694 UAAUUGUAAUCUGAAUAAA B UAAUUGUAAUCUGAAUAAATT B 3234R-008397123-000D 2938  694 UAAUUGUAAUCUGAAUAAA UUUAUUCAGAUUACAAUUAUU3235 R-008397126-000E 2940  695 AUUGUAAUCUGAAUAAAGUACUUUAUUCAGAUUACAAUUU 3237 R-008397126-000E 2940  695AUUGUAAUCUGAAUAAAGU B AUUGUAAUCUGAAUAAAGUTT B 3236 R-008397129-000F 2027 696 CGAAUUGUUAUCAGAGGAC B CGAAUUGUUAUCAGAGGACTT B 3238 R-008397129-000F2027  696 CGAAUUGUUAUCAGAGGAC GUCCUCUGAUAACAAUUCGUU 3239R-008397132-000M  448  697 CCAAGUCCUGUAUGAGUGG CCACUCAUACAGGACUUGGUU3241 R-008397132-000M  448  697 CCAAGUCCUGUAUGAGUUGB CCAAGUCCUGUAUGAGUGGTT B 3240 R-008397135-000N 1328  698AAGCCGGCUAUUGUAGAAG B AAGCCGGCUAUUGUAGAAGTT B 3242 R-008397135-000N 1328 698 AAGCCGGCUAUUGUAGAAG CUUCUACAAUAGCCGGCUUUU 3243 R-008397138-000P1970   33 GAAAUAGUUGAAGGUUGUA UACAACCUUCAACUAUUUCUU 3245R-008397138-000P 1970   33 GAAAUAGUUGAAGGUUGUA B GAAAUAGUUGAAGGUUGUATT B3244 R-008397141-000W 2406  699 AUCCUAGCUAUCGUUCUUUAAAGAACGAUAGCUAGGAUUU 3247 R-008397141-000W 2406  699AUCCUAGCUAUCGUUCUUU B AUCCUAGCUAUCGUUCUUUTT B 3246 R-008397144-000X  924 700 AUAACCUUUCCCAUCAUCG B AUAACCUUUCCCAUCAUCGTT B 3248 R-008397144-000X 924  700 AUAACCUUUCCCAUCAUCG CGAUGAUGGGAAAGGUUAUUU 3249R-008397147-000Y 1584  701 GCCAAGUGGGUGGUAUAGA UCUAUACCACCCACUUGGCUU3251 R-008397147-000Y 1584  701 GCCAAGUGGGUGGUAUAGAB GCCAAGUGGGUGGUAUAGATT B 3250 R-008397150-000E 1871  702CGACUAGUUCAGUUGCUUG B CGACUAGUUCAGUUGCUUGTT B 3252 R-008397150-000E 1871 702 CGACUAGUUCAGUUGCUUG CAAGCAACUGAACUAGUCGUU 3253 R-008397153-000F 999  703 UUGGUUCACCAGUGGAUUC B UUGGUUCACCAGUGGAUUCTT B 3254R-008397153-000F  999  703 UUGGUUCACCAGUGGAUUC GAAUCCACUGGUGAACCAAUU3255 R-008397156-000G 1400  704 GUUCAGAACUGUCUUUGGAUCCAAAGACAGUUCUGAACUU 3257 R-008397156-000G 1400  704GUUCAGAACUGUCUUUGGA B GUUCAGAACUGUCUUUGGATT B 3256 R-008397159-000H 3180 705 UGCUGUGAUACGAUGCUUC GAAGCAUCGUAUCACAGCAUU 3259 R-008397159-000H3180  705 UGCUGUGAUACGAUGCUUC B UGCUGUGAUACGAUGGUUCTT B 3258R-008397162-000P 2569  706 UCCAGGUGACAGCAAUCAG CUGAUUGCUGUCACCUGGAUU3261 R-008397162-000P 2569  706 UCCAGGUGACAGCAAUCAGB UCCAGGUGACAGCAAUCAGTT B 3260 R-008397165-000R  787  707UAUGGUCCAUCAGCUUUCU AGAAAGCUGAUGGACCAUAUU 3263 R-008397165-000R  787 707 UAUGGUCCAUCAGCUUUCU B UAUGGUCCAUCAGCUUUCUTT B 3262 R-008397168-000S1861  708 UGCCAUUCCACGACUAGUU B UGCCAUUCCACGACUAGUUTT B 3264R-008397168-000S 1861  708 UGCCAUUCCACGACUAGUU AACUAGUCGUGGAAUGGCAUU3265 R-008397171-000Y 1190  709 AACCAAGAAAGCAAGCUCAUGAGCUUGCUUUCUUGGUUUU 3267 R-008397171-000Y 1190  709AACCAAGAAAGCAAGCUCA B AACCAAGAAAGCAAGCUCATT B 3266 R-008397174-000Z 1557 710 AUAAUUAUAAGAACAAGAU AUCUUGUUCUUAUAAUUAUUU 3269 R-008397174-000Z1557  710 AUAAUUAUAAGAACAAGAU B AUAAUUAUAAGAACAAGAUTT B 3268R-008397177-000A 1751  711 GUUAAGCUCUUACACCCAC B GUUAAGCUCUUACACCCACTT B3270 R-008397177-000A 1751  711 GUUAAGCUCUUACACCCACGUGGGUGUAAGAGCUUAACUU 3271 R-008397180-000G 2897  712UUGAGUAAUGGUGUAGAAC B UUGAGUAAUGGUGUAGAACTT B 3271 R-008397180-000G 2897 712 UUGAGUAAUGGUGUAGAAC GUUCUACACCAUUACUCAAUU 3273 R-008397183-000H2217  713 GUGUGGCGACAUAUGCAGC GCUGCAUAUGUCGCCACACUU 3275R-008397183-000H 2217  713 GUGUGGCGACAUAUGCAGC B GUGUGGCGACAUAUGCAGCTT B3274 R-008397186-000J 2302  714 GACCAGCUCUCUCUUCAGAUCUGAAGAGAGAGCUGGUCUU 3277 R-008397186-000J 2302  714GACCAGCUCUCUCUUCAGA B GACCAGCUCUCUCUUCAGATT B 3276 R-008397189-000K 1984 715 UUGUACCGGAGCCCUUCAC GUGAAGGGCUCCGGUACAAUU 3279 R-008397189-000K1984  715 UUGUACCGGAGCCCUUCAC B UUGUACCGGAGCCCUUCACTT B 3278R-008397192-000S  302  716 AUGGCCAUGGAACCAGACA B AUGGCCAUGGAACCAGACATT B3280 R-008397192-000S  302  716 AUGGCCAUGGAACCAGACAUGUCUGGUUCCAUGGCCAUUU 3281 R-008397195-000T 2431  717UGGUGGAUAUGGCCAGGAU B UGGUGGAUAUGGCCAGGAUTT B 3282 R-008397195-000T 2431 717 UGGUGGAUAUGGCCAGGAU AUCCUGGCCAUAUCCACCAUU 3283 R-008397198-000U2183  718 CCUCUGACAGAGUUACUUC GAAGUAACUCUGUCAGAGGUU 3285R-008397198-000U 2183  718 CCUCUGACAGAGUUACUUC B CCUCUGACAGAGUUACUUCTT B3284 R-008397201-000L 2403  719 AUGAUCCUAGCUAUCGUUCGAACGAUAGCUAGGAUCAUUU 3287 R-008397201-000L 2403  719AUGAUCCUAGCUAUCGUUC B AUGAUCCUAGCUAUCGUUCTT B 3286 R-008397204-000M  788 720 AUGGUCCAUCAGCUUUCUA B AUGGUCCAUCAGCUUUCUATT B 3288 R-008397204-000M 788  720 AUGGUCCAUCAGCUUUCUA UAGAAAGCUGAUGGACCAUUU 3289R-008397207-000N 1476  721 GGACUCUUGUUCAGGUUCU B GGACUCUUGUUGAGCUUCUTT B3290 R-008397207-000N 1476  721 GGACUCUUGUUCAGGUUCUAGAAGCUGAACAAGAGUCCUU 3291 R-008397210-000V  827  722GCUAUCAUGCGUUCUCCUC B GCUAUCAUGCGUUCUCCUCTT B 3292 R-008397210-000V  827 722 GGUAUCAUGCGUUCUCCUC GAGGAGAACGCAUGAUAGCUU 3293 R-008397213-000W2299  723 GCUGACCAGCUCUCUCUUC B GCUGACCAGCUCUCUCUUCTT B 3294R-008397213-000W 2299  723 GCUGACCAGCUCUCUCUUC GAAGAGAGAGCUGGUCAGCUU3295 R-008397216-000X 1891  724 UCGUGCACAUCAGGAUACCB UCGUGCACAUCAGGAUACCTT B 3296 R-008397216-000X 1891  724UCGUGCACAUCAGGAUACC GGUAUCCUGAUGUGCACGAUU 3297 R-008397219-000Y 2196 725 UACUUCACUCUAGGAAUGA UCAUUCCUAGAGUGAAGUAUU 3299 R-008397219-000Y2196  725 UACUUCACUCUAGGAAUGA B UACUUCACUCUAGGAAUGATT B 3298R-008397222-000E  663  726 UGAAACAUGCAGUUGUAAA UUUACAACUGCAUGUUUCAUU3301 R-008397222-000E  663  726 UGAAACAUGCAGUUGUAAAB UGAAACAUGCAGUUGUAAATT B 3300 R-008397225-000F 1028  727UAUGCCAUUACAACUCUCC GGAGAGUUGUAAUGGCAUAUU 3303 R-008397225-000F 1028 727 UAUGCCAUUACAACUCUCC B UAUGCCAUUACAACUCUCCTT B 3302 R-008397228-000G2032  728 UGUUAUCAGAGGACUAAAU AUUUAGUCCUCUGAUAACAUU 3305R-008397228-000G 2032  728 UGUUAUCAGAGGACUAAAU B UGUUAUCAGAGGACUAAAUTT B3304 R-008397231-000N 1459  729 GAUGGAAGGUCUCCUUGGGB GAUGGAAGGUCUCCUUGGGTT B 3306 R-008397231-000N 1459  729GAUGGAAGGUCUCCUUGGG CCCAAGGAGACCUUCCAUCUU 3307 R-008397234-000P 2095 730 CAUCCAAAGAGUAGCUGCA UGCAGCUACUCUUUGGAUGUU 3309 R-008397234-000P2095  730 CAUCCAAAGAGUAGCUGCA B CAUCCAAAGAGUAGCUGCATT B 3308R-008397237-000R 1686  731 GCCGACACCAAGAAGCAGA B GCCGACACCAAGAAGCAGATT B3310 R-008397237-000R 1686  731 GCCGACACCAAGAAGCAGAUCUGCUUCUUGGUGUCGGCUU 3311 R-008397240-000X 1412  732CUUUGGACUCUCAGGAAUC B CUUUGGACUCUCAGGAAUCTT B 3312 R-008397240-000X 1412 732 CUUUGGACUCUCAGGAAUC GAUUCCUGAGAGUCCAAAGUU 3313 R-008397243-000Y2473  733 GGAACAUGAGAUGGGUGGC GCCACCCAUCUCAUGUUCCUU 3315R-008397243-000Y 2473  733 GGAACAUGAGAUGGGUGGC B GGAACAUGAGAUGGGUGGCTT B3314 R-008397246-000Z 1080  734 UGGCAGUGCGUUUAGCUGGCCAGCUAAACGCACUGCCAUU 3317 R-008397246-000Z 1080  734UGGCAGUGCGUUUAGCUGG B UGGCAGUGCGUUUAGCUGGTT B 3316 R-008397249-000A 2143 735 GGAAGGUGCAGAAGCUAUU AAUAGCUUCUGCAGCUUCCUU 3319 R-008397249-000A2143  735 GGAAGGUGCAGAAGCUAUU B GGAAGCUGCAGAAGCUAUUTT B 3318R-008397252-000G 2203  736 CUCUAGGAAUGAAGGUGUG B CUCUAGGAAUGAAGGUGUGTT B3320 R-008397252-000G 2203  736 CUCUAGGAAUGAAGGUGUGCACACCUUCAUUCCUAGAGUU 3321 R-008397255-000H  548  737GUACGAGCUGCUAUGUUCC B GUACGAGCUGCUAUGUUCCTT B 3322 R-008397255-000H  548 737 GUACGAGCUGCUAUGUUCC GGAACAUAGCAGCUCGUACUU 3323 R-008397258-000J2050   45 UACCAUUCCAUUGUUUGUG CACAAACAAUGGAAUGGUAUU 3325R-008397258-000J 2050   45 UACCAUUCCAUUGUUUGUG B UACCAUUCCAUUGUUUGUGTT B3324 R-008397261-000R 1867  738 UCCACGACUAGUUCAGUUGB UCCACGACUAGUUCAGUUGTT B 3326 R-008397261-000R 1867  738UCCACGACUAGUUCAGUUG CAACUGAACUAGUCGUGGAUU 3327 R-008397264-000S  842 739 CCUCAGAUGGUGUCUGCUA B CCUCAGAUGGUGUCUGCUATT B 3328 R-008397264-000S 842  739 CCUCAGAUGGUGUCUGCUA UAGCAGACACCAUCUGAGGUU 3329R-008397267-000T 2120  740 CUCUGUGAACUGGCUCAGG CCUGAGCAAGUUCACAGAGUU3331 R-008397267-000T 2120  740 CUCUGUGAACUUGCUCAGGB CUCUGUGAACUUGCUCAGGTT B 3330 R-008397270-000Z  782  741GCAGUUAUGGUCCAUCAGC B GCAGUUAUGGUCCAUCAGCTT B 3332 R-008397270-000Z  782 741 GCAGUUAUGGUCCAUCAGC GCUGAUGGACCAUAACUGCUU 3333 R-008397273-000A1758  742 UCUUACACCCACCAUCCCA UGGGAUGGUGGGUGUAAGAUU 3335R-008397273-000A 1758  742 UCUUACACCCACCAUCCCA B UCUUACACCCACCAUCCCATT B3334 R-008397276-000B 2396  743 CGCCAGGAUGAUCCUAGCUB CGCCAGGAUGAUCCUAGCUTT B 3336 R-008397276-000B 2396  743CGCCAGGAUGAUCCUAGCU AGCUAGGAUCAUCCUGGCGUU 3337 R-008397279-000C 1373 744 CACCUGACAGAUCCAAGUC GACUUGGAUCUGUCAGGUGUU 3339 R-008397279-000C1373  744 CACCUGACAGAUCCAAGUC B CACCUGACAGAUCCAAGUCTT B 3338R-008397282-000J 1518  745 UCACCUGUGCAGCUGGAAU B UCACCUGUGCAGCUGGAAUTT B3340 R-008397282-000J 1518  745 UCACCUGUGCAGCUGGAAUAUUCCAGCUGCACAGGUGAUU 3341 R-008397285-000K 2557  746GGAUGGGCUGCCUCCAGGU ACCUGGAGGCAGCCCAUCCUU 3343 R-008397285-000K 2557 746 GGAUGGGCUGCCUCCAGGU B GGAUGGGCUGCCUCCAGGUTT B 3342 R-008397288-000L1987  747 UACCGGAGCCCUUCACAUC B UACCGGAGCCCUUCACAUCTT B 3344R-008397288-000L 1987  747 UACCGGAGCCCUUCACAUC GAUGUGAAGGGCUCCGGUAUU3345 R-008397291-000T  568  748 UGAGACAUUAGAUGAGGGCGCCCUCAUCUAAGGUCUCAUU 3347 R-008397291-000T  568  748UGAGACAUUAGAUGAGGGC B UGAGACAUUAGAUGAGGGCTT B 3346 R-008397294-000U 2201 749 CACUCUAGGAAUGAAGGUG B CACUCUAGGAAUGAAGGUGTT B 3348 R-008397294-000U2201  749 CACUCUAGGAAUGAAGGUG CACCUUCAUUCCUAGAGUGUU 3349R-008397297-000V  609  750 UUGAUGCUGCUCAUCCCAC GUGGGAUGAGCAGCAUCAAUU3351 R-008397297-000V  609  750 UUGAUGCUGCUCAUCCCACB UUGAUGCUGCUCAUCCCACTT B 3350 R-008397300-000M  400  751UUCUCUGAGUGGUAAAGGC GCCUUUACCACUCAGAGAAUU 3353 R-008397300-000M  400 751 UUCUCUGAGUGGUAAAGGC B UUCUCUGAGUGGUAAAGGCTT B 3352 R-008397303-000N 331  752 UGUUAGUCACUGGCAGCAA UUGCUGCCAGUGACUAACAUU 3355R-008397303-000N  331  752 UGUUAGUCACUGGCAGCAA B UGUUAGUCACUGGCAGCAATT B3354 R-008397306-000P 1967  753 GAAGAAAUAGUUGAAGGUUAACCUUCAACUAUUUCUUCUU 3357 R-008397306-000P 1967  753GAAGAAAUAGUUGAAGGUU B GAAGAAAUAGUUGAAGGUUTT B 3356 R-008397309-000R 2198 754 CUUCACUCUAGGAAUGAAG CUUCAUUCCUAGAGUGAAGUU 3359 R-008397309-000R2198  754 CUUCACUCUAGGAAUGAAG B CUUCACUCUAGGAAUGAAGTT B 3358R-008397312-000X 1493  755 CUGGGUUCAGAUGAUAUAA UUAUAUCAUCUGAACCCAGUU3361 R-008397312-000X 1493  755 CUGGGUUCAGAUGAUAUAAB CUGGGUUCAGAUGAUAUAATT B 3360 R-008397315-000Y 2260  756GGACAAGCCACAAGAUUAC GUAAUCUUGUGGCUUGUCCUU 3363 R-008397315-000Y 2260 756 GGACAAGCCACAAGAUUAC B GGACAAGCCACAAGAUUACTT B 3362 R-008397318-000Z2496  757 ACCCUGGUGCUGACUAUCC B ACCCUGGUGCUGACUAUCCTT B 3364R-008397318-000Z 2496  757 ACCCUGGUGCUGACUAUCC GGAUAGUCAGCACCAGGGUUU3365 R-008397321-000F 2361  758 UUGAUAUUGGUGCCCAGGGB UUGAUAUUGGUGCCCAGGGTT B 3366 R-008397321-000F 2361  758UUGAUAUUGGUGCCCAGGG CCCUGGGCACCAAUAUCAAUU 3367 R-008397324-000G  443 759 ACCUCCCAAGUCCUGUAUG CAUACAGGACUUGGGAGGUUU 3369 R-008397324-000G 443  759 ACCUCCCAAGUCCUGUAUG B ACCUCCCAAGUCCUGUAUGTT B 3368R-008397327-000H  523  760 GUAUGCAAUGACUCGAGCU B GUAUGCAAUGACUCGAGCUTT B3370 R-008397327-000H  523  760 GUAUGGAAUGACUCGAGCUAGCUCGAGUCAUUGCAUACUU 3371 R-008397330-000P 1742  761CCAGUUGUGGLUAAGCUCU B CCAGUUGUGGUUAAGCUCUTT B 3372 R-008397330-000P 1742 761 CCAGUUGUGGLUAAGCUCU AGAGCUUAACCACAACUGGUU 3373 R-008397333-000R 530  762 AUGACUCGAGCUCAGAGGG B AUGACUCGAGCUCAGAGGGTT B 3374R-008397333-000R  530  762 AUGACUCGAGCUCAGAGGG CCCUCUGAGCUCGAGUCAUUU3375 R-008397336-000S 3169  763 UUGUUGUAACCUGCUGUGAB UUGUUGUAACCUGGUGUGATT B 3376 R-008397336-000S 3169  763UUGUUGUAACCUGCUGUGA UCACAGCAGGUUACAACAAUU 3377 R-008397339-000T 1385 764 CCAAGUCAACGUCUUGUUC B CCAAGUCAACGUCUUGUUCTT B 3378 R-008397339-000T1385  764 CCAAGUCAACGUCUUGUUC GAACAAGACGUUGACUUGGUU 3379R-008397342-000Z 2123  131 UGUGAACUUGCUCAGGACA B UGUGAACUUGCUCAGGACATT B3380 R-008397342-000Z 2123  131 UGUGAACUUGCUCAGGACAUGUCCUGAGCAAGUUCACAUU 3381 R-008397345-000A 2036  765AUCAGAGGACCAAAUACCA B AUCAGAGGACUAAAUACCATT B 3382 R-008397345-000A 2036 765 AUCAGAGGACUAAAUACCA UGGUAUUUAGUCCUCUGAUUU 3383 R-008397348-000B3088  766 UGUAUGGGUAGGGUAAAUC GAUUUACCCUACCCAUACAUU 3385R-008397348-000B 3088  766 UGUAUGGGUAGGGUAAAUC B UGUAUGGGUAGGGUAAAUCTT B3384 R-008397351-000H 2051   56 ACCAUUCCAUUGUUUGUGCGCACAAACAAUGGAAUGGUUU 3387 R-008397351-000H 2051   56ACCAUUCCAUUGUUUGUGC B ACCAUUCCAUUGUUUGUGCTT B 3386 R-008397354-000J  288 170 UGAUGGAGUUGGACAUGGC GCCAUGUCCAACUCCAUCAUU 3389 R-008397354-000J 288  170 UGAUGGAGUUGGACAUGGC B UGAUGGAGUUGGACAUGGCTT B 3388R-008397357-000K 1850  767 CGUGAGCAGGGUGCCAUUC B CGUGAGCAGGGUGCCAUUCTT B3390 R-008397357-000K 1850  767 CGUGAGCAGGGUGCCAUUCGAAUUGCACCCUGCUCACGUU 3391 R-008397360-000S 2548   82GGACCUCAUGGAUGGGCUG B GGACCUCAUGGAUGGGCUGTT B 3392 R-008397360-000S 2548  82 GGACCUCAUGGAUGGGCUG CAGCCCAUCCAUGAGGUCCUU 3393 R-008397363-000T2518  768 UGAUGCGCUGCCAGAUCUG B UGAUGGGCUGCCAGAUCUGTT B 3394R-008397363-000T 2518  768 UGAUGCGCUGCCAGAUCUG CAGAUCUGGCAGCCCAUCAUU3395 R-008397366-000U 1886  769 CUUGUUCGUGCACAUCAGGB CUUGUUCGUGCACAUCAGGTT B 3396 R-008397366-000U 1886  769CUUGUUCGUGCACAUCAGG CCUGAUGUGCACGAACAAGUU 3397 R-008397369-000V  650 770 CCAUCACAGAUGCUGAAAC GUUUCAGCAUCUGUGAUGGUU 3399 R-008397369-000V 650  770 CCAUCACAGAUGCUGAAAC B CCAUCACAGAUGCUGAAACTT B 3398R-008397372-000B 3139  771 ACAGUUUACCAGUUGCCUU AAGGCAACUGGUAAACUGUUU3401 R-008397372-000B 3139  771 ACAGUUUACCAGUUGCCUUB ACAGUUUACCAGUUGCCUUTT B 3400 R-008397375-000C 2025  772ACCGAAUUGUUAUCAGAGG CCUCUGAUAACAAUUCGGUUU 3403 R-008397375-000C 2025 772 ACCGAAUUGUUAUCAGAGG B ACCGAAUUGUUAUCAGAGGTT B 3402 R-008397378-000D1082  773 GCAGUGCGUDUAGCUGGUG CACCAGCUAAACGCACUGCUU 3405R-008397378-000D 1082  773 GCAGUGCGUUUAGCUGGUG B GCAGUGCGUUUAGCUGGUGTT B3404 R-008397381-000K 2475  774 AACAUGAGAUGGGUGGCCAUGGCCACCCAUCUCAUGUUUU 3407 R-008397381-000K 2475  774AACAUGAGAUGGGUGGCCA B AACAUGAGAUGGGUGGCCATT B 3406 R-008397384-000L 1375 775 CCUGACAGAUCCAAGUCAA UUGACUUGGAUCUGUCAGGUU 3409 R-008397384-000L1375  775 CCUGACAGAUCCAAGUCAA B CCUGACAGAUCCAAGUCAATT B 3408R-008397387-000M 2013  776 GGGAUGUUCACAACCGAAU B GGGAUGUUCACAACCGAAUTT B3410 R-008397387-000M 2013  776 GGGAUGUUCACAACCGAAUAUUCGCUUGUGAACAUCCCUU 3411 R-008397390-000U 1236   41CUDUAGUAAAUAUAAUGAG CUCAUUAUAUUUACUAAAGUU 3413 R-008397390-000U 1236  41 CUDUAGUAAAUAUAAUGAG B CUUUAGUAAAUAUAAUGAGTT B 3412 R-008397393-000V1653  128 AGCCUGCCAUCUGUGCUCU B AGCCUGCCAUCUGUGCUCUTT B 3414R-008397393-000V 1653  128 AGCCUGCCAUCUGUGCUCU AGAGCACAGAUGGCAGGCUUU3415 R-008397396-000W 1802  777 GGAUUGAUUCGAAAUCUUGB GGAUUGAUUCGAAAUCUUGTT B 3416 R-008397396-000W 1802  777GGAUUGAUUCGAAAUCUUG CAAGAUUUCGAAUCAAUCCUU 3417 R-008397399-000X 2144 778 GAAGCUGCAGAAGCUAUUG CAAUAGCUUCUGCAGCUUCUU 3419 R-008397399-000X2144  778 GAAGCUGCAGAAGCUAUUG B GAAGCUGCAGAAGCUAUUGTT B 3418R-008397402-000P  529  779 AAUGACUCGAGCUCAGAGG B AAUGACUCGAGCUCAGAGGTT B3420 R-008397402-000P  529  779 AAUGACUCGAGCUCAGAGGCCUCUGAGCUCGAGUCAUUUU 3421 R-008397405-000R 1482  780UUGUUCAGCUUCUGGGUUC GAACCCAGAAGCUGAACAAUU 3423 R-008397405-000R 1482 780 UUGUUCAGCUUCUGGGUUC B UUGUUCAGCUUCUGGGUUCTT B 3422 R-008397408-000S1546  781 CCUCACUUGCAAUAAUUAU B CCUCACUUGCAAUAAUUAUTT B 3424R-008397408-000S 1546  781 CCUCACUUGCAAUAAUUAU AUAAUUAUUGCAAGUGAGGUU3425 R-008397411-000Y  845  782 CAGAUGGUGUGUGCUAUUGCAAUAGCAGACACCAUCUGUU 3427 R-008397411-000Y  845  782CAGAUGGUGUGUGCUAUUG B CAGAUGGUGUCUGCUAUUGTT B 3426 R-008397414-000Z  487 783 CUUCACUCAAGAACAAGUA B CUUCACUCAAGAACAAGUATT B 3428 R-008397414-000Z 487  783 CUUCACUCAAGAACAAGUA UACUUGUUCUUGAGUGAAGUU 3429R-008397417-000A  652  784 AUCACAGAUGCUGAAACAU AUGUUUCAGCAUCUGUGAUUU3431 R-008397417-000A  652  784 AUCACAGAUGCUGAAACAUB AUCACAGAUGCUGAAACAUTT B 3430 R-008397420-000G 1720  785AGUUCGCCUUCACUAUGGA UCCAUAGUGAAGGCGAACUUU 3433 R-008397420-000G 1720 785 AGUUCGCCUUCACUAUGGA B AGUUCGCCUUCACUAUGGATT B 3432 R-008397423-000H 951  786 UACUGGCCAUCUUUAAGUC GACUUAAAGAUGGCCAGUAUU 3435R-008397423-000H  951  786 UACUGGCCAUCUUUAAGUC B UACUGGCCAUCUUUAAGUCTT B3434 R-008397426-000J 1232  787 CAAGCUUUAGUAAAUAUAAUUAUAUUUACUAAAGCUUGUU 3437 R-008397426-000J 1232  787CAAGCUUUAGUAAAUAUAA B CAAGCUUUAGUAAAUAUAATT B 3436 R-008397429-000K 2269  28 ACAAGAUUACAAGAAACGG B ACAAGAUUACAAGAAACGGTT B 3438 R-008397429-000K2269   28 ACAAGAUUACAAGAAACGG CCGUUUCUUGUAAUCUUGUUU 3439R-008397432-000S 2265  788 AGCCACAAGAUUACAAGAA B AGCCACAAGAUUACAAGAATT B3440 R-008397432-000S 2265  788 AGCCACAAGAUUACAAGAAUUCUUGUAAUCUUGUGGCUUU 3441 R-008397435-000T 1698  789AAGCAGAGAUGGCCCAGAA B AAGCAGAGAUGGCCCAGAATT B 3442 R-008397435-000T 1698 789 AAGCAGAGAUGGCCCAGAA UUCUGGGCCAUCUCUGCUUUU 3443 R-008397438-000U 701  790 GAUGCAGAACUUGCCACAC GUGUGGCAAGUUCUGCAUCUU 3445R-008397438-000U  701  790 GAUGCAGAACUUGCCACAC B GAUGCAGAACUUGCCACACTT B3444 R-008397441-000A 1428  791 AUCUUUCAGAUGCUGCAACGUUGCAGCAUCUGAAAGAUUU 3447 R-008397441-000A 1428  791AUCUUUCAGAUGCUGCAAC B AUCUUUCAGAUGCUGCAACTT B 3446 R-008397444-000B 1930 792 UGGGACACAGCAGCAAUUU B UGGGACACAGCAGCAAUUUTT B 3448 R-008397444-000B1930  792 UGGGACACAGCAGCAAUUU AAAUUGCUGCUGUGUCCCAUU 3449R-008397447-000C 1379  793 ACAGAUCCAAGUCAACGUC GACGUUGACUUGGAUCUGUUU3451 R-008397447-000C 1379  793 ACAGAUCCAAGUCAACGUCB ACAGAUCCAAGUCAACGUCTT B 3450 R-008397450-000J 1936  794ACAGCAGCAAUUUGUGGAG B ACAGCAGCAAUUUGUGGAGTT B 3452 R-008397450-000J 1936 794 ACAGCAGCAAUUUGUGGAG CUCCACAAAUUGCUGCUGUUU 3453 R-008397453-000K1441  795 UGCAACUAAACAGGAAGGG CCCUUCCUGUUUAGUUGCAUU 3455R-008397453-000K 1491  795 UGCAACUAAACAGGAAGGG B UGCAACUAAACAGGAAGGGTT B3454 R-008397456-000L 2132  796 GCUCAGGACAAGGAAGCUGCAGCUUCCUUGUCCUGAGCUU 3457 R-008397456-000L 2132  796GCUCAGGACAAGGAAGCUG B GCUCAGGACAAGGAAGCUGTT B 3456 R-008397459-000M 2443 165 CCAGGAUGCCUUGGGUAUG B CCAGGAUGCCUUGGGUAUGTT B 3458 R-008397459-000M2443  165 CCAGGAUGCCUUGGGUAUG CAUACCCAAGGCAUCCUGGUU 3459R-008397462-000U 1800  163 UUGGAUUGAUUCGAAAUCU AGAUUUCGAAUCAAUCCAAUU3461 R-008397462-000U 1800  163 UUGGAUUGAUUCGAAAUCUB UUGGAUUGAUUCGAAAUCUTT B 3460 R-008397465-000V  403  185UCUGAGUGGUAAAGGCAAU AUGGCCUUUACCACUCAGAUU 3463 R-008397465-000V  403 185 UCUGAGUGGUAAAGGCAAU B UCUGAGUGGUAAAGGCAAUTT B 3462 R-008397468-000W1007  105 CCAGUGGAUUCUGUGUUGU ACAACACAGAAUCCACUGGUU 3465R-008397468-000W 1007  105 CCAGUGGAUUCUGUGUUGU B CCAGUGGAUUCUGUGUUGUTT B3464 R-008397471-000C 1057  113 AUUACAUCAAGAAGGAGCUAGCUCCUUCUUGAUGUAAUUU 3467 R-008397471-000C 1057  113AUUACAUCAAGAAGGAGCU B AUUACAUCAAGAAGGAGCUTT B 3466 R-008397474-000D 2267  87 CCACAAGAUUACAAGAAAC B CCACAAGAUUACAAGAAACTT B 3468 R-008397474-000D2267   87 CCACAAGAUUACAAGAAAC GUUUCUUGUAAUCUUGUGGUU 3469R-008397477-000E 1240  158 AGUAAAUAUAAuGAGGACC B AGUAAAUAUAAUGAGGACCTT B3470 R-008397477-000E 1240  158 AGUAAAUAUAAuGAGGACCGGUCCUCAUUAUAUUUACUUU 3471 R-008397480-000L 2043  797GACUAAAUACCAUUCCAUU AAUGGAAUGGUAUUUAGUCUU 3473 R-008397480-000L 2043 797 GACUAAAUACCAUUCCAUU B GACUAAAUACCAUUCCAUUTT B 3472 R-008397483-000M 608  798 UUUGAUGCUGCUCAUCCCA UGGGAUGAGCAGCAUCAAAUU 3475R-008397483-000M  608  798 UUUGAUGCUGCUCAUCCCA B UUUGAUGCUGCUCAUCCCATT B3474 R-008397486-000N  341  799 UGGCAGCAACAGUCUUACCB UGGCAGCAACAGUCUUACCTT B 3476 R-008397486-000N  341  799UGGCAGCAACAGUCUUACC GGUAAGACUGUUGCUGCCAUU 3477 R-008397489-000P 1194 800 AAGAAAGCAAGCUCAUCAU B AAGAAAGCAAGCUCAUCAUTT B 3478 R-008397489-000P1194  800 AAGAAAGCAAGCUCAUCAU AUGAUGAGCUUGCUUUCUUUU 3479R-008397492-000W 2350  801 UGAUCUUGGACUUGAUAUU B UGAUCUUGGACUUGAUAUUTT B3480 R-008397492-000W 2350  801 UGAUCUUGGACUUGAUAUUAAUAUCAAGUCCAAGAUCAUU 3481 R-008397495-000X 2948  802CUGAAUAAAGUGUAACAAU B CUGAAUAAAGUGUAACAAUTT B 3482 R-008397495-000X 2948 802 CUGAAUAAAGUGUAACAAU AUUGUUACACUUUAUUCAGUU 3483 R-008397507-000T2044  803 ACUAAAUACCAUUCCAUUG B ACUAAAUACCAUUCCAUUGTT B 3484R-008397507-000T 2044  803 ACUAAAUACCAUUCCAUUG CAAUGGAAUGGUAUUUAGUUU3485 R-008397510-000Z  621  804 AUCCCACUAAUGUCCAGCGCGCUGGACAUUAGUGGGAUUU 3487 R-008397510-000Z  621  804AUCCCACUAAUGUCCAGCG B AUCCCACUAAUGUCCAGCGTT B 3486 R-008397513-000A  384 805 CCACUACCACAGCUCCUUC B CCACUACCACAGCUCCUUCTT B 3488 R-008397513-000A 384  805 CCACUACCACAGCUCCUUC GAAGGAGCUGUGGUAGUGGUU 3489R-008397516-000B 1898  806 CAUCAGGAUACCCAGCGCC B CAUCAGGAUACCCAGCGCCTT B3490 R-008397516-000B 1898  806 CAUCAGGAUACCCAGCGCCGGCGCUGGGUAUCCUGAUGUU 3491 R-008397519-000C 1795   15UACUGUUGGAUUGAUUCGA UCGAAUCAAUCCAACAGUAUU 3493 R-008397519-000C 1795  15 UACUGUUGGAUUGAUUCGA B UACUGUUGGAUUGAUUCGATT B 3492 R-008397522-000J 653  807 UCACAGAUGCUGAAACAUG CAUGUUUCAGCAUCUGUGAUU 3495R-008397522-000J  653  807 UCACAGAUGCUGAAACAUG B UCACAGAUGCUGAAACAUGTT B3494 R-008397525-000K 1846  808 UUUGCGUGAGCAGGGUGCCGGCACCCUGCUCACGCAAAUU 3497 R-008397525-000K 1846  808UUUGCGUGAGCAGGGUGCC B UUUGCGUGAGCAGGGUGCCTT B 3496 R-008397528-000L 2348 809 GCUGAUCUUGGACUUGAUA UAUCAAGUCCAAGAUCAGCUU 3499 R-008397528-000L2348  809 GCUGAUCUUGGACUUGAUA B GCUGAUCUUGGACUUGAUATT B 3498R-008397531-000T 1798   19 UGUUGGAUUGAUUCGAAAU AUUUCGAAUCAAUCCAACAUU3501 R-008397531-000T 1798   19 UGUUGGAUUGAUUCGAAAUB UGUUGGAUUGAUUCGAAAUTT B 3500 R-008397534-000U 1150  810GGCUAUUACGACAGACUGC B GGCUAUUACGACAGACUGCTT B 3502 R-008397534-000U 1150 810 GGCUAUUACGACAGACUGC GCAGUCUGUCGUAAUAGCCUU 3503 R-008397537-000V1009  180 AGUGGAUUCUGUGUUGUUU AAACAACACAGAAUCCACUUU 3505R-008397537-000V 1009  180 AGUGGAUUCUGUGUUGUUU B AGUGGAUUCUGUGUUGUUUTT B3504 R-008397540-000B  654  178 CACAGAUGCUGAAACAUGCB CACAGAUGCUGAAACAUGCTT B 3506 R-008397540-000B  654  178CACAGAUGCUGAAACAUGC GCAUGUUUCAGCAUCUGUGUU 3507 R-008397543-000C  298 811 GGACAUGGCCAUGGAACCA B GGACAUGGCCAUGGAACCATT B 3508 R-008397543-000C 298  811 GGACAUGGCCAUGGAACCA UGGUUCCAUGGCCAUGUCCUU 3509R-008397546-000D 1568  812 AACAAGAUGAUGGUCUGCC B AACAAGAUGAUGGUCUGCCTT B3510 R-008397546-000D 1568  812 AACAAGAUGAUGGUCUGCCGGCAGACCAUCAUCUUGUUUU 3511 R-008397549-000E 1058  813UUACAUCAAGAAGGAGCUA B UUACAUCAAGAAGGAGCUATT B 3512 R-008397549-000E 1058 813 UUACAUCAAGAAGGAGCUA UAGCUCCUUCUUGAUGUAAUU 3513 R-008397552-000L1835  814 AAUCAUGCACCUUUGCGUG B AAUCAUGCACCUUUGCGUGTT B 3514R-008397552-000L 1835  814 AAUCAUGCACCUUUGCGUG CACGCAAAGGUGCAUGAUUUU3515 R-008397555-000M 1832  815 GCAAAUCAUGCACCUUUGCB GCAAAUCAUGCACCUUUGCTT B 3516 R-008397555-000M 1832  815GCAAAUCAUGCACCUUUGC GCAAAGGUGCAUGAUUUGCUU 3517 R-008397558-000N 2550  55 ACCUCAUGGAUGGGCUGCC GGCAGCCCAUCCAUGAGGUUU 3519 R-008397558-000N2550   55 ACCUCAUGGAUGGGCUGCC B ACCUCAUGGAUGGGCUGCCTT B 3518R-008397561-000V  406  816 GAGUGGUAAAGGCAAUCCU AGGAUUGCCUUUACCACUCUU3521 R-008397561-000V  406  816 GAGUGGUAAAGGCAAUCCUB GAGUGGUAAAGGCAAUCCUTT B 3520 R-008397564-000W 1723  817UCGCCUUCACUAUGGACUA B UCGCCUUCACUAUGGACUATT B 3522 R-008397564-000W 1723 817 UCGCCUUCACUAUGGACUA UAGUCCAUAGUGAAGGCGAUU 3523 R-008397567-000X 371  818 AUCCAUUCUGGUGCCACUA UAGUGGCACCAGAAUGGAUUU 3525R-008397567-000X  371  818 AUCCAUUCUGUUGCCACUA B AUCCAUUCUGGUGCCACUATT B3524 R-008397570-000D 1899  519 AUCAGGAUACCCAGCGCCGCGGCGCUGGGUAUCCUGAUUU 3527 R-008397570-000D 1899  819AUCAGGAUACCCAGCGCCG B AUCAGGAUACCCAGCGCCGTT B 3526 R-008397573-000E  522 820 AGUAUGCAAUGACUCGAGC B AGUAUGCAAUGACUCGAGCTT B 3528 R-008397573-000E 522  820 AGUAUGCAAUGACUCGAGC GCUCGAGUCAUUGCAUACUUU 3529R-008397576-000F 2285  821 CGGCUUUCAGUUGAGCUGA B CGGCUUUCAGUUGAGCUGATT B3530 R-008397576-000F 2285  821 CGGCUUUCAGUUGAGCUGAUCAGCUCAACUGAAAGCCGUU 3531 R-008397579-000G  779  822GCUGCAGUUAUGGUCCAUC GAUGGACCAUAACUGCAGCUU 3533 R-008397579-000G  779 822 GCUGCAGUUAUGGUCCAUC B GCUGCAGUUAUGGUCCAUCTT B 3532 R-008397582-000N2896  823 AUUGAGUAAUGGUGUAGAA B AUUGAGUAAUGGUGUAGAATT B 3534R-008397582-000N 2896  823 AUUGAGUAAUGGUGUAGAA UUCUACACCAUUAGUCAAUUU3535 R-008397588-000R 2943  824 GUAAUCUGAAUAAAGUGUAUACACUUUAUUCAGAUUACUU 3537 R-008397588-000R 2943  824GUAAUCUGAAUAAAGUGUA B GUAAUCUGAAUAAAGUGUATT B 3536 R-008397591-000X  513 825 UUGAUGGACAGUAUGCAAU B UUGAUGGACAGUAUGCAAUTT B 3538 R-008397591-000X 513  825 UUGAUGGACAGUAUGCAAU AUUGCAUACUGUCCAUCAAUU 3539R-008397594-000Y 3084  826 GAUAUGUAUGGGUAGGGUA B GAUAUGUAUGGGUAGGGUATT B3540 R-008397594-000Y 3084  826 GAUAUGUAUGGGUAGGGUAUACCCUACCCAUACAUAUCUU 3541 R-008397597-000Z 1567  827GAACAAGAUGAUGGUCUGC B GAACAAGAUGAUGGUCUGCTT B 3542 R-008397597-000Z 1567 827 GAACAAGAUGAUGGUCUGC GCAGACCAUCAUCUUGUUCUU 3543 R-008397600-000S2034  828 UUAUCAGAGGACUAAAUAC B UUAUCAGAGGACUAAAUACTT B 3544R-008397600-000S 2034  828 UUAUCAGAGGACUAAAUAC GUAUUUAGUCCUCUGAUAAUU3545 R-008397603-000T 1003  829 UUCACCAGUGGAUUCUGUGB UUCACCAGUGGAUUCUGUGTT B 3546 R-008397603-000T 1003  829UUCACCAGUGGAUUCUGUG CACAGAAUCCACUGGUGAAUU 3547 R-008397606-000U 1980 830 AAGGUUGUACCGGAGCCCU AGGGCUCCGGUACAACCUUUU 3549 R-008397606-000U1980  830 AAGGUUGUACCGGAGCCCU B AAGGUUGUACCGGAGCCCUTT B 3548R-008397609-000V 1340  831 GUAGAAGCUGGUGGAAUGC GCAUUCCACCAGCUUCUACUU3551 R-008397609-000V 1340  831 GUAGAAGCUGGUGGAAUGCB GUAGAAGCUGGUGGAAUGCTT B 3550 R-008397612-000B 1437  832AUGCUGCAACUAAACAGGA B AUGCUGCAAGUAAACAGGATT B 3552 R-008397612-000B 1437 832 AUGCUGCAACUAAACAGGA UCCUGUUUAGUUGCAGCAUUU 3553 R-008397615-000C2499  145 CUGGUGCUGACUAUCCAGU B CUGGUGCUGACUAUCCAGUTT B 3554R-008397615-000C 2499  145 CUGGUGCUGACUAUCCAGU ACUGGAUAGUCAGCACCAGUU3555 R-008397618-000D  785   64 GUUAUGGUCCAUCAGCUUUAAAGCUGAUGGACCAUAACUU 3557 R-008397618-000D  785     64GUUAUGGUCCAUCAGCUUU B GUUAUGGUCCAUCAGCUUUTT B 3556 R-008397621-000K 2425 833 UCACUCUGGUGGAUAUGGC B UCACUCUGGUGGAUAUGGCTT B 3558 R-008397621-000K2425  833 UCACUCUGGUGGAUAUGGC GCCAUAUCCACCAGAGUGAUU 3559R-008397624-000L  282  834 CUGAUUUGAUGGAGUUGGA UCCAACUCCAUCAAAUCAGUU3561 R-008397624-000L  282  834 CUGAUUUGAUGGAGUUGGAB CUGAUUUGAUGGAGUUGGATT B 3560 R-008397627-000M 1206  835UCAUCAUACUGGCUAGUGG B UCAUCAUACUGGCUAGUGGTT B 3562 R-008397627-000M 1206 835 UCAUCAUACUGGCUAGUGG CCACUAGCCAGUAUGAUGAUU 3563 R-008397630-000U1885  836 GCUUGUUCGUGCACAUCAG CUGAUGUGCACGAACAAGCUU 3565R-008397630-000U 1885  836 GCUUGUUCGUGCACAUCAG B GCUUGUUCGUGCACAUCAGTT B3564 R-008397633-000V 1314  837 UCUGCUCUAGUAAAUAGCCB UCUGCUCUAGUAAUAAGCCTT B 3566 R-008397633-000V 1314  837UCUGCUCUAGUAAAUAGCC GGCUUAUUACUAGAGCAGAUU 3567 R-008397636-000W 2388 174 UUGGAUAUCGCCAGGAUGA B UUGGAUAUCGCCAGGAUGATT B 3568 R-008397636-000W2388  174 UUGGAUAUCGCCAGGAUGA UCAUCCUGGCGAUAUCCAAUU 3569R-008397639-000X 1308  838 UAUCUGUCUGCUCUAGUAA B UAUCUGUCUGCUCUAGUAUTT B3570 R-008397639-000X 1308  838 UAUCUGUCUGCUGUAGUAAUUACUAGAGCAGACAGAUAUU 3571 R-008397642-000D 1200  839GCAAGCUCAUCAUACUGGC GCCAGUAUGAUGAGCUUGCUU 3573 R-008397642-000D 1200 839 GCAAGCUCAUCAUACUGGC B GCAAGCUCAUCAUACUGGCTT B 3572 R-008397645-000E 543  840 AGAGGGUACGAGCUGCUAU B AGAGGGUACGAGCUGCUAUTT B 3574R-008397645-000E  543  840 AGAGGGUACGAGCUGCUAU AUAGCAGCUCGUACCCUCUUU3575 R-008397648-000F 1609  841 UGUGCGUACUGUCCUUCGGB UGUGCGUACUGUCCUUCGGTT B 3576 R-008397648-000F 1609  841UGUGCGUACUGUCCUUCGG CCGAAGGACAGUACGCACAUU 3577 R-008397651-000M 1453 842 GGAAGGGAUGGAAGGUCUC B GGAAGGGAUGGAAGGUCUCTT B 3578 R-008397651-000M1453  842 GGAAGGGAUGGAAGGUCUC GAGACCUUCCAUCCCUUCCUU 3579R-008397654-000N 2127  138 AACUUGCUCAGGAGAAGGA B AACUUGCUCAGGACAAGGATT B3580 R-008397654-000N 2127  138 AACUUGCUCAGGACAAGGAUCCUUGUCCUGAGCAAGUUUU 3581 R-008397657-000P  833  843AUGCGUUCUCCUCAGAUGG B AUGCGUUCUCCUCAGAUGGTT B 3582 R-008397657-000P  833 843 AUGCGUUCUCCUCAGAUGG CCAUCUGAGGAGAACGCAUUU 3583 R-008397660-000W2188  844 GACAGAGUUACUUCACUCU B GACAGAGUUACUUCACUCUTT B 3584R-008397660-000W 2188  844 GACAGAGUUACUUCACUCU AGAGUGAAGUAACUCUGUCUU3585 R-008397663-000X 1148  845 UUGGCUAUUACGACAGACUB UUGGCUAUUACGACAGACUTT B 3586 R-008397663-000x 1148  845UUGGCUAUUACGACAGACU AGUCUGUCGUAAUAGCCAAUU 3587 R-008397666-000Y 1736 846 GGACUACCAGUUGUGGUUA B GGACUACCAGUUGUGGUUATT B 3588 R-008397666-000Y1736  846 GGACUACCAGUUGUGGUUA UAACCACAACUGGUAGUCCUU 3589R-008397669-000Z 1401  847 UUCAGAACUGUCUUUGGAC GUCCAAAGACAGUUCUGAAUU3591 R-008397669-000Z 1401  847 UUCAGAACUGUCUUUGGACB UUCAGAACUGUCUUUGGACTT B 3590 R-008397672-000F 1677  848AUCUGACCAGCCGACACCA UGGUGUCGGCUGGUCAGAUUU 3593 R-008397672-000F 1677 848 AUCUGACCAGCCGACACCA B AUCUGACCAGCCGACACCATT B 3592 R-008397675-000G1934  849 ACACAGCAGCAAUUUGUGG B ACACAGCAGCAAUUUGUGGTT B 3594R-008397675-000G 1934  849 ACACAGCAGCAAUUUGUGG CCACAAAUUGCUGCUGUGUUU3595 R-008397678-000H  388  850 UACCACAGCUCCUUCUCUGCAGAGAAGGAGCUGUGGUAUU 3597 R-108397678-000H  388  850UACCACAGCUCCUUCUCUG B UACCACACCUCCUUCUCUGTT B 3596 R-008397681-000P 1920 851 CGUCCAUGGGUGGUACACA B CGUCCAUGGGUGGGACACATT B 3598 R-008397681-000P1920  851 CGUCCAUGGGUGGUACACA UGUGUCCCACCCAUGGACGUU 3599R-008397684-000R 1747  852 UGUGGUUAAGCUCUUACAC GUGUAAGAGCUUAACCACAUU3601 R-008397684-000R 1747  852 UGUGGUUAAGCUCUUACACB UGUGGUUAAGCUCUUACACTT B 3600 R-008397687-000S  861  853UUGUACGUACCAUGCAGAA B UUGUACGUACCAUGCAGAATT B 3602 R-008397687-000S  861 853 UUGUACGUACCAUGCAGAA UUCUGCNUGGUACGUACAAUU 3603 R-008397690-000Y1904  854 GAUACCCAGCGCCGUACGU B GAUACCCAGCGCCGUAUGUTT B 3604R-008397690-000Y 1904  854 GAUACCCAGCGCCGUACGU ACGUACGGCGCUGGGUAUCUU3605 R-008397693-000Z  831  855 UCAUGCGUUCUCCUCAGAUB UCAUGCGUUCUCCUCAGAUTT B 3606 R-008397693-000Z  831  855UCAUGCGUUCUCCUCAGAU AUCUGAGGAGAACGCAUGAUU 3607 R-008397696-000A 1895 856 GCACAUCAGGAUACCCAGC GCUGGGUAUCCUGAUGUGCUU 3609 R-008397696-000A1895  856 GCACAUCAGGAUACCCAGC B GCACAUCAGGAUACCCAGCTT B 3608R-008397699-000B 2273  857 GAUUACAAGAAACGGCUUU AAAGCCGUUUCUUGUAAUCUU3611 R-008397699-000B 2273  857 GAUUACAAGAAACGGCUUUB GAUUACAAGAAACGGCUUUTT B 3610 R-008397702-000U 1738  858ACUACCAGUUGUGGUUAAG B ACUACCAGUUGUGGUUAAGTT B 3612 R-008397702-000U 1738 858 ACUACCAGUUGUGGUUAAG CUUAACCACAACUGGUAGUUU 3613 R-008397705-000V1395  859 GUCUUGUUCAGAACUGUCU B GUCUUGUUCAGAACUGUCUTT B 3614R-008397705-000V 1395  859 GUCUUGUUCAGAACUGUCU AGACAGUUCUGAACAAGACUU3615 R-008397708-000W 1675  860 UCAUCUGACCAGCCGACACB UCAUCUGACCAGCCGACACTT B 3616 R-008397708-000W 1675  860UCAUCUGACCAGCCGACAC GUGUCGGCUGGUCAGAUGAUU 3617 R-008397711-000C 1895 861 CUCUCCGUGAGCAGGGUGC B CUUUGCGUGAGCAGGGUGCTT B 3618 R-008397711-000C1845  861 CUUUGCGUGAGCAGGGUGC GCACCCUGCUCACGCAAAGUU 3619R-008397714-000D 1408  862 CUGUCUUUGGACUCUCAGG CCUGAGAGUCCAAAGACAGUU3621 R-008397714-000D 1408  862 CUGUCUUUGGACUCUCAGGB CUGUCUUUGGACUCUCAGGTT B 3620 R-008397717-000E 1059  863UACAUCAAGAAGGAGCUAA B UACAUCAAGAAGGAGCUAATT B 3622 R-008397717-000E 1059 863 UACAUCAAGAAGGAGCUAA UUAGCUCCUDCUUGAUGUAUU 3623 R-008397720-000L1381  864 AGAUCCAAGUCAACGUCUU AAGACGUUGACUUGGAUCUUU 3625R-008397720-000L 1381  864 AGAUCCAAGUCAACGUCUU B AGAUCCAAGUCAACGUCUUTT B3624 R-008397723-000M 1386  865 CAAGUCAACGUCUUGUUCAB CAAGUCAACGUCUUGUUCATT B 3626 R-008397723-000M 1386  865CAAGUCAACGUCUUGUUCA UGAACAAGACGUUGACUUGUU 3627 R-008397726-000N 1470 866 UCCUUGGGACUCUUGUUCA UGAACAAGAGUCCCAAGGAUU 3629 R-008397726-000N1470  866 UCCUUGGGACUCUUGUUCA B UCCUUGGGACUCUUGUUCATT B 3628R-008397729-000P 1349  867 GGUGGAAUGCAAGCUUUAG CUAAAGCUUGCAUUCCACCUU3631 R-008397729-000P 1349  867 GGUGGAAUGCAAGCUUUAGB GGUGGAAUGCAAGCUUUAGTT B 3630 R-008397732-000W 1440  868CUGCAACUAAACAGGAAGG CCUUCCUGUUUAGUUGCAGUU 3633 R-008397732-000W 1490 868 CUGCAACUAAACAGGAAGG B CUGCAACUAAACAGGAAGGTT B 3632 R-008397735-000X1364  869 UUAGGACUUCACCUGACAG CUGUCAGGUGNAGUCCUAAUU 3635R-008397735-000X 1364  869 UUAGGACUUCACCUGACAG B UUAGGACUUCACCUGACAGTT B3634 R-008397738-000Y  502  870 AGUAGCUGAUAUUGAUGGAB AGUAGCUGAUAUUGAUGGATT B 3636 R-008397738-000Y  502  870AGUAGCUGAUAUUGAUGGA UCCAUCAAUAUCAGCUACUUU 3637 R-008397791-000E 1246 871 UAUAAUGAGGACCUAUACU AGUAUAGGUCCUCAUUAUAUU 3639 R-008397741-000E1246  871 UAUAAUGAGGACCUAUACU B UAUAAUGAGGACCUAUACUTT B 3638R-008397794-000F 3178  872 CCUGCUGUGAUACGAUGCU AGCAUCGUAUCACAGCAGGUU3641 R-008397744-000F 3178  872 CCUGCUGUGAUACGAUGCUB CCUGCUGUGAUACGAUGCUTT B 3640 R-008397797-000G 2483  873AUGGGUGGCCACCACCCUG B AUGGGUGGCCACCACCCUGTT B 3642 R-008397747-000G 2483 873 AUGGGUGGCCACCACCCUG CAGGGUGGUGGCCACCCAUUU 3643 R-008397750-000N1417  874 GACUCUCAGGAAUCUUUCA B GACUCUCAGGAAUCUUUCATT B 3644R-008397750-000N 1417  874 GACUCUCAGGAAUCUUUCA UGAAAGAUUCCUGAGAGUCUU3645 R-008397753-000P 1893  875 GUGCACAUCAGGAUACCCAB GUGCACAUCAGGAUACCCATT B 3646 R-008397753-000P 1893  875GUGCACAUCAGGAUACCCA UGGGUAUCCUGAUGUGCACUU 3647 R-008397756-000R  817 876 UUCCAGACACGCUAUCAUG CAUGAUAGCGUGUCUGGAAUU 3649 R-008397756-000R 817  876 UUCCAGACACGCUAUCAUG B UUCCAGACACGCUAUCAUGTT B 3648R-008397759-000S  711  877 UUGCCACACGUGCAAUCCC GGGAUUGCACGUGUGGCAAUU3651 R-008397759-000S  711  877 UUGCCACACGUGCAAUCCCB UUGCCACACGUGCAAUCCCTT B 3650 R-008397762-000Y 1433  878UCAGAUGCUGCAACUAAAC GUUUAGUUGCAGCAUCUGAUU 3653 R-008397762-000Y 1433 878 UCAGAUGCUGCAACUAAAC B UCAGAUGCUGCAACUAAACTT B 3652 R-008397765-000Z1362  879 CUUUAGGACUUCACCUGAC GUCAGGUGAAGUCCUAAAGUU 3655R-008397765-000Z 1362  879 CUUUAGGACUUCACCUGAC B CUUUAGGACUUCACCUGACTT B3654 R-008397768-000A 1838  880 CAUGCACCUUUGCGUGAGCB CAUGCACCUUUGCGUGAGCTT B 3656 R-008397768-000A 1838  880CAUGCACCUUUGCGUGAGC GCUCACGCAAAGGUGCAUGUU 3657 R-008397771-000G 1037 881 ACAACUCUCCACAACCUUU AAAGGUUGUGGAGAGUUGUUU 3659 R-008397771-000G1037  881 ACAACUCUCCACAACCUUU B ACAACUCUCCACAACCUUUTT B 3658R-008397774-000H 1474  882 UGGGACUCUUGUUCAGCUU B UGGGACUCUUGUUCAGCUUTT B3660 R-008397774-000H 1474  882 UGGGACUCUUGUUCAGCUUAAGCUGAACAAGAGUCCCAUU 3661 R-008397777-000J  997  883GCUUGGUUCACCAGUGGAU B GCUUGGUUCACCAGUGGAUTT B 3662 R-008397777-000J  997 883 GCUUGGUUCACCAGUGGAU AUCCACUGGUGAACCAAGCUU 3663 R-008397780-000R 931  884 UUCCCAUCAUCGUGAGGGC B UUCCCAUCAUCGUGAGGGCTT B 3664R-008397780-000R  931  884 UUCCCAUCAUCGUGAGGGC GCCCUCACGAUGAUGGGAAUU3665 R-008397783-000S 1313  885 GUCUGCUCUAGUAAUAAGCGCUUAUUACUAGAGCAGACUU 3667 R-008397783-000S 1313  885GUCUGCUCUAGUAAUAAGC B GUCUGCUCUAGUAAUAAGCTT B 3666 R-008397786-000T 1487 886 CAGCUUCUGGGUUCAGAUG B CAGCUCCUGGGUUCAGAUGTT B 3668 R-008397786-000T1487  886 CAGCUUCUGGGUUCAGAUG CAUCUGAACCCAGAAGCUGUU 3669R-008397789-000U 1673  887 CGUCAUCUGACCAGCCGAC B CGUCAUCUGACCAGCCGACTT B3670 R-008397789-000U 1673  887 CGUCAUCUGACCAGCCGACGUCGGCUGGUCAGAUGACGUU 3671 R-008397792-000A  561  888UGUUCCCUGAGACAUUAGA UCUAAUGUCUCAGGGAACAUU 3673 R-008397792-000A  561 888 UGUUCCCUGAGACAUUAGA B UGUUCCCUGAGACAUUAGATT B 3672 R-008397795-000B1188  889 GCAACCAAGAAAGCAAGCU B GCAACCAAGAAAGCAAGCUTT B 3674R-008397795-000B 1188  889 GCAACCAAGAAAGCAAGGU AGCUUGCUUUCUUGGUUGCUU3675 R-008397798-000C  292  890 GGAGUUGGACAUGGCCAUGB GGAGUUGGACAUGGCCAUGTT B 3676 R-008397798-000C  292  890GGAGUUGGACAUGGCCAUG CAUGGCCAUGUCCAACUCCUU 3677 R-008397801-000V 1958 891 GUCCGCAUGGAAGAAAUAG B GUCCGCAUGGAAGAAAUAGTT B 3678 R-008397801-000V1958  891 GUCCGCAUGGAAGAAAUAG CUAUUUCUUCCAUGCGGACUU 3679R-008397804-000W 2349  892 CUGAUCUUGGACUUGAUAU B CUGAUCUUGGACUUGAUAUTT B3680 R-008397804-000W 2349  892 CUGAUCUUGGACUUGAUAUAUAUCAAGUCCAAGAUCAGUU 3681 R-008397807-000X 1460  893AUGGAAGGUCUCCUUGGGA UCCCAAGGAGACCUUCCAUUU 3683 R-008397807-000X 1460 893 AUGGAAGGUCUCCUUGGGA B AUGGAAGGUCUCCUUGGGATT B 3682 R-008397810-000D1576  894 GAUGGUCUGCCAAGUGGGU B GAUGGUCUGCCAAGUGGGUTT B 3684R-008397810-000D 1576  894 GAUGGUCUGCCAAGUGGGU ACCCACUUGGCAGACCAUCUU3685 R-008397813-000E  536    4 CGAGCUCAGAGGGUACGAGB CGAGCUCAGAGGGUACGAGTT B 3686 R-008397813-000E  536    4CGAGCUCAGAGGGCACGAG CUCGUACCCUCUGAGCUCGUU 3687 R-008397816-000F  690 895 ACUAUCAAGAUGAUGCAGA UCUGCAUCAUCUUGAUAGUUU 3689 R-008397816-000F 690  895 ACUAUCAAGAUGAUGCAGA B ACUAUCAAGAUGAUGGAGATT B 3688R-008397819-000G  655  896 ACAGAUGCUGAAACAUGCA B ACAGAUGCUGAAACAUGCATT B3690 R-008397819-000G  655  896 ACAGAUGCUGAAACAUGCAUGCAUGUUUCAGCAUCUGUUU 3691 R-008397822-000N 2290  897UUCAGUUGAGCUGACCACC GCUGGUCAGCUCAACUGAAUU 3693 R-008397822-000N 2290 897 UUCAGUUGAGCUGACCACC B UUCAGUUGAGCUGACCAGCTT B 3692 R-008397825-000P1600  898 AGAGGCUCUUGUGCGUACU B AGAGGCUCUUGUGCGUACUTT B 3694R-008397825-000P 1600  898 AGAGGCUCUUGUGCGUACU AGUACGCACAAGAGCCUCUUU3695 R-008397828-000R 2432  899 GGUGGADAUGGCCAGGAUGCAUCCUGGCCAUAUCCACCUU 3697 R-008397828-000R 2432  899GGUGGAUAUGGCCAGGAUG B GGUGGAUAUGGCCAGGAUGTT B 3696 R-008397831-000X  710 900 CUUGCCACACGUGCAAUCC B CUUGCCACACGUGCAAUCCTT B 3698 R-008397831-000X 710  900 CUUGCCACACGUGCAAUCC GGAUUGCACGUGUGGCAAGUU 3699R-008397834-000Y 1714  901 GAAUGCAGUUCGCCUUCAC B GAAUGCAGUUCGCCUUCACTT B3700 R-008397834-000Y 1714  901 GAAUGCAGUUCGCCUUCACGUGAAGGCGAACUGCAUUCUU 3701 R-008397837-000Z 2005  902CCUAGCUCGGGAUGUUCAC B CCUAGCUCGGGAUGUUCACTT B 3702 R-008397837-000Z 2005 902 CCUAGCUCGGGAUGUUCAC GUGAACAUCCCGAGCUAGGUU 3703 R-008397840-000F1728  903 UUCACUAUGGAGUACCAGU B UUCACUAUGGACUACCAGUTT B 3704R-008397840-000F 1728  903 UUCACUAUGGACUACCAGU ACUGGUAGUCCAUAGUGAAUU3705 R-008397843-000G 2482  904 GAUGGGUGGCCACCACCCUAGGGUGGUGGCCACCCAUCUU 3707 R-008397843-000G 2482  904GAUGGGUGGCCACCACCCU B GAUGGGUGGCCACCACCCUTT B 3706 R-008397846-000H  768 905 UGGUUAAUAAGGCUGCAGU B UGGUUAAUAAGGCUGCAGUTT B 3708 R-008397846-000H 768  905 UGGUUAAUAAGGCUGCAGU ACUGCAGCCUUAUUAACCAUU 3709R-008397849-000J  693  906 AUCAAGAUGAUGCAGAACU B AUCAAGAUGAUGCAGAACUTT B3710 R-008397849-000J  693  906 AUCAAGAUGAUGCAGAACUAGUUCUGCAUCAUCUUGAUUU 3711 R-008397852-000R 3179  907CUGCUGUGAUACGAUGCUU B CUGCUGUGAUACGAUGCUUTT B 3712 R-008397852-000R 3179 907 CUGCUGUGAUACGAUGCUU AAGCAUCGUAUCACAGCAGUU 3713 R-008397855-000S1549   89 CACUUGCAAUAAUUAUAAG CUUAUAAUUAUUGCAAGUGUU 3715R-008397855-000S 1549   89 CACUUGCAAUAAUUAUAAG B CACUUGCAAUAAUUAUAAGTT B3714 R-008397858-000T 1792  167 GGCUACUGUUGGAUUGAUUAAUCAAUCCAACAGUAGCCUU 3717 R-008397858-000T 1792  167GGCUACUGUUGGAUUGAUU B GGCUACUGUUGGAUUGAUUTT B 3716 R-008397861-000Z 2448 908 AUGCCUUGGGUAUGGACCC GGGUCCAUACCCAAGGCAUUU 3719 R-008397861-000Z2448  908 AUGCUUUGGGUAUGGACCC B AUGCCUUGGGUAUGGACCCTT B 3718R-008397864-000A 3183  909 UGUGAUACGAUGCUUCAAG B UGUGAUACGAUGCUUCAAGTT B3720 R-008397864-000A 3183  909 UGUGAUACGAUGCUUCAAGCUUCAAGCAUCGUAUCACAUU 3721 R-008397867-000B 1293  910GAGUGCUGAAGGUGCUAUC GAUAGCACCUUCAGCACUCUU 3723 R-008397867-000B 1293 910 GAGUGCUGAAGGUGCUAUC B GAGUGCUGAAGGUGCUAUCTT B 3722 R-008397870-000H 544  911 GAGGGUACGAGCUGCUAUG CAUAGCAGCUCGUACCCUCUU 3725R-008397870-000H  544  911 GAGGGUACGAGCUGCUAUG B GAGGGUACGAGCUGCUAUGTT B3724 R-008397873-000J 1676   26 CAUCUGACCAGCCGACACCGGUGUCGGCUGGUCAGAUGUU 3727 R-008397873-000J 1676   26CAUCUGACCAGCCGACACC B CAUCUGACCAGCCGACACCTT B 3726 R-008397876-000K 2937 912 UUAAUUGUAAUCUGAAUAA B UUAAUUGUAAUCUGAAUAATT B 3728 R-008397876-000K2937  912 UUAAUUGUAAUCUGAAUAA UUAUUCAGAUUACAAUUAAUU 3729R-008397879-000L 1691  913 CACCAAGAAGCAGAGAUGG CCAUCUCUGCUUCUUGGUGUU3731 R-008397879-000L 1691  913 CACCAAGAAGCAGAGAUGGB CACCAAGAAGCAGAGAUGGTT B 3730 R-008397882-000T 2195  120UUACUUCACUCUAGGAAUG B UUACUUCACUCUAGGAAUGTT B 3732 R-008397882-000T 2195 120 UUACUUCACUCUAGGAAUG CAUUCCUAGAGUGAAGUAAUU 3733 R-008397885-000U1356  186 UGCAAGCUUUAGGACUUCA B UGCAAGCUUUAGGACUUCATT B 3734R-008397885-000U 1356  186 UGCAAGCUUUAGGACUUCA UGAAGUCCUAAAGCUUGCAUU3735 R-008397888-000V  557  184 GCUAUGUUCCCUGAGACAUAUGUCUCAGGGAACAUAGCUU 3737 R-008397888-000V  557  184GCUAUGUUCCCUGAGACAU B GCUAUGUUCCCUGAGACAUTT B 3736 R-008397897-000D 1353 914 GAAUGCAAGCUUUAGGACU AGUCCUAAAGCUUGCAUUCUU 3739 R-008397897-000D1353  914 GAAUGCAAGCUUUAGGACU B GAAUGCAAGCUUUAGGACUTT B 3738R-008397900-000W 1843  915 ACCUUUGCGUGAGCAGGGU B ACCUUUGCGUGAGCAGGGUTT B3740 R-008397900-000W 1843  915 ACCUUUGCGUGAGCAGGGUACCCUGCUCACGCAAAGGUUU 3741 R-008397903-000X 1302  916AGGUGGUAUCUGUCUGCUC B AGGUGCUAUCUGUCUGCUCTT B 3742 R-008397903-000X 1302 916 AGGUGGUAUCUGUCUGCUC GAGCAGACAGAUAGCACCUUU 3743 R-008397906-000Y2130  917 UUGCUCAGGACAAGGAAGC B UUGCUCAGGACAAGGAAGCTT B 3744R-008397906-000Y 2130  917 UUGCUCAGGACAAGGAAGC GCUUCCUUGUCCUGAGCAAUU3745 R-008397909-000Z 2165  918 GCUGAGUGAGCCACAGCUCB GCUGAGGGAGCCACAGCUCTT B 3746 R-008397909-000Z 2165  918GCUGAGGGAGCCACAGCUC GAGCUGUGGCUCCCUCAGCUU 3747 R-008397912-000F  387 919 CUACCACAGCUCCUUCUCU B CUACCACAGCUCCUUCUCUTT B 3748 R-008397912-000F 387  919 CUACCACAGCUCCUUCUCU AGAGAAGGAGCUGUGGUAGUU 3749R-008397915-000G 2472  920 UGGAACAUGAGAUGGGUGG CCACCCAUCUCAUGUUCCAUU3751 R-008397915-000G 2472  920 UGGAACAUGAGAUGGGUGGB UGGAACAUGAGAUGGGUGGTT B 3750 R-008397918-000H  857  921GCUAUUGUACGUACCAUGC B GCUAUUGUACGUACCAUGCTT B 3752 R-008397918-000H  857 921 GCUAUUGUACGUACCAUGC GCAUGGUACGUACAAUAGCUU 3753 R-008397921-000P1816  922 UCUUGCCCUUUGUCCCGCA UGCGGGACAAAGGGCAAGAUU 3755R-008397921-000P 1816  922 UCUUGCCCUUUGUCCCGCA B UCUUGCCCUUUGUCCCGCATT B3754 R-008397924-000R 1561  923 UUAUAAGAACAAGAUGAUGCAUCAUCUUGUUCUUAUAAUU 3757 R-008397924-000R 1561  923UUAUAAGAACAAGAUGAUG B UUAUAAGAACAAGAUGAUGTT B 3756 R-008397927-000S  811 924 GGAAGCUUCCAGAGACGCU B GGAAGCUUCCAGACACGCUTT B 3758 R-008397927-000S 811  924 GGAAGCUUCCAGAGACGCU AGCGUGUCUGGAAGCUUCCUU 3759R-008397930-000Y 1327  925 UAAGCCGGCUAUUGUAGAA B UAAGCCGGCUAUUGUAGAATT B3760 R-008397930-000Y 1327  925 UAAGCCGGCUAUUGUAGAAUUCUACAAUAGCCGGCUUAUU 3761 R-008397933-000Z  757  926GGACCAGGUGGUGGUUAAU B GGACCAGGUGGUGGUUAAUTT B 3762 R-008397933-000Z  757 926 GGACCAGGUGGUGGUUAAU AUUAACCACCACCUGGUCCUU 3763 R-008397936-000A 507  927 CUGAUAUUGAUGGACAGUA B CUGAUAUUGAUGGACAGUATT B 3764R-008397936-000A  507  927 CUGAUAUUGAUGGACAGUA UACUGUCCAUCAAUAUCAGUU3765 R-008397939-000B 3092  928 UGGGUAGGGUAAAUCAGUAB UGGGUAGGGUAAAUCAGUATT B 3766 R-008397939-000B 3092  928UGGGUAGGGUAAAUCAGUA UACUGAUUUACCCUACCCAUU 3767 R-008397942-000H 2359 929 ACUUGAUAUUGGUGCCCAG B ACUUGAUAUUGGUGCCCAGTT B 3768 R-008397942-000H2359  929 ACUUGAUAUUGGUGCCCAG CUGGGCACCAAUAUCAAGUUU 3769R-008397945-000J 1753  930 UAAGCUCUUACACCCACCA B UAAGCUCUUACACCCACCATT B3770 R-008397945-000J 1753  930 UAAGCUCUUACACCCACCAUGGUGGGUGUAAGAGCUUAUU 3771 R-008397948-000K  273  931CUACUCAAGCUGAUUUGAU AUCAAAUCAGCUUGAGUAGUU 3773 R-008397948-000K  273 931 CUACUCAAGCUGAUUUGAU B CUACUCAAGCUGAUUUGAUTT B 3772 R-008397951-000S1859  932 GGUGCCAUUCCACGACUAG CUAGUCGUGGAAUGGCACCUU 3775R-008397951-000S 1859  932 GGUGCCAUUCCACGACUAG B GGUGCCAUUCCACGACUAGTT B3774 R-008397954-000T  296  933 UUGGACAUGGCCAUGGAACB UUGGACAUGGCCAUGGAACTT B 3776 R-008397954-000T  296  933UUGGACAUGGCCAUGGAAC GUUCCAUGGCCAUGUCCAAUU 3777 R-008397957-000U  615 934 CUGCUCAUCCCACUAAUGU ACAUUAGUGGGAUGAGCAGUU 3779 R-008397957-000U 615  934 CUGCUCAUCCCACUAAUGU B CUGCUCAUCCCACUAAUGUTT B 3778R-008397960-000A  301  935 CAUGGCCAUGGAACCAGAC GUCUGGUUCCAUGGCCAUGUU3781 R-008397960-000A  301  935 CAUGGCCAUGGAACCAGACB CAUGGCCAUGGAACCAGACTT B 3780 R-008397963-000B 1184  936UAUGGCAACCAAGAAAGCA B UAUGGCAACCAAGAAAGCATT B 3782 R-008397963-000B 1184 936 UAUGGCAACCAAGAAAGCA UGCUUUCUUGGUUGCCAUAUU 3783 R-008397966-000C1006  937 ACCAGUGGAUUCUGUGUUG B ACCAGUGGAUUCUGUGUUGTT B 3784R-008397966-000C 1006  937 ACCAGUGGAUUCUGUGUUG CAACACAGAAUCCACUGGUUU3785 R-008397969-000D 2189  938 ACAGAGUUACUUCACUCUAB ACAGAGUUACUUCACUCUATT B 3786 R-008397969-000D 2189  938ACAGAGUUACUUCACUCUA UAGAGUGAAGUAACUCUGUUU 3787 R-008397972-000K 1365 939 UAGGACUUCACCUGACAGA UCUGUCAGGUGAAGUCCUAUU 3789 R-008397972-000K1365  939 UAGGACUUCACCUGACAGA B UAGGACUUCACCUGACAGATT B 3788R-008397975-000L 2442  940 GCCAGGAUGCCUUGGGUAU B GCCAGGAUGCCUUGGGUAUTT B3790 R-008397975-000L 2442  940 GCCAGGAUGCCUUGGGUAUAUACCCAAGGCAUCCUGGCUU 3791 R-008397978-000M 1249  941AAUGAGGACCUAUACUUAC B AAUGAGGACCUAUACUUACTT B 3792 R-008397978-000M 1249 941 AAUGAGGACCUAUACUUAC GUAAGUAUAGGUCCUCAUUUU 3793 R-008397981-000U1144  942 AUUCUUGGCUAUUACGACA B AUUCUUGGCUAUUACGACATT B 3794R-008397981-000U 1144  942 AUUCUUGGCUAUUACGACA UGUCGUAAUAGCCAAGAAUUU3795 R-008397984-000V 2075  943 CUUUAUUCUCCCAUUGAAAB CUUUAUUCUCCCAUUGAAATT B 3796 R-008397984-000V 2075  943CUUUAUUCUCCCAUUGAAA UUUCAAUGGGAGAAUAAAGUU 3797 R-008397987-000W  759  94 ACCAGGUGGUGGUUAAUAA B ACCAGGUGGUGGUUAAUAATT B 3798 R-008397987-000W 759   94 ACCAGGUGGUGGUUAAUAA UUAUUAACCACCACCUGGUUU 3799R-008397990-000C 1545   44 ACCUCACUUGCAAUAAUUA B ACCUCACUUGCAAUAAUUATT B3800 R-008397990-000C 1545   44 ACCUCACUUGCAAUAAUUAUAAUUAUUGCAAGUGAGGUUU 3801 R-008397993-000D  504  944UAGCUGAUAUUGAUGGACA UGUCCAUCAAUAUCAGCUAUU 3803 R-008397993-000D  504 944 UAGCUGAUAUUGAUGGACA B UAGCUGAUAUUGAUGGACATT B 3802 R-008397996-000E1405  945 GAACUGUCULUGGACUCUC B GAACUGUCUUUGGACUCUCTT B 3804R-008397996-000E 1405  945 GAACUGUCUUUGGACUCUC GAGAGUCCAAAGACAGUUCUU3805 R-008397999-000F  333  946 UUAGUCACUGGCAGCAAGAUGUUGCUGCCAGUGACUAAUU 3807 R-008397999-000F  333  946UUAGUCACUGGCAGCAAGA B UUAGUCACUGGCAGCAACATT B 3806 R-008398002-000V 1032 947 CCAUUACAACUCUCCACAA B CCAUUACAACUCUCCACAATT B 3808 R-008398002-000V1032  947 CCAUUACAACUCUCCACAA UUGUGGAGAGUUGUAAUGGUU 3809R-008398005-000W 1748  948 GUGGUUAAGCUCUUACACC B GUGGUUAAGCUCUUACACCTT B3810 R-008398005-000W 1748  948 GUGGUUAAGCUCUUACACCGGUGUAAGAGCUUAACCACUU 3811 R-008398008-000X  283  949UGAUUUGAUGGAGUUGGAC GUCCAACUCCAUCAAAUCAUU 3813 R-008398008-000X  283 949 UGAUUUGAUGGAGUUGGAC B UGAUUGAUUGGAGUUGGACTT B 3812 R-008398011-000D1700  950 GCAGAGAUGGCCCAGAAUG B GCAGAGAUGGCCCAGAAUGTT B 3814R-008398011-000D 1700  950 GCAGAGAUGGCCCAGAAUG CAUUCUGGGCCAUGUCUGCUU3815 R-008398014-000E 1445  951 ACUAAACAGGAAGGGAUGGB ACUAAACAGGAAGGGAUGGTT B 3816 R-008398014-000E 1445  951ACUAAACAGGAAGGGAUGG CCAUCCCUUCCUGUUUAGUUU 3817 R-008398017-000F 1133 952 ACAAAUGUUAAAUUCUUGG CCAAGAAUUUAACAUUUGUUU 3819 R-008398017-000F1133  952 ACAAAUGUUAAAUUCUUGG B ACAAAUGUUAAAUUCUUGGTT B 3818R-008398020-000M  527  953 GCAAUGACUCGAGCUCAGA UCUGAGCUCGAGUCAUUGCUU3821 R-008398020-000M  527  953 GCAAUGACUCGAGCUCAGAB GCAAUGACUCGAGCUCAGATT B 3820 R-008398023-000N 2010  954CUCGGGAUGUUCACAACCG CGGUUGUGAACAUCCCGAGUU 3823 R-008398023-000N 2010 954 CUCGGGAUGUUCACAACCG B CUCGGGAUGUUCACAACCGTT B 3822 R-008398026-000P 851  955 GUGUCUGCUAUUGUACGUA UACGUACAAUAGCAGACACUU 3825R-008398026-000P  851  955 GUGUCUGCUAUUGUACGUA B GUGUCUGCUAUUGUACGUATT B3824 R-008398029-000R  436  956 UGUGGAUACCUCCCAAGUCB UGUGGAUACCUCCCAAGUCTT B 3826 R-008398029-000R  436  956UGUGGAUACCUCCCAAGUC GACUUGGGAGGUAUCCACAUU 3827 R-008398032-000X 1601   2 GAGGCUCUUGUGCGUACUG B GAGGCUCUUGUGCGUACUGTT B 3828 R-008398032-000X1601    2 GAGGCUCUUGUGCGUACUG CAGUACGCACAAGAGCCUCUU 3829R-008398035-000Y 2446  957 GGAUGCCUUGGGUAUGGAC B GGAUGCCUUGGGUAUGGACTT B3830 R-008398035-000Y 2446  957 GGAUGCCUUGGGUAUGGACGUCCAUACCCAAGGCAUCCUU 3831 R-008398038-000Z 1142  958AAAUUCUUGGCUAUUACGA B AAAUUCUUGGCUAUUACGATT B 3832 R-008398038-000Z 1142 958 AAAUUCUUGGCUAUUACGA UCGUAAUAGCCAAGAAUUUUU 3833 R-008398041-000F 599  959 UACGAGCUGCUAUGUUCCC B UACGAGCUGCUAUGUUCCCTT B 3834R-008398091-000F  549  959 UACGAGCUGCUAUGUUCCC GGGAACAUAGCAGCUCGUAUU3835 R-008398044-000G 1083  960 CAGUGCGUUUAGCUGGUGGCCACCAGCUAAACGGACUGUU 3837 R-008398044-000G 1083  960CAGUGCGUUUAGCUGGUGG B CAGUGCGUUUAGCUGGUGGTT B 3836 R-008398047-000H  695 961 CAAGAUGAUGCAGAACUUG CAAGUUCUGCAUCAUCUUGUU 3839 R-008398047-000H 695  961 CAAGAUGAUGCAGAACUUG B CAAGAUGAUGCAGAACUUGTT B 3838R-008398050-000P  885  962 AUGAUGUAGAAACAGCUCG B AUGAUGUAGAAACAGCUCGTT B3840 R-008398050-000P  885  962 AUGAUGUAGAAACAGCUCGCGAGCUGUUUCUACAUCAUUU 3841 R-008398056-000S 2067  963UGCAGCUGCUUUAUUCUCC B UUCAGCUGCUUUAUUCUCCTT B 3842 R-008398056-000S 2067 963 UGCAGCUGCUUUAUUCUCC GGAGAAUAAAGCAGCUGCAUU 3843 R-008398059-000T 390  964 CCACAGCUCCUUCUCUGAG CUCAGAGAAGGAGCUGUGGUU 3845R-008398059-000T  390  964 CCACAGCUCCUUCUCUGAG B CCACAGCUCCUUCUCUGAGTT B3844 R-008398062-000Z 1719  965 CAGUUCGCCUUCACUAUGGB CAGUUCGCCUUCACUAUGGTT B 3846 R-008398062-000Z 1719  965CAUUUCGCCUUCACUAUGG CCAUAGUGAAGGCGAACUGUU 3847 R-008398065-000A  813 966 AAGCUUCCAGACACGCUAU AUAGCGUGUCUGGAAGCUUUU 3849 R-008398065-000A 813  966 AAGCUUCCAGACACGCUAU B AAGCUUCCAGACACGCUAUTT B 3848R-008398068-000B 2289  967 UUUCAGUUGAGCUGACCAG B UUUCAGUUGAGCUGACCAGTT B3850 R-008398068-000B 2289  967 UUUCAGUUGAGCUGACCAGCUGGUCAGCUCAACUGAAAUU 3851 R-008398071-000H  377  968UCUGGUGCCACUACCACAG B UCUGGUGCCACUACCACAGTT B 3852 R-008398071-000H  377 968 UCUGGUGCCACUACCACAG CUGUGGUAGUGGCACCAGAUU 3853 R-008398074-000J 826  969 CGCUAUCAUGCGUUCUCCU AGGAGAACGCAUGAUAGCGUU 3855R-008398074-000J  826  969 CGCUAUCAUGCGUUCUCCU B CGCUAUCAUGCUTUCUCCUTT B3854 R-008398077-000K 1634  970 GACAGGGAAGACAUCACUGCAGUGAUGUCUUCCCUGUCUU 3857 R-008398077-000K 1634  970GACAGGGAAGACAUCACUG B GACAGGGAAGACAUCACUGTT B 3856 R-008398080-000S 1208 971 AUCAUACUGGCUAGUGGUG B AUCAUACUGGCUAGUGGUGTT B 3858 R-008398080-000S1208  971 AUCAUACUGGCUAGUGGUG CACCACUAGCCAGUAUGAUUU 3859R-008398083-000T 1628  972 GCUGGUGACAGGGAAGACA UGUCUUCCCUGUCACCAGCUU3861 R-008398083-000U 1628  972 GCUGGUGACAGGGAAGACAB GCUGGUGACAGGGAAGACATT B 3860 R-008398086-000U 2003  973AUCCUAGCUCGGGAUGUUC GAACAUCCCGAGCUAGGAUUU 3863 R-008398086-000U 2003 973 AUCCUAGCUCGGGAUGUUC B AUCCUAGCUCUGGAUGUUCTT B 3862 R-008398089-000V 452  974 GUCCUGUAUGAGUGGGAAC B GUCCUGUAUGAGUGGGAACTT B 3864R-008398089-000V  452  974 GUCCUGUAUGAGUGGGAAC GUUCCCACUCAUACAGGACUU3865 R-008398092-000B 2543  175 GCCCAGGACCUCAUGGAUGCAUCCAUGAGGUCCUGGGCUU 3867 R-008398092-000B 2543  175GCCCAGGACCUCAUGGAUG B GCCCAGGACCUCAUGGAUGTT B 3866 R-008398095-000C 3081 975 UGGGAUAUGUAUGGGUAGG CCUACCCAUACAUAUCCCAUU 3869 R-008398095-000C3081  975 UGGGAUAUGUAUGGGUAGG B UGGGAUAUGUAUGGGUAGGTT B 3868R-008398098-000D 2354  976 CUUGGACUUGAUAUUGGUG B CUUGGACUUGAUAUUGGUGTT B3870 R-008398098-000D 2354  976 CUUGGACUUGAUAUUGGUGCACCAAUAUCAAGUCCAAGUU 3871 R-008398101-000W 1822  977CCUUUGUCCCGCAAAUCAU B CCUUUGUCCCGCAAAUCAUTT B 3872 R-008398101-000W 1822 977 CCUUUGUCCCGCAAAUCAU AUGAUUUGCGGGACAAAGGUU 3873 R-008398107-000Y1299  978 UGAAGGUGCUAUCUGUCUG CAGACAGAUAGCACCUUCAUU 3875R-008398107-000Y 1299  978 UGAAGGUGCUAUCUGUCUG B UGAAGGUGCUAUCUGUCUGTT B3874 R-008398110-000E  486  979 CCUUCACUCAAGAACAAGUB CCUUCACUCAAGAACAAGUTT B 3876 R-008398110-000E  486  979CCUUCACUCAAGAACAAGU ACUUGUUCUUGAGUGAAGGUU 3877 R-008398116-000G 1463 980 GAAGGUCUCCUUGGGACUC B GAAGGLCUCCUUGGGACUCTT B 3878 R-008398116-000G1463  980 GAAGGUCUCCUUGGGACUC GAGUCCCAAGGAGACCUUCUU 3879R-008398119-000H 2280  981 AGAAACGGCUUUCAGUUGA B AGAAACGGCUUUCAGUUGATT B3880 R-008398119-000H 2280  981 AGAAACGGCUUUCAGUUGAUCAACUGAAAGCCGUUUCUUU 3881 R-008398122-000P 1907  982ACCCAGCGCCGUACGUCCA B ACCCAGCGCCGUACGUCCATT B 3882 R-008398122-000P 1907 982 ACCCAGCGCCGUACGUCCA UGGACGUACGGCGCUGGGUUU 3883 R-008398125-000R 923  983 CAUAACCUUUCCCAUCAUC B CAUAACCUUUCCCAUCAUCTT B 3884R-008398125-000R  923  983 CAUAACCUUUCCCAUCAUC GAUGAUGGGAAAGGUUAUGUU3885 R-008398128-000S 1979  984 GAAGGUUGUACCGGAGCCCB GAAGGUUGUACCGGAGCCCTT B 3886 R-008398128-000S 1979  984GAAGGUUGUACCGGAGCCC GGGCUCCGGUACAACCUUCUU 3887 R-008398131-000Y 1827 985 GUCCCGCAAAUCAUGCACC B GUCCCGCAAAUCAUGCACCTT B 3888 R-008398131-000Y1827  985 GUCCCGCAAAUCAUGCACC GGUGCAUGAUUUGCGGGACUU 3889R-008398134-000Z 1201  986 CAAGCUCAUCAUACUGGCU AGCCAGUAUGAUGAGCUUGUU3891 R-008398134-000Z 1201  986 CAAGCUCAUCAUACUGGCUB CAAGCUCAUCAUACUGGCUTT B 3890 R-008398137-000A 1913  987CGCCGUACGUCCAUGGGUG B CGCCGUACGUCCAUGGGUGTT B 3892 R-008398137-000A 1913 987 CGCCGUACGUCCAUGGGUG CACCCAUGGACGUACGGCGUU 3893 R-008398140-000G2191  988 AGAGUUACUUCACUCUAGG CCUAGAGUGAAGUAACUCUUU 3895R-008398140-000G 2191  988 AGAGUUACUUCACUCUAGG B AGAGUUACUUCACUCUAGGTT B3894 R-008398143-000H  295  989 GUUGGACAUGGCCAUGGAAUUCCAUGGCCAUGUCCAACUU 3897 R-008398143-000H  295  989GUUGGACAUGGCCAUGGAA B GUUGGACAUGGCCAUGGAATT B 3896 R-008398146-000J 1149 990 UGGCUAUUACGACAGACUG B UGGCUAUUACGACAGACUGTT B 3898 R-008398146-000J1149  990 UGGCUAUUACGACAGACUG CAGUCUGUCGUAAUAGCCAUU 3899R-008398149-000K  533  991 ACUCGAGCUCAGAGGGUAC B ACUCGAGCUCAGAGGGUACTT B3900 R-008398149-000K  533  991 ACUCGAGCUCAGAGGGUACGUACCCUCUGAGCUCGAGUUU 3901 R-008398152-000S  604  992ACAGUUUGAUGCUGCUCAU B ACAGUUUGAUGCUGCUCAUTT B 3902 R-008398152-000S  604 992 ACAGUUUGAUGCUGCUCAU AUGAGCAGCAUCAAACUGUUU 3903 R-008398155-000T 766  993 GGUGGUUAAUAAGGCUGCA B GGUGGUUAAUAAGGCUGCATT B 3904R-008398155-000T  766  993 GGUGGUUAAUAAGGCUGCA UGCAGCCUUAUUAACCACCUU3905 R-008398158-000U 1823  994 CUUUGUCCCGCAAAUCAUGB CUUUGUCCCGCAAAUCAUGTT B 3906 R-008398158-000U 1823  994CUUUGUCCCGCAAAUCAUG CAUGAUUUGCGGGACAAAGUU 3907 R-008398161-000A 2048 995 AAUACCAUUCCAUUGUUUG CAAACAAUGGAAUGGUAUUUU 3909 R-008398161-000A2048  995 AAUACCAUUCCAUUGUUUG B AAUACCAUUCCAUUGUUUGTT B 3908R-008398164-000B  714  996 CCACACGUGCAAUCCCUGA B CCACACGUGCAAUCCCUGATT B3910 R-008398164-000B  714  996 CCACACGUGCAAUCCCUGAUCAGGGAUUGCACGUGUGGUU 3911 R-008398167-000C 2439  997AUGGCCAGGAUGCCUUGGG CCCAAGGCAUCCUGGCCAUUU 3913 R-008398167-000C 2439 997 AUGGCCAGGAUGCCUUGGG B AUGGCCAGGAUGCCUUGGGTT B 3912 R-008398170-000J1903  998 GGAUACCCAGCGCCGUACG B GGAUACCCAGCGCCGUACGTT B 3914R-008398170-000J 1903  998 GGAUACCCAGCGCCGUACG CGUACGGCGCUGGGUAUCCUU3915 R-008398173-000K 2395  999 UCGCCAGGAUGAUCCUAGCGCUAGGAUCAUCCUGGCGAUU 3917 R-008398173-000K 2395  999UCGCCAGGAUGAUCCUAGC B UCGCCAGGAUGAUCCUAGCTT B 3916 R-008398176-000L  7891000 UGGUCCAUCAGCUUUCUAA UUAGAAAGCUGAUGGACCAUU 3919 R-008398176-000L 789 1000 UGGUCCAUCAGCUUUCUAA B UGGUCCAUCAGUTUUCUAATT B 3918R-008398179-000M 3085 1001 AUAUGUAUGGGUAGGGUAA UUACCCUACCCAUACAUAUUU3921 R-008398179-000M 3085 1001 AUAUGUAUGGGUAGGGUAAB AUAUGUAUGGGUAGGGUAATT B 3920 R-008398182-000U 1710 1002CCCAGAAUGCAGUUCGCCU B CCCAGAAUGCAGUUCGCCUTT B 3922 R-008398182-000U 17101002 CCCAGAAUGCAGUUCGCCU AGGCGAACUGCAUUCUGGGUU 3923 R-008398185-000V1336 1003 UAUUGUAGAAGCUGGUGGA B UAUUGUAGAAGCUGGUGGATT B 3924R-008398185-000V 1336 1003 UAUUGUAGAAGCUGGUGGA UCCACCAGCUUCUACAAUAUU3925 R-008398188-000W 3089 1004 GUAUGGGUAGGGUAAAUCAUGAUUUACCCUACCCAUACUU 3927 R-008398188-000W 3089 1004GUAUGGGUAGGGUAAAUCA B GUAUGGGUAGGGUAAAUCATT B 3926 R-008398191-000C 23511005 GAUCUUGGACUUGAUAUUG B GAUCUUGGACUUGAUAUUGTT B 3928 R-008398191-000C2351 1005 GAUCUUGGACUUGAUAUUG CAAUAUCAAGUCCAAGAUCUU 3929R-008398194-000D  716 1006 ACACGUGCAAUCCCUGAAC B ACACGUGCAAUCCCUGAACTT B3930 R-008398194-000D  716 1006 ACACGUGCAAUCCCUGAACGUUCAGGGAUUGCACGUGUUU 3931 R-008398197-000E 1911 1007AGCGCCGUACGUCCAUGGG B AGCGCCGUACGUCCAUGGGTT B 3932 R-008398197-000E 19111007 AGCGCCGUACGUCCAUGGG CCCAUGGACGUACGGCGCUUU 3933 R-008398200-000X1985 1008 UGUACCGGAGCCCUUCACA UGUGAAGGGCUCCGGUACAUU 3935R-008398200-000X 1985 1008 UGUACCGGAGCCCUUCACA B UGUACCGGAGCCCUUCACATT B3934 R-008398203-000Y 2516 1009 GUUGAUGGGCUGCCAGAUCB GUUGAUGGGCUGCCAGAUCTT B 3936 R-008398203-000Y 2516 1009GUUGAUGGGCUGCCAGAUC GAUCUGGCAGCCCAUCAACUU 3937 R-008398206-000Z 17621010 ACACCCACCAUCCCACUGG CCAGUGGGAUGGUGGGUGUUU 3939 R-008398206-000A1762 1010 ACACCCACCAUCCCACUGG B ACACCCACCAUCCCACUGGTT B 3938R-008398209-000A 1156 1011 UACGACAGACUGCCUUCAA B UACGACAGACUGCCUUCAATT B3940 R-008398209-000A 1156 1011 UACGACAGACUGCCUUCAAUUGAAGGCAGUCUGUCGUAUU 3941 R-008398212-000G 1887 1012UUGUUCGUGCACAUCAGGA B UUGUUCGUGCACAUCAGGATT B 3942 R-008398212-000G 18871012 UUGUUCGUGCACAUCAGGA UCCUGAUGUGCACGAACAAUU 3943 R-008398215-000H1833 1013 CAAAUCAUGCACCUUUGCG CGCAAAGGUGCAUGAUUUGUU 3945R-008398215-000H 1833 1013 CAAAUCAUGCACCUUUGCG B CAAAUCAUGCACCUUUGCGTT B3944 R-008398218-000J  967 1014 GUCUGGAGGCAUUCCUGCCGGCAGGAAUGCCUCCAGACUU 3947 R-008398218-000J  967 1014GUCUGGAGGCAUUCCUGCC B GUCUGGAGGCAUUCCUGCCTT B 3946 R-008398221-000R 17301015 CACUAUGGACUACCAGUUG CAACUGGUAGUCCAUAGUGUU 3949 R-008398221-000R1730 1015 CACUAUGGACUACCAGUUG B CACUAUGGACUACCAGUUGTT B 3948R-008398224-000S  829 1016 UAUCAUGCGUUCUCCUCAG CUGAGGAGAACGCAUGAUAUU3951 R-008398224-000S  829 1016 UAUCAUGCGUUCUCCUCAGB UAUCAUGCGUUGUCCUCAGTT B 3950 R-008398227-000T  890 1017GUAGAAACAGCUCGUUGUA B GUAGAAACAGCUCGUUGUATT B 3952 R-008398227-000T  8901017 GUAGAAACAGCUCGUUGUA UACAACGAGCUGUUUCUACUU 3953 R-008398230-000Z2181 1018 CUCCUCUGACAGAGUUACU AGUAACUCUGUCAGAGGAGUU 3955R-008398230-000Z 2181 1018 CUCCUCUGACAGAGUUACU B CUCCUCUGACAGAGUUACUTT B3954 R-008398233-000A 2131 1019 UGCUCAGGACAAGGAAGCUB UGCUCAGGACAAGGAAGCUTT B 3956 R-008398233 000A 2131 1019UGCUCAGGACAAGGAAGCU AGCUUCCUUGUCCUGAGCAUU 3957 R-008398236-000B 15861020 CAAGUGGGUGGUAUAGAGG B CAAGUGGGUGGUAUAGAGGTT B 3958 R-008398236-000B1586 1020 CAAGUGGGUGGUAUAGAGG CCUCUAUACCACCCACUUGUU 3959R-008398239-000C  765 1021 UGGUGGUUAAUAAGGCUGC B UGGUGGUUAAUAAGGCUGCTT B3960 R-008398239-000C  765 1021 UGGUGGUUAAUAAGGCUGCGCAGCCUUAUUAACCACCAUU 3961 R-008398242-000J 1369 1022ACUUCACCUGACAGAUCCA B ACUUCACCUGACAGAUCCATT B 3962 R-008398242-000J 13691022 ACUUCACCUGACAGAUCCA UGGAUCUGUCAGGUGAAGUUU 3963 R-008398245-000K1724 1023 CGCCUUCACUAUGGACUAC GUAGUCCAUAGUGAAGGCGUU 3965R-008398245-000K 1724 1023 CGCCUUCACUAUGGACUAC B CGCCUUCACUAUGGACUACTT B3964 R-008398248-000L  834 1024 UGCGUUCUCCUCAGAUGGUACCAUCUGAGGAGAACGCAUU 3967 R-008398248-000L  834 1024UGCGUUCUCCUCAGAUGGU B UGCGUUCUCCUCAGAUGGUTT B 3966 R-008398251-000T 19831025 GUUGUACCGGAGCCCUUCA B GUUGUACCGGAGCCCUUCATT B 3968 R-008398251-000T1983 1025 GUUGUACCGGAGCCCUUCA UGAAGGGCUCCGGUACAACUU 3969R-008398254-000U 1688 1026 CGACACCAAGAAGCAGAGA B CGACACCAAGAAGCAGAGATT B3970 R-008398254-000U 1688 1026 CGACACCAAGAAGCAGAGAUCUCUGCUUCUUGGUGUCGUU 3971 R-008398257-000V 1004 1027UCACCAGUGGAUUCUGUGU B UCACCAGUGGAUUCUGUGUTT B 3972 R-008398257-000V 10041027 UCACCAGUGGAUUCUGUGU ACACAGAAUCCACUGGUGAUU 3973 R-008398260-000B1631 1028 GGUGACAGGGAAGACAUCA UGAUGUCUUCCCUGUCACCUU 3975R-008398260-000B 1631 1028 GGUGACAGGGAAGACAUCA B GGUGACAGGGAAGACAUCATT B3974 R-008398263-000C 1319 1029 UCUAGUAAUAAGCCGGCUAUAGCCGGCUUAUUACUAGAUU 3977 R-008398263-000C 1319 1029UCUAGUAAUAAGCCGGCUA B UCUAGUAAUAAGCCGGCUATT B 3976 R-008398266-000D  7671030 GUGGUUAAUAAGGCUGCAG B GUGGUUAAUAAGGCUGCAGTT B 3978 R-008398266-000D 767 1030 GUGGUUAAUAAGGCUGCAG CUGCAGCCUUAUUAACCACUU 3979R-008398269-000E  841 1031 UCCUCAGAUGGUGUCUGCU AGCAGACACCAUCUGAGGAUU3981 R-008398269-000E  841 1031 UCCUCAGAUGGUGUCUGCUB UCCUCAGAUGGUGUCUGCUTT B 3980 R-008398272-000L  516 1032AUGGACAGUAUGCAAUGAC B AUGGACAGUAUGCAAUGACTT B 3982 R-008398272-000L  5161032 AUGGACAGUAUGCAAUGAC GUCAUUGCAUACUGUCCAUUU 3983 R-008398275-000M1848 1033 UGCGUGAGCAGGGUGCCAU AUGGCACCCUGCUCACGCAUU 3985R-008398275-000M 1848 1033 UGCGUGAGCAGGGUGCCAU B UGCGUGAGCAGGGUGCCAUTT B3984 R-008398278-000N 2202 1034 ACUCUAGGAAUGAAGGUGUB ACUCUAGGAAUGAAGGUGUTT B 3986 R-008398278-000N 2202 1034ACUCUAGGAAUGAAGGUGU ACACCUUCAUUCCUAGAGUUU 3987 R-008398281-000V  5711035 GACAUUAGAUGAGGGCAUG B GACAUUAGAUGAGGGCAUGTT B 3988 R-008398281-000V 571 1035 GACAUUAGAUGAGGGCAUG CAUGCCCUCAUCUAAUGUCUU 3989R-008394284-000W 1629 1036 CUGGUGACAGGGAAGACAU B CUGGUGACAGGGAAGACAUTT B3990 R-008398284-000W 1629 1036 CUGGUGACAGGGAAGACAUAUGUCUUCCCUGUCACCAGUU 3991 R-008398287-000x 1806 1037UGAUUCGAAAUCUUGCCCU B UGAUUCGAAAUCUUGCCCUTT B 3992 R-008398287-000X 18061037 UGAUUCGAAAUCUUGCCCU AGGGCAAGAUUUCGAAUCAUU 3993 R-008398290-000D1756 1038 GCUCUUACACCCACCAUCC B GCUCUUACACCCACCAUCCTT B 3994R-008398290-000D 1756 1038 GCUCUUACACCCACCAUCC GGAUGGUGGGUGUAAGAGCUU3995 R-008398293-000E 1619 1039 GUCCUUCGGGCUGGUGACAUGUCACCAGCCCGAAGGACUU 3997 R-008398293-000E 1619 1039GUCCUUCGGGCUGGUGACA B GUCCUUCGGGCUGGUGACATT B 3996 R-008398296-000F 16101040 GUGCGUACUGUCCUUCGGG B GUGCGUACUGUCCUUCGGGTT B 3998 R-008398296-000F1610 1040 GUGCGUACUGUCCUUCGGG CCCGAAGGACAGUACGCACUU 3999R-008398299-000G 2500 1041 UGGUGCUGACUAUCCAGUU B UGGUGCUGACUAUCCAGUUTT B4000 R-008398299-000G 2500 1041 UGGUGCUGACUAUCCAGUUAACUGGAUAGUCAGCACCAUU 4001 R-008398302-000Z 2156 1042GCUAUUGAAGGUGAGGGAG B GCUAUUGAAGCUGAGGGAGTT B 4002 R-008398302-000Z 21561042 GCUAUUGAAGCUGAGGGAG CUUCCUCAGCUUCAAUAGCUU 4003 R-008398305-000A1189 1043 CAACCAAGAAAGCAAGCUC GAGCUUGCUUUCUUGGUUGUU 4005R-008398305-000A 1189 1043 CAACCAAGAAAGCAAGCUC B CAACCAAGAAAGCAAGCUCTT B4004 R-008398308-000B 2066 1044 GUGCAGCUGCUUUAUUCUCGAGAAUAAAGCAGCUGCACUU 4007 R-008398308-000B 2066 1044GUGCAGCUGCUUUAUUCUC B GUGCAGCUGCUUUAUUCUCTT B 4006 R-008398311-000H 13071045 CUAUCUGUCUGCUCUAGUA UACUAGAGGAGACAGAUAGUU 4009 R-008398311-000H1307 1045 CUAUCUGUCUGCUCUAGUA B CUAUCUGUCUGCUCUAGUATT B 4008R-008398314-000J 1448 1046 AAACAGGAAGGGAUGGAAG CUUCCAUCCCUUCCUGUUUUU4011 R-008398314-000J 1448 1046 AAACAGGAAGGGAUGGAAGB AAACAUGAAGGGAUGGAAGTT B 4010 R-008398317-000K 1213 1047ACUGGCUAGUGGUGGACCC B ACUGGCUAGUGGUGGACCCTT B 4012 R-008398317-000K 12131047 ACUGGCUAGUGGUGGACCC GGGUCCACCACUAGCCAGUUU 4013 R-008398320-000S2119 1048 CCUCUGUGAACUUGCUCAG B CCUCUGUGAACUUGCUCAGTT B 4014R-008398320-000S 2119 1048 CCUCUGUGAACUUGCUCAG CUGAGCAAGUUCACAGAGGUU4015 R-008398323-000T 2546   72 CAGGACCUCAUGGAUGGGCB CAGGACCUCAUGGAUGGGCTT B 1016 R-008398323-000T 2546   72CAGGACCUCAUGGAUGGGC GCCCAUCCAUGAGGUCCUGUU 4017 R-008398326-000U  8891049 UGUAGAAACAGCUCGUUGU B UGUAGAAACAGCUCGUUGUTT B 4018 R-008398326-000U 889 1049 UGUAGAAACAGCUCGUUGU ACAACGAGCUGUUUCUACAUU 4019R-008398329-000V 1376 1050 CUGACAGAUCCAAGUCAAC B CUGACAGAUCCAAGUCAACTT B4020 R-008398329-000V 1376 1050 CUGACAGAUCCAAGUCAACGUUGACUUGGAUCUGUCAGUU 4021 R-008398332-000B  427 1051GGAAGAGGAUGUGGAUACC GGUAUCCACAUCCUCUUCCUU 4023 R-008398332-000B  4271051 GGAAGAGGAUGUGGAUACC B GGAAGAGGAUGUGGAUACCTT B 4022 R-008398335-000C 649 1052 ACCAUCACAGAUGCUGAAA B ACCAUCACAGAUGCUGAAATT B 4024R-008398335-000C  649 1052 ACCAUCACAGAUGCUGAAA UUUCAGCAUCUGUGAUGGUUU4025 R-008398338-000D 1915 1053 CCGUACGUCCAUGGGUGGGB CCGUACGUCCAUGGGUGGGTT B 4026 R-008398338-000D 1915 1053CCGUACGUCCAUGGGUGGG CCCACCCAUGGACGUACGGUU 4027 R-008398341-000K 20531054 CAUUCCAUUGUUUGUGCAG B CAUUCCAUUGUUUGUGCAGTT B 4028 R-008398341-000K2053 1054 CAUUCCAUUGUUUGUGCAG CUGCACAAACAAUGGAAUGUU 4029R-008398344-000L 2000   24 CACAUCCUAGCUCGGGAUG CAUCCCGAGCUAGGAUGUGUU4031 R-008398344-000L 2000   24 CACAUCCUAGCUCGGGAUGB CACAUCCUAGCUCGGGAUGTT B 4030 R-008398347-000M 2568 1055CUCCAGGUGACAGCAAUCA B CUCCAGGUGACAGCAAUCATT B 4032 R-008398397-000M 25681055 CUCCAGGUGACAGCAAUCA UGAUUGCUGUCACCUGGAGUU 4033 R-008398350-000U1739 1056 CUACCAGUUGUGGUUAAGC GCUUAACCACAACUGGUAGUU 4035R-008398350-000U 1739 1056 CUACCAGUUGUGGUUAAGC B CUACCAGUUGUGGUUAAGCTT B4034 R-008398353-000V 1746 1057 UUGUGGUUAAGCUCUUACAB UUGUGGUUAAGCUCUUACATT B 4036 R-008398353-000V 1746 1057UUGUGGUUAAGCUCUUACA UGUAAGAGCUUAACCACAAUU 4037 R-008398356-000W 13211058 UAGUAAUAAGCCGGCUAUU AAUAGCCGGCUUAUUACUAUU 4039 R-008398356-000W1321 1058 UAGUAAUAAGCCGGCUAUU B UAGUAAUAAGCCGGCUAUUTT B 4038R-008398359-000X  482 1059 CAGUCCUUCACUCAAGAAC GUUCUUGAGUGAAGGACUGUU4041 R-008398359-000X  482 1059 CAGUCCUUCACUCAAGAACB CAGUCCUUCACUCAAGAACTT B 4040 R-008398362-000D  280 1060AGCUGAUUUGAUGGAGUUG CAACUCCAUCAAAUCAGGUUU 4043 R-008398362-000D  2801060 AGCUGAUUUGAUGGAGUUG B AGCUGAUUUGAUGGAGUUGTT B 4042 R-008398365-000E1465 1061 AGGUCUCCUUGGGACUCUU B AGGUCUCCUUGGGACUCUUTT B 4044R-008398365-000E 1465 1061 AGGUCUCCUUGGGACUCUU AAGAGUCCCAAGGAGACCUUU4045 R-008398368-000F 1731 1062 ACUAUGGACUACCAGUUGUACAACUGGUAGUCCAUAGUUU 4047 R-008398368-000F 1731 1062ACUAUGGACUACCAGUUGU B ACUAUGGACUACCAGUUGUTT B 4046 R-008398371-000M 19371063 CAGCAGCAAUUUGUGGAGG B CAGCAGCAAUUUGUGGAGGTT B 4048 R-008398371-000M1937 1063 CAGCAGCAAUUUGUGGAGG CCUCCACAAMAJGCUGCUGUU 4049R-008398374-000N 1892 1064 CGUGCACAUCAGGAUACCC B CGUGCACAUGAGGAUACCCTT B4050 R-008398374-000N 1892 1064 CGUGCACAUCAGGAUACCCGGGUAUCCUGAUGUGCACGUU 4051 R-008398377-000P  836 1065CGUUCUCCUCAGAUGGUGU B CGUUCUCCUCAGAUGGUGUTT B 4052 R-008398377-000P  8361065 CGUUCUCCUCAGAUGGUGU ACACCAUCUGAGGAGAACGUU 4053 R-008398380-000W 521 1066 CAGUAUGCAAUGACUCGAG CUCGAGUCAUUGCAUACUGUU 4055R-008398380-000W  521 1066 CAGUAUGCAAUGACUCGAG B CAGUAUGCAAUGACUCGAGTT B4054 R-008398383-000X 1595 1067 GGUAUAGAGGCUCUUGUGCGCACAAGAGCCUCUAUACCUU 4057 R-008398383-000X 1595 1067GGUAUAGAGGCUCUUGUGC B GGUAUAGAGGCUCUUGUGCTT B 4056 R-008398386-000Y 25111068 AUCCAGUUGAUGGGCUGCC GGCAGCCCAUCAACUGGAUUU 4059 R-008398386-000Y2511 1068 AUCCAGUUGAUGGGCUGCC B AUCCAGUUGAUGGGCUGCCTT B 4058R-008398389-000Z 1583 1069 UGCCAAGUGGGUGGUAUAG B UGCCAAGUGGGUGGUAUAGTT B4060 R-008398389-000Z 1583 1069 UGCCAAGUGGGUGGUAUAGCUAUACCACCCACUUGGCAUU 4061 R-008398392-000F 1897 1070ACAUCAGGAUACCCAGCGC GCGCUGGGUAUCCUGAUGUUU 4063 R-008398392-000F 18971070 ACAUCAGGAUACCCAGCGC B ACAUCAGGAUACCCAGCGCTT B 4062 R-008398395-000G 956 1071 GCCAUCUUUAAGUCUGGAG CUCCAGACUUAAAGAUGGCUU 4065R-008398395-000G  956 1071 GCCAUCUUUAAGUCUGGAG B GCCAUCUUUAAGUCUGGAGTT B4064 R-008398398-000H  926 1072 AACCUUUCCCAUCAUCGUGB AACCUUUCCCAUCAUCGUGTT B 4066 R-008398398-000H  926 1072AACCUUUCCCAUCAUCGUG CACGAUGAUGGGAAAGGUUUU 4067 R-008398401-000A 18741073 CUAGUUCAGUUGCUUGUUC GAACAAGCAACUGAACUAGUU 4069 R-008398101-000A1874 1073 CUAGUUCAGUUGCUUGUUC B CUAGUUCAGUUGCUUGUUCTT B 4068R-008398404-000B  488 1074 UUCACUCAAGAACAAGUAG B UUCACUCAAGAACAAGUAGTT B4070 R-008398404-000B  488 1074 UUCACUCAAGAACAAGUAGCUACUUGUUCUUGAGUGAAUU 4071 R-008398407-000C 1602   21AGGCUCUUGUGCGUACUGU B AGGCUCUUGUGCGUACUGUTT B 4072 R-008398407-000C 1602  21 AGGCUCUUGUGCGUACUGU ACAGUACGCACAAGAGCCUUU 4073 R-008398410-000J1695 1075 AAGAAGCAGAGAUGGCCCA UGGGCCAUCUCUGGUUCUUUU 4075R-008398410-000J 1695 1075 AAGAAGCAGAGAUGGCCCA B AAGAAGCAGAGAUGGCCCATT B4074 R-008398413-000K 2182 1076 UCCUCUGACAGAGUUACUUB UCCUCUGACAGAGUUACUUTT B 4076 R-008398413-000K 2182 1076UCCUCUGACAGAGUUACUU AAGUAACUCUGUCAGAGGAUU 4077 R-008398416-000L 20291077 AAUUGUUAUCAGAGGACUA UAGUCCUCUGAUAACAAUUUU 4079 R-008398416-000L2029 1077 AAUUGUUAUCAGAGGACUA B AAUUGUUAUCAGAGGACUATT B 4078R-008398419-000M  479 1078 UCUCAGUCCUUCACUCAAG B UCUCAGUCCUUCACUCAAGTT B4080 R-008398419-000M  479 1078 UCUCAGUCCUUCACUCAAGCUUGAGUGAAGGACUGAGAUU 4081 R-008398422-000U  818 1079UCCAGACACGCUAUCAUGC GCAUGAUAGCGUGUCUGGAUU 4083 R-008398422-000U  8181079 UCCAGACACGCUAUCAUGC B UCCAGACACGCUAUCAUGCTT B 4082 R-008398425-000V 625 1080 CACUAAUGUCCAGCGUUUG B CACUAAUGUCCAGCGUUUGTT B 4084R-008398425-000V  625 1080 CACUAAUGUCCAGCGUUUG CAAACGCUGGACAUUAGUGUU4085 R-008398428-000W 3172 1181 UUGUAACCUGCUGUGAUACB UUGUAACCUGCUGUGAUACTT B 4086 R-008398428-000W 3172 1081UUGUAACCUGCUGUGAUAC GUAUCACAGCAGGUUACAAUU 4087 R-008398431-000C 14901082 CUUCUGGGUUCAGAUGAUA B CUUCUGGGUUCAGAUGAUATT B 4088 R-008398431-000C1490 1082 CUUCUGGGUUCAGAUGAUA UAUCAUCUGAACCCAGAAGUU 4089R-008398434-000D 1914 1083 GCCGUACGUCCAUGGGUGG B GCCGUACGUCCAUGGGUGGTT B4090 R-008398434-000D 1914 1083 GCCGUACGUCCAUGGGUGGCCACCCAUGGACGUACGGCUU 4091 R-008398437-000E  882  100CAAAUGAUGUAGAAACAGC GCUGUUUCUACAUCAUUUGUU 4093 R-008398437-000E  882 100 CAAAUGAUGUAGAAACAGC B CAAAUGAUGUAGAAACAGCTT B 4092 R-008398440-000L1974 1084 UAGUUGAAGGUUGUACCGG CCGGUACAACCUUCAACUAUU 4095R-008398440-000L 1974 1084 UAGUUGAAGGUUGUACCGG B UAGUUGAAGGUUGUACCGGTT B4094 R-008398443-000M 2258 1085 GAGGACAAGCCACAAGAUUB GAGGACAAGCCACAAGAUUTT B 4096 R-008398443-000M 2258 1085GAGGACAAGCCACAAGAUU AAUCUUGUGGCUUGUCCUCUU 4097 R-008398446-000N 21701086 GGGAGCCACAGCUCCUCUG CAGAGGAGCUGUGGCUCCCUU 4099 R-008398446-000N2170 1086 GGGAGCCACAGCUCCUCUG B GGGAGCCACAGCUCCUCUGTT B 4098R-008398449-000P 1370 1087 CUUCACCUGACAGAUCCAA B CUUCACCUGACAGAUCCAATT B4100 R-008398449-000P 1370 1087 CUUCACCUGACAGAUCCAAUUGGAUCUGUCAGGUGAAGUU 4101 R-008398452-000W 1429 1088UCUUUCAGAUGCUGCAACU B UCUUUCAGAUGCUGCAACUTT B 4102 R-008398452-000W 14291088 UCUUUCAGAUGCUGCAACU AGUUGCAGCAUCUGAAAGAUU 4103 R-008398455-000X3173 1089 UGUAACCUGCUGUGAUACG B UGUAACCUGCUGUGAUACGTT B 4104R-008398455-000X 3173 1089 UGUAACCUGCUGUGAUACG CGUAUCACAGCAGGUUACAUU4105 R-008398458-000Y  444 1090 CCUCCCAAGUCCUGUAUGAB CCUCCCAAGUCCUGUAUGATT B 4106 R-008398458-000Y  444 1090CCUCCCAAGUCCUGUAUGA UCAUACAGGACUUGGGAGGUU 4107 R-008398461-000E 10811091 GGCAGUGCGUUUAGCUGGU B GGCAGUGCGUUUAGCUGGUTT B 4108 R-008398461-000E1081 1091 GGCAGUGCGUUUAGCUGGU ACCAGCUAAACGCACUGCCUU 4109R-098398464-000F 1318 1092 CUCUAGUAAUAAGCCGGCU AGCCGGCUUAUUACUAGAGUU4111 R-008398464-000F 1318 1092 CUCUAGUAAUAAGCCGGCUB CUCUAGUAAUAAGCCGGCUTT B 4110 R-008398467-000G  329 1093GCUGUUAGUCACUGGCAGC B GCUGUUAGUCACUGGCAGCTT B 4112 R-008398467-000G  3291093 GCUGUUAGUCACUGGCAGC GCUGCCAGUGACUAACAGCUU 4113 R-098398470-000N1389 1094 GUCAACGUCUUGUUCAGAA UUCUGAACAAGACGUUGACUU 4115R-008398470-000N 1389 1094 GUCAACGUCUUGUUCAGAA B GUCAACGUCUUGUUCAGAATT B4114 R-008398473-000P  428 1095 GAAGAGGAUGUGGAUACCUAGGUAUCCACAUCCUCUUCUU 4117 R-008398473-000P  428 1095GAAGAGGAUGUGGAUACCU B GAAGAGGAUGUGGAUACCUTT B 4116 R-098398476-000R 31751096 UAACCUGCUGUGAUACGAU AUCGUAUCACAGCAGGUUAUU 4119 R-008398476-000R3175 1096 UAACCUGCUGUGAUACGAU B UAACCUGCUGUGAUACGAUTT B 4118R-008398479-000S 1422  114 UCAGGAAUCUUUCAGAUGC B UCAGGAAUCUUUCAGAUGCTT B4120 R-008398479-000S 1422  114 UCAGGAAUCUUUCAGAUGCGCAUCUGAAAGAUUCCUGAUU 4121 R-008398482-000Y 1500   97CAGAUGAUAUAAAUGUGGU ACCACAUUUAUAUCAUCUGUU 4123 R-008398482-000Y 1500  97 CAGAUGAUAUAAAUGUGGU B CAGAUGAUAUAAAUGUGGUTT B 4122 R-008398485-000Z3117 1097 GUUAUUUGGAACCUUGUUU B GUUAUUUGGAACCUUGUUUTT B 4124R-008398485-000Z 3117 1097 GUUAUUUGGAACCUUGUUU AAACAAGGUUGCAAAUAACUU4125 R-008398488-000A 2020 1098 UCACAACCGAAUUGUUAUCB UCACAACCGAAUUGUUAUCTT B 4126 R-008398488-000A 2020 1098UCACAACCGAAUUGUUAUC GAUAACAAUUCGGUUGUGAUU 4127 R-008398491-000G 16251099 CGGGCUGGUGACAGGGAAG B CGGGCUGGUGACAGGGAAGTT B 4128 R-008398491-000G1625 1099 CUGGCUGGUGACAGGGAAG CUUCCCUGUCACCAGCCCGUU 4129R-008398494-000H 2022 1100 ACAACCGAAUUGUUAUCAG B ACAACCGAAUUGUUAUCAGTT B4130 R-008398494-000H 2022 1100 ACAACCGAAUUGUUAUCAGCUGAUAACAAUUCGGUUGUUU 4131 R-008398497-000J  624 1101CCACUAAUGUCCAGCGUUU B CCACUAAUGUCCAGCGUUUTT B 4132 R-008398497-000J  6241101 CCACUAAUGUCCAGCGUUU AAACGCUGGACAUUAGUGGUU 4133 R-008398500-000B1648 1102 CACUGAGCCUGCCAUCUGU ACAGAUGGCAGGCUCAGUGUU 4135R-008398500-000B 1648 1102 CACUGAGCCUGCCAUCUGU B CACUGAGCCUGCCAUCUGUTT B4134 R-008398503-000C  790 1103 GGUCCAUCAGCUUUCUAAAB GGUCCAUCAGUUUUCUAAATT B 4136 R-008398503-000C  790 1103GGUCCAUCAGCUUUCUAAA UUUAGAAAGCUGAUGGACCUU 4137 R-008398506-000D 2122  59 CUGUGAACUUGCUCAGGAC B CUGUGAACUUGCUCAGGACTT B 4138 R-008398506-000D2122   59 CUGUGAACUUGCUCAGGAC GUCCUGAGCAAGUUCACAGUU 4139R-008398509-000E 3160 1104 AUCCCAAAGUUGUUGUAAC B AUCCCAAAGUUGUUGUAACTT B4140 R-008398509-000E 3160 1104 AUCCCAAAGUUGUUGUAACGUUACAACAACUUUGGGAUUU 4141 R-008398512-000L 1251 1105UGAGGACCUAUACUUACGA B UGAGGACCUAUACUUACGATT B 4142 R-008398512-000L 12511105 UGAGGACCUAUACUUACGA UCGUAAGUAUAUGUCCUCAUU 4143 R-008398518-000N2253 1106 UGUCUGAGGACAAGCCACA UGUGGCUUGUCCUCAGACAUU 4145R-008398518-000N 2253 1106 UGUCUGAGGACAAGCCACA B UGUCUGAGGACAAGCCACATT B4144 R-008398521-000V 2515 1107 AGUUGAUGGGCUGCCAGAUB AGUUGAUGGGCUGCCAGAUTT B 4146 R-008398521-000V 2515 1107AGUUGAUGGGCUGCCAGAU AUCUGGCAGCCCAUCAACUUU 4147 R-008398524-000W 16801108 UGACCAGCCGACACCAAGA B UGACCAGCCGACACCAAGATT B 4148 R-008398524-000W1680 1108 UGACCAGCCGACACCAAGA UCUUGGUGUCGGCUGGUCAUU 4149R-008398527-000X 2169 1109 AGGGAGCCACAGCUCCUCU B AGGGAGCCACAGCUCCUCUTT B4150 R-008398527-000X 2169 1109 AGGGAGCCACAGCUCCUCUAGAUGAGCLGUGGCUCCCUUU 4151 R-008398530-000D 3165 1110AAAGUUGUUGUAACCUGCU AGCAGGUUACAACAACUUUUU 4153 R-008398530-000D 31651110 AAAGUUGUUGUAACCUGCU B AAAGUUGUUGUAACCUGCUTT B 4152 R-008398533-000E 780 1111 CUGGAGUUAUGGUCCAUCA UGAUGGACCAUAACUGCAGUU 4155R-008398533-000E  780 1111 CUGCAGUUAUGGUCCAUCA B CUGCAGUUAUGGUCCAUCATT B4154 R-008398536-000F 1978 1112 UGAAGGUUGUACCGGAGCCB UGAAGGUUGUACCGGAGCCTT B 4156 R-008398536-000F 1978 1112UGAAGGUUGUACCGGAGCC GGCUCCGGUACAACCUUCAUU 4157 R-008398539-000G  661 122 GCUGAAACAUGCAGUUGUA B GCUGAAACAUGCAGUUGUATT B 4158 R-008398539-000G 661  122 GCUGAAACAUGCAGUUGUA UACAACUGCAUGUUUCAGCUU 4159R-008398542-000N 1354  181 AAUGCAAGCUUUAGGACUU B AAUGCAAGCUUUAGGACUUTT B4160 R-008398542-000N 1354  181 AAUGCAAGCUUUAGGACUUAAGUCCUAAAGCUUGCAUUUU 4161 R-008398545-000P  563 1113UUCCCUGAGACAUUAGAUG B UUCCCUGAGACAUUAGAUGTT B 4162 R-008398545-000P  5631113 UUCCCUGAGACAUUAGAUG CAUCUAAUGUCUCAGGGAAUU 4163 R-008398548-000R1622 1114 CUUCGGGCUGGUGACAGGG B CUUCGGGCUGGUGACAGGGTT B 4164R-008398548-000R 1622 1114 CUUCGGGCUGGUGACAGGG CCCUGUCACCAGCCCGAAGUU4165 R-008398551-000X 2295 1115 UUGAGCUGACCAGCUCUCUAGAGAGCUGGUCAGCUCAAUU 4167 R-008398551-000X 2295 1115UUGAGCUGACCAGCUCUCU B UUGAGCUGACCAGCUCUCUTT B 4166 R-008398554-000Y 21261116 GAACUUGCUCAGGACAAGG CCUUGUCCUGAGCAAGUUCUU 4169 R-008398554-000Y2126 1116 GAACUUGCUCAGGACAAGG B GAACUUGCUCAGGACAAGGTT B 4168R-008398557-000Z 1683 1117 CCAGCCGACACCAAGAAGC GCUUCUUGGUGUCGGCUGGUU4171 R-008398557-000Z 1683 1117 CCAGCCGACACCAAGAAGCB CCAGCCGACACCAAGAAGCTT B 4170 R-008398560-000F 1857 1118AGGGUGCCAUUCCACGACU AGUCGUGGAAUGGCACCCUUU 4173 R-008398560-000F 18571118 AGGGUGCCAUUCCACGACU B AGGGUGCCAUUCCACGACUTT B 4172 R-008398563-000G2064 1119 UUGUGCAGCUGCUUUAUUC GAAUAAAGCAGCUGCACAAUU 4175R-008398563-000G 2064 1119 UUGUGCAGCUGCUUUAUUC B UUGUGCAGCUGCUUUAUUCTT B4174 R-008398566-000H 1245   31 AUAUAAUGAGGACCUAUACGUAUAGGUCCUCAUUAUAUUU 4177 R-008398566-000H 1245   31AUAUAAUGAGGACCUAUAC B AUAUAAUGAGGACCUAUACTT B 4176 R-008398569-000J  4891120 UCACUCAAGAACAAGUAGC B UCACUCAAGAACAAGCAGCTT B 4178 R-008398569-000J 489 1120 UCACUCAAGAACAAGUAGC GCUACUUGUUCUUGAGUGAUU 4179R-008398572-000R 1346 1121 GCUGGUGGAAUGCAAGCUU B CCUGGUGGAAUGCAAGCUUTT B4180 R-008398572-000R 1346 1121 GCUGGUGGAAUGCAAGCUUAAGCUUGCAUUCCACCAGCUU 4181 R-008398575-000S 1442 1122GCAACUAAACAGGAAGGGA UCCCUUCCUGUUUAGUUGCUU 4183 R-008398575-000S 14421122 GCAACUAAAAGGAAGGGA B GCAACUAAACAGGAAGGGATT B 4182 R-008398578-000T1981 1123 AGGUUGUACCGGAGCCCUU B AGGUUGUACCGGAGCCCUUTT B 4184R-008398578-000T 1981 1123 AGGUUGUACCGGAGCCCUU AAGGGCUCCGGUACAACCUUU4185 R-008398581-000Z  777 1124 AGGCUGCAGUUAUGGUCCAUGGACCAUAACUGCAGCGUUU 4187 R-008398581-000Z  777 1124AGGCUGCAGUUAUGGUCCA B AGGCUGCAGUUAUGGUCCATT B 4186 R-008398584-000A  5891125 GCAGAUCCCAUCUACACAG CUGUGUAGAUGGGAUCUGCUU 4189 R-008398584-000A 589 1125 GCAGAUCCCAUCUACACAG B GCAGAUCCCAUCUACACAGTT B 4188R-008398587-000B 2205 1126 CUAGGAAUGAAGGUGUGGC GCCACACCUUCAUUCCUAGUU4191 R-008398587-000B 2205 1126 CUAGGAAUGAAGGUGUGGCB CUAGGAAUGAAGGUGUGGCTT B 4190 R-008398590-000H  394 1127AGCUCCUUCUCUGAGUGGU B AGCUCCUUCUCUGAGUGGUTT B 4192 R-008398590-000H  3941127 AGCUCCUUCUCUGAGUGGU ACCACUCAGAGAAGGAGCUUU 4193 R-008398593-000J1035 1128 UUACAACUCUCCACAACCU B UUACAACUCUCCACAACCUTT B 4194R-008398593-000J 1035 1128 UUACAACUCUCCACAACCU AGGUUGUGGAGAGUUGUAAUU4195 R-008398605-000E  410 1129 GGUAAAGGCAAUCCUGAGGB GGUAAAGGCAAUCCUGAGGTT B 4196 R-008398605-000E  410 1129GGUAAAGGCAAUCCUGAGG CCUCAGGAUUGCCUUUACCUU 4197 R-008398608-000F 17211130 GUUCGCCUUCACUAUGGAC GUCCAUAGUGAAGGCGAACUU 4199 R-008398608-000F1721 1130 GUUCGCCUUCACUAUGGAC B GUUCGCCUUCACUAUGGACTT B 4198R-008398611-000M 1134 1131 CAAAUGUUAAAUUCUUGGC GCCAAGAAUUUAACAUUUGUU4201 R-008398611-000M 1134 1131 CAAAUGUUAAAUUCUUGGCB CAAAUGUUAAAUUCUUGGCTT B 4200 R-008398614-000N 3182 1132CUGUGAUACGAUGCUUCAA B CUGUGAUACGAUGCUUCAATT B 4202 R-008398614-000N 31821132 CUGUGAUACGAUGCUUCAA UUGAAGCAUCGUAUCACAGUU 4203 R-008398617-000P 881 1133 ACAAAUGAUGUAGAAACAG B ACAAAUGAUGUAGAAACAGTT B 4204R-008398617-000P  881 1133 ACAAAUGAUGUAGAAACAG CUGUUUCUACAUCAUUUGUUU4205 R-008398620-000W  547 1134 GGUACGAGCUGCUAUGUUCGAACAUAGCAGCUCGUACCUU 4207 R-008398620-000W  547 1134GGUACGAGCUGCUAUGUUC B GGUACGAGCUGCUAUGUUCTT B 4206 R-008398623-000X 20281135 GAAUUGUUAUCAGAGGACU AGUCCUCUGAUAACAAUUCUU 4209 R-008398623-000X2028 1135 GAAUUGUUAUCAGAGGACU B GAAUUGUUAUCAGAGGACUTT B 4208R-008398629-000Z 2023 1136 CAACCGAAUUGUUAUCAGA B CAACCGAAUUGUUAUCAGATT B4210 R-008398629-000Z 2023 1136 CAACCGAAUUGUUAUCAGAUCUGAUAACAAUUCGGUUGUU 4211 R-008398632-000F 3184 1137GUGAUACGAUGCUUCAAGA B GUGAUACGAUGCUUCAAGATT B 4212 R-008398632-000F 31841137 GUGAUACGAUGCUUCAAGA UCUUGAAGCAUCGUAUCACUU 4213 R-008398635-000G 413 1138 AAAGGCAAUCCUGAGGAAG CUUCCUCAGGAUUGCCUUUUU 4215R-008398635-000G  413 1138 AAAGGCAAUCCUGAGGAAG B AAAGGCAAUCCUGAGGAAGTT B4214 R-008398638-000H 2178 1139 CAGCUCCUCUGACAGAGUUB CAGCUCCUCUGACAGAGUUTT B 4216 R-008398638-000H 2178 1139CAGCUCCUCUGACAGAGUU AACUCUGUCAGAGGAGCUGUU 4217 R-008398641-000P  618 143 CUCAUCCCACUAAUGUCCA B CUCAUCCCACUAAUGUCCATT B 4218 R-008398641-000P 618  143 CUCAUCCCACUAAUGUCCA UGGACAUUAGUGGGAUGAGUU 4219R-008398644-000R 1577 1140 AUGGUCUGCCAAGUGGGUG B AUGGUCUGCCAAGUGGGUGTT B4220 R-008398644-000R 1577 1140 AUGGUCUGCCAAGUGGGUGCACCCACUUGGCAGACCAUUU 4221 R-008398647-000S 1793 1141GCUACUGUUGGAUUGAUUC GAAUCAAUCCAACAGUAGCUU 4223 R-008398647-000S 17931141 GCUACUGUUGGAUUGAUUC B GCUACUGUUGGAUUGAUUCTT B 4222 R-008398650-000Y 526 1142 UGCAAUGACUCGAGCUCAG B UGCAAUGACUCGAGCUCAGTT B 4224R-008398650-000Y  526 1142 UGCAAUGACUCGAGCUCAG CUGAGCUCGAGUCAUUGCAUU4225 R-008398653-000Z 2358 1143 GACUUGAUAUUGGUGCCCAUGGGCACCAAUAUCAAGUCUU 4227 R-008398653-000Z 2358 1143GACUUGAUAUUGGUGCCCA B GACUUGAUAUUGGUGCCCATT B 4226 R-008398656-000A  852  11 UGUCUGCUAUUGUACGUAC B UGUCUGCUAUUGUACGUACTT B 4228 R-008398656-000A 852   11 UGUCUGCUAUUGUACGUAC GUACGUACAAUAGCAGACAUU 4229R-008398659-000B 1403 1144 CAGAACUGUCUUUGGACUC GAGUCCAAAGACAGUUCUGUU4231 R-008398659-000B 1403 1144 CAGAACUGUCUUUGGACUCB CAGAACUGUCUUUGGACUCTT B 4230 R-008398662-000H 1875 1145UAGUUCAGUUGCUUGUUCG CGAACAAGCAACUGAACUAUU 4233 R-008398662-000H 18751145 UAGUUCAGUUGCUUGUUCG B UAGUUCAGUUGCUUGUUCGTT B 4232 R-008398665-000J1160 1146 ACAGACUGCCUUCAAAUUU B ACAGACUGCCUUCAAAUUUTT B 4234R-008398665-000J 1160 1146 ACAGACUGCCUUCAAAUUU AAAUUUGAAGGCAGUCUGUUU4235 R-008398668-000K 1591 1147 GGGUGGUAUAGAGGCUCUUAAGAGCCUCUAUACCACCCUU 4237 R-008398668-000K 1591 1147GGGUGGUAUAGAGGCUCUU B GGGUGGUAUAGAGGCUCUUTT B 4236 R-008398671-000S 17341148 AUGGACUACCAGUUGUGGU B AUGGACUACCAGUUGUGGUTT B 4238 R-008398671-000S1734 1148 AUGGACUACCAGUUGUGGU ACCACAACUGGUAGUCCAUUU 4239R-008398674-000T 2030 1149 AUUGUUAUCAGAGGACUAA UUAGUCCUCUGAUAACAAUUU4241 R-008398674-000T 2030 1149 AUUGUUAUCAGAGGACUAAB AUUGUUAUCAGAGGACUAATT B 4240 R-008398677-000U  775 1150UAAGGCUGCAGUUAUGGUC GACCAUAACUGCAGCCUUAUU 4243 R-008398677-000U  7751150 UAAGGCUGCAGUUAUGGUC B UAAGGCUGCAGUUAUGGUCTT B 4242 R-008398680-000A1813 1151 AAAUCUUGCCCUUUGUCCC GGGACAAAGGGCAAGAUUUUU 4245R-008398680-000A 1813 1151 AAAUCUUGCCCUUUGUCCC B AAAUCUUGCCCUUUGUCCCTT B4244 R-008398683-000B 1938 1152 AGCAGCAAUUUGUGGAGGGB AGCAGCAAUUUGUGGAGGGTT B 4246 R-008398683-000B 1938 1152AGCAGCAAUUUGUGGAGGG CCCUCCACAAAUUGGUGCUUU 4247 R-008398686-000C 20391153 AGAGGACUAAAUACCAUUC B AGAGGACUAAAUACCAUUCTT B 4248 R-008398686-000C2039 1153 AGAGGACUAAAUACCAUUC GAAUGGUAUUUAGUCCUCUUU 4249R-008398689-000D 1297 1154 GCUGAAGGUGCUAUCUGUC B GCUGAAGGUGCUAUCUGUCTT B4250 R-008398689-000D 1297 1154 GCUGAAGGUGCUAUCUGUCGACAGAUAGCACCUUCAGCUU 4251 R-008398692-000K  456 1155UGUAUGAGUGGGAACAGGG CCCUGUUCCCACUCAUACAUU 4253 R-008398692-000K  4561155 UGUAUGAGUGGGAACAGGG B UGUAUGAGUGGGAACAGGGTT B 4252 R-008398695-000L 869   51 ACCAUGCAGAAUACAAAUG B ACCAUGCAGAAUACAAAUGTT B 4254R-008398695-000L  869   51 ACCAUGCAGAAUACAAAUG CAUUUGUAUUCUGCAUGGUUU4255 R-008398698-000M  590 1156 CAGAUCCCAUCUACACAGUB CAGAUCCCAUCUACACAGUTT B 4256 R-008398698-000M  590 1156CAGAUCCCAUCUACACAGU ACUGUGUAGAUGGGAUCUGUU 4257 R-008398701-000E 19331157 GACACAGCAGCAAUUUGUG B GACACAGCAGCAAUUUGUGTT B 4258 R-008398701-000E1933 1157 GACACAGCAGCAAUUUGUG CACAAAUUGCUGCUGUGUCUU 4259R-008398704-000F  583 1158 GGGCAUGCAGAUCCCAUCU AGAUGGGAUCUGCAUGCCCUU4261 R-008398704-000F  583 1158 GGGCAUGCAGAUCCCAUCUB GGGCAUGCAGAUCCCAUCUTT B 4260 R-008398707-000G 2540 1159CAUGCCCAGGACCUCAUGG B CAUGCCCAGGACCUCAUGGTT B 4262 R-008398707-000G 25401159 CAUGCCCAGGACCUCAUGG CCAUGAGGUCCUGGGCAUGUU 4263 R-008398710-000N2162 1160 GAAGCUGAGGGAGCCACAG B GAAGCUGAGGGAGCCACAGTT B 4264R-008398710-000N 2162 1160 GAAGCUGAGGGAGCCACAG CUGUGGCUCCCUCAGCUUCUU4265 R-008398713-000P  330 1161 CUGUUAGUCACUGGCAGCAB CUGUUAGUCACUGGCAGCATT B 4266 R-008398713-000P  330 1161CUGUUAGUCACUGGCAGCA UGCUGCCAGUGACUAACAGUU 4267 R-008398716-000R 14811162 CUUGUUCAGCUUCUGGGUU B CUUGUUCAGCUUCUGGGUUTT B 4268 R-008398716-000R1481 1162 CUUGUUCAGCUUCUGGGUU AACCCAGAAGCUCAACAAGUU 4269R-008398719-000S 1612   22 GCGUACUGUCCUUCGGGCU AGCCCGAAGGACAGUACGCUU4271 R-008398719-000S 1612   22 GCGUACUGUCCUUCGGGCUB GCGUACUGUCCUUCGGGCUTT B 4270 R-008398722-000Y 1709    3GCCCAGAAUGCAGUUCGCC GGCGAACUGCAUUCUGGGCUU 4273 R-008398722-000Y 1709   3 GCCCAGAAUGCAGUUCGCC B GCCCAGAAUGCAGUUCGCCTT B 4272 R-008398725-000Z1344 1163 AAGCUGGUGGAAUGCAAGC GCUUGCAUUCCACCAGCUUUU 4275R-008398725-000Z 1344 1163 AAGCUGGUGGAAUGCAAGC B AAGCUGGUGGAAUGCAAGCTT B4274 R-008398728-000A  431 1164 GAGGAUGUGGAUACCUCCCGGGAGGUAUCCACAUCCUCUU 4277 R-008398728-000A  431 1164GAGGAUGUGGAUACCUCCC B GAGGAUGUGGAUACCUCCCTT B 4276 R-008398731-000G 15081165 AUAAAUGUGGUCACCUGUG CACAGGUGACCACAUUUAUUU 4279 R-008398731-000G1508 1165 AUAAAUGUGGUCACCUGUG B AUAAAUGUGGUCACCUGUGTT B 4278R-008398734-000H 1918 1166 UACGUCCAUGGGUGGGACA B UACGUCCAUGGGUGGGACATT B4280 R-008398734-000H 1918 1166 UACGUCCAUGGGUGGGACAUGUCCCACCCAUGGACGUAUU 4281 R-008398737-000J  289 1167GAUGGAGUUGGACAUGGCC UGCCAUGUCCAACUCCAUCUU 4283 R-008398737-000J  2891167 GAUGUAGUUGGACAUGGCC B GAUGGAGUUGGACAUGGCCTT B 4282 R-008398740-000R 631 1168 UGUCCAGCGUUUGGCUGAA B UGUCCAGCGUUUGGCUGAATT B 4284R-008398740-000R  631 1168 UGUCCAGCGUUUGGCUGAA UUCAGCCAAACGCUGGACAUU4285 R-008398743-000S 1642   60 AGACAUCACUGAGCCUGCCB AGACAUCACUGAGCCUGCUTT B 4286 R-008398743-000S 1642   60AGACAUCACUGAGCCUGCC GGCAGGCUCAGUGAUGUCUUU 4287 R-008398746-000T 18531169 GAGCAGGGUGCCAUUCCAC B GAGCAGGGUGCCAUUCCACTT B 4288 R-008398746-000T1853 1169 GAGCAGGGUGCCAUUCCAC GUGGAAUGGCACCCUGCUCUU 4289R-008398749-000U 1243 1170 AAAUAUAAUGAGGACCUAU AUAGGUCCUCAUUAUAUUUUU4291 R-008398749-000U 1243 1170 AAAUAUAAUGAGGACCUAUB AAAUAUAAUGAGGACCUAUTT B 4290 R-008398752-000A 1212 1171UACUGGCUAGUGGUGGACC GGUCCACCACUAGCCAGUAUU 4293 R-008398752-000A 12121171 UACUGGCUAGUGGUGGACC B UACUGGCUAGUGGUGGACCTT B 4292 R-008398755-000B 996 1172 UGCUUGGUUCACCAGUGGA UCCACUGGUGAACCAAGCAUU 4295R-008398755-000B  996 1172 UGCUUGGUUCACCAGUGGA B UGCUUGGUUCACCAGUGGATT B4294 R-008398758-000C 2256 1173 CUGAGGACAAGCCACAAGAB CUGAGGACAAGCCACAAGATT B 4296 R-008398758-000C 2256 1173CUGAGGACAAGCCACAAGA UCUUGUGGCUUGUCCUCAGUU 4297 R-008398761-000J 16071174 CUUGUGCGUACUGUCCUUC GAAGGACAGUACGCACAAGUU 4299 R-008398761-000J1607 1174 CUUGUGCGUACUGUCCUUC B CUUGUGCGUACUGUCCUUCTT B 4298R-008398764-000K 3116 1175 UGUUAUUUGGAACCUUGUU B UGUUAUUUGGAACCUUGUTTT B4300 R-008398764-000K 3116 1175 UGUUAUUUGGAACCUUGUUAACAAGGUUCCAAAUAACAUU 4301 R-008398767-000L 1179 1176UAGCUUAUGGCAACCAAGA UCUUGGUUGCCAUAAGCUAUU 4303 R-008398767-000L 11791176 UAGCUUAUGGCAACCAAGA B UAGCUUAUGGCAACCAAGATT B 4302 R-008398770-000T3185 1177 UGAUACCAUGCUUCAAGAG CUCUUGAAGCAUCGUAUCAUU 4305R-008398770-000T 3185 1177 UGAUACCAUGCUUCAAGAG B UGAUAGCAUGCUUCAAGAGTT B4304 R-008398773-000U 1594 1178 UGGUAUAGAGGCUCUUGUGCACAAGAGCCUCUAUACCAUU 4307 R-008398773-000U 1594 1178UGGUAUAGAGGCUCUUGUG B UGGUAUAGAGGCUCUUGUGTT B 4306 R-008398776-000V  8871179 GAUGUAGAAACAGCUCGUG B GAUGUAGAAACAGCUCGUUTT B 4308 R-008398776-000V 887 1179 GAUGUAGAAACAGCUCGUG AACGAGCUGUUUCUACAUCUU 4309R-008398779-000W  928 1180 CCUUUCCCAUCAUCGUGAG B CCUUUCCCAUCAUCGUGAGTT B4310 R-008398779-000W  928 1180 CCUUUCCCAUCAUCGUGAGCUCACGAUGAUGGGAAAGGUU 4311 R-008398782-000C  835 1181GCGUUCUCCUCAGAUGGUG CACCAUCUGAGGAGAACGCUU 4313 R-008398782-000C  8351181 GCGUUCUCCUCAGAUGGUG B GCGUUCUCCUCAGAUGGUGTT B 4312 R-008398785-000D1900 1182 UCAGGAUACCCAGCGCCGU B UCAGGAUACCCAGCGCCGUTT B 4314R-008398785-000D 1900 1182 UCAGGAUACCCAGCGCCGU ACGGCGCUGGGUAUCCUGAUU4315 R-008398788-000E 2284 1183 ACGGCUUUCAGUUGAGCUGB ACGGCUUUCAGUUGAGCUGTT B 4316 R-008398788-000E 2284 1183ACGGCUUUCAGUUGAGCUG CAGCUCAACUGAAAGCCGUUU 4317 R-008398791-000L 19761184 GUUGAAGGUUGUACCGGAG CUCCGGUACAACCUUCAACUU 4319 R-008398791-000L1976 1184 GUUGAAGGUUGUACCGGAG B GUUGAAGGUUGUACCGGAGTT B 4318R-008398794-000M 2393 1185 UAUCGCCAGGAUGAUCCUA B UAUCGCCAGGAUGAUCCUATT B4320 R-008398794-000M 2393 1185 UAUCGCCAGGAUGAUCCUAUAGGAUGCCAGGAUGAUCCUATT B 4321 R-008398797-000N 1295 1186GUGCUGAAGGUGCUAUCUG B GUGCUGAAGGUGCUAUCUGTT B 4322 R-008398797-000N 12951186 GUGCUGAAGGUGCUAUCUG CAGAUAGCACCUUCAGCACUU 4323 R-008398800-000F1410 1187 GUCUUUGGACUCUCAGGAA UUCCUGAGAGUCCAAAGACUU 4325R-008398800-000F 1410 1187 GUCUUUGGACUCUCAGGAA B GUCUUUGGACUCUCAGGAATT B4324 R-008398803-000G 1457 1188 GGGAUGGAAGGUCUCCUUGB GGGAUGGAAGGUCUCCUUGTT B 4326 R-008398803-000G 1457 1188GGGAUGGAAGGUCUCCUUG CAAGGAGACCUUCCAUCCCUU 4327 R-008398806-000H 22961189 UGAGCUGACCAGCUCUCUC B UGAGCUGACCAGCUCUCUCTT B 4328 R-008398806-000H2296 1189 UGAGCUGACCAGCUCUCUC GAGAGAGCUGGUCAGCUCAUU 4329R-008398809-000J  929 1190 CUUUCCCAUCAUCGUGAGG CCUCACGAUGAUGGGAAAGUU4331 R-008398809-000J  929 1190 CUUUCCCAUCAUCGUGAGGB CUUUCCCAUCAUCGUGAGGTT B 4330 R-008398812-000R 1359 1191AAGCUUUAGGACUUCACCU B AAGCUUUAGGACUUCACCUTT B 4332 R-008398812-000R 13591191 AAGCUUUAGGACUUCACCU AGGUGAAGUCCUAAAGCUUUU 4333 R-008398815-000S1351 1192 UGGAAUGCAAGCUUUAGGA B UGGAAUGCAAGCUUUAGGATT B 4334R-008398815-000S 1351 1192 UGGAAUGCAAGCUUUAGGA UCCUAAAGCUUGCAUUCCAUU4335 R-008398818-000T  969 1193 CUGGAGGCAUUCCUGCCCUB CUGGAGGCAUUCCUGCCCUTT B 4336 R-008398818-000T  969 1193CUGGAGGCAUUCCUGCCCU AGGGCAGGAAUGCCUCCAGUU 4337 R-008398821-000Z 18761194 AGUUCAGUUGGUUGUUCGU ACGAAGAAGCAACUGAACUUU 4339 R-008398821-000Z1876 1194 AGUUCAGUUGCUUGUUCGU B AGUUCAGUUGCUUGUUCGUTT B 4338R-008398824-000A  552 1195 GAGCUGCUAUGUUCCCUGA B GAGCUGCUAUGUUCCCUGATT B4340 R-008398824-000A  552 1195 GAGCUGCUAUGUUCCCUGAUCAGGGAACAUAGCAGCUCUU 4341 R-008398827-000B 2441 1196GGCCAGGAUGCCUUGGGUA B GGCCAGGAUGCCUUGGGUATT B 4342 R-008398827-000B 24411196 GGCCAGGAUGCCUUGGGUA UACCCAAGGCAUCCUGGCCUU 4343 R-008398830-000H2402 1197 GAUGAUCCUAGCUAUCGUU B GAUGAUCCUAGGUAUCGUUTT B 4344R-008398830-000H 2402 1197 GAUGAUCCUAGCUAUCGUU AACGAUAGCUAGGAUCAUCUU4345 R-008398833-000J 1803 1198 GAUUGAUUCGAAAUCUUGCGCAAGAUUUCGAAUCAAUCUU 4347 R-008398833-000J 1803 1198GAUUGAUUCGAAAUCUUGC B GAUUGAUUCGAAAUCUUGCTT B 4346 R-008398836-000K  1011199 CAGAGAUGGCCCAGAAUGC B CAGAGAUGGCCCAGAAUGCTT B 4348 R-008398836-000K1701 1199 CAGAGAUGGCCCAGAAUGC GCAUUCUGGGCCAUCUCUGUU 4349R-008398839-000L 1910 1200 CAGCGCCGUACGUCCAUGG CCAUGGACGUAUGGCGCUGUU4351 R-008398839-000L 1910 1200 CAGCGCCGUACGUCCAUGGB CAGCGCCGUACGUCCAUGGTT B 4350 R-008398842-000T  888 1201AUGUAGAAACAGCUCGUUG CAACGAGCUGUUUCUACAUUU 4353 R-008398842-000T  8881201 AUGUAGAAACAGCUCGUUG B AUGUAGAAACAGCUCGUUGTT B 4352 R-008398845-000U1294 1202 AGUGCUGAAGGUGCUAUCU AGAUAGCACCUUCAGCACUUU 4355R-008398845-000U 1294 1202 AGUGCUGAAGGUGCUAUCU B AGUGCUGAAGGUGCUAUCUTT B4354 R-008398898-000V 1737 1203 GACUACCAGUUGUGGUUAAUUAACCACAACUGGUAGUCUU 4357 R-008398848-000V 1737 1203GACUACCAGUUGUGGUUAA B GACUACCAGULGUGGUUAATT B 4356 R-008398851-000B 14501204 ACAGGAAGGGAUGGAAGGU B ACAGGAAGGGAUGGAAGGUTT B 4358 R-008398851-000B1450 1204 ACAGGAAGGGAUGGAAGGU ACCUUCCAUCCCUUCCUGUUU 4359R-008398854-000C  761 1205 CAGGUGGUGGUUAAUAAGG CCUUAUUAACCACCACCUGUU4361 R-008398854-000C  761 1205 CAGGUGGUGGUUAAUAAGGB CAGGCUGUGGUUAAUAAGGTT B 4360 R-008398857-000D  776 1206AAGGCUGCAGUUAUGGUCC B AAGGCUGCAGUUAUGGUCCTT B 4362 R-008398857-000D  7761206 AAGGCUGCAGUUAUGGUCC GGACCAUAACUGCAGCCUUUU 4363 R-008398860-000K1509 1207 UAAAUGUGGUCACCUGUGC GCACAGGUGACCACAUUUAUU 4365R-008398860-000K 1509 1207 UAAAUGUGGUCACCUGUGC B UAAAUGUGGUCACCUGUGCTT B4364 R-008398863-000L 1788 1208 UAAAGGCUACUGUUGGAUUB UAAAGGCUACUGUUGGAUUTT B 4366 R-008398863-000L 1788 1208UAAAGGCUACUGUUGGAUU AAUCCAACAGUAGCCUUUAUU 4367 R-008398866-000M  5151209 GAUGGACAGUAUGCAAUGA UCAUUGCAUACUGUCCAUCUU 4369 R-008398866-000M 515 1209 GAUGGACAGUAUGCAAUGA B GAUGGACAGUAUGCAAUGATT B 4368R-008398869-000N 1491 1210 UUCUGGGUUCAGAUGAUAU B UUCUGGGUUCAGAUGAUAUTT B4370 R-008398869-000N 1491 1210 UUCUGGGUUCAGAUGAUAUAUAUCAUCUGAACCCAGAAUU 4371 R-008398872-000V 1614 1211GUACUGUCCUUCGGGCUGG B GUACUGUCCUUCGGGCUGGTT B 4372 R-008398872-000V 16141211 GUACUGUCCUUCGGGCUGG CCAGCCCGAAGGACAGUACUU 4373 R-008398875-000W 998 1212 CUUGGUUCACCAGUGGAUU B CUUGGUUCACCAGUGGAUUTT B 4374R-008398875-000W  998 1212 CUUGGUUCACCAGUGGAUU AAUCCACUGGUGAACCAAGUU4375 R-008398878-000X 2158 1213 UAUUGAAGCUGAGGGAGCCB UAUUGAAGCUGAGGGAGCCTT B 4376 R-008398878-000X 2158 1213UAUUGAAGCUGAGGGAGCC GGCUCCCUCAGCUUCAAUAUU 4377 R-008398881-000D 31681214 GUUGUUGUAACCUGCUGUG B GUUGUUGUAACCUGCUGUGTT B 4378 R-008398881-000D3168 1214 GUUGUUGUAACCUGCUGUG CACAGCAGGUUACAACAACUU 4379R-008398884-000E 1854 1215 AGCAGGGUGCCAUUCCACG B AGCAGGGUGCCAUUCCACUTT B4380 R-008398884-000E 1854 1215 AGCAGGGUGCCAUUCCACGCGUGGAAUGGCACCCUGCUUU 4381 R-008398887-000F 2117 1216GUCCUCUGUGAACUUGCUC GAGCAAGUUCACAGAGGACUU 4383 R-008398887-000F 21171216 GUCCUCUGUGAACUUGCUC B GUCCUCUGUGAACUUGCUCTT B 4382 R-008398890-000M1678 1217 UCUGACCAGCCGACACCAA UUGGUGUCGGCUGGUCAGAUU 4385R-008398890-000M 1678 1217 UCUGACCAGCCGACACCAA B UCUGACCAGCCGACACCAATT B4384 R-008398893-000N 2159   63 AUUGAAGCUGAGGGAGCCAB AUUGAAGCUGAGGGAGCCATT B 4386 R-008398893-000N 2159   63AUUGAAGCUGAGGGAGCCA UGGCUCCCUCAGCUUCAAUUU 4387 R-008398896-000P  3051218 GCCAUGGAACCAGACAGAA UUCUGUCUGGUUCCAUGGCUU 4389 R-008398896-000P 305 1218 GCCAUGGAACCAGACAGAA B GCCAUGGAACCAGACAGAATT B 4388R-008398899-000R 2154 1219 AAGCUAUUGAAGCUGAGGG B AAGCUAUUGAAGCUGAGGGTT B4390 R-008398899-000R 2154 1219 AAGCUAUUGAAGCUGAGGGCCCUCAGCUUCAAUAGCUUUU 4391 R-008398902-000H 1807 1220GAUUCGAAAUCUUGCCCUU B GAUUCGAAAUCUUGCCCUUTT B 4392 R-008398902-000H 18071220 GAUUCGAAAUCUUGCCCUU AAGGGCAAGAUUUCGAAUCUU 4393 R-008398905-000J1881 1221 AGUUGCUUGUUCGUGCACA B AGUUGCUUGUUCGUGCACATT B 4394R-008398905-000J 1881 1221 AGUUGCUUGUUCGUGCACA UGUGCACGAACAAGCAACUUU4395 R-008398908-000K 1565 1222 AAGAACAAGAUGAUGGUCUB AAGAACAAGAUGAUGGUCUTT B 4396 R-008398908-000K 1565 1222AAGAACAAGAUGAUGGUCU AGACCAUCAUCUUGUUCUUUU 4397 R-008398911-000S  4071223 AGUGGUAAAGGCAAUCCUG B AGUGGUAAAGGCAAUCCUGTT B 4398 R-008398911-000S 407 1223 AGUGGUAAAGGCAAUCCUG CAGGAUUGCCUUUACCACUUU 4399R-008398914-000T 1434 1224 CAGAUGCUGCAACUAAACA UGUUUAGUUGCAGCAUCUGUU4401 R-008398914-000T 1434 1224 CAGAUGCUGCAACUAAACAB CAGAUGCUGCAACUAAACATT B 4400 R-008398917-000U  566 1225CCUGAGACAUUAGAUGAGG B CCUGAGACAUUAGAUGAGGTT B 4402 R-008398917-000U  5661225 CCUGAGACAUUAGAUGAGG CCUCAUCUAAUGUCUCAGGUU 4403 R-008398920-000A3161 1226 UCCCAAAGUUGUUGUAACC GGUUACAACAACUUUGGGAUU 4405R-008398920-000A 3161 1226 UCCCAAAGUUGUUGUAACC B UCCCAAAGUUGUUGUAACCTT B4404 R-008398923-000B  666  117 AACAUGCAGUUGUAAACUUAAGUUUACAACUGCAUGUUUU 4407 R-008398923-000B  666  117AACAUGCAGUUGUAAACUU B AACAUGCAGUUGUAAACUUTT B 4406 R-008398926-000C  848  98 AUGGUGUCUGCUAUUGUAC GUACAAUAGCAGACACCAUUU 4409 R-008398926-000C 848   98 AUGGUGUCUGCUAUUGUAC B AUGGUGUCUGCUAUUGUACTT B 4408R-008398929-000D 1679 1227 CUGACCAGCCGACACCAAG B CUGACCAGCCGACACCAAGTT B4410 R-008398929-000D 1679 1227 CUGACCAGCCGACACCAAGCUUGGUGUCGGCUGGUCAGUU 4411 R-008398932-000K 2096 1228AUCCAAAGAGUAGCUGCAG B AUCCAAAGAGUAGCUGCAGTT B 4412 R-008398932-000K 20961228 AUCCAAAGAGUAGCUGCAG CUGCAGCUACUCUUUGGAUUU 4413 R-008398935-000L 630 1229 AUGUCCAGCGUUUGGCUGA B AUGUCCAGCGUUUGGCUGATT B 4414R-008398935-000L  630 1229 AUGUCCAGCGUUUGGCUGA UCAGCCAAACGCUGGACAUUU4415 R-008398938-000M 1606 1230 UCUUGUGCGUACUGUCCUUAAGGACAGUACGCACAAGAUU 4417 R-008398938-000M 1606 1230UCUUGUGCGUACUGUCCUU B UCUUGUGCGUACUGUCCUUTT B 4416 R-008398941-000U  4321231 AGGAUGUGGAUACCUCCCA UGGGAGGUAUCCACAUCCUUU 4419 R-008398941-000U 432 1231 AGGAUGUGGAUACCUCCCA B AGGAUGUGGAUACCUCCCATT B 4418R-008398994-000V  778 1232 GGCUGCAGUUAUGGUCCAU B GGCUGCAGUUAUGGUCCAUTT B4420 R-008398944-000V  778 1232 GGCUGCAGUUAUGGUCCAUAUGGACCAUAALUGCAGCCUU 4421 R-008398947-000W 1999 1233UCACAUCCUAGCUCGGGAU B UCACAUCCUAGCUCGGGAUTT B 4422 R-008398947-000W 19991233 UCACAUCCUAGCUCGGGAU AGCCCGAGCUAGGAUGUGAUU 4423 R-008398950-000C1692 1234 ACCAAGAAGCAGAGAUGGC GCCAUCUCUGCUUCUUGGUUU 4425R-008398950-000C 1692 1234 ACCAAGAAGCAGAGAUGGC B ACCAAGAAGCAGAGAUGGCTT B4424 R-008398953-000D 2490 1235 GCCACCACCGUGGUGCUGAB GCCACCACCCUGGUGCUGATT B 4426 R-008398953-000D 2490 1235GCCACCACCCUGGUGGUGA UCAGCACCAGGGUGGUGGCUU 4427 R-008398956-000E  6231236 CCCACUAAUGUCCAGCGUU AACGCUGGACAUUAGUGGGUU 4429 R-008398956-000E 623 1236 CCCACUAAUGUCCAGCGUU B CCCACUAAUGUCCAGCGUUTT B 4428R-008398959-000F  339 1237 ACUGGCAGCAACAGUCUUA B ACUGGCAGCAACAGUCUUATT B4430 R-008398959-000F  339 1237 ACUGGCAGCAACAGUCUUAUAAGACUGUUGCUGCCAGUUU 4431 R-008398962-000M 2471  166AUGGAACAUGAGAUGGGUG CACCCAUCUCAUGUUCCAUUU 4433 R-008398962-000M 2471 166 AUGGAACAUGAGAUGGGUG B AUGGAACAUGAGAUGGGUGTT B 4432 R-008398965-000N2037  164 UCAGAGGACUAAAUACCAU AUGGUAUUUAGUCCUCUGAUU 4435R-008398965-000N 2037  164 UCAGAGGACUAAAUACCAU B UCAGAGGACUAAAUACCAUTT B4434 R-008398968-000P  912  179 CUGGGACCUUGCAUAACCUAGGUUAUGCAAGGUCCCAGUU 4437 R-008398968-000P  912  179CUGGGACCUUGCAUAACCU B CUGGGACCUUGCAUAACCUTT B 4436 R-008398971-000W 29461238 AUCUGAAUAAAGUGUAACA B AUCUGAAUAAAGUGUAACATT B 4438 R-008398971-000W2946 1238 AUCUGAAUAAAGUGUAACA UGUUACACUUUAUUCAGAUUU 4439R-008398974-000X 1654 1239 GCCUGCCAUCUGUGCUCUU AAGAGCACAGAUGGCAGGCUU4441 R-008398974-000X 1654 1239 GCCUGCCAUCUGUGCUCUUB GCCUGCCAUCUGUGCUCUUTT B 4440 R-008398977-000Y 1033 1240CAUUACAACUCUCCACAAC B CAUUACAACUCUCCACAACTT B 4442 R-008398977-000Y 10331240 CAUUACAACUCUCCACAAC GUUGUGGAGAGUUGUAAUGUU 4443 R-008398980-000E 840 1241 CUCCUCAGAUGGUGUCUGC GCAGACACCAUCUGAGGAGUU 4445R-008398980-000E  840 1241 CUCCUCAGAUGGUGUCUGC B CUCCUCAGAUGGUGUCUGCTT B4444 R-008398983-000F 1880 1242 CAGUUGCUUGUUCGUGCACGUGCACGAACAAGCAACUGUU 4447 R-008398983-000F 1880 1242CAGUUGCUUGUUCGUGCAC B CAGUUGCUUGUUCGUGCACTT B 4446 R-008398986-000G  4201243 AUCCUGAGGAAGAGGAUGU B AUCCUGAGGAAGAGGAUGUTT B 4448 R-008398986-000G 420 1243 AUCCUGAGGAAGAGGAUGU ACAUCCUCUUCCUCAGGAUUU 4449R-008398989-000H 1005 1244 CACCAGUGGAUUCUGUGUU B CACCAGUGGAUUCUGUGUUTT B4450 R-008398989-000H 1005 1244 CACCAGUGGAUUCUGUGUUAACACAGAAUCCACUGGUGUU 4451 R-008398992-000P 1193 1245CAAGAAAGCAAGCUCAUCA B CAAGAAAGCAAGCUCAUCATT B 4452 R-008398992-000P 11931245 CAAGAAAGCAAGCUCAUCA UGAUGAGCUUGCUUUCUUGUU 4453 R-008398995-000R 919 1246 CUUGCAUAACCUUUCCCAU AUGGGAAAGGUUAUGCAAGUU 4455R-008398995-000R  919 1246 CUUGCAUAACCUUUCCCAU B CUUGCAUAACCUUUCCCAUTT B4454 R-008399001-000F 1727 1247 CUUCACUAUGGACUACCAGCUGGUAGUCCAUAGUGAAGUU 4457 R-008399001-000F 1727 1247CUUCACUAUGGACUACCAG B CUUCACUAUGGACUACCAGTT B 4456 R-008399004-000G 18831248 UUGCUUGUUCGUGCACAUC B UUGCUUGUUCGUGCACAUCTT B 4458 R-008399004-000G1883 1248 UUGCUUGUUCGUGCACAUC GAUGUGCACGAACAAGCAAUU 4459R-008399007-000H  859 1249 UAUUGUACGUACCAUGCAG B UAUUGUACGUACCAUGCAGTT B4460 R-008399007-000H  859 1249 UAUUGUACGUACCAUGCAGCUGCAUGGUACGUACAAUAUU 4461 R-008399010-000P  870   57CCAUGCAGAAUACAAAUGA B CCAUGCAGAAUACAAAUGATT B 4462 R-008399010-000P  870  57 CCAUGCAGAAUACAAAUGA UCAUUUGUAUUCUGCAUGGUU 4463 R-008399013-000R1812 1250 GAAAUCUUGCCCUUUGUCC GGACAAAGGGCAAGAUUUCUU 4465R-008399013-000R 1812 1250 GAAAUCUUGCCCUUUGUCC B GAAAUCUUGCCCUUUGUCCTT B4464 R-008399016-000S 1605 1251 CUCUUGUGCGUACUGUCCUAGGACAGUACGCACAAGAGUU 4467 R-008399016-000S 1605 1251CUCUUGUGCGUACUGUCCU B CUCUUGUGCGUACUGUCCUTT B 4466 R-008399019-000T 20211252 CACAACCGAAUUGUUAUCA UGAUAACAAUUCGGUUGUGUU 4469 R-008399019-000T2021 1252 CACAACCGAAUUGUUAUCA B CACAACCGAAUUGUUAUCATT B 4468R-008399022-000Z 2180 1253 GCUCCUCUGACAGAGUUAC GUAACUCUGUCAGAGGAGCUU4471 R-008399022-000Z 2180 1253 GCUCCUCUGACAGAGUUACB GCUCCUCUGACAGAGUUACTT B 4470 R-008399025-000A  636 1254AGCGUUUGGCUGAACCAUC B AGCGUUUGGCUGAACCAUCTT B 4472 R-008399025-000A  6361254 AGCGUUUGGCUGAACCAUC GAUGGUUCAGCCAAACGCUUU 4473 R-008399031-000H 871   48 CAUGCAGAAUACAAAUGAU B CAUGCAGAAUACAAAUGAUTT B 4474R-008399031-000H  871   48 CAUGCAGAAUACAAAUGAU AUCAUUUGUAUUCUGCAUGUU4475 R-008399034-000J 1801   96 UGGAUUGAUUCGAAAUCUUB UGGAUUGAUUCGAAAUCUUTT B 4476 R-008399034-000J 1801   96UGGAUUGAUUCGAAAUCUU AAGAUUUCGAAUCAAUCCAUU 4477 R-008399037-000K 22821255 AAACGGCUUUCAGUUGAGC GCUCAACUGAAAGCCGUUUUU 4479 R-008399037-000K2282 1255 AAACGGCUUUCAGUUGAGC B AAACGGCUUUCAGUUGAGCTT B 4478R-008399040-000S 1824 1256 UUUGUCCCGCAAAUCAUGC GCAUGAUUUGCGGGACAAAUU4481 R-008399040-000S 1824 1256 UUUGUCCCGCAAAUCAUGCB UUUGUCCCGCAAAUCAUGCTT B 4480 R-008399043-000T 2204 1257UCUAGGAAUGAAGGUGUGG CCACACCUUCAUUCCUAGAUU 4483 R-008399043-000T 22041257 UCUAGGAAUGAAGGUGUGG B UCUAGGAAUGAAGGUGUGGTT B 4482 R-008399046-000U 450 1258 AAGUCCUGUAUGAGUGGGA B AAGUCCUGUAUGAGUGGGATT B 4484R-008399046-000U  450 1258 AAGUCCUGUAUGAGUGGGA UCCCACUCAUACAGGACUUUU4485 R-008399049-000V 1001 1259 GGUUCACCAGUGGAUUCUGB GGUUCACCAGUGGAUUCUGTT B 4486 R-008399049-000V 1001 1259GGUUCACCAGUGGAUUCUG CAGAAUCCACUGGUGAACCUU 4487 R-008399052-000B 15791260 GGUCUGCCAAGUGGGUGGU ACCACCCACUUGGCAGACCUU 4489 R-008399052-000B1579 1260 GGUCUGCCAAGUGGGUGGU B GGUCUGCCAAGUGGGUGGUTT B 4488R-008399055-000C 2179 1261 AGCUCCUCUGACAGAGUUA UAACUCUGUCAGAGGAGCUUU4491 R-008399055-000C 2179 1261 AGCUCCUCUGACAGAGUUAB AGCUCCUCUGACAGAGUUATT B 4490 R-008399058-000D  376 1262UUCUGGUGCCACUACCACA B UUCUGGUGCCACUACCACATT B 4492 R-008399058-000D  3761262 UUCUGGUGCCACUACCACA UGUGGUAGUGGCACCAGAAUU 4493 R-008399061-000K 556 1263 UGCUAUGUUCCCUGAGACA B UGCUAUGUUCCCUGAGACATT B 4494R-008399061-000K  556 1263 UGCUAUGUUCCCUGAGACA UGUCUCAGGGAACAUAGCAUU4495 R-008399064-000L 1804 1264 AUUGAUUCGAAAUCUUGCCB AUUGAUUCGAAAUCUUGCCTT B 4496 R-008399064-000L 1804 1264AUUGAUUCGAAAUCUUGCC GGCAAGAUUUCGAAUCAAUUU 4497 R-008399067-000M 25521265 CUCAUGGAUGGGCUGCCUC B CUCAUGGAUGGGCUGCCUCTT B 4498 R-008399067-000M2552 1265 CUCAUGGAUGGGCUGCCUC GAGGCAGCCCAUCCAUGAGUU 4499R-008399070-000U 2071 1266 GCUGCUUUAUUCUCCCAUU B GCUGCUUUAUUCUCCCAUUTT B4500 R-008399070-000U 2071 1266 GCUGCUUUAUUCUCCCAUUAAUGGGAGAAUAAAGCAGCUU 4501 R-008399073-000V 1145   16UUCUUGGCUAUUACGACAG B UUCUUGGCUAUUACGACAGTT B 4502 R-008399073-000V 1145  16 UUCUUGGCUAUUACGACAG CUGUCGUAAUAGCCAAGAAUU 4503 R-008399076-000W1836 1267 AUCAUGCACCUUUGCGUGA UCACGCAAAGGUGCAUGAUUU 4505R-008399076-000W 1836 1267 AUCAUGCACCUUUGCGUGA B AUCAUGCACCUUUGCGUGATT B4504 R-008399079-000X  336 1268 GUCACUGGCAGCAACAGUCB GUCACUGGCAGCAACAGUCTT B 4506 R-008399079-000X  336 1268GUCACUGGCAGCAACAGUC GACUGUUGCUGCCAGUGACUU 4507 R-008399082-000D  4601269 UGAGUGGGAACAGGGAUUU AAAUCCCUGUUCCCACUCAUU 4509 R-008399082-000D 460 1269 UGAGUGGGAACAGGGAUUU B UGAGUGGGAACAGGGAUUUTT B 4508R-008399085-000E 1559 1270 AAUUAUAAGAACAAGAUGA B AAUUAUAAGAACAAGAUGATT B4510 R-008399085-000E 1559 1270 AAUUAUAAGAACAAGAUGAUCAUCUUGUUCUUAUAAUUUU 4511 R-008399091-000M 3136 1271UGGACAGUUUACCAGUUGC B UGGACAGUUUACCAGUUGCTT B 4512 R-008399091-000M 31361271 UGGACAGUUUACCAGUUGC GCAACUGGUAAACUGUCCAUU 4513 R-008399097-000P1250 1272 AUGAGGACCUAUACUUACG B AUGAGGACCUAUACUUACGTT B 4514R-008399097-000P 1250 1272 AUGAGGACCUAUACUUACG CGUAAGUAUAGGUCCUCAUUU4515 R-008399100-000G 1462 1273  GGAAGGUCUCCUUGGGACUB GGAAGGUCUCCUUGGGACUTT B 4516 R-008399100-000G 1462 1273GGAAGGUCUCCUUGGGACU AGUCCCAAGGAGACCUUCCUU 4517 R-008399103-000H 19651274 UGGAAGAAAUAGUUGAAGG B UGGAAGAAAUAGUUGAAGGTT B 4518 R-008399103-000H1965 1274 UGGAAGAAAUAGUUGAAGG CCUUCAACUAUUUCUUCCAUU 4519R-008399109-000K 3114 1275 GGUGUUAUUUGGAACCUUG CAAGGUUCCAAAUAACACCUU4521 R-008399109-000K 3114 1275 GGUGUUAUUUGGAACCUUGB GGUGUUAUUUGGAACCUUGTT B 4520 R-008399112-000S 1665 1276GUGCUVUUCGUCAUCUGAC B GUGCUCUUCGUCAUCUGACTT B 4522 R-008399112-000S 16651276 GUGCUVUUCGUCAUCUGAC GUCAGAUGACGAAGAGCACUU 4523 R-008399115-000T 304 1277 GGCCAUGGAACCAGACAGA UCUGUCUGGUUCCAUGGCCUU 4525R-008399115-000T  304 1277 GGCCAUGGAACCAGACAGA B GGCCAUGGAACCAGACAGATT B4524 R-008399118-000U  327 1278 CGGCUGUUAGUCACUGGCAUGCCAGUGACUAACAGCCGUU 4527 R-008399118-000U  327 1278CGGCUGUUAGUCACUGGCA B CGGCUGUUAGUCACUGGCATT B 4526 R-008399121-000A 18661279 UUCCACGACUAGUUCAGUU B UUCCACGACUAGUUCAGUUTT B 4528 R-008399121-000A1866 1279 UUCCACGACUAGUUCAGUU AACUGAACUAGUCGUGGAAUU 4529R-008399124-000B 1699 1280 AGCAGAGAUGGCCCAGAAU AUUCUGGGCCAUCUCUGCUUU4531 R-008399124-000B 1699 1280 AGCAGAGAUGGCCCAGAAUB AGCAGAGAUGGCCCAGAAUTT B 4530 R-008399127-000C 2397 1281GCCAGGAUGAUCCUAGCUA UAGCUAGGAUCAUCCUGGCUU 4533 R-008399127-000C 23971281 GCCAGGAUGAUCCUAGCUA B GCCAGGAUGAUCCUAGCUATT B 4532 R-008399130-000J1658 1282 GCCAUCUGUGCUCUUCGUC B GCCAUCUGUGCUCUUCGUCTT B 4534R-008399130-000J 1658 1282 GCCAUCUGUGCUCUUCGUC GACGAAGAGCACAGAUGGCUU4535 R-008399133-000K  891 1283 UAGAAACAGCUCGUUGUACGUACAACGAGCUGUUUCUAUU 4537 R-008399133-000K  891 1283UAGAAACAGCUCGUUGUAC B UAGAAACAGCUCGUUGUACTT B 4536 R-008399136-000L 15721284 AGAUGAUGGUCUGCCAAGU B AGAUGAUGGUCUGCCAAGUTT B 4538 R-008399136-000L1572 1284 AGAUGAUGGUCUGCCAAGU ACUUGGCAGACCAUCAUCUUU 4539R-008399139-000M  927 1285 ACCUUUCCCAUCAUCCUGA B ACCUUUCCCAUCAUCGUGATT B4540 R-008399139-000M  927 1285 ACCUUUCCCAUCAUCGUGAUCACGAUGAUGGGAAAGGUUU 4541 R-008399142-000U  290 1286AUGGAGUUGGACAUGGCCA UGGCCAUGUCCAACUCCAUUU 4543 R-008399142-000U  2901286 AUGGAGUUGGACAUGGCCA B AUGGAGUUGGACAUGGCCATT B 4542 R-008399145-000V1663 1287 CUGUGCUCUUCGUCAUCUG CAGAUGACGAAGAGCACAGUU 4545R-0083991454000V 1663 1287 CUGUGCUCUUCGUCAUCUG B CUGUGCUCUUCGUCAUCUGTT B4544 R-008399198-000W 1562 1288 UAUAAGAACAAGAUGAUGGB UAUAAGAACAAGAUGAUGGTT B 4546 R-008399148-000W 1562 1288UAUAAGAACAAGAUGAUGG CCAUCAUCUUGUUCUUAUAUU 4547 R-008399154-000D 29471289 UCUGAAUAAAGUGUAACAA UUGUUACACUUUAUUCAGAUU 4549 R-008399159-000D2947 1289 UCUGAAUAAAGUGUAACAA B UCUGAAUAAAGUGUAACAATT B 4548R-008399157-000E 1711 1290 CCAGAAUGCAGUUCGCCUU AAGGCGAACUGCAUUCUGGUU4551 R-008399157-000E 1711 1290 CCAGAAUGCAGUUCGCCUUB CCAGAAUGCAGUUCGCCUUTT B 4550 R-008399160-000L 1566 1291AGAACAAGAUGAUGGUCUG B AGAACAAGAUGAUGGUCUGTT B 4552 R-008399160-000L 15661291 AGAACAAGAUGAUGGUCUG CAGACCAUCAUCUUGUUCUUU 4553 R-008399163-000M1815 1292 AUCUUGCCCUUUGUCCCGC GCGGGACAAAGGGCAAGAUUU 4555R-008399163-000M 1815 1292 AUCUUGCCCUUUGUCCCGC B AUCUUGCCCUUUGUCCCGCTT B4554 R-008399166-000N 1087 1293 GCCUUUAGCUGGUGGGCUGCAGCCCACCAGCUAAACGCUU 4557 R-008399166-000N 1087 1293GCCUUUAGCUGGUGGGCUG B GCGUUUAGCUGGUGGGCUGTT B 4556 R-008399169-000P 14951294 GGGUUCAGAUGAUAUAAAU B GGGUUCAGAUGAUAUAAAUTT B 4558 R-008399169-000P1495 1294 GGGUUCAGAUGAUAUAAAU AUUUAUAUCAUCUGAACCCUU 4559R-008399172-000W 1363 1295 UUUAGGACUUCACCUGACA B UUUAGGACUUCACCUGACATT B4560 R-008399172-000W 1363 1295 UUUAGGACUUCACCUGACAUGUCAGGUGAAGUCCUAAAUU 4561 R-008399175-000X  391 1296CACAGCUCCUUCUCUGAGU ACUCAGAGAAGGAGCUGUGUU 4563 R-008399175-000X  3911296 CACAGCUCCUUCUCUGAGU B CACAGCUCCUUCUCUGAGUTT B 4562 R-008399178-000Y1392 1297 AACGUCUUGUUCAGAACUG CAGUUCUGAACAAGACGUUUU 4565R-008399178-000Y 1392 1297 AACGUCUUGUUCAGAACUG B AACGUCUUGUUCAGAACUGTT B4564 R-008399181-000E 1935 1298 CACAGCAGCAAUUUGUGGAB CACAGCAGCAAUUUGUGCATT B 4566 R-008399181-000E 1935 1298CACAGCAGCAAUUUGUGUA UCCACAAAUUGCUGCUGUGUU 4567 R-008399184-000F 18721299 GACUAGUUCAGUUGCUUGU B GACUAGUUCAGUUGCUUGUTT B 4568 R-008399184-000F1872 1299 GACUAGUUCAGUUGCUUGU ACAAGCAACUGAACUAGUCUU 4569R-008399187-000G 1159 1300 GACAGACUGCCUUCAAAUU AAUUUGAAGGCAGUCUGUCUU4571 R-008399187-000G 1159 1300 GACAGACUGCCUUCAAAUUB GACAGACUGCCUUCAAAUUTT B 4570 R-008399190-000N 2308 1301CUCUCUCUUCAGAACAGAG CUCUGUUCUGAAGAGAGAGUU 4573 R-008399190-000N 23081301 CUCUCUCUUCAGAACAGAG B CUCUCUCUUCAGAACAGAGTT B 4572 R-008399193-000P 632 1302 GUCCAGCGUUUGGCUGAAC GUUCAGCCAAACGCUGGACUU 4575R-008399193-000P  632 1302 GUCCAGCGUUUGGCUGAAC B GUCCAGCGUUUGGCUGAACTT B4574 R-008399196-000R  580  173 UGAGGGCAUGCAGAUCCCAB UGAGGGCAUGCAGAUCCCATT B 4576 R-008399196-000R  580  173UGAGGGCAUGCAGAUCCCA UGGGAUCUGCAUGCCCUCAUU 4577 R-008399199-000S 15641303 UAAGAACAAGAUGAUGGUC B UAAGAACAAGAUGAUGGUCTT B 4578 R-008399199-000S1564 1303 UAAGAACAAGAUGAUGGUC GACCAUCAUCUUGUUCUUAUU 4579R-008399202-000J 1384 1304 UCCAAGUCAACGUCUUGUU B UCCAAGUCAACGUCUUGUUTT B4580 R-008399202-000J 1384 1304 UCCAAGUCAACGUCUUGUUAACAAGACGUUGACUUGGAUU 4581 R-008399205-000K 1690 1305ACACCAAGAAGCAGAGAUG B ACACCAAGAAGCAGAGAUGTT B 4582 R-008399205-000K 16901305 ACACCAAGAAGCAGAGAUG CAUCUCUGCUUCUUGGUGUUU 4583 R-008399208-000L1421 1306 CUCAGGAAUCUUUCAGAUG B CUCAGGAAUCUUUCAGAUGTT B 4584R-008399208-000L 1421 1306 CUCAGGAAUCUUUCAGAUG CAUCUGAAAGAUUCCUGAGUU4585 R-008399211-000T 1141 1307 UAAAUUCUUGGCUAUUACGB UAAAUUCUUGGCUAUUACGTT B 4586 R-008399211-000T 1141 1307UAAAUUCUUGGCUAUUACG CGUAAUAGCCAAGAAUUUAUU 4587 R-008399214-000U 17321308 CUAUGGACUACCAGUUGUG B CUAUGGACUACCAGUUGUGTT B 4588 R-008399214-000U1732 1308 CUAUGGACUACCAGUUGUG CACAACUGGUAGUCCAUAGUU 4589R-008399217-000V  634 1309 CCAGCGUUUGGCUGAACCA B CCAGCGUUUGGCUGAACCATT B4590 R-008399217-000V  634 1309 CCAGCGUUUGGCUGAACCAUGGUUCAGCCAAACGCUGGUU 4591 R-008399220-000B  932 1310UCCCAUCAUCGUGAGGGCU B UCCCAUCAUCGUGAGGGCUTT B 4592 R-008399220-000B  9321310 UCCCAUCAUCGUGAGGGCU AGCCCUCACGAUGAUGGGAUU 4593 R-008399223-000C 579  171 AUGAGGGCAUGCAGAUCCC GGGAUCUGCAUGCCCUCAUUU 4595R-008399223-000C  579  171 AUGAGGGCAUGCAGAUCCC B AUGAGGGCAUGCAGAUCCCTT B4594 R-008399226-000D 1366 1311 AGGACUUCACCUGACAGAUAUCUGUCAGGUGAAGUCCUUU 4597 R-008399226-000D 1366 1311AGGAGUUCACCUGACAGAU B AGGACUUCACCUGACAGAUTT B 4596 R-008399229-000E 16081312 UUGUGCGUACUGUCCUUCG B UUGUGCGUACUGUCCUUCGTT B 4598 R-008399229-000E1608 1312 UUGUGCGUACUGUCCUUCG CGAAGGACAGUACGCACAAUU 4599R-008399232-000L  814   10 AGCUUCCAGACACGCUAUC GAUAGCGUGUCUGGAAGCUUU4601 R-008399232-000L  814   10 AGCUUCCAGACACGCUAUCB AGCUUCCAGACACGCUAUCTT B 4600 R-008399235-000M 1923 1313CCAUGGGUGGGACACAGCA B CCAUGGGUGGGACACAGCATT B 4602 R-008399235-000M 19231313 CCAUGGGUGGGACACAGCA UGCUGUGUCCCACCCAUGGUU 4603 R-008399238-000N1458 1314 GGAUGGAAGGUCUCCUUGG CCAAGGAGACCUUCCAUCCUU 4605R-008399238-000N 1458 1314 GGAUGGAAGGUCUCCUUGG B GGAUGGAAGGUCUCCUUGGTT B4604 R-008399241-000V 1908 1315 CCCAGCGCCGUACGUCCAUB CCCAGCGCCGUACGUCCAUTT B 4606 R-008399241-000V 1908 1315CCCAGCGCCGUACGUCCAU AUGGACGUACGGCGCUGGGUU 4607 R-008399244-000W  5391316 GCUCAGAGGGUACGAGCUG CAGCUCGUACCCUCUGAGCUU 4609 R-008399244-000W 539 1316 GCUCAGAGGGUACGAGCUG B GCUCAGAGGGUACGAGCUGTT B 4608R-008399247-000X 2016 1317 AUGUUCACAACCGAAUUGU ACAAUUCGGUUGUGAACAUUU4611 R-008399247-000X 2016 1317 AUGUUCACAACCGAAUUGUB AUGUUCACAACCGAAUUGUTT B 4610 R-008399250-000D 1884 1318UGCUUGUUCGUGCACAUCA B UGCUUGUUCGUGCACAUCATT B 4612 R-008399250-000D 18841318 UGCUUGUUCGUGCACAUCA UGAUGUGCACGAACAAGCAUU 4613 R-008399253-000E 560 1319 AUGUUCCCUGAGACAUUAG B AUGUUCCCUGAGACAUUAGTT B 4614R-008399253-000E  560 1319 AUGUUCCCUGAGACAUUAG CUAAUGUCUCAGGGAACAUUU4615 R-008399256-000F  411 1320 GUAAAGGCAAUCCUGAGGAUCCUCAGGAUUGCCUUUACUU 4617 R-008399256-000F  411 1320GUAAAGGCAAUCCUGAGGA B GUAAAGGCAAUCCUGAGGATT B 4616 R-008399259-000G  3381321 CACUGGCAGCAACAGUCUU AAGACUGUUGCUGCCAGUGUU 4619 R-008399259-000G 338 1321 CACUGGCAGCAACAGUCUU B CACUGGCAGCAACAGUCUUTT B 4618R-008399262-000N  830 1322 AUCAUGCGUUCUCCUCAGA UCUGAGGAGAACGCAUGAUUU4621 R-008399262-000N  830 1322 AUCAUGCGUUCUCCUCAGAB AUCAUGCGUUGUCCUCAGATT B 4620 R-008399265-000P 3086 1323UAUGUAUGGGUAGGGUAAA B UAUGUAUGGGUAGGGUAAATT B 4622 R-008399265-000P 30861323 UAUGUAUGGGUAGGGUAAA UUUACCCUACCCAUACAUAUU 4623 R-008399268-000R3115 1324 GUGUUAUUUGGAACCUUGU ACAAGGUUCCAAAUAACACUU 4625R-008399268-000R 3115 1324 GUGUUAUUUGGAACCUUGU B GUGUUAUUUGGAACCUUGUTT B4624 R-008399271-000X 2177 1325 ACAGCUCCUCUGACAGAGUB ACAGCUCCUCUGACAGAGUTT B 4626 R-008399271-000X 2177 1325ACAGCUCCUCUGACAGAGU ACUCUGUCAGAGGAGCUGUUU 4627 R-008399274-000Y 17331326 UAUGGACUACCAGUUGUGG B UAUGGACUACCAGUUGUGGTT B 4628 R-008399274-000Y1733 1326 UAUGGACUACCAGUUGUGG CCACAACUGGUAGUCCAUAUU 4629R-008399277-000Z  375 1327 AUUCUGGUGCCACUACCAC GUGGUAGUGGCACCAGAAUUU4631 R-008399277-000Z  375 1327 AUUCUGGUGCCACUACCACB AUUCUGGUGCCACUACCACTT B 4630 R-008399280-000F 2565 1328UGCCUCCAGGUGACAGCAA B UGCCUCCAGGUGACAGCAATT B 4632 R-008399280-000F 25651328 UGCCUCCAGGUGACAGCAA UUGCUGUCACCUGGAGGCAUU 4633 R-008399283-000G 442 1329 UACCUCCCAAGUCCUGUAU AUACAGGACUUGGGAGGUAUU 4635R-008399283-000G  442 1329 UACCUCCCAAGUCCUGUAU B UACCUCCCAAGUCCUGUAUTT B4634 R-008399286-000H  819 1330 CCAGACACGCUAUCAUGCGCGCAUGAUAGCGUGUCUGGUU 4637 R-008399286-000H  819 1330CCAGACACGCUAUCAUGCG B CCAGACACGCUAUCAUGCGTT B 4636 R-008399289-000J  7001331 UGAUGCAGAACUUGCCACA B UGAUGCAGAACUUGCCACATT B 4638 R-008399289-000J 700 1331 UGAUGCAGAACUUGCCACA UGUGGCAAGUUCUGCAUCAUU 4639R-008399292-000R 1089 1332 GUUUAGCUGGUGGGCUGCA B GUUUAGCUGGUGGGCUGCATT B4640 R-008399292-000R 1089 1332 GUUUAGCUGGUGGGCUGCAUGCAGCCCACCAGCUAAACUU 4641 R-008399295-000S 1580 1333GUCUGCCAAGUGGGUGGUA UACCACCCACUUGGCAGACUU 4643 R-008399295-000S 15801333 GUCUGCCAAGUGGGUGGUA B GUCUGCCAAGUGGGUGGUATT B 4642 R-008399298-000T1982 1334 GGUUGUACCGGAGCCCUUC GAAGGGCUCCGGUACAACCUU 4645R-008399298-000T 1982 1334 GGUUGUACCGGAGCCCUUC B GGUUGUACCGGAGCCCUUCTT B4644 R-008399301-000K 1986 1335 GUACCGGAGCCCUUCACAUB GUACCGGAGCCCUUCACAUTT B 4646 R-008399301-000K 1986 1335GUACCGGAGCCCUUCACAU AUGUGAAGGGCUCCGGUACUU 4647 R-008399304-000L  4181336 CAAUCCUGAGGAAGAGGAU AUCCUCUUCCUCAGGAUUGUU 4649 R-008399304-000L 418 1336 CAAUCCUGAGGAAGAGGAU B CAAUCCUGAGGAAGAGGAUTT B 4648R-008399307-000M 1306 1337 GCUAUCUGUCUGCUCUAGU ACUAGAGCAGACAGAUAGCUU4651 R-008399307-000M 1306 1337 GCUAUCUGUCUGCUCUAGUB GCUAUCUGUCUGCUCUAGUTT B 4650 R-008399310-000U 1377 1338UGACAGAUCCAAGUCAACG CGUUGACUUGGAUCUGUCAUU 4653 R-008399310-000U 13771338 UGACAGAUCCAAGUCAACG B UGACAGAUCCAAGUCAACGTT B 4652 R-008399313-000V2467 1339 CAUGAUGGAACAUGAGAUG CAUCUCAUGUUCCAUCAUGUU 4655R-008399313-000V 2467 1339 CAUGAUGGAACAUGAGAUG B CAUGAUGGAACAUGAGAUGTT B4654 R-008399316-000W 1414 1340 UUGGACUCUCAGGAAUCUUB UUGGACUCUCAGGAAUCUUTT B 4656 R-008399316-000W 1414 1340UUGGACUCUCAGGAAUCUU AAGAUUCCUGAGAGUCCAAUU 4657 R-008399319-000X 16681341 CUCUUCGUCAUCUGACCAG B CUCUUCGUCAUCUGACCAGTT B 4658 R-008399319-000X1668 1341 CUCUUCGUCAUCUGACCAG CUGGUCAGAUGACGAAGAGUU 4659R-008399322-000D 1818 1342 UUGCCCUUUGUCCCGCAAA B UUGCCCUUUGUCCCGCAAATT B4660 R-008399322-000D 1818 1342 UUGCCCUUUGUCCCGCAAAUUUGCGGGACAAAGGGCAAUU 4661 R-008399325-000E 1697 1343GAAGCAGAGAUGGCCCAGA B GAAGCAGAGAUGGCCCAGATT B 4662 R-008399325-000E 16971343 GAAGCAGAGAUGGCCCAGA UCUGGGCCAUCUCUGCUUCUU 4663 R-008399328-000F 918 1344 CCUUGCAUAACCUUUCCCA B CCUUGCAUAACCUUUCCCATT B 4664R-008399328-000F  918 1344 CCUUGCAUAACCUUUCCCA UGGGAAAGGUUAUGCAAGGUU4665 R-008399331-000M  605 1345 CAGUUUGAUGCUGCUCAUCGAUGAGCAGCAUCAAACUGUU 4667 R-008399331-000M  605 1345CAGUUUGAUGCUGCUCAUC B CAGUUUGAUGCUGCUCAUCTT B 4666 R-008399334-000N 13741346 ACCUGACAGAUCCAAGUCA B ACCUGACAGAUCCAAGUCATT B 4668 R-008399334-000N1374 1346 ACCUGACAGAUCCAAGUCA UGACUUGGAUCUGUCAGGUUU 4669R-008399337-000P 1430 1347 CUUUCAGAUGCUGCAACUA UAGUUGCAGCAUCUGAAAGUU4671 R-008399337-000P 1430 1347 CUUUCAGAUGCUGCAACUAB CUUUCAGAUGCUGCAACUATT B 4670 R-008399340-000W 3186 1348GAUACGAUGCCUCAAGAGA UCUCUUGAAGCAUCGUAUCUU 4673 R-008399340-000W 31861348 GAUACGAUGCUUCAAGAGA B GAUACGAUGCUUCAAGAGATT B 4672 R-008399343-000X1355 1349 AUGCAAGCUUUAGGACUUC B AUGCAAGCUUUAGGACUUCTT B 4674R-008399343-000X 1355 1349 AUGCAAGCUUUAGGACUUC GAAGUCCUAAAGCUUGCAUUU4675 R-008399346-000Y  433 1350 GGAUGUGGAUACCUCCCAAUUGGGAGGUAUCCACAUCCUU 4677 R-008399346-000Y  433 1350GGAUGUGGAUACCUCCCAA B GGAUGUGGAUACCUCCCAATT B 4676 R-008399349-000Z 1901  13 CAGGAUACCCAGCGCCGUA B CAGGAUACCCAGCGCCGUATT B 4678 R-008399349-000Z1901   13 CAGGAUACCCAGCGCCGUA UACGGCGCUGGGUAUCCUGUU 4679R-008399352-000F 1713 1351 AGAAUGCAGUUCGCCUUCA UGAAGGCGAACUGCAUUCUUU4681 R-008399352-000F 1713 1351 AGAAUGCAGUUCGCCUUCAB AGAAUGCAGUUCGCCUUCATT B 4680 R-008399355-000G  823   17ACACGCUAUCAUGCGUUCU AGAACGCAUGAUAGCGUGUUU 4683 R-008399355-000G  823  17 ACACGCUAUCAUGCGUUCU B ACACGCUAUCAUGCGUUCUTT B 4682 R-008399358-000H1811 1352 CGAAAUCUUGCCCUUUGUC B CGAAAUCUUGCCCUUUGUCTT B 4684R-008399358-000H 1811 1352 CGAAAUCUUGCCCUUUGUC GACAAAGGGCAAGAUUUCGUU4685 R-008399361-000P  491 1353 ACCCAAGAACAAGUAGCUGB ACUCAAGAACAAGUAGCUGTT B 4686 R-008399361-000P  491 1353ACCCAAGAACAAGUAGCUG CAGCUACUUGUUCUUGAGUUU 4687 R-008399364-000R 22091354 GAAUGAAGGUGUGGCGACA UGUCGCCACACCUUCAUUCUU 4689 R-008399364-000R2209 1354 GAAUGAAGGUGUGGCGACA B GAAUGAAGGUGUGGCGACATT B 4688R-008399367-000S 1840 1355 UGCACCCUUGCGUGAGCAG B UGCACCUUUGCGUGAGCAGTT B4690 R-008399367-000S 1840 1355 UGCACCCUUGCGUGAGCAGCUGCUCACGCAAAGGUGCAUU 4691 R-008399370-000Y  550 1356ACGAGCUGCUAUGUUCCCU AGGGAACAUAGCAGCUCGUUU 4693 R-008399370-000Y  5501356 ACGAGCUGCUAUGUUCCCU B ACGAGCUGCUAUGUUCCCUTT B 4692 R-008399373-000Z 429 1357 AAGAGGAUGUGGAUACCUC GAGGUAUCCACAUCCUCUUUU 4695R-008399373-000Z  429 1357 AAGAGGAUGUGGAUACCUC B AAGAGGAUGUGGACACCUCTT B4694 R-008399376-000A 2436 1358 GAUAUGGCCAGGAUGCCUUAAGGCAUCCUGGCCAUAUCUU 4697 R-008399376-000A 2436 1358GAUAUGGCCAGGAUGCCUU B GAUAUGGCCAGGAUGCCUUTT B 4696 R-008399379-000B 15971359 UAUAGAGGCUCUUGUGCGC B UAUAGAGGCUCUUGUGCGUTT B 4698 R-008399379-000B1597 1359 UAUAGAGGCUCUUGUGCGC ACGCACAAGAGCCUCUAUAUU 4699R-008399382-000H 1496 1360 GGUUCAGAUGAUAUAAAUG B GGUUCAGAUGAUAUAAAUGTT B4700 R-008399382-000H 1496 1360 GGUUCAGAUGAUAUAAAUGCAUUUAUAUCAUCUGAACCUU 4701 R-008399385-000J 1456 1361AGGGAUGGAAGGUCUCCUU AAGGAGACCUUCCAUCCCUUU 4703 R-008399385-000J 14561361 AGGGAUGGAAGGUCUCCUU B AGGGAUGGAAGGUCUCCUUTT B 4702 R-008399388-000K3159 1362 UAUCCCAAAGUUGUUGUAA UUACAACAACUUUGGGAUAUU 4705R-008399388-000K 3159 1362 UAUCCCAAAGUUGUUGUAA B UAUCCCAAAGUUGUUGUAATT B4704 R-008399391-000S 2309 1363 UCUCUCUUCAGAACAGAGCB UCUCUCUUCAGAACAGAGCTT B 4706 R-008399391-000S 2309 1363UCUCUCUUCAGAACAGAGC GCUCUGUUCUGAAGAGAGAUU 4707 R-008399394-000T 23001364 CUGACCAGCUCUCUCUUCA B CUGACCAGCUCUCUCUUCATT B 4708 R-008399394-000T2300 1364 CUGACCAGCUCUCUCUUCA UGAAGAGAGAGCUGGUCAGUU 4709R-008399397-000U 3177 1365 ACCUGCUGUGAUACGAUGC B ACCUGCUGUGAUACGAUGCTT B4710 R-008399397-000U 3177 1365 ACCUGCUGUGAUACGAUGCGCAUCGUAUCACAGCAGGUUU 4711 R-008399400-000L 1079 1366AUGGCAGUGCGUUUAGCUG B AUGGCAGUGCGUUUAGCUGTT B 4712 R-008399400-000L 10791366 AUGGCAGUGCGUUUAGCUG CAGCUAAACGCACUGCCAUUU 4713 R-008399403-000M1383 1367 AUCCAAGUCAACGUCUUGU ACAAGACGUUGACUUGGAUUU 4715R-008399403-000M 1383 1367 AUCCAAGUCAACGUCUUGU B AUCCAAGUCAACGUCUUGUTT B4714 R-008399406-000N 2563 1368 GCUGCCUCCAGGUGACAGCGCUGUCACCUGGAGGCAGCUU 4717 R-008399406-000N 2563 1368GCUGCCUCCAGGUGACAGC B GCUGCCUCCAGGUGACAGCTT B 4716 R-008399409-000P 10841369 AGUGCGUUUAGCUGGUGGG B AGUGCGUUUAGCUGGGUGGTT B 4718 R-008399409-000P1084 1369 AGUGCGUUUAGCUGGUGGG CCCACCAGCUAAACGCACUUU 4719R-008399412-000W 1329 1370 AGCCGGCUAUUGUAGAAGC B AGCCGGCUAUUGUAGAAGCTT B4720 R-008399412-000W 1329 1370 AGCCGGCUAUUGUAGAAGCGCUUCUACAAUAGCCGGCUUU 4721 R-008399415-000X 1662  169UCUGUGCUCUUCGUCAUCU AGAUGACGAAGAGCACAGAUU 4723 R-008399415-000X 1662 169 UCUGUGCUCUUCGUCAUCU B UCUGUGCUCUUCGUCAUCUTT B 4722 R-008399418-000Y2268   99 CACAAGAUUACAAGAAACG CGUUUCUUGUAAUCUUGUGUU 4725R-008399418-000Y 2268   99 CACAAGAUUACAAGAAACG B CACAAGAUUACAAGAAACGTT B4724 R-008399421-000E 2470  108 GAUGGAACAUGAGAUGGGUB GAUGGAACAUGAGAUGGGUTT B 4726 R-008399421-000E 2470  108GAUGGAACAUGAGAUGGGU ACCCAUCUCAUGUUCCAUCUU 4727 R-008399424-000F  5731371 CAUUAGAUGAGGGCAUGCA B CAUUAGAUGAGGGCAUGCATT B 4728 R-008399424-000F 573 1371 CAUUAGAUGAGGGCAUGCA UGCAUGCCCUCAUCUAAUGUU 4729R-008399427-000G 2213 1372 GAAGGUGUGGCGACAUAUG B GAAGGUGUGGCGACAUAUGTT B4730 R-008399427-000G 2213 1372 GAAGGUGUGGCGACAUAUGCAUAUGUCGCCACACCUUCUU 4731 R-008399430-000N 1587 1373AAGUGGGUGGUAUAGAGGC B AAGUGGGUGGUAUAGAGGCTT B 4732 R-008399430-000N 15871373 AAGUGGGUGGUAUAGAGGC GCCUCUAUACCACCCACUUUU 4733 R-008399433-000P2166 1374 CUGAGGGAGCCACAGCUCC B CUGAGGGAGCCACAGCUCCTT B 4734R-008399433-000P 2166 1374 CUGAGGGAGCCACAGCUCC GGAGCUGUGGCUCCCUCAGUU4735 R-008399436-000R  637 1375 GCGUUUGGCUGAACCAUCAUGAUGGUUCAGCCAAACGCUU 4737 R-008399436-000R  637 1375GCGUUUGGCUGAACCAUCA B GCGUUUGGCUGAACCAUCATT B 4736 R-008399439-000S  3971376 UCCUUCUCUGAGUGGUAAA B UCCUUCUCUGAGUGGUAAATT B 4738 R-008399439-000S 397 1376 UCCUUCUCUGAGUGGUAAA UUUACCACUCAGAGAAGGAUU 4739R-008399442-000Y 1718 1377 GCAGUUCGCCUUCACUAUG B GCAGUUCGCCUUCACUAUGTT B4740 R-008399442-000Y 1718 1377 GCAGUUCGCCUUCACUAUGCAUAGUGAAGGCGAACUGCUU 4741 R-008399445-000Z 1415  111UGGACUCUCAGGAAUCUUU B UGGACUCUCAGGAAUCUUUTT B 4742 R-008399445-000Z 1415 111 UGGACUCUCAGGAAUCUUU AAAGAUUCCUGAGAGUCCAUU 4743 R-008399448-000A1413  162 UUUGGACUCUCAGGAAUCU B UUUGGACUCUCAGGAAUCUTT B 4744R-008399448-000A 1413  162 UUUGGACUCUCAGGAAUCU AGAUUCCUGAGAGUCCAAAUU4745 R-008399451-000G 2445  160 AGGAUGCCUUGGGUAUGGAB AGGAUGCCUUGGGUAUGGATT B 4746 R-008399451-000G 2445  160AGGAUGCCUUGGGUAUGGA UCCAUACCCAAGGCAUCCUUU 4747 R-008399454-000H  567 157 CUGAGACAUUAGAUGAGGG B CUGAGACAUUAGAUGAGGGTT B 4748 R-008399454-000H 567  157 CUGAGACAUUAGAUGAGGG CCCUCAUCUAAUGUCUCAGUU 4749R-008399457-000J 1498   86 UUCAGAUGAUAUAAAUGUG CACAUUUAUAUCAUCUGAAUU4751 R-008399457-000J 1498   86 UUCAGAUGAUAUAAAUGUGB UUCAGAUGAUAUAAAUGUGTT B 4750 R-008399460-000R 2357 1378GGACUUGAUAUUGGUGCCC B GGACUUUGAAUUGGUGCCCTT B 4752 R-008399460-000R 23571378 GGACUUGAUAUUGGUGCCC GGGCACCAAUAUCAAGUCCUU 4753 R-008399463-000S 639 1379 GUUUGGCUGAACCAUCACA UGUGAUGGUUCAGCCAAACUU 4755R-008399463-000S  639 1379 GUUUGGCUGAACCAUCACA B GUUUGGCUGAACCAUCACATT B4754 R-008399466-000T  585 1380 GCAUGCAGAUCCCAUCUACGUAGAUGGGAUCUGCAUGCUU 4757 R-008399466-000T  585 1380GCAUGCAGAUCCCAUCUAC B GCAUGCAGAUCCCAUCUACTT B 4756 R-008399469-000U 25191381 GAUGGGCUGCCAGAUCUGG B GAUGGGCUGCCAGAUCUGGTT B 4758 R-008399469-000U2519 1381 GAUGGGCUGCCAGAUCUGG CCAGAUCUGGCAGCCCAUCUU 4759R-008399472-000A 1367 1382 GGACUUCACCUGACAGAUC B GGACUUCACCUGACAGAUCTT B4760 R-008399472-000A 1367 1382 GGACUUCACCUGACAGAUCGAUCUGUCAGGUGAAGUCCUU 4761 R-008399475-000B 1391 1383CAACGUCUUGUUCAGAACU B CAACGUCUUGUUCAGAACUTT B 4762 R-008399475-000B 13911383 CAACGUCUUGUUCAGAACU AGUUCUGAACAAGACGUUGUU 4763 R-008399478-000C 509 1384 GAUAUUGAUGUACAGUAUG B GAUAUUGAUGGACAGUAUGTT B 4764R-008399478-000C  509 1384 GAUAUUGAUGUACAGUAUG CAUACUGUCCAUCAAUAUCUU4765 R-008399481-000J  303 1385 UGGCCAUGGAACCAGACAGB UGGCCAUGGAACCAGACAGTT B 4766 R-008399481-000J  303 1385UGGCCAUGGAACCAGACAG CUGUCUGGUUCCAUGGCCAUU 4767 R-008399484-000K  4941386 CAAGAACAAGUAGCUGAUA UAUCAGCUACUUGUUCUUGUU 4769 R-008399484-000K 494 1386 CAAGAACAAGUAGCUGAUA B CAAGAACAAGUAGCUGAUATT B 4768R-008399487-000L  328 1387 GGCUGUUAGUCACUGGCAG CUGCCAGUGACUAACAGCCUU4771 R-008399487-000L  328 1387 GGCUGUUAGUCACUGGCAGB GGCUGUUAGUCACUGGCAGTT B 4770 R-008399490-000T 2058 1388CAUUGUUUGUGCAGCUGCU AGCAGCUGCACAAACAAUGUU 4773 R-008399490-000T 20581388 CAUUGUUUGUGCAGCUGCU B CAUUGUUUGUGCAGUUGCUTT B 4772 R-008399493-000U1447 1389 UAAACAGGAAGGGAUGGAA B UAAACAGGAAGGGAUGGAATT B 4774R-008399493-000U 1447 1389 UAAACAGGAAGGGAUGGAA UUCCAUCCCUUCCUGUUUAUU4775 R-008399496-000V 1563 1390 AUAAGAACAAGAUGAUGGUACCAUCAUCUUGUUCUUAUUU 4777 R-008399496-000V 1563 1390AUAAGAACAAGAUGAUGGU B AUAAGAACAAGAUGAUGGUTT B 4776 R-008399499-000W 13501391 GUGGAAUGCAAGCUUUAGG CCUAAAGUTUGCAUUCCACUU 4779 R-008399499-000W1350 1391 GUGGAAUGCAAGCUUUAGG B GUGGAAUGCAAGUTUUAGGTT B 4778R-008399502-000N 2208 1392 GGAAUGAAGGUGUGGCGAC GUCGCCACACCUUCAUUCCUU4781 R-008399502-000N 2208 1392 GGAAUGAAGGUGUGGCGACB GGAAUGAAGGUGUGGCGACTT B 4780 R-008399505-000P 1689 1393GACACCAAGAAGCAGAGAU AUCUCUGUTUCUUGGUGUCUU 4783 R-008399505-000P 16891393 GACACCAAGAAGCAGAGAU B GACACCAAGAAGCAGAGAUTT B 4782 R-008399508-000R1407 1394 ACUGUCUUUGGACUCUCAG B ACUGUCUUUGGACUCUCAGTT B 4784R-008399508-000R 1407 1394 ACUGUCUUUGGACUCUCAG CUGAGAGUCCAAAGACAGUUU4785 R-008399511-000X 2137 1395 GGACAAGGAAGCUGCAGAAB GGACAAGGAAGCUGCAGAATT B 4786 R-008399511-000X 2137 1395GGACAAGGAAGCUGCAGAA UUCUGCAGCUUCCUUGUCCUU 4787 R-008399519-000Y  8541396 UCUGCUAUUGUACGUACCA B UCUGCUAUUGUACGUACCATT B 4788 R-008399514-000Y 854 1396 UCUGCUAUUGUACGUACCA UGGUACGUACAAUAGGAGAUU 4789R-008399517-000Z 2070 1397 AGCUGCUUUAUUCUCCCAU AUGGGAGAAUAAAGCAGCUUU4791 R-008399517-000Z 2070 1397 AGCUGCUUUAUUCUCCCAUB AGCUGCUUUAUUCUCCCAUTT B 4790 R-008399520-000F  545 1398AGGGUACGAGCUGCUAUGU ACAUAGCAGCUCGUACCCUUU 4793 R-008399520-000F  5451398 AGGGUACGAGCUGCUAUGU B AGGGUACGAGCUGCUAUGUTT B 4792 R-008399523-000G1640 1399 GAAGACAUCACUGAGCCUG B GAAGACAUCAGUGAGCCUGTT B 4794R-008399523-000G 1640 1399 GAAGACAUCACUGAGCCUG CAGGCUCAGUGAUGUCUUCUU4795 R-008399526-000H 2012 1400 CGGGAUGUUCACAACCGAAUUCGGUUGUGAACAUCCCGUU 4797 R-008399526-000H 2012 1400CGGGAUGUUCACAACCGAA B CGGGAUGUUCACAAGGGAATT B 4796 R-008399529-000J 16841401 CAGCCGACACCAAGAAGCA B CAGCCGACACCAAGAAGCATT B 4798 R-008399529-000J1684 1401 CAGCCGACACCAAGAAGCA UGGUUCUUGGUGUCGGCUGUU 4799R-008399535-000S  520    9 ACAGUAUGCAAUGAGUCGA UCGAGUCAUUGCAUACUGUUU4801 R-008399535-000S  520    9 ACAGUAUGCAAUGACUCGAB AGAGUAUGCAAUGACUCGATT B 4800 R-008399538-000T 1969  182AGAAAUAGUUGAAGGUUGU B AGAAAUAGUUGAAGGUUGUTT B 4802 R-008399538-000T 1969 182 AGAAAUAGUUGAAGGUUGU ACAACCUUCAACUAUUUCUUU 4803 R-008399541-000Z2017 1402 UGUUCACAACCGAAUUGUU B UGUUCACAACCGAAUUGUUTT B 4804R-008399591-000Z 2017 1402 UGUUCACAACCGAAUUGUU AACAAUUCGGUUGUGAACAUU4805 R-008399544-000A 2307 1403 GCUCUCUCUUCAGAACAGAB GCUCUCUCUUCAGAACAGATT B 4806 R-008399544-000A 2307 1403GCUCUCUCUUCAGAACAGA UCUGUUCUGAAGAGAGAGGUU 4807 R-008399547-000B  8441404 UCAGAUGGUGUCUGCUAUU B UCAGAUGGUGUCUGCUAUUTT B 4808 R-008399597-000B 844 1404 UCAGAUGGUGUCUGCUAUU AAUAGCAGACACCAUCUGAUU 4809R-008399550-000H  405 1405 UGAGUGGUAAAGGCAAUCC GGAUUGCCUUUACCACUCAUU4811 R-008399550-000H  405 1405 UGAGUGGUAAAGGCAAUCCB UGAGUGGUAAAGGCAAUCCTT B 4810 R-008399553-000J  379 1406UGGUGCCACUACCACAGCU B UGGUGCCACUACCACAGCUTT B 4812 R-008399553-000J  3791406 UGGUGCCACUACCACAGCU AGCUGUGGUAGUGGCACCAUU 4813 R-008399556-000K1825 1407 UUGUCCCGCAAAUCAUGCA B UUGUCCCGCAAAUCAUGCATT B 4814R-008399556-000K 1825 1407 UUGUCCCGCAAAUCAUGCA UGCAUGAUUUGCGGGACAAUU4815 R-008399559-000L 2495 1408 CACCCUGGUGCUGACUAUCGAUAGUCAGCACCAGGGUGUU 4817 R-008399559-000L 2495 1408CACCCUGGUGCUGACUAUC B CACCCUGGUGCUGACUAUCTT B 4816 R-008399562-000T  6291409 AAUGUCCAGCGUUUGGCUG B AAUGUCCAGCGUUUGGCUGTT B 4818 R-008399562-000T 629 1409 AAUGUCCAGCGUUUGGCUG CAGCCAAACGCUGGACAUUUU 4819R-008399565-000U 2561 1410 GGGCUGCCUCCAGGUGAGA UGUCACCUGGAGGCAGCCCUU4821 R-008399565-000U 2561 1410 GGGCUGCCUCCAGGUGACAB GGGCUGCCUCCAGGUGACATT B 4820 R-008399568-000V 2192 1411GAGUUACUUCACUCUAGUA B GAGUUACUUCACUCUAGGATT B 4822 R-008399568-000V 21921411 GAGUUACUUCACUCUAGUA UCCUAGAGUGAAGUAACUCUU 4823 R-008399571-000B1809 1412 UUCGAAAUCUUGCCCUUUG B UUCGAAAUCUUGCCCUUUGTT B 4824R-008399571-000B 1809 1412 UUCGAAAUCUUGCCCUUUG CAAAGGGCAAGAUUUCGAAUU4825 R-008399574-000C 1596 1413 GUAUAGAGGCUCUUGUGCGB GUAUAGAGGCUCUUGUGCGTT B 4826 R-008399574-000C 1596 1413GUAUAGAGGCUCUUGUGCG CGCACAAGAGCCUCUAUACUU 4827 R-008399577-000D 22981414 AGCUGACCAGCUCUCUCUU AAGAGAGAGCUGGUCAGCUUU 4829 R-008399577-000D2298 1414 AGCUGACCAGCUCUCUCUU B AGCUGACCAGCUCUCUCUUTT B 4828R-008399580-000K  858 1415 CUAUUGUACGUACCAUGCA UGCAUGGUACGUACAAUAGUU4831 R-008399580-000K  858 1415 CUAUUGUACGUACCAUGCAB CUAUUGUACGUACCAUGCATT B 4830 R-008399583-000L  524 1416UAUGCAAUGACUCGAGCUC B UAUGCAAUGACUCGAGCUCTT B 4832 R-008399583-000L  5241416 UAUGCAAUGACUCGAGCUC GAGCUCGAGUCAUUGCAUAUU 4833 R-008399586-000M2542 1417 UGCCCAGGACCUCAUGGAU B UGCCCAGGACCUCAUGGAUTT B 4834R-008399586-000M 2542 1417 UGCCCAGGACCUCAUGGAU AUCCAUGAGGUCCUGGGCAUU4835 R-008399589-000N  498 1418 AACAAGUAGCUGAUAUUGAB AACAAGUAGCUGAUAUUGATT B 4836 R-008399589-000N  498 1418AACAAGUAGCUGAUAUUGA UCAAUAUCAGCUACUUGUUUU 4837 R-008399592-000V  4141419 AAGGCAAUCCUGAGGAAGA UCUUCCUCAGGAUUGCCUUUU 4839 R-008399592-000V 414 1419 AAGGCAAUCCUGAGGAAGA B AAGGCAAUCCUGAGGAAGATT B 4838R-008399595-000W 1570 1420 CAAGAUGAUGGUCUGCCAA B CAAGAUGAUGGUCUGCCAATT B4840 R-008399595-000W 1570 1420 CAAGAUGAUGGUCUGCCAAUUGGCAGACCAUCAUCUUGUU 4841 R-008399598-000X 1030 1421UGCCAUUACAACUCUCCAC GUGGAGAGUUGUAAUGGCAUU 4843 R-008399598-000X 10301421 UGCCAUUACAACUCUCCAC B UGCCAUUACAACUCUCCACTT B 4842 R-008399601-000P1380   20 CAGAUCCAAGUCAACGUCU AGACGUUGACUUGGAUCUGUU 4845R-008399601-000P 1380   20 CAGAUCCAAGUCAACGUCU B CAGAUCCAAGUCAACGUCUTT B4844 R-008399604-000R 3087 1422 AUGUAUGGGUAGGGUAAAUB AUGUAUGGGUAGGGUAAAUTT B 4846 R-008399604-000R 3087 1422AUGUAUGGGUAGGGUAAAU AUUUACCCUACCCAUACAUUU 4847 R-008399607-000S 16641423 UGUGCUCUUCGUCAUCUGA B UGUGCUCUUCGUCAUCUGATT B 4848 R-008399607-000S1664 1423 UGUGCUCUUCGUCAUCUGA UCAGAUGACGAAGAGCACAUU 4849R-008399610-000Y 1790 1424 AAGGCUACUGUUGGAUUGA B AAGGCUACUGUUGGAUUGATT B4850 R-008399610-000Y 1790 1424 AAGGCUACUGUUGGAUUGAUCAAUCCAACAGUAGCCUUUU 4851 R-008399613-000Z 1615 1425UACUGUCCUUCGGGCUGGU ACCAGCCCGAAGGACAGUAUU 4853 R-008399613-000Z 16151425 UACUGUCCUUCGGGCUGGU B UACUGUCCUUCGGGCUGGUTT B 4852 R-008399616-000A 774 1426 AUAAGGCUGCAGUUAUGGU ACCAUAACUGCAGCCUUAUUU 4855R-008399616-000A  774 1426 AUAAGGCUGCAGUUAUGGU B AUAAGGCUGCAGUUAUGGUTT B4854 R-008399619-000B 1672 1427 UCGUCAUCUGACCAGCCGAUCGGCUGGUCAGAUGACGAUU 4857 R-008399619-000B 1672 1427UCGUCAUCUGACCAGCCGA B UCGUCAUCUGACCAGCCGATT B 4856 R-008399625-000J 31711428 GUUGUAACCUGCUGUGAUA UAUCACAGCAGGUUACAACUU 4859 R-008399625-000J3171 1428 GUUGUAACCUGCUGUGAUA B GUUGUAACCUGCUGUGAUATT B 4858R-008399628-000K 2271 1429 AAGAUUACAAGAAACGGCU B AAGAUUACAAGAAACGGCUTT B4860 R-008399628-000K 2271 1429 AAGAUUACAAGAAACGGCUAGCCGUUUCUUGUAAUCUUUU 4861 R-008399631-000S 1183 1430UUAUGGCAACCAAGAAAGC B UUAUGGCAACCAAGAAAGCTT B 4862 R-008399631-000S 11831430 UUAUGGCAACCAAGAAAGC GCUUUCUUGGUUGCCAUAAUU 4863 R-008399634-000T2512 1431 UCCAGUUGAUGGGCUGCCA B UCCAGUUGAUGGGCUGCCATT B 4864R-008399634-000T 2512 1431 UCCAGUUGAUGGGCUGCCA UGGCAGCCCAUCAACUGGAUU4865 R-008399637-000U 1521  132 CCUGUGGAGCUGGAAUUCUAGAAUUCCAGCUGCACAGGUU 4867 R-008399637-000U 1521  132CCUGUGCAGCUGGAAUUCU B CCUGUGCAGCUGGAAUUCUTT B 4866 R-008399640-000A 19311432 GGGACACAGCAGCAAUUUG CAAAUUGCUGCUGUGUCCCUU 4869 R-008399640-000A1931 1432 GGGACACAGCAGCAAUUUG B GGGACACAGCAGCAAUUUGTT B 4868R-008399643-000B 2468 1433 AUGAUGGAACAUGAGAUGG B AUGAUGGAACAUGAGAUGGTT B4870 R-008399643-000B 2468 1433 AUGAUGGAACAUGAGAUGGCCAUCUCAUGAUCCAUCAUUU 4871 R-008399646-000C 3077 1434UAUUUGGGAUAUGUAUGGG B UAUUUGGGAUAUGUAUGGGTT B 4872 R-008399646-000C 30771434 UAUUUGGGAUAUGUAUGGG CCCAUACAUAUCCCAAAUAUU 4873 R-008399649-000D2069 1435 CAGCUGCUUUAUUCUCCCA UGGGAGAAUAAAUCAGCUGUU 4875R-008399649-000D 2069 1435 CAGCUGCUUUAUUCUCCCA B CAGCUGCUUUAUUCUCCCATT B4874 R-008399652-000K  272 1436 GCUACUCAAGCUGAUUUGAB GCUACUCAAGCUGAUUUGATT B 4876 R-008399652-000K  272 1436GCUACUCAAGCUGAUUUGA UCAAAUCAGCUUGAGUAGCUU 4877 R-008399655-000L  5641437 UCCCUGAGACAUUAGAUGA UCAUCUAAUGUCUCAGGGAUU 4879 R-008399655-000L 564 1437 UCCCUGAGACAUUAGAUGA B UCCCUGAGACAUUAGAUGATT B 4878R-008399658-000M  437 1438 GUGGAUACCUCCCAAGUCC GGACUUGGGAGGUAUCCACUU4881 R-008399658-000M  437 1438 GUGGAUACCUCCCAAGUCCB GUGGAUACCUCCCAAGUCCTT B 4880 R-008399661-000U 2206 1439UAGGAAUGAAGGUGUGGCG B UAGGAAUGAAGGUGUGGCGTT B 4882 R-008399661-000U 22061439 UAGGAAUGAAGGUGUGGCG CGCCACACCUUCAUUCCUAUU 4883 R-008399664-000V2187 1440 UGACAGAGUUACUUCACUC GAGUGAAGUAACUCUGUCAUU 4885R-008399664-000V 2187 1440 UGACAGAGUUACUUCACUC B UGACAGAGUUACUUCACUCTT B4884 R-008399667-000W  325 1441 AGCGGCUGUUAGUCACUGGCCAGUGACUAACAGCCGCUUU 4887 R-008399667-000W  325 1441AGCGGCUGUUAGUCACUGG B AGCGGCUGUUAGUCACUGGTT B 4886 R-008399670-000C 32221442 AUGGUUCAGAAUUAAACUU B AUGGUUCAGAAUUAAACUUTT B 4888 R-008399670-000C3222 1442 AUGGUUCAGAAUUAAACUU AAGUUUAAUUCUGAACCAUUU 4889R-008399673-000D 2024 1443 AACCGAAUUGUUAUCAGAG B AACCGAAUUGUUAUCAGAGTT B4890 R-008399673-000D 2024 1443 AACCGAAUUGUUAUCAGAGCUCUGAUAACAAUUCGGUUUU 4891 R-008399676-000E 1858 1444GGGUGCCAUUCCACGACUA B GGGUGCCAUUCCACGACUATT B 4892 R-008399676-000E 18581444 GGGUGCCAUUCCACGACUA UAGUCGUGGAAUGGCACCCUU 4893 R-008399679-000F1574 1445 AUGAUGGUCUGCCAAGUGG B AUGAUGGUCUGCCAAGUGGTT B 4894R-008399679-000F 1574 1445 AUGAUGGUCUGCCAAGUGG CCACUUGGCAGACCAUCAUUU4895 R-008399682-000M 1638   78 GGGAAGACAUCACUGAGCCB GGGAAGACAUCACUGAGCCTT B 4896 R-008399682-000M 1638   78GGGAAGACAUCACUGAGCC GGCUCAGUGAUGUCUUCCCUU 4897 R-008399685-000N 18961446 CACAUCAGGAUACCCAGCG B CACAUCAGGAUACCCAGCGTT B 4898 R-008399685-000N1896 1446 CACAUCAGGAUACCCAGCG CGCUGGGUAUCCUGAUGUGUU 4899R-008399688-000P 2207 1447 AGGAAUGAAGGUGUGGCGA B AGGAAUGAAGGUGUGGCGATT B4900 R-008399688-000P 2207 1447 AGGAAUGAAGGUGUGGCGAUCGCCACACCUUCAUUCCUUU 4901 R-008399691-000W 1300 1448GAAGGUGCUAUCUGUCUGC B GAAGGUGCUAUCUGUCUGCTT B 4902 R-008399691-000W 13001448 GAAGGUGCUAUCUGUCUGC GCAGACAGAUAGCACCUUCUU 4903 R-008399694-000X1192 1449 CCAAGAAAGCAAGCUCAUC GAUGAGCUUGCUUUCUUGGUU 4905R-008399694-000X 1192 1449 CCAAGAAAGCAAGCUCAUC B CCAAGAAAGCAAGCUCAUCTT B4904 R-008399697-000Y  551 1450 CGAGCUGCUAUGUUCCCUGB CGAGCUGCUAUGUUCCCUGTT B 4906 R-008399697-000Y  551 1450CGAGCUGCUAUGUUCCCUG CAGGGAACAUAGCAGCUCGUU 4907 R-008399700-000R 24981451 CCUGGUGCUGACUAUCCAG B CCUGGUGCUGACUAUCCAGTT B 4908 R-008399700-000R2498 1451 CCUGGUGCUGACUAUCCAG CUGGAUAGUCAGCACCAGGUU 4909R-008399703-000S 1305 1452 UGCUAUCUGUCUGCUCUAG B UGCUAUCUGUCUGCUCUAGTT B4910 R-008399703-000S 1305 1452 UGCUAUCUGUCUGCUCUAGCUAGAGCAGACAGAUAGCAUU 4911 R-008399706-000T 1337 1453AUUGUAGAAGCUGGUGGAA B AUUGUAGAAGCUGGUGGAATT B 4912 R-008399706-000T 13371153 AUUGUAGAAGCUGGUGGAA UUCCACCAGCUUCUACAAUUU 4913 R-008472717-000G1870  194 ACGACUAGUUCAGUUGCUU B aCgaC UAguUCAGUUGCU U UsU B 2147R-008472717-000G 1870  194 ACGACUAGUUCAGUUGCUU aaGCAAcUgAAcuagUCGUUsU6367 R-008472765-000B 1870  194 ACGACUAGUUCAGUUGCUUaaGCaAcUGAAcuaGUCGUUsU 6368 R-008472765-000B 1870  194ACGACUAGUUCAGUUGCUU B aCgaC UAguUCAGUUGCU U UsU B 2147 R-008488882-000B1797    5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUU B 6370R-008488882-000B 1797    5 CUGUUGGAUUGAUUCGAAA uuucGAauCaAUCcAaCaGUU6369 R-008488887-000V 1870  194 ACGACUAGUUCAGUUGCUUaaGCAAcUgAaCuagUcGUUU 6371 R-008488887-000V 1870  194ACGACUAGUUCAGUUGCUU B aCgaC UAguUCAGUUGCU U UU B 6372 R-008488885-000C1870  194 ACGACUAGUUCAGUUGCUU aaGCAAcUgAAcuagUCGUUU 6373R-008488885-000C 1870  194 ACGACUAGUUCAGUUGCUU B aCgaC UAguUCAGUUGCU UUU B 6372 R-008488889-000M 1870  194 ACGACUAGUUCAGUUGCUU B aCgaCUAguUCAGUUGCU U UU B 6372 R-008488889-000M 1870  194 ACGACUAGUUCAGUUGCUUaaGCaAcUGAAcuaGUCGUUU 6374 wherein: A, C, G, and U = ribose A, C, G or Ua, g, c and u = 2′-deoxy-2′-fluoro A, G, C or U A, U, C and G= 2′-O-methyl (2′-OMe) A, U, C, or G A, U, C, and G = deoxy A, U, C, orG B = inverted abasic T = thymidine I = inosine s = phosphorothioatelinkage

Further Synthesis Steps for Commercial Preparation

Once analysis indicates that the target product purity has been achievedafter the annealing step, the material is transferred to the tangentialflow filtration (TFF) system for concentration and desalting, as opposedto doing this prior to the annealing step.

Ultrafiltration: The annealed product solution is concentrated using aTFF system containing an appropriate molecular weight cut-off membrane.Following concentration, the product solution is desalted viadiafiltration using water until the conductivity of the filtrate is thatof water.

Lyophilization: The concentrated solution is transferred to a bottle,flash frozen and attached to a lyophilizer. The product is thenfreeze-dried to a powder. The bottle is removed from the lyophilizer andis now ready for use.

Initial Screening Protocol (96-Well Plate Transfections)

Cell Culture Preparation:

Human hepatoma cell line, HepG2, rhesus kidney epithelial cell line,LLC-MK2 Derivative, and the Huh7 cell line, were grown in modifiedEagle's medium. All the culture media were supplemented with 10% fetalbovine serum, 100 μg/ML streptomycin, 100 U/ml, penicillin, and 1%sodium bicarbonate.

Transfection and Screening

Cells were plated in all wells of tissue-culture treated, plates at afinal count of 3500 (HepG2 find LLC-MK2 Derivative and Huh7) cells/wellin 100 μL of the appropriate culture media. The cells were cultured forovernight after plating at 37° C. in the presence of 5% CO₂.

On the next day, complexes containing siNA and RNAiMax (invitrogen) werecreated as follows. A solution of RNAiMax diluted 33-fold in OPTI-MEMwas prepared. In parallel, solutions of the siNAs for testing wereprepared to a final concentration of 120 nM in OPTI-MEM. Afterincubation of RNAiMax/OPTI-MEM solution at room temperature for 5 ruin,an equal volume of the siNA solution and the RNAiMax solution were addedtogether for each of the siNAs.

Mixing resulted in a solution of siNA/RNAiMax where the concentration ofsiNA was 60 nM. This solution was incubated at room temperature for 20minutes. After incubation, 20 μK of the solution was added to each ofthe relevant wells. The final concentration of siNA in each well was 10nM and the final volume of RNAiMax in each well was 0.3 ul.

For low concentration screens, siNAs were transfected at 200, 150, 100or 75 pM per well. For 12-point dose response curve studies, the siNAseries are 6-fold serial dilution starting at 300 nM or 4-fold serialdilution starting at 40 nM. All transfections were set up as multiplebiological replicates.

The time of incubation with the RNAiMax-siNA complexes was 24 hours andthere was no change in media between transfection and harvesting forscreening and dose response curve studies. For duration assays, the timeof incubation with the RNAiMax-siNA complexes was 24, 72, and 120 hours.There was no change in media between transfection and harvesting for 24-and 72-hour time points. Media was replaced with fresh media 72 hoursafter transfection for 120-hour time point.

Cells-to-Ct and Reverse Transcription Reactions

The culture medium was aspirated and discarded from the wells of theculture plates at the desired time points. The transfected cells werewashed once with 50 uL DPBS solution per well. Fifty microliters perwell of the Lysis Solution from the TaqMan® Gene Expression Cells-to-CT™Kit (Applied Biosystems, Cat #4399002) supplemented with DNase I wasadded directly to the plates to lyse the cells. Five microliters perwell of Stop Solution from the same kit was added to the plates toinactivate DNase I 5 minutes later. The lysis plates were incubated forat least 2 minutes at room temperature. The plates can be stored for 2hours at 4° C., or −80° C. tor two months.

Each well of the reverse transcription plate required 10 uL of 2×reverse transcriptase buffer, 1 uL of 20× reverse transcription enzymeand 2 uL of nuclease-free water. The reverse transcription master mixwas prepared by mixing 2× reverse transcription buffer, 20× reversetranscription enzyme mix, and nuclease-free water. 13 uL of the reversetranscription master mix was dispensed into each well of the reversetranscription plate (semi-skirted). A separate reverse transcriptionplate was prepared for each cell plate. A separate reverse transcriptionplate was prepared for each cell plate. Seven microliters per lysatefrom the cell lysis procedure described above was added into each wellof the reverse transcription plate. The plate was sealed and spun on acentrifuge (1000 rpm for 30 seconds) to settle the contents to thebottom of the reverse transcription plate. The plate was placed in athermocycler at 37° C. for 60 min, 95° C. for 5 min, and 4° C. until theplate is removed from the thermocycler. Upon removal, if not usedimmediately, the plate was frozen at −20° C.

For duration assays, a similar protocol was followed, however, the cellswere lysed 1, 3, or 5 days after transfection. cDNA was generated usingCells-to-Ct™ Kit (Applied Biosystems).

Quantitative RT-PCR (Taqman)

A series of probes and primers were used to detect the various mRNAtranscripts of the genes of CTNNB1 and GAPDH. All Taqman probes andprimers for the experiments here-in described were supplied aspre-validated sets by Applied Biosystems, Inc. (see Table 2).

TABLE 2 Probes and primers used to carry out Real-Time RT/PCR (Taqman)reactions for CTNNB1 mRNA analysis. Species Gene ABI Cat. # Human CTNNB1Hs00355045_m1 Human GAPDH 4310884E Rhesus GAPDH Rh02621745_g1 MouseCTNNB1 Mm00483033_m1 Mouse GAPDH 4352339E

The assays were performed on an ABI 7900 instrument, according to themanufacturer's instructions. A TagMan Gene Expression Master Mix(provided in the Cells-to-CT™ Kit, Applied Biosystems, Cat #4399002) wasused. The PCR reactions were carried out at 50° C. for 2 min, 95° C. for10 min followed by 40 cycles at 95° C. for 15 sees and 60° C. for 1minute.

Within each experiment, the baseline was set in the exponential phase ofthe amplification curve, and based on the intersection point of thebaselines with the amplification curve, a Ct value was assigned by theinstrument.

Calculations

The expression level of the gene of interest and % inhibition of geneexpression (% KD) was calculated using Comparative Ct method:

ΔCt=Ct _(Target) −Ct _(GAPDH)

ΔΔCt(Log 2(fold change))=ΔCt _((Target siNA)) −ΔCt _((NTC))

Relative expression level=^(−ΔΔCt)

% KD=100×(1−2^(−ΔΔCt))

The non-targeting control siNA was, unless otherwise indicated, chosenas the value against which to calculate the percent inhibition(knockdown) of gene expression, because it is the most relevant control.

Additionally, only normalized data, which reflects the general health ofthe cell and quality of the RNA extraction, was examined. This was doneby looking at the level of two different mRNAs in the treated cells, thefirst being the target LANA and the second being the normalizer mRNA.This allowed for elimination of siNAs that might be potentially toxic tocells rather than solely knocking down the gene of interest. This wasdone by comparing the Ct for GAPDH in each well relative to the GAPDH Ctfor the entire plate.

All calculations of IC₅₀s were performed using R.2.9.2 software. Thedata were analyzed using the sigmoidal dose-response (variable slope)equation for simple ligand binding. In all of the calculations of thepercent inhibition (knock-down), the calculation was made relative tothe normalized level of expression of the gene of interest in thesamples treated with the non-targeting control (Ctrl siNA) unlessotherwise indicated.

The level of protein was quantified using the Bio-Rad VersaDoc Imageraccording to the protocols of that piece of equipment. A pixel count wasperformed in each lane using an area of identical size. Each sample wasthen compared to the appropriate control treated sample and converted toa percent of protein remaining compared to control.

The effects of lead siNAs on CTNNB1 protein level were compared to theeffects of the universal control using a two tail Student's T-test toobtain a P value. P<0.05 was considered significant.

Results:

The CTNNB1 siNAs were designed and synthesized as described previously.Various siNAs were screened in HepG2, MK2D and Huh7 cells. The log 2(fold change) in CTNNB1 gene expression data upon treatment with variousmodified CTNNB1 siNAs in human cells is shown in Table 3a. Each screenwas performed at 24 hrs. Quantitative RT-PCR was used to assess thelevel of CTNNB1 mRNA and the data were normalized to the expressionlevel of GAPDH (an ubiquitously expressed ‘house-keeping’ gene). Eachtreatment was then normalized against the non-CTNNB1 targeting control.

TABLE 3a Primary screening data in HepG2 Cells, MK2D Cells and Huh7Cells (n = 2), recorded as log 2(fold change) in CTNNB1 gene expression.HEPG2 HEPG2 MK2D MK2D Huh7 Huh7 Mean SD Mean SD Mean SD siNA Duplex IDΔΔCt ΔΔCt ΔΔCt ΔΔCt ΔΔCt ΔΔCt R-008362875-000L 5.06 0.28 5.05 0.05 4.100.12 R-008362785-000U 4.92 0.24 4.98 0.05 4.05 0.14 R-008362959-000W4.76 0.11 4.90 0.14 3.99 0.05 R-008363073-000K 4.54 0.16 5.15 0.14 3.980.60 R-008308997-000F 4.27 0.32 4.86 0.17 3.97 0.16 R-008362932-000A4.57 0.50 5.13 0.13 3.97 0.11 R-008362713-000E 4.52 0.02 4.56 0.00 3.960.20 R-008362791-000B 5.14 0.21 5.96 0.04 3.94 0.06 R-008362689-000U5.16 0.20 5.24 0.04 3.94 0.08 R-008362692-000A 0.84 0.06 4.30 0.09 3.940.00 R-008363055-000T 4.87 0.16 5.19 0.11 3.86 0.13 R-008309033-000Y4.39 0.08 5.35 0.15 3.83 0.04 R-008363058-000U 4.20 0.23 4.68 0.22 3.830.43 R-008362755-000S 4.18 0.21 4.37 0.08 3.83 0.10 R-008362821-000P4.29 0.53 4.95 0.11 3.83 0.09 R-008362722-000N 5.37 0.36 5.27 0.19 3.820.25 R-008362824-000R 4.36 0.23 4.92 0.06 3.80 0.05 R-008363070-000J4.51 0.03 4.54 0.01 3.79 0.14 R-008362686-000T 4.84 0.26 5.03 0.08 3.790.34 R-008362947-000L 4.45 0.25 4.74 0.04 3.79 0.44 R-008362728-000R4.66 0.15 4.47 0.12 3.77 0.15 R-008363019-000H 4.75 0.08 5.06 0.05 3.770.21 R-008362833-000Z 4.26 0.11 4.61 0.15 3.75 0.09 R-008362812-000F4.79 0.14 4.93 0.17 3.75 0.37 R-008363064-000B 4.54 0.11 4.87 0.16 3.750.49 R-008362980-000V 1.07 0.02 4.48 0.13 3.73 0.09 R-008362992-000E0.35 0.09 4.24 0.04 3.72 0.00 R-008362872-000K 4.28 0.26 4.77 0.11 3.700.02 R-008362677-000J 4.37 0.06 4.60 0.01 3.68 0.08 R-008362878-000M3.85 0.09 4.54 0.06 3.67 0.01 R-008363031-000Y 4.82 0.26 5.19 0.14 3.650.00 R-008363043-000H 4.89 0.27 5.61 0.03 3.65 0.04 R-008362797-000D4.77 0.03 4.31 0.09 3.63 0.09 R-008362842-000H 3.92 0.00 4.71 0.09 3.630.26 R-008362704-000W 4.11 0.16 4.38 0.12 3.60 0.17 R-008362740-000F0.66 0.11 4.74 0.10 3.60 0.00 R-008362839-000B 4.10 0.22 4.43 0.16 3.570.40 R-008362950-000T 4.73 0.08 4.80 0.21 3.55 0.03 R-008363010-000E4.28 0.12 4.44 0.09 3.51 0.40 R-008362752-000R 3.42 0.03 2.93 0.04 3.500.33 R-008362854-000T 0.72 0.26 3.93 0.09 3.49 0.00 R-008362830-000Y4.59 0.12 4.90 0.04 3.48 0.03 R-008363016-000G 4.14 0.09 4.35 0.02 3.450.05 R-008362998-000G 4.29 0.18 4.05 0.12 3.45 0.01 R-008362674-000H4.55 0.14 4.55 0.01 3.45 0.32 R-008362938-000C 4.27 0.10 5.01 0.22 3.440.27 R-008362788-000V 4.11 0.21 4.48 0.09 3.44 0.11 R-008362884-000V4.11 0.08 4.90 0.13 3.44 0.11 R-008362896-000E 3.91 0.18 3.86 0.06 3.440.29 R-008363061-000A 3.84 0.17 4.34 0.01 3.43 0.14 R-008362782-000T3.73 0.60 5.27 0.13 3.43 0.43 R-008362776-000K 4.08 0.15 4.33 0.15 3.430.12 R-008362764-000A 1.00 0.02 4.82 0.14 3.40 0.31 R-008362683-000S0.85 0.00 4.80 0.12 3.39 0.32 R-008362869-000D 4.65 0.02 4.57 0.06 3.360.24 R-008309054-000S 0.88 0.01 4.27 0.08 3.36 0.12 R-008362746-000H4.22 0.08 4.85 0.07 3.35 0.47 R-008362935-000B 4.51 0.01 5.00 0.14 3.330.15 R-008362995-000F 3.52 0.02 4.80 0.02 3.31 0.25 R-008362923-000S4.16 0.16 4.15 0.08 3.31 0.09 R-008309099-000E 3.72 0.38 4.49 0.03 3.300.23 R-008362794-000C 3.97 0.05 3.81 0.05 3.30 0.12 R-008308556-000N4.54 0.04 4.69 0.19 3.29 0.13 R-008309087-000V 4.04 0.06 4.19 0.14 3.280.01 R-008362893-000D 0.66 0.15 4.31 0.05 3.27 0.20 R-008362725-000P4.20 0.22 4.54 0.23 3.26 0.05 R-008362863-000B 1.04 0.13 4.27 0.09 3.260.20 R-008362941-000J 3.93 0.42 4.38 0.16 3.24 0.34 R-008362929-000U1.45 0.05 3.98 0.08 3.23 0.04 R-008363052-000S 0.43 0.13 4.30 0.07 3.230.03 R-008362857-000U 1.73 0.12 3.70 0.08 3.23 0.37 R-008362758-000T0.70 0.16 4.19 0.10 3.22 0.41 R-008309048-000J 4.21 0.15 4.23 0.09 3.210.14 R-008363004-000X 3.76 0.12 4.55 0.07 3.20 0.43 R-008362719-000G3.88 0.16 4.61 0.31 3.20 0.09 R-008362671-000G 4.56 0.19 4.71 0.19 3.200.06 R-008363049-000K 3.40 0.08 3.01 0.01 3.19 0.22 R-008362902-000Y3.79 0.29 3.92 0.12 3.19 0.07 R-008363022-000P 4.32 0.21 4.06 0.12 3.140.43 R-008362848-000K 3.83 0.04 4.04 0.18 3.09 0.08 R-008362743-000G4.46 0.16 5.28 0.10 3.09 0.69 R-008362737-000Z 4.41 0.09 4.88 0.24 3.090.19 R-008362881-000U 0.77 0.02 4.08 0.10 3.09 0.05 R-008308601-000T4.21 0.54 4.56 0.02 3.08 0.17 R-008362983-000W 4.09 0.03 4.38 0.00 3.040.12 R-008362800-000W 4.42 0.15 4.69 0.06 3.02 0.38 R-008362971-000L4.10 0.14 4.48 0.05 3.02 0.01 R-008308661-000X 3.68 0.27 4.68 0.21 3.000.09 R-008362956-000V 3.89 0.10 3.97 0.19 3.00 0.05 R-008363001-00W 3.970.05 4.25 0.06 2.99 0.02 R-008362680-000R 4.22 0.16 4.33 0.12 2.99 0.31R-008309081-000T 3.97 0.11 4.21 0.01 2.99 0.35 R-008362860-000A 3.390.49 3.39 0.01 2.98 0.19 R-008362716-000F 3.87 0.10 4.27 0.19 2.96 0.20R-008362809-000Z 0.82 0.00 3.79 0.06 2.95 0.18 R-008308562-000W 3.850.14 4.09 0.09 2.94 0.01 R-008362989-000Y 4.11 0.07 4.27 0.01 2.94 0.01R-008309102-000X 3.95 0.05 3.89 0.20 2.90 0.11 R-008362773-000J 3.920.23 3.99 0.02 2.89 0.06 R-008362779-000L 4.30 0.20 4.46 0.02 2.85 0.86R-008362962-000C 3.67 0.08 3.59 0.09 2.82 0.00 R-008362905-000Z 3.330.22 3.81 0.08 2.78 0.14 R-008362707-000X 3.53 0.49 4.13 0.15 2.78 0.03R-008362977-000N 3.29 0.34 4.18 0.01 2.76 0.27 R-008362944-000K 3.560.19 3.31 0.13 2.75 0.19 R-008309018-000G 3.53 0.13 4.22 0.07 2.72 0.16R-008362770-000H 3.92 0.15 3.97 0.01 2.72 0.12 R-008362749-000J 3.290.13 3.60 0.02 2.68 0.09 R-008308496-000Y 3.83 0.21 4.49 0.11 2.67 0.41R-008362836-000A 0.49 0.02 3.94 0.05 2.67 0.81 R-008308667-000Z 4.420.01 4.60 0.03 2.65 0.45 R-008362926-000T 4.22 0.08 5.81 0.12 2.60 0.18R-008362851-000S 4.01 0.80 4.57 0.01 2.53 0.95 R-008363007-000Y 3.230.05 2.93 0.15 2.51 0.19 R-008362701-000V 3.94 0.09 4.32 0.13 2.51 0.48R-008362698-000C 4.10 0.03 4.15 0.13 2.50 0.24 R-008308625-000M 3.770.09 3.42 0.24 2.46 0.03 R-008362815-000G 4.27 0.20 4.14 0.09 2.46 0.51R-008363067-000C 4.14 0.27 5.42 0.16 2.46 0.06 R-008362914-000H 3.780.03 3.66 0.06 2.41 0.25 R-008363028-000S 0.86 0.01 4.10 0.07 2.39 0.09R-008362866-000C 3.42 0.03 3.68 0.01 2.38 0.07 R-008362695-000B 3.060.18 2.78 0.06 2.37 0.27 R-008363013-000F 3.56 0.24 3.93 0.11 2.37 0.16R-008362908-000A 3.20 0.11 2.63 0.01 2.35 0.09 R-008362917-000J 3.010.04 3.23 0.05 2.34 0.15 R-008308508-000U 4.18 0.04 4.17 0.02 2.29 0.58R-008308526-000L 0.59 0.04 3.87 0.09 2.27 0.15 R-008363034-000Z 0.780.17 3.95 0.02 2.27 0.30 R-008362827-000S 3.74 0.00 3.12 0.05 2.25 0.09R-008362968-000E 4.00 0.02 3.46 0.12 2.24 0.62 R-008309006-000X 2.950.26 2.59 0.04 2.24 0.07 R-008362734-000Y 4.06 0.02 4.33 0.15 2.21 0.41R-008362767-000B 4.22 0.05 4.19 0.13 2.13 0.41 R-008362806-000Y 0.730.04 2.89 0.02 2.08 0.56 R-008308724-000N 3.34 0.05 3.55 0.01 2.06 0.04R-008362818-000H 1.49 0.14 3.44 0.05 2.05 0.18 R-008309051-000R 2.380.12 2.71 0.06 2.04 0.30 R-008362920-000R 2.82 0.31 3.00 0.13 1.98 0.03R-008362965-000D 1.24 0.07 2.76 0.00 1.98 0.05 R-008308544-000D 0.530.03 3.67 0.07 1.97 0.04 R-008308523-000K 3.15 0.01 3.69 0.12 1.94 0.17R-008362986-000X 3.24 0.08 3.50 0.13 1.92 0.01 R-008362731-000X 3.620.04 2.96 0.09 1.77 1.24 R-008363046-000J 2.67 0.02 3.94 0.05 1.75 0.07R-008308733-000X 3.32 0.16 2.63 0.08 1.74 0.15 R-008362911-000G 0.750.04 2.74 0.10 1.73 0.26 R-008308706-000W 3.31 0.01 4.09 0.17 1.61 0.09R-008308709-000X 3.29 0.13 3.95 0.00 1.54 0.30 R-008362890-000C 0.900.03 1.03 0.22 1.35 0.34 R-008363025-000R 2.95 0.06 3.05 0.08 1.32 0.81R-008362953-000U 2.33 0.03 2.67 0.10 1.24 0.10 R-008362899-000F 1.500.17 2.77 0.03 1.24 0.13 R-008308697-000B 2.18 0.11 2.19 0.04 1.17 0.02R-008308589-000S 2.17 0.22 3.42 0.03 1.12 0.08 R-008308634-000W 2.410.11 2.66 0.01 1.09 0.11 R-008362710-000D 0.71 0.10 2.17 0.11 1.06 0.18R-008308493-000X 0.55 0.03 2.12 0.24 1.00 0.05 R-008308703-000V 0.870.02 1.69 0.02 0.95 0.13 R-008308568-000Y 2.84 0.14 2.85 0.23 0.63 0.41R-008362887-000W 0.83 0.14 0.93 0.09 0.33 0.07 R-008362974-000M 0.800.07 0.96 0.02 0.23 0.02 R-008363037-000A 0.69 0.09 0.85 0.05 0.12 0.03R-008363040-000G −0.07 0.02 −0.22 0.05 −0.19 0.09 R-008362845-000J −4.370.21 −1.50 0.07 −1.25 0.33 R-008362761-000Z −2.03 0.11 −3.54 0.05 −1.880.24 R-008308586-000R −1.64 0.18 −1.83 0.01 −2.27 0.31 R-008362803-000X−4.04 0.51 −4.61 0.01 −4.03 0.44

A subset of siNAs from Table 3a having a large log 2 (fold change in theprimary screen were rescreened in Huh7 cells. The results are shown inTable 3b.

TABLE 3b Primary screening data in Huh7 Cells (n = 2), recorded as log2(fold change) in CTNNB1 gene expression. Huh7 Huh7 Mean SD siNA DuplexID ΔΔCt ΔΔCt R-008362791-000B 4.24 0.05 R-008362812-000F 4.17 0.02R-008362689-000U 4.17 0.01 R-008362722-000N 4.17 0.04 R-008362932-000A4.07 0.17 R-008363043-000H 4.05 0.02 R-008362875-000L 4.03 0.12R-008308997-000F 3.99 0.35 R-008362947-000L 3.99 0.18 R-008362821-000P3.95 0.11 R-008362686-000T 3.94 0.13 R-008363070-000J 3.91 0.08R-008362824-000R 3.91 0.16 R-008362785-000U 3.88 0.06 R-008363031-000Y3.88 0.10 R-008363073-000K 3.87 0.19 R-008362782-000T 3.86 0.04R-008309033-000Y 3.85 0.00 R-008363064-000B 3.84 0.08 R-008362950-000T3.84 0.05 R-008362959-000W 3.83 0.28 R-008363019-000H 3.82 0.02R-008362842-000H 3.82 0.14 R-008363058-000U 3.75 0.11 R-008362713-000E3.73 0.08 R-008362938-000C 3.72 0.05 R-008362755-000S 3.71 0.16R-008362746-000H 3.59 0.22 R-008362830-000Y 3.56 0.16 R-008362704-000W3.55 0.11 R-008362839-000B 3.48 0.23 R-008362992-000E 3.45 0.04R-008363055-000T 3.44 0.26 R-008363061-000A 3.38 0.07 R-008362995-000F3.35 0.01

The CTNNB1 siNAs were designed and synthesized as described previously.Various siNAs were screened in M1K2D cells. The log 2 (fold change) inCTNNB1 gene expression data upon treatment with various modified CTNNB1siNAs in human cells is shown in Table 3c. Each screen was performed at24 hrs. Quantitative RT-PCR was used to assess the level of CTNNB1 mRNAand the data were normalized to the expression level of GAPDH (aubiquitously expressed ‘house-keeping’ gene). Each treatment was thennormalized against the non-CTNNB1 targeting control.

TABLE 3c Primary screening data in MK2D Cells (n = 2), recorded as log2(fold change) CTNNB1 gene expression. MK2D MK2D MEAN SD siNA Duplex IDΔΔCT ΔΔCT R-008395722-000P 4.06 0.06 R-008395725-000R 3.78 0.08R-008395749-000K 4.20 0.02 R-008395752-000S 5.53 0.06 R-008395758-000U2.41 0.01 R-008395761-000A 5.61 0.08 R-008395767-000C 3.00 0.00R-008395770-000J 5.53 0.18 R-008395779-000M 4.93 0.16 R-008395785-000V2.56 0.19 R-008395791-000C 6.76 0.23 R-008395800-000X 2.87 0.07R-008395827-000T 2.89 0.14 R-008395863-000C 1.65 0.22 R-008395881-000V3.94 0.05 R-008395887-000X 4.54 0.24 R-00839.5977-000P 5.63 0.47R-008395980-000W 4.31 0.27 R-008395995-000G 4.83 0.12 R-008396004-000Y3.16 0.01 R-008396022-000R 4.83 0.13 R-008396052-000T 4.08 0.08R-008396061-000B −0.99 0.08 R-008396067-000D 3.52 0.39 R-008396070-000K4.84 0.03 R-008396079-000N 4.32 0.04 R-008396103-000Z 3.67 0.07R-008396106-000A 5.34 0.03 R-008396109-000B −1.10 0.03 R-008396112-000H5.19 0.26 R-008396118-000K 3.23 0.01 R-008396136-000C −2.56R-008396142-000K −0.95 0.10 R-008396148-000M 3.84 0.24 R-008396151-000U4.60 0.08 R-008396154-000V 4.77 0.07 R-008396172-000M 6.28 0.06R-008396214-000K 2.82 0.29 R-008396220-000T 5.40 0.05 R-008396223-000U4.57 0.06 R-008396226-000V 2.27 0.12 R-008396247-000N 3.32 0.08R-008396250-000V 3.79 1.00 R-008396253-000W 6.42 0.03 R-008396259-000Y2.14 0.03 R-008396274-000P 5.39 0.18 R-008396292-000G 3.85 0.05R-008396295-000H 2.57 0.08 R-008396298-000J 3.00 0.22 R-008396301-000B2.10 0.24 R-008396304-000C 3.24 0.04 R-008396343-000N 2.49 0.07R-008396349-000R 4.00 0.08 R-008396379-000T 4.29 0.22 R-008396382-000Z−0.44 0.02 R-008396388-000B 3.90 0.18 R-008396391-000H 2.23 0.05R-008396409-000F 3.96 0.26 R-008396415-000N 4.72 0.00 R-008396418-000P4.48 0.20 R-008396421-000W 3.78 0.14 R-008396457-000A 3.89 0.01R-008396478-000U 4.62 0.03 R-008396481-000A 4.29 0.14 R-008396529-000A4.69 0.10 R-008396532-000G 4.46 0.05 R-008396538-000J 5.59 0.05R-008396544-000S 5.04 0.20 R-008396550-000Z 3.79 0.18 R-008396553-000A2.32 0.01 R-008396556-000B 2.85 0.07 R-008396559-000C 5.20 0.12R-008396613-000R 4.92 0.10 R-008396616-000S 2.90 0.01 R-008396619-000T4.67 0.37 R-008396622-000Z 4.09 0.08 R-008396631-000H 4.28 0.13R-008396685-000E 4.01 0.10 R-008396694-000N 4.73 0.12 R-008396697-000P1.56 0.16 R-008396730-000J 2.19 0.02 R-008396730-000J 3.24 0.03R-008396733-000K 1.43 0.10 R-008396736-000L 5.14 0.04 R-008396742-000U0.78 0.28 R-008396751-000C 3.62 0.13 R-008396754-000D 4.17 0.05R-008396793-000P 2.68 0.01 R-008396796-000R 4.94 0.03 R-008396820-000B4.70 0.08 R-008396826-000D 4.73 0.20 R-008396832-000L 3.63 0.10R-008396835-000M 2.84 0.85 R-008396838-000N 3.40 0.20 R-008396868-000R3.99 0.14 R-008396871-000X 4.62 0.12 R-008396874-000Y 4.01 0.02R-008396898-000T 3.11 0.32 R-008396904-000L 2.46 0.06 R-008396910-000U2.30 0.03 R-008396919-000X 4.06 0.23 R-008396934-000N 3.37 0.18R-008396943-000X 3.77 0.01 R-008396949-000Z 3.40 0.07 R-008396958-000H5.29 0.05 R-008396985-000J 5.25 0.09 R-008396994-000T 3.08 0.40R-008397015-000U 4.41 0.08 R-008397018-000V 1.73 0.03 R-008397021-000B5.50 0.05 R-008397024-000C 3.45 0.27 R-008397039-000N 4.21 0.04R-008397060-000M 1.76 0.08 R-008397069-000R 3.16 0.14 R-008397072-000X3.94 0.17 R-008397081-000F 3.02 0.02 R-008397108-000M 5.62 0.08R-008397111-000U 4.08 0.10 R-008397114-000V 3.50 0.03 R-008397132-000M3.97 0.16 R-008397138-000P 6.60 0.17 R-008397141-000W 4.58 0.02R-008397147-000Y 3.73 0.00 R-008397150-000E 6.44 0.11 R-008397153-000F2.43 0.03 R-008397156-000G 4.04 0.31 R-008397165-000R 3.44 0.01R-008397168-000S 3.29 0.15 R-008397180-000G 4.46 0.02 R-008397186-000J5.22 0.06 R-008397237-000R 2.77 0.04 R-008397243-000Y 3.31 0.23R-008397246-000Z 3.21 0.21 R-008397255-000H 3.77 0.05 R-008397258-000J1.91 0.02 R-008397306-000P 3.04 0.05 R-008397309-000R 3.16 0.05R-008397312-000X 5.97 0.13 R-008397315-000Y 4.19 0.33 R-008397342-000Z3.04 0.06 R-008397345-000A 4.87 0.03 R-008397348-000B 3.62 0.04R-008397351-000H 2.29 0.15 R-008397354-000J 4.81 0.09 R-008397372-000B4.40 0.10 R-008397381-000K 3.38 0.08 R-008397384-000L 3.95 0.14R-008397387-000M 6.11 0.04 R-008397390-000U 3.84 0.16 R-008397396-000W6.69 0.24 R-008397408-000S 5.61 0.05 R-008397417-000A 3.92 0.49R-008397420-000G 4.53 0.02 R-008397429-000K 2.91 0.05 R-008397450-000J2.53 0.05 R-008397459-000M 4.75 0.00 R-008397462-000U 5.28 0.17R-008397465-000V 4.45 0.18 R-008397468-000W 4.05 0.09 R-008397471-000C3.22 0.12 R-008397474-000D 4.06 0.21 R-008397519-000C 3.67 0.03R-008397531-000T 5.94 0.10 R-008397537-000V 4.20 0.07 R-008397540-000B5.04 0.12 R-008397564-000W 5.95 0.12 R-008397576-000F 3.39 0.05R-008397579-000G 2.94 0.02 R-008397582-000N 3.95 0.12 R-008397588-000R4.25 0.07 R-008397591-000X 5.25 0.06 R-008397594-000Y 3.81 0.00R-008397618-000D 4.58 0.03 R-008397630-000U 3.46 0.15 R-008397645-000E3.71 0.07 R-008397657-000P −1.50 0.14 R-008397660-000W 4.85 0.04R-008397663-000X 2.62 0.03 R-008397666-000Y 3.68 0.09 R-008397669-000Z2.80 0.78 R-008397702-000U 2.34 0.78 R-008397705-000V 5.13 0.20R-008397732-000W 3.27 0.01 R-008397735-000X 2.92 0.03 R-008397738-000Y3.97 0.06 R-008397768-000A 1.62 0.05 R-008397771-000G 4.45 0.17R-008397774-000H −1.15 0.02 R-008397777-000J −1.16 0.09 R-008397783-000S−1.16 0.03 R-008397807-000X 2.52 0.05 R-008397828-000R 4.36 0.27R-008397855-000S 1.94 0.01 R-008397858-000T 4.43 0.17 R-008397882-000T5.26 0.10 R-008397885-000U 2.53 0.01 R-008397888-000V 3.55 0.03R-008397933-000Z 4.19 0.22 R-008397966-000C 5.19 0.17 R-008397969-000D3.35 0.11 R-008397987-000W 4.95 0.16 R-008397990-000C 4.69 0.09R-008397993-000D 2.17 0.01 R-008397996-000E −1.14 002 R-008398002-000V3.74 0.10 R-008398020-000M 3.51 0.06 R-008398026-000P 5.64 0.06R-008398050-000P 3.57 0.10 R-008398056-000S 4.46 0.13 R-008398086-000U3.65 0.18 R-008398098-000D 3.93 0.04 R-008398119-000H 2.68 0.25R-008398137-000A 5.16 0.02 R-008398140-000G 3.87 0.14 R-008398140-000G4.86 0.03 R-008398143-000H 1.74 0.05 R-008398146-000J 3.95 0.12R-008398149-000K 4.45 0.03 R-008398155-000T 4.37 0.25 R-008398161-000A3.82 0.05 R-008398176-000L 3.83 0.14 R-008398182-000U 4.52 0.06R-008398227-000T 6.28 0.06 R-008398239-000C 2.48 0.02 R-008398242-000J3.81 0.03 R-008398245-000K 5.34 0.23 R-008398275-000M 1.53 0.08R-008398278-000N 2.71 0.07 R-008398281-000V 4.31 0.14 R-008398326-000U5.66 0.09 R-008398329-000V 3.83 0.26 R-008398332-000B 4.63 0.02R-008398362-000D 2.98 0.17 R-008398365-000E 5.06 0.06 R-008398368-000F4.37 0.03 R-008398374-000N 3.66 0.03 R-008398377-000P −1.12 0.02R-008398401-000A 4.57 0.18 R-008398413-000K 3.23 0.07 R-008398419-000M3.78 0.10 R-008398422-000U 2.63 0.05 R-008398425-000V 3.31 0.02R-008398428-000W 4.20 0.05 R-008398431-000C 4.82 0.02 R-008398434-000D2.54 0.06 R-008398437-000E 5.38 0.09 R-008398479-000S 5.16 0.41R-008398482-000Y 1.55 0.01 R-008398533-000E 3.60 0.01 R-008398539-000G4.85 0.07 R-008398542-000N 3.64 0.01 R-008398563-000G 5.22 0.27R-008398566-000H 2.69 0.13 R-008398575-000S 4.79 0.03 R-008398584-000A2.92 0.04 R-008398590-000H 4.97 0.13 R-008398593-000J 4.52 0.03R-008398617-000P 3.50 0.01 R-008398647-000S 4.34 0.23 R-008398650-000Y4.26 0.01 R-008398653-000Z 3.27 0.22 R-008398656-000A 5.36 0.15R-008398662-000H 5.03 0.42 R-008398665-000J 3.28 0.08 R-008398668-000K5.53 0.41 R-008398677-000U 4.94 0.03 R-008398686-000C 1.43 0.14R-008398701-000E 4.38 0.10 R-008398740-000R 3.54 0.04 R-008398749-000U2.72 0.18 R-008398782-000C 2.87 0.02 R-008398785-000D −1.10 0.05R-008398788-000E 5.61 0.09 R-008398815-000S 3.68 0.14 R-008398821-000Z5.75 0.00 R-008398830-000H 4.45 0.21 R-008398833-000J 4.61 0.05R-008398836-000K 3.83 0.01 R-008398863-000L −1.22 0.03 R-008398866-000M3.99 0.02 R-008398869-000N 4.06 0.32 R-008398872-000V 4.32 0.18R-008398875-000W 3.28 0.08 R-008398902-000H 5.58 0.03 R-008398917-000U2.05 0.13 R-008398923-000B 5.33 0.13 R-008398926-000C 2.22 0.07R-008398956-000E 3.78 0.15 R-008398962-000M 1.67 0.04 R-008398965-000N4.87 0.13 R-008398968-000P 3.76 0.21 R-008399031-000H 4.84 0.16R-008399034-000J 5.71 0.05 R-008399037-000K 2.86 0.08 R-008399049-000V3.77 0.01 R-008399058-000D 3.88 0.26 R-008399070-000U 5.31 0.00R-008399091-000M 4.67 0.01 R-008399103-000H 3.75 0.18 R-008399109-000K5.39 0.14 R-008399133-000K 3.73 0.05 R-008399145-000V 4.27 0.01R-008399172-000W 3.39 0.07 R-008399175-000X 3.44 0.11 R-008399181-000E3.37 0.06 R-008399184-000F 6.50 0.11 R-008399187-000G 4.29 0.10R-008399202-000J 4.09 0.44 R-008399205-000K 2.85 0.21 R-008399208-000L4.45 0.00 R-008399211-000T 4.08 0.08 R-008399214-000U 4.54 0.01R-008399226-000D 2.02 0.05 R-008399262-000N 4.13 0.06 R-008399265-000P3.87 0.03 R-008399268-000R 5.89 0.30 R-008399271-000X 4.44 0.18R-008399274-000Y 1.24 0.07 R-008399334-000N 2.96 0.22 R-008399343-000X3.86 0.02 R-008399370-000Y 1.45 0.92 R-008399373-000Z 3.64 0.17R-008399376-000A 4.79 0.22 R-008399382-000H 4.33 0.06 R-008399394-000T4.40 0.09 R-008399415-000X 3.21 0.15 R-008399418-000Y 3.33 0.13R-008399421-000E 3.57 0.21 R-008399436-000R −1.18 0.08 R-008399439-000S3.23 0.13 R-008399442-000Y 4.12 0.04 R-008399445-000Z −0.90 0.12R-008399451-000G 2.57 0.66 R-008399454-000H 1.55 0.01 R-008399457-000J2.95 0.00 R-008399481-000J 2.30 0.08 R-008399487-000L 2.81 0.26R-008399526-000H 5.38 0.35 R-008399535-000S 3.24 0.04 R-008399538-000T4.18 0.28 R-008399568-000V 3.85 0.13 R-008399571-000B 4.51 0.28R-008399589-000N 2.43 0.07 R-008399592-000V 5.11 0.02 R-008399604-000R−1.15 0.03 R-008399610-000Y 4.97 0.16 R-008399616-000A 2.18 0.03R-008399628-000K 4.04 0.00 R-008399634-000T 3.53 0.23 R-008399640-000A3.90 0.16 R-008399652-000K 4.94 0.03 R-008399655-000L 3.57 0.14R-008399658-000M 3.74 0.42 R-008399661-000U 3.01 0.06 R-008399664-000V3.84 0.16 R-008399670-000C 5.25 0.09 R-008399679-000F 3.51 0.29R-008399682-000M 1.20 0.08

Select high ranking siNAs from Tables 3a & 3b were further analyzed forefficacy and potency in Huh7 cells use dose response curves. The resultsfor these siNAs are shown in Table 4. The potency 50 is the calculatedsiNA transfection concentration that produces 50% target mRNA knockdown.The IC50 was determined after 24 hour exposure time.

TABLE 4 Dose response data for various siNAs in Huh 7 cells. Calculatedmaximum ΔΔCt is determined from the dose response curve. Mean SD POTENCYIC50 siNA Duplex ID ΔΔCt ΔΔCt 50 (nM) (nM) R-008362824-000R 4.18 0.090.02 0.02 R-008362821-000P 4.16 0.01 0.02 0.02 R-008363031-000Y 4.100.24 0.01 0.01 R-008362785-000U 4.00 0.31 0.03 0.03 R-008362686-000T3.98 0.18 0.07 0.06 R-008362782-000T 3.95 0.55 0.05 0.04R-008362875-000L 3.61 036 0.02 0.02 R-008308997-000F 3.59 0.14 0.02 0.02R-008362722-000N 3.58 0.23 0.03 0.02 R-008362791-000B 3.51 0.89 0.020.01 R-008362932-000A 3.48 0.46 0.02 0.02 R-008362689-000U 3.39 0.810.02 0.02 R-008363043-000H 3.29 0.01 0.02 0.02 R-008363073-000K 3.210.45 0.10 0.08 R-008362812-000F 3.07 0.40 0.03 0.03 R-008362947-000L3.07 0.28 0.02 0.01 R-008363070-000J 2.91 0.10 0.01 0.01

Additional siNAs from Tables 3a & 3b were farther analyzed for efficacyand potency in MK2D cells using dose response curves. The results forthese siNAs are shown in Table 5. The potency 50 is the calculated siNAtransfection concentration that produces 50% target mRNA knockdown. TheIC50 was determined after 24 hour exposure time.

TABLE 5 Dose response data for various siNAs in MK2D cells. Calculatedmaximum ΔΔCt is determined from the dose response curve. Mean SD IC50siNA Duplex ID ΔΔCt ΔΔCt (nM) R-008380929-000H002 6.8 0.03 0.004R-008488882-000B001 5.8 0.01 0.004 R-008488885-000C001 6.1 0.03 0.007R-008488887-000V001 6.6 0.02 0.004 R-008488889-000M001 6.4 0.23 0.005

Example 2: Determining In Vitro Serum Stability of siNAs

siNAs are reconstituted as 50 μM to 100 μM stock solution with H₂O andadded to human serum pre-warmed to 37° C. to a final concentration of 20μg/mL. The mixture is then incubated at 37° C. for 0, 1 and 2 hours. Atthe end of each time point, the reactions are stopped by mixing withequal volume of Phenomenex Lysis-Loading Buffer. Oligotrucleotides arepurified in 96-well format by Phenomenex Solid Phase Extraction andlyophilized until dry with Labconco Triad Lyo-00417. The lyophilizedsamples are reconstituted in 150 μL, of 1 mM EDTA prepared withRNase-free H₂O. The sample solutions re then diluted 5 fold with 1 mMEDTA for liquid chromatography/mass spectrometry (LC/MS) analysis onThermoFisher Orbitrap. Scrum metabolites of the siNAs were determinedbased on the measured molecular weights.

Example 3: Testing of Cytokine Induction

To assess immunostimulative effects of various siNAs of the inventionloaded in lipid nanoparticles (DLinDMA/Cholesterol/S-PEG-C-DMA/DSPC in a40/48/2/10 ratio), C57Bl/6 mice are dosed with a single 3 mpk dose ofLNP formulated siNAs through tail vein injection. Serum or plasmasamples are collected at 3 and 24 hours post-dose. The cytokine andchemokine levels in these samples is measured with the SearchLight IRCytokine Array from Aushon Biosciences according to the manufacturer'sinstruction. The cytokines and chemokines measured are IL-1α, IL-1β,IL-6, KC, IL-10, IFNγ, TNF, GMCSF, MIP-1β, MCP-1/JE, and RANTES.

Example 4: Efficacy Studies in Mouse

Mice are dosed IV via tail vein injections with LNP encapsulated siNAsor vehicle control using 2 different 3-week dosing schemes: one 1 mg/kgdose for 3 consecutive days or a single 6 mg/kg does per week. In someexperiments, the mice are co-dosed with sorafertib at a dose of 100mg/kg BID every day for 3 weeks. Total tumor burden is measured bymicro-CT scan imaging. The animals are sacrificed 5 days after the lastsiNA dose (Day 23), and normal liver and tumor tissues from each animalis collected for RNA purification. Total RNA is purified using RNeasy 96kit (Qiagen, Cat #74182), cDNA is generated from total RNA using HighCapacity cDNA Reverse Transcription Kit (Cat #: 4368813). QuantitativePCR reactions are performed with TaqMan. Universal PCR Master Mix (Cat#:4304437). Human CTNNB1 TaqMan Gene Expression Assay (Hs00355045_m1)and human GAPDH TaqMan. Gene Expression Assay is used to monitor themRNA level of both transcripts in tumor tissue. Mouse CTNNB1 TaqMan.Gene Expression Assay (Mm00483033_m1) and mouse GAPDH TaqMan GeneExpression Assay is used to monitor the mRNA level of both transcriptsin liver tissue. The expression level of CTNNB1 is normalized againstGAPDH to minimize technical variations.

Example 5: Pharmacodynamic Study in Non-Human Primates

Rhesus macaque monkeys are dosed with a single 2.5 mpk dose of siNAloaded lipid nanoparticles through intravenous infusion. To monitortarget mRNA knockdown, liver biopsies are performed at various timepoints pre- and post-dose with 16T gauge Menghini needles for about 20mg tissue per animal. Whole blood and serum/plasma is also collected atdifferent time points pre- and post-dose to monitor potential toxicityassociated with the treatments. All procedures adhere to the regulationsoutlined in the USDA Animal Welfare Act (9 CFR, Parts 1, 2 and 3) andthe conditions specified in The Guide for Care and Use of LaboratoryAnimals (ILAR publication, 1996, National Academy Press). Total RNA fromthe liver biopsy tissue was purified using RNeasy 96 kit (Qiagen, Cat;74182). cDNA was generated from total RNA using High Capacity cDNAReverse Transcription Kit (Cat #: 4368813). Quantitative PCR reactionswere performed with TagMan Universal PCR Master Mix (Cat #: 4304437),Human CTNNB1 TaqMan Gene Expression Assay (Hs00355045_ml) and rhesusGAPDH TagMan Gene Expression Assay (Rh02621745_g1) is used to monitorthe mRNA level of both transcripts in liver biopsy tissue. Theexpression level of CTNNB1 is normalized against GAPDH to minimizetechnical variations.

LNP formulations (DLinDMA/Cholesterol/S-PEG-C-DMA/DSPC in a 40/48/2/10ratio) comprising the siNA are tested. Log 2 (fold change) in CTNNB1gene expression is determined on days 3, 7, 11, and 28 days post-dosing.Pre-dose CTNNB1 expression levels for the monkey is measured 7 daysbefore the first dosing.

Example 6: Pharmacodynamic Studies in Mouse

Mice were dosed IV via tail vein injections with LNP encapsulated siNAsor vehicle control using a single 0.33 mg/kg. Five animals whichreceived each treatment were sacrificed 2, 7, 14 and 21 days after thesiNA dose, and liver tissues from each animal was collected for RNApurification. Total RNA was purified using RNeasy 96 kit (Qiagen, Cat#74182). cDNA was generated from total RNA using High Capacity cDNAReverse Transcription Kit (Cat #: 4368813). Quantitative PCR reactionswere performed with TagMan Universal PCR Master Mix (Cat #: 4304437).Mouse CTNNB1 TaqMan Gene Expression Assay (Mm00483033_ml) and mouseGAPDH TaqMan Gene Expression Assay was used to monitor the mRNA level ofboth transcripts. The expression level of CTNNB1 was normalized againstGAPDH to minimize technical variations. Data is shown in Table 6.

TABLE 6 In vivo screening data in C57Bl/6 mice, recorded as log 2(foldchange) in CTNNB1 gene expression. Day 2 Day 7 Day 14 Day 21 Mouse MouseMouse Mouse Mouse Mouse Mouse Mouse Mean SD Mean SD Mean SD Mean SD ΔΔCTΔΔCT ΔΔCT ΔΔCT ΔΔCT ΔΔCT ΔΔCT ΔΔCT PBS 0.00 0.23 0.00 0.21 0.00 0.160.00 0.15 R-008380929-000H 2.95 0.27 2.76 0.14 2.33 0.09 1.95 0.33R-008381104-000W 2.90 0.21 2.43 0.26 1.77 0.30 1.32 0.23R-008488882-000B 3.21 0.37 2.86 0.33 2.34 0.14 1.93 0.18R-008488885-000C 2.44 0.13 1.35 0.22 0.59 0.17 0.58 0.31R-008488887-000V 2.11 0.31 1.76 0.14 0.94 0.42 1.05 0.32R-008488889-000M 2.31 0.22 1.87 0.35 1.30 0.10 0.86 0.17

Example 7: Pharmacodynamic Study in Non-Human Primates

Rhesus macaque monkeys were dosed with a single 3.34 mg/m² of bodysurface area dose of siNA loaded lipid nanoparticles through intravenousinfusion. To monitor target snRNA knockdown, liver biopsies wereperformed at various time points pre- and post-dose with 16T gaugeMenghini needles for about 20 mg tissue per animal. Whole blood andserum/plasma is also collected at different time points pre- andpost-dose to monitor potential toxicity associated with the treatments.All procedures adhered to the regulations outlined in the USDA AnimalWelfare Act (9 CFR, Parts 1, 2 and 3) and the conditions specified inThe Guide for Care and Use of Laboratory Animals (ILAR publication,1996, National Academy Press). Total RNA from the liver biopsy tissuewas purified using RNeasy 96 kit (Qiagen, Cat #74182), cDNA wasgenerated from total RNA using High Capacity cDNA Reverse TranscriptionKit (Cat #: 4368813). Quantitative PCR reactions were, performed withTaqMan Universal PCR Master Mix (Cat #: 4304437). Human CTNNB1 TaqManGene Expression Assay (Hs00355045_m1) and rhesus GAPDH TaqMan GeneExpression Assay (Rh02621745_g1) was used to monitor the mRNA level ofboth transcripts in liver biopsy tissue. The expression level of CTNNB1was normalized against GAPDH to minimize technical variations. Data isshown in Table 7. LNP formulations (DLinDMA/Cholesterol/S-PEG-C-DMA/DSPCin a 40/48/2/10 ratio) comprising the siNA were tested. Log 2 (foldchange) in CTNNB1 gene expression was determined on days 2 and 7 dayspost-dosing. Pre-dose CTNNB1 expression levels for the monkey ismeasured 6 days before the first dosing.

TABLE 7 In vivo screening data in rhesus, recorded as log 2(fold change)in CTNNB1 gene expression. Day −6 Day 2 Day 7 Rhesus Rhesus RhesusRhesus Rhesus Rhesus Mean SD Mean SD Mean SD LNP siNA duplex ΔΔCT ΔΔCTΔΔCT ΔΔCT ΔΔCT ΔΔCT PBS 0.00 0.37 0.00 0.24 0.00 0.25 LNP-2R-008488882-000B −0.11 0.20 1.41 0.35 0.73 0.56 LNP-4 R-008488885-000C−0.15 0.13 1.79 0.46 1.64 0.59 LNP-1 R-008488889-000M 0.02 0.29 1.590.43 1.44 0.60 LNP-3 R-008380929-000H −0.10 0.25 1.89 0.17 1.60 0.04

Example 8: Short interfering nucleic acid Lipid Nanoparticle (LNP)Formulations A. General LNP Process Description for LAP Formulations:

The lipid nanoparticles were prepared by an impinging jet process. Theparticles were formed by mixing lipids dissolved in alcohol with siNAdissolved in a citrate buffer. The lipid solution contained a cationiclipid, a helper lipid (cholesterol), PEG (e.g. PEG-C-DMA, PEG-DMG)lipid, and DSPC at a concentration of 5-15 mg/mL with a target of 9-12mg/mL in an alcohol (for example ethanol). The ratio of the lipids had amole percent range of 25-98 for the cationic lipid with a target of35-65, the helper lipid had a mole percent range from 0-75 with a targetof 30-50, the PEG lipid has a mole percent range from 1-15 with a targetof 1-6, and the DSPC had a mole percent range of 0-15 with a target of0-12. The siNA solution contained one or more siNA sequences at aconcentration range from 0.3 to 0.6 mg/mL with a target of 0.3-0.9 mg/mLin a sodium citrate buffered salt solution with pH in the range of3.5-5. The two solutions were heated to a temperature in the range of15-40° C., targeting 30-40° C., and then mixed in an impinging jet mixerinstantly forming the LNP. The teeID had a range from 0.25 to 1.0 mm anda total flow rate from 10-600 mL/minute. The combination of flow rateand tubing ID had the effect of controlling the particle size of theLNPs between 30 and 200 inn. The LNP suspension was then mixed with abuffered solution at a higher pH with a mixing ratio in the range of 1:1to 1:3 vol:vol, but targeting 1:2 vol:vol. This buffered solution was ata temperature in the range of 15-40° C., targeting 30-40° C. This LNPsuspension was further mixed with a buffered solution at a higher pH andwith a mixing ratio in the range of 1:1 to 1:3 vol:vol, but targeting1:2 vol:vol. The buffered solution was at a temperature in the range of15-40° C., targeting 30-40° C. The mixed LNPs were held from 30 minutesto 2 hrs prior to an anion exchange filtration step. The temperatureduring incubating was in the range of 15−40° C., targeting 30-40° C.After incubating, the LNP suspension was filtered through a 0.8 umfilter containing an anion exchange separation step. This process usedtubing IDs ranging from 1 mm ID to 5 mm ID and a flow rate from 10 to2000 mL/minute The LNPs were concentrated and diafiltered via anultrafiltration process where the alcohol was removed and the citratebuffer was exchanged for the final buffer solution such as phosphatebuffered saline. The ultrafiltration process used a tangential flowfiltration format (TFF). This process used a membrane nominal molecularweight cutoff range from 30-500 KD. The membrane format was hollow fiberor flat sheet cassette. The TFF processes with the proper molecularweight cutoff retained the LNP in the retentate and the filtrate orpermeate contained the alcohol; citrate buffer; and final buffer wastes.The TFF process is a multiple step process with an initial concentrationto a siNA concentration of 1-3 mg/mL. Following concentration, the LNPsuspension was diafiltered against the final buffer for 10-20 volumes toremove the alcohol and perform buffer exchange. The material was thenconcentrated an additional 1-3 fold. The final steps of the LNP processwere to sterile filter the concentrated LNP solution and vial theproduct.

Analytical Procedure:

1) siNA Concentration

The siNA duplex concentrations were determined by Strong Anion-ExchangeHigh-Performance Liquid Chromatography (SAX-H PLC) using Waters 2695Alliance system (Water Corporation, Milford Mass.) with a 2996 PDAdetector. The LNPs, otherwise referred to as RNAi Delivery Vehicles(RDVs), were treated with 0.5% Triton X-100 to free total siNA andanalyzed by SAX separation using a Dionex BioLC DNAPac PA 200 (4×250 mm)column with UV detection at 254 nm. Mobile phase was composed of A: 25mM NaClO₄, 10 mM Tris, 20% EtOH, pH 7.0 and B: 250 mM. NaClO₄, 10 mMTris, 20% EtOH, pH 7.0 with a liner gradient from 0-15 min and a flowrate of 1 ml/minute. The siNA amount was determined by comparing to thesiNA standard curve.

2) Encapsulation Rate

Fluorescence reagent SYBR Gold was employed for RNA quantitation tomonitor the encapsulation rate of RDVs. RDVs with or without TritonX-100 were used to determine the free siNA and total siNA amount. Theassay is performed using a SpectraMax M5e microplate spectrophotometerfrom Molecular Devices (Sunnyvale, Calif.). Samples were excited at 485nm and fluorescence emission was measured at 530 nm. The siNA amount isdetermined by comparing to an siNA standard curve.

Encapsulation rate=(1−free siNA/total SiNA)×00%

3) Particle Size and Polydispersity

RDVs containing 1 μg siNA were diluted to a final volume of 3 ml with1×PBS. The particle size and polydispersity of the samples was measuredby a dynamic light scattering method using ZetaPALS instrument(Brookhaven instruments Corporation, Holtsville, N.Y.). The scatteredintensity was measured with He—Ne laser at 25° C. with a scatteringangle of 90°.

4) Zeta Potential Analysis

RDVs containing 1 μg siNA were diluted to a final volume of 2 ml with 1mM Tris buffer (pH 7.4). Electrophoretic mobility of samples wasdetermined using ZetaPALS instrument (Brookhaven instrumentsCorporation, Holtsville, N.Y.) with electrode and He—Ne laser as a lightsource. The Smoluchowski limit was assumed in the calculation of zetapotentials,

5) Lipid Analysis

Individual lipid concentrations were determined by Reverse PhaseHigh-Performance Liquid Chromatography (RP-HPLC) using Waters 2695Alliance system (Water Corporation, Milford Mass.) with a Corona chargedaerosol detector (CAD) (ESA Biosciences, Inc, Chelmsford, Mass.).Individual lipids in RDVs were analyzed using an Agilent Zorbax SB-C18(50×4.6 runt, 1.8 μm particle size) column with CAD at 60° C. The mobilephase was composed of A: 0.1% TEA in H₂O and B: 0.1% TEA in IPA. Thegradient changed from 60% mobile phase A and 40% mobile phase B fromtime 0 to 40% mobile phase A and 60% mobile phase B at 1.00 min; 40%mobile phase A and 60% mobile phase B from 1.00 to 5.00 min; 40% mobilephase A and 60% mobile phase B from 5.00 min to 25% mobile phase A and75% mobile phase B at 10.00 min; 25% mobile phase A and 75% mobile phaseB from 10.00 min to 5% mobile phase A and 95% mobile phase B at 15.00min and 5% mobile phase A and 95% mobile phase B from 15.00 to 60%mobile phase A and 40% mobile phase B at 20.00 min with a flow rate of 1ml/minute. The individual lipid concentration was determined bycomparing to the standard curve with all the lipid components in theRDVs with a quadratic curve fit. The molar percentage of each lipid wascalculated based on its molecular weight.

B. General LNP Preparation For Various Formulations in Table 11

siNA nanoparticle suspensions in Table 11 were prepared by dissolvingsiNAs and/or carrier molecules in 20 mM sodium citrate buffer (pH 5.0)at a concentration of about 0.40 mg/mL. Lipid solutions were prepared bydissolving a mixture of cationic lipid (e.g.,(13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, see structurein Table 12), DSPC, Cholesterol, and PEG-DMG (ratios shown in Table 11)in absolute ethanol at a concentration of about 8 mg/mL. The nitrogen tophosphate ratio was approximated to 6:1.

Nearly equal volumes of siNA/carrier and lipid solutions were deliveredwith two FPLC pumps at the same flow rates to a mixing T connector. Aback pressure valve wais used to adjust to the desired particle size.The resulting milky mixture was collected in a sterile glass bottle.This mixture was then diluted with an equal volume of citrate buffer,followed by equal volume of PBS (pH 7.4), and filtered through anion-exchange membrane to remove any free siNA/carrier in the mixture.Ultra filtration against PBS (7.4)) was employed to remove ethanol andto exchange buffer. The final LNP was obtained by concentrating to thedesired volume and sterile filtered through a 0.2 μm filter. Theobtained LNPs were characterized in term of particle size, Zetapotential, alcohol content, total lipid content, nucleic acidencapsulated, and total nucleic acid concentration.

LNP Manufacture Process

In a non-limiting example, LNPs were prepared in bulk as follows. Theprocess consisted of (1) preparing a lipid solution; (2) preparing ansiNA/carrier solution; (3) mixing/particle formation; (4) incubation;(5) dilution; (6) ultrafiltration and concentration.

1. Preparation of Lipid Solution

2 L glass reagent bottles and measuring cylinders were depyrogenated.The lipids were warmed to room temperature. Into the glass reagentbottle was transferred 8.0 g of(13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine with a pipetteand 1.2 g of DSPC, 3.5 g of Cholesterol, 0.9 g of PEG-DMG were added. Tothe mixture is added 1 L of ethanol. The reagent bottle was placed inheated water bath, at a temperature not exceeding 50° C. The lipidsuspension was stirred with a stir bar. A thermocouple probe was putinto the suspension through one neck of the round bottom flask with asealed adapter. The suspension was heated at 30-40° C. until it becameclear. The solution was allowed to cool to room temperature.

2. Preparation of siNA/Carrier Solution

Into a sterile container (Corning storage bottle) was weighed 0.4 gtimes the water correction factor (approximately 1.2) of siNA powder.The siNA was transferred to a depyrogenated 2 L glass reagent bottle.The weighing container was rinsed 3× with citrate buffer (20 mM, pH 5.0)and the rinses were placed into the 2 L glass bottle, QS with citratebuffer to 1 L. The concentration of the siNA solution was determinedwith a UV spectrometer using the following procedure. 20 μL at wasremoved from the solution, diluted 50 times to 1000 μL, and the UVreading recorded at A260 nm after blanking with citrate buffer. This wasrepeated. Note, if the readings for the two samples are consistent, anaverage can be taken and the concentration calculated based on theextinction coefficients of the siNAs. If the final concentration is outof the range of 0.40±0.01 mg/mL, the concentration can be adjusted byadding more siNA/carrier powder, or adding more citrate buffer. Thisprocess can be repeated for the second siNA, if applicable

When the siNA/carrier solution comprised a single siNA duplex instead ofa cocktail of two or more siNA duplexes and/or carriers, then thesiNA/carrier was dissolved in 20 mM citrate buffer (pH 5.0) to give afinal concentration of 0.4 mg/mL.

The lipid and ethanol solutions were then sterile filtered through aPall Acropak 20 0.8/0.2 μm sterile filter PN 12203 into a depyrogenatedglass vessel using a Master Flex Peristaltic Pump Model 7520-40 toprovide a sterile starting material for the encapsulation process. Thefiltration process was run at an 80 ml, scale with membrane area of 20cm². The flow rate was 280 mL/minute. This process can be scaled byincreasing the tubing diameter and the filtration area.

3. Particle Formation—Mixing Step

Using a two-barrel syringe driven pump (Harvard 33 Twin Syringe), thesterile lipid/ethanol solution and the sterile siNA/carrier orsiNA/carrier cocktail/citrate buffer (20 mM citrate buffer, pH 5.0)solutions were mixed in a 0.5 mm ID T-mixer (Mixing Stage 1) at equal,or nearly equal, flow rates. The resulting outlet LNP suspensioncontained 40-50 vol % ethanol. To obtain a 45 vol % ethanol outletsuspension, the sterile lipid/ethanol and the sterile siNA/carrier orsiNA/carrier cocktail/citrate buffer solutions were mixed at flow ratesof 54 mL/min and 66 mL/min, respectively, such that the total flow rateof the mixing outlet is 120 mL/min.

4. Dilution

The outlet stream of Mixing Stage I was fed directly into a 4 mm IDT-mixer (Mixing Stage II), where it was diluted with a buffered solutionat higher pH (20 mM sodium citrate, 300 mM sodium chloride, pH 6.0) at aratio of 1:1 vol:vol 1%. This buffered solution was at a temperature inthe range of 30-40′C, and was delivered to the 4 mm T-mixer via aperistaltic pump (Cole Parmer Masterflex L/S 600 RPM) at a flow rate of120 mL/min.

The outlet stream of Mixing Stage II was fed directly into a 6 min IDT-mixer (Mixing Stage III), where it was diluted with a bufferedsolution at higher pH (PBS, pH 7.4) at a ratio of 1:1 vol:vol %. Thisbuffered solution was at a temperature in the range of 15-25° C., andwas delivered to the 6 mm T-mixer via peristaltic pump (Cole ParmerMasterFlex L/S 600 RPM) at a flow rate of 240 mil min.

5. Incubation Free siNA Removal

The outlet stream of Mixing Stage III was held after mixing for 30minute incubation. The incubation was conducted at temperature of 35-40°C. and the in-process suspension was protected from light. Followingincubation, free (un-encapsulated) siNA was removed via anion exchangewith Mustang Q chromatography filters (capsules). Prior to use, thechromatography filters were pre-treated sequentially with flushes of 1NNa0H, 1M NaCl, and a final solution of 12.5 vol % ethanol in PBS. The pHof the final flush was checked to ensure pH <8. The incubated LNP streamwas then filtered via Mustang Q filters via peristaltic pump (ColePartner MasterFlex L/S 600 RPM) at flow rate of approximately 100mL/min. The filtered stream was received into a sterile glass containerfor ultrafiltration and concentration as follows.

6. Ultrafiltration, Concentration and Sterile Filtration

The ultrafiltration process is a timed process and the flow rates mustbe monitored carefully. This is a two step process; the first is aconcentration step taking the diluted material and concentratingapproximately 8-fold, to a concentration of approximately 0.3-0.6 mg/mLsiNA.

In the first step, a ring-stand with a ultrafiltration membrane 100 kDaPES (Spectrum Labs) installed was attached to a peristaltic pump(Spectrum KrosFloII System). 9.2 L of sterile distilled water was addedto the reservoir; 3 L was drained to waste and the remainder was drainedthrough permeate to waste. 5.3 L of 0.25 N sodium hydroxide was added tothe reservoir with 1.5 L drained to waste and 3.1 L drained throughpermeate to waste. The remaining sodium hydroxide was held in the systemfor sanitization (at least 10 minutes), and then the pump was drained,9.2 L of 70 (v/v) % isopropyl alcohol was added to the reservoir with1.5 L drained to waste and the remainder drained through permeate towaste. 6 L of conditioning buffer (12.5% ethanol in phosphate bufferedsaline) was added with 1.5 L drained to waste and the remainder drainedthough the permeate until the waste was of neutral pH (7-8). A membraneflux value was recorded, and the pump was then drained.

The diluted LNP solution was placed into the reservoir to the 1.1 Lmark. The pump was turned on at 2.3 L/min. After 5 minutes ofrecirculation, the permeate pump was turned on at 62.5 mL/min and theliquid level was constant at approximately 950 mL in the reservoir. Thediluted LNP solution was concentrated from 9.8 L to 1.1 L in 140minutes, and the pump was paused when all the diluted LNP solution hasbeen transferred to the reservoir.

The second step was a diafiltration step exchanging the ethanol/aqueousbuffer to phosphate buffered saline. During this step, approximately10-20 diafiltration volumes of phosphate buffered saline were used.Following diafiltration, a second concentration was undertaken toconcentrate the LNP suspension 3-fold to approximately 1-1.5 mg/mLsiRNA. The concentrated suspension was collected into sterile, plasticPETG bottles. The final suspension was then filtered sequentially viaPall 0.45 um PES and Pall 0.2 um PES titters for terminal sterilizationprior to vial filling.

The obtained LNPs were characterized in terms of particle size, Zetapotential, alcohol content, total lipid content, nucleic acidencapsulated, and total nucleic acid concentration.

C. Synthesis of Novel Cationic Lipids

Synthesis of the novel cationic lipids is a linear process starting fromlipid acid (i). Coupling to N,O-dimethyl hydroxylamine gives the Weinrebamide ii. Grignard addition generates ketone iii. Titanium mediatedreductive amination gives final products of type iv.

Synthesis of the single carbon homologated cationic lipids v is a linearprocess starting from lipid ketone (iii). Conversion of the ketone tothe nitrile (iv) is accomplished via treatment with TOSMIC and potassiumtert-butoxide. Reduction of the nitrite to the primary amine followed byreductive amination provides final cationic lipids v.

Synthesis of two carbon homologated cationic lipids vii is a linearprocess starting from lipid ketone (iii). Conversion of the ketone tothe α,β-unsaturated amide vi is accomplished under Peterson conditions.Conjugate reduction of the α,β-unsaturation is performed usingLS-Selectride to give amide vii. Reduction of the amide with lithiumaluminum hydride provides final cationic lipids viii.

Cyclopropyl containing lipids are prepared according to General Scheme4. Unsaturated Weinreb amides ii are subjected to Simmons-Smithcyclopropanation conditions to give cyclopropyl containing Weinrebamides ix. These are carried on to final products as outlined in GeneralSchemes 1-3.

Synthesis of allylic amine cationic lipids xv is a linear processstarting with aldehyde x. Addition of t-butyl acetate generatesP-hydroxy ester xi. Conversion of the hydroxyl functionality to a fluorogroup followed by acid treatment generates β-fluoro acid xii. Conversionof the acid to the Weinreb amide followed by Grignard addition gives theβ-fluoro ketone xiv. Reductive amination results in simultaneouselimination to generate the desired allylic amine xv.

20,23-nonacosadien-10-amine, N,N-dimethyl-, (20Z,23Z) (Compound 1)

11,14-Eicosadienoic acid, (11Z,14Z)— (50 g, 162 mmol),N,O-Dimethythydroxylamine hydrochloride (31.6 g, 324 mmol), HOAt (44.1g, 324 mmol), Et₃N (45.2 mL, 324 mmol), and EDC (62.1 g, 324 mmol) weremixed in DCM (810 mL) and stirred overnight at ambient temperature.Reaction was then washed 5×700 mL water, then washed 1×600 mL, 1 M NaOH,dried with sodium sulfate, filtered through celite and evaporated toobtain 53.06 g (93%) 11,14-eicosadienamide, N-methoxy-N-methyl-,(11Z,14Z) as a clear golden oil.

¹H NMR (400 MHz, CDCl₃) δ 5.35 (m, 4H), 3.68 (s, 3H), 3.18 (s, 3H), 2.77(m, 2H), 2.41 (t, J=7 Hz, 2H), 2.05 (m, 4H), 1.63 (m, 2H), 1.40-1.26 (m,18H), 0.89 (t, J=7 Hz, 3H).

11,14-eicosadienamide, N-methoxy-N-methyl-, (11Z,14Z)-1 (4 g, 11.38mmol) was dissolved in dry THF (50.0 ml) in a 250 mL flask then 1 Mnonylmagnesium bromide (22.76 22.76 mmol) was added under nitrogen atambient temperature. After 10 min, the reaction was slowly quenched withexcess sat. aq NH₄Cl. The reaction was washed into a separator), funnelwith hexane and water, shaken, the lower aqueous layer discarded, theupper layer dried with sodium sulfate, filtered, and evaporated to givecrude ketone as a golden oil. To the above crude ketone was addeddimethylamine (2 M in THF) (14.22 ml, 28.4 mmol) followed by Ti(O-i-Pr)₄(6.67 ml, 22.76 mmol) and let stir overnight. The next day, added EtOH(50 ml) followed by NaBH₄ (0.646 g, 17.07 mmol). After 5 min ofstirring, directly injected entire reaction onto a 40 g silica columnthat was in hue with a 330 g silica column. Eluted 10 min 100% DCM, then30 min 0-15% MeOH/DCM, collected 20,23-nonacosadien-10-amine,N,N-dimenthyl, (20Z,23Z) (1) (2.45 g, 5.47 mmol, 48.1% yield) as afaintly golden oil. ¹H NMR (400 MHz, CDCl₃) δ 5.35 (m, 4H), 2.78 (m,2H), 2.23 (m, 1H), 2.21 (s, 6H), 2.05 (m, 4H), 1.45-1.16 (n, 38H), 0.89(m, 6H), HRMS calcd for C31H61N, 448.4877, found 448.4872.

Compounds 2-30 are novel cationic lipids and were prepared according tothe General Scheme 1 above.

Compound Structure HRMS  2

calcd C28H56N 406.4407, found 406.4405.  3

calcd C27H54N 392.4251, found 392.4250.  4

calcd C24H48N 350.3781, found 350.3770.  5

calcd C23H46N 336.3625, found 336.3613.  6

calcd C25H50N 364.3938, found 364.3941.  7

calcd C26H52N 378.4094, found 378.4081.  8

calcd C29H58N 420.4564, found 420.4562.  9

calcd C26H52N 378.4094, found 378.4089. 10

calcd C25H50N 364.3938, found 364.3931. 11

calcd C30H60N 434.4720, found 434.4717. 12

calcd C29H58N 420.4564, found 420.4561. 13

calcd C28H56N 406.4407, found 406.4404. 14

calcd C27H54N 392.4251, found 392.4245. 15

calcd C33H66N 476.5190, found 476.5196. 16

calcd C32H64N 462.5033, found 462.5045. 17

calcd C29H59N 422.4720, found 422.4726. 18

calcd C28H57N 408.4564, found 408.4570. 19

calcd C30H59N 434.4720, found 434.4729. 20

calcd C29H61N 424.4877, found 424.4875. 21

calcd C32H64N 462.5033, found 462.5023. 22

calcd C33H64N 474.5033, found 474.5033. 23

calcd C29H60N 422.4720, found 422.4716. 24

calcd C29H60N 422.4720, found 422.4718. 25

calcd C31H64N 450.5033, found 450.5031. 26

calcd C31H64N 450.5033, found 450.5034. 27

calcd C35H72N 506.5659, found 506.5635. 28

calcd C31H64N 450.5033, found 450.5037. 29

calcd C33H68N 478.5346, found 478.5358. 30

calcd C27H56N 394.4407, found 394.4407.

(12Z,15Z)—N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine (Compound 31)

A solution of keton iii (4.0 g, 9.55 mmol), TOSMIC (2.4 g, 12.4 mmol) indimethoxyethane (45 mL) was cooled to 0° C. and treated with potassiumCert-butoxide (19.1 mmol, 19.1 mL of a 1M solution in tBuOH). After 90minutes, the reaction was partitioned between hexanes and water. Theorganics were washed with water, dried over sodium sulfate, filtered andevaporated in vacuo. This material was purified by flash chromatography(0-5% EtOAc/hexanes) to give desired product (containing ˜20% of s.m.).This mixture was carried into next step as is, LC/MS (M+H)=430.6.

Lithium aluminum hydride (23.9 mmol, 23.9 mL of a 1M solution in THF)was added directly to nitrile iv (3.42 g, 8 mmol) at ambient temperatureand the reaction was stirred for 20 minutes. The reaction was dilutedwith 100 mL THF, cooled to 0° C. and carefully quenched with sodiumsulfate decahydrate solution. The solids were filtered off and washedwith THF. The filtrate was evaporated in vacuo and carried directly intonext reaction crude. LC/MS (M+H)=434.6.

A solution of primary amine (3.45 g, 6.2 mmol) in dichloroethane (100mL) was treated with formaldehyde (1.6 mL, 21.7 mmol) followed by sodiumtriacetoxyborohydride (6.6 g, 31 mmol). After 5 minutes, the reactionwas partitioned between dichloromethane and 1N NaOH. The organics weredried over sodium sulfate, filtered and evaporated in vacuo. The crudemixture was purified by reverse phase preparative chromatography (C8column) to provide(12Z,15Z)—N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine. HRMS calc'd462.5033, found 462.5026. ¹H NMR (400 MHz, CDCl₃) δ 5.35 (m, 4H), 2.78(2H, t, J=5.6 Hz), 2.18 (s, 6H), 2.05 (m, 6H), 1.3 (m, 39H), 0.89 (m,6H).

(13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine (Compound 32)

The silyl amide Peterson reagent (3.1 g, 16.7 mmol) was dissolved in THF(35 mL) and cooled to −63° C. To this solution was added nBuLi (16.7mmol, 6.7 mL of a 2,5M solution). The reaction was warmed to ambienttemperature for 30 minutes. The ketone (5.0 g, 11.9 mmol) was dissolvedin THF (25 mL) in a second flask. The Peterson reagent was transferredto the ketone solution at −60 The reaction was warmed to −40° C. for 1hour, then warmed to 0° C. for 30 minutes. The reaction was quenchedwith sodium bicarbonate, diluted with additional water and partitionedbetween water/hexanes. The organics were washed with brine, dried oversodium sulfate, filtered and evaporated in vacuo. Purification by flashchromatography (0-40% MTBE/hexanes) gave α,β-unsutured amide vi. ¹H NMR(400 MHz, CDCl₃) δ 5.75 (s, 1H), 5.36 (m, 4H), 3.01 (s, 3H), 2.99 (s,3H), 2.78 (t, 2H), 2.28 (t, 2H), 2.05 (m, 6H), 1.35 (m, 34H), 0.89 (m,6H).

α,β-unsatured amide vi (1 g, 2.1 mmol) and LS-Selectride (4.1 mmol, 4.1mL of a 1M solution) were combined in a sealed tube and heated to 60° C.for 24 hours. The reaction was cooled to ambient temperature andpartitioned between ammonium chloride solution and heptane. The organicswere dried over sodium sulfate, filtered and evaporated in vacuo to giveamide vii. This intermediate was carried directly into next reactioncrude.

To a solution of amide vii (2.85 g, 5.8 mmol) was added lithium aluminumhydride (8.7 mmol, 8.7 mL of a 1M solution). The reaction was stirred atambient temperature for 10 minutes then quenched by slow addition ofsodium sulfate decahydrate solution. The solids were filtered and washedwith THF and the filtrate evaporated in vacuo. The crude mixture waspurified by reverse phase preparative chromatography (C8 column) toprovide (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine(Compound 32) as an oil. FIRMS (M+H) calc'd 476.5190, found 476.5189. ¹HNMR (400 MHz, CDCl₃) δ 5.37 (m, 4H), 2.78 (t, 2H), 2.42 (m, 8H), 2.05(q, 4H), 1.28 (m, 41H), 0.89 (m, 6H).

N,N-dimethyl-1-(2-octylcyclopropyl)heptadecan-8-amine (Compound 33)

To a solution of oleic acid (1 g, 3.5 mmol) in DCM (500 mL) cooled to 0°C. was added CDI (0.63 g, 3.9 mmol). The reaction was warmed to ambienttemperature for 30 minutes before cooling to 0° C. and treating firstwith triethylamine (0.39 g, 3.9 mmol) and then dimethyl hydroxylaminehydrochloride (0.38 g, 3.9 mmol). After 1 hour the reaction waspartitioned between water and heptane. The organics were dried overmagnesium sulfate, filtered and evaporate in vacuo to give crude Weinrebamide ii which was carried directly into next reaction.

A solution of diethylzine (70.3 mmol, 70.3 mL of a 1M solution) indichloromethane (130 mL) was cooled to −1° C. and treated dropwise withTEA (8.0 g, 70.3 mmol). After 30 minutes, diiodomethane (18.8 g, 70.3mmol) was added and this was aged for 30 minutes in the ice bath. Tothis solution was added Weinreb amide ii (7.6 g, 23.4 mmol). Thereaction was warmed to ambient temperature and stirred for 1 hour. Thereaction was quenched with ammonium chloride solution (100 mL) andorganic layer partitioned off, washed with 10% sodium thiosulfate, driedover magnesium sulfate, filtered and evaporated in vacuo. Purificationwas flash chromatography (0-30% MTBE/heptane) gave desired product ix.¹H NMR (400 MHz, CDCl₃) δ 3.72 (s, 3H), 3.22 (s, 3H), 2.48 (t, 2H), 1.65(m, 2H), 1.39 (m, 22H), 1.18 (m, 2H), 0.91 (t, 3H), 0.68 (m, 21), 0.59(m, −0.32 (m, 1H).

Conversion of Weinreb amide ix to Compound 33 was carried out in amanner analogous to that described for Compound 1 above (nonyl Grignardaddition followed by reductive amination). LC/MS (M+H)=436.6. ¹H NMR(400 MHz, CDCl₃) δ 2.25 (s, 6H), 1.30 (m, 45H), 0.91 (m, 6H), 0.68 (m,2H), 0.59 (m, 1H), −0.31 (m, 1H).

Compounds 34-43 are novel cationic lipids and were prepared according toGeneral Schemes 1-4 above.

Compound Structure HRMS 34

calcd C30H62N 436.4877, found 436.4872. 35

calcd C32H66N 464.5190, found 464.5186. 36

calcd C34H70N 492.5503, found 492.5496. 37

calcd C33H66N 476.5190, found 476.5174. 38

caled C29H60N 422.4720, found 422.4701. 39

calcd C30H62N 436.4877, found 436.4880. 40

calcd C32H66N 464.5190, found 464.5199. 41

calcd C30H62N 436.4877, found 436.4877. 42

caled C30H62N 436.4877, found 436.4875. 43

LC/MS (M + H) 408.6.

(11E,20Z,23Z)—N,N-dimethylnonacosa-11,20,23-trien-10-amine (Compound 44)

To a solution of LDA (95 mmol, 47.5 mL of a 2M solution) in THF (127 mL)cooled to −78° C. was added t-butyl acetate. The reaction was stirredfor 15 minutes followed by addition of aldehyde x. The reaction wasimmediately quenched with ammonium chloride solution, warmed to ambienttemperature and partitioned between water/pentane. The organics weredried over sodium sulfate, filtered and evaporated in vacuo. LC/MS(M+H−tBu)=325.4.

Hydroxy ketone xi (7 g, 18.4 mmol) was dissolved in dichloromethane (150mL) and cooled to 0° C. and treated with deoxofluor (7.3 g, 33.1 mmol).The reaction was warmed to ambient temperature with stirring for 16hours followed by quenching with sodium bicarbonate solution. Thereaction was partitioned and the organics dried over sodium sulfate,filtered and evaporate in vacuo. Flash column chromotagraphy (0-5% ethylacetate/hexanes) gave the—fluoro ester.

Fluoro ester intermediate (6 g, 15.6 mmol) in dichloromethane wastreated with hydrogen chloride (157 mmol, 39.2 mL of a 4M solution indioxane) and the reaction was stirred at ambient temperature for 16hours. The reaction was evaporated in vacuo to give desired β-fluoroacid xii. LC/MS (M+H)=327.3.

Fluoro carboxylic acid xii (5.1 g, 15.7 mmol), EDC (6.0 g, 31.4 mmol),N,O-dimethylhydroxylamine hydrochloride (3.1 g, 31.4 mmol),trimethylamine (4.0 g, 39.2 mmol), and HOAt (4.3 g, 31.4 mmol) werecombined in DCM (78 mL) and stirred at ambient temperature for 16 hours.The reaction was partitioned between water/DCM and the organics werewashed with water (3×) and NaOH solution (1×), dried over sodiumsulfate, filtered and evaporated in vacuo. Crude material was purifiedby reverse phase preparative chromatography to give desired Weinrebamide xiii. LC/MS (M+H)=370.4.

A solution of Weinreb amide xiii (4.3 g, 11.7 mmol) in THF (50 mL) wastreated with nonylmagnesium bromide (23.4 mmol, 23.4 mL of a 1Msolution) at ambient temperature. The reaction was quenched withammonium chloride solution after 1 hour and partitioned between waterand pentane. The organics were dried over sodium sulfate; filtered andevaporated in vacuo. This material was carried into next step crude.

Ketone xiv (5.1 g, 11.7 mmol) was treated with dimethylamine (29.3 mmol,14.7 mL of a 2M solution in THF) and titanium(IV) isopropoxide (6.7 g,23.5 mmol) and the reaction was stirred at ambient temperature for 16hours. To the reaction mixture was added ethanol (50 mL) followed bysodium borohydride (0.67 g, 17.6 mmol). The reaction was loaded directlyonto a silica column and purified by flash chromatography (0-15%MeOH/DCM). The material required a second purification by preparativereverse phase chromatography to give(11E,20Z,23Z)—N,N-dimethylnonacosa-11,20,23-trien-10-amine. HRMS calc'd446.4720, found 446.4724, ¹H NMR (400 MHz, CDCl₃) δ 5.48 (m, 1H), 5.37(m, 4H), 5.23 (m, 1H), 2.78 (t, 2H), 2.58 (m, 1H), 2.22 (5, 6H), 2.04(m, 6H), 1.56 (m, 1H), 1.30 (m, 31H), 0.89 (m, 6H).

Compound 45 is DLinKC2DMA as described in Nature Biotechnology, 2010,28, 172-176, WO 2010/042877 A1, WO 2010/048536 A2, WO 2010/088537 A2,and WO 2009/127060 A1.

Compound 46 is MC3 as described in WO 2010/054401, and WO 2010/144740A1.

D. Lipid Nonoparticle Compositions

The following lipid nanoparticle compositions (LNPs) of the instantinvention are useful for the delivery of oligonucleotides, specificallysiNA molecules of the invention:

Cationic Lipid/Cholesterol/PEG-DMG 56.6/38/5.4; CationicLipid/Cholesterol/PEG-DMG 60/38/2; Cationic Lipid/Cholesterol/PEG-DMG67.3/29/3.7; Cationic Lipid/Cholesterol/PEG-DMG 49.3/47/3.7; CationicLipid/Cholesterol/PEG-DMG 50.3/44.3/5.4; CationicLipid/Cholesterol/PEG-C-DMA/DSPC 40/48/2/10; CationicLipid/Cholesterol/PEG-DMG/DSPC 40/48/2/10; and CationicLipid/Cholesterol/PEG-DMG/DSPC 58/30/2/1.0.

One skilled in the art would readily appreciate that the presentinvention is well adapted to carry out the objects and obtain the endsand advantages mentioned, as well as those inherent therein. The methodsand compositions described herein, as presently representative ofpreferred embodiments, are exemplary and are not intended as limitationson the scope of the invention. Changes therein and other uses will occurto those skilled in the art, which are encompassed within the spirit ofthe invention, are defined by the scope of the claims.

TABLE 8 CTNNB1 Accession Numbers   NM_001098210 Homo sapiens catenin(cadherin-associated protein), beta 1, 88 kDa. (CTNNB1), transcriptvariant 3, mRNA. NM_001098210.1 GI:148227671 NM_007614 Mus musculuscatenin (cadherin associated protein), beta 1 (Ctnnb1), transcriptvariant 1, mRNA NM_007614.2 GI:31560726 NM_001115474 Macaca mulattacatenin (cadherin-associated protein), beta 1, 88 kDa. transcriptvariant (CTNNB1), mRNA. NM_001115474.1 GI:109041278

TABLE 9 Non-limiting examples of Stabilization Chemistries forchemically modified siNA constructs Chemistry pyrimidine purine caps p =S Strand “Stab 00” Ribo Ribo TT at 3'- S/AS ends “Stab 1” Ribo Ribo — 5at 5'-end S/AS 1 at 3'-end “Stab 2” Ribo Ribo — All linkages Usually AS“Stab 3” 2'-fluoro Ribo — 4 at 5'-end Usually S 4 at 3'-end “Stab 4”2'-fluoro Ribo 5' and 3'- — Usually S ends “Stab 5” 2'-fluoro Ribo — 1at 3'-end Usually AS “Stab 6” 2'-O-Methyl Ribo 5' and 3'- — Usually Sends “Stab 7” 2'-fluoro 2'-deoxy 5' and 3'- — Usually S ends “Stab 8”2'-fluoro 2'-O- — 1 at 3'-end S/AS Methyl “Stab 9” Ribo Ribo 5' and 3'-— Usually S ends “Stab 10” Ribo Ribo — 1 at 3'-end Usually AS “Stab 11”2'-fluoro 2'-deoxy — 1 at 3'-end Usually AS “Stab 12” 2'-fluoro LNA 5'and 3'- Usually S ends “Stab 13” 2'-fluoro LNA 1 at 3'-end Usually AS“Stab 14” 2'-fluoro 2'-deoxy 2 at 5'-end Usually AS 1 at 3'-end “Stab15” 2'-deoxy 2'-deoxy 2 at 5'-end Usually AS 1 at 3'-end “Stab 16” Ribo2'-O-Methyl 5' and 3'- Usually S ends “Stab 17” 2'-O-Methyl 2'-O-Methyl5' and 3'- Usually S ends “Stab 18” 2'-fluoro 2'-O-Methyl 5' and 3'-Usually S ends “Stab 19” 2'-fluoro 2'-O-Methyl 3'-end S/AS “Stab 20”2'-fluoro 2'-deoxy 3'-end Usually AS “Stab 21” 2'-fluoro Ribo 3'-endUsually AS “Stab 22” Ribo Ribo 3'-end Usually AS “Stab 23” 2'-fluoro*2'-deoxy* 5' and 3'- Usually S ends “Stab 24” 2'-fluoro* 2'-O-Methyl* —1 at 3'-end S/AS “Stab 25” 2'-fluoro* 2'-O-Methyl* — 1 at 3'-end S/AS“Stab 26” 2'-fluoro* 2'-O-Methyl* — S/AS “Stab 27” 2'-fluoro*2'-O-Methyl* 3'-end S/AS “Stab 28” 2'-fluoro* 2'-O-Methyl* 3'-end S/AS“Stab 29” 2'-fluoro* 2'-O-Methyl* 1 at 3'-end S/AS “Stab 30” 2'-fluoro*2'-O-Methyl* S/AS “Stab 31” 2'-fluoro* 2'-O-Methyl* 3'-end S/AS “Stab32” 2'-fluoro* 2'-O-Methyl* S/AS “Stab 33” 2'-fluoro 2'-deoxy* 5' and3'- — Usually S ends “Stab 34” 2'-fluoro 2'-O-Methyl* 5' and 3'- UsuallyS ends “Stab 35” 2'-fluoro*† 2'-O-Methyl*† Usually AS “Stab 36”2'-fluoro*† 2'-O-Methyl*† Usually AS “Stab04H” 2'-fluoro‡ Ribo‡ 5' and3'- 1 at 3'-end Ususally S ends “Stab06C” 2'-O-Methyl‡ Ribo‡ 5' and 3'-Ususally S ends “Stab07H” 2'-fluoro‡ 2'-deoxy‡ 5' and 3'- 1 at 3'-endUsusally S ends “Stab07mU” 2'-fluoro‡ 2'-deoxy‡ 5' and 3'- Ususally Sends “Stab09H” Ribo‡ Ribo‡ 5' and 3'- 1 at 3'-end Ususally S ends“Stab16C” Ribo‡ 2'-O-Methyl‡ 5' and 3'- Ususally S ends “Stab16H” Ribo‡2'-O-Methyl‡ 5' and 3'- 1 at 3'-end Ususally S ends “Stab18C” 2'-fluoro‡2'-O-Methyl‡ 5' and 3'- Ususally S ends “Stab18H” 2'-fluoro‡2'-O-Methyl‡ 5' and 3'- 1 at 3'-end Ususally S ends “Stab52H”2'-O-Methyl‡ Ribo‡ 5' and 3'- 1 at 3'-end Ususally S ends “Stab05C”2'-fluoro‡ Ribo‡ Ususally AS “Stab05N” 2'-fluoro‡ Ribo‡ 1 at 3'-endUsusally AS “Stab10C” Ribo‡ Ribo‡ Ususally AS “Stab10N” Ribo‡ Ribo‡ 1 at3'-end Ususally AS “Stab35G-*” 2-fluoro‡ 2'-O-Methyl‡ Ususally AS“Stab35N*” 2'-fluoro‡ 2'-O-Methyl‡ 1 at 3'-end Ususally AS “Stab35rev*”2'-O-Methyl‡ 2'-fluoro‡ Ususally AS “Stab50*” Ribo‡ 2'-O-Methyl‡Ususally AS “Stab53” 2'-O-Methyl‡ Ribo‡ Ususally AS “Stab53N*”2'-O-Methyl‡ Ribo‡ 1 at 3'-end Ususally AS Stab54 Ribo‡ 2'-fluoro‡Ususally AS CAP = any terminal cap, see for example FIG. 6. All Stabchemistries can be used in combination with each other for duplexes ofthe invention (e.g. as combinations of sense and antisense strandchemistries), or alternately can be used in isolation, e.g., for singlestranded nucleic acid molecules of the invention. All Stab chemistriescan comprise 3'-overhang nucleotides having 2'-O-alkyl, 2'-deoxy-2'-fluoro, 2’-deoxy, LNA or other modified nucleotides or non-nucleotides.All Stab chemistries typically comprise about 19-21 nucleotides, but canvary as described herein. All Stab chemistries can also include a singleribonucleotide in the sense or passenger strand at the 11^(th) basepaired position of the double-stranded nucleic acid duplex as determinedfrom the 5'-end of the antisense or guide strand. All Stab chemistriescan also have in place of the Stab designation above a2'-deoxy-2'-fluoro modification at position 14 from the 5'end of theantisense strand regardless of whether it is a purine or pyrimidine atthat position. All Stab chemistries of the antisense strand presentedabove can have a thymidine in place of a 2'-deoxy uridine at position 1,2, and/or 3 from the 5' end of the antisense strand. S = sense strand.AS = antisense strand. *Stab 23 has a single ribonucleotide adjacent to3'-CAP. *Stab 24 and Stab 28 have a single ribonucleotide at5'-terminus. *Stab 25, Stab 26, Stab 27, Stab 35, Stab 35G*, Stab 35N*,Stab 35rev*, Stab 36, Stab 50*, Stab53*, Stab 53N*, and Stab 54 havethree ribonucleotides at 5'-terminus. *Stab 29, Stab 30, Stab 31, Stab33, and Stab 34 any purine at first three nucleotide positions from5’-terminus are ribonucleotides. p = phosphorothioate linkage. †Stab 35has 2'-O-methyl U at 3'-overhangs and three ribonucleotides at5'-terminus. †Stab 36 has 2'-O-methyl overhangs that are complementaryto the target sequence, (naturally occurring overhangs) and threeribonucleotides at 5'-terminus. ‡Stab 04H, Stab 06C, Stabl07H, Stab07mU,Stab09H, Stab16C, Stab 16H, Stab18C, Stab 18H, Stab 52H, Stab05C,Stab05N, Stab10C, Stab10N, Stab35G*, Stab35N*, Stab35N*, Stab35rev*,Stab 50*, Stab 53*, Stab 53N*, Stab 54 have two 2'-O-methyl U3'-overhangs. Stab35G*, Stab 35N*, Stab35rev*, Stab50*, Stab53*, andStab53N* do not allow for a 2'-O- methyl modification at position 14 ofthe guide strand as determined from the 5'-end.

TABLE 10 Exemplary Solid Phase Oligonucleotide Synthsis Conditions WaitWait Wait Time* Time* Time* Reagent Equivalents Amount DNA 2'-O-methylRNA A. 2.5 μmol Synthesis Cycle ABI 394 Instrument Phosphoramidites 6.5163 μL 45 sec 2.5 min 7.5 min S-Ethyl Tetrazole 23.8 238 μL 45 sec 2.5min 7.5 min Acetic 100 233 μL 5 sec 5 sec 5 sec Anhydride N- 186 233 μL5 sec 5 sec 5 sec CTNNB1hyl IMidazole ICA 176 2.3 mL 21 sec 21 sec 21sec Iodine 11.2 1.7 mL 45 sec 45 sec 45 sec Beaucage 12.9 645 μL 100 sec300 sec 300 sec Acetonitrile NA 6.67 mL NA NA NA B. 0.2 μmol SynthesisCycle ABI 394 Instrument Phosphoramidites 15 31 μL 45 sec 233 sec 465sec S-Ethyl Tetrazole 38.7 31 μL 45 sec 233 min 465 sec Acetic 655 124μL 5 sec 5 sec 5 sec Anhydride N- 1245 124 μL 5 sec 5 sec 5 secCTNNB1hyl Imidazole TCA 700 732 μL 10 sec 10 sec 10 sec Iodine 20.6 244μL 15 sec 15 sec 15 sec Beaucage 7.7 232 μL 100 sec 300 sec 300 secAcetonitrile NA 2.64 mL NA NA NA C. 0.2 μmol Synthesis Cycle 96 wellInstrument Equivalents: Wait Wait Wait DNA/2'-O- Amount: Time* Time*Time* Reagent methyl/Ribo DNA/2'-O-methyl/Ribo DNA 2'-O-methyl RiboPhospheramidites 22/33/66  40/60/120 μL 60 sec 180 sec 360 sec S-EthylTetrazole  70/105/210 40/60/120 μL 60 sec 180 min 360 sec Acetic265/265/265 50/50/50 μL 10 sec 10 sec 10 sec Anhydride N- 502/502/50250/50/50 μL 10 sec 10 sec 10 sec CTNNB1hyl Imidazole TCA 238/475/475250/500/500 μL 15 sec 15 sec 15 sec Iodine 6.8/6.8/6.8  80/80/80 μL 30sec 30 sec 30 see Beaucage 34/51/51   80/120/120 100 sec 200 sec 200 secAcctonitrile NA 1150/1150/1150 μL NA NA NA *Wait time contact timeduring does not include delivery, *Tandem synthesis utilizes doublecoupling of linker molecule

TABLE 11 Composition of Select Lipid Nanoparticle Formulations LNP siNAIdentifier Lipid Components and Molar Ratios Duplex N/P LNP-1 CompoundCholesterol DSPC PEG-DMG R-008488889- 6 32 (30%) (10%) (2%) 000M (50%)LNP-2 Compound Cholesterol DSPC PEG-DMG R-008488882- 6 32 (30%) (10%)(2%) 000B (50%) LNP-3 Compound Cholesterol DSPC PEG-DMG R-008380929- 632 (30%) (10%) (2%) 000H (50%) LNP-4 Compound Cholesterol DSPC PEG-DMGR-008488885- 6 32 (30%) (10%) (2%) 000C (50%) N/P ratio =Nitrogen:Phosphorous ratio between cationic lipid and nucleic acid

TABLE 12 Chemical Structures of Lipids in Formulations of Table 11 LipidChemical Structure Compound 32

Cholesterol

DSPC

PEG-DMG

1. An isolated double-stranded short interfering nucleic acid (siNA)molecule that inhibits the expression of cadherin-associated protein,beta 1 (CTNNB1), wherein (a) the siNA comprises a sense strand and anantisense strand; (b) each strand is independently 15 to 30 nucleotidesin length; and (c) at least one strand comprises at least a 15nucleotide sequence of any one of the nucleotide sequences selected fromthe group consisting of SEQ ID NO:1-6374. 2.-5. (canceled)
 6. Thedouble-stranded short interfering nucleic acid (siNA) molecule accordingto claim 1, wherein at least one nucleotide is a chemically modifiednucleotide.
 7. The double-stranded short interfering nucleic acid (siNA)molecule according to claim 1 further comprising at least onenon-nucleotide.
 8. The double-stranded short interfering nucleic acid(siNA) molecule according to claim 1, wherein at least one nucleotidecomprises a universal base.
 9. The double-stranded short interferingnucleic acid (siNA) molecule according to claim 1, having at least onephosphorothioate internucleotide linkage.
 10. The double-stranded shortinterfering nucleic acid (siNA) molecule according to claim 1,comprising a cap on the 3′-end, 5′-end or both 3′ and 5′ ends of atleast one strand.
 11. The double-stranded short interfering nucleic acid(siNA) molecule according to claim 1, comprising one or more 3′-overhangnucleotides on one or both strands.
 12. (canceled)
 13. Thedouble-stranded short interfering nucleic acid (siNA) molecule of claim11, wherein the 3′-overhang nucleotides on at least one strand are2′-O-methyl nucleotides.
 14. The double-stranded short interferingnucleic acid (siNA) molecule of claim 13, wherein the 2′-O-methylnucleotides are linked with a phosphorothioate internucleotide linkage15. The double-stranded short interfering nucleic acid (siNA) moleculeof claim 6, wherein the chemically modified nucleotide is a2′-deoxy-2′-fluoro nucleotide.
 16. The double-stranded short interferingnucleic acid (siNA) molecule of claim 6, wherein the chemically modifiednucleotide is a 2′-deoxy nucleotide.
 17. The double-stranded shortinterfering nucleic acid (siNA) molecule of claim 6, wherein thechemically modified nucleotide is a 2′-0-alkyl nucleotide. 18.-29.(canceled)
 30. A composition comprising the double-stranded shortinterfering nucleic acid (siNA) according to claim 1 in apharmaceutically acceptable carrier or diluent. 31.-37. (canceled)
 38. Amethod of treating a human subject suffering from a condition which ismediated by the action, or by loss of action, of CTNNB1, which comprisesadministering to said subject an effective amount of the double-strandedshort interfering nucleic acid (siNA) molecule of claim
 1. 39. Themethod according to claim 38, wherein the condition is cancer.
 40. Amethod of treating a human subject suffering from a condition which ismediated by the action, or by loss of action, of CTNNB1, which comprisesadministering to the subject an effective amount of the composition ofclaim
 30. 41. The method according to claim 40, wherein the condition iscancer.